Browse by Poster Presenter

Schedule at a Glance

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

唐, 雷

Peking University Cancer Hospital
(P 180) TUMOR VASCULAR SIGN IN THE RESPONSE ASSESSMENT OF GASTROINTESTINAL STROMAL TUMOR TREATED WITH RIPRETINIB: A MULTICENTER STUDY
雷唐
Favorite
州, 永健

Fujian Medical University Union Hospital
(P 180) TUMOR VASCULAR SIGN IN THE RESPONSE ASSESSMENT OF GASTROINTESTINAL STROMAL TUMOR TREATED WITH RIPRETINIB: A MULTICENTER STUDY
永健州
Favorite
州, 燕冰

The Affiliated Hospital of Qingdao University
(P 180) TUMOR VASCULAR SIGN IN THE RESPONSE ASSESSMENT OF GASTROINTESTINAL STROMAL TUMOR TREATED WITH RIPRETINIB: A MULTICENTER STUDY
燕冰州
Favorite
州, 耶

Fudan University Shanghai Cancer Center
(P 180) TUMOR VASCULAR SIGN IN THE RESPONSE ASSESSMENT OF GASTROINTESTINAL STROMAL TUMOR TREATED WITH RIPRETINIB: A MULTICENTER STUDY
耶州
Favorite
吉田, 恵一

Osaka International Cancer Institut
(P 05) DEVELOPMENT OF SARCOMA ORGANOID MODELS WITH AIR-LIQUID INTERFACE ORGANOID CULTURES
恵一吉田
Favorite
倩, 浩兰

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
(P 180) TUMOR VASCULAR SIGN IN THE RESPONSE ASSESSMENT OF GASTROINTESTINAL STROMAL TUMOR TREATED WITH RIPRETINIB: A MULTICENTER STUDY
浩兰倩
Favorite
A
Abballe, Luana

Ospedale Pediatrico Bambino Gesù
(P 311) QUANTIFICATION OF TUMOUR-INFILTRATING IMMUNE CELLS THROUGH DECONVOLUTION OF DNA METHYLATION DATA IN EWING SARCOMAS
Luana Abballe
Favorite
Abbas, Doaa

SQCCCRC
(P 68) FEASIBILITY OF FIVE-DRUG INTERVAL-COMPRESSED CHEMOTHERAPY FOR ADOLESCENTS AND YOUNG ADULTS WITH EWING SARCOMA FAMILY TUMORS IN THE REAL-WORLD SETTING IN OMAN
Doaa Abbas
Favorite
Abbou, Samuel

Gustave Roussy
(P 82) PLASMA CIRCULATING PROTEOMIC MARKERS ARE ASSOCIATED WITH METASTATIC SPREAD AND OUTCOME IN OSTEOSARCOMA
Samuel Abbou
Favorite
Abd Alqader, Asma

Research Institute McGill University Health Center
(P 69) H3.3G34W ONCOHISTONE IN OSTEOSARCOMA
Asma Abd Alqader
Favorite
Abdelmessih, Joseph

Sarcoma Oncology Center
(P 251) UPDATE ON SAINT: A PHASE 2 STUDY USING TRABECTEDIN (T) IN COMBINATION WITH IPILIMUMAB (L) AND NIVOLUMAB (N) IN PREVIOUSLY TREATED SOFT TISSUE SARCOMA (NCT03138161)
Joseph Abdelmessih
Favorite
Abdul Razak, Albiruni

Toronto Sarcoma Program, Princess Margaret Cancer Center
(P 135) SURVIVAL OUTCOMES AND TREATMENT PATTERNS FOR PATIENTS WITH DEDIFFERENTIATED LIPOSARCOMA: A RETROSPECTIVE COHORT STUDY IN ONTARIO, CANADA
Albiruni Abdul Razak
Favorite
(P 153) PATTERNS, MANAGEMENT AND SURVIVAL OUTCOMES OF PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA: A NATIONWIDE ANALYSIS FROM THE CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION DATABASE
Albiruni Abdul Razak
Favorite
(P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE
Albiruni Abdul Razak
Favorite
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Albiruni Abdul Razak
Favorite
Abdulla, Suha

UCLH
(P 146) EXPLORING THE CLINICAL UTILITY OF WHOLE GENOME SEQUENCING FOR PAEDIATRIC, TYA AND ADULT SARCOMA PATIENTS WITHIN THE LONDON SARCOMA SERVICE: A RETROSPECTIVE COHORT ANALYSIS
Suha Abdulla
Favorite
Abecasis, Nuno

Instituto Português de Oncologia de Lisboa Francisco Gentil
(P 128) DYNAMIC HETEROGENEITY AMONGST LIPOSARCOMAS
Nuno Abecasis
Favorite
Abed El Razak, Murad

Tzafon Medical Center
(P 312) RARE CASE OF INTRAOSSEOUS RHABDOMYOSARCOMA IN A YOUNG CHILD
Murad Abed El Razak
Favorite
Abrahao, Renata

University of California
(P 205) MULTI-MODAL TREATMENT IS ASSOCIATED WITH IMPROVED SURVIVAL IN AYA PATIENTS WITH METASTATIC NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA
Renata Abrahao
Favorite
(P 356) RADIATION PRACTICE PATTERNS AND OUTCOMES IN ADOLESCENT YOUNG ADULT PATIENTS WITH VISCERAL NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA
Renata Abrahao
Favorite
Abreu, Miguel

Portuguese Institute of Oncology of Porto
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Miguel Abreu
Favorite
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Miguel Abreu
Favorite
Abu El Naaj, Imad

Tzafon Medical Center
(P 312) RARE CASE OF INTRAOSSEOUS RHABDOMYOSARCOMA IN A YOUNG CHILD
Imad Abu El Naaj
Favorite
Acar, Simge

Washington University in St. Louis School of Medicine, Division of Oncology
(P 10) GENERATION OF A CHROMOSOME 8 GAIN;NF1-/- HUMAN INDUCED PLURIPOTENT STEM CELL DERIVED SCHWANN CELL PRECURSOR MODEL
Simge Acar
Favorite
Acem, Ibtissam

Erasmus Medical Center
(P 154) PREOPERATIVE CLASSIFICATION OF NERVE SHEATH TUMORS USING RADIOMICS-BASED MACHINE LEARNING
Ibtissam Acem
Favorite
Adámková Krákorová, Dagmar

Masaryk Memorial Cancer Institute Brno, Czech Republic
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Dagmar Adámková Krákorová
Favorite
Adamnson, Travis

Memorial Sloan Kettering Cancer Center
(P 229) EXPRESSION OF TRANSPOSABLE ELEMENTS AND IKZF1 PREDICTS IMMUNE INFILTRATES IN SARCOMAS AND CORRELATES WITH OUTCOMES AFTER IMMUNE CHECKPOINT INHIBITION
Travis Adamnson
Favorite
Adnan, Noufil

University of Kansas Medical Center
(P 250) UPDATE ON GALLANT: A PHASE 2 STUDY USING METRONOMIC GEMCITABINE, DOXORUBICIN AND DOCETAXEL PLUS NIVOLUMAB IN PREVIOUSLY TREATED SARCOMA (NCT04535713)
Noufil Adnan
Favorite
Adriazola Vicente, Paul

Hospital Nacional Edgardo Rebagliati Martins
(P 367) AGE AS A PROGNOSTIC FACTOR IN RETROPERITONEAL SARCOMA: A MULTICENTER LATIN AMERICAN STUDY
Paul Adriazola Vicente
Favorite
松岡, 由紀子

Osaka International Cancer Institut
(P 05) DEVELOPMENT OF SARCOMA ORGANOID MODELS WITH AIR-LIQUID INTERFACE ORGANOID CULTURES
由紀子松岡
Favorite
A
Affar, El Bachir

Hospital Maisonneuve-Rosement, University of Montreal
(P 394) IDENTIFYING THE INTERACTOME OF THE ONCOGENIC FUSIONS OF SARCOMAS TO REVEAL NOVEL THERAPEUTIC TARGETS
El Bachir Affar
Favorite
Afuta, Liad

Sarcoma Oncology Center
(P 106) DELTAREX-G, A TUMOR TARGETED CCNG1 INHIBITOR, DEMONSTRATES CLINICAL BENEFIT IN ADVANCED CHEMORESISTANT SARCOMA FOLLOWING FDA CBER AUTHORIZATION FOR USE AS PLATFORM THERAPY WITH FDA APPROVED DRUGS
Liad Afuta
Favorite
Agaram, Narasimhan

Memorial Sloan Kettering Cancer Center
(P 101) AN OPEN LABEL PHASE IIA STUDY EVALUATING THE PRELIMINARY EFFICACY OF INTRATUMORAL TIGILANOL TIGLATE (TT) IN ADVANCED AND/OR METASTATIC SOFT TISSUE SARCOMA (STS, NCT05755113)
Narasimhan Agaram
Favorite
Agarwal, Anmol

Sarcoma Oncology Center
(P 106) DELTAREX-G, A TUMOR TARGETED CCNG1 INHIBITOR, DEMONSTRATES CLINICAL BENEFIT IN ADVANCED CHEMORESISTANT SARCOMA FOLLOWING FDA CBER AUTHORIZATION FOR USE AS PLATFORM THERAPY WITH FDA APPROVED DRUGS
Anmol Agarwal
Favorite
(P 241) LINNOVATE: A PHASE 1/2 STUDY OF SAFETY/EFFICACY USING LURBINECTEDIN COMBINED WITH IPILUMUMAB AND NIVOLUMAB FOR ADVANCED SOFT TISSUE SARCOMA (NCT05876715)
Anmol Agarwal
Favorite
(P 248) TNT: A PHASE 2 STUDY USING TALIMOGENE LAHERPAREPVEC, NIVOLUMAB, AND TRABECTEDIN FOR ADVANCED LEIOMYOSARCOMA AND LIPOSARCOMA (NCT # 03886311)
Anmol Agarwal
Favorite
(P 250) UPDATE ON GALLANT: A PHASE 2 STUDY USING METRONOMIC GEMCITABINE, DOXORUBICIN AND DOCETAXEL PLUS NIVOLUMAB IN PREVIOUSLY TREATED SARCOMA (NCT04535713)
Anmol Agarwal
Favorite
(P 251) UPDATE ON SAINT: A PHASE 2 STUDY USING TRABECTEDIN (T) IN COMBINATION WITH IPILIMUMAB (L) AND NIVOLUMAB (N) IN PREVIOUSLY TREATED SOFT TISSUE SARCOMA (NCT03138161)
Anmol Agarwal
Favorite
Agarwal, Rishi

Tata Memorial Hospital
(P 306) LONG TERM OUTCOMES OF TYPE BIIIA ROTATIONPLASTY AFTER TOTAL FEMUR EXCISION IN CHILDREN
Rishi Agarwal
Favorite
Aggerholm-Pedersen, Ninna

Department of Oncology, Aarhus University Hospital
(P 104) CIRQUESARC: A NATIONAL PROSPECTIVE OBSERVATIONAL STUDY OF CIRCULATING TUMOR DNA AND QUALITY OF LIFE IN PATIENTS WITH SARCOMA – PRELIMINARY RESULTS FROM THE SURGICAL COHORT
Ninna Aggerholm-Pedersen
Favorite
(P 228) EXPLORING THE LINK BETWEEN TUMOUR INFILTRATING IMMUNE CELLS AND PATIENT OUTCOME IN SOFT TISSUE SARCOMA: A CLOSER LOOK AT MACROPHAGES
Ninna Aggerholm-Pedersen
Favorite
(P 357) RADIATION THERAPY OF EXTREMITY SOFT TISSUE SARCOMAS: A NATIONWIDE COHORT STUDY OF LATE SIDE EFFECTS - TRIAL IN PROGRESS
Ninna Aggerholm-Pedersen
Favorite
(P 411) PROPANE AN OPEN LABEL PHASE 2 STUDY ON PROPRANOLOL AND PEMBROLIZUMAB IN ADVANCED ANGIOSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA A SCANDINAVIAN SARCOMA GROUP COLLABORATION
Ninna Aggerholm-Pedersen
Favorite
Agloro, Anna

Oregon Health & Science University
(P 285) A NOVEL METHOD TO PREDICT HEIGHT AT SKELETAL MATURITY IN PEDIATRIC SARCOMA PATIENTS
Anna Agloro
Favorite
Agostinelli, Claudio

Universiti of Bologna
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Claudio Agostinelli
Favorite
Agra, Carolina

Hospital General Universitario Gregorio Marañón
(P 432) THE ROLE OF SYSTEMIC TREATMENT IN ADVANCED SOLITARY FIBROUS TUMORS: EXPERIENCE AT A REFERRAL CENTER.
Carolina Agra
Favorite
Aguiar Jr., Samuel

AC Camargo Cancer Center
(P 300) GASTROINTESTINAL STROMAL TUMORS (GIST) IN YOUNG ADULTS (YA): A BRAZILIAN COHORT OF PATIENTS
Samuel Aguiar Jr.
Favorite
Agulnik, Mark

Keck School of Medicine, University of Southern California
(P 95) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN PATIENTS WITH CHONDROSARCOMA: UPDATED RESULTS FROM A PHASE 1 STUDY
Mark Agulnik
Favorite
Ahlstrom, Marie

Dpt of Oncology, Skane University Hospital, Lund, Sweden
(P 172) GIST WITH ATYPICAL MORPHOLOGY INITIALLY MISDIAGNOSED-THE IMPORTANCE OF BROAD IMMUNOCHEMISTRY-A CASE REPORT
Marie Ahlstrom
Favorite
(P 286) ADAMANTINOMA - LIKE EWING SARCOMA WITH ATYPICAL PRESENTATION AND FATAL OUTCOME IN 20-YEAR-OLD WOMAN - A CASE REPORT
Marie Ahlstrom
Favorite
Ahmed, Jibran

National Cancer Institute
(P 413) SUSTAINED EFFICACY DURING DRUG HOLIDAY ON ATEZOLIZUMAB IN PATIENTS WITH ALVEOLAR SOFT PART SARCOMA (ASPS)
Jibran Ahmed
Favorite
Ahmed, Safia

Mayo Clinic Arizona
(P 305) LOCAL THERAPY APPROACHES IN RELAPSED PEDIATRIC SOFT TISSUE SARCOMA AND EWING SARCOMA PATIENTS: A SINGLE INSTITUTION SERIES
Safia Ahmed
Favorite
Ahn, Bo Young

University of Calgary
(P 289) APPLICATION AND ANALYSIS OF SPATIAL TRANSCRIPTOMIC PROFILING TO CLINICAL ALVEOLAR SOFT PART SARCOMA SAMPLES TO UNDERSTAND IMMUNOTHERAPY-RELEVANT VARIABLES
Bo Young Ahn
Favorite
Aiduk, Michael

Duke University
(P 301) GENOME-WIDE CRISPR/CAS9 VIABILITY SCREENS UNCOVER NOVEL GENETIC DEPENDENCIES IN CIC::DUX4 SARCOMA
Michael Aiduk
Favorite
Akimoto, Tetsuo

Tokyo Jikei University
(P 354) PROTON BEAM THERAPY FOR PEDIATRIC AND ADOLESCENT SARCOMA FROM OVERSEAS
Tetsuo Akimoto
Favorite
Akshintala, Srivandana

National Cancer Institute
(P 414) TENOSYNOVIAL GIANT CELL TUMOR IN CHILDREN: INTERIM RESULTS FROM A PHASE 1 STUDY OF TURALIO®
Srivandana Akshintala
Favorite
Aksoy, Arman

Obsidian Therapeutics
(P 235) INFILTRATION OF MUCOSAL-ASSOCIATED INVARIANT T CELLS (MAITS) INTO CHONDROSARCOMA TUMORS
Arman Aksoy
Favorite
Akula Bala, Pramod

Sanford Burnham Prebys Medical Discovery Institute
(P 27) SUMO2 INHIBITION REVERSES ABERRANT EPIGENETIC REWIRING DRIVEN BY SYNOVIAL SARCOMA FUSION ONCOPROTEINS AND IMPAIRS SARCOMAGENESIS
Pramod Akula Bala
Favorite
Al Hosni, Mohammad

SQCCCRC
(P 193) DISTRIBUTION OF CONNECTIVE TISSUE TUMORS BY HISTOLOGY AND DEGREE OF MALIGNANCY IN A SINGLE INSTITUTION IN OMAN
Mohammad Al Hosni
Favorite
Al Shaibi, Maha

SQCCCRC
(P 193) DISTRIBUTION OF CONNECTIVE TISSUE TUMORS BY HISTOLOGY AND DEGREE OF MALIGNANCY IN A SINGLE INSTITUTION IN OMAN
Maha Al Shaibi
Favorite
al Sharif, Hisham

The Ohio State University James Comprehensive Cancer Center
(P 207) PATIENT-REPORTED GLOBAL HEALTH PREDICTS ADVERSE HEALTH OUTCOMES IN PATIENTS WITH ADVANCED SARCOMA
Hisham al Sharif
Favorite
Alaggio, Rita

Bambino Gesu Children's Hospital, IRCCS
(P 298) EWING SARCOMA OF MAXILLOFACIAL REGION AND SKULL: A RETROSPECTIVE MONOINSTITUTIONAL PEDIATRIC SERIES
Rita Alaggio
Favorite
(P 311) QUANTIFICATION OF TUMOUR-INFILTRATING IMMUNE CELLS THROUGH DECONVOLUTION OF DNA METHYLATION DATA IN EWING SARCOMAS
Rita Alaggio
Favorite
Alamilla-Garcia, Gabriela C

National Cancer Institute
(P 374) FACTORS ASSOCIATED WITH RECURRENCE IN DEDIFFERENTIATED RETROPERITONEAL LIPOSARCOMA: ANALYSIS AT A REFERENCE CENTER
Gabriela C Alamilla-Garcia
Favorite
Albert, Catherine

Seattle Children's Hospital/University of Washington School of Medicine
(P 226) EARLY EXPERIENCE ON ENLIGHTEN-01: A PHASE 1 STUDY OF BISPECIFIC ADAPTER MOLECULE- CONTROLLED FOLATE RECEPTOR CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY OSTEOSARCOMA
Catherine Albert
Favorite
(P 393) EFFICACY AND SAFETY OF LAROTRECTINIB AS FIRST-LINE TREATMENT IN PATIENTS WITH TRK FUSION SARCOMAS
Catherine Albert
Favorite
Albert, Catherine

Seattle Children’s Hospital, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
(P 417) VITAS: ATEZOLIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY SOLID TUMORS: AN OPEN-LABEL, PHASE I/II, SINGLE-ARM, MULTI-CENTER TRIAL IN PROGRESS
Catherine Albert
Favorite
Albertsmeier, Markus

LMU Hospital, Ludwigs-Maximilians-Universität Munich
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Markus Albertsmeier
Favorite
Alemany Alonso, Regina

University of the Balearic Islands
(P 13) GENOMIC PROFILING OF ADULT SOFT TISSUE SARCOMAS FROM A SINGLE CENTER EXPERIENCE
Regina Alemany Alonso
Favorite
(P 322) A NEW PLAYER IN SOFT TISSUE SARCOMA PROGRESSION: WNT5A IS A PROGNOSIS BIOMARKER AND A POTENTIAL ACTIONABLE TARGET
Regina Alemany Alonso
Favorite
Alese, Olatunji

Winship Cancer Institute of Emory University
(P 95) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN PATIENTS WITH CHONDROSARCOMA: UPDATED RESULTS FROM A PHASE 1 STUDY
Olatunji Alese
Favorite
Alessandrino, Francesco

Sylvester Comprehensive Cancer Center
(P 381) OLIGOMETASTATIC LEIOMYOSARCOMA: ASSOCIATION BETWEEN TREATMENT TYPE, METASTATIC PATTERN AND SURVIVAL
Francesco Alessandrino
Favorite
Alexe, Gabriela

Dana Farber
(P 66) EWING TUMORS WITH STAG2 LOSS DEMOSNTRATE ALTERED INTERFERON SIGNATURES AND IMPAIRED CXCL10 EXPRESSION
Gabriela Alexe
Favorite
Alexiev, Borislav

Northwestern Memorial Hospital
(P 179) PRIMARY MANAGEMENT OF LOCALIZED GASTROINTESTINAL STROMAL TUMORS WITH IMATINIB MONOTHERAPY: AN ALTERNATIVE TO RESECTION FOR PATIENTS PRECLUDED FROM SURGERY
Borislav Alexiev
Favorite
Alfaro, Alejandro

Moffitt Cancer Center
(P 237) INTRALESIONAL ADMINISTRATION OF TALIMOGENE LAHERPAREPVEC (T-VEC) INDUCES TUMOR REGRESSION IN PATIENTS WITH CUTANEOUS ANGIOSARCOMA
Alejandro Alfaro
Favorite
Alfaro-Goldaracena, Alejandro

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
(P 213) REGIONAL KNOWLEDGE TRANSLATION IN RETROPERITONEAL SARCOMAS: IMPACT OF AN EDUCATIONAL WEBINAR SERIES BY THE MEXICAN SARCOMA GROUP
Alejandro Alfaro-Goldaracena
Favorite
Alfonso, Matthew

University of Miami, Sylvester Comprehensive Cancer Center
(P 358) RADIOMIC EVALUATION OF MRIS IN PATIENTS WITH SOFT TISSUE SARCOMA TREATED WITH STEREOTACTIC BOSY RADIATION THERAPY
Matthew Alfonso
Favorite
Ali Kawsar, Khandkar

Queen Elizabeth Hospital
(P 261) EVALUATION OF CT ARTIFACTS AFTER SPINAL OLIGOMETASTATIC DISEASE RESECTION AND RECONSTRUCTION: A COMPARATIVE STUDY OF CARBON-FIBER VS. TITANIUM IMPLANTS
Khandkar Ali Kawsar
Favorite
Aliberti, Sandra

Candiolo Cancer Institute, FPO – IRCCS
(P 234) IMMUNOSARC II MASTER TRIAL (PHASE II OF SUNITINIB AND NIVOLUMAB): RESULTS FROM THE CLEAR CELL SARCOMA (CCS) COHORT. A GEIS, ISG, AND UCL STUDY
Sandra Aliberti
Favorite
(P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Sandra Aliberti
Favorite
Alice, Chen

National Institutes of Health
(P 413) SUSTAINED EFFICACY DURING DRUG HOLIDAY ON ATEZOLIZUMAB IN PATIENTS WITH ALVEOLAR SOFT PART SARCOMA (ASPS)
Chen Alice
Favorite
Ali, Hassan

Mercy Catholic Medical Center
(P 310) PROGNOSTICATION AND EPIDEMIOLOGY OF CLEAR CELL SARCOMA: A SEER STAT RETROSPECTIVE ANALYSIS
Hassan Ali
Favorite
Ali, Nahla

Alexandria University Faculty of Medicine
(P 191) CLINICOPATHOLOGICAL CHARACTERISTICS OF ANGIOSARCOMA AND THE RISK OF MULTIPLE PRIMARY MALIGNANCIES
Nahla Ali
Favorite
Ali, Siraj

Lunit
(P 123) ARTIFICIAL INTELLIGENCE-POWERED MITOSIS EVALUATION TO COMPLEMENT HUMAN MITOTIC RATE INTERPRETATION IN PREDICTING PROGNOSIS IN LIPOSARCOMA
Siraj Ali
Favorite
Allen-Rhoades, Wendy

Mayo Clinic
(P 307) OUTCOMES OF PEDIATRIC NON-RHABDOMYOSARCOMA SOFT-TISSUE SARCOMAS OF THE EXTREMITIES
Wendy Allen-Rhoades
Favorite
Alman, Benjamin

Duke University
(P 15) HISTONE DEACETYLASE-3 PLAYS A ROLE IN THE METASTATIC POTENTIAL OF A SUBPOPULATION OF CELLS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Benjamin Alman
Favorite
Al-Marayaty, Rusul

Medstar-Georgetown/ Washington Hospital Center
(P 179) PRIMARY MANAGEMENT OF LOCALIZED GASTROINTESTINAL STROMAL TUMORS WITH IMATINIB MONOTHERAPY: AN ALTERNATIVE TO RESECTION FOR PATIENTS PRECLUDED FROM SURGERY
Rusul Al-Marayaty
Favorite
(P 222) ANALYSIS OF THE CITN-13 SARCOMA ARM: PEMBROLIZUMAB AND INTERFERON GAMMA FOR SYNOVIAL SARCOMA AND MYXOID/ ROUND CELL LIPOSARCOMA
Rusul Al-Marayaty
Favorite
(P 235) INFILTRATION OF MUCOSAL-ASSOCIATED INVARIANT T CELLS (MAITS) INTO CHONDROSARCOMA TUMORS
Rusul Al-Marayaty
Favorite
Almassalha, Luay

Northwestern University Feinberg School of Medicine
(P 04) CHROMOSOME SPECIFIC ORGANIZATIONAL CHARACTERISTICS IN RHABDOMYOSARCOMA AND NORMAL MYOGENIC CELLS
Luay Almassalha
Favorite
Almond, max

Queen Elizabeth Hospital Birmingham
(P 383) PRE-OPERATIVE SPLIT RENAL FUNCTION RADIONUCLIDE IMAGING IN SURGICAL PLANNING FOR MULTI-VISCERAL RESECTION OF RETROPERITONEAL SARCOMA: A RETROSPECTIVE COHORT STUDY
max Almond
Favorite
Al-Mosuli, Yusra

The Ottawa Hospital
(P 153) PATTERNS, MANAGEMENT AND SURVIVAL OUTCOMES OF PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA: A NATIONWIDE ANALYSIS FROM THE CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION DATABASE
Yusra Al-Mosuli
Favorite
alshibany, aisha

princess margaret cancer centre
(P 153) PATTERNS, MANAGEMENT AND SURVIVAL OUTCOMES OF PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA: A NATIONWIDE ANALYSIS FROM THE CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION DATABASE
aisha alshibany
Favorite
Althouse, Sandra

Indiana University School of Medicine
(P 365) A SINGLE INSTITUTION COMPARISON OF OUTCOMES IN PEDIATRIC AND ADULT PATIENTS WITH GYNECOLOGIC ORIGIN RHABDOMYOSARCOMA
Sandra Althouse
Favorite
Alvarez, Elysia

University of California, Davis
(P 205) MULTI-MODAL TREATMENT IS ASSOCIATED WITH IMPROVED SURVIVAL IN AYA PATIENTS WITH METASTATIC NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA
Elysia Alvarez
Favorite
Alvarez, Elysia

UC Davis
(P 356) RADIATION PRACTICE PATTERNS AND OUTCOMES IN ADOLESCENT YOUNG ADULT PATIENTS WITH VISCERAL NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA
Elysia Alvarez
Favorite
Alvarez, Jasmine

Thomas Jefferson University
(P 344) TRANSCRIPTOMIC ANALYSIS OF DESMOID TUMOR RESPONSE TO NIROGACESTAT: NOVEL MECHANISMS OF RESISTANCE?
Jasmine Alvarez
Favorite
Alvarez, Rosa

HU Gregorio Marañón
(P 432) THE ROLE OF SYSTEMIC TREATMENT IN ADVANCED SOLITARY FIBROUS TUMORS: EXPERIENCE AT A REFERRAL CENTER.
Rosa Alvarez
Favorite
Amant, Frederic

Antoni van Leeuwenhoek Nederlands Kanker Instituut, Amsterdam
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Frederic Amant
Favorite
Amatruda, James

Children's Hospital Los Angeles
(P 88) SPATIAL TRANSCRIPTOMICS OF EWING SARCOMA: EVOLUTION OF TUMOR MICROENVIRONMENT ASSOCIATED EXTRACELLULAR MATRIX FROM LOCALIZED TO METASTASIS-ASSOCIATED PRIMARY TUMORS
James Amatruda
Favorite
Ameline, Baptiste

University hospital Basel
(P 56) CHROME: PREDICTING CHONDROSARCOMA RISK OUTCOME FROM METHYLATION
Baptiste Ameline
Favorite
(P 114) METHYLOME PROFILING OF CARTILAGE TUMOURS: A PROMISING NEW TOOL FOR BIOPSY MATERIAL?
Baptiste Ameline
Favorite
Amoruccio, Vincent

SpringWorks Therapeutics, Inc.
(P 33) DESCRIPTIVE EVALUATION OF PATIENTS WITH DESMOID TUMOR AND CO-OCCURRING SOMATIC MUTATIONS OF CTNNB1 AND APC IN THE PHASE 3 DEFI TRIAL
Vincent Amoruccio
Favorite
Amundson, Adam

Mayo Clinic
(P 210) RADIATION-ASSOCIATED ANGIOSARCOMA OF THE BREAST (RAASB): A NOMOGRAM FOR PREDICTING RECURRENCE AND PROGNOSIS
Adam Amundson
Favorite
Anderson, Alexander

Moffitt Cancer Center
(P 421) CHARACTERIZATION OF INTRA-PATIENT, INTER-LESIONAL RESPONSE AND RESISTANCE DYNAMICS IN METASTATIC, FUSION-POSITIVE RHABDOMYOSARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Alexander Anderson
Favorite
Anderson, Colin

Atrium Health
(P 430) QUANTITATIVE EMT GENE SCORES AT DIAGNOSIS INDICATE METASTASIS RISK AND SURVIVAL IN SYNOVIAL SARCOMA
Colin Anderson
Favorite
Anderson, Peter

Cleveland Clinic
(P 351) OSTEOSARCOMA STEREOTACTIC BODY RADIOTHERAPY: OUTCOMES AND PATTERN OF FAILURE
Peter Anderson
Favorite
Andrei, Vanghelita

University Hospital Basel
(P 114) METHYLOME PROFILING OF CARTILAGE TUMOURS: A PROMISING NEW TOOL FOR BIOPSY MATERIAL?
Vanghelita Andrei
Favorite
Andrulis, Irene

The Lunenfeld-Tanenbaum Research Institute
(P 225) DETERMINING THE CONTRIBUTIONS OF STAT1 AND THE Y701 PHOSPHORYLATION TO THE UPS ANTI-TUMOR MICROENVIRONMENT
Irene Andrulis
Favorite
(P 238) INTRA-TUMORAL DC-LAMP EXPRESSION IS ASSOCIATED WITH PROGNOSIS IN SOFT TISSUE SARCOMA
Irene Andrulis
Favorite
Angele, Martin

LMU University Hospital
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Martin Angele
Favorite
Angeles, Christina

University of Michigan Rogel Cancer Center
(P 45) UTILIZATION OF MENTAL HEALTH AND SUPPORTIVE CARE RESOURCES AMONG PATIENTS WITH DESMOID TUMORS
Christina Angeles
Favorite
(P 131) HETEROGENEITY OF THE IMMUNE MICROENVIRONMENT AND IMMUNOTHERAPY RESPONSE IN A DEDIFFERENTIATED LIPOSARCOMA MOUSE MODEL
Christina Angeles
Favorite
(P 308) PALLIATIVE CARE INVOLVEMENT FOR ADOLESCENTS AND YOUNG ADULTS WITH BONE AND SOFT TISSUE SARCOMAS
Christina Angeles
Favorite
(P 341) THE EFFECTS OF ULTRASOUND-GUIDED HISTOTRIPSY ON SOFT TISSUE SARCOMA
Christina Angeles
Favorite
(P 423) COMPARISON OF CLINICAL COURSE AND FEATURES BETWEEN SCLEROSING EPITHELOID FIBROSARCOMA AND LOW-GRADE FIBROMYXOID SARCOMA
Christina Angeles
Favorite
Angelotti, Giovanni

IRCCS Humanitas Research Hospital
(P 290) ARTIFICIAL INTELLIGENCE-BASED COMPARISON OF ADULT AND ADOLESCENT AND YOUNG ADULTS (AYA) SARCOMAS: A PILOT STUDY
Giovanni Angelotti
Favorite
Annesley, Colleen

Seattle Children's Hospital, University of Washington
(P 226) EARLY EXPERIENCE ON ENLIGHTEN-01: A PHASE 1 STUDY OF BISPECIFIC ADAPTER MOLECULE- CONTROLLED FOLATE RECEPTOR CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY OSTEOSARCOMA
Colleen Annesley
Favorite
Annett, Alva

Research Institute of the McGill University Health Center
(P 78) NOVEL EPIGENETIC MECHANISMS DRIVE AGGRESSIVE OSTEOSARCOMA PATHOGENESIS AND DRUG RESISTANCE
Alva Annett
Favorite
Antkowiak, Mark

University of California, San Diego
(P 162) ANALYSIS OF 3,144 CASE REPORTS IN THE GASTROINTESTINAL STROMAL TUMOR LITERATURE: IDENTIFICATION OF UNDERAPPRECIATED DEMOGRAPHICS, CLINICAL PRESENTATIONS, AND BIOLOGY
Mark Antkowiak
Favorite
(P 165) COMPLETE PERITONEAL CYTOREDUCTIVE SURGERY IN HIGHLY SELECTED PATIENTS WITH AGGRESSIVE METASTATIC SDH-DEFICIENT GIST CAN PROLONG EVENT-FREE SURVIVAL
Mark Antkowiak
Favorite
(P 175) KIT AND DOG-1 EXPRESSING GASTROINTESTINAL STROMAL TUMORS HARBORING ETV6-NTRK3 FUSIONS DO EXIST, CASE OF NEAR COMPLETE PATHOLOGIC RESPONSE FOLLOWING LAROTRECTINIB AND REVIEW OF THE LITERATURE
Mark Antkowiak
Favorite
Antonacci, Celeste

Ospedale Pediatrico Bambino Gesù
(P 311) QUANTIFICATION OF TUMOUR-INFILTRATING IMMUNE CELLS THROUGH DECONVOLUTION OF DNA METHYLATION DATA IN EWING SARCOMAS
Celeste Antonacci
Favorite
Antonescu, Cristina R.

Memorial Sloan Kettering Cancer Center
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Cristina R. Antonescu
Favorite
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Cristina R. Antonescu
Favorite
(P 121) ACQUIRED CYCLIN D AMPLIFICATION IS A MECHANISM FOR RESISTANCE TO CDK4/6 INHIBITORS IN DEDIFFERENTIATED LIPOSARCOMA
Cristina R. Antonescu
Favorite
(P 229) EXPRESSION OF TRANSPOSABLE ELEMENTS AND IKZF1 PREDICTS IMMUNE INFILTRATES IN SARCOMAS AND CORRELATES WITH OUTCOMES AFTER IMMUNE CHECKPOINT INHIBITION
Cristina R. Antonescu
Favorite
Ao, Zheng

Obsidian Therapeutics
(P 235) INFILTRATION OF MUCOSAL-ASSOCIATED INVARIANT T CELLS (MAITS) INTO CHONDROSARCOMA TUMORS
Zheng Ao
Favorite
Apollonio, Giulia

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 171) GASTROINTESTINAL STROMAL TUMOURS (GISTS) IN NEUROFIBROMATOSIS TYPE (NF1): A SINGLE-CENTER OBSERVATIONAL RETROSPECTIVE STUDY
Giulia Apollonio
Favorite
Aragone, Lucia

Buenos Aires British Hospital
(P 25) PRIMARY TREATED VERSUS REFERRED TRUNK AND EXTREMITIES SOFT TISSUE SARCOMAS: ANALYSIS OF TREATMENT IMPACT IN A SPECIALIZED CENTER IN ARGENTINA.
Lucia Aragone
Favorite
Araujo, Dejka

The University of Texas MD Anderson Cancer Center
(P 202) IMPACT OF AFAMI-CEL ON THE HEALTH STATE OF PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR MYXOID/ROUND CELL LIPOSARCOMA: COHORT 1 OF SPEARHEAD-1
Dejka Araujo
Favorite
(P 233) IMMUNE CLASSES OF LEIOMYOSARCOMA DRIVEN BY B CELL INFILTRATE AND CTLA4 EXPRESSION
Dejka Araujo
Favorite
Argraves, Kelley

Clear Cell Sarcoma Foundation
(P 189) CLEAR CELL SARCOMA - REAL WORLD DATA ANALYSIS
Kelley Argraves
Favorite
Arguello, Alexandra

Mayo Clinic
(P 278) ROTATIONPLASTY AS AN EFFECTIVE LIMB SALVAGE OPTION IN THE ADULT POPULATION
Alexandra Arguello
Favorite
ariyan, Charlotte

Memorial Sloan Kettering Cancer Center
(P 101) AN OPEN LABEL PHASE IIA STUDY EVALUATING THE PRELIMINARY EFFICACY OF INTRATUMORAL TIGILANOL TIGLATE (TT) IN ADVANCED AND/OR METASTATIC SOFT TISSUE SARCOMA (STS, NCT05755113)
Charlotte ariyan
Favorite
Armstrong, Amy

Washington University, St. Louis Children’s Hospital
(P 149) LACK OF CORRELATION OF FDG-PET/CT SUV MAXIMUM AND MALIGNANT TRANSFORMATION IN NEUROFIBROMATOSIS TYPE 1-RELATED PLEXIFORM NEUROFIBROMAS
Amy Armstrong
Favorite
Armstrong, Samantha

Indiana University Melvin and Bren Simon Cancer Center
(P 365) A SINGLE INSTITUTION COMPARISON OF OUTCOMES IN PEDIATRIC AND ADULT PATIENTS WITH GYNECOLOGIC ORIGIN RHABDOMYOSARCOMA
Samantha Armstrong
Favorite
(P 384) REAL WORLD EXPERIENCE IN TREATING HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA: AN ULTRA-RARE VASCULAR TUMOR
Samantha Armstrong
Favorite
Arregui Valles, Marta

Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
(P 432) THE ROLE OF SYSTEMIC TREATMENT IN ADVANCED SOLITARY FIBROUS TUMORS: EXPERIENCE AT A REFERRAL CENTER.
Marta Arregui Valles
Favorite
Arrighetti, Noemi

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 137) TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS
Noemi Arrighetti
Favorite
Arvidsson, Yvonne

Sahlgrenska comprehensive cancer center
(P 170) GASTRIN RELEASING PEPTIDE RECEPTOR EXPRESSION IN GASTROINTESTINAL STROMAL TUMORS (GIST)
Yvonne Arvidsson
Favorite
Asaftei, Sebastian Dorin

Regina Margherita Children Hospital
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Sebastian Dorin Asaftei
Favorite
Ashour, Dina

Johns Hopkins All Children's Hospital
(P 316) SECONDARY RHABDOMYOSARCOMA IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS
Dina Ashour
Favorite
Attar, Samer

Northwestern Memorial Hospital
(P 235) INFILTRATION OF MUCOSAL-ASSOCIATED INVARIANT T CELLS (MAITS) INTO CHONDROSARCOMA TUMORS
Samer Attar
Favorite
Attia, Steven

Mayo Clinic
(P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE
Steven Attia
Favorite
(P 202) IMPACT OF AFAMI-CEL ON THE HEALTH STATE OF PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR MYXOID/ROUND CELL LIPOSARCOMA: COHORT 1 OF SPEARHEAD-1
Steven Attia
Favorite
Aubrey, Rachel

Princess Margaret Cancer Center, Canadian Sarcoma Research Clinical Collaboration (CanSaRCC), McMaster University
(P 320) WHAT IS THE ROLE OF CHEMOTHERAPY IN PATIENTS (PTS) WITH SPINDLE CELL/SCLEROSING RHABDOMYOSARCOMA (SCRMS): A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Rachel Aubrey
Favorite
Audinot, Baptiste

Gustave Roussy
(P 82) PLASMA CIRCULATING PROTEOMIC MARKERS ARE ASSOCIATED WITH METASTATIC SPREAD AND OUTCOME IN OSTEOSARCOMA
Baptiste Audinot
Favorite
Auger, Alexandra

CIUSSS Est-de-l'Île-de-Montréal
(P 212) REFERENCE SYSTEM OPTIMIZATION, ANALYSES OF THE IMPLEMENTATION OF A PROVINCIAL MULTIDISCIPLINARY SARCOMA NETWORK
Alexandra Auger
Favorite
Aurelio, Claudia

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 137) TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS
Claudia Aurelio
Favorite
Avilés, Pablo

Research Department, PharmaMar S.A.
(P 340) THE DNA MINOR GROOVE BINDING AGENTS ECUBECTEDIN AND PM54 DEMONSTRATE ANTITUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT MODELS OF SOFT TISSUE SARCOMA
Pablo Avilés
Favorite
Aviles-Rodriguez, Giselle

Stanford University
(P 74) MATRIX DENSITY INDUCES CHEMORESISTANCE WITHIN A TISSUE-ENGINEERED MODEL OF OSTEOSARCOMA
Giselle Aviles-Rodriguez
Favorite
Avutu, Viswatej

Memorial Sloan Kettering Cancer Center
(P 229) EXPRESSION OF TRANSPOSABLE ELEMENTS AND IKZF1 PREDICTS IMMUNE INFILTRATES IN SARCOMAS AND CORRELATES WITH OUTCOMES AFTER IMMUNE CHECKPOINT INHIBITION
Viswatej Avutu
Favorite
Aye, Jamie

University of Alabama at Birmingham
(P 309) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT SOFT TISSUE SARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Jamie Aye
Favorite
Azcarate, Ivana

Angel H. Roffo Institute of Oncology
(P 273) PRIMARY SOFT-TISSUE SARCOMAS OF THE UPPER LIMBS
Ivana Azcarate
Favorite
Azmy, Christeen

NYU Langone Long Island
(P 50) ANALYSIS OF CLINICAL FEATURES AND OUTCOMES FOR PATIENTS WITH MULTIFOCAL OSTEOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Christeen Azmy
Favorite
B
Baad-Hansen, Thomas

Department of Orthopedic Surgery, Aarhus University Hospital
(P 104) CIRQUESARC: A NATIONAL PROSPECTIVE OBSERVATIONAL STUDY OF CIRCULATING TUMOR DNA AND QUALITY OF LIFE IN PATIENTS WITH SARCOMA – PRELIMINARY RESULTS FROM THE SURGICAL COHORT
Thomas Baad-Hansen
Favorite
Babatunde, Olayode

Memorial Sloan Kettering Cancer Center
(P 121) ACQUIRED CYCLIN D AMPLIFICATION IS A MECHANISM FOR RESISTANCE TO CDK4/6 INHIBITORS IN DEDIFFERENTIATED LIPOSARCOMA
Olayode Babatunde
Favorite
Babichev, Yael

Lunenfeld-Tanenbaum Research Institute
(P 159) USING THE TRANSCRIPTIONAL SPECTRUM OF UTERINE SMOOTH MUSCLE TUMORS TO IDENTIFY PROGNOSTIC SIGNATURES FOR ABNORMAL LEIOMYOMAS AND SMOOTH MUSCLE TUMOURS OF UNCERTAIN MALIGNANT POTENTIAL
Yael Babichev
Favorite
(P 329) DEVELOPING ARMS METASTATIC MODELS TO RECAPITULATE THE TUMOR MICROENVIRONMENTS OF THE AXILLA/LYMPH NODE AND LUNGS
Yael Babichev
Favorite
(P 433) TUMOR HYPOXIA AND THE RISK OF METASTASIS IN HIGH-RISK LOCALIZED UPS/MFS
Yael Babichev
Favorite
Bacci, Claudia

IRCCS Humanitas Research Hospital
(P 431) REAL-WORLD EXPERIENCE OF EFFICACY AND TOLERABILITY OF CONTINUOS INFUSION IFOSFAMIDE AMONG ADVANCED SOFT TISSUE AND BONE SARCOMAS PATIENTS: A SINGLE CENTRE RETROSPECTIVE COHORT.
Claudia Bacci
Favorite
Badalamenti, Giuseppe

Policlinico P. Giaccone
(P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Giuseppe Badalamenti
Favorite
Badejo, Megan

Duke University
(P 142) CORE NEEDLE BIOPSY OF PERIACETABULAR CHONDROSARCOMA OFTEN RESULTS IN UNDER-GRADING BUT DOES NOT CHANGE MANAGEMENT BY EXPERIENCED ORTHOPAEDIC ONCOLOGISTS.
Megan Badejo
Favorite
Badger, Nathalie

Queen Elizabeth Hospital
(P 383) PRE-OPERATIVE SPLIT RENAL FUNCTION RADIONUCLIDE IMAGING IN SURGICAL PLANNING FOR MULTI-VISCERAL RESECTION OF RETROPERITONEAL SARCOMA: A RETROSPECTIVE COHORT STUDY
Nathalie Badger
Favorite
Badgett, Thomas

University of Kentucky
(P 309) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT SOFT TISSUE SARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Thomas Badgett
Favorite
Badura, Irene

Chordoma Foundation
(P 201) GLOBAL CROSS-SECTIONAL SURVEY ON SARCOMA DIAGNOSIS PATHWAY: A CURRENT STATE ANALYSIS
Irene Badura
Favorite
Bae, Jeong Mo

Seoul National University Hospital
(P 428) OLIGOMETASTASES IN EXTREMITY SOFT TISSUE SARCOMA : SUBTYPE-SPECIFIC ANALYSES OF CHARACTERISTICS AND OUTCOMES
Jeong Mo Bae
Favorite
Bae, Susie

Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Susie Bae
Favorite
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Susie Bae
Favorite
Bagaria, Sanjay

Mayo Clinic
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Sanjay Bagaria
Favorite
Bahadoor, Hriday

UMR CNRS 7021, University of Strasbourg
(P 89) TARGETED THERAPY OF MET, TYROSINE KINASE RECEPTOR, IN PEDIATRIC HIGH-GRADE OSTEOSARCOMAS : A NEW WAY TO TREAT PATIENTS ?
Hriday Bahadoor
Favorite
Bai, Jane

Adaptimmune
(P 202) IMPACT OF AFAMI-CEL ON THE HEALTH STATE OF PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR MYXOID/ROUND CELL LIPOSARCOMA: COHORT 1 OF SPEARHEAD-1
Jane Bai
Favorite
Bailey, Keith

Alnylam Pharmaceuticals
(P 79) NOVEL THERAPEUTIC POTENTIAL THROUGH HYPERACTIVATION OF THE ANTICIPATORY UNFOLDED PROTEIN RESPONSE PATHWAY IN BONE CANCER TREATMENT
Keith Bailey
Favorite
Bailey, Kelly

Department of Pediatrics, University of Pittsburgh
(P 64) ENTINOSTAT ENHANCES PRO-INFLAMMATORY CHEMOKINE PRODUCTION AND INCREASES RADIATION-INDUCED APOPTOSIS IN EWING SARCOMA
Kelly Bailey
Favorite
(P 66) EWING TUMORS WITH STAG2 LOSS DEMOSNTRATE ALTERED INTERFERON SIGNATURES AND IMPAIRED CXCL10 EXPRESSION
Kelly Bailey
Favorite
Baker, Jordan

The University of Kansas Medical Center
(P 36) EARLY REAL-WORLD EXPERIENCE WITH THE USE OF NIROGACESTAT FOR THE TREATMENT OF DESMOID FIBROMATOSIS
Jordan Baker
Favorite
Bakhsh, Sameer

India Institute of Medical Sciences
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Sameer Bakhsh
Favorite
Baldi, Giacomo

Department of Oncology, Hospital of Prato, Azienda USL Toscana centro
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Giacomo Baldi
Favorite
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Giacomo Baldi
Favorite
(P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Giacomo Baldi
Favorite
(P 429) PATIENTS WITH ADVANCED EPITHELIOID HEMANGIOENDOTHELIOMA TREATED WITH SIROLIMUS: OUTCOME FOLLOWING SIROLIMUS DISCONTINUATION.
Giacomo Baldi
Favorite
Balint, Flávia

A.C.Camargo Cancer Center
(P 300) GASTROINTESTINAL STROMAL TUMORS (GIST) IN YOUNG ADULTS (YA): A BRAZILIAN COHORT OF PATIENTS
Flávia Balint
Favorite
Ballman, Karla

Mayo Clinic
(P 102) ANALYSIS OF BLOOD-BASED BIOMARKERS AS PROGNOSTIC FACTORS IN PATIENTS WITH EHE TREATED WITH TRAMETINIB IN SARC033
Karla Ballman
Favorite
(P 412) SARC044: A PHASE II TRIAL OF BEZUCLASTINIB IN COMBINATION WITH SUNITINIB IN PATIENTS WITH GIST WHO PROGRESSED ON SUNITINIB MONOTHERAPY
Karla Ballman
Favorite
Ballon, Jason

Sarcoma Oncology Center
(P 248) TNT: A PHASE 2 STUDY USING TALIMOGENE LAHERPAREPVEC, NIVOLUMAB, AND TRABECTEDIN FOR ADVANCED LEIOMYOSARCOMA AND LIPOSARCOMA (NCT # 03886311)
Jason Ballon
Favorite
Balzarini, Luca

Department of Radiology, Humanitas Clinical and Research Center, IRCCS, Rozzano, 20089, Italy.
(P 124) ASSESSMENT OF THE MECHANISMS OF ACTION OF ERIBULIN IN PATIENTS WITH ADVANCED LIPOSARCOMA THROUGH THE EVALUATION OF THE RADIOLOGICAL, FUNCTIONAL AND TISSUE RESPONSE: A MONOCENTRIC PROSPECTIVE STUDY
Luca Balzarini
Favorite
Banerji, Shantanu

CancerCare Manitoba
(P 293) CIC-REARRANGED SOFT TISSUE SARCOMAS: DOES CHEMOTHERAPY CHANGE NATURAL HISTORY AND PROGNOSIS? A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Shantanu Banerji
Favorite
Banga, Pankaj

Sarcoma Cancer Care Foundation
(P 188) BURDENS OF A CAREGIVER TO SARCOMA PATIENT AND HOW TO REDUCE THEM
Pankaj Banga
Favorite
Banga, Priyanka

Sarcoma Cancer Care Foundation
(P 188) BURDENS OF A CAREGIVER TO SARCOMA PATIENT AND HOW TO REDUCE THEM
Priyanka Banga
Favorite
Baniel, Claire

Stanford
(P 356) RADIATION PRACTICE PATTERNS AND OUTCOMES IN ADOLESCENT YOUNG ADULT PATIENTS WITH VISCERAL NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA
Claire Baniel
Favorite
Ban, Joy

Duke University
(P 15) HISTONE DEACETYLASE-3 PLAYS A ROLE IN THE METASTATIC POTENTIAL OF A SUBPOPULATION OF CELLS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Joy Ban
Favorite
Banks, Lauren

Memorial Sloan Kettering Cancer Center
(P 229) EXPRESSION OF TRANSPOSABLE ELEMENTS AND IKZF1 PREDICTS IMMUNE INFILTRATES IN SARCOMAS AND CORRELATES WITH OUTCOMES AFTER IMMUNE CHECKPOINT INHIBITION
Lauren Banks
Favorite
Baraban, Ezra

Johns hopkins
(P 152) NOVEL PAX3::MAML3 FUSION IDENTIFIED IN ALVEOLAR RHABDOMYOSARCOMA: USING DNA METHYLATION TO EXPANDE THE GENETIC SPECTRUM OF "FUSION POSITIVE" CASES
Ezra Baraban
Favorite
Barbone, Alessandro

IRCCS Humanitas Research Hospital
(P 155) PRIMARY MESENCHYMAL TUMORS OF THE HEART: A 8-YEARS, SINGLE INSTITUTION EXPERIENCE
Alessandro Barbone
Favorite
Barger, Zara

Children's Cancer Institute
(P 299) EXPLORING THE POTENTIAL OF PHOSPHOPROTEOMIC PROFILING FOR TARGET DISCOVERY IN HIGH-RISK OSTEOSARCOMA: A PATHWAY TO NOVEL THERAPIES?
Zara Barger
Favorite
Baril, Jackson

Indiana University School of Medicine
(P 384) REAL WORLD EXPERIENCE IN TREATING HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA: AN ULTRA-RARE VASCULAR TUMOR
Jackson Baril
Favorite
Barisella, Marta

ASST Fatebenefratelli Sacco
(P 137) TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS
Marta Barisella
Favorite
Barisella, Marta

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 420) CELLULARITY DEGREES IN PRIMARY MYXOID LIPOSARCOMA: ASSOCIATION WITH TUMOR IMMUNE INFILTRATE AND PATIENT OUTCOMES
Marta Barisella
Favorite
Barkauskas, Donald

Keck School of Medicine of the University of Southern California
(P 06) DIFFICULTIES IN ASSESSING THE PROGNOSTIC SIGNIFICANCE OF A NOVEL BIOMARKER IN THE CONTEXT OF A TISSUE BANKING STUDY
Donald Barkauskas
Favorite
Barker, Holly

WEHI - Walter and Eliza Hall Institute of Medical Research
(P 325) CAN PROTEOMICS PREDICT METASTATIC RELAPSE IN LEIOMYOSARCOMA? DEVELOPMENT OF AN 8 PROTEIN SIGNATURE IN A >350 SAMPLE STUDY INCLUDING A VALIDATION COHORT
Holly Barker
Favorite
Barlebo Ahlborn, Lise

Center for Genomic Medicine, Copenhagen University Hospital, Rigshospitalet
(P 104) CIRQUESARC: A NATIONAL PROSPECTIVE OBSERVATIONAL STUDY OF CIRCULATING TUMOR DNA AND QUALITY OF LIFE IN PATIENTS WITH SARCOMA – PRELIMINARY RESULTS FROM THE SURGICAL COHORT
Lise Barlebo Ahlborn
Favorite
Barlow, Adam

Leeds Teaching Hospitals NHS Trust
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Adam Barlow
Favorite
Barlow, Ray

SynOx Therapeutics
(P 401) A PHASE 3 MULTI-CENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO ASSESS THE EFFICACY AND SAFETY OF EMACTUZUMAB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR (TANGENT)
Ray Barlow
Favorite
Barradas da Silva, Ariana

University College London Hospital
(P 185) ADDRESSING THE GAP FOR SYMPTOM CONTROL THROUGH THE IMPLEMENTATION OF ENHANCED SUPPORTIVE CARE AT THE LONDON SARCOMA SERVICE
Ariana Barradas da Silva
Favorite
Barredo, Julio

University of Miami
(P 58) COMBINATORY THERAPIES UTILIZING INHIBITION OF CARBONIC ANHYDRASE IX TO POTENTIATE RESPONSE IN RELAPSED/REFRACTORY OSTEOSARCOMA
Julio Barredo
Favorite
Barresi, Sabina

Ospedale Pediatrico Bambino Gesù
(P 311) QUANTIFICATION OF TUMOUR-INFILTRATING IMMUNE CELLS THROUGH DECONVOLUTION OF DNA METHYLATION DATA IN EWING SARCOMAS
Sabina Barresi
Favorite
Barreto coelho, Priscila

University of Miami
(P 224) COMPREHENSIVE EVALUATION OF DNA DAMAGE RESPONSE PATHWAY ALTERATIONS AND ASSOCIATED IMMUNOTHERAPY-RESPONSE BIOMARKERS IN SARCOMAS
Priscila Barreto coelho
Favorite
(P 314) RETROSPECTIVE EVALUATION OF DISPARITIES IN ADOLESCENT AND YOUNG ADULT (AYA) PATIENTS WITH SYNOVIAL SARCOMA: A SINGLE INSTITUTION STUDY
Priscila Barreto coelho
Favorite
Barreto-Coelho, Priscila

University of Miami/Sylvester Comprehensive Cancer Center
(P 381) OLIGOMETASTATIC LEIOMYOSARCOMA: ASSOCIATION BETWEEN TREATMENT TYPE, METASTATIC PATTERN AND SURVIVAL
Priscila Barreto-Coelho
Favorite
Barr, Frederic

National Cancer Institute
(P 152) NOVEL PAX3::MAML3 FUSION IDENTIFIED IN ALVEOLAR RHABDOMYOSARCOMA: USING DNA METHYLATION TO EXPANDE THE GENETIC SPECTRUM OF "FUSION POSITIVE" CASES
Frederic Barr
Favorite
Barry, Janie

CEMTL
(P 212) REFERENCE SYSTEM OPTIMIZATION, ANALYSES OF THE IMPLEMENTATION OF A PROVINCIAL MULTIDISCIPLINARY SARCOMA NETWORK
Janie Barry
Favorite
Bartlett, Edmund

Memorial Sloan Kettering Cancer Center
(P 101) AN OPEN LABEL PHASE IIA STUDY EVALUATING THE PRELIMINARY EFFICACY OF INTRATUMORAL TIGILANOL TIGLATE (TT) IN ADVANCED AND/OR METASTATIC SOFT TISSUE SARCOMA (STS, NCT05755113)
Edmund Bartlett
Favorite
Basile, Georges

CIUSSS de l'Est-de-l'Île-de-Montréal
(P 212) REFERENCE SYSTEM OPTIMIZATION, ANALYSES OF THE IMPLEMENTATION OF A PROVINCIAL MULTIDISCIPLINARY SARCOMA NETWORK
Georges Basile
Favorite
Basit, Raja Haseeb

Queen Elizabeth Hospital
(P 383) PRE-OPERATIVE SPLIT RENAL FUNCTION RADIONUCLIDE IMAGING IN SURGICAL PLANNING FOR MULTI-VISCERAL RESECTION OF RETROPERITONEAL SARCOMA: A RETROSPECTIVE COHORT STUDY
Raja Haseeb Basit
Favorite
Baslan, Timour

University of Pennsylvania
(P 129) ELUCIDATING THE EVOLUTIONARY DYNAMICS OF DDLS LIPOSARCOMA USING SINGLE-CELL SEQUENCING AND MATHEMATICAL LINEAGE TRACING
Timour Baslan
Favorite
Bastianelli, Wynn

Children's Hospital of Philadelphia
(P 318) SYNOVIAL SARCOMA REGISTRY AND BIOSPECIMEN REPOSITORY: DESCRIBING THE COHORT AND SURVIVAL OUTCOMES TO DATE
Wynn Bastianelli
Favorite
Batash, Ron

Orthopedic Oncology Unit, Barzilai Medical Center, Ashkelon, Israel
(P 182) A NOVEL MODEL FOR THE DIRECT REFERRAL OF ONCOLOGIC PATIENTS IN A PUBLIC HEALTH CARE SYSTEM
Ron Batash
Favorite
(P 252) A NOVEL MULTIDISCIPLINARY SURGICAL APPROACH TO PERIPHERAL NERVE SHEATH TUMORS AND SOFT TISSUE SARCOMAS.
Ron Batash
Favorite
Bauer, Sebastian

Department of Medical Oncology, Sarcoma Center, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, and German Cancer Consortium (DKTK), Partner Site University Hospital Essen
(P 173) IN VITRO PROFILING OF IDRX-42 AGAINST SECONDARY MUTATIONS FOUND IN TKI-RESISTANT GIST
Sebastian Bauer
Favorite
(P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE
Sebastian Bauer
Favorite
Baumhoer, Daniel

University Hospital Basel
(P 03) CDK4 IS CO-AMPLIFIED WITH EITHER TP53 PROMOTER GENE FUSIONS OR MDM2 THROUGH DISTINCT MECHANISMS IN OSTEOSARCOMA
Daniel Baumhoer
Favorite
(P 26) SARCDBASE: A TOOL FOR DETECTION OF GENETIC ALTERATIONS IN SARCOMA
Daniel Baumhoer
Favorite
(P 56) CHROME: PREDICTING CHONDROSARCOMA RISK OUTCOME FROM METHYLATION
Daniel Baumhoer
Favorite
(P 114) METHYLOME PROFILING OF CARTILAGE TUMOURS: A PROMISING NEW TOOL FOR BIOPSY MATERIAL?
Daniel Baumhoer
Favorite
Bayer, Jack

Atlantic Health System
(P 260) EMERGING TECHNOLOGY IN ORTHOPEDIC ONCOLOGY: ROBOTIC ARM-ASSISTED TOTAL KNEE ARTHROPLASTY HAS EXCEPTIONAL FUNCTION OUTCOMES FOR PATIENTS WITH BENIGN AND MALIGNANT MUSCULOSKELETAL DISEASE
Jack Bayer
Favorite
(P 266) LONG STEM CEMENTED ROBTIC ARM-ASSISTED TOTAL HIP ARTHROPLASTY: OUTCOMES IN PATIENTS WITH PRIOR ONCOLOGIC DISEASE
Jack Bayer
Favorite
(P 405) LIPOSOMAL BUPIVACAINE DOESN'T REDUCE NARCOTIC USE OR PAIN SCORES COMPARED TO A MULTIDRUG COCKTAIL FOLLOWING SOFT TISSUE TUMOR REMOVAL: PRELIM RESULTS OF A PROSPECTIVE, RANDOMIZED DOUBLE-BLINDED STUDY
Jack Bayer
Favorite
Bayer, Paige

Adaptimmune
(P 202) IMPACT OF AFAMI-CEL ON THE HEALTH STATE OF PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR MYXOID/ROUND CELL LIPOSARCOMA: COHORT 1 OF SPEARHEAD-1
Paige Bayer
Favorite
Bay, Jacques-Olivier

CHU de Clermont-Ferrand
(P 169) FRENCH LONG TERM REGISTRY WITH LONGITUDINAL FOLLOW UP OF PDGFRA D842V GIST PATIENTS (AVIATOR2020)
Jacques-Olivier Bay
Favorite
Bazzurri, Serena

Department of Medical Oncology, Hospital of Prato, Prato, Italy
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Serena Bazzurri
Favorite
Beale, Holly

UC Santa Cruz
(P 147) INVESTIGATING THE POTENTIAL OF EXTRACELLULAR VESICLE BIOMARKERS IN SYNOVIAL SARCOMA DETECTION
Holly Beale
Favorite
(P 295) DEFINING OSTEOSARCOMA HETEROGENEITY: CONSENSUS CLUSTERING REVEALS GENE EXPRESSION SUBTYPES
Holly Beale
Favorite
Beal, Juliana

Hospital Israelita Albert Einstein
(P 122) ACTIONABLE FUSIONS IN DEDIFFERENTIATED LIPOSARCOMA: AN ANALYSIS OF 402 CASES IN THE AACR GENIE DATABASE
Juliana Beal
Favorite
(P 141) COMPREHENSIVE GENOMIC PROFILING OF PATIENTS DIAGNOSED WITH SARCOMA IN BRAZIL: MOLECULAR PROFILE AND ACTIONABILITY
Juliana Beal
Favorite
Beane, Joal

The Ohio State University
(P 136) TARGETING MIR-138-5P TO TREAT DEDIFFERENTIATED LIPOSARCOMA
Joal Beane
Favorite
Beaulieu, Marie-Eve

Peptomyc, S.L.
(P 408) OSTEOMYC: A PHASE 2 PILOT STUDY TO EVALIATE THE SAFETY AND THE ANTITUMOR ACTIVITY OF THE MYC INHIBITOR OMO-103 ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH ADVANCED HIGH GRADE OSTEOSARCOMA
Marie-Eve Beaulieu
Favorite
Bedadala, Mayur

University of Miami, Sylvester Comprehensive Cancer Center
(P 358) RADIOMIC EVALUATION OF MRIS IN PATIENTS WITH SOFT TISSUE SARCOMA TREATED WITH STEREOTACTIC BOSY RADIATION THERAPY
Mayur Bedadala
Favorite
Beird, Hannah

MD Anderson Cancer Center
(P 233) IMMUNE CLASSES OF LEIOMYOSARCOMA DRIVEN BY B CELL INFILTRATE AND CTLA4 EXPRESSION
Hannah Beird
Favorite
(P 398) PREDICTORS OF EFFICACY IN PATIENTS WITH SOFT TISSUE SARCOMAS TREATED WITH PAZOPANIB
Hannah Beird
Favorite
Bektas, Aaron

Washington University in St. Louis School of Medicine
(P 149) LACK OF CORRELATION OF FDG-PET/CT SUV MAXIMUM AND MALIGNANT TRANSFORMATION IN NEUROFIBROMATOSIS TYPE 1-RELATED PLEXIFORM NEUROFIBROMAS
Aaron Bektas
Favorite
Belayneh, Rebekah

University of Pittsburgh Medical Center
(P 117) THE TUMOR IMMUNE MICROENVIRONMENT OF DEDIFFERENTIATED SARCOMAS: DIGITAL SPATIAL PROFILING SHOWS IMMUNE TRANSCRIPTIONAL DIFFERENCES BETWEEN DEDIFFERENTIATED LIPOSARCOMA AND CHONDROSARCOMA
Rebekah Belayneh
Favorite
Bellan, Elena

University of Padua
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Elena Bellan
Favorite
Bello, Alexa

The University of Texas MD Anderson Cancer Center
(P 398) PREDICTORS OF EFFICACY IN PATIENTS WITH SOFT TISSUE SARCOMAS TREATED WITH PAZOPANIB
Alexa Bello
Favorite
Bellotti, Chiara

Istituto Ortopedico Rizzoli IRCCS, Osteoncology- Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, Bologna, Italy
(P 336) IMPROVEMENT OF PHOTODYNAMIC THERAPY IN SARCOMA: IN VITRO VALIDATION ON OSTEOSARCOMA AND MYXOFIBROSARCOMA
Chiara Bellotti
Favorite
Bell, Timothy

SpringWorks Therapeutics, Inc.
(P 34) DESMOID TUMOR COHORT CREATION AND CHARACTERISTICS IN THE VETERANS AFFAIRS (VA) NATIONAL DATABASE
Timothy Bell
Favorite
Belzarena, Ana

University of Missouri
(P 62) DOES LIQUID NITROGEN RECYCLED AUTOGRAFT FOR TREATMENT OF BONE SARCOMA IMPACT LOCAL RECURRENCE RATE? A SYSTEMATIC REVIEW
Ana Belzarena
Favorite
(P 254) ATYPICAL FEMUR FRACTURE IN A TEENAGER ON CHRONIC IMATINIB THERAPY
Ana Belzarena
Favorite
Benavente, Mónica

Hospital General Universitario Gregorio Marañón
(P 432) THE ROLE OF SYSTEMIC TREATMENT IN ADVANCED SOLITARY FIBROUS TUMORS: EXPERIENCE AT A REFERRAL CENTER.
Mónica Benavente
Favorite
BENMAMECHE-MEDJAHED, Sakina

CENTRE LEON BERARD
(P 169) FRENCH LONG TERM REGISTRY WITH LONGITUDINAL FOLLOW UP OF PDGFRA D842V GIST PATIENTS (AVIATOR2020)
Sakina BENMAMECHE-MEDJAHED
Favorite
Ben-Neriah, Yinon

The Hebrew University of Jerusalem
(P 402) A PILOT STUDY OF BTX-A51 IN PATIENTS WITH METASTATIC AND/OR RECURRENT LIPOSARCOMAS CHARACTERIZED BY MDM2 AMPLIFICATIONS
Yinon Ben-Neriah
Favorite
Bennett, Alexandra

Mayo Clinic
(P 210) RADIATION-ASSOCIATED ANGIOSARCOMA OF THE BREAST (RAASB): A NOMOGRAM FOR PREDICTING RECURRENCE AND PROGNOSIS
Alexandra Bennett
Favorite
Benson, charlotte

The Royal Marsden Hospital
(P 183) A RETROSPECTIVE STUDY OF THE EFFECTS OF PATIENT, DISEASE, AND TREATMENT FACTORS ON SURVIVAL OUTCOMES IN PATIENTS WITH SOFT TISSUE SARCOMA BRAIN METASTASES
charlotte Benson
Favorite
Beretta, Alessia

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 137) TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS
Alessia Beretta
Favorite
Bergamaschi, Laura

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 420) CELLULARITY DEGREES IN PRIMARY MYXOID LIPOSARCOMA: ASSOCIATION WITH TUMOR IMMUNE INFILTRATE AND PATIENT OUTCOMES
Laura Bergamaschi
Favorite
Bergonio, Jessica

University of California Davis
(P 08) ELUCIDATING THE ROLE OF YAP IN SARCOMA DEVELOPMENT
Jessica Bergonio
Favorite
Berndsen, Marta

Sahlgrenska University Hospital
(P 20) LEIOMYOSARCOMA OF THE THORACIC AORTA - A RARE CASE REPORT
Marta Berndsen
Favorite
(P 170) GASTRIN RELEASING PEPTIDE RECEPTOR EXPRESSION IN GASTROINTESTINAL STROMAL TUMORS (GIST)
Marta Berndsen
Favorite
Bernstein, Bradley

Dana-Farber Cancer Institute, Ludwig Center at Harvard Medical School
(P 371) ELUCIDATING THE CLINICAL UTILITY OF TARGETED GENE EXPRESSION PROFILING IN RETROPERITONEAL LIPOSARCOMA
Bradley Bernstein
Favorite
Bernthal, Nicholas

University of California Los Angeles
(P 43) SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
Nicholas Bernthal
Favorite
Berrino, Enrico

Candiolo Cancer Institute, FPO - IRCCS
(P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Enrico Berrino
Favorite
Bertolotti, Alessia

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 137) TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS
Alessia Bertolotti
Favorite
(P 420) CELLULARITY DEGREES IN PRIMARY MYXOID LIPOSARCOMA: ASSOCIATION WITH TUMOR IMMUNE INFILTRATE AND PATIENT OUTCOMES
Alessia Bertolotti
Favorite
Bertulli, Rossella

Mesenchymal and rare cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(P 171) GASTROINTESTINAL STROMAL TUMOURS (GISTS) IN NEUROFIBROMATOSIS TYPE (NF1): A SINGLE-CENTER OBSERVATIONAL RETROSPECTIVE STUDY
Rossella Bertulli
Favorite
Bertuzzi, Alexia

Humanitas Research Hospital
(P 124) ASSESSMENT OF THE MECHANISMS OF ACTION OF ERIBULIN IN PATIENTS WITH ADVANCED LIPOSARCOMA THROUGH THE EVALUATION OF THE RADIOLOGICAL, FUNCTIONAL AND TISSUE RESPONSE: A MONOCENTRIC PROSPECTIVE STUDY
Alexia Bertuzzi
Favorite
(P 155) PRIMARY MESENCHYMAL TUMORS OF THE HEART: A 8-YEARS, SINGLE INSTITUTION EXPERIENCE
Alexia Bertuzzi
Favorite
(P 290) ARTIFICIAL INTELLIGENCE-BASED COMPARISON OF ADULT AND ADOLESCENT AND YOUNG ADULTS (AYA) SARCOMAS: A PILOT STUDY
Alexia Bertuzzi
Favorite
(P 431) REAL-WORLD EXPERIENCE OF EFFICACY AND TOLERABILITY OF CONTINUOS INFUSION IFOSFAMIDE AMONG ADVANCED SOFT TISSUE AND BONE SARCOMAS PATIENTS: A SINGLE CENTRE RETROSPECTIVE COHORT.
Alexia Bertuzzi
Favorite
Berz, David

Valkyrie Clinical Trials
(P 95) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN PATIENTS WITH CHONDROSARCOMA: UPDATED RESULTS FROM A PHASE 1 STUDY
David Berz
Favorite
Bestul, Daniel

Adaptimmune
(P 202) IMPACT OF AFAMI-CEL ON THE HEALTH STATE OF PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR MYXOID/ROUND CELL LIPOSARCOMA: COHORT 1 OF SPEARHEAD-1
Daniel Bestul
Favorite
Beveridge, Robert Diaz

Hospital Universitario y Politécnico La Fe
(P 234) IMMUNOSARC II MASTER TRIAL (PHASE II OF SUNITINIB AND NIVOLUMAB): RESULTS FROM THE CLEAR CELL SARCOMA (CCS) COHORT. A GEIS, ISG, AND UCL STUDY
Robert Diaz Beveridge
Favorite
Bevill, Samantha

Dana-Farber Cancer Institute
(P 371) ELUCIDATING THE CLINICAL UTILITY OF TARGETED GENE EXPRESSION PROFILING IN RETROPERITONEAL LIPOSARCOMA
Samantha Bevill
Favorite
Bhadri, Vivek

Chris O’Brien Lifehouse
(P 157) REAL WORLD CLINICAL UTILITY OF NEXT GENERATION SEQUENCING IN ADOLESCENT AND YOUNG ADULT SARCOMA PATIENTS
Vivek Bhadri
Favorite
Bhalla, Angela

The University of Texas MD Anderson Cancer Center
(P 360) TREATMENT OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR WITH BROMODOMAIN EXTRA TERMINAL INHIBITOR (BETI) IN COMBINATION WITH RADIOTHERAPY
Angela Bhalla
Favorite
Bhandari, Pashupati

University of Saskatchewan
(P 01) A PILOT STUDY ON SINGLE-NUCLEUS RNA SEQUENCING IN CANINE SOFT TISSUE SARCOMAS
Pashupati Bhandari
Favorite
Bhaskar, Shanthi

University of Pittsburgh
(P 66) EWING TUMORS WITH STAG2 LOSS DEMOSNTRATE ALTERED INTERFERON SIGNATURES AND IMPAIRED CXCL10 EXPRESSION
Shanthi Bhaskar
Favorite
Bhatia, Himanshi

Washington University
(P 10) GENERATION OF A CHROMOSOME 8 GAIN;NF1-/- HUMAN INDUCED PLURIPOTENT STEM CELL DERIVED SCHWANN CELL PRECURSOR MODEL
Himanshi Bhatia
Favorite
Bialick, Steven

University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center
(P 224) COMPREHENSIVE EVALUATION OF DNA DAMAGE RESPONSE PATHWAY ALTERATIONS AND ASSOCIATED IMMUNOTHERAPY-RESPONSE BIOMARKERS IN SARCOMAS
Steven Bialick
Favorite
(P 253) ASSESSING THE LINK BETWEEN MYXOFIBROSARCOMA RECURRENCE AND TREATMENT ORDER: A MULTIDISCIPLINARY RETROSPECTIVE COHORT STUDY
Steven Bialick
Favorite
(P 296) DISPARITIES IN OVERALL SURVIVAL FOR AYA PATIENTS WITH EWINGS SARCOMA: A RETROSPECTIVE COHORT STUDY AT A SINGLE SARCOMA CENTER
Steven Bialick
Favorite
(P 314) RETROSPECTIVE EVALUATION OF DISPARITIES IN ADOLESCENT AND YOUNG ADULT (AYA) PATIENTS WITH SYNOVIAL SARCOMA: A SINGLE INSTITUTION STUDY
Steven Bialick
Favorite
(P 412) SARC044: A PHASE II TRIAL OF BEZUCLASTINIB IN COMBINATION WITH SUNITINIB IN PATIENTS WITH GIST WHO PROGRESSED ON SUNITINIB MONOTHERAPY
Steven Bialick
Favorite
Bickley, Sorrel

Sarcoma UK
(P 201) GLOBAL CROSS-SECTIONAL SURVEY ON SARCOMA DIAGNOSIS PATHWAY: A CURRENT STATE ANALYSIS
Sorrel Bickley
Favorite
Bilbao Cortes, Daniel

University of Miami Miller School of Medicine
(P 434) UTILIZATION OF IMAGING MASS CYTOMETRY TO EVALUATE THE IMMUNE LANDSCAPE OF PEDIATRIC AND ADULT PATIENTS WITH SARCOMA TREATED WITH AN AUTOLOGOUS DENDRITIC CELL VACCINE
Daniel Bilbao Cortes
Favorite
Billington, Lucy

University College London Hospital
(P 185) ADDRESSING THE GAP FOR SYMPTOM CONTROL THROUGH THE IMPLEMENTATION OF ENHANCED SUPPORTIVE CARE AT THE LONDON SARCOMA SERVICE
Lucy Billington
Favorite
Binitie, Odion

Moffitt cancer center
(P 150) MODERN BIOPSY PRACTICE PATTERNS: A SURVEY OF THE MSTS MEMBERSHIP
Odion Binitie
Favorite
(P 257) COMPARATIVE OUTCOMES OF CONSTRAINED ACETABULAR LINERS VS. DUAL MOBILITY CUPS IN COMPLEX HIP RECONSTURCTION FOR METASTATIC BONE DISEASE
Odion Binitie
Favorite
(P 262) EVALUATION OF STAGED RESECTION WITH TEMPORIZING VAC OF SOFT TISSUE SARCOMAS
Odion Binitie
Favorite
(P 263) HEMI- VS. REVERSE SHOULDER ARTHROPLASTY OUTCOMES FOLLOWING PROXIMAL HUMERAL ONCOLOGIC RESECTION
Odion Binitie
Favorite
(P 279) SIGNIFICANCE OF TIP-APEX DISTANCE IN ACTUAL AND IMPENDING PATHOLOGICAL FRACTURES OF THE PROXIMAL FEMUR
Odion Binitie
Favorite
(P 347) CAN UPFRONT RADIOTHERAPY PRECLUDE THE NEED FOR OPERATIVE STABILIZATION IN IMPENDING EXTREMITY FRACTURES FROM LUNG CANCER METASTASES?
Odion Binitie
Favorite
Bishop, Andrew

The University of Texas MD Anderson Cancer Center
(P 130) HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RESECTABLE RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA (DDLPS) TREATED WITH NEOADJUVANT CHECKPOINT BLOCKADE IN A RANDOMIZED PHASE II CLINICAL TRIAL.
Andrew Bishop
Favorite
Bishop, Michael

St. Jude Children's Research Hospital
(P 50) ANALYSIS OF CLINICAL FEATURES AND OUTCOMES FOR PATIENTS WITH MULTIFOCAL OSTEOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Michael Bishop
Favorite
(P 288) ANGIOA: A SAFETY AND TOLERABILITY STUDY OF TRIPLE ANTI-ANGIOGENIC THERAPY COMBINED WITH PD-L1 BLOCKADE IN PEDIATRIC, ADOLESCENT AND YOUNG ADULT RECURRENT/REFRACTORY SOLID TUMORS
Michael Bishop
Favorite
Bishr, Mai

The Royal Marsden Hospital
(P 183) A RETROSPECTIVE STUDY OF THE EFFECTS OF PATIENT, DISEASE, AND TREATMENT FACTORS ON SURVIVAL OUTCOMES IN PATIENTS WITH SOFT TISSUE SARCOMA BRAIN METASTASES
Mai Bishr
Favorite
Bisschop, Peter

Amsterdam Univeristy Medical Center
(P 42) RANKL-INHIBITION FOR GIANT CELL LESIONS OF THE JAW: A RETROSPECTIVE COHORT ANALYSIS
Peter Bisschop
Favorite
Bissinger, Stefan

iOmx AG
(P 337) OMX-0407 A NOVEL SPECTRUM-SELECTIVE SMALL MOLECULE KINASE INHIBITOR IS ACTIVE IN THE TREATMENT OF ANGIOSARCOMA
Stefan Bissinger
Favorite
Black, Ralph

Fred Hutchinson Research Center
(P 222) ANALYSIS OF THE CITN-13 SARCOMA ARM: PEMBROLIZUMAB AND INTERFERON GAMMA FOR SYNOVIAL SARCOMA AND MYXOID/ ROUND CELL LIPOSARCOMA
Ralph Black
Favorite
Black, Vandy

Deciphera Pharmaceuticals, LLC
(P 403) DCC-3116 IN COMBINATION WITH RIPRETINIB FOR PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A PHASE 1/2 STUDY
Vandy Black
Favorite
Blakely, Andrew

Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
(P 163) CHARACTERIZATION OF INTRAHEPATIC RECURRENCE FOLLOWING LIVER-DIRECTED SURGERY IN PATIENTS WITH METASTATIC SDH-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST): RISE AND STABILIZATION OF THE GISTLETS
Andrew Blakely
Favorite
Blank, Alan

Rush University Medical Center
(P 31) CLINICAL CHALLENGES AND EVOLVING TREATMENT STRATEGIES IN DESMOID FIBROMATOSIS: A SINGLE INSTITUTION EXPERIENCE
Alan Blank
Favorite
(P 80) OUTCOMES AND MANAGEMENT OF POSITIVE MARGINS IN CHONDROSARCOMA WITH SOFT TISSUE EXTENSION: A CASE SERIES AND REVIEW OF LITERATURE
Alan Blank
Favorite
(P 92) THE IMPACT OF CHONDROSARCOMA WITH POSITIVE MARGINS AND EXTRAOSSEOUS EXTENSION ON PATIENT OUTCOMES
Alan Blank
Favorite
(P 126) CHARACTERIZING THE TRANSFORMATION AND DIAGNOSIS OF ATYPICAL LIPOMATOUS TUMOR OF THE EXTREMITIES TO DEDIFFERENTIATED LIPOSARCOMA: SINGLE INSTITUTIONAL OUTCOMES
Alan Blank
Favorite
(P 270) OPIOID USE IN IMPENDING VERSUS PATHOLOGIC PROXIMAL FEMUR FRACTURES
Alan Blank
Favorite
(P 271) OUTCOMES OF DISTAL FEMORAL REPLACEMENT VS INTERNAL FIXATION FOR METASTATIC BONE DISEASE OF THE DISTAL FEMUR
Alan Blank
Favorite
Blay, Jean-Yves

Centre Léon Bérard
(P 43) SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
Jean-Yves Blay
Favorite
(P 77) MULTI-PARAMETRICAL PROFILING OF CHONDROSARCOMA
Jean-Yves Blay
Favorite
(P 87) SAFETY AND EFFICACY OF OLUTASIDENIB, AN IDH1 MUTANT INHIBITOR, FOR THE TREATMENT OF RECURRENT/ RELAPSED LOCALLY ADVANCED OR METASTATIC IDH1 MUTATED CHONDROSARCOMA
Jean-Yves Blay
Favorite
Blay, Jean-Yves

Centre Leon Berard
(P 125) CHARACTERISTICS, MANAGEMENT AND SURVIVAL OF N=7314 LIPOSARCOMAS FROM THE NATIONWIDE NETSARC REGISTRY IN FRANCE SINCE 2010
Jean-Yves Blay
Favorite
Blay, Jean-Yves

Centre Léon Bérard and Université Claude Bernard, Lyon, France
(P 125) CHARACTERISTICS, MANAGEMENT AND SURVIVAL OF N=7314 LIPOSARCOMAS FROM THE NATIONWIDE NETSARC REGISTRY IN FRANCE SINCE 2010
Jean-Yves Blay
Favorite
Blay, Jean-Yves

Centre Léon Bérard
(P 169) FRENCH LONG TERM REGISTRY WITH LONGITUDINAL FOLLOW UP OF PDGFRA D842V GIST PATIENTS (AVIATOR2020)
Jean-Yves Blay
Favorite
(P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE
Jean-Yves Blay
Favorite
(P 202) IMPACT OF AFAMI-CEL ON THE HEALTH STATE OF PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR MYXOID/ROUND CELL LIPOSARCOMA: COHORT 1 OF SPEARHEAD-1
Jean-Yves Blay
Favorite
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Jean-Yves Blay
Favorite
(P 401) A PHASE 3 MULTI-CENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO ASSESS THE EFFICACY AND SAFETY OF EMACTUZUMAB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR (TANGENT)
Jean-Yves Blay
Favorite
Blazer, Dan

Duke University
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Dan Blazer
Favorite
Blomain, Erik

Thomas Jefferson University
(P 344) TRANSCRIPTOMIC ANALYSIS OF DESMOID TUMOR RESPONSE TO NIROGACESTAT: NOVEL MECHANISMS OF RESISTANCE?
Erik Blomain
Favorite
Bode, Beata

SwissSarcomaNetwork
(P 184) A SYSTEMATIC REVIEW ABOUT CLINICAL PROGNOSTIC MODELS FOR SARCOMAS
Beata Bode
Favorite
Bogani, Giorgio

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 160) UTERINE PECOMA: REPORT OF MOLECULAR AND CLINICAL FEATURES IN A SERIES OF PATIENTS TREATED AT A REFERRAL INSTITUTION
Giorgio Bogani
Favorite
Bogefors, Karolina

Dpt of oncology, Skane University Hospital, Lund, Sweden
(P 286) ADAMANTINOMA - LIKE EWING SARCOMA WITH ATYPICAL PRESENTATION AND FATAL OUTCOME IN 20-YEAR-OLD WOMAN - A CASE REPORT
Karolina Bogefors
Favorite
Bogossian, Ana

University of Calgary
(P 422) COMPARISON OF ANNOTATION METHODS FOR PAN-SARCOMA SINGLE CELL DATA
Ana Bogossian
Favorite
(P 424) CROSS-COHORT INTEGRATION AS A STRATEGY TO CLASSIFY IMMUNE CHECKPOINT BLOCKADE RESPONSE IN SARCOMA
Ana Bogossian
Favorite
BOLLARD, Julien

Centre Léon Bérard
(P 169) FRENCH LONG TERM REGISTRY WITH LONGITUDINAL FOLLOW UP OF PDGFRA D842V GIST PATIENTS (AVIATOR2020)
Julien BOLLARD
Favorite
Bompas, Emmanuelle

ICO
(P 125) CHARACTERISTICS, MANAGEMENT AND SURVIVAL OF N=7314 LIPOSARCOMAS FROM THE NATIONWIDE NETSARC REGISTRY IN FRANCE SINCE 2010
Emmanuelle Bompas
Favorite
(P 169) FRENCH LONG TERM REGISTRY WITH LONGITUDINAL FOLLOW UP OF PDGFRA D842V GIST PATIENTS (AVIATOR2020)
Emmanuelle Bompas
Favorite
Boni, Joseph

ADC Therapeutics
(P 116) QUANTITATIVE SYSTEMS PHARMACOLOGY MODELING OF MIPASETAMAB UZOPTERINE INTEGRATES KNOWLEDGE AND DEFINES DOSING STRATEGY FOR PATIENTS WITH SARCOMA
Joseph Boni
Favorite
Boni, Valentina

NEXT oncology Madrid
(P 337) OMX-0407 A NOVEL SPECTRUM-SELECTIVE SMALL MOLECULE KINASE INHIBITOR IS ACTIVE IN THE TREATMENT OF ANGIOSARCOMA
Valentina Boni
Favorite
Bonvalot, Sylvie

Institut Curie
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Sylvie Bonvalot
Favorite
Borcherding, Dana

Washington University in St. Louis School of Medicine
(P 145) EXPLORING L-TYPE AMINO ACID TRANSPORTER 1 (LAT1) AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)
Dana Borcherding
Favorite
(P 335) FOCAL ADHESION KINASE (FAK) IS A THERPEUTIC TARGET IN CHROMOSOME 8 GAIN-ASSOCIATED MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)
Dana Borcherding
Favorite
Borghi, Alessandra

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 376) IMPACT OF SITE OF ORIGIN ON THE PROGNOSIS OF PATIENTS WITH PRIMARY RESECTABLE NON-UTERINE ABDOMINAL LEIOMYOSARCOMA
Alessandra Borghi
Favorite
Borgions, Kathleen

UZ Leuven
(P 291) CASE REPORT: RADICAL EN BLOC MULTI-LEVEL SPONDYLECTOMY FOR A LOCALLY RECURRENT OSTEOSARCOMA
Kathleen Borgions
Favorite
Borgmeister, Kristin

Region Östergötland
(P 172) GIST WITH ATYPICAL MORPHOLOGY INITIALLY MISDIAGNOSED-THE IMPORTANCE OF BROAD IMMUNOCHEMISTRY-A CASE REPORT
Kristin Borgmeister
Favorite
Borgmeister, Kristin

Dpt of Oncology, Linköping University Hospital
(P 286) ADAMANTINOMA - LIKE EWING SARCOMA WITH ATYPICAL PRESENTATION AND FATAL OUTCOME IN 20-YEAR-OLD WOMAN - A CASE REPORT
Kristin Borgmeister
Favorite
Borinstein, Scott

Vanderbilt University Medical Center
(P 73) LONGER TIME INTERVAL BETWEEN NEOADJUVANT CHEMOTHERAPY AND SURGERY IS ASSOCIATED WITH DECREASED TUMOR PERCENT NECROSIS IN OSTEOSARCOMA
Scott Borinstein
Favorite
(P 199) FINANCIAL TOXICITY AMONG SARCOMA PATIENTS AND ASSOCIATED FACTORS
Scott Borinstein
Favorite
(P 264) INTRAOPERATIVE FROZEN BONE MARROW MARGINS: A HELP OR A HINDRANCE IN EWING SARCOMA RESECTION?
Scott Borinstein
Favorite
(P 268) LOWER TUMOR PERCENT NECROSIS IS ASSOCIATED WITH POSITIVE FINAL SURGICAL MARGINS IN OSTEOSARCOMA
Scott Borinstein
Favorite
(P 297) ESTABLISHING A PEDIATRIC, ADOLESCENT AND YOUNG ADULT COHORT OF SARCOMA PATIENTS TO STUDY ONCOLOGIC AND NON-ONCOLOGIC OUTCOMES
Scott Borinstein
Favorite
(P 309) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT SOFT TISSUE SARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Scott Borinstein
Favorite
Borkowska, Aneta

Maria Sklodowska-Curie National Research Institute of Oncology, Department of Soft Tissue/Bone Sarcoma and Melanoma, Warsaw Poland
(P 245) PRELIMINARY RESULTS FROM A PHASE 2 EFTISARC-NEO TRIAL OF NEOADJUVANT SOUBLE LAG-3 PROTEIN EFTILAGIMOD ALPHA, PEMBROLIZUMAB, AND CONCURRENT RADIOTHERAPY IN PATIENTS WITH RESECTABLE SOFT TISSUE SARCOMA
Aneta Borkowska
Favorite
Bosmans, Anne-Claire

Netherlands Cancer Institute
(P 317) SMARCB1-DEFICIENT SARCOMA OF THE GENITAL REGION/EPITHELIOID SARCOMA OF THE PROXIMAL TYPE VS EPITHELIOID SARCOMA OF THE DISTAL TYPE
Anne-Claire Bosmans
Favorite
Bouché, Olivier

CHU de Reims
(P 169) FRENCH LONG TERM REGISTRY WITH LONGITUDINAL FOLLOW UP OF PDGFRA D842V GIST PATIENTS (AVIATOR2020)
Olivier Bouché
Favorite
Bouchard-Fortier, Antoine

University of Calgary
(P 174) INCIDENCE, TREATMENT PATTERNS, AND SURVIVAL OUTCOMES FOR ADULT PATIENTS WITH GASTROINTESTINAL STROMAL TUMOURS (GIST) IN ALBERTA, CANADA FROM 2008 - 2022.
Antoine Bouchard-Fortier
Favorite
Boudhouche, Hanane

Gustave Roussy
(P 53) CHARACTERIZING THE SPATIAL TRANSCRIPTOMIC LANDSCAPE OF OSTEOSARCOMA FROM DIAGNOSIS TO RELAPSE
Hanane Boudhouche
Favorite
Bovee, Judith

LUMC
(P 56) CHROME: PREDICTING CHONDROSARCOMA RISK OUTCOME FROM METHYLATION
Judith Bovee
Favorite
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Judith Bovee
Favorite
(P 114) METHYLOME PROFILING OF CARTILAGE TUMOURS: A PROMISING NEW TOOL FOR BIOPSY MATERIAL?
Judith Bovee
Favorite
(P 349) LONG-TERM SURVIVAL OF PARTICIPANTS IN THE PASART-1 AND PASART-2 TRIALS OF NEO-ADJUVANT PAZOPANIB AND RADIOTHERAPY IN SOFT TISSUE SARCOMA
Judith Bovee
Favorite
Boye, Kjetil

Oslo University Hospital
(P 40) PEGYLATED LIPOSOMAL DOXORUBICIN IN SYMPTOMATIC DESMOID TUMOR
Kjetil Boye
Favorite
(P 411) PROPANE AN OPEN LABEL PHASE 2 STUDY ON PROPRANOLOL AND PEMBROLIZUMAB IN ADVANCED ANGIOSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA A SCANDINAVIAN SARCOMA GROUP COLLABORATION
Kjetil Boye
Favorite
Bradic, Martina

Memorial Sloan Kettering Cancer Center
(P 121) ACQUIRED CYCLIN D AMPLIFICATION IS A MECHANISM FOR RESISTANCE TO CDK4/6 INHIBITORS IN DEDIFFERENTIATED LIPOSARCOMA
Martina Bradic
Favorite
(P 229) EXPRESSION OF TRANSPOSABLE ELEMENTS AND IKZF1 PREDICTS IMMUNE INFILTRATES IN SARCOMAS AND CORRELATES WITH OUTCOMES AFTER IMMUNE CHECKPOINT INHIBITION
Martina Bradic
Favorite
Brahmi, Mehdi

Centre Leon Berard
(P 125) CHARACTERISTICS, MANAGEMENT AND SURVIVAL OF N=7314 LIPOSARCOMAS FROM THE NATIONWIDE NETSARC REGISTRY IN FRANCE SINCE 2010
Mehdi Brahmi
Favorite
(P 169) FRENCH LONG TERM REGISTRY WITH LONGITUDINAL FOLLOW UP OF PDGFRA D842V GIST PATIENTS (AVIATOR2020)
Mehdi Brahmi
Favorite
Bramer, Jos

Amsterdam University Medical Centers
(P 319) THE SURVIVAL DISPARITY BETWEEN CHILDREN AND ADOLESCENTS & YOUNG ADULTS WITH EWING SARCOMA IN THE NETHERLANDS DID NOT CHANGE SINCE THE 1990S DESPITE IMPROVED SURVIVAL: A POPULATION-BASED STUDY
Jos Bramer
Favorite
Braun, David

Yale University
(P 98) A MULTIEPITOPE MRNA VACCINE FOR KAPOSI SARCOMA: AN IMMUNOINFORMATIC APPROACH
David Braun
Favorite
Brega, Nicoletta

Bayer Pharmaceuticals
(P 393) EFFICACY AND SAFETY OF LAROTRECTINIB AS FIRST-LINE TREATMENT IN PATIENTS WITH TRK FUSION SARCOMAS
Nicoletta Brega
Favorite
Bregman, Dana
(P 353) PREDICTING WOUND COMPLICATIONS FOLLOWING SOFT-TISSUE SARCOMA RESECTION AMONG PATIENTS WHO RECEIVED PRE-OPERATIVE RADIATION
Dana Bregman
Favorite
Brems, Jillian

National Cancer Institute
(P 414) TENOSYNOVIAL GIANT CELL TUMOR IN CHILDREN: INTERIM RESULTS FROM A PHASE 1 STUDY OF TURALIO®
Jillian Brems
Favorite
Brennan, Bernadette

Royal Manchester Children's Hospital
(P 60) DIAGNOSIS AND MANAGEMENT OF PAEDIATRIC EWING SARCOMA PATIENTS IN ENGLAND 2014-2017: A COMPARISON OF NATIONAL DATA WITH THE EURO-EWING 2012 CLINICAL TRIAL
Bernadette Brennan
Favorite
Brewer, Martin

The Royal Marsden Hospital
(P 183) A RETROSPECTIVE STUDY OF THE EFFECTS OF PATIENT, DISEASE, AND TREATMENT FACTORS ON SURVIVAL OUTCOMES IN PATIENTS WITH SOFT TISSUE SARCOMA BRAIN METASTASES
Martin Brewer
Favorite
Brich, Silvia

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 137) TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS
Silvia Brich
Favorite
(P 420) CELLULARITY DEGREES IN PRIMARY MYXOID LIPOSARCOMA: ASSOCIATION WITH TUMOR IMMUNE INFILTRATE AND PATIENT OUTCOMES
Silvia Brich
Favorite
Brien, Earl

Cedars-Sinai Medical Center
(P 140) CIRCULATING TUMOR DNA AS A TOOL OF SURVEILLANCE AND EARLY INDICATOR OF RELAPSE IN SARCOMA PATIENTS
Earl Brien
Favorite
Brien, Gerard

Institute of Genetics and Cancer University of Edinburgh
(P 27) SUMO2 INHIBITION REVERSES ABERRANT EPIGENETIC REWIRING DRIVEN BY SYNOVIAL SARCOMA FUSION ONCOPROTEINS AND IMPAIRS SARCOMAGENESIS
Gerard Brien
Favorite
Brigman, Brian

Duke University Hospital
(P 54) CHONDROBLASTIC OSTEOSARCOMA IS A RISK FACTOR FOR LOCAL RECURRENCE IN PATIENTS WITH SKELETAL OSTEOSARCOMA
Brian Brigman
Favorite
(P 142) CORE NEEDLE BIOPSY OF PERIACETABULAR CHONDROSARCOMA OFTEN RESULTS IN UNDER-GRADING BUT DOES NOT CHANGE MANAGEMENT BY EXPERIENCED ORTHOPAEDIC ONCOLOGISTS.
Brian Brigman
Favorite
Brigoni, Hugo

Angel H. Roffo Institute of Oncology
(P 273) PRIMARY SOFT-TISSUE SARCOMAS OF THE UPPER LIMBS
Hugo Brigoni
Favorite
Briones Miranda, María Paz

Facultad Psicología. Universidad Complutense de Madrid
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
María Paz Briones Miranda
Favorite
Brockman, Qierra

University of Iowa
(P 12) GENETIC LANDSCAPE OF MPNST DETERMINES METABOLIC STRATEGIES AND THERAPEUTIC OPPORTUNITIES FOR COPING WITH REDOX STRESS
Qierra Brockman
Favorite
(P 395) INTEGRATED EPIGENETIC ANALYSES IDENTIFY A MULTI-SARCOMA DNA METHYLATION SIGNATURE OF TUMOR PROGRESSION AND METASTASIS
Qierra Brockman
Favorite
Brockstein, Bruce

NorthShore University HealthSystem
(P 247) THE REAL-WORLD EFFICACY OF IMMUNE CHECKPOINT INHIBITORS WITH CONCURRENT RADIATION OR SURGERY IN MULTIMODAL TREATMENT OF SOFT TISSUE SARCOMAS: A RETROSPECTIVE STUDY
Bruce Brockstein
Favorite
Brohl, Andrew

Moffitt Cancer Center
(P 237) INTRALESIONAL ADMINISTRATION OF TALIMOGENE LAHERPAREPVEC (T-VEC) INDUCES TUMOR REGRESSION IN PATIENTS WITH CUTANEOUS ANGIOSARCOMA
Andrew Brohl
Favorite
Broida, Samuel

Mayo Clinic
(P 267) LONG-TERM FUNCTIONAL OUTCOMES OF SHOULDER ARTHRODESIS FOR TUMOR RESECTION
Samuel Broida
Favorite
(P 294) COMPARING HIGH-GRADE NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA IN ADULT AND PEDIATRIC POPULATIONS
Samuel Broida
Favorite
Brookes, Marcus

The Newcastle upon Tyne Hospitals NHS Foundation Trust
(P 22) MECHANISMS OF PREFERENTIAL TUMOUR UPTAKE OF INDOCYANINE GREEN IN SARCOMA
Marcus Brookes
Favorite
(P 269) LYMPHOEDEMA FOLLOWING LIMB SALVAGE SURGERY FOR EXTREMITY SARCOMA: A RETROSPECTIVE ANALYSIS OF 282 PATIENTS
Marcus Brookes
Favorite
(P 323) AN IN-VITRO INVESTIGATION OF 5-AMINOLEVULINIC ACID MEDIATED PHOTODYNAMIC THERAPY IN SOFT-TISSUE SARCOMA
Marcus Brookes
Favorite
Brosius, Samantha

Memorial Sloan Kettering Cancer Center
(P 338) PRECLINICAL EFFICACY OF DAN-222, A NOVEL POLYMERIC NANOPARTICLE, IN PEDIATRIC SOLID TUMOR MODELS
Samantha Brosius
Favorite
Broski, Julie

The University of Kansas Medical Center
(P 36) EARLY REAL-WORLD EXPERIENCE WITH THE USE OF NIROGACESTAT FOR THE TREATMENT OF DESMOID FIBROMATOSIS
Julie Broski
Favorite
Brossier, Nicole

Washington University in St. Louis School of Medicine
(P 149) LACK OF CORRELATION OF FDG-PET/CT SUV MAXIMUM AND MALIGNANT TRANSFORMATION IN NEUROFIBROMATOSIS TYPE 1-RELATED PLEXIFORM NEUROFIBROMAS
Nicole Brossier
Favorite
Brothers, Shaun P.

University of Miami
(P 58) COMBINATORY THERAPIES UTILIZING INHIBITION OF CARBONIC ANHYDRASE IX TO POTENTIATE RESPONSE IN RELAPSED/REFRACTORY OSTEOSARCOMA
Shaun P. Brothers
Favorite
Brouwer de Koning, Irene

Netherlands Cancer Institute
(P 28) THE INFLUENCE OF MARGINS ON OUTCOME IN CUTANEOUS LOCATED SOFT TISSUE SARCOMAS IN THE HEAD AND NECK
Irene Brouwer de Koning
Favorite
Brouwers, Xander
(P 291) CASE REPORT: RADICAL EN BLOC MULTI-LEVEL SPONDYLECTOMY FOR A LOCALLY RECURRENT OSTEOSARCOMA
Xander Brouwers
Favorite
Brown, Christopher

Seattle Children's Research Institute
(P 226) EARLY EXPERIENCE ON ENLIGHTEN-01: A PHASE 1 STUDY OF BISPECIFIC ADAPTER MOLECULE- CONTROLLED FOLATE RECEPTOR CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY OSTEOSARCOMA
Christopher Brown
Favorite
Browne, MaKenna

Duke University
(P 301) GENOME-WIDE CRISPR/CAS9 VIABILITY SCREENS UNCOVER NOVEL GENETIC DEPENDENCIES IN CIC::DUX4 SARCOMA
MaKenna Browne
Favorite
(P 303) INVESTIGATING THE THERAPEUTIC POTENTIAL OF TRIPTOLIDE PRODRUG, MINNELIDE, AS A TREATMENT ALTERNATIVE FOR CIC-DUX4 SARCOMA
MaKenna Browne
Favorite
Brown, Joel

Moffitt
(P 421) CHARACTERIZATION OF INTRA-PATIENT, INTER-LESIONAL RESPONSE AND RESISTANCE DYNAMICS IN METASTATIC, FUSION-POSITIVE RHABDOMYOSARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Joel Brown
Favorite
Brown, Leanne

Yale-New Haven Hospital
(P 371) ELUCIDATING THE CLINICAL UTILITY OF TARGETED GENE EXPRESSION PROFILING IN RETROPERITONEAL LIPOSARCOMA
Leanne Brown
Favorite
Brown, Maia

University of Pittsburgh School of Medicine
(P 240) INVESTIGATING MACROPHAGE POPULATION VARIABILITY IN METASTATIC SARCOMA SAMPLES
Maia Brown
Favorite
Brugger, Jon

University Hospital Basel
(P 114) METHYLOME PROFILING OF CARTILAGE TUMOURS: A PROMISING NEW TOOL FOR BIOPSY MATERIAL?
Jon Brugger
Favorite
Brun Knudsen, Christina

Department of Oncology, Herlev University Hospital
(P 104) CIRQUESARC: A NATIONAL PROSPECTIVE OBSERVATIONAL STUDY OF CIRCULATING TUMOR DNA AND QUALITY OF LIFE IN PATIENTS WITH SARCOMA – PRELIMINARY RESULTS FROM THE SURGICAL COHORT
Christina Brun Knudsen
Favorite
Brunello, Antonella

Oncology 1 Unit, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Antonella Brunello
Favorite
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Antonella Brunello
Favorite
Brunello, Antonella

Istituto oncologico Veneto
(P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Antonella Brunello
Favorite
Brunello, Antonella

Oncology 1 Unit, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
(P 429) PATIENTS WITH ADVANCED EPITHELIOID HEMANGIOENDOTHELIOMA TREATED WITH SIROLIMUS: OUTCOME FOLLOWING SIROLIMUS DISCONTINUATION.
Antonella Brunello
Favorite
Bruno, Tullia

Department of Immunology, University of Pittsburgh
(P 240) INVESTIGATING MACROPHAGE POPULATION VARIABILITY IN METASTATIC SARCOMA SAMPLES
Tullia Bruno
Favorite
Brusco, Silvia

Department of Oncology, University of Turin
(P 345) TRANSCRIPTOMIC AND PHENOTYPIC CHARACTERIZATION OF AN IMMUNOCOMPETENT LEIOMYOSARCOMA MOUSE MODEL.
Silvia Brusco
Favorite
Bruzzone, Francesco

IRCCS Humanitas Research Hospital
(P 290) ARTIFICIAL INTELLIGENCE-BASED COMPARISON OF ADULT AND ADOLESCENT AND YOUNG ADULTS (AYA) SARCOMAS: A PILOT STUDY
Francesco Bruzzone
Favorite
Brzezinski, Jack

Hospital for Sick Children and University of Toronto
(P 293) CIC-REARRANGED SOFT TISSUE SARCOMAS: DOES CHEMOTHERAPY CHANGE NATURAL HISTORY AND PROGNOSIS? A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Jack Brzezinski
Favorite
(P 304) LOCAL CONTROL FOR PEDIATRIC RHABDOMYOSARCOMA OF THE EXTREMITIES. IS RADIOTHERAPY ALWAYS REQUIRED AFTER ADEQUATE SURGICAL RESECTION?
Jack Brzezinski
Favorite
Büchler, Tomáš

Department of Oncology, 2nd Medical Faculty, Charles University and University Hospital Motol
(P 355) PROTON RADIOTHERAPY FOR DESMOID TUMORS: A SINGLE-CENTER EXPERIENCE
Tomáš Büchler
Favorite
Bucio-Noble, Daniel

ProCan®, Children’s Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, NSW, Australia
(P 325) CAN PROTEOMICS PREDICT METASTATIC RELAPSE IN LEIOMYOSARCOMA? DEVELOPMENT OF AN 8 PROTEIN SIGNATURE IN A >350 SAMPLE STUDY INCLUDING A VALIDATION COHORT
Daniel Bucio-Noble
Favorite
Buendia, Javier

Hospital Clinico san Carlos
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Javier Buendia
Favorite
Bui, Nam

Division of Oncology, Department of Medicine, Stanford University
(P 143) EARLY ASSESSMENT OF DISEASE RESPONSE TO IMMUNOTHERAPY VIA CIRCULATING TUMOR DNA IN ADVANCED SOFT TISSUE SARCOMAS
Nam Bui
Favorite
(P 161) UTILITY OF CTDNA MONITORING IN THE ADJUVANT AND METASTATIC SETTING IN SOFT TISSUE SARCOMA
Nam Bui
Favorite
(P 209) RACE AND ETHNICITY ON DIAGNOSIS, METASTASIS, AND MORTALITY OF SOFT TISSUE SARCOMAS IN RETROSPECTIVE COHORT STUDY
Nam Bui
Favorite
(P 214) REPRESENTATION OF CHILDREN AND OLDER ADULTS IN SARCOMA CLINICAL TRIALS SINCE THE INCLUSION ACROSS THE LIFESPAN POLICY
Nam Bui
Favorite
(P 215) REPRESENTATION OF RACIAL AND ETHNIC MINORITIES IN SARCOMA CLINICAL TRIALS
Nam Bui
Favorite
Bukowiec, Lainey

Mayo Clinic
(P 294) COMPARING HIGH-GRADE NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA IN ADULT AND PEDIATRIC POPULATIONS
Lainey Bukowiec
Favorite
(P 307) OUTCOMES OF PEDIATRIC NON-RHABDOMYOSARCOMA SOFT-TISSUE SARCOMAS OF THE EXTREMITIES
Lainey Bukowiec
Favorite
Buonadonna, Angela

4 Centro di Riferimento Oncologico di Aviano (CRO Aviano)
(P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Angela Buonadonna
Favorite
Burbank, Katherine

Georgetown University School of Medicine
(P 38) LOCAL RECURRENCE OF DIFFUSE PIGMENTED VILLONODULAR SYNOVITIS IN MAJOR JOINTS: A 15 YEAR-LONG CASE SERIES AT A SINGLE INSTITUTION
Katherine Burbank
Favorite
(P 39) PATIENT OUTCOMES FOLLOWING MINIMALLY INVASIVE TREATMENT OF ANEURYSMAL BONE CYSTS USING DOXYCYCLINE
Katherine Burbank
Favorite
(P 406) LONG-TERM DENOSUMAB THERAPY IN GIANT CELL TUMOR PATIENTS MAY POTENTIALLY LEAD TO THE DEVELOPMENT OF OTHER PRIMARY TUMORS: AN INITIAL OBSERVATION
Katherine Burbank
Favorite
Burcoveanu, Domnita-Ileana

Bayer HealthCare Pharmaceuticals, Inc.
(P 393) EFFICACY AND SAFETY OF LAROTRECTINIB AS FIRST-LINE TREATMENT IN PATIENTS WITH TRK FUSION SARCOMAS
Domnita-Ileana Burcoveanu
Favorite
(P 396) LONG-TERM FOLLOW-UP EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Domnita-Ileana Burcoveanu
Favorite
Burga, Rachel

Obsidian Therapeutics
(P 235) INFILTRATION OF MUCOSAL-ASSOCIATED INVARIANT T CELLS (MAITS) INTO CHONDROSARCOMA TUMORS
Rachel Burga
Favorite
Burgess, Melissa

University of Pittsburgh Medical Center
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Melissa Burgess
Favorite
(P 392) ATRX LOSS IN UTERINE LEIOMYOSARCOMA IS ASSOCIATED WITH WORSE OVERALL SURVIVAL AND A DISTINCT PATTERN OF GENE EXPRESSION ACROSS SUBTYPES
Melissa Burgess
Favorite
(P 413) SUSTAINED EFFICACY DURING DRUG HOLIDAY ON ATEZOLIZUMAB IN PATIENTS WITH ALVEOLAR SOFT PART SARCOMA (ASPS)
Melissa Burgess
Favorite
Burgoyne, Adam

UC San Diego Moores Cancer Center
(P 165) COMPLETE PERITONEAL CYTOREDUCTIVE SURGERY IN HIGHLY SELECTED PATIENTS WITH AGGRESSIVE METASTATIC SDH-DEFICIENT GIST CAN PROLONG EVENT-FREE SURVIVAL
Adam Burgoyne
Favorite
Burke, Chelsey

Memorial Sloan Kettering Cancer Center
(P 338) PRECLINICAL EFFICACY OF DAN-222, A NOVEL POLYMERIC NANOPARTICLE, IN PEDIATRIC SOLID TUMOR MODELS
Chelsey Burke
Favorite
Burke, Katy

University College London Hospital
(P 185) ADDRESSING THE GAP FOR SYMPTOM CONTROL THROUGH THE IMPLEMENTATION OF ENHANCED SUPPORTIVE CARE AT THE LONDON SARCOMA SERVICE
Katy Burke
Favorite
Burke, Zachary

University of Toronto
(P 150) MODERN BIOPSY PRACTICE PATTERNS: A SURVEY OF THE MSTS MEMBERSHIP
Zachary Burke
Favorite
Burrow, Trevor

Texas Tech University Health Sciences Center
(P 292) CHARACTERIZATION OF TELOMERE MAINTENANCE MECHANISMS IN OSTEOSARCOMA PATIENT-DERIVED LABORATORY MODELS
Trevor Burrow
Favorite
Burt, Alastair

Newcastle University
(P 22) MECHANISMS OF PREFERENTIAL TUMOUR UPTAKE OF INDOCYANINE GREEN IN SARCOMA
Alastair Burt
Favorite
Bush, Jonathan

BC Children's Hospital, University of British Columbia
(P 293) CIC-REARRANGED SOFT TISSUE SARCOMAS: DOES CHEMOTHERAPY CHANGE NATURAL HISTORY AND PROGNOSIS? A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Jonathan Bush
Favorite
Bus, Michaël

Leiden University Medical Center
(P 274) PROXIMAL HUMERAL ENDOPROSTHETIC RECONSTRUCTION: RESULTS FROM THE MUTARS ORTHOPEDIC REGISTRY EUROPE (MORE)
Michaël Bus
Favorite
Butler, Zachary

Rush University Medical Center
(P 31) CLINICAL CHALLENGES AND EVOLVING TREATMENT STRATEGIES IN DESMOID FIBROMATOSIS: A SINGLE INSTITUTION EXPERIENCE
Zachary Butler
Favorite
(P 80) OUTCOMES AND MANAGEMENT OF POSITIVE MARGINS IN CHONDROSARCOMA WITH SOFT TISSUE EXTENSION: A CASE SERIES AND REVIEW OF LITERATURE
Zachary Butler
Favorite
(P 92) THE IMPACT OF CHONDROSARCOMA WITH POSITIVE MARGINS AND EXTRAOSSEOUS EXTENSION ON PATIENT OUTCOMES
Zachary Butler
Favorite
(P 126) CHARACTERIZING THE TRANSFORMATION AND DIAGNOSIS OF ATYPICAL LIPOMATOUS TUMOR OF THE EXTREMITIES TO DEDIFFERENTIATED LIPOSARCOMA: SINGLE INSTITUTIONAL OUTCOMES
Zachary Butler
Favorite
(P 270) OPIOID USE IN IMPENDING VERSUS PATHOLOGIC PROXIMAL FEMUR FRACTURES
Zachary Butler
Favorite
(P 271) OUTCOMES OF DISTAL FEMORAL REPLACEMENT VS INTERNAL FIXATION FOR METASTATIC BONE DISEASE OF THE DISTAL FEMUR
Zachary Butler
Favorite
Butrynski, James

US Oncology Research/Oncology Associate of Oregon P.C
(P 133) REAL-WORLD ANALYSIS OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS) IN A US COMMUNITY ONCOLOGY SETTING
James Butrynski
Favorite
C
Cabral, Sara

Instituto Português de Oncologia de Lisboa
(P 128) DYNAMIC HETEROGENEITY AMONGST LIPOSARCOMAS
Sara Cabral
Favorite
Cabrolier, Jorge

Teodore Gebauer Institute
(P 274) PROXIMAL HUMERAL ENDOPROSTHETIC RECONSTRUCTION: RESULTS FROM THE MUTARS ORTHOPEDIC REGISTRY EUROPE (MORE)
Jorge Cabrolier
Favorite
Cacciatore, John

University of Miami Miller School of Medicine
(P 369) BLAND EMBOLIZATION AS ADJUNCT TREATMENT FOR HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA
John Cacciatore
Favorite
Cai, Jungang

Peking University International Hospital
(P 186) ANALYSIS OF FACTORS INFLUENCING POSTOPERATIVE VENOUS THROMBOEMBOLISM FORMATION IN PATIENTS WITH MASSIVE BLOOD LOSS DURING RETROPERITONEAL TUMOR RESECTION
Jungang Cai
Favorite
(P 379) KEY POINTS OF ANESTHESIA MANAGEMENT AND PROGNOSIS ANALYSIS OF ELDERLY PATIENTS WITH RETROPERITONEAL TUMOR
Jungang Cai
Favorite
Cai, Mingzhe

Singapore General Hospital
(P 370) DEFYING NORMS - CENTRALIZATION OF SARCOMA CARE ON AN ISLAND NATION
Mingzhe Cai
Favorite
(P 375) FROM SAPLING TO SHADE: GROWTH OF A HIGH VOLUME ASIAN TERTIARY SARCOMA SPECIALISED CENTRE
Mingzhe Cai
Favorite
Cai, Qiyan

Sun Yat-sen University Cancer Center
(P 409) PHASE 2 STUDY EVALUATING SURUFATINIB IN PATIENTS WITH OSTEOSARCOMA AND SOFT TISSUE SARCOMA WHO HAVE FAILED STANDARD CHEMOTHERAPY
Qiyan Cai
Favorite
Cai, Simon

ProCan, Children’s Medical Research Institute
(P 325) CAN PROTEOMICS PREDICT METASTATIC RELAPSE IN LEIOMYOSARCOMA? DEVELOPMENT OF AN 8 PROTEIN SIGNATURE IN A >350 SAMPLE STUDY INCLUDING A VALIDATION COHORT
Simon Cai
Favorite
Cai, YiQi

Department of Gastrointestinal Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
(P 164) CLINICAL BENEFITS OF RIPRETINIB AND CYTOREDUCTIVE SURGERY IN IMATINIB-RESISTANT ADVANCED GASTROINTESTINAL STROMAL TUMORS (GISTS): A RETROSPECTIVE DUAL-CENTER STUDY
YiQi Cai
Favorite
cai, zhengdong

Shanghai General Hospital, School of Medicine Shanghai Jiao Tong University
(P 83) PREDICTION OF HIGH-RISK OSTEOSARCOMA PATIENTS BASED ON MACHINE LEARNING USING TRANSCRIPTOME AND METHYLATION DATA FROM SGH-COHORT
zhengdong cai
Favorite
(P 90) TARGETING HIGH RISK MYC- AMPLIFIED OSTEOSARCOMA BY AURORA KINASE INHIBITOR--RESULT FROM A NGS BASED UMBRELLA TRIAL
zhengdong cai
Favorite
Calder, Paul

Memorial Sloan Kettering Cancer Center
(P 338) PRECLINICAL EFFICACY OF DAN-222, A NOVEL POLYMERIC NANOPARTICLE, IN PEDIATRIC SOLID TUMOR MODELS
Paul Calder
Favorite
Califano, Andrea

Columbia University Irving Medical Center
(P 418) A SYSTEMS BIOLOGY APPROACH FOR CHARACTERIZING TUMOR HETEROGENEITY AND CELL STATE-SPECIFIC THERAPEUTIC VULNERABILITIES FROM SINGLE NUCLEUS RNA-SEQ PROFILING OF DESMOPLASTIC SMALL ROUND CELL TUMORS
Andrea Califano
Favorite
Callahan, Alison

Stanford Health Care
(P 209) RACE AND ETHNICITY ON DIAGNOSIS, METASTASIS, AND MORTALITY OF SOFT TISSUE SARCOMAS IN RETROSPECTIVE COHORT STUDY
Alison Callahan
Favorite
Callegaro, Dario

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 137) TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS
Dario Callegaro
Favorite
(P 171) GASTROINTESTINAL STROMAL TUMOURS (GISTS) IN NEUROFIBROMATOSIS TYPE (NF1): A SINGLE-CENTER OBSERVATIONAL RETROSPECTIVE STUDY
Dario Callegaro
Favorite
(P 213) REGIONAL KNOWLEDGE TRANSLATION IN RETROPERITONEAL SARCOMAS: IMPACT OF AN EDUCATIONAL WEBINAR SERIES BY THE MEXICAN SARCOMA GROUP
Dario Callegaro
Favorite
(P 376) IMPACT OF SITE OF ORIGIN ON THE PROGNOSIS OF PATIENTS WITH PRIMARY RESECTABLE NON-UTERINE ABDOMINAL LEIOMYOSARCOMA
Dario Callegaro
Favorite
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Dario Callegaro
Favorite
Calles Blanco, Antonio

Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
(P 432) THE ROLE OF SYSTEMIC TREATMENT IN ADVANCED SOLITARY FIBROUS TUMORS: EXPERIENCE AT A REFERRAL CENTER.
Antonio Calles Blanco
Favorite
Call, Jerry

The Life Raft Group
(P 166) D842V - A TALE OF TWO STAGES: COMPARATIVE ANALYSIS OF OVERALL SURVIVAL AND TREATMENT RESPONSE IN GIST PATIENTS WITH PDGFRA D842V MUTATIONS
Jerry Call
Favorite
(P 176) LOSS OF PTEN EXPRESSION IN MINIGISTS AND CLINICALLY RELEVANT GISTS
Jerry Call
Favorite
Calpona, sebastiano

Irst
(P 144) EXPLORATORY ANALYSIS OF 68GA-FAPI-46 PET-CT IN SOFT TISSUE SARCOMA
sebastiano Calpona
Favorite
Calvo, Emiliano

Director of START CIOCC Madrid
(P 337) OMX-0407 A NOVEL SPECTRUM-SELECTIVE SMALL MOLECULE KINASE INHIBITOR IS ACTIVE IN THE TREATMENT OF ANGIOSARCOMA
Emiliano Calvo
Favorite
Camilio, Ketil

Lytix Biopharma AS
(P 243) MYELOSUPPRESSION FOLLOWING LYMPHODEPLETING CHEMOTHERAPY AS PART OF ADOPTIVE CELL THERAPY FOR PATIENTS WITH PROGRESSIVE SOFT TISSUE SARCOMA AFTER STANDARD CHEMOTHERAPY
Ketil Camilio
Favorite
Campanacci, Domenico Andrea

Department of Orthopaedic Oncology and Reconstructive Surgery, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy
(P 274) PROXIMAL HUMERAL ENDOPROSTHETIC RECONSTRUCTION: RESULTS FROM THE MUTARS ORTHOPEDIC REGISTRY EUROPE (MORE)
Domenico Andrea Campanacci
Favorite
Campano, Dominic

University of Miami
(P 346) BRACHYTHERAPY FOR SOFT TISSUE SARCOMA: MAINTAINING LOCAL CONTROL WHILE MINIMIZING COMPLICATIONS
Dominic Campano
Favorite
Campbell, Matthew

University of Texas Southwestern Medical Center
(P 417) VITAS: ATEZOLIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY SOLID TUMORS: AN OPEN-LABEL, PHASE I/II, SINGLE-ARM, MULTI-CENTER TRIAL IN PROGRESS
Matthew Campbell
Favorite
Campbell, Shauna

Cleveland Clinic Foundation
(P 351) OSTEOSARCOMA STEREOTACTIC BODY RADIOTHERAPY: OUTCOMES AND PATTERN OF FAILURE
Shauna Campbell
Favorite
Campos, Fernando

A.C.Camargo Cancer Center
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Fernando Campos
Favorite
(P 300) GASTROINTESTINAL STROMAL TUMORS (GIST) IN YOUNG ADULTS (YA): A BRAZILIAN COHORT OF PATIENTS
Fernando Campos
Favorite
Cananzi, Ferdinando

IRCCS Humanitas Research Hospital
(P 362) A NEW ROCK BAND FOR DIAPHRAGMATIC RECONSTRUCTION IN LEFT RETROPERITONEAL SARCOMA SURGERY
Ferdinando Cananzi
Favorite
(P 363) A NEW SURGICAL TECHNIQUE FOR THE RECONSTRUCTION OF INGUINAL 'NEOLIGAMENT' AFTER SOFT TISSUE SARCOMA RESECTION
Ferdinando Cananzi
Favorite
(P 373) EVALUATION OF HISTOLOGIC ORGAN INFILTRATION (HOI) AND VISCERAL RESECTION MARGINS (VRM) IN PRIMARY RETROPERITONEAL SARCOMAS: PROGNOSTIC IMPLICATIONS FOR LOCAL RECURRENCE
Ferdinando Cananzi
Favorite
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Ferdinando Cananzi
Favorite
(P 388) THE ROAD TO CURATIVE SURGERY IN RETROPERITONEAL SOFT TISSUE SARCOMA: A DIFFERENT PATH IN THE ELDERLY?
Ferdinando Cananzi
Favorite
(P 389) THE ROLE OF NUTRITIONAL STATUS ON POSTOPERATIVE AND ONCOLOGICAL OUTCOMES IN RETROPERITONEAL SARCOMA
Ferdinando Cananzi
Favorite
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Ferdinando Cananzi
Favorite
(P 431) REAL-WORLD EXPERIENCE OF EFFICACY AND TOLERABILITY OF CONTINUOS INFUSION IFOSFAMIDE AMONG ADVANCED SOFT TISSUE AND BONE SARCOMAS PATIENTS: A SINGLE CENTRE RETROSPECTIVE COHORT.
Ferdinando Cananzi
Favorite
Canter, Robert

Division of Surgical Oncology, Department of Surgery, University of California Davis
(P 230) HIGHER BODY MASS INDEX IS ASSOCIATED WITH DECREASED CIRCULATING AND INTRATUMORAL NATURAL KILLER CELLS IN SOFT TISSUE SARCOMA
Robert Canter
Favorite
Cantor, Nicole

Campbell University
(P 142) CORE NEEDLE BIOPSY OF PERIACETABULAR CHONDROSARCOMA OFTEN RESULTS IN UNDER-GRADING BUT DOES NOT CHANGE MANAGEMENT BY EXPERIENCED ORTHOPAEDIC ONCOLOGISTS.
Nicole Cantor
Favorite
Cappadocia, Alison

Boehringer Ingelheim Canada Ltd
(P 135) SURVIVAL OUTCOMES AND TREATMENT PATTERNS FOR PATIENTS WITH DEDIFFERENTIATED LIPOSARCOMA: A RETROSPECTIVE COHORT STUDY IN ONTARIO, CANADA
Alison Cappadocia
Favorite
Caradonio, Olivia

Children's Hospital of Philadelphia
(P 318) SYNOVIAL SARCOMA REGISTRY AND BIOSPECIMEN REPOSITORY: DESCRIBING THE COHORT AND SURVIVAL OUTCOMES TO DATE
Olivia Caradonio
Favorite
Caramella, Chiara

Fondazione IRCSS Istituto Nazionale dei Tumori
(P 171) GASTROINTESTINAL STROMAL TUMOURS (GISTS) IN NEUROFIBROMATOSIS TYPE (NF1): A SINGLE-CENTER OBSERVATIONAL RETROSPECTIVE STUDY
Chiara Caramella
Favorite
Cardona, Kenneth

Winship Cancer Institute
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Kenneth Cardona
Favorite
Cardoso, Sara

Leiden University Medical Center / Leiden Center for Computational Oncology
(P 56) CHROME: PREDICTING CHONDROSARCOMA RISK OUTCOME FROM METHYLATION
Sara Cardoso
Favorite
(P 114) METHYLOME PROFILING OF CARTILAGE TUMOURS: A PROMISING NEW TOOL FOR BIOPSY MATERIAL?
Sara Cardoso
Favorite
Cargill, Andre

Rush University Medical Center
(P 270) OPIOID USE IN IMPENDING VERSUS PATHOLOGIC PROXIMAL FEMUR FRACTURES
Andre Cargill
Favorite
Cariboni, Umberto

Humanitas Research Hospital
(P 155) PRIMARY MESENCHYMAL TUMORS OF THE HEART: A 8-YEARS, SINGLE INSTITUTION EXPERIENCE
Umberto Cariboni
Favorite
(P 290) ARTIFICIAL INTELLIGENCE-BASED COMPARISON OF ADULT AND ADOLESCENT AND YOUNG ADULTS (AYA) SARCOMAS: A PILOT STUDY
Umberto Cariboni
Favorite
Carnaghi, Carlo

IRCCS, Humanitas Research Hospital
(P 155) PRIMARY MESENCHYMAL TUMORS OF THE HEART: A 8-YEARS, SINGLE INSTITUTION EXPERIENCE
Carlo Carnaghi
Favorite
Caro, Claudia Haydee

The National Cancer Institute
(P 213) REGIONAL KNOWLEDGE TRANSLATION IN RETROPERITONEAL SARCOMAS: IMPACT OF AN EDUCATIONAL WEBINAR SERIES BY THE MEXICAN SARCOMA GROUP
Claudia Haydee Caro
Favorite
(P 374) FACTORS ASSOCIATED WITH RECURRENCE IN DEDIFFERENTIATED RETROPERITONEAL LIPOSARCOMA: ANALYSIS AT A REFERENCE CENTER
Claudia Haydee Caro
Favorite
Caroli, Paola

IRST - Meldola
(P 144) EXPLORATORY ANALYSIS OF 68GA-FAPI-46 PET-CT IN SOFT TISSUE SARCOMA
Paola Caroli
Favorite
Carr-Ascher, Janai

University of California, Davis
(P 08) ELUCIDATING THE ROLE OF YAP IN SARCOMA DEVELOPMENT
Janai Carr-Ascher
Favorite
(P 11) GENETIC AND EPIGENETIC CHARACTERIZATION OF SARCOMA STEM CELLS ACROSS SUBTYPES IDENTIFIES EZH2 AS A THERAPEUTIC TARGET
Janai Carr-Ascher
Favorite
(P 205) MULTI-MODAL TREATMENT IS ASSOCIATED WITH IMPROVED SURVIVAL IN AYA PATIENTS WITH METASTATIC NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA
Janai Carr-Ascher
Favorite
Carrasco, Irene

Hospital Virgen del Rocio
(P 37) HEALTH-RELATED QUALITY OF LIFE FROM A PHASE 4 STUDY TO EVALUATE DISCONTINUATION AND RECHALLENGE OF PEXIDARTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR PREVIOUSLY TREATED WITH PEXIDARTINIB
Irene Carrasco
Favorite
Carrère, Sébastien

Surgical Oncology, Institut régional du Cancer Montpellier
(P 125) CHARACTERISTICS, MANAGEMENT AND SURVIVAL OF N=7314 LIPOSARCOMAS FROM THE NATIONWIDE NETSARC REGISTRY IN FRANCE SINCE 2010
Sébastien Carrère
Favorite
Carter, Lucas

Northwestern University Feinberg School of Medicine
(P 04) CHROMOSOME SPECIFIC ORGANIZATIONAL CHARACTERISTICS IN RHABDOMYOSARCOMA AND NORMAL MYOGENIC CELLS
Lucas Carter
Favorite
Carter, Rheanna

BostonGene, Inc.
(P 106) DELTAREX-G, A TUMOR TARGETED CCNG1 INHIBITOR, DEMONSTRATES CLINICAL BENEFIT IN ADVANCED CHEMORESISTANT SARCOMA FOLLOWING FDA CBER AUTHORIZATION FOR USE AS PLATFORM THERAPY WITH FDA APPROVED DRUGS
Rheanna Carter
Favorite
Carvalho, Sara

Portuguese Institute of Oncology of Porto
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Sara Carvalho
Favorite
Casado, Antonio

HU Clinico San Carlos
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Antonio Casado
Favorite
Casado, Antonio

Hospital Universitario Clínico San Carlos
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Antonio Casado
Favorite
Casali, Paolo Giovanni

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 160) UTERINE PECOMA: REPORT OF MOLECULAR AND CLINICAL FEATURES IN A SERIES OF PATIENTS TREATED AT A REFERRAL INSTITUTION
Paolo Giovanni Casali
Favorite
(P 171) GASTROINTESTINAL STROMAL TUMOURS (GISTS) IN NEUROFIBROMATOSIS TYPE (NF1): A SINGLE-CENTER OBSERVATIONAL RETROSPECTIVE STUDY
Paolo Giovanni Casali
Favorite
(P 368) AGGRESSIVE PERINEAL ANGIOMYXOMA UNDERGOING SYSTEMIC TREATMENT: AN UPDATED REPORT OF 8-YEARS' EXPERIENCE IN A REFERRAL CENTER
Paolo Giovanni Casali
Favorite
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Paolo Giovanni Casali
Favorite
(P 429) PATIENTS WITH ADVANCED EPITHELIOID HEMANGIOENDOTHELIOMA TREATED WITH SIROLIMUS: OUTCOME FOLLOWING SIROLIMUS DISCONTINUATION.
Paolo Giovanni Casali
Favorite
Casanova, Michela

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 393) EFFICACY AND SAFETY OF LAROTRECTINIB AS FIRST-LINE TREATMENT IN PATIENTS WITH TRK FUSION SARCOMAS
Michela Casanova
Favorite
Castaneda-Wysocka, Patrycja

Maria Sklodowska-Curie National Research Institute of Oncology
(P 245) PRELIMINARY RESULTS FROM A PHASE 2 EFTISARC-NEO TRIAL OF NEOADJUVANT SOUBLE LAG-3 PROTEIN EFTILAGIMOD ALPHA, PEMBROLIZUMAB, AND CONCURRENT RADIOTHERAPY IN PATIENTS WITH RESECTABLE SOFT TISSUE SARCOMA
Patrycja Castaneda-Wysocka
Favorite
Castro, Anthony

Temple University
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Anthony Castro
Favorite
Catalani, Elena

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 137) TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS
Elena Catalani
Favorite
Cates, Justin

PathGroup Laboratories
(P 427) MULTI-OMIC AND MULTI-REGION PROFILING OF DESMOID TUMORS REVEALS INTRA- AND INTER-TUMOR HETEROGENEITY
Justin Cates
Favorite
Catton, Charles

Princess Margaret Cancer Centre
(P 352) OUTCOMES OF PRIMARY INTRATHORACIC SOFT TISSUE SARCOMA
Charles Catton
Favorite
Cebrian, Juan Luis

Hospital Clinico san Carlos
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Juan Luis Cebrian
Favorite
Cecchi, Luigi Giovanni

IRCCS Humanitas Research Hospital
(P 290) ARTIFICIAL INTELLIGENCE-BASED COMPARISON OF ADULT AND ADOLESCENT AND YOUNG ADULTS (AYA) SARCOMAS: A PILOT STUDY
Luigi Giovanni Cecchi
Favorite
Cechini, Maria

Sarcoma Oncology Center
(P 250) UPDATE ON GALLANT: A PHASE 2 STUDY USING METRONOMIC GEMCITABINE, DOXORUBICIN AND DOCETAXEL PLUS NIVOLUMAB IN PREVIOUSLY TREATED SARCOMA (NCT04535713)
Maria Cechini
Favorite
Cenzi, Lavinia

IRCCS Humanitas Research Hospital
(P 373) EVALUATION OF HISTOLOGIC ORGAN INFILTRATION (HOI) AND VISCERAL RESECTION MARGINS (VRM) IN PRIMARY RETROPERITONEAL SARCOMAS: PROGNOSTIC IMPLICATIONS FOR LOCAL RECURRENCE
Lavinia Cenzi
Favorite
Cervelo, Gonzalo

Angel H Roffo Institute of Oncology
(P 273) PRIMARY SOFT-TISSUE SARCOMAS OF THE UPPER LIMBS
Gonzalo Cervelo
Favorite
Cesari, Marilena

IRCCS Istituto Ortopedico Rizzoli
(P 37) HEALTH-RELATED QUALITY OF LIFE FROM A PHASE 4 STUDY TO EVALUATE DISCONTINUATION AND RECHALLENGE OF PEXIDARTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR PREVIOUSLY TREATED WITH PEXIDARTINIB
Marilena Cesari
Favorite
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Marilena Cesari
Favorite
Chabaud, Sylvie
(P 169) FRENCH LONG TERM REGISTRY WITH LONGITUDINAL FOLLOW UP OF PDGFRA D842V GIST PATIENTS (AVIATOR2020)
Sylvie Chabaud
Favorite
Chacon, Matias

Latin American Cooperative Oncology Group
(P 192) CURRENT SCENARIO OF SARCOMA CLINICAL TRIALS IN SOUTH AMERICA: A REPORT BY THE LACOG SARCOMA GROUP
Matias Chacon
Favorite
(P 216) SARCOMA CARE PATHWAYS AND MULTIDISCIPLINARY TUMOR BOARDS IN LATIN AMERICA: AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Matias Chacon
Favorite
(P 217) SARCOMA DRUG APPROVALS IN LATIN AMERICA COMPARED TO THE FDA AND EMA: AN ANALYSIS BY THE LACOG SARCOMA GROUP
Matias Chacon
Favorite
(P 219) SOCIAL MEDIA USE AMONG MEDICAL PROFESSIONALS THAT TREAT PATIENTS WITH SARCOMA IN LATIN AMERICA: RESULTS OF AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Matias Chacon
Favorite
Chaigneau, Loic

CHU de Besançon
(P 169) FRENCH LONG TERM REGISTRY WITH LONGITUDINAL FOLLOW UP OF PDGFRA D842V GIST PATIENTS (AVIATOR2020)
Loic Chaigneau
Favorite
Chailse, Prabhakar

The University of Kansas Medical Center
(P 36) EARLY REAL-WORLD EXPERIENCE WITH THE USE OF NIROGACESTAT FOR THE TREATMENT OF DESMOID FIBROMATOSIS
Prabhakar Chailse
Favorite
Chainsukh Loya, Anand

Department of Pathology, Copenhagen University Hospital, Rigshospitalet
(P 104) CIRQUESARC: A NATIONAL PROSPECTIVE OBSERVATIONAL STUDY OF CIRCULATING TUMOR DNA AND QUALITY OF LIFE IN PATIENTS WITH SARCOMA – PRELIMINARY RESULTS FROM THE SURGICAL COHORT
Anand Chainsukh Loya
Favorite
(P 386) SOLITARY FIBROUS TUMOUR: A DANISH SAMPLE FROM 2013 – 2018
Anand Chainsukh Loya
Favorite
Chambers, Krizia

University of California-Santa Cruz
(P 295) DEFINING OSTEOSARCOMA HETEROGENEITY: CONSENSUS CLUSTERING REVEALS GENE EXPRESSION SUBTYPES
Krizia Chambers
Favorite
Chan, Corey

Translational and Clinical Research Institute, Newcastle University, UK
(P 22) MECHANISMS OF PREFERENTIAL TUMOUR UPTAKE OF INDOCYANINE GREEN IN SARCOMA
Corey Chan
Favorite
Chandana, Sreenivasa

START Midwest, The Cancer & Hematology Centers
(P 403) DCC-3116 IN COMBINATION WITH RIPRETINIB FOR PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A PHASE 1/2 STUDY
Sreenivasa Chandana
Favorite
Chandran, Nisha

Boehringer Ingelheim Canada Ltd
(P 135) SURVIVAL OUTCOMES AND TREATMENT PATTERNS FOR PATIENTS WITH DEDIFFERENTIATED LIPOSARCOMA: A RETROSPECTIVE COHORT STUDY IN ONTARIO, CANADA
Nisha Chandran
Favorite
Chandran, Uma

University of Pittsburgh
(P 117) THE TUMOR IMMUNE MICROENVIRONMENT OF DEDIFFERENTIATED SARCOMAS: DIGITAL SPATIAL PROFILING SHOWS IMMUNE TRANSCRIPTIONAL DIFFERENCES BETWEEN DEDIFFERENTIATED LIPOSARCOMA AND CHONDROSARCOMA
Uma Chandran
Favorite
Chan, Jason

Memorial Sloan Kettering Cancer Center
(P 229) EXPRESSION OF TRANSPOSABLE ELEMENTS AND IKZF1 PREDICTS IMMUNE INFILTRATES IN SARCOMAS AND CORRELATES WITH OUTCOMES AFTER IMMUNE CHECKPOINT INHIBITION
Jason Chan
Favorite
Chan, Jennifer

University of Calgary
(P 422) COMPARISON OF ANNOTATION METHODS FOR PAN-SARCOMA SINGLE CELL DATA
Jennifer Chan
Favorite
(P 424) CROSS-COHORT INTEGRATION AS A STRATEGY TO CLASSIFY IMMUNE CHECKPOINT BLOCKADE RESPONSE IN SARCOMA
Jennifer Chan
Favorite
Chattopadhyay, Priya

University of Miami and Jackson Health Systems
(P 253) ASSESSING THE LINK BETWEEN MYXOFIBROSARCOMA RECURRENCE AND TREATMENT ORDER: A MULTIDISCIPLINARY RETROSPECTIVE COHORT STUDY
Priya Chattopadhyay
Favorite
(P 296) DISPARITIES IN OVERALL SURVIVAL FOR AYA PATIENTS WITH EWINGS SARCOMA: A RETROSPECTIVE COHORT STUDY AT A SINGLE SARCOMA CENTER
Priya Chattopadhyay
Favorite
Chawla, Akhil

Northwestern Memorial Hospital
(P 179) PRIMARY MANAGEMENT OF LOCALIZED GASTROINTESTINAL STROMAL TUMORS WITH IMATINIB MONOTHERAPY: AN ALTERNATIVE TO RESECTION FOR PATIENTS PRECLUDED FROM SURGERY
Akhil Chawla
Favorite
Chawla, Neal

Sarcoma Oncology Center
(P 106) DELTAREX-G, A TUMOR TARGETED CCNG1 INHIBITOR, DEMONSTRATES CLINICAL BENEFIT IN ADVANCED CHEMORESISTANT SARCOMA FOLLOWING FDA CBER AUTHORIZATION FOR USE AS PLATFORM THERAPY WITH FDA APPROVED DRUGS
Neal Chawla
Favorite
(P 241) LINNOVATE: A PHASE 1/2 STUDY OF SAFETY/EFFICACY USING LURBINECTEDIN COMBINED WITH IPILUMUMAB AND NIVOLUMAB FOR ADVANCED SOFT TISSUE SARCOMA (NCT05876715)
Neal Chawla
Favorite
(P 248) TNT: A PHASE 2 STUDY USING TALIMOGENE LAHERPAREPVEC, NIVOLUMAB, AND TRABECTEDIN FOR ADVANCED LEIOMYOSARCOMA AND LIPOSARCOMA (NCT # 03886311)
Neal Chawla
Favorite
(P 250) UPDATE ON GALLANT: A PHASE 2 STUDY USING METRONOMIC GEMCITABINE, DOXORUBICIN AND DOCETAXEL PLUS NIVOLUMAB IN PREVIOUSLY TREATED SARCOMA (NCT04535713)
Neal Chawla
Favorite
(P 251) UPDATE ON SAINT: A PHASE 2 STUDY USING TRABECTEDIN (T) IN COMBINATION WITH IPILIMUMAB (L) AND NIVOLUMAB (N) IN PREVIOUSLY TREATED SOFT TISSUE SARCOMA (NCT03138161)
Neal Chawla
Favorite
Chawla, Sant

Sarcoma Oncology Research Center
(P 95) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN PATIENTS WITH CHONDROSARCOMA: UPDATED RESULTS FROM A PHASE 1 STUDY
Sant Chawla
Favorite
(P 106) DELTAREX-G, A TUMOR TARGETED CCNG1 INHIBITOR, DEMONSTRATES CLINICAL BENEFIT IN ADVANCED CHEMORESISTANT SARCOMA FOLLOWING FDA CBER AUTHORIZATION FOR USE AS PLATFORM THERAPY WITH FDA APPROVED DRUGS
Sant Chawla
Favorite
(P 241) LINNOVATE: A PHASE 1/2 STUDY OF SAFETY/EFFICACY USING LURBINECTEDIN COMBINED WITH IPILUMUMAB AND NIVOLUMAB FOR ADVANCED SOFT TISSUE SARCOMA (NCT05876715)
Sant Chawla
Favorite
(P 248) TNT: A PHASE 2 STUDY USING TALIMOGENE LAHERPAREPVEC, NIVOLUMAB, AND TRABECTEDIN FOR ADVANCED LEIOMYOSARCOMA AND LIPOSARCOMA (NCT # 03886311)
Sant Chawla
Favorite
(P 250) UPDATE ON GALLANT: A PHASE 2 STUDY USING METRONOMIC GEMCITABINE, DOXORUBICIN AND DOCETAXEL PLUS NIVOLUMAB IN PREVIOUSLY TREATED SARCOMA (NCT04535713)
Sant Chawla
Favorite
(P 251) UPDATE ON SAINT: A PHASE 2 STUDY USING TRABECTEDIN (T) IN COMBINATION WITH IPILIMUMAB (L) AND NIVOLUMAB (N) IN PREVIOUSLY TREATED SOFT TISSUE SARCOMA (NCT03138161)
Sant Chawla
Favorite
Chebib, Ivan

Massachusetts General Hospital
(P 63) DOES TUMOR NECROSIS IMPACT PROGNOSIS IN CHONDROBLASTIC AND OSTEOBLASTIC OSTEOSARCOMA? A STUDY FROM A LARGE TERTIARY CARE ACADEMIC CENTER
Ivan Chebib
Favorite
Chebli, Caroline

USF Morsani College of Medicine
(P 263) HEMI- VS. REVERSE SHOULDER ARTHROPLASTY OUTCOMES FOLLOWING PROXIMAL HUMERAL ONCOLOGIC RESECTION
Caroline Chebli
Favorite
Chenard, Stephen

Vanderbilt University School of Medicine
(P 73) LONGER TIME INTERVAL BETWEEN NEOADJUVANT CHEMOTHERAPY AND SURGERY IS ASSOCIATED WITH DECREASED TUMOR PERCENT NECROSIS IN OSTEOSARCOMA
Stephen Chenard
Favorite
Chenard, Stephen

Vanderbilt University Medical Center
(P 264) INTRAOPERATIVE FROZEN BONE MARROW MARGINS: A HELP OR A HINDRANCE IN EWING SARCOMA RESECTION?
Stephen Chenard
Favorite
(P 265) IS THERE AN IDEAL STEM TO CANAL RATIO IN LOWER EXTREMITY ONCOLOGIC ENDOPROSTHESIS RECONSTRUCTION?
Stephen Chenard
Favorite
Chenard, Stephen

Vanderbilt University School of Medicine
(P 268) LOWER TUMOR PERCENT NECROSIS IS ASSOCIATED WITH POSITIVE FINAL SURGICAL MARGINS IN OSTEOSARCOMA
Stephen Chenard
Favorite
Chenard, Stephen

Vanderbilt University Medical Center
(P 404) ENHANCED RECOVERY AFTER SURGERY (ERAS) PROTOCOL FOR PATENTS WITH SOFT TISSUE SARCOMA OF THE EXTREMITY: A PROSPECTIVE, NON-RANDOMIZED, CONSECUTIVELY ENROLLED TRIAL
Stephen Chenard
Favorite
Chen, Bo

Department of Osteopathic Oncology, Honghui Hospital, Xi'an Jiaotong University, Xi'an, Shanxi
(P 407) LONG-TERM EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): PHASE 1B UPDATE.
Bo Chen
Favorite
Chen, James

The Ohio State University Comprehensive Cancer Center
(P 109) INTEGRATED TRANSCRIPTOMIC ANALYSIS OF CIC::DUX4 FUSION SARCOMAS REVEALS ELEVATED PROLIFERATION SIGNALING AND IMPLICATES DNA REPAIR GENE POLE
James Chen
Favorite
(P 207) PATIENT-REPORTED GLOBAL HEALTH PREDICTS ADVERSE HEALTH OUTCOMES IN PATIENTS WITH ADVANCED SARCOMA
James Chen
Favorite
(P 244) PREDICTIVE VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO IN IMMUNOTHERAPY OUTCOMES IN ADVANCED SARCOMA
James Chen
Favorite
(P 328) DETERMINING BIOMARKERS FOR GEMCITABINE RESPONSE IN SOFT TISSUE SARCOMAS: LESSONS LEARNED FROM PANCREATIC CANCER
James Chen
Favorite
(P 413) SUSTAINED EFFICACY DURING DRUG HOLIDAY ON ATEZOLIZUMAB IN PATIENTS WITH ALVEOLAR SOFT PART SARCOMA (ASPS)
James Chen
Favorite
Chen, Jenny

Levine Cancer Institute
(P 430) QUANTITATIVE EMT GENE SCORES AT DIAGNOSIS INDICATE METASTASIS RISK AND SURVIVAL IN SYNOVIAL SARCOMA
Jenny Chen
Favorite
Chen, Jiahui

Department of Gastric surgery ，Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.
(P 164) CLINICAL BENEFITS OF RIPRETINIB AND CYTOREDUCTIVE SURGERY IN IMATINIB-RESISTANT ADVANCED GASTROINTESTINAL STROMAL TUMORS (GISTS): A RETROSPECTIVE DUAL-CENTER STUDY
Jiahui Chen
Favorite
Chen, Jing

Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, PR China
(P 132) PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND DISEASE BURDEN OF DEDIFFERENTIATED LIPOSARCOMA IN CHINA: A REAL-WORLD STUDY BASED ON NATIONAL CANCER REGISTRY
Jing Chen
Favorite
Chen, Jun

Peking University People's Hospital
(P 186) ANALYSIS OF FACTORS INFLUENCING POSTOPERATIVE VENOUS THROMBOEMBOLISM FORMATION IN PATIENTS WITH MASSIVE BLOOD LOSS DURING RETROPERITONEAL TUMOR RESECTION
Jun Chen
Favorite
(P 377) INCIDENCE, RISK FACTORS, AND EFFECT ON 60-DAYS SURVIVAL OF ACUTE KIDNEY INJURY OCCURRED WITHIN 7 DAYS AFTER SURGERY IN ELDERLY PATIENTS WITH RETROPERITONEALL TUMORS: A RETROSPECTIVE COHORT STUDY
Jun Chen
Favorite
Chen, Kai

Zhengzhou University
(P 97) TRANSCRIPTOMICS REVEALS THAT OVEREXPRESSION OF LNCRNA HOTTIP REGULATES PKC PROTEIN ACTIVATION OF THE RAP1 SIGNALING PATHWAY FOR SYNOVIAL SARCOMA CELL PROGRESSION
Kai Chen
Favorite
Chen, Katherine

Department of Surgery, University of California San Diego
(P 165) COMPLETE PERITONEAL CYTOREDUCTIVE SURGERY IN HIGHLY SELECTED PATIENTS WITH AGGRESSIVE METASTATIC SDH-DEFICIENT GIST CAN PROLONG EVENT-FREE SURVIVAL
Katherine Chen
Favorite
Chen, Kenneth

University of Texas Southwestern Medical Center
(P 417) VITAS: ATEZOLIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY SOLID TUMORS: AN OPEN-LABEL, PHASE I/II, SINGLE-ARM, MULTI-CENTER TRIAL IN PROGRESS
Kenneth Chen
Favorite
Chen, Tom Wei-Wu

National Taiwan University Hospital
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Tom Wei-Wu Chen
Favorite
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Tom Wei-Wu Chen
Favorite
(P 348) EVALUATING THE IMPACT OF BIOLOGICAL EFFECTIVE DOSE AND DELAYED RADIOTHERAPY ON THE SYNERGISTIC EFFICACY OF TRABECTEDIN IN METASTATIC SOFT TISSUE SARCOMA PATIENTS
Tom Wei-Wu Chen
Favorite
Chen, XiaoLei

Department of Gastrointestinal Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
(P 164) CLINICAL BENEFITS OF RIPRETINIB AND CYTOREDUCTIVE SURGERY IN IMATINIB-RESISTANT ADVANCED GASTROINTESTINAL STROMAL TUMORS (GISTS): A RETROSPECTIVE DUAL-CENTER STUDY
XiaoLei Chen
Favorite
Chen, Yanjiang

Pathology and Molecular Pathology USZ
(P 99) ACQUIRED NF2 MUTATION CONFERS RESISTANCE TO TRK INHIBITION IN AN EX VIVO LMNA::NTRK1-REARRANGED SOFT TISSUE SARCOMA CELL MODEL
Yanjiang Chen
Favorite
(P 118) UNRAVELING HOMOLOGOUS RECOMBINATION REPAIR DEFICIENCY AND THERAPEUTIC OPPORTUNITIES IN SOFT TISSUE AND BONE SARCOMA
Yanjiang Chen
Favorite
Chen, Yongjie

Peking University International Hospital
(P 186) ANALYSIS OF FACTORS INFLUENCING POSTOPERATIVE VENOUS THROMBOEMBOLISM FORMATION IN PATIENTS WITH MASSIVE BLOOD LOSS DURING RETROPERITONEAL TUMOR RESECTION
Yongjie Chen
Favorite
(P 379) KEY POINTS OF ANESTHESIA MANAGEMENT AND PROGNOSIS ANALYSIS OF ELDERLY PATIENTS WITH RETROPERITONEAL TUMOR
Yongjie Chen
Favorite
Chen, Yong-Jie

Peking University International Hospital
(P 377) INCIDENCE, RISK FACTORS, AND EFFECT ON 60-DAYS SURVIVAL OF ACUTE KIDNEY INJURY OCCURRED WITHIN 7 DAYS AFTER SURGERY IN ELDERLY PATIENTS WITH RETROPERITONEALL TUMORS: A RETROSPECTIVE COHORT STUDY
Yong-Jie Chen
Favorite
Cheung, Adam

UCLH
(P 146) EXPLORING THE CLINICAL UTILITY OF WHOLE GENOME SEQUENCING FOR PAEDIATRIC, TYA AND ADULT SARCOMA PATIENTS WITHIN THE LONDON SARCOMA SERVICE: A RETROSPECTIVE COHORT ANALYSIS
Adam Cheung
Favorite
Cheung, Nai-Kong

Memorial Sloan Kettering Cancer Center
(P 302) HER2 PRETARGETED ALPHA PARTICLE RADIOIMMUNOTHERAPY FOR DESMOPLASTIC SMALL ROUND CELL TUMORS
Nai-Kong Cheung
Favorite
Chia, Claramae

Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore
(P 370) DEFYING NORMS - CENTRALIZATION OF SARCOMA CARE ON AN ISLAND NATION
Claramae Chia
Favorite
(P 375) FROM SAPLING TO SHADE: GROWTH OF A HIGH VOLUME ASIAN TERTIARY SARCOMA SPECIALISED CENTRE
Claramae Chia
Favorite
Chiang, Sarah

Memorial Sloan Kettering Cancer Center, New York (United States of America)
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Sarah Chiang
Favorite
Chiang, Yi-Ju

University of Texas MD Anderson Cancer Center
(P 130) HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RESECTABLE RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA (DDLPS) TREATED WITH NEOADJUVANT CHECKPOINT BLOCKADE IN A RANDOMIZED PHASE II CLINICAL TRIAL.
Yi-Ju Chiang
Favorite
Chiarappa, Frank

University of California, San Diego
(P 52) CEMENT-AUGMENTED INTERNAL FIXATION FOR TEMPORIZING BONE SARCOMAS OF THE HIP
Frank Chiarappa
Favorite
Childers-Quiñones, Robert

University of Arizona College of Medicine - Tucson, AZ
(P 148) ISOCITRATE DEHYDROGENASE MUTATIONS IN CHONDROSARCOMA: A META-ANALYSIS
Robert Childers-Quiñones
Favorite
Chi, Ping

Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine
(P 121) ACQUIRED CYCLIN D AMPLIFICATION IS A MECHANISM FOR RESISTANCE TO CDK4/6 INHIBITORS IN DEDIFFERENTIATED LIPOSARCOMA
Ping Chi
Favorite
(P 229) EXPRESSION OF TRANSPOSABLE ELEMENTS AND IKZF1 PREDICTS IMMUNE INFILTRATES IN SARCOMAS AND CORRELATES WITH OUTCOMES AFTER IMMUNE CHECKPOINT INHIBITION
Ping Chi
Favorite
(P 403) DCC-3116 IN COMBINATION WITH RIPRETINIB FOR PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A PHASE 1/2 STUDY
Ping Chi
Favorite
Chitnis, Saurabh

The Ohio State University James Comprehensive Cancer Center
(P 207) PATIENT-REPORTED GLOBAL HEALTH PREDICTS ADVERSE HEALTH OUTCOMES IN PATIENTS WITH ADVANCED SARCOMA
Saurabh Chitnis
Favorite
Chiusole, Benedetta

Oncology 1 Unit, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Benedetta Chiusole
Favorite
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Benedetta Chiusole
Favorite
Chi, Yueh-Yun

Children's Hospital Los Angeles
(P 76) MOLECULAR AND CHROMOSOMAL MICROARRAY PROFILING OF OSTEOSARCOMA IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS: A SINGLE INSTITUTION REPORT
Yueh-Yun Chi
Favorite
Choe, Michelle

Fred Hutchinson Cancer Center
(P 226) EARLY EXPERIENCE ON ENLIGHTEN-01: A PHASE 1 STUDY OF BISPECIFIC ADAPTER MOLECULE- CONTROLLED FOLATE RECEPTOR CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY OSTEOSARCOMA
Michelle Choe
Favorite
Chopra, Shefali

Department of Pathology, University of Southern California
(P 158) RECURRENT RADIATION-INDUCED SARCOMA IN A PATIENT WITH HEREDITARY RETINOBLASTOMA: PRESENTATION AND OUTCOME
Shefali Chopra
Favorite
Chose, Chloe

USF Health Morsani College of Medicine
(P 257) COMPARATIVE OUTCOMES OF CONSTRAINED ACETABULAR LINERS VS. DUAL MOBILITY CUPS IN COMPLEX HIP RECONSTURCTION FOR METASTATIC BONE DISEASE
Chloe Chose
Favorite
(P 262) EVALUATION OF STAGED RESECTION WITH TEMPORIZING VAC OF SOFT TISSUE SARCOMAS
Chloe Chose
Favorite
(P 279) SIGNIFICANCE OF TIP-APEX DISTANCE IN ACTUAL AND IMPENDING PATHOLOGICAL FRACTURES OF THE PROXIMAL FEMUR
Chloe Chose
Favorite
Cho, Sooick

Lunit
(P 123) ARTIFICIAL INTELLIGENCE-POWERED MITOSIS EVALUATION TO COMPLEMENT HUMAN MITOTIC RATE INTERPRETATION IN PREDICTING PROGNOSIS IN LIPOSARCOMA
Sooick Cho
Favorite
Cho, Sunny

SpringWorks Therapeutics, Inc.
(P 33) DESCRIPTIVE EVALUATION OF PATIENTS WITH DESMOID TUMOR AND CO-OCCURRING SOMATIC MUTATIONS OF CTNNB1 AND APC IN THE PHASE 3 DEFI TRIAL
Sunny Cho
Favorite
Cho, Sunny

SpringWorks Therapeutics Inc
(P 34) DESMOID TUMOR COHORT CREATION AND CHARACTERISTICS IN THE VETERANS AFFAIRS (VA) NATIONAL DATABASE
Sunny Cho
Favorite
Choy, Edwin

Massachusetts General Hospital
(P 107) DOES THE USE OF ADJUVANT CHEMOTHERAPY IN LOCALIZED, RESECTABLE SOFT TISSUE SARCOMA LEAD TO BETTER SURVIVAL OUTCOMES? - A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Edwin Choy
Favorite
Cho, Yoon Joo

The Catholic University of Korea
(P 218) SEX DIFFERENCES IN THE ASSOCIATION OF ALCOHOL INTAKE WITH THE RISK OF SOFT-TISSUE SARCOMA: A NATIONWIDE POPULATION-BASED RETROSPECTIVE COHORT STUDY
Yoon Joo Cho
Favorite
Christensen, Anthony

St. Jude Children's Research Hospital
(P 288) ANGIOA: A SAFETY AND TOLERABILITY STUDY OF TRIPLE ANTI-ANGIOGENIC THERAPY COMBINED WITH PD-L1 BLOCKADE IN PEDIATRIC, ADOLESCENT AND YOUNG ADULT RECURRENT/REFRACTORY SOLID TUMORS
Anthony Christensen
Favorite
Christ, Sebastian

SwissSarcomaNetwork
(P 184) A SYSTEMATIC REVIEW ABOUT CLINICAL PROGNOSTIC MODELS FOR SARCOMAS
Sebastian Christ
Favorite
Chua, Victoria

Sarcoma Oncology Center
(P 241) LINNOVATE: A PHASE 1/2 STUDY OF SAFETY/EFFICACY USING LURBINECTEDIN COMBINED WITH IPILUMUMAB AND NIVOLUMAB FOR ADVANCED SOFT TISSUE SARCOMA (NCT05876715)
Victoria Chua
Favorite
(P 248) TNT: A PHASE 2 STUDY USING TALIMOGENE LAHERPAREPVEC, NIVOLUMAB, AND TRABECTEDIN FOR ADVANCED LEIOMYOSARCOMA AND LIPOSARCOMA (NCT # 03886311)
Victoria Chua
Favorite
(P 250) UPDATE ON GALLANT: A PHASE 2 STUDY USING METRONOMIC GEMCITABINE, DOXORUBICIN AND DOCETAXEL PLUS NIVOLUMAB IN PREVIOUSLY TREATED SARCOMA (NCT04535713)
Victoria Chua
Favorite
(P 251) UPDATE ON SAINT: A PHASE 2 STUDY USING TRABECTEDIN (T) IN COMBINATION WITH IPILIMUMAB (L) AND NIVOLUMAB (N) IN PREVIOUSLY TREATED SOFT TISSUE SARCOMA (NCT03138161)
Victoria Chua
Favorite
Chudasama, Priya

German Cancer Research Center
(P 345) TRANSCRIPTOMIC AND PHENOTYPIC CHARACTERIZATION OF AN IMMUNOCOMPETENT LEIOMYOSARCOMA MOUSE MODEL.
Priya Chudasama
Favorite
Chugh, Rashmi

University of Michigan Rogel Comprehensive Cancer Center
(P 45) UTILIZATION OF MENTAL HEALTH AND SUPPORTIVE CARE RESOURCES AMONG PATIENTS WITH DESMOID TUMORS
Rashmi Chugh
Favorite
Chugh, Rashmi

University of Michigan, Department of Hematology/Oncology
(P 95) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN PATIENTS WITH CHONDROSARCOMA: UPDATED RESULTS FROM A PHASE 1 STUDY
Rashmi Chugh
Favorite
Chugh, Rashmi

University of Michigan Rogel Comprehensive Cancer Center
(P 131) HETEROGENEITY OF THE IMMUNE MICROENVIRONMENT AND IMMUNOTHERAPY RESPONSE IN A DEDIFFERENTIATED LIPOSARCOMA MOUSE MODEL
Rashmi Chugh
Favorite
(P 308) PALLIATIVE CARE INVOLVEMENT FOR ADOLESCENTS AND YOUNG ADULTS WITH BONE AND SOFT TISSUE SARCOMAS
Rashmi Chugh
Favorite
(P 423) COMPARISON OF CLINICAL COURSE AND FEATURES BETWEEN SCLEROSING EPITHELOID FIBROSARCOMA AND LOW-GRADE FIBROMYXOID SARCOMA
Rashmi Chugh
Favorite
Chung, Paul

University of California, San Diego School of Medicine
(P 52) CEMENT-AUGMENTED INTERNAL FIXATION FOR TEMPORIZING BONE SARCOMAS OF THE HIP
Paul Chung
Favorite
Chung, Peter

Princess Margaret Cancer Centre
(P 352) OUTCOMES OF PRIMARY INTRATHORACIC SOFT TISSUE SARCOMA
Peter Chung
Favorite
Cicala, Carlo

Vall d'Hebron Institute of Oncology
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Carlo Cicala
Favorite
Ciobanu-Caraus, Olga

SwissSarcomaNewtwork
(P 184) A SYSTEMATIC REVIEW ABOUT CLINICAL PROGNOSTIC MODELS FOR SARCOMAS
Olga Ciobanu-Caraus
Favorite
Clerici, Elena

Rozzano, Milan IRCCS Humanitas Research Hospital
(P 431) REAL-WORLD EXPERIENCE OF EFFICACY AND TOLERABILITY OF CONTINUOS INFUSION IFOSFAMIDE AMONG ADVANCED SOFT TISSUE AND BONE SARCOMAS PATIENTS: A SINGLE CENTRE RETROSPECTIVE COHORT.
Elena Clerici
Favorite
Cleven, Arjen

University Medical Center Groningen
(P 42) RANKL-INHIBITION FOR GIANT CELL LESIONS OF THE JAW: A RETROSPECTIVE COHORT ANALYSIS
Arjen Cleven
Favorite
Clever, David

University of Toronto
(P 71) LIMB-SALVAGE SURGERY AFTER UNPLANNED SURGERY FOR EXTREMITY BONE SARCOMAS: 30-YEAR EXPERIENCE AT A TERTIARY REFERRAL CENTER
David Clever
Favorite
(P 238) INTRA-TUMORAL DC-LAMP EXPRESSION IS ASSOCIATED WITH PROGNOSIS IN SOFT TISSUE SARCOMA
David Clever
Favorite
(P 281) THE UTILITY OF INTRAOPERATIVE MARROW MARGIN FROZEN SECTION IN EXTREMITY BONE SARCOMA RESECTION
David Clever
Favorite
Close, Julia

University of Florida
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Julia Close
Favorite
Clugston, Andrew

UCSF
(P 65) EPIGENETIC HETEROGENEITY AND STATE SPECIFIC TRANSCRIPTIONAL PROGRAMS DRIVE DRUG RESPONSE IN OSTEOSARCOMA
Andrew Clugston
Favorite
Clunk, Marilee

Massachusetts General Hospital
(P 63) DOES TUMOR NECROSIS IMPACT PROGNOSIS IN CHONDROBLASTIC AND OSTEOBLASTIC OSTEOSARCOMA? A STUDY FROM A LARGE TERTIARY CARE ACADEMIC CENTER
Marilee Clunk
Favorite
Cocchi, Claudia

Istituto Scientifico Romagnolo per lo studio dei Tumori "Dino Amadori", Preclinic and Osteoncology Unit, Meldola, Italy
(P 336) IMPROVEMENT OF PHOTODYNAMIC THERAPY IN SARCOMA: IN VITRO VALIDATION ON OSTEOSARCOMA AND MYXOFIBROSARCOMA
Claudia Cocchi
Favorite
Coccoli, Luca

Stem Cell Transplantation, S. Chiara Hospital, AOUP, Pisa,
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Luca Coccoli
Favorite
Cohen, Sonia

Massachusetts General Hospital
(P 371) ELUCIDATING THE CLINICAL UTILITY OF TARGETED GENE EXPRESSION PROFILING IN RETROPERITONEAL LIPOSARCOMA
Sonia Cohen
Favorite
Coimbra, Felipe

A.C.Camargo Cancer Center
(P 300) GASTROINTESTINAL STROMAL TUMORS (GIST) IN YOUNG ADULTS (YA): A BRAZILIAN COHORT OF PATIENTS
Felipe Coimbra
Favorite
Colasacco, Bryan

TouroCOM Middletown
(P 260) EMERGING TECHNOLOGY IN ORTHOPEDIC ONCOLOGY: ROBOTIC ARM-ASSISTED TOTAL KNEE ARTHROPLASTY HAS EXCEPTIONAL FUNCTION OUTCOMES FOR PATIENTS WITH BENIGN AND MALIGNANT MUSCULOSKELETAL DISEASE
Bryan Colasacco
Favorite
(P 266) LONG STEM CEMENTED ROBTIC ARM-ASSISTED TOTAL HIP ARTHROPLASTY: OUTCOMES IN PATIENTS WITH PRIOR ONCOLOGIC DISEASE
Bryan Colasacco
Favorite
Collier III, Anderson

Nemours Children’s Health
(P 309) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT SOFT TISSUE SARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Anderson Collier III
Favorite
Collini, Paola

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 137) TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS
Paola Collini
Favorite
(P 160) UTERINE PECOMA: REPORT OF MOLECULAR AND CLINICAL FEATURES IN A SERIES OF PATIENTS TREATED AT A REFERRAL INSTITUTION
Paola Collini
Favorite
(P 368) AGGRESSIVE PERINEAL ANGIOMYXOMA UNDERGOING SYSTEMIC TREATMENT: AN UPDATED REPORT OF 8-YEARS' EXPERIENCE IN A REFERRAL CENTER
Paola Collini
Favorite
(P 420) CELLULARITY DEGREES IN PRIMARY MYXOID LIPOSARCOMA: ASSOCIATION WITH TUMOR IMMUNE INFILTRATE AND PATIENT OUTCOMES
Paola Collini
Favorite
Collins, Natalie

Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
(P 417) VITAS: ATEZOLIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY SOLID TUMORS: AN OPEN-LABEL, PHASE I/II, SINGLE-ARM, MULTI-CENTER TRIAL IN PROGRESS
Natalie Collins
Favorite
COLMAN, HOWARD

Huntsman Cancer Institute
(P 87) SAFETY AND EFFICACY OF OLUTASIDENIB, AN IDH1 MUTANT INHIBITOR, FOR THE TREATMENT OF RECURRENT/ RELAPSED LOCALLY ADVANCED OR METASTATIC IDH1 MUTATED CHONDROSARCOMA
HOWARD COLMAN
Favorite
Colman, Matthew

Rush University Medical Center
(P 92) THE IMPACT OF CHONDROSARCOMA WITH POSITIVE MARGINS AND EXTRAOSSEOUS EXTENSION ON PATIENT OUTCOMES
Matthew Colman
Favorite
(P 270) OPIOID USE IN IMPENDING VERSUS PATHOLOGIC PROXIMAL FEMUR FRACTURES
Matthew Colman
Favorite
(P 271) OUTCOMES OF DISTAL FEMORAL REPLACEMENT VS INTERNAL FIXATION FOR METASTATIC BONE DISEASE OF THE DISTAL FEMUR
Matthew Colman
Favorite
Colombo, Chiara

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 137) TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS
Chiara Colombo
Favorite
(P 171) GASTROINTESTINAL STROMAL TUMOURS (GISTS) IN NEUROFIBROMATOSIS TYPE (NF1): A SINGLE-CENTER OBSERVATIONAL RETROSPECTIVE STUDY
Chiara Colombo
Favorite
Colombo, Piergiuseppe

Pathology Unit, Humanitas Clinical and Research Center, IRCCS, Rozzano, 20089, Italy
(P 124) ASSESSMENT OF THE MECHANISMS OF ACTION OF ERIBULIN IN PATIENTS WITH ADVANCED LIPOSARCOMA THROUGH THE EVALUATION OF THE RADIOLOGICAL, FUNCTIONAL AND TISSUE RESPONSE: A MONOCENTRIC PROSPECTIVE STUDY
Piergiuseppe Colombo
Favorite
Conkling, Paul

Ontada
(P 133) REAL-WORLD ANALYSIS OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS) IN A US COMMUNITY ONCOLOGY SETTING
Paul Conkling
Favorite
Conley, Anthony

The University of Texas MD Anderson Cancer Center
(P 233) IMMUNE CLASSES OF LEIOMYOSARCOMA DRIVEN BY B CELL INFILTRATE AND CTLA4 EXPRESSION
Anthony Conley
Favorite
(P 413) SUSTAINED EFFICACY DURING DRUG HOLIDAY ON ATEZOLIZUMAB IN PATIENTS WITH ALVEOLAR SOFT PART SARCOMA (ASPS)
Anthony Conley
Favorite
Connolly, Elizabeth

Chris O Brien Lifehouse
(P 325) CAN PROTEOMICS PREDICT METASTATIC RELAPSE IN LEIOMYOSARCOMA? DEVELOPMENT OF AN 8 PROTEIN SIGNATURE IN A >350 SAMPLE STUDY INCLUDING A VALIDATION COHORT
Elizabeth Connolly
Favorite
Connolly, Joseph

Massachusetts General Hospital
(P 107) DOES THE USE OF ADJUVANT CHEMOTHERAPY IN LOCALIZED, RESECTABLE SOFT TISSUE SARCOMA LEAD TO BETTER SURVIVAL OUTCOMES? - A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Joseph Connolly
Favorite
Conti, Ilaria

ADC Therapeutics
(P 116) QUANTITATIVE SYSTEMS PHARMACOLOGY MODELING OF MIPASETAMAB UZOPTERINE INTEGRATES KNOWLEDGE AND DEFINES DOSING STRATEGY FOR PATIENTS WITH SARCOMA
Ilaria Conti
Favorite
Cook, David

Edgewood Oncology
(P 402) A PILOT STUDY OF BTX-A51 IN PATIENTS WITH METASTATIC AND/OR RECURRENT LIPOSARCOMAS CHARACTERIZED BY MDM2 AMPLIFICATIONS
David Cook
Favorite
Cook, James

University of Missouri
(P 62) DOES LIQUID NITROGEN RECYCLED AUTOGRAFT FOR TREATMENT OF BONE SARCOMA IMPACT LOCAL RECURRENCE RATE? A SYSTEMATIC REVIEW
James Cook
Favorite
(P 254) ATYPICAL FEMUR FRACTURE IN A TEENAGER ON CHRONIC IMATINIB THERAPY
James Cook
Favorite
Copperman, Jeremy

OHSU
(P 72) LIVE-CELL TISSUE MODELS REVEAL SOURCES OF DYNAMIC HETEROGENEITY IN THE OSTEOSARCOMA METASTATIC NICHE
Jeremy Copperman
Favorite
Cornett, Ashley

University of Michigan
(P 341) THE EFFECTS OF ULTRASOUND-GUIDED HISTOTRIPSY ON SOFT TISSUE SARCOMA
Ashley Cornett
Favorite
Corona, Juan Antonio

Hospital Clinico san Carlos
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Juan Antonio Corona
Favorite
Cortes, Jose Antonio

Hospital Clinico san Carlos
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Jose Antonio Cortes
Favorite
Costa, Philippos

Yale University
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Philippos Costa
Favorite
(P 98) A MULTIEPITOPE MRNA VACCINE FOR KAPOSI SARCOMA: AN IMMUNOINFORMATIC APPROACH
Philippos Costa
Favorite
(P 224) COMPREHENSIVE EVALUATION OF DNA DAMAGE RESPONSE PATHWAY ALTERATIONS AND ASSOCIATED IMMUNOTHERAPY-RESPONSE BIOMARKERS IN SARCOMAS
Philippos Costa
Favorite
Cote, Gregory M.

Massachusetts General Hospital
(P 107) DOES THE USE OF ADJUVANT CHEMOTHERAPY IN LOCALIZED, RESECTABLE SOFT TISSUE SARCOMA LEAD TO BETTER SURVIVAL OUTCOMES? - A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Gregory M. Cote
Favorite
Covello, Eva

IRCCS Humanitas Research Hospital
(P 389) THE ROLE OF NUTRITIONAL STATUS ON POSTOPERATIVE AND ONCOLOGICAL OUTCOMES IN RETROPERITONEAL SARCOMA
Eva Covello
Favorite
Coward, Victoria

The Lunenfeld-Tanenbaum Research Institute
(P 225) DETERMINING THE CONTRIBUTIONS OF STAT1 AND THE Y701 PHOSPHORYLATION TO THE UPS ANTI-TUMOR MICROENVIRONMENT
Victoria Coward
Favorite
Cox, Paulina

Deciphera Pharmaceuticals, LLC
(P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE
Paulina Cox
Favorite
Cozzaglio, Luca

IRCCS Humanitas Research Hospital
(P 389) THE ROLE OF NUTRITIONAL STATUS ON POSTOPERATIVE AND ONCOLOGICAL OUTCOMES IN RETROPERITONEAL SARCOMA
Luca Cozzaglio
Favorite
Crago, Aimee

Memorial Sloan Kettering Cancer Center
(P 101) AN OPEN LABEL PHASE IIA STUDY EVALUATING THE PRELIMINARY EFFICACY OF INTRATUMORAL TIGILANOL TIGLATE (TT) IN ADVANCED AND/OR METASTATIC SOFT TISSUE SARCOMA (STS, NCT05755113)
Aimee Crago
Favorite
(P 121) ACQUIRED CYCLIN D AMPLIFICATION IS A MECHANISM FOR RESISTANCE TO CDK4/6 INHIBITORS IN DEDIFFERENTIATED LIPOSARCOMA
Aimee Crago
Favorite
(P 380) MULTIDISCIPLINARY MANAGEMENT OF INTRA-ABDOMINAL DESMOID-TYPE FIBROMATOSIS: A 30-YEARS EXPERIENCE
Aimee Crago
Favorite
Crane, Jacquelyn

Children's Hospital of Philadelphia
(P 318) SYNOVIAL SARCOMA REGISTRY AND BIOSPECIMEN REPOSITORY: DESCRIBING THE COHORT AND SURVIVAL OUTCOMES TO DATE
Jacquelyn Crane
Favorite
Crawford, Brooke

University of Miami
(P 346) BRACHYTHERAPY FOR SOFT TISSUE SARCOMA: MAINTAINING LOCAL CONTROL WHILE MINIMIZING COMPLICATIONS
Brooke Crawford
Favorite
Crespo, Ana Maria

Hospital Clinico san Carlos
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Ana Maria Crespo
Favorite
Crimella, Jessica

Moffitt Cancer Center
(P 309) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT SOFT TISSUE SARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Jessica Crimella
Favorite
Crist, Jamie

The University of Kansas Medical Center
(P 36) EARLY REAL-WORLD EXPERIENCE WITH THE USE OF NIROGACESTAT FOR THE TREATMENT OF DESMOID FIBROMATOSIS
Jamie Crist
Favorite
Croce, Sabrina

Institut Bergonié, Bordeaux (France)
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Sabrina Croce
Favorite
Crochiere, Marsha

Pyxis Oncology
(P 339) SARCOMAS EXPRESS EXTRA DOMAIN B OF FIBRONECTIN AND PRECLINICAL PATIENT-DERIVED XENOGRAFT MODELS OF SEVERAL SARCOMA SUBTYPES ARE SENSITIVE TO THE STROMA TARGETING ANTIBODY DRUG CONJUGATE PYX-201
Marsha Crochiere
Favorite
Crompton, Brian

Department of Pediatrics, Dana-Farber / Boston Children’s Cancer and Blood Disorders Center Harvard Medical School
(P 115) PROSPECTIVE EVALUATION OF THORACOSCOPIC METASTASECTOMY IN DOGS: A NOVEL TRANSLATIONAL DRUG DEVELOPMENT PIPELINE TAGETING METASTATIC OSTEOSARCOMA
Brian Crompton
Favorite
(P 408) OSTEOMYC: A PHASE 2 PILOT STUDY TO EVALIATE THE SAFETY AND THE ANTITUMOR ACTIVITY OF THE MYC INHIBITOR OMO-103 ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH ADVANCED HIGH GRADE OSTEOSARCOMA
Brian Crompton
Favorite
(P 412) SARC044: A PHASE II TRIAL OF BEZUCLASTINIB IN COMBINATION WITH SUNITINIB IN PATIENTS WITH GIST WHO PROGRESSED ON SUNITINIB MONOTHERAPY
Brian Crompton
Favorite
Croxford, William

The Christie NHS Foundation Trust
(P 60) DIAGNOSIS AND MANAGEMENT OF PAEDIATRIC EWING SARCOMA PATIENTS IN ENGLAND 2014-2017: A COMPARISON OF NATIONAL DATA WITH THE EURO-EWING 2012 CLINICAL TRIAL
William Croxford
Favorite
Cruzado, Juan Antonio

Universidad Complutense de Madrid
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Juan Antonio Cruzado
Favorite
Cruz, Josefina

HU Canarias
(P 234) IMMUNOSARC II MASTER TRIAL (PHASE II OF SUNITINIB AND NIVOLUMAB): RESULTS FROM THE CLEAR CELL SARCOMA (CCS) COHORT. A GEIS, ISG, AND UCL STUDY
Josefina Cruz
Favorite
Cruz, Sylvia

Division of Surgical Oncology, Department of Surgery, University of California Davis
(P 230) HIGHER BODY MASS INDEX IS ASSOCIATED WITH DECREASED CIRCULATING AND INTRATUMORAL NATURAL KILLER CELLS IN SOFT TISSUE SARCOMA
Sylvia Cruz
Favorite
Cuadrado, Nuria

Hospital Clinico san Carlos
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Nuria Cuadrado
Favorite
Cuenca, Concepcion

Hospital Clinico san Carlos
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Concepcion Cuenca
Favorite
Cuevas Marchante, Maria del Carmen

PharmaMar
(P 340) THE DNA MINOR GROOVE BINDING AGENTS ECUBECTEDIN AND PM54 DEMONSTRATE ANTITUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT MODELS OF SOFT TISSUE SARCOMA
Maria del Carmen Cuevas Marchante
Favorite
Cui, Xiaoxia

Genome Engineering & Stem Cell Center (GESC@MGI) Dept. of Genetics, Washington University in St. Louis School of Medicine
(P 10) GENERATION OF A CHROMOSOME 8 GAIN;NF1-/- HUMAN INDUCED PLURIPOTENT STEM CELL DERIVED SCHWANN CELL PRECURSOR MODEL
Xiaoxia Cui
Favorite
Curioni, Carolina

Maastricht University Medical Center
(P 361) WOUND COMPLICATIONS AFTER SOFT TISSUE SARCOMA RESECTION: A SINGLE-CENTER RETROSPECTIVE ANALYSIS
Carolina Curioni
Favorite
Cypel, Marcelo

University Health Network
(P 352) OUTCOMES OF PRIMARY INTRATHORACIC SOFT TISSUE SARCOMA
Marcelo Cypel
Favorite
Cyr, David P.

University of Toronto
(P 376) IMPACT OF SITE OF ORIGIN ON THE PROGNOSIS OF PATIENTS WITH PRIMARY RESECTABLE NON-UTERINE ABDOMINAL LEIOMYOSARCOMA
David P. Cyr
Favorite
王, 志龙

Peking University Cancer Hospital
(P 180) TUMOR VASCULAR SIGN IN THE RESPONSE ASSESSMENT OF GASTROINTESTINAL STROMAL TUMOR TREATED WITH RIPRETINIB: A MULTICENTER STUDY
志龙王
Favorite
C
Czarnecka, Anna

Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
(P 77) MULTI-PARAMETRICAL PROFILING OF CHONDROSARCOMA
Anna Czarnecka
Favorite
D
Dávila Fajardo, Raquel

Princess Máxima Center for pediatric oncology
(P 319) THE SURVIVAL DISPARITY BETWEEN CHILDREN AND ADOLESCENTS & YOUNG ADULTS WITH EWING SARCOMA IN THE NETHERLANDS DID NOT CHANGE SINCE THE 1990S DESPITE IMPROVED SURVIVAL: A POPULATION-BASED STUDY
Raquel Dávila Fajardo
Favorite
D’Amato, Gina

Sylvester Comprehensive Cancer Center, University of Miami
(P 224) COMPREHENSIVE EVALUATION OF DNA DAMAGE RESPONSE PATHWAY ALTERATIONS AND ASSOCIATED IMMUNOTHERAPY-RESPONSE BIOMARKERS IN SARCOMAS
Gina D’Amato
Favorite
(P 246) THE GENOMIC AND IMMUNE LANDSCAPE OF LIPOSARCOMA AND ITS SUBTYPES
Gina D’Amato
Favorite
(P 253) ASSESSING THE LINK BETWEEN MYXOFIBROSARCOMA RECURRENCE AND TREATMENT ORDER: A MULTIDISCIPLINARY RETROSPECTIVE COHORT STUDY
Gina D’Amato
Favorite
(P 296) DISPARITIES IN OVERALL SURVIVAL FOR AYA PATIENTS WITH EWINGS SARCOMA: A RETROSPECTIVE COHORT STUDY AT A SINGLE SARCOMA CENTER
Gina D’Amato
Favorite
(P 314) RETROSPECTIVE EVALUATION OF DISPARITIES IN ADOLESCENT AND YOUNG ADULT (AYA) PATIENTS WITH SYNOVIAL SARCOMA: A SINGLE INSTITUTION STUDY
Gina D’Amato
Favorite
(P 381) OLIGOMETASTATIC LEIOMYOSARCOMA: ASSOCIATION BETWEEN TREATMENT TYPE, METASTATIC PATTERN AND SURVIVAL
Gina D’Amato
Favorite
(P 434) UTILIZATION OF IMAGING MASS CYTOMETRY TO EVALUATE THE IMMUNE LANDSCAPE OF PEDIATRIC AND ADULT PATIENTS WITH SARCOMA TREATED WITH AN AUTOLOGOUS DENDRITIC CELL VACCINE
Gina D’Amato
Favorite
Daffinoti, Anabela

University of Buenos Aires, Angel H Roffo Institute of Oncology
(P 273) PRIMARY SOFT-TISSUE SARCOMAS OF THE UPPER LIMBS
Anabela Daffinoti
Favorite
Dagrada, Gianpaolo

Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(P 137) TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS
Gianpaolo Dagrada
Favorite
(P 420) CELLULARITY DEGREES IN PRIMARY MYXOID LIPOSARCOMA: ASSOCIATION WITH TUMOR IMMUNE INFILTRATE AND PATIENT OUTCOMES
Gianpaolo Dagrada
Favorite
Dai, Dong

Daiichi Sankyo, Inc.
(P 37) HEALTH-RELATED QUALITY OF LIFE FROM A PHASE 4 STUDY TO EVALUATE DISCONTINUATION AND RECHALLENGE OF PEXIDARTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR PREVIOUSLY TREATED WITH PEXIDARTINIB
Dong Dai
Favorite
(P 211) REAL-WORLD EXPERIENCE OF PATIENTS NEWLY INITIATED ON PEXIDARTINIB FOR TENOSYNOVIAL GIANT CELL TUMOR
Dong Dai
Favorite
Dai, Zhenwu

Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co.
(P 83) PREDICTION OF HIGH-RISK OSTEOSARCOMA PATIENTS BASED ON MACHINE LEARNING USING TRANSCRIPTOME AND METHYLATION DATA FROM SGH-COHORT
Zhenwu Dai
Favorite
Daley, Jessica

University of Pittsburgh, UPMC Children's Hospital of Pittsburgh
(P 64) ENTINOSTAT ENHANCES PRO-INFLAMMATORY CHEMOKINE PRODUCTION AND INCREASES RADIATION-INDUCED APOPTOSIS IN EWING SARCOMA
Jessica Daley
Favorite
(P 66) EWING TUMORS WITH STAG2 LOSS DEMOSNTRATE ALTERED INTERFERON SIGNATURES AND IMPAIRED CXCL10 EXPRESSION
Jessica Daley
Favorite
D'Almeida Costa, Felipe

A.C.Camargo Cancer Center
(P 152) NOVEL PAX3::MAML3 FUSION IDENTIFIED IN ALVEOLAR RHABDOMYOSARCOMA: USING DNA METHYLATION TO EXPANDE THE GENETIC SPECTRUM OF "FUSION POSITIVE" CASES
Felipe D'Almeida Costa
Favorite
Daly, Roger

Monash University
(P 299) EXPLORING THE POTENTIAL OF PHOSPHOPROTEOMIC PROFILING FOR TARGET DISCOVERY IN HIGH-RISK OSTEOSARCOMA: A PATHWAY TO NOVEL THERAPIES?
Roger Daly
Favorite
D'Amato, Vittoria

IRCCS Humanitas Research Hospital
(P 362) A NEW ROCK BAND FOR DIAPHRAGMATIC RECONSTRUCTION IN LEFT RETROPERITONEAL SARCOMA SURGERY
Vittoria D'Amato
Favorite
(P 363) A NEW SURGICAL TECHNIQUE FOR THE RECONSTRUCTION OF INGUINAL 'NEOLIGAMENT' AFTER SOFT TISSUE SARCOMA RESECTION
Vittoria D'Amato
Favorite
(P 373) EVALUATION OF HISTOLOGIC ORGAN INFILTRATION (HOI) AND VISCERAL RESECTION MARGINS (VRM) IN PRIMARY RETROPERITONEAL SARCOMAS: PROGNOSTIC IMPLICATIONS FOR LOCAL RECURRENCE
Vittoria D'Amato
Favorite
(P 388) THE ROAD TO CURATIVE SURGERY IN RETROPERITONEAL SOFT TISSUE SARCOMA: A DIFFERENT PATH IN THE ELDERLY?
Vittoria D'Amato
Favorite
(P 389) THE ROLE OF NUTRITIONAL STATUS ON POSTOPERATIVE AND ONCOLOGICAL OUTCOMES IN RETROPERITONEAL SARCOMA
Vittoria D'Amato
Favorite
D'Ambrosio, Lorenzo

Department of Oncology, University of Turin
(P 345) TRANSCRIPTOMIC AND PHENOTYPIC CHARACTERIZATION OF AN IMMUNOCOMPETENT LEIOMYOSARCOMA MOUSE MODEL.
Lorenzo D'Ambrosio
Favorite
(P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Lorenzo D'Ambrosio
Favorite
Damman, Bryce

Mayo Clinic
(P 200) FRAILTY ASSESSMENT IN OLDER PATIENTS RECEIVING SARCOMA THERAPY
Bryce Damman
Favorite
Damsky, William

Yale University
(P 98) A MULTIEPITOPE MRNA VACCINE FOR KAPOSI SARCOMA: AN IMMUNOINFORMATIC APPROACH
William Damsky
Favorite
Danese, Mark

Outcomes Insights, Inc.
(P 91) THE EFFECT OF CHEMOTHERAPY AND SURGERY TIMING ON MORTALITY IN THE TREATMENT OF UPPER AND LOWER EXTREMITY OSTEOSARCOMA: A DATABASE STUDY
Mark Danese
Favorite
D'Angelo, Sandra

Memorial Sloan Kettering Cancer Center
(P 101) AN OPEN LABEL PHASE IIA STUDY EVALUATING THE PRELIMINARY EFFICACY OF INTRATUMORAL TIGILANOL TIGLATE (TT) IN ADVANCED AND/OR METASTATIC SOFT TISSUE SARCOMA (STS, NCT05755113)
Sandra D'Angelo
Favorite
(P 121) ACQUIRED CYCLIN D AMPLIFICATION IS A MECHANISM FOR RESISTANCE TO CDK4/6 INHIBITORS IN DEDIFFERENTIATED LIPOSARCOMA
Sandra D'Angelo
Favorite
(P 222) ANALYSIS OF THE CITN-13 SARCOMA ARM: PEMBROLIZUMAB AND INTERFERON GAMMA FOR SYNOVIAL SARCOMA AND MYXOID/ ROUND CELL LIPOSARCOMA
Sandra D'Angelo
Favorite
(P 229) EXPRESSION OF TRANSPOSABLE ELEMENTS AND IKZF1 PREDICTS IMMUNE INFILTRATES IN SARCOMAS AND CORRELATES WITH OUTCOMES AFTER IMMUNE CHECKPOINT INHIBITION
Sandra D'Angelo
Favorite
Danieau, Geoffroy

Research Institute of the McGill University Health Center
(P 69) H3.3G34W ONCOHISTONE IN OSTEOSARCOMA
Geoffroy Danieau
Favorite
(P 78) NOVEL EPIGENETIC MECHANISMS DRIVE AGGRESSIVE OSTEOSARCOMA PATHOGENESIS AND DRUG RESISTANCE
Geoffroy Danieau
Favorite
Darrow, Morgan

Pathology and Laboratory Medicine, University of California Davis
(P 230) HIGHER BODY MASS INDEX IS ASSOCIATED WITH DECREASED CIRCULATING AND INTRATUMORAL NATURAL KILLER CELLS IN SOFT TISSUE SARCOMA
Morgan Darrow
Favorite
Das, Sandip

Research Institute of McGill University Health Centre
(P 19) INVOLVEMENT OF O-GLCNAC TRANSFERASE IN RESISTANCE TO DOXORUBICIN AND CELL DEATH IN PRECLINICAL MODELS OF LEIOMYOSARCOMA AND DESMOID TUMORS
Sandip Das
Favorite
David, Bruna

Instituto Nacional de Câncer
(P 192) CURRENT SCENARIO OF SARCOMA CLINICAL TRIALS IN SOUTH AMERICA: A REPORT BY THE LACOG SARCOMA GROUP
Bruna David
Favorite
(P 216) SARCOMA CARE PATHWAYS AND MULTIDISCIPLINARY TUMOR BOARDS IN LATIN AMERICA: AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Bruna David
Favorite
(P 217) SARCOMA DRUG APPROVALS IN LATIN AMERICA COMPARED TO THE FDA AND EMA: AN ANALYSIS BY THE LACOG SARCOMA GROUP
Bruna David
Favorite
(P 219) SOCIAL MEDIA USE AMONG MEDICAL PROFESSIONALS THAT TREAT PATIENTS WITH SARCOMA IN LATIN AMERICA: RESULTS OF AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Bruna David
Favorite
David, Michel

Buenos Aires British Hospital
(P 366) ABDOMINAL AORTA RESECTION EN-BLOC WITH PRIMARY RETROPERITONEAL SOFT-TISSUE SARCOMA AND BI-ILIAC GRAFT RECONSTRUCTION.
Michel David
Favorite
Davies, Alexander

Oregon Health and Science University
(P 72) LIVE-CELL TISSUE MODELS REVEAL SOURCES OF DYNAMIC HETEROGENEITY IN THE OSTEOSARCOMA METASTATIC NICHE
Alexander Davies
Favorite
Davies, Madhu

SynOx Therapeutics
(P 401) A PHASE 3 MULTI-CENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO ASSESS THE EFFICACY AND SAFETY OF EMACTUZUMAB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR (TANGENT)
Madhu Davies
Favorite
Davis, Elizabeth

Vanderbilt University Medical Center
(P 199) FINANCIAL TOXICITY AMONG SARCOMA PATIENTS AND ASSOCIATED FACTORS
Elizabeth Davis
Favorite
(P 297) ESTABLISHING A PEDIATRIC, ADOLESCENT AND YOUNG ADULT COHORT OF SARCOMA PATIENTS TO STUDY ONCOLOGIC AND NON-ONCOLOGIC OUTCOMES
Elizabeth Davis
Favorite
Davis, Elizabeth

Vanderbilt University Cancer Center
(P 413) SUSTAINED EFFICACY DURING DRUG HOLIDAY ON ATEZOLIZUMAB IN PATIENTS WITH ALVEOLAR SOFT PART SARCOMA (ASPS)
Elizabeth Davis
Favorite
Davis, Erika

Deciphera Pharmaceuticals, LLC
(P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE
Erika Davis
Favorite
(P 403) DCC-3116 IN COMBINATION WITH RIPRETINIB FOR PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A PHASE 1/2 STUDY
Erika Davis
Favorite
Davis, Jeremy

Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health
(P 163) CHARACTERIZATION OF INTRAHEPATIC RECURRENCE FOLLOWING LIVER-DIRECTED SURGERY IN PATIENTS WITH METASTATIC SDH-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST): RISE AND STABILIZATION OF THE GISTLETS
Jeremy Davis
Favorite
Davis, Jessica

Indiana University
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Jessica Davis
Favorite
(P 364) A PHASE 1B TRIAL OF PREOPERATIVE ERIBULIN AND RADIATION FOR RETROPERITONEAL LIPOSARCOMA
Jessica Davis
Favorite
(P 365) A SINGLE INSTITUTION COMPARISON OF OUTCOMES IN PEDIATRIC AND ADULT PATIENTS WITH GYNECOLOGIC ORIGIN RHABDOMYOSARCOMA
Jessica Davis
Favorite
Davis, Lara

Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University
(P 364) A PHASE 1B TRIAL OF PREOPERATIVE ERIBULIN AND RADIATION FOR RETROPERITONEAL LIPOSARCOMA
Lara Davis
Favorite
(P 408) OSTEOMYC: A PHASE 2 PILOT STUDY TO EVALIATE THE SAFETY AND THE ANTITUMOR ACTIVITY OF THE MYC INHIBITOR OMO-103 ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH ADVANCED HIGH GRADE OSTEOSARCOMA
Lara Davis
Favorite
Davison, Zoe

Bone Cancer Research Trust
(P 196) ESTABLISHING THE BONE CANCER RESEARCH TRUST'S PATIENT & PUBLIC INVOLVEMENT PANEL
Zoe Davison
Favorite
De Bellis, Chelsea

McGill University
(P 427) MULTI-OMIC AND MULTI-REGION PROFILING OF DESMOID TUMORS REVEALS INTRA- AND INTER-TUMOR HETEROGENEITY
Chelsea De Bellis
Favorite
de Boisanger, James

The Royal Marsden Hospital
(P 183) A RETROSPECTIVE STUDY OF THE EFFECTS OF PATIENT, DISEASE, AND TREATMENT FACTORS ON SURVIVAL OUTCOMES IN PATIENTS WITH SOFT TISSUE SARCOMA BRAIN METASTASES
James de Boisanger
Favorite
De Cecco, Loris

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 137) TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS
Loris De Cecco
Favorite
De Cock, Lore

Department of General Medical Oncology, University Hospitals Leuven and Laboratory of Experimental Oncology, KU Leuven, Leuven Cancer Institute
(P 331) EFFICACY OF NOVEL UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN TARGETED ANTIBODY-DRUG CONJUGATES IN PATIENT-DERIVED XENOGRAFTS OF SOFT TISSUE SARCOMA
Lore De Cock
Favorite
De Cock, Lore

KULeuven
(P 334) EXPANDING THE LANDSCAPE OF PRECLINICAL MODELS OF SYNOVIAL SARCOMA: FROM 2-DIMENSIONS TO 3-DIMENSIONS TO MICE
Lore De Cock
Favorite
De Cock, Lore

Department of General Medical Oncology, University Hospitals Leuven and Laboratory of Experimental Oncology, KU Leuven, Leuven Cancer Institute
(P 340) THE DNA MINOR GROOVE BINDING AGENTS ECUBECTEDIN AND PM54 DEMONSTRATE ANTITUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT MODELS OF SOFT TISSUE SARCOMA
Lore De Cock
Favorite
de Groot, Tom

Massachusetts General Hospital
(P 108) FIXATION OF IMPENDING OR PATHOLOGIC FRACTURES DUE TO METASTATIC DISEASE WITH CARBON FIBER INTRAMEDULLARY NAILS-A PROPENSITY-SCORE MATCHED COST ANALYSIS
Tom de Groot
Favorite
(P 284) WOUND VAC TEMPORIZATION AFTER TUMOR RESECTION OF SOFT TISSUE SARCOMAS - A COST ANALYSIS IN A PROPENSITY-SCORE MATCHED POPULATION
Tom de Groot
Favorite
de Haan, Jacco

University Medical Center Groningen
(P 319) THE SURVIVAL DISPARITY BETWEEN CHILDREN AND ADOLESCENTS & YOUNG ADULTS WITH EWING SARCOMA IN THE NETHERLANDS DID NOT CHANGE SINCE THE 1990S DESPITE IMPROVED SURVIVAL: A POPULATION-BASED STUDY
Jacco de Haan
Favorite
de Jongh, Renate

Amsterdam University Medical Center
(P 42) RANKL-INHIBITION FOR GIANT CELL LESIONS OF THE JAW: A RETROSPECTIVE COHORT ANALYSIS
Renate de Jongh
Favorite
de Kleijn, Robert

Maastricht University Medical Center
(P 361) WOUND COMPLICATIONS AFTER SOFT TISSUE SARCOMA RESECTION: A SINGLE-CENTER RETROSPECTIVE ANALYSIS
Robert de Kleijn
Favorite
DE LA FUENTE, Macarena

Sylvester Comprehensive Cancer Center
(P 87) SAFETY AND EFFICACY OF OLUTASIDENIB, AN IDH1 MUTANT INHIBITOR, FOR THE TREATMENT OF RECURRENT/ RELAPSED LOCALLY ADVANCED OR METASTATIC IDH1 MUTATED CHONDROSARCOMA
Macarena DE LA FUENTE
Favorite
de Lange, Jan

Amsterdam University Medical Center
(P 42) RANKL-INHIBITION FOR GIANT CELL LESIONS OF THE JAW: A RETROSPECTIVE COHORT ANALYSIS
Jan de Lange
Favorite
de Lima, Larissa

Hospital Israelita Albert Einstein
(P 141) COMPREHENSIVE GENOMIC PROFILING OF PATIENTS DIAGNOSED WITH SARCOMA IN BRAZIL: MOLECULAR PROFILE AND ACTIONABILITY
Larissa de Lima
Favorite
De Miguel García, Alberto

Facultad Psicología. Universidad Complutense de Madrid
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Alberto De Miguel García
Favorite
de Miranda, Noel

LUMC
(P 56) CHROME: PREDICTING CHONDROSARCOMA RISK OUTCOME FROM METHYLATION
Noel de Miranda
Favorite
De Mola, Stefania

IRCCS Humanitas Research Hospital
(P 362) A NEW ROCK BAND FOR DIAPHRAGMATIC RECONSTRUCTION IN LEFT RETROPERITONEAL SARCOMA SURGERY
Stefania De Mola
Favorite
(P 363) A NEW SURGICAL TECHNIQUE FOR THE RECONSTRUCTION OF INGUINAL 'NEOLIGAMENT' AFTER SOFT TISSUE SARCOMA RESECTION
Stefania De Mola
Favorite
De Oliveira, José Reinaldo

A.C.Camargo Cancer Center
(P 300) GASTROINTESTINAL STROMAL TUMORS (GIST) IN YOUNG ADULTS (YA): A BRAZILIAN COHORT OF PATIENTS
José Reinaldo De Oliveira
Favorite
de pasquale, maria debora

BAMBINO GESU CHILDREN HOSPITAL
(P 298) EWING SARCOMA OF MAXILLOFACIAL REGION AND SKULL: A RETROSPECTIVE MONOINSTITUTIONAL PEDIATRIC SERIES
maria debora de pasquale
Favorite
(P 311) QUANTIFICATION OF TUMOUR-INFILTRATING IMMUNE CELLS THROUGH DECONVOLUTION OF DNA METHYLATION DATA IN EWING SARCOMAS
maria debora de pasquale
Favorite
de Pree, Ilse

Erasmus University Medical Center
(P 349) LONG-TERM SURVIVAL OF PARTICIPANTS IN THE PASART-1 AND PASART-2 TRIALS OF NEO-ADJUVANT PAZOPANIB AND RADIOTHERAPY IN SOFT TISSUE SARCOMA
Ilse de Pree
Favorite
De Rosa, francesco

Irst
(P 144) EXPLORATORY ANALYSIS OF 68GA-FAPI-46 PET-CT IN SOFT TISSUE SARCOMA
francesco De Rosa
Favorite
De Sloovere, Veerle

UZ Leuven
(P 291) CASE REPORT: RADICAL EN BLOC MULTI-LEVEL SPONDYLECTOMY FOR A LOCALLY RECURRENT OSTEOSARCOMA
Veerle De Sloovere
Favorite
De Sutter, Luna

UZ Leuven
(P 331) EFFICACY OF NOVEL UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN TARGETED ANTIBODY-DRUG CONJUGATES IN PATIENT-DERIVED XENOGRAFTS OF SOFT TISSUE SARCOMA
Luna De Sutter
Favorite
De Sutter, Luna

Laboratory of Experimental Oncology, KU Leuven, Leuven Cancer Institute
(P 334) EXPANDING THE LANDSCAPE OF PRECLINICAL MODELS OF SYNOVIAL SARCOMA: FROM 2-DIMENSIONS TO 3-DIMENSIONS TO MICE
Luna De Sutter
Favorite
De Sutter, Luna

UZ Leuven
(P 340) THE DNA MINOR GROOVE BINDING AGENTS ECUBECTEDIN AND PM54 DEMONSTRATE ANTITUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT MODELS OF SOFT TISSUE SARCOMA
Luna De Sutter
Favorite
De Vita, Alessandro

Istituto Scientifico Romagnolo per lo studio dei Tumori "Dino Amadori", Preclinic and Osteoncology Unit, Meldola, Italy
(P 336) IMPROVEMENT OF PHOTODYNAMIC THERAPY IN SARCOMA: IN VITRO VALIDATION ON OSTEOSARCOMA AND MYXOFIBROSARCOMA
Alessandro De Vita
Favorite
De Wilde, Kristen

Atlantic Health System
(P 255) CAN LARGE, LIPOMATOUS LESIONS ADJACENT TO THE SUPINATOR MUSCLE BE REMOVED WITHOUT INJURING THE POSTERIOR INTEROSSEOUS NERVE? A RETROSPECTIVE REVIEW
Kristen De Wilde
Favorite
(P 260) EMERGING TECHNOLOGY IN ORTHOPEDIC ONCOLOGY: ROBOTIC ARM-ASSISTED TOTAL KNEE ARTHROPLASTY HAS EXCEPTIONAL FUNCTION OUTCOMES FOR PATIENTS WITH BENIGN AND MALIGNANT MUSCULOSKELETAL DISEASE
Kristen De Wilde
Favorite
(P 266) LONG STEM CEMENTED ROBTIC ARM-ASSISTED TOTAL HIP ARTHROPLASTY: OUTCOMES IN PATIENTS WITH PRIOR ONCOLOGIC DISEASE
Kristen De Wilde
Favorite
Deasy, Joseph

Memorial Sloan Kettering Cancer Center
(P 129) ELUCIDATING THE EVOLUTIONARY DYNAMICS OF DDLS LIPOSARCOMA USING SINGLE-CELL SEQUENCING AND MATHEMATICAL LINEAGE TRACING
Joseph Deasy
Favorite
Debiec-Rychter, Maria

KU Leuven
(P 176) LOSS OF PTEN EXPRESSION IN MINIGISTS AND CLINICALLY RELEVANT GISTS
Maria Debiec-Rychter
Favorite
(P 334) EXPANDING THE LANDSCAPE OF PRECLINICAL MODELS OF SYNOVIAL SARCOMA: FROM 2-DIMENSIONS TO 3-DIMENSIONS TO MICE
Maria Debiec-Rychter
Favorite
Decramer, Thomas

UZ Leuven
(P 291) CASE REPORT: RADICAL EN BLOC MULTI-LEVEL SPONDYLECTOMY FOR A LOCALLY RECURRENT OSTEOSARCOMA
Thomas Decramer
Favorite
Dei Tos, Angelo Paolo

Department of Medicine, University of Padua School of Medicine, Padova, Italy
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Angelo Paolo Dei Tos
Favorite
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Angelo Paolo Dei Tos
Favorite
(P 160) UTERINE PECOMA: REPORT OF MOLECULAR AND CLINICAL FEATURES IN A SERIES OF PATIENTS TREATED AT A REFERRAL INSTITUTION
Angelo Paolo Dei Tos
Favorite
(P 345) TRANSCRIPTOMIC AND PHENOTYPIC CHARACTERIZATION OF AN IMMUNOCOMPETENT LEIOMYOSARCOMA MOUSE MODEL.
Angelo Paolo Dei Tos
Favorite
(P 368) AGGRESSIVE PERINEAL ANGIOMYXOMA UNDERGOING SYSTEMIC TREATMENT: AN UPDATED REPORT OF 8-YEARS' EXPERIENCE IN A REFERRAL CENTER
Angelo Paolo Dei Tos
Favorite
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Angelo Paolo Dei Tos
Favorite
(P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Angelo Paolo Dei Tos
Favorite
del baldo, giada

BAMBINO GESU CHILDREN HOSPITAL
(P 298) EWING SARCOMA OF MAXILLOFACIAL REGION AND SKULL: A RETROSPECTIVE MONOINSTITUTIONAL PEDIATRIC SERIES
giada del baldo
Favorite
Dela Cruz, Filemon

Memorial Sloan Kettering Cancer Center
(P 292) CHARACTERIZATION OF TELOMERE MAINTENANCE MECHANISMS IN OSTEOSARCOMA PATIENT-DERIVED LABORATORY MODELS
Filemon Dela Cruz
Favorite
(P 338) PRECLINICAL EFFICACY OF DAN-222, A NOVEL POLYMERIC NANOPARTICLE, IN PEDIATRIC SOLID TUMOR MODELS
Filemon Dela Cruz
Favorite
(P 418) A SYSTEMS BIOLOGY APPROACH FOR CHARACTERIZING TUMOR HETEROGENEITY AND CELL STATE-SPECIFIC THERAPEUTIC VULNERABILITIES FROM SINGLE NUCLEUS RNA-SEQ PROFILING OF DESMOPLASTIC SMALL ROUND CELL TUMORS
Filemon Dela Cruz
Favorite
DelRocco, Natalie

Childrens Oncology Group
(P 50) ANALYSIS OF CLINICAL FEATURES AND OUTCOMES FOR PATIENTS WITH MULTIFOCAL OSTEOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Natalie DelRocco
Favorite
Demanelis, Kathryn

University of Pittsburgh, Hillman Cancer Center
(P 392) ATRX LOSS IN UTERINE LEIOMYOSARCOMA IS ASSOCIATED WITH WORSE OVERALL SURVIVAL AND A DISTINCT PATTERN OF GENE EXPRESSION ACROSS SUBTYPES
Kathryn Demanelis
Favorite
Demetri, George

Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School
(P 402) A PILOT STUDY OF BTX-A51 IN PATIENTS WITH METASTATIC AND/OR RECURRENT LIPOSARCOMAS CHARACTERIZED BY MDM2 AMPLIFICATIONS
George Demetri
Favorite
Demetrious, Matthew

Rush University Medical Center
(P 31) CLINICAL CHALLENGES AND EVOLVING TREATMENT STRATEGIES IN DESMOID FIBROMATOSIS: A SINGLE INSTITUTION EXPERIENCE
Matthew Demetrious
Favorite
(P 80) OUTCOMES AND MANAGEMENT OF POSITIVE MARGINS IN CHONDROSARCOMA WITH SOFT TISSUE EXTENSION: A CASE SERIES AND REVIEW OF LITERATURE
Matthew Demetrious
Favorite
(P 92) THE IMPACT OF CHONDROSARCOMA WITH POSITIVE MARGINS AND EXTRAOSSEOUS EXTENSION ON PATIENT OUTCOMES
Matthew Demetrious
Favorite
(P 126) CHARACTERIZING THE TRANSFORMATION AND DIAGNOSIS OF ATYPICAL LIPOMATOUS TUMOR OF THE EXTREMITIES TO DEDIFFERENTIATED LIPOSARCOMA: SINGLE INSTITUTIONAL OUTCOMES
Matthew Demetrious
Favorite
Demicco, Elizabeth

University Health Network
(P 238) INTRA-TUMORAL DC-LAMP EXPRESSION IS ASSOCIATED WITH PROGNOSIS IN SOFT TISSUE SARCOMA
Elizabeth Demicco
Favorite
(P 320) WHAT IS THE ROLE OF CHEMOTHERAPY IN PATIENTS (PTS) WITH SPINDLE CELL/SCLEROSING RHABDOMYOSARCOMA (SCRMS): A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Elizabeth Demicco
Favorite
(P 329) DEVELOPING ARMS METASTATIC MODELS TO RECAPITULATE THE TUMOR MICROENVIRONMENTS OF THE AXILLA/LYMPH NODE AND LUNGS
Elizabeth Demicco
Favorite
Deng, Luyue

Zhengzhou University
(P 97) TRANSCRIPTOMICS REVEALS THAT OVEREXPRESSION OF LNCRNA HOTTIP REGULATES PKC PROTEIN ACTIVATION OF THE RAP1 SIGNALING PATHWAY FOR SYNOVIAL SARCOMA CELL PROGRESSION
Luyue Deng
Favorite
Denu, Ryan

MD Anderson Cancer Center
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Ryan Denu
Favorite
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Ryan Denu
Favorite
(P 233) IMMUNE CLASSES OF LEIOMYOSARCOMA DRIVEN BY B CELL INFILTRATE AND CTLA4 EXPRESSION
Ryan Denu
Favorite
Derdak, Joanne

National Cancer Institute
(P 414) TENOSYNOVIAL GIANT CELL TUMOR IN CHILDREN: INTERIM RESULTS FROM A PHASE 1 STUDY OF TURALIO®
Joanne Derdak
Favorite
Dermawan, Josephine

Cleveland Clinic
(P 152) NOVEL PAX3::MAML3 FUSION IDENTIFIED IN ALVEOLAR RHABDOMYOSARCOMA: USING DNA METHYLATION TO EXPANDE THE GENETIC SPECTRUM OF "FUSION POSITIVE" CASES
Josephine Dermawan
Favorite
Desai, Anant

Queen Elizabeth Hospital
(P 383) PRE-OPERATIVE SPLIT RENAL FUNCTION RADIONUCLIDE IMAGING IN SURGICAL PLANNING FOR MULTI-VISCERAL RESECTION OF RETROPERITONEAL SARCOMA: A RETROSPECTIVE COHORT STUDY
Anant Desai
Favorite
Desai, Jayesh

Royal Melbourne Hospital and Peter MacCallum Cancer Centre
(P 37) HEALTH-RELATED QUALITY OF LIFE FROM A PHASE 4 STUDY TO EVALUATE DISCONTINUATION AND RECHALLENGE OF PEXIDARTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR PREVIOUSLY TREATED WITH PEXIDARTINIB
Jayesh Desai
Favorite
(P 43) SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
Jayesh Desai
Favorite
(P 44) TUMOR RESPONSE AND REGROWTH IN RELATION TO CLINICAL EVENTS AMONG PEXIDARTINIB-TREATED SUBJECTS IN THE PHASE 3 ENLIVEN TRIAL
Jayesh Desai
Favorite
Desai, Krishna

Cleveland Clinic
(P 310) PROGNOSTICATION AND EPIDEMIOLOGY OF CLEAR CELL SARCOMA: A SEER STAT RETROSPECTIVE ANALYSIS
Krishna Desai
Favorite
Desai, Viral

Adaptimmune
(P 202) IMPACT OF AFAMI-CEL ON THE HEALTH STATE OF PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR MYXOID/ROUND CELL LIPOSARCOMA: COHORT 1 OF SPEARHEAD-1
Viral Desai
Favorite
Desar, Iingrid M.E.

Radboud University Medical Center Nijmegen
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Iingrid M.E. Desar
Favorite
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Iingrid M.E. Desar
Favorite
Deshpande, Anagha

National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
(P 27) SUMO2 INHIBITION REVERSES ABERRANT EPIGENETIC REWIRING DRIVEN BY SYNOVIAL SARCOMA FUSION ONCOPROTEINS AND IMPAIRS SARCOMAGENESIS
Anagha Deshpande
Favorite
Deshpande, Aniruddha

National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
(P 27) SUMO2 INHIBITION REVERSES ABERRANT EPIGENETIC REWIRING DRIVEN BY SYNOVIAL SARCOMA FUSION ONCOPROTEINS AND IMPAIRS SARCOMAGENESIS
Aniruddha Deshpande
Favorite
Devaud, Nicolas

Instituto Oncologico Fundacion Arturo Lopez Perez
(P 367) AGE AS A PROGNOSTIC FACTOR IN RETROPERITONEAL SARCOMA: A MULTICENTER LATIN AMERICAN STUDY
Nicolas Devaud
Favorite
(P 376) IMPACT OF SITE OF ORIGIN ON THE PROGNOSIS OF PATIENTS WITH PRIMARY RESECTABLE NON-UTERINE ABDOMINAL LEIOMYOSARCOMA
Nicolas Devaud
Favorite
Deyell, Rebecca

British Columbia Children's Hospital
(P 293) CIC-REARRANGED SOFT TISSUE SARCOMAS: DOES CHEMOTHERAPY CHANGE NATURAL HISTORY AND PROGNOSIS? A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Rebecca Deyell
Favorite
(P 320) WHAT IS THE ROLE OF CHEMOTHERAPY IN PATIENTS (PTS) WITH SPINDLE CELL/SCLEROSING RHABDOMYOSARCOMA (SCRMS): A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Rebecca Deyell
Favorite
(P 321) WHOLE ABDOMINAL RADIOTHERAPY IN CHILDREN AND YOUNG ADULTS WITH SARCOMA: A CANADIAN SARCOMA AND CLINICAL COLLABORATION (CANSARCC) STUDY
Rebecca Deyell
Favorite
Dhir, Aditi

University of Miami/Sylvester Comprehensive Cancer Center
(P 58) COMBINATORY THERAPIES UTILIZING INHIBITION OF CARBONIC ANHYDRASE IX TO POTENTIATE RESPONSE IN RELAPSED/REFRACTORY OSTEOSARCOMA
Aditi Dhir
Favorite
(P 224) COMPREHENSIVE EVALUATION OF DNA DAMAGE RESPONSE PATHWAY ALTERATIONS AND ASSOCIATED IMMUNOTHERAPY-RESPONSE BIOMARKERS IN SARCOMAS
Aditi Dhir
Favorite
(P 296) DISPARITIES IN OVERALL SURVIVAL FOR AYA PATIENTS WITH EWINGS SARCOMA: A RETROSPECTIVE COHORT STUDY AT A SINGLE SARCOMA CENTER
Aditi Dhir
Favorite
(P 309) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT SOFT TISSUE SARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Aditi Dhir
Favorite
(P 314) RETROSPECTIVE EVALUATION OF DISPARITIES IN ADOLESCENT AND YOUNG ADULT (AYA) PATIENTS WITH SYNOVIAL SARCOMA: A SINGLE INSTITUTION STUDY
Aditi Dhir
Favorite
(P 434) UTILIZATION OF IMAGING MASS CYTOMETRY TO EVALUATE THE IMMUNE LANDSCAPE OF PEDIATRIC AND ADULT PATIENTS WITH SARCOMA TREATED WITH AN AUTOLOGOUS DENDRITIC CELL VACCINE
Aditi Dhir
Favorite
Di Benedetto, Mattia

IRCCS Humanitas Research Hospital
(P 363) A NEW SURGICAL TECHNIQUE FOR THE RECONSTRUCTION OF INGUINAL 'NEOLIGAMENT' AFTER SOFT TISSUE SARCOMA RESECTION
Mattia Di Benedetto
Favorite
Di Biasi, Elena

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 376) IMPACT OF SITE OF ORIGIN ON THE PROGNOSIS OF PATIENTS WITH PRIMARY RESECTABLE NON-UTERINE ABDOMINAL LEIOMYOSARCOMA
Elena Di Biasi
Favorite
Di Blasi, Elena

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 137) TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS
Elena Di Blasi
Favorite
Di Giannatale, Angela

BAMBINO GESU CHILDREN HOSPITAL
(P 298) EWING SARCOMA OF MAXILLOFACIAL REGION AND SKULL: A RETROSPECTIVE MONOINSTITUTIONAL PEDIATRIC SERIES
Angela Di Giannatale
Favorite
(P 311) QUANTIFICATION OF TUMOUR-INFILTRATING IMMUNE CELLS THROUGH DECONVOLUTION OF DNA METHYLATION DATA IN EWING SARCOMAS
Angela Di Giannatale
Favorite
Di Gioia, Dorit

Department of Medicine III, LMU University Hospital, LMU Munich
(P 410) PHASE I STUDY OF THE001 (DPPG2-TSL-DOX) COMBINED WITH REGIONAL HYPERTHERMIA IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Dorit Di Gioia
Favorite
Di Ruscio, Valentina

bambino gesu children hospital
(P 298) EWING SARCOMA OF MAXILLOFACIAL REGION AND SKULL: A RETROSPECTIVE MONOINSTITUTIONAL PEDIATRIC SERIES
Valentina Di Ruscio
Favorite
Dias e Silva, Douglas

Hospital Israelita Albert Einstein
(P 122) ACTIONABLE FUSIONS IN DEDIFFERENTIATED LIPOSARCOMA: AN ANALYSIS OF 402 CASES IN THE AACR GENIE DATABASE
Douglas Dias e Silva
Favorite
(P 192) CURRENT SCENARIO OF SARCOMA CLINICAL TRIALS IN SOUTH AMERICA: A REPORT BY THE LACOG SARCOMA GROUP
Douglas Dias e Silva
Favorite
(P 217) SARCOMA DRUG APPROVALS IN LATIN AMERICA COMPARED TO THE FDA AND EMA: AN ANALYSIS BY THE LACOG SARCOMA GROUP
Douglas Dias e Silva
Favorite
(P 232) IMMUNE CHECKPOINT INHIBITORS COMBINED WITH TYROSINE KINASE INHIBITORS FOR SOFT-TISSUE SARCOMAS: A SYSTEMATIC REVIEW AND SINGLE-ARM META-ANALYSIS
Douglas Dias e Silva
Favorite
(P 242) MICROSATELLITE INSTABILITY AND CLINICAL USE IN SARCOMAS: A SYSTEMATIC REVIEW
Douglas Dias e Silva
Favorite
Dickinson, Shannon

Memorial Sloan Kettering Cancer Center
(P 101) AN OPEN LABEL PHASE IIA STUDY EVALUATING THE PRELIMINARY EFFICACY OF INTRATUMORAL TIGILANOL TIGLATE (TT) IN ADVANCED AND/OR METASTATIC SOFT TISSUE SARCOMA (STS, NCT05755113)
Shannon Dickinson
Favorite
Dickson, Brendan

Mount Sinai Hospital
(P 159) USING THE TRANSCRIPTIONAL SPECTRUM OF UTERINE SMOOTH MUSCLE TUMORS TO IDENTIFY PROGNOSTIC SIGNATURES FOR ABNORMAL LEIOMYOMAS AND SMOOTH MUSCLE TUMOURS OF UNCERTAIN MALIGNANT POTENTIAL
Brendan Dickson
Favorite
(P 329) DEVELOPING ARMS METASTATIC MODELS TO RECAPITULATE THE TUMOR MICROENVIRONMENTS OF THE AXILLA/LYMPH NODE AND LUNGS
Brendan Dickson
Favorite
Dickson, Mark

Memorial Sloan Kettering Cancer Center
(P 121) ACQUIRED CYCLIN D AMPLIFICATION IS A MECHANISM FOR RESISTANCE TO CDK4/6 INHIBITORS IN DEDIFFERENTIATED LIPOSARCOMA
Mark Dickson
Favorite
(P 229) EXPRESSION OF TRANSPOSABLE ELEMENTS AND IKZF1 PREDICTS IMMUNE INFILTRATES IN SARCOMAS AND CORRELATES WITH OUTCOMES AFTER IMMUNE CHECKPOINT INHIBITION
Mark Dickson
Favorite
Didychuk, Allison

Yale University
(P 98) A MULTIEPITOPE MRNA VACCINE FOR KAPOSI SARCOMA: AN IMMUNOINFORMATIC APPROACH
Allison Didychuk
Favorite
Diegaarde, Brenda
(P 258) COMPARING OUTCOMES FOLLOWING INTRALESIONAL VERSUS WIDE RESECTION PROCEDURES IN THE TREATMENT OF RENAL CELL CARCINOMA BONE METASTASES
Brenda Diegaarde
Favorite
(P 353) PREDICTING WOUND COMPLICATIONS FOLLOWING SOFT-TISSUE SARCOMA RESECTION AMONG PATIENTS WHO RECEIVED PRE-OPERATIVE RADIATION
Brenda Diegaarde
Favorite
Diehl, Diane

Count Me In, The Broad Institute of MIT and Harvard
(P 195) ENHANCING PARTICIPANT ENGAGEMENT IN A NOVEL PATIENT-PARTNERED CANCER GENOMICS RESEARCH EFFORT FOR RARE AND AGGRESSIVE SARCOMAS
Diane Diehl
Favorite
Dierselhuis, Edwin

RadboudUMC Nijmegen
(P 274) PROXIMAL HUMERAL ENDOPROSTHETIC RECONSTRUCTION: RESULTS FROM THE MUTARS ORTHOPEDIC REGISTRY EUROPE (MORE)
Edwin Dierselhuis
Favorite
Dietz, Matthew

University of Utah, Primary Children's Hospital
(P 94) THE ROLE OF CMYC AMPLIFICATION VERSUS CMYC PROTEIN EXPRESSION AS A PROGNOSTIC BIOMARKER IN OSTEOSARCOMA
Matthew Dietz
Favorite
Difilippo, Valeria

Lund University
(P 03) CDK4 IS CO-AMPLIFIED WITH EITHER TP53 PROMOTER GENE FUSIONS OR MDM2 THROUGH DISTINCT MECHANISMS IN OSTEOSARCOMA
Valeria Difilippo
Favorite
(P 26) SARCDBASE: A TOOL FOR DETECTION OF GENETIC ALTERATIONS IN SARCOMA
Valeria Difilippo
Favorite
Dilling, Thomas

Moffitt Cancer Center
(P 347) CAN UPFRONT RADIOTHERAPY PRECLUDE THE NEED FOR OPERATIVE STABILIZATION IN IMPENDING EXTREMITY FRACTURES FROM LUNG CANCER METASTASES?
Thomas Dilling
Favorite
Dimino, Alessandra

Università degli studi di Palermo
(P 429) PATIENTS WITH ADVANCED EPITHELIOID HEMANGIOENDOTHELIOMA TREATED WITH SIROLIMUS: OUTCOME FOLLOWING SIROLIMUS DISCONTINUATION.
Alessandra Dimino
Favorite
D'Incalci, Maurizio

IRCCS Humanitas Research Hospital
(P 124) ASSESSMENT OF THE MECHANISMS OF ACTION OF ERIBULIN IN PATIENTS WITH ADVANCED LIPOSARCOMA THROUGH THE EVALUATION OF THE RADIOLOGICAL, FUNCTIONAL AND TISSUE RESPONSE: A MONOCENTRIC PROSPECTIVE STUDY
Maurizio D'Incalci
Favorite
Ding, Yu-Qin

Zhongshan Hospital, Fudan University, Shanghai, China
(P 416) TRIPLR COMNINATION THERAPY IN THE FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA WITH HIGH TUMOR BURDEN: INTERIM ANALYSIS FROM ALTER-S007 STUDY
Yu-Qin Ding
Favorite
Dlova, Ncoza

University of KwaZulu-Natal
(P 98) A MULTIEPITOPE MRNA VACCINE FOR KAPOSI SARCOMA: AN IMMUNOINFORMATIC APPROACH
Ncoza Dlova
Favorite
Dlugosz, Andrzej

University of Michigan
(P 131) HETEROGENEITY OF THE IMMUNE MICROENVIRONMENT AND IMMUNOTHERAPY RESPONSE IN A DEDIFFERENTIATED LIPOSARCOMA MOUSE MODEL
Andrzej Dlugosz
Favorite
Dodd, Rebecca

University of Iowa
(P 12) GENETIC LANDSCAPE OF MPNST DETERMINES METABOLIC STRATEGIES AND THERAPEUTIC OPPORTUNITIES FOR COPING WITH REDOX STRESS
Rebecca Dodd
Favorite
(P 395) INTEGRATED EPIGENETIC ANALYSES IDENTIFY A MULTI-SARCOMA DNA METHYLATION SIGNATURE OF TUMOR PROGRESSION AND METASTASIS
Rebecca Dodd
Favorite
Doherty, Terence M.

University of California San Diego
(P 162) ANALYSIS OF 3,144 CASE REPORTS IN THE GASTROINTESTINAL STROMAL TUMOR LITERATURE: IDENTIFICATION OF UNDERAPPRECIATED DEMOGRAPHICS, CLINICAL PRESENTATIONS, AND BIOLOGY
Terence M. Doherty
Favorite
(P 175) KIT AND DOG-1 EXPRESSING GASTROINTESTINAL STROMAL TUMORS HARBORING ETV6-NTRK3 FUSIONS DO EXIST, CASE OF NEAR COMPLETE PATHOLOGIC RESPONSE FOLLOWING LAROTRECTINIB AND REVIEW OF THE LITERATURE
Terence M. Doherty
Favorite
Do, Khanh Tu

Dana Farber Cancer Institute
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Khanh Tu Do
Favorite
Dolat, Lee

Chordoma Foundation
(P 02) A PRECLINICAL ASSAY PIPELINE TO IDENTIFY AND OPTIMIZE BRACHYURY-TARGETED THERAPIES IN CHORDOMA AND OTHER SOLID TUMORS
Lee Dolat
Favorite
(P 425) EXPLORING MECHANISMS OF EGFR INHIBITOR RESISTANCE IN CHORDOMA
Lee Dolat
Favorite
Donati, Davide Maria

IRCCS Istituto Ortopedico Rizzoli
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Davide Maria Donati
Favorite
Dong, Qun

Department of Bioinformatics and Biostatistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China
(P 93) THE PROTEOGENOMIC SUBTYPING OF OSTEOSARCOMA
Qun Dong
Favorite
Dong, Yang

Department of Orthopedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital
(P 407) LONG-TERM EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): PHASE 1B UPDATE.
Yang Dong
Favorite
Donoghue, Mark

Memorial Sloan Kettering Cancer Center
(P 229) EXPRESSION OF TRANSPOSABLE ELEMENTS AND IKZF1 PREDICTS IMMUNE INFILTRATES IN SARCOMAS AND CORRELATES WITH OUTCOMES AFTER IMMUNE CHECKPOINT INHIBITION
Mark Donoghue
Favorite
Dontenwill, Monique

UMR CNRS 7021
(P 75) METABOLIC EVALUATION OF THE RELATIONSHIP BETWEEN MACROPHAGES AND OSTEOSARCOMA TUMOR CELLS
Monique Dontenwill
Favorite
(P 89) TARGETED THERAPY OF MET, TYROSINE KINASE RECEPTOR, IN PEDIATRIC HIGH-GRADE OSTEOSARCOMAS : A NEW WAY TO TREAT PATIENTS ?
Monique Dontenwill
Favorite
(P 426) GD2 HETEROGENEIC EXPRESSION IN OSTEOSARCOMAS AND EWING SARCOMAS UNDERLYING A WORST PROGNOSIS
Monique Dontenwill
Favorite
D'Orazio, Federico

Humanitas Research Hospital
(P 124) ASSESSMENT OF THE MECHANISMS OF ACTION OF ERIBULIN IN PATIENTS WITH ADVANCED LIPOSARCOMA THROUGH THE EVALUATION OF THE RADIOLOGICAL, FUNCTIONAL AND TISSUE RESPONSE: A MONOCENTRIC PROSPECTIVE STUDY
Federico D'Orazio
Favorite
(P 389) THE ROLE OF NUTRITIONAL STATUS ON POSTOPERATIVE AND ONCOLOGICAL OUTCOMES IN RETROPERITONEAL SARCOMA
Federico D'Orazio
Favorite
(P 431) REAL-WORLD EXPERIENCE OF EFFICACY AND TOLERABILITY OF CONTINUOS INFUSION IFOSFAMIDE AMONG ADVANCED SOFT TISSUE AND BONE SARCOMAS PATIENTS: A SINGLE CENTRE RETROSPECTIVE COHORT.
Federico D'Orazio
Favorite
Dore, Leocadia

IRCCS Humanitas Research Hospital
(P 373) EVALUATION OF HISTOLOGIC ORGAN INFILTRATION (HOI) AND VISCERAL RESECTION MARGINS (VRM) IN PRIMARY RETROPERITONEAL SARCOMAS: PROGNOSTIC IMPLICATIONS FOR LOCAL RECURRENCE
Leocadia Dore
Favorite
Doroshow, James

National Institutes of Health
(P 413) SUSTAINED EFFICACY DURING DRUG HOLIDAY ON ATEZOLIZUMAB IN PATIENTS WITH ALVEOLAR SOFT PART SARCOMA (ASPS)
James Doroshow
Favorite
Dorsey, Jennifer

Lunenefeld Tanenbaum
(P 329) DEVELOPING ARMS METASTATIC MODELS TO RECAPITULATE THE TUMOR MICROENVIRONMENTS OF THE AXILLA/LYMPH NODE AND LUNGS
Jennifer Dorsey
Favorite
(P 433) TUMOR HYPOXIA AND THE RISK OF METASTASIS IN HIGH-RISK LOCALIZED UPS/MFS
Jennifer Dorsey
Favorite
dos Santos, Gabriel

A.C.Camargo Cancer Center
(P 300) GASTROINTESTINAL STROMAL TUMORS (GIST) IN YOUNG ADULTS (YA): A BRAZILIAN COHORT OF PATIENTS
Gabriel dos Santos
Favorite
Doshi, Dipam

SpringWorks Therapeutics
(P 34) DESMOID TUMOR COHORT CREATION AND CHARACTERISTICS IN THE VETERANS AFFAIRS (VA) NATIONAL DATABASE
Dipam Doshi
Favorite
Dossa, Fahima

Memorial Sloan Kettering Cancer Center
(P 380) MULTIDISCIPLINARY MANAGEMENT OF INTRA-ABDOMINAL DESMOID-TYPE FIBROMATOSIS: A 30-YEARS EXPERIENCE
Fahima Dossa
Favorite
Douchy, Thomas

UZ Leuven
(P 291) CASE REPORT: RADICAL EN BLOC MULTI-LEVEL SPONDYLECTOMY FOR A LOCALLY RECURRENT OSTEOSARCOMA
Thomas Douchy
Favorite
Doung, Yee-Cheen

Oregon Health & Science University
(P 34) DESMOID TUMOR COHORT CREATION AND CHARACTERISTICS IN THE VETERANS AFFAIRS (VA) NATIONAL DATABASE
Yee-Cheen Doung
Favorite
(P 223) ASSOCIATION OF POSTOPERATIVE INFECTION (POI) WITH SOFT TISSUE SARCOMA (STS) RESECTION OUTCOMES
Yee-Cheen Doung
Favorite
(P 285) A NOVEL METHOD TO PREDICT HEIGHT AT SKELETAL MATURITY IN PEDIATRIC SARCOMA PATIENTS
Yee-Cheen Doung
Favorite
Doval, Anxela

Hospital Clinico San Carlos
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Anxela Doval
Favorite
Drilon, Alexander

Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College
(P 393) EFFICACY AND SAFETY OF LAROTRECTINIB AS FIRST-LINE TREATMENT IN PATIENTS WITH TRK FUSION SARCOMAS
Alexander Drilon
Favorite
(P 396) LONG-TERM FOLLOW-UP EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Alexander Drilon
Favorite
Drnevich, jenny

University of Illinois Urbana-Champaign
(P 79) NOVEL THERAPEUTIC POTENTIAL THROUGH HYPERACTIVATION OF THE ANTICIPATORY UNFOLDED PROTEIN RESPONSE PATHWAY IN BONE CANCER TREATMENT
jenny Drnevich
Favorite
Drubay, Damien

Gustave Roussy
(P 82) PLASMA CIRCULATING PROTEOMIC MARKERS ARE ASSOCIATED WITH METASTATIC SPREAD AND OUTCOME IN OSTEOSARCOMA
Damien Drubay
Favorite
Druta, Mihaela

Moffitt Cancer Center & Research Institute
(P 202) IMPACT OF AFAMI-CEL ON THE HEALTH STATE OF PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR MYXOID/ROUND CELL LIPOSARCOMA: COHORT 1 OF SPEARHEAD-1
Mihaela Druta
Favorite
(P 237) INTRALESIONAL ADMINISTRATION OF TALIMOGENE LAHERPAREPVEC (T-VEC) INDUCES TUMOR REGRESSION IN PATIENTS WITH CUTANEOUS ANGIOSARCOMA
Mihaela Druta
Favorite
Duan, Zhenfeng

University of Miami
(P 58) COMBINATORY THERAPIES UTILIZING INHIBITION OF CARBONIC ANHYDRASE IX TO POTENTIATE RESPONSE IN RELAPSED/REFRACTORY OSTEOSARCOMA
Zhenfeng Duan
Favorite
DuBois, Steven

Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, MA, USA
(P 393) EFFICACY AND SAFETY OF LAROTRECTINIB AS FIRST-LINE TREATMENT IN PATIENTS WITH TRK FUSION SARCOMAS
Steven DuBois
Favorite
ducimetiere, francoise

Centre Léon Bérard
(P 169) FRENCH LONG TERM REGISTRY WITH LONGITUDINAL FOLLOW UP OF PDGFRA D842V GIST PATIENTS (AVIATOR2020)
francoise ducimetiere
Favorite
Duensing, Anette

University of Pittsburgh School of Medicine
(P 117) THE TUMOR IMMUNE MICROENVIRONMENT OF DEDIFFERENTIATED SARCOMAS: DIGITAL SPATIAL PROFILING SHOWS IMMUNE TRANSCRIPTIONAL DIFFERENCES BETWEEN DEDIFFERENTIATED LIPOSARCOMA AND CHONDROSARCOMA
Anette Duensing
Favorite
DUFFAUD, FLORENCE

La Timone University and Aix-Marseille University
(P 87) SAFETY AND EFFICACY OF OLUTASIDENIB, AN IDH1 MUTANT INHIBITOR, FOR THE TREATMENT OF RECURRENT/ RELAPSED LOCALLY ADVANCED OR METASTATIC IDH1 MUTATED CHONDROSARCOMA
FLORENCE DUFFAUD
Favorite
Duffaud, Florence

Timone
(P 125) CHARACTERISTICS, MANAGEMENT AND SURVIVAL OF N=7314 LIPOSARCOMAS FROM THE NATIONWIDE NETSARC REGISTRY IN FRANCE SINCE 2010
Florence Duffaud
Favorite
Dufresne, Armelle

Centre Leon Berard
(P 169) FRENCH LONG TERM REGISTRY WITH LONGITUDINAL FOLLOW UP OF PDGFRA D842V GIST PATIENTS (AVIATOR2020)
Armelle Dufresne
Favorite
Dujovny, Tal

Emek General Hospital
(P 312) RARE CASE OF INTRAOSSEOUS RHABDOMYOSARCOMA IN A YOUNG CHILD
Tal Dujovny
Favorite
Dumit, Therese

Yale University
(P 98) A MULTIEPITOPE MRNA VACCINE FOR KAPOSI SARCOMA: AN IMMUNOINFORMATIC APPROACH
Therese Dumit
Favorite
Dutour, Aurélie

CRCL, University Claude Bernard Lyon 1, Lyon, France
(P 77) MULTI-PARAMETRICAL PROFILING OF CHONDROSARCOMA
Aurélie Dutour
Favorite
Du, Xinhui

Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital
(P 407) LONG-TERM EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): PHASE 1B UPDATE.
Xinhui Du
Favorite
E
Ebb, David

Mass General for Children
(P 50) ANALYSIS OF CLINICAL FEATURES AND OUTCOMES FOR PATIENTS WITH MULTIFOCAL OSTEOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
David Ebb
Favorite
Eckardt, Mark

Mass General Brigham / Dana-Farber Cancer Institute
(P 371) ELUCIDATING THE CLINICAL UTILITY OF TARGETED GENE EXPRESSION PROFILING IN RETROPERITONEAL LIPOSARCOMA
Mark Eckardt
Favorite
Edelenos, Esther

Amsterdam University Medical Center
(P 42) RANKL-INHIBITION FOR GIANT CELL LESIONS OF THE JAW: A RETROSPECTIVE COHORT ANALYSIS
Esther Edelenos
Favorite
Eeles, Christopher

Princess Margaret Cancer Centre, University Health Network
(P 399) SIMILARITY NETWORK FUSION IDENTIFIES DNA METHYLATION SUBTYPES OF LEIOMYOSARCOMA ASSOCIATED WITH CLINICAL OUTCOME
Christopher Eeles
Favorite
(P 427) MULTI-OMIC AND MULTI-REGION PROFILING OF DESMOID TUMORS REVEALS INTRA- AND INTER-TUMOR HETEROGENEITY
Christopher Eeles
Favorite
Efthymiadis, Konstantinos

University College London Hospitals NHS Foundation Trust
(P 23) METASTATIC ALVEOLAR SOFT PART SARCOMA: PREGNANCY-RELATED WORSENING AND SPONTANEOUS EXCEPTIONAL REMISSION POSTPARTUM- A CASE REPORT.
Konstantinos Efthymiadis
Favorite
Eil, Robert

OHSU
(P 364) A PHASE 1B TRIAL OF PREOPERATIVE ERIBULIN AND RADIATION FOR RETROPERITONEAL LIPOSARCOMA
Robert Eil
Favorite
Ekert, Paul

Children's Cancer Institute
(P 299) EXPLORING THE POTENTIAL OF PHOSPHOPROTEOMIC PROFILING FOR TARGET DISCOVERY IN HIGH-RISK OSTEOSARCOMA: A PATHWAY TO NOVEL THERAPIES?
Paul Ekert
Favorite
Elabd, Ahmed

MedStar Georgetown Cancer Institute
(P 406) LONG-TERM DENOSUMAB THERAPY IN GIANT CELL TUMOR PATIENTS MAY POTENTIALLY LEAD TO THE DEVELOPMENT OF OTHER PRIMARY TUMORS: AN INITIAL OBSERVATION
Ahmed Elabd
Favorite
Elefante, Anjana

Roswell Park Comprehensive Cancer Center
(P 35) EARLY REAL WORLD EXPERIENCE WITH NIROGACESTAT IN PATIENTS WITH DESMOID FIBROMATOSIS
Anjana Elefante
Favorite
El-hossiny, Ahmed

University of Michigan
(P 131) HETEROGENEITY OF THE IMMUNE MICROENVIRONMENT AND IMMUNOTHERAPY RESPONSE IN A DEDIFFERENTIATED LIPOSARCOMA MOUSE MODEL
Ahmed El-hossiny
Favorite
Elias, Erik

University of Gothenburg/Institute of Clinical Sciences
(P 20) LEIOMYOSARCOMA OF THE THORACIC AORTA - A RARE CASE REPORT
Erik Elias
Favorite
(P 170) GASTRIN RELEASING PEPTIDE RECEPTOR EXPRESSION IN GASTROINTESTINAL STROMAL TUMORS (GIST)
Erik Elias
Favorite
(P 382) PARAGANGLIOMA AND CONGENITAL HEART DISEASE - A RARE CASE REPORT
Erik Elias
Favorite
Elliott, Andrew

Caris Life Sciences
(P 224) COMPREHENSIVE EVALUATION OF DNA DAMAGE RESPONSE PATHWAY ALTERATIONS AND ASSOCIATED IMMUNOTHERAPY-RESPONSE BIOMARKERS IN SARCOMAS
Andrew Elliott
Favorite
(P 246) THE GENOMIC AND IMMUNE LANDSCAPE OF LIPOSARCOMA AND ITS SUBTYPES
Andrew Elliott
Favorite
Elsner, Cole

University of Arizona College of Medicine - Phoenix
(P 76) MOLECULAR AND CHROMOSOMAL MICROARRAY PROFILING OF OSTEOSARCOMA IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS: A SINGLE INSTITUTION REPORT
Cole Elsner
Favorite
Enciso Holm, Christina

Rigshospitalet
(P 391) VISCERAL ANGIOSARCOMA: A NATIONWIDE STUDY WITH LONG-TERM FOLLOW-UP
Christina Enciso Holm
Favorite
Endo, Makoto

Kyushu University
(P 203) IMPACT OF COVID-19 PANDEMIC ON BONE AND SOFT TISSUE SARCOMA PATIENTS' CONSULTATION AND DIAGNOSIS
Makoto Endo
Favorite
Engelen, Sanne

Maastricht University Medical Center
(P 361) WOUND COMPLICATIONS AFTER SOFT TISSUE SARCOMA RESECTION: A SINGLE-CENTER RETROSPECTIVE ANALYSIS
Sanne Engelen
Favorite
Engelhardt, Ellen

Netherlands Cancer Institute
(P 194) EFFECTIVENESS OF A RISK PREDICTION TOOL (PERSARC) ON THE QUALITY OF TREATMENT DECISIONS IN SOFT-TISSUE SARCOMA PATIENTS (VALUE-PERSARC TRIAL)
Ellen Engelhardt
Favorite
Engelmann, Bodil

Department of Oncology, Copenhagen University Hospital, Herlev & Gentofte Hospital
(P 104) CIRQUESARC: A NATIONAL PROSPECTIVE OBSERVATIONAL STUDY OF CIRCULATING TUMOR DNA AND QUALITY OF LIFE IN PATIENTS WITH SARCOMA – PRELIMINARY RESULTS FROM THE SURGICAL COHORT
Bodil Engelmann
Favorite
(P 357) RADIATION THERAPY OF EXTREMITY SOFT TISSUE SARCOMAS: A NATIONWIDE COHORT STUDY OF LATE SIDE EFFECTS - TRIAL IN PROGRESS
Bodil Engelmann
Favorite
(P 411) PROPANE AN OPEN LABEL PHASE 2 STUDY ON PROPRANOLOL AND PEMBROLIZUMAB IN ADVANCED ANGIOSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA A SCANDINAVIAN SARCOMA GROUP COLLABORATION
Bodil Engelmann
Favorite
Entz-Werlé, Natacha

UMR7021 CNRS -Laboratory of Bioimaging and Pathologies
(P 75) METABOLIC EVALUATION OF THE RELATIONSHIP BETWEEN MACROPHAGES AND OSTEOSARCOMA TUMOR CELLS
Natacha Entz-Werlé
Favorite
(P 89) TARGETED THERAPY OF MET, TYROSINE KINASE RECEPTOR, IN PEDIATRIC HIGH-GRADE OSTEOSARCOMAS : A NEW WAY TO TREAT PATIENTS ?
Natacha Entz-Werlé
Favorite
(P 426) GD2 HETEROGENEIC EXPRESSION IN OSTEOSARCOMAS AND EWING SARCOMAS UNDERLYING A WORST PROGNOSIS
Natacha Entz-Werlé
Favorite
Eom, Rachel

Georgetown University School of Medicine
(P 38) LOCAL RECURRENCE OF DIFFUSE PIGMENTED VILLONODULAR SYNOVITIS IN MAJOR JOINTS: A 15 YEAR-LONG CASE SERIES AT A SINGLE INSTITUTION
Rachel Eom
Favorite
Erbasi, Neslihan

Oregon Health & Science University
(P 223) ASSOCIATION OF POSTOPERATIVE INFECTION (POI) WITH SOFT TISSUE SARCOMA (STS) RESECTION OUTCOMES
Neslihan Erbasi
Favorite
Ercolano, Lisa

Allegheny Health Network
(P 256) CHARACTERIZING ORTHOPAEDIC ONCOLOGIC POLYTRAUMAS: A COMPARISON OF PATIENTS UNDERGOING OPERATIVE FIXATION OF MULTIPLE LESIONS WITH THOSE WITH SOLITARY LESIONS
Lisa Ercolano
Favorite
Erdem, Zeynep

Leiden University Medical Center / Leiden Center for Computational Oncology
(P 56) CHROME: PREDICTING CHONDROSARCOMA RISK OUTCOME FROM METHYLATION
Zeynep Erdem
Favorite
(P 114) METHYLOME PROFILING OF CARTILAGE TUMOURS: A PROMISING NEW TOOL FOR BIOPSY MATERIAL?
Zeynep Erdem
Favorite
Espejo-Freire, Andrea

University of Minnesota
(P 30) CLINICAL BENEFIT OF PEGYLATED-LIPOSOMAL DOXORUBICIN IN THE MANAGEMENT DESMOID TYPE FIBROMATOSIS: A SINGLE INSTITUTION EXPERIENCE
Andrea Espejo-Freire
Favorite
(P 224) COMPREHENSIVE EVALUATION OF DNA DAMAGE RESPONSE PATHWAY ALTERATIONS AND ASSOCIATED IMMUNOTHERAPY-RESPONSE BIOMARKERS IN SARCOMAS
Andrea Espejo-Freire
Favorite
Espinosa-Cotton, Madelyn

Memorial Sloan Kettering Cancer Center
(P 302) HER2 PRETARGETED ALPHA PARTICLE RADIOIMMUNOTHERAPY FOR DESMOPLASTIC SMALL ROUND CELL TUMORS
Madelyn Espinosa-Cotton
Favorite
Evans, Denisse

The Life Raft Group
(P 166) D842V - A TALE OF TWO STAGES: COMPARATIVE ANALYSIS OF OVERALL SURVIVAL AND TREATMENT RESPONSE IN GIST PATIENTS WITH PDGFRA D842V MUTATIONS
Denisse Evans
Favorite
(P 176) LOSS OF PTEN EXPRESSION IN MINIGISTS AND CLINICALLY RELEVANT GISTS
Denisse Evans
Favorite
Evenhuis, Richard

Leiden University Medical Center
(P 274) PROXIMAL HUMERAL ENDOPROSTHETIC RECONSTRUCTION: RESULTS FROM THE MUTARS ORTHOPEDIC REGISTRY EUROPE (MORE)
Richard Evenhuis
Favorite
Evseev, Danyel

Arnie Charbonneau Cancer Institute and McCaig Institute for Bone and Joint Health
(P 239) INVESTIGATING HOW TUMOUR ASSOCIATED MACROPHAGES INFLUENCE THE EFFICACY OF CAR T THERAPY IN A MURINE MODEL OF SOFT TISSUE SARCOMA
Danyel Evseev
Favorite
Eward, William

Department of Orthopedic Surgery, Duke University
(P 16) HOW TO GROW A BONE IN 60 DAYS: EXPLORING THE UNIQUE PRO-GROWTH, ANTI-CANCER ENVIRONMENT IN ELK ANTLERS
William Eward
Favorite
(P 54) CHONDROBLASTIC OSTEOSARCOMA IS A RISK FACTOR FOR LOCAL RECURRENCE IN PATIENTS WITH SKELETAL OSTEOSARCOMA
William Eward
Favorite
(P 142) CORE NEEDLE BIOPSY OF PERIACETABULAR CHONDROSARCOMA OFTEN RESULTS IN UNDER-GRADING BUT DOES NOT CHANGE MANAGEMENT BY EXPERIENCED ORTHOPAEDIC ONCOLOGISTS.
William Eward
Favorite
F
Fabbroni, Chiara

Fondazione IRCCS Istituto Nazionale dei Tumori MILANO
(P 160) UTERINE PECOMA: REPORT OF MOLECULAR AND CLINICAL FEATURES IN A SERIES OF PATIENTS TREATED AT A REFERRAL INSTITUTION
Chiara Fabbroni
Favorite
Fabbroni, Chiara

Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori
(P 171) GASTROINTESTINAL STROMAL TUMOURS (GISTS) IN NEUROFIBROMATOSIS TYPE (NF1): A SINGLE-CENTER OBSERVATIONAL RETROSPECTIVE STUDY
Chiara Fabbroni
Favorite
(P 368) AGGRESSIVE PERINEAL ANGIOMYXOMA UNDERGOING SYSTEMIC TREATMENT: AN UPDATED REPORT OF 8-YEARS' EXPERIENCE IN A REFERRAL CENTER
Chiara Fabbroni
Favorite
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Chiara Fabbroni
Favorite
(P 420) CELLULARITY DEGREES IN PRIMARY MYXOID LIPOSARCOMA: ASSOCIATION WITH TUMOR IMMUNE INFILTRATE AND PATIENT OUTCOMES
Chiara Fabbroni
Favorite
Facchin, Caterina

Research Institute McGill University Health Center
(P 69) H3.3G34W ONCOHISTONE IN OSTEOSARCOMA
Caterina Facchin
Favorite
Facklam, Amanda

Pyxis Oncology
(P 339) SARCOMAS EXPRESS EXTRA DOMAIN B OF FIBRONECTIN AND PRECLINICAL PATIENT-DERIVED XENOGRAFT MODELS OF SEVERAL SARCOMA SUBTYPES ARE SENSITIVE TO THE STROMA TARGETING ANTIBODY DRUG CONJUGATE PYX-201
Amanda Facklam
Favorite
Fagan-Kellogg, Sarah

Duke University Hospital
(P 54) CHONDROBLASTIC OSTEOSARCOMA IS A RISK FACTOR FOR LOCAL RECURRENCE IN PATIENTS WITH SKELETAL OSTEOSARCOMA
Sarah Fagan-Kellogg
Favorite
Fagioli, Franca

University of Turin
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Franca Fagioli
Favorite
Fairweather, Mark

Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Mark Fairweather
Favorite
Falcon Gonzalez, Alejandro

Hospital Universitario Virgen del Rocío Sevilla and Instituto de BioMedicina de Sevilla
(P 43) SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
Alejandro Falcon Gonzalez
Favorite
Fang, Mei-Yu

Department of Head and Neck and Rare Tumors Internal Medicine, ZheJiang Cancer Hospital, Hangzhou, China
(P 416) TRIPLR COMNINATION THERAPY IN THE FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA WITH HIGH TUMOR BURDEN: INTERIM ANALYSIS FROM ALTER-S007 STUDY
Mei-Yu Fang
Favorite
Fanta, Paul

University of California, San Diego
(P 165) COMPLETE PERITONEAL CYTOREDUCTIVE SURGERY IN HIGHLY SELECTED PATIENTS WITH AGGRESSIVE METASTATIC SDH-DEFICIENT GIST CAN PROLONG EVENT-FREE SURVIVAL
Paul Fanta
Favorite
(P 175) KIT AND DOG-1 EXPRESSING GASTROINTESTINAL STROMAL TUMORS HARBORING ETV6-NTRK3 FUSIONS DO EXIST, CASE OF NEAR COMPLETE PATHOLOGIC RESPONSE FOLLOWING LAROTRECTINIB AND REVIEW OF THE LITERATURE
Paul Fanta
Favorite
Fan, Timothy

University of Illinois Urbana-Champaign
(P 79) NOVEL THERAPEUTIC POTENTIAL THROUGH HYPERACTIVATION OF THE ANTICIPATORY UNFOLDED PROTEIN RESPONSE PATHWAY IN BONE CANCER TREATMENT
Timothy Fan
Favorite
(P 419) BONE MECHANICS INFLUENCE CANCER STEM CELL FORMATION IN OSTEOSARCOMA
Timothy Fan
Favorite
Fantini, Lorenzo

IRST - Meldola
(P 144) EXPLORATORY ANALYSIS OF 68GA-FAPI-46 PET-CT IN SOFT TISSUE SARCOMA
Lorenzo Fantini
Favorite
Fan, Zheng-Fu

Beijing Cancer Hospital
(P 416) TRIPLR COMNINATION THERAPY IN THE FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA WITH HIGH TUMOR BURDEN: INTERIM ANALYSIS FROM ALTER-S007 STUDY
Zheng-Fu Fan
Favorite
Faria Andrade, Augusto

Research Institute McGill University Health Center
(P 69) H3.3G34W ONCOHISTONE IN OSTEOSARCOMA
Augusto Faria Andrade
Favorite
Farinatti, Sara

IRCCS Humanitas Research Hospital
(P 124) ASSESSMENT OF THE MECHANISMS OF ACTION OF ERIBULIN IN PATIENTS WITH ADVANCED LIPOSARCOMA THROUGH THE EVALUATION OF THE RADIOLOGICAL, FUNCTIONAL AND TISSUE RESPONSE: A MONOCENTRIC PROSPECTIVE STUDY
Sara Farinatti
Favorite
Farinetti, Sara

IRCCS Humanitas Research Hospital
(P 290) ARTIFICIAL INTELLIGENCE-BASED COMPARISON OF ADULT AND ADOLESCENT AND YOUNG ADULTS (AYA) SARCOMAS: A PILOT STUDY
Sara Farinetti
Favorite
Farley, Lauren

Division of Surgical Oncology, Department of Surgery, University of California Davis
(P 230) HIGHER BODY MASS INDEX IS ASSOCIATED WITH DECREASED CIRCULATING AND INTRATUMORAL NATURAL KILLER CELLS IN SOFT TISSUE SARCOMA
Lauren Farley
Favorite
Farma, Jeffery

Fox Chase Cancer Center
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Jeffery Farma
Favorite
Farooqi, Ahsan

The University of Texas MD Anderson Cancer Center
(P 360) TREATMENT OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR WITH BROMODOMAIN EXTRA TERMINAL INHIBITOR (BETI) IN COMBINATION WITH RADIOTHERAPY
Ahsan Farooqi
Favorite
Faruqi, Ayra

Northwestern Medicine
(P 179) PRIMARY MANAGEMENT OF LOCALIZED GASTROINTESTINAL STROMAL TUMORS WITH IMATINIB MONOTHERAPY: AN ALTERNATIVE TO RESECTION FOR PATIENTS PRECLUDED FROM SURGERY
Ayra Faruqi
Favorite
Faruqi, Fahad

Northwestern Medicine
(P 179) PRIMARY MANAGEMENT OF LOCALIZED GASTROINTESTINAL STROMAL TUMORS WITH IMATINIB MONOTHERAPY: AN ALTERNATIVE TO RESECTION FOR PATIENTS PRECLUDED FROM SURGERY
Fahad Faruqi
Favorite
Fatehi, Amirreza

MedStar Georgetown Cancer Institute
(P 39) PATIENT OUTCOMES FOLLOWING MINIMALLY INVASIVE TREATMENT OF ANEURYSMAL BONE CYSTS USING DOXYCYCLINE
Amirreza Fatehi
Favorite
FATTORI, Antonin

University Hospitals of Strasbourg
(P 426) GD2 HETEROGENEIC EXPRESSION IN OSTEOSARCOMAS AND EWING SARCOMAS UNDERLYING A WORST PROGNOSIS
Antonin FATTORI
Favorite
Faulkner, Lisa

Clear Cell Sarcoma Foundation
(P 189) CLEAR CELL SARCOMA - REAL WORLD DATA ANALYSIS
Lisa Faulkner
Favorite
Fausti, Valentina

Clinical and Experimental Oncology, Immunotherapy, Rare Cancers and Biological Resource Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy
(P 144) EXPLORATORY ANALYSIS OF 68GA-FAPI-46 PET-CT IN SOFT TISSUE SARCOMA
Valentina Fausti
Favorite
Federico, Sara

St. Jude Children's Research Hospital
(P 288) ANGIOA: A SAFETY AND TOLERABILITY STUDY OF TRIPLE ANTI-ANGIOGENIC THERAPY COMBINED WITH PD-L1 BLOCKADE IN PEDIATRIC, ADOLESCENT AND YOUNG ADULT RECURRENT/REFRACTORY SOLID TUMORS
Sara Federico
Favorite
Federman, Noah

Departments of Pediatrics and Orthopaedic Surgery, David Geffen School of Medicine, University of California Los Angeles
(P 33) DESCRIPTIVE EVALUATION OF PATIENTS WITH DESMOID TUMOR AND CO-OCCURRING SOMATIC MUTATIONS OF CTNNB1 AND APC IN THE PHASE 3 DEFI TRIAL
Noah Federman
Favorite
Federman, Noah

UCLA David Geffen School of Medicine
(P 393) EFFICACY AND SAFETY OF LAROTRECTINIB AS FIRST-LINE TREATMENT IN PATIENTS WITH TRK FUSION SARCOMAS
Noah Federman
Favorite
Feinberg, Tamar

Memorial Sloan Kettering Cancer Center
(P 338) PRECLINICAL EFFICACY OF DAN-222, A NOVEL POLYMERIC NANOPARTICLE, IN PEDIATRIC SOLID TUMOR MODELS
Tamar Feinberg
Favorite
Fei, Yuewei

Yale University
(P 98) A MULTIEPITOPE MRNA VACCINE FOR KAPOSI SARCOMA: AN IMMUNOINFORMATIC APPROACH
Yuewei Fei
Favorite
Felser, Brandi

Sarcoma Foundation of America
(P 206) PATIENT PERSPECTIVE ON LIPOSARCOMA DIAGNOSTIC JOURNEY: INTERIM PATIENT SURVEY RESULTS
Brandi Felser
Favorite
Femino, J. Dominic

Department of Orthopaedic Surgery, Keck School of Medicine of the University of Southern California
(P 197) EVALUATION OF REVIEWS OF ORTHOPAEDIC ONCOLOGISTS ON INSTITUITIONAL AND PATIENT REVIEW WEBSITES
J. Dominic Femino
Favorite
Fenger, Joelle

Ethos Discovery
(P 115) PROSPECTIVE EVALUATION OF THORACOSCOPIC METASTASECTOMY IN DOGS: A NOVEL TRANSLATIONAL DRUG DEVELOPMENT PIPELINE TAGETING METASTATIC OSTEOSARCOMA
Joelle Fenger
Favorite
Feng, feifei

Zhengzhou University
(P 97) TRANSCRIPTOMICS REVEALS THAT OVEREXPRESSION OF LNCRNA HOTTIP REGULATES PKC PROTEIN ACTIVATION OF THE RAP1 SIGNALING PATHWAY FOR SYNOVIAL SARCOMA CELL PROGRESSION
feifei Feng
Favorite
Feng, Xiaolan

Tom Baker Cancer Center
(P 153) PATTERNS, MANAGEMENT AND SURVIVAL OUTCOMES OF PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA: A NATIONWIDE ANALYSIS FROM THE CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION DATABASE
Xiaolan Feng
Favorite
Feng, Xiaolan

Tom Baker Cancer Centre
(P 174) INCIDENCE, TREATMENT PATTERNS, AND SURVIVAL OUTCOMES FOR ADULT PATIENTS WITH GASTROINTESTINAL STROMAL TUMOURS (GIST) IN ALBERTA, CANADA FROM 2008 - 2022.
Xiaolan Feng
Favorite
Feng, Xiaolan

Tom Baker Cancer Center
(P 176) LOSS OF PTEN EXPRESSION IN MINIGISTS AND CLINICALLY RELEVANT GISTS
Xiaolan Feng
Favorite
(P 293) CIC-REARRANGED SOFT TISSUE SARCOMAS: DOES CHEMOTHERAPY CHANGE NATURAL HISTORY AND PROGNOSIS? A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Xiaolan Feng
Favorite
(P 320) WHAT IS THE ROLE OF CHEMOTHERAPY IN PATIENTS (PTS) WITH SPINDLE CELL/SCLEROSING RHABDOMYOSARCOMA (SCRMS): A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Xiaolan Feng
Favorite
(P 321) WHOLE ABDOMINAL RADIOTHERAPY IN CHILDREN AND YOUNG ADULTS WITH SARCOMA: A CANADIAN SARCOMA AND CLINICAL COLLABORATION (CANSARCC) STUDY
Xiaolan Feng
Favorite
Feng, Yi

Memorial Sloan Kettering Cancer Center
(P 302) HER2 PRETARGETED ALPHA PARTICLE RADIOIMMUNOTHERAPY FOR DESMOPLASTIC SMALL ROUND CELL TUMORS
Yi Feng
Favorite
Feng, Yi

Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
(P 416) TRIPLR COMNINATION THERAPY IN THE FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA WITH HIGH TUMOR BURDEN: INTERIM ANALYSIS FROM ALTER-S007 STUDY
Yi Feng
Favorite
Fennessy, Fiona

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Fiona Fennessy
Favorite
Ferguson, Michael

Division of Pediatric Hematology/Oncology, Riley Hospital for Children
(P 365) A SINGLE INSTITUTION COMPARISON OF OUTCOMES IN PEDIATRIC AND ADULT PATIENTS WITH GYNECOLOGIC ORIGIN RHABDOMYOSARCOMA
Michael Ferguson
Favorite
Ferguson, Peter

University of Toronto
(P 71) LIMB-SALVAGE SURGERY AFTER UNPLANNED SURGERY FOR EXTREMITY BONE SARCOMAS: 30-YEAR EXPERIENCE AT A TERTIARY REFERRAL CENTER
Peter Ferguson
Favorite
(P 238) INTRA-TUMORAL DC-LAMP EXPRESSION IS ASSOCIATED WITH PROGNOSIS IN SOFT TISSUE SARCOMA
Peter Ferguson
Favorite
(P 281) THE UTILITY OF INTRAOPERATIVE MARROW MARGIN FROZEN SECTION IN EXTREMITY BONE SARCOMA RESECTION
Peter Ferguson
Favorite
(P 352) OUTCOMES OF PRIMARY INTRATHORACIC SOFT TISSUE SARCOMA
Peter Ferguson
Favorite
Fernandes, Italo

Hospital Israelita Albert Einstein
(P 242) MICROSATELLITE INSTABILITY AND CLINICAL USE IN SARCOMAS: A SYSTEMATIC REVIEW
Italo Fernandes
Favorite
Fernandes, Matheus

UERN
(P 232) IMMUNE CHECKPOINT INHIBITORS COMBINED WITH TYROSINE KINASE INHIBITORS FOR SOFT-TISSUE SARCOMAS: A SYSTEMATIC REVIEW AND SINGLE-ARM META-ANALYSIS
Matheus Fernandes
Favorite
Fernandes, Milena

Hospital Israelita Albert Einstein
(P 141) COMPREHENSIVE GENOMIC PROFILING OF PATIENTS DIAGNOSED WITH SARCOMA IN BRAZIL: MOLECULAR PROFILE AND ACTIONABILITY
Milena Fernandes
Favorite
Fernández, Elena

Hospital Clínico San Carlos
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Elena Fernández
Favorite
Ferraresi, Virginia

IRCCS Istituto Nazionale Tumori Regina Elena
(P 43) SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
Virginia Ferraresi
Favorite
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Virginia Ferraresi
Favorite
(P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Virginia Ferraresi
Favorite
Ferreira De Souza, Felipe

University of Miami Miller School of Medicine
(P 369) BLAND EMBOLIZATION AS ADJUNCT TREATMENT FOR HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA
Felipe Ferreira De Souza
Favorite
Ferrena, Alexander

Albert Einstein College of Medicine
(P 59) COMPREHENSIVE SINGLE CELL TRANSCRIPTOMICS ANALYSIS OF MURINE OSTEOSARCOMA UNCOVERS SKP2 FUNCTION IN METASTASIS, GENOMIC INSTABILITY AND IMMUNE ACTIVATION AND REALS ADDITIONAL TARGET PATHWAYS
Alexander Ferrena
Favorite
Ferrero, Giulio

Department of Clinical and Biological Sciences, University of Turin
(P 345) TRANSCRIPTOMIC AND PHENOTYPIC CHARACTERIZATION OF AN IMMUNOCOMPETENT LEIOMYOSARCOMA MOUSE MODEL.
Giulio Ferrero
Favorite
Ferrillo, Giuseppe

IRCCS Humanitas Research Hospital
(P 124) ASSESSMENT OF THE MECHANISMS OF ACTION OF ERIBULIN IN PATIENTS WITH ADVANCED LIPOSARCOMA THROUGH THE EVALUATION OF THE RADIOLOGICAL, FUNCTIONAL AND TISSUE RESPONSE: A MONOCENTRIC PROSPECTIVE STUDY
Giuseppe Ferrillo
Favorite
Fetting, Nikki

Washington University in St. Louis School of Medicine
(P 145) EXPLORING L-TYPE AMINO ACID TRANSPORTER 1 (LAT1) AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)
Nikki Fetting
Favorite
Fetzer, Erin

The Ohio State University
(P 244) PREDICTIVE VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO IN IMMUNOTHERAPY OUTCOMES IN ADVANCED SARCOMA
Erin Fetzer
Favorite
(P 328) DETERMINING BIOMARKERS FOR GEMCITABINE RESPONSE IN SOFT TISSUE SARCOMAS: LESSONS LEARNED FROM PANCREATIC CANCER
Erin Fetzer
Favorite
Fetzko, Stephanie

Baylor College of Medicine
(P 315) SALVAGE THERAPY EFFICACY IS MODIFIED BY RISK GROUP AT DIAGNOSIS IN PATIENTS WITH RELAPSED RHABDOMYOSARCOMA
Stephanie Fetzko
Favorite
Fierstein, Jamie

Epidemiology and Biostatistics Shared Resource, Johns Hopkins All Children's Institute for Clinical and Translational Research, Johns Hopkins All Children's Hospital
(P 316) SECONDARY RHABDOMYOSARCOMA IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS
Jamie Fierstein
Favorite
Finkbeiner, Melanie

Alberta Children's Hospital
(P 320) WHAT IS THE ROLE OF CHEMOTHERAPY IN PATIENTS (PTS) WITH SPINDLE CELL/SCLEROSING RHABDOMYOSARCOMA (SCRMS): A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Melanie Finkbeiner
Favorite
Finlay, Darren

National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
(P 27) SUMO2 INHIBITION REVERSES ABERRANT EPIGENETIC REWIRING DRIVEN BY SYNOVIAL SARCOMA FUSION ONCOPROTEINS AND IMPAIRS SARCOMAGENESIS
Darren Finlay
Favorite
Finnegan, Maureen

Roswell Park Comprehensive Cancer Center
(P 35) EARLY REAL WORLD EXPERIENCE WITH NIROGACESTAT IN PATIENTS WITH DESMOID FIBROMATOSIS
Maureen Finnegan
Favorite
Fiocco, Marta

Leiden University Medical Center
(P 194) EFFECTIVENESS OF A RISK PREDICTION TOOL (PERSARC) ON THE QUALITY OF TREATMENT DECISIONS IN SOFT-TISSUE SARCOMA PATIENTS (VALUE-PERSARC TRIAL)
Marta Fiocco
Favorite
(P 274) PROXIMAL HUMERAL ENDOPROSTHETIC RECONSTRUCTION: RESULTS FROM THE MUTARS ORTHOPEDIC REGISTRY EUROPE (MORE)
Marta Fiocco
Favorite
(P 349) LONG-TERM SURVIVAL OF PARTICIPANTS IN THE PASART-1 AND PASART-2 TRIALS OF NEO-ADJUVANT PAZOPANIB AND RADIOTHERAPY IN SOFT TISSUE SARCOMA
Marta Fiocco
Favorite
Fiore, Marco

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 160) UTERINE PECOMA: REPORT OF MOLECULAR AND CLINICAL FEATURES IN A SERIES OF PATIENTS TREATED AT A REFERRAL INSTITUTION
Marco Fiore
Favorite
(P 171) GASTROINTESTINAL STROMAL TUMOURS (GISTS) IN NEUROFIBROMATOSIS TYPE (NF1): A SINGLE-CENTER OBSERVATIONAL RETROSPECTIVE STUDY
Marco Fiore
Favorite
(P 213) REGIONAL KNOWLEDGE TRANSLATION IN RETROPERITONEAL SARCOMAS: IMPACT OF AN EDUCATIONAL WEBINAR SERIES BY THE MEXICAN SARCOMA GROUP
Marco Fiore
Favorite
(P 376) IMPACT OF SITE OF ORIGIN ON THE PROGNOSIS OF PATIENTS WITH PRIMARY RESECTABLE NON-UTERINE ABDOMINAL LEIOMYOSARCOMA
Marco Fiore
Favorite
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Marco Fiore
Favorite
Firmin, Nelly

ICM, Institut du Cancer de Montpellier
(P 125) CHARACTERISTICS, MANAGEMENT AND SURVIVAL OF N=7314 LIPOSARCOMAS FROM THE NATIONWIDE NETSARC REGISTRY IN FRANCE SINCE 2010
Nelly Firmin
Favorite
Fischerova, Daniela

Charles University and General University Hospital in Prague, Prague
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Daniela Fischerova
Favorite
Fisher, Lauren

Dana-Farber Cancer Institute
(P 195) ENHANCING PARTICIPANT ENGAGEMENT IN A NOVEL PATIENT-PARTNERED CANCER GENOMICS RESEARCH EFFORT FOR RARE AND AGGRESSIVE SARCOMAS
Lauren Fisher
Favorite
Flacher, Vincent

UPR3572 CNRS Laboratory Institute of Molecular and Cellular Biology
(P 75) METABOLIC EVALUATION OF THE RELATIONSHIP BETWEEN MACROPHAGES AND OSTEOSARCOMA TUMOR CELLS
Vincent Flacher
Favorite
Fletcher, Christopher

Brigham & Women's Hospital and Harvard Medical School
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Christopher Fletcher
Favorite
FLETCHER, Jonathan

Harvard Medical School
(P 19) INVOLVEMENT OF O-GLCNAC TRANSFERASE IN RESISTANCE TO DOXORUBICIN AND CELL DEATH IN PRECLINICAL MODELS OF LEIOMYOSARCOMA AND DESMOID TUMORS
Jonathan FLETCHER
Favorite
(P 412) SARC044: A PHASE II TRIAL OF BEZUCLASTINIB IN COMBINATION WITH SUNITINIB IN PATIENTS WITH GIST WHO PROGRESSED ON SUNITINIB MONOTHERAPY
Jonathan FLETCHER
Favorite
Fleuren, Emmy

Children's Cancer Institute
(P 299) EXPLORING THE POTENTIAL OF PHOSPHOPROTEOMIC PROFILING FOR TARGET DISCOVERY IN HIGH-RISK OSTEOSARCOMA: A PATHWAY TO NOVEL THERAPIES?
Emmy Fleuren
Favorite
Fling, Steven

Fred Hutchinson Cancer Center
(P 222) ANALYSIS OF THE CITN-13 SARCOMA ARM: PEMBROLIZUMAB AND INTERFERON GAMMA FOR SYNOVIAL SARCOMA AND MYXOID/ ROUND CELL LIPOSARCOMA
Steven Fling
Favorite
Florio, Michela

Ospedale Pediatrico Bambino Gesù
(P 311) QUANTIFICATION OF TUMOUR-INFILTRATING IMMUNE CELLS THROUGH DECONVOLUTION OF DNA METHYLATION DATA IN EWING SARCOMAS
Michela Florio
Favorite
Florou, Vaia

University of Utah
(P 246) THE GENOMIC AND IMMUNE LANDSCAPE OF LIPOSARCOMA AND ITS SUBTYPES
Vaia Florou
Favorite
Foijer, Floris

University Medical Centre Groningen
(P 03) CDK4 IS CO-AMPLIFIED WITH EITHER TP53 PROMOTER GENE FUSIONS OR MDM2 THROUGH DISTINCT MECHANISMS IN OSTEOSARCOMA
Floris Foijer
Favorite
Foppolo, Sophie

UMR CNRS 7021, university of Strasbourg
(P 426) GD2 HETEROGENEIC EXPRESSION IN OSTEOSARCOMAS AND EWING SARCOMAS UNDERLYING A WORST PROGNOSIS
Sophie Foppolo
Favorite
Forbes, Thomas

National Institute of Health
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Thomas Forbes
Favorite
Fordham, Ashleigh

Children's Cancer Institute
(P 299) EXPLORING THE POTENTIAL OF PHOSPHOPROTEOMIC PROFILING FOR TARGET DISCOVERY IN HIGH-RISK OSTEOSARCOMA: A PATHWAY TO NOVEL THERAPIES?
Ashleigh Fordham
Favorite
Ford, Samuel

Queen Elizabeth Hospital
(P 383) PRE-OPERATIVE SPLIT RENAL FUNCTION RADIONUCLIDE IMAGING IN SURGICAL PLANNING FOR MULTI-VISCERAL RESECTION OF RETROPERITONEAL SARCOMA: A RETROSPECTIVE COHORT STUDY
Samuel Ford
Favorite
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Samuel Ford
Favorite
Foster, Jared

NCI CTEP
(P 413) SUSTAINED EFFICACY DURING DRUG HOLIDAY ON ATEZOLIZUMAB IN PATIENTS WITH ALVEOLAR SOFT PART SARCOMA (ASPS)
Jared Foster
Favorite
Fourman, Mitchell

Montefiore Medical Center
(P 284) WOUND VAC TEMPORIZATION AFTER TUMOR RESECTION OF SOFT TISSUE SARCOMAS - A COST ANALYSIS IN A PROPENSITY-SCORE MATCHED POPULATION
Mitchell Fourman
Favorite
Fox, Amanda

University of Michigan
(P 45) UTILIZATION OF MENTAL HEALTH AND SUPPORTIVE CARE RESOURCES AMONG PATIENTS WITH DESMOID TUMORS
Amanda Fox
Favorite
(P 308) PALLIATIVE CARE INVOLVEMENT FOR ADOLESCENTS AND YOUNG ADULTS WITH BONE AND SOFT TISSUE SARCOMAS
Amanda Fox
Favorite
Fraile, Carlos

Hospital Clinico San Carlos
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Carlos Fraile
Favorite
Franchi, Alessandro

University of Pisa,
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Alessandro Franchi
Favorite
Franchini, Melania

Columbia University Irving Medical Center
(P 418) A SYSTEMS BIOLOGY APPROACH FOR CHARACTERIZING TUMOR HETEROGENEITY AND CELL STATE-SPECIFIC THERAPEUTIC VULNERABILITIES FROM SINGLE NUCLEUS RNA-SEQ PROFILING OF DESMOPLASTIC SMALL ROUND CELL TUMORS
Melania Franchini
Favorite
Franza, Andrea

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
(P 160) UTERINE PECOMA: REPORT OF MOLECULAR AND CLINICAL FEATURES IN A SERIES OF PATIENTS TREATED AT A REFERRAL INSTITUTION
Andrea Franza
Favorite
(P 368) AGGRESSIVE PERINEAL ANGIOMYXOMA UNDERGOING SYSTEMIC TREATMENT: AN UPDATED REPORT OF 8-YEARS' EXPERIENCE IN A REFERRAL CENTER
Andrea Franza
Favorite
Fraser, Luke

The University of Kansas Medical Center
(P 36) EARLY REAL-WORLD EXPERIENCE WITH THE USE OF NIROGACESTAT FOR THE TREATMENT OF DESMOID FIBROMATOSIS
Luke Fraser
Favorite
Freed, Daniel

Chordoma Foundation
(P 02) A PRECLINICAL ASSAY PIPELINE TO IDENTIFY AND OPTIMIZE BRACHYURY-TARGETED THERAPIES IN CHORDOMA AND OTHER SOLID TUMORS
Daniel Freed
Favorite
(P 425) EXPLORING MECHANISMS OF EGFR INHIBITOR RESISTANCE IN CHORDOMA
Daniel Freed
Favorite
Freeland, Jack

University of California Los Angeles
(P 08) ELUCIDATING THE ROLE OF YAP IN SARCOMA DEVELOPMENT
Jack Freeland
Favorite
Frega, Giorgio

Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies, IRCCS, Istituto Ortopedico Rizzoli, Bologna, Italy
(P 77) MULTI-PARAMETRICAL PROFILING OF CHONDROSARCOMA
Giorgio Frega
Favorite
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Giorgio Frega
Favorite
Frey, Alexandre

Yale University
(P 98) A MULTIEPITOPE MRNA VACCINE FOR KAPOSI SARCOMA: AN IMMUNOINFORMATIC APPROACH
Alexandre Frey
Favorite
Friedlander, Michael

Prince of Wales Hospital
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Michael Friedlander
Favorite
Friedman, Debra

Vanderbilt University Medical Center
(P 199) FINANCIAL TOXICITY AMONG SARCOMA PATIENTS AND ASSOCIATED FACTORS
Debra Friedman
Favorite
(P 297) ESTABLISHING A PEDIATRIC, ADOLESCENT AND YOUNG ADULT COHORT OF SARCOMA PATIENTS TO STUDY ONCOLOGIC AND NON-ONCOLOGIC OUTCOMES
Debra Friedman
Favorite
Friedman, Elizabeth

University of Kansas
(P 36) EARLY REAL-WORLD EXPERIENCE WITH THE USE OF NIROGACESTAT FOR THE TREATMENT OF DESMOID FIBROMATOSIS
Elizabeth Friedman
Favorite
Fritchie, Karen

Cleveland Clinic
(P 152) NOVEL PAX3::MAML3 FUSION IDENTIFIED IN ALVEOLAR RHABDOMYOSARCOMA: USING DNA METHYLATION TO EXPANDE THE GENETIC SPECTRUM OF "FUSION POSITIVE" CASES
Karen Fritchie
Favorite
Fuchs, Bruno

Swiss Sarcoma Network
(P 184) A SYSTEMATIC REVIEW ABOUT CLINICAL PROGNOSTIC MODELS FOR SARCOMAS
Bruno Fuchs
Favorite
(P 204) IMPACT OF UNPéLANNED EXCISION ON THE SURVIVAL OF SARCOMA PATIENTS - A TARGET TRIAL EMULATION
Bruno Fuchs
Favorite
Fujii, Hiromasa

Nara Medical University
(P 85) PTEROSTILBENE SENSITIZES OSTEOSARCOMA CELLS TO KILLING BY C-MYC INHIBITORS
Hiromasa Fujii
Favorite
(P 313) RELATION BETWEEN NUTRITIONAL/INFLAMMATORY PARAMETERS AND PROGNOSIS IN CHILDHOOD SARCOMA PATIENTS
Hiromasa Fujii
Favorite
Fujimoto, Hiroyuki

Department of Urology, National Cancer Center Hospital, Tokyo, Japan
(P 134) REAL-WORLD CLINICAL OUTCOME OF NEOADJUVANT CHEMOTHERAPY FOR RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA
Hiroyuki Fujimoto
Favorite
Fujisawa, Takeshi

National Cancer Center Hospital East
(P 354) PROTON BEAM THERAPY FOR PEDIATRIC AND ADOLESCENT SARCOMA FROM OVERSEAS
Takeshi Fujisawa
Favorite
Fujito, Takeo

Nagoya university hospital
(P 280) SURGICAL OUTCOMES OF PELVIC CHONDROSARCOMA WITH A FOCUS ON WALKING ABILITY
Takeo Fujito
Favorite
Fujiwara, Toshifumi

Kyushu University
(P 203) IMPACT OF COVID-19 PANDEMIC ON BONE AND SOFT TISSUE SARCOMA PATIENTS' CONSULTATION AND DIAGNOSIS
Toshifumi Fujiwara
Favorite
Fukushima, Suguru

National Cancer Center Hospital
(P 134) REAL-WORLD CLINICAL OUTCOME OF NEOADJUVANT CHEMOTHERAPY FOR RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA
Suguru Fukushima
Favorite
(P 220) SPORTS ACTIVITIES IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT SURVIVORS OF MALIGNANT BONE SARCOMAS
Suguru Fukushima
Favorite
Fumagalli, Elena

Fondazione IRCCS Istituto Nazionale Dei Tumori Di Milano
(P 160) UTERINE PECOMA: REPORT OF MOLECULAR AND CLINICAL FEATURES IN A SERIES OF PATIENTS TREATED AT A REFERRAL INSTITUTION
Elena Fumagalli
Favorite
Fumagalli, Elena

Istituto Nazionale Tumori
(P 171) GASTROINTESTINAL STROMAL TUMOURS (GISTS) IN NEUROFIBROMATOSIS TYPE (NF1): A SINGLE-CENTER OBSERVATIONAL RETROSPECTIVE STUDY
Elena Fumagalli
Favorite
Fumagalli, Elena

Fondazione IRCCS Istituto Nazionale Dei Tumori Di Milano
(P 368) AGGRESSIVE PERINEAL ANGIOMYXOMA UNDERGOING SYSTEMIC TREATMENT: AN UPDATED REPORT OF 8-YEARS' EXPERIENCE IN A REFERRAL CENTER
Elena Fumagalli
Favorite
Futreal, P Andrew

MD Anderson Cancer Center
(P 233) IMMUNE CLASSES OF LEIOMYOSARCOMA DRIVEN BY B CELL INFILTRATE AND CTLA4 EXPRESSION
P Andrew Futreal
Favorite
(P 398) PREDICTORS OF EFFICACY IN PATIENTS WITH SOFT TISSUE SARCOMAS TREATED WITH PAZOPANIB
P Andrew Futreal
Favorite
Fu, Xiao-Hong

RWE, Boehringer Ingelheim, Shanghai, China
(P 132) PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND DISEASE BURDEN OF DEDIFFERENTIATED LIPOSARCOMA IN CHINA: A REAL-WORLD STUDY BASED ON NATIONAL CANCER REGISTRY
Xiao-Hong Fu
Favorite
G
Güler, Sinan E.

Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
(P 410) PHASE I STUDY OF THE001 (DPPG2-TSL-DOX) COMBINED WITH REGIONAL HYPERTHERMIA IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Sinan E. Güler
Favorite
Gónzalez, María Lucila

Instituto Nacional del Cáncer
(P 192) CURRENT SCENARIO OF SARCOMA CLINICAL TRIALS IN SOUTH AMERICA: A REPORT BY THE LACOG SARCOMA GROUP
María Lucila Gónzalez
Favorite
(P 216) SARCOMA CARE PATHWAYS AND MULTIDISCIPLINARY TUMOR BOARDS IN LATIN AMERICA: AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
María Lucila Gónzalez
Favorite
(P 217) SARCOMA DRUG APPROVALS IN LATIN AMERICA COMPARED TO THE FDA AND EMA: AN ANALYSIS BY THE LACOG SARCOMA GROUP
María Lucila Gónzalez
Favorite
(P 219) SOCIAL MEDIA USE AMONG MEDICAL PROFESSIONALS THAT TREAT PATIENTS WITH SARCOMA IN LATIN AMERICA: RESULTS OF AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
María Lucila Gónzalez
Favorite
Gains, Jennifer

University College Hospitals London
(P 60) DIAGNOSIS AND MANAGEMENT OF PAEDIATRIC EWING SARCOMA PATIENTS IN ENGLAND 2014-2017: A COMPARISON OF NATIONAL DATA WITH THE EURO-EWING 2012 CLINICAL TRIAL
Jennifer Gains
Favorite
Galoaa, Bishoy

Massachusetts General Hospital
(P 100) ADVANCING PROGNOSTICS IN ONCOLOGY: MACHINE LEARNING MODELS FOR PREDICTING 2-YEAR AND 5-YEAR SURVIVAL RATES IN PATIENTS WITH UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Bishoy Galoaa
Favorite
Galoian, Karina

University o f Miami, Miller School of Medicine, Department of Orthopedic Surgery
(P 55) CHONDROSARCOMA PATIENT CHARACTERISTICS AND DIAGNOSTIC AND TREATMENT PATHWAYS: GLOBAL CHONDROSARCOMA PATIENT REGISTRY
Karina Galoian
Favorite
Gambarotti, Marco

Department of Pathology, IRCCS, Istituto Ortopedico Rizzoli
(P 77) MULTI-PARAMETRICAL PROFILING OF CHONDROSARCOMA
Marco Gambarotti
Favorite
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Marco Gambarotti
Favorite
Ganapathi, Shireen

Seattle Children's Research Institute
(P 330) EFFICACY OF NON-CARDIOTOXIC ANTHRACYCLINES IN EWING SARCOMA
Shireen Ganapathi
Favorite
Ganjoo, Kristen

Stanford Comprehensive Cancer Center
(P 143) EARLY ASSESSMENT OF DISEASE RESPONSE TO IMMUNOTHERAPY VIA CIRCULATING TUMOR DNA IN ADVANCED SOFT TISSUE SARCOMAS
Kristen Ganjoo
Favorite
(P 161) UTILITY OF CTDNA MONITORING IN THE ADJUVANT AND METASTATIC SETTING IN SOFT TISSUE SARCOMA
Kristen Ganjoo
Favorite
(P 202) IMPACT OF AFAMI-CEL ON THE HEALTH STATE OF PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR MYXOID/ROUND CELL LIPOSARCOMA: COHORT 1 OF SPEARHEAD-1
Kristen Ganjoo
Favorite
(P 427) MULTI-OMIC AND MULTI-REGION PROFILING OF DESMOID TUMORS REVEALS INTRA- AND INTER-TUMOR HETEROGENEITY
Kristen Ganjoo
Favorite
Gantzer, Justine

ICANS
(P 125) CHARACTERISTICS, MANAGEMENT AND SURVIVAL OF N=7314 LIPOSARCOMAS FROM THE NATIONWIDE NETSARC REGISTRY IN FRANCE SINCE 2010
Justine Gantzer
Favorite
García Maroto, Roberto

Hospital Clinico san Carlos
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Roberto García Maroto
Favorite
Garcia Garcia-Esquinas, Marta

Hospital Clinico san Carlos
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Marta Garcia Garcia-Esquinas
Favorite
Garcia, Jacob

Umoja Biopharma
(P 226) EARLY EXPERIENCE ON ENLIGHTEN-01: A PHASE 1 STUDY OF BISPECIFIC ADAPTER MOLECULE- CONTROLLED FOLATE RECEPTOR CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY OSTEOSARCOMA
Jacob Garcia
Favorite
Garcia, Josep

Inhibrx Biosciences, Inc.
(P 95) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN PATIENTS WITH CHONDROSARCOMA: UPDATED RESULTS FROM A PHASE 1 STUDY
Josep Garcia
Favorite
Garcia, Nicolas

Seattle Children's Research Institute
(P 330) EFFICACY OF NON-CARDIOTOXIC ANTHRACYCLINES IN EWING SARCOMA
Nicolas Garcia
Favorite
Garcia-Ortega, Dorian

National Cancer Institute Mexico
(P 213) REGIONAL KNOWLEDGE TRANSLATION IN RETROPERITONEAL SARCOMAS: IMPACT OF AN EDUCATIONAL WEBINAR SERIES BY THE MEXICAN SARCOMA GROUP
Dorian Garcia-Ortega
Favorite
(P 367) AGE AS A PROGNOSTIC FACTOR IN RETROPERITONEAL SARCOMA: A MULTICENTER LATIN AMERICAN STUDY
Dorian Garcia-Ortega
Favorite
(P 374) FACTORS ASSOCIATED WITH RECURRENCE IN DEDIFFERENTIATED RETROPERITONEAL LIPOSARCOMA: ANALYSIS AT A REFERENCE CENTER
Dorian Garcia-Ortega
Favorite
Gardner, Rebecca

St. Jude Children's Research Hospital
(P 226) EARLY EXPERIENCE ON ENLIGHTEN-01: A PHASE 1 STUDY OF BISPECIFIC ADAPTER MOLECULE- CONTROLLED FOLATE RECEPTOR CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY OSTEOSARCOMA
Rebecca Gardner
Favorite
Garland-Kledzik, Mary

West Virginia University
(P 342) THE ROLE OF MYELOPEROXIDASE IN SARCOMA TREATMENT
Mary Garland-Kledzik
Favorite
Garofalo, Serena

Fondazione Policlinico Campus Bio-Medico of Rome
(P 178) PREDICTION OF PRIMARY IMATINIB-REFRACTORY PATIENTS WITH LOCALLY ADVANCED OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) USING RADIOMICS AND ARTIFICIAL INTELLIGENCE (AI)
Serena Garofalo
Favorite
Gartner, Jared

Surgery Branch, NCI, NIH
(P 231) IDENTIFICATION OF NEOANTIGEN FROM PECOMA-LIKE NEOPLASM PROVIDES RATIONALE FOR TREATMENT WITH CELLULAR THERAPY
Jared Gartner
Favorite
Gartrell, Jessica

St. Jude Children’s Research Hospital
(P 288) ANGIOA: A SAFETY AND TOLERABILITY STUDY OF TRIPLE ANTI-ANGIOGENIC THERAPY COMBINED WITH PD-L1 BLOCKADE IN PEDIATRIC, ADOLESCENT AND YOUNG ADULT RECURRENT/REFRACTORY SOLID TUMORS
Jessica Gartrell
Favorite
Garzia, Livia

McGill University and RI-MUHC
(P 69) H3.3G34W ONCOHISTONE IN OSTEOSARCOMA
Livia Garzia
Favorite
(P 78) NOVEL EPIGENETIC MECHANISMS DRIVE AGGRESSIVE OSTEOSARCOMA PATHOGENESIS AND DRUG RESISTANCE
Livia Garzia
Favorite
Gasho, Jordan

Keck School of Medicine of the University of Southern California
(P 197) EVALUATION OF REVIEWS OF ORTHOPAEDIC ONCOLOGISTS ON INSTITUITIONAL AND PATIENT REVIEW WEBSITES
Jordan Gasho
Favorite
Gaspar, Nathalie

Gustave Roussy Cancer Campus
(P 49) A WORKING GROUP FOR THE DEVELOPMENT OF A CLINICAL FRAMEWORK THAT STRATIFIES OSTEOSARCOMA PATIENTS USING BIOMARKERS OF CLINICAL RISK AND BIOLOGY
Nathalie Gaspar
Favorite
(P 53) CHARACTERIZING THE SPATIAL TRANSCRIPTOMIC LANDSCAPE OF OSTEOSARCOMA FROM DIAGNOSIS TO RELAPSE
Nathalie Gaspar
Favorite
Gaspar, Nathalie

Gustave Roussy
(P 82) PLASMA CIRCULATING PROTEOMIC MARKERS ARE ASSOCIATED WITH METASTATIC SPREAD AND OUTCOME IN OSTEOSARCOMA
Nathalie Gaspar
Favorite
Gaulier, Patrick

University of Michigan
(P 45) UTILIZATION OF MENTAL HEALTH AND SUPPORTIVE CARE RESOURCES AMONG PATIENTS WITH DESMOID TUMORS
Patrick Gaulier
Favorite
Gaunt, Piers

University of Birmingham
(P 60) DIAGNOSIS AND MANAGEMENT OF PAEDIATRIC EWING SARCOMA PATIENTS IN ENGLAND 2014-2017: A COMPARISON OF NATIONAL DATA WITH THE EURO-EWING 2012 CLINICAL TRIAL
Piers Gaunt
Favorite
Gazendam, Aaron

University of Toronto
(P 71) LIMB-SALVAGE SURGERY AFTER UNPLANNED SURGERY FOR EXTREMITY BONE SARCOMAS: 30-YEAR EXPERIENCE AT A TERTIARY REFERRAL CENTER
Aaron Gazendam
Favorite
(P 281) THE UTILITY OF INTRAOPERATIVE MARROW MARGIN FROZEN SECTION IN EXTREMITY BONE SARCOMA RESECTION
Aaron Gazendam
Favorite
Geary, Elizabeth

University of Iowa
(P 14) HDAC INHIBITORS DOWNREGULATE THE EXPRESSION LEVELS OF THE MINI-CHROMOSOME MAINTENANCE PROTEINS, AND INHIBIT DNA REPLICATION, IN EWING SARCOMA CELLS
Elizabeth Geary
Favorite
ge, 赛

Peking University Cancer Hospital
(P 180) TUMOR VASCULAR SIGN IN THE RESPONSE ASSESSMENT OF GASTROINTESTINAL STROMAL TUMOR TREATED WITH RIPRETINIB: A MULTICENTER STUDY
赛 ge
Favorite
Geiger, Erik

University of Miami, Sylvester Comprehensive Cancer Center
(P 358) RADIOMIC EVALUATION OF MRIS IN PATIENTS WITH SOFT TISSUE SARCOMA TREATED WITH STEREOTACTIC BOSY RADIATION THERAPY
Erik Geiger
Favorite
Gelderblom, Hans

Leiden University Medical Center
(P 37) HEALTH-RELATED QUALITY OF LIFE FROM A PHASE 4 STUDY TO EVALUATE DISCONTINUATION AND RECHALLENGE OF PEXIDARTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR PREVIOUSLY TREATED WITH PEXIDARTINIB
Hans Gelderblom
Favorite
(P 42) RANKL-INHIBITION FOR GIANT CELL LESIONS OF THE JAW: A RETROSPECTIVE COHORT ANALYSIS
Hans Gelderblom
Favorite
(P 43) SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
Hans Gelderblom
Favorite
(P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE
Hans Gelderblom
Favorite
(P 319) THE SURVIVAL DISPARITY BETWEEN CHILDREN AND ADOLESCENTS & YOUNG ADULTS WITH EWING SARCOMA IN THE NETHERLANDS DID NOT CHANGE SINCE THE 1990S DESPITE IMPROVED SURVIVAL: A POPULATION-BASED STUDY
Hans Gelderblom
Favorite
(P 349) LONG-TERM SURVIVAL OF PARTICIPANTS IN THE PASART-1 AND PASART-2 TRIALS OF NEO-ADJUVANT PAZOPANIB AND RADIOTHERAPY IN SOFT TISSUE SARCOMA
Hans Gelderblom
Favorite
(P 401) A PHASE 3 MULTI-CENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO ASSESS THE EFFICACY AND SAFETY OF EMACTUZUMAB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR (TANGENT)
Hans Gelderblom
Favorite
Geller, David

Montefiore Medical Center - Orthopaedic Oncology
(P 147) INVESTIGATING THE POTENTIAL OF EXTRACELLULAR VESICLE BIOMARKERS IN SYNOVIAL SARCOMA DETECTION
David Geller
Favorite
(P 156) PROFILING SYNOVIAL SARCOMA EXTRACELLULAR VESICLES FOR DIAGNOSTIC RNA BIOMARKERS
David Geller
Favorite
Geoerger, Birgit

Gustave Roussy Cancer Center, Department of Pediatric and Adolescent Oncology, Université Paris-Saclay, INSERM U1015, Villejuif, France
(P 53) CHARACTERIZING THE SPATIAL TRANSCRIPTOMIC LANDSCAPE OF OSTEOSARCOMA FROM DIAGNOSIS TO RELAPSE
Birgit Geoerger
Favorite
Geoerger, Birgit

Gustave Roussy
(P 82) PLASMA CIRCULATING PROTEOMIC MARKERS ARE ASSOCIATED WITH METASTATIC SPREAD AND OUTCOME IN OSTEOSARCOMA
Birgit Geoerger
Favorite
George, Suzanne

Dana-Farber Cancer Institute
(P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE
Suzanne George
Favorite
(P 195) ENHANCING PARTICIPANT ENGAGEMENT IN A NOVEL PATIENT-PARTNERED CANCER GENOMICS RESEARCH EFFORT FOR RARE AND AGGRESSIVE SARCOMAS
Suzanne George
Favorite
(P 402) A PILOT STUDY OF BTX-A51 IN PATIENTS WITH METASTATIC AND/OR RECURRENT LIPOSARCOMAS CHARACTERIZED BY MDM2 AMPLIFICATIONS
Suzanne George
Favorite
Gerber, David

University of Texas Southwestern Medical Center
(P 417) VITAS: ATEZOLIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY SOLID TUMORS: AN OPEN-LABEL, PHASE I/II, SINGLE-ARM, MULTI-CENTER TRIAL IN PROGRESS
David Gerber
Favorite
Gerrand, Craig

Royal National Orthopaedic Hospital, NHS England
(P 60) DIAGNOSIS AND MANAGEMENT OF PAEDIATRIC EWING SARCOMA PATIENTS IN ENGLAND 2014-2017: A COMPARISON OF NATIONAL DATA WITH THE EURO-EWING 2012 CLINICAL TRIAL
Craig Gerrand
Favorite
Gervais, Mai-Kim

Hôpital Maisonneuve Rosemont
(P 321) WHOLE ABDOMINAL RADIOTHERAPY IN CHILDREN AND YOUNG ADULTS WITH SARCOMA: A CANADIAN SARCOMA AND CLINICAL COLLABORATION (CANSARCC) STUDY
Mai-Kim Gervais
Favorite
Gervais, Thomas

µFO Lab, Polytechnique Montréal, Montréal, Canada, Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), Montréal, Canada, Institut du Cancer de Montréal (ICM), Montréal, Canada
(P 326) CELL-FREE DNA AS A BIOMARKER FOR CELL DEATH AND TREATMENT RESPONSE IN ON-CHIP THREE-DIMENSIONAL SARCOMA TUMOR MODELS
Thomas Gervais
Favorite
Ge, Xinyi

University of Utah
(P 332) ENHANCING THERAPEUTIC EFFICACY IN SYNOVIAL SARCOMA BY TARGETING P53-MDM2 AXIS AND HDAC PATHWAYS
Xinyi Ge
Favorite
(P 343) TLE1 DISRUPTION DOES NOT IMPEDE SYNOVIAL SARCOMAGENESIS
Xinyi Ge
Favorite
Ghani, Saeed

Helios Klinikum Berlin-Buch and Medical School Berlin
(P 410) PHASE I STUDY OF THE001 (DPPG2-TSL-DOX) COMBINED WITH REGIONAL HYPERTHERMIA IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Saeed Ghani
Favorite
Ghini, Virginia

Irst - Meldola
(P 144) EXPLORATORY ANALYSIS OF 68GA-FAPI-46 PET-CT IN SOFT TISSUE SARCOMA
Virginia Ghini
Favorite
Giacalone, Joseph

Atlantic Health System
(P 405) LIPOSOMAL BUPIVACAINE DOESN'T REDUCE NARCOTIC USE OR PAIN SCORES COMPARED TO A MULTIDRUG COCKTAIL FOLLOWING SOFT TISSUE TUMOR REMOVAL: PRELIM RESULTS OF A PROSPECTIVE, RANDOMIZED DOUBLE-BLINDED STUDY
Joseph Giacalone
Favorite
Giani, Claudia

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Claudia Giani
Favorite
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Claudia Giani
Favorite
(P 429) PATIENTS WITH ADVANCED EPITHELIOID HEMANGIOENDOTHELIOMA TREATED WITH SIROLIMUS: OUTCOME FOLLOWING SIROLIMUS DISCONTINUATION.
Claudia Giani
Favorite
Giannikou, Krinio

Children's Hospital Los Angeles
(P 88) SPATIAL TRANSCRIPTOMICS OF EWING SARCOMA: EVOLUTION OF TUMOR MICROENVIRONMENT ASSOCIATED EXTRACELLULAR MATRIX FROM LOCALIZED TO METASTASIS-ASSOCIATED PRIMARY TUMORS
Krinio Giannikou
Favorite
Gildea, Carolynn

National Disease Registration Service, NHS England
(P 60) DIAGNOSIS AND MANAGEMENT OF PAEDIATRIC EWING SARCOMA PATIENTS IN ENGLAND 2014-2017: A COMPARISON OF NATIONAL DATA WITH THE EURO-EWING 2012 CLINICAL TRIAL
Carolynn Gildea
Favorite
Gill, Gurveer

University of Calgary
(P 289) APPLICATION AND ANALYSIS OF SPATIAL TRANSCRIPTOMIC PROFILING TO CLINICAL ALVEOLAR SOFT PART SARCOMA SAMPLES TO UNDERSTAND IMMUNOTHERAPY-RELEVANT VARIABLES
Gurveer Gill
Favorite
Gill, Jaya

Precision NextGen Oncology and Research Center
(P 140) CIRCULATING TUMOR DNA AS A TOOL OF SURVEILLANCE AND EARLY INDICATOR OF RELAPSE IN SARCOMA PATIENTS
Jaya Gill
Favorite
Gingrich, Alicia

University of Nevada
(P 233) IMMUNE CLASSES OF LEIOMYOSARCOMA DRIVEN BY B CELL INFILTRATE AND CTLA4 EXPRESSION
Alicia Gingrich
Favorite
Giordano, Giorgia

Candiolo Cancer Institute IRCCS FPO
(P 345) TRANSCRIPTOMIC AND PHENOTYPIC CHARACTERIZATION OF AN IMMUNOCOMPETENT LEIOMYOSARCOMA MOUSE MODEL.
Giorgia Giordano
Favorite
Giordano, Laura

Humanitas Research Hospital
(P 431) REAL-WORLD EXPERIENCE OF EFFICACY AND TOLERABILITY OF CONTINUOS INFUSION IFOSFAMIDE AMONG ADVANCED SOFT TISSUE AND BONE SARCOMAS PATIENTS: A SINGLE CENTRE RETROSPECTIVE COHORT.
Laura Giordano
Favorite
Giordano, Marco

Ospedale Pediatrico Bambino Gesù
(P 311) QUANTIFICATION OF TUMOUR-INFILTRATING IMMUNE CELLS THROUGH DECONVOLUTION OF DNA METHYLATION DATA IN EWING SARCOMAS
Marco Giordano
Favorite
Giovannoni, Isabella

Ospedale Pediatrico Bambino Gesù
(P 311) QUANTIFICATION OF TUMOUR-INFILTRATING IMMUNE CELLS THROUGH DECONVOLUTION OF DNA METHYLATION DATA IN EWING SARCOMAS
Isabella Giovannoni
Favorite
Girgis, Andrew

Massachusetts General Hospital
(P 100) ADVANCING PROGNOSTICS IN ONCOLOGY: MACHINE LEARNING MODELS FOR PREDICTING 2-YEAR AND 5-YEAR SURVIVAL RATES IN PATIENTS WITH UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Andrew Girgis
Favorite
Gitelis, Steven

Rush University Medical Center
(P 31) CLINICAL CHALLENGES AND EVOLVING TREATMENT STRATEGIES IN DESMOID FIBROMATOSIS: A SINGLE INSTITUTION EXPERIENCE
Steven Gitelis
Favorite
(P 80) OUTCOMES AND MANAGEMENT OF POSITIVE MARGINS IN CHONDROSARCOMA WITH SOFT TISSUE EXTENSION: A CASE SERIES AND REVIEW OF LITERATURE
Steven Gitelis
Favorite
(P 92) THE IMPACT OF CHONDROSARCOMA WITH POSITIVE MARGINS AND EXTRAOSSEOUS EXTENSION ON PATIENT OUTCOMES
Steven Gitelis
Favorite
(P 126) CHARACTERIZING THE TRANSFORMATION AND DIAGNOSIS OF ATYPICAL LIPOMATOUS TUMOR OF THE EXTREMITIES TO DEDIFFERENTIATED LIPOSARCOMA: SINGLE INSTITUTIONAL OUTCOMES
Steven Gitelis
Favorite
(P 270) OPIOID USE IN IMPENDING VERSUS PATHOLOGIC PROXIMAL FEMUR FRACTURES
Steven Gitelis
Favorite
Gladdy, Rebecca

Lunenefeld Tanenbaum, Mount Sinai Hospital, University Health Network, University Of Toronto
(P 159) USING THE TRANSCRIPTIONAL SPECTRUM OF UTERINE SMOOTH MUSCLE TUMORS TO IDENTIFY PROGNOSTIC SIGNATURES FOR ABNORMAL LEIOMYOMAS AND SMOOTH MUSCLE TUMOURS OF UNCERTAIN MALIGNANT POTENTIAL
Rebecca Gladdy
Favorite
(P 329) DEVELOPING ARMS METASTATIC MODELS TO RECAPITULATE THE TUMOR MICROENVIRONMENTS OF THE AXILLA/LYMPH NODE AND LUNGS
Rebecca Gladdy
Favorite
Gladdy, Rebecca

Department of Surgery, Mount Sinai Hospital; Department of Surgery, University of Toronto; Department of Surgical Oncology, Princess Margaret Cancer Centre, University of Toronto; CanSaRCC, Princess Margaret Cancer Centre, Toronto
(P 376) IMPACT OF SITE OF ORIGIN ON THE PROGNOSIS OF PATIENTS WITH PRIMARY RESECTABLE NON-UTERINE ABDOMINAL LEIOMYOSARCOMA
Rebecca Gladdy
Favorite
Gladdy, Rebecca

Lunenefeld Tanenbaum, Mount Sinai Hospital, University Health Network, University Of Toronto
(P 433) TUMOR HYPOXIA AND THE RISK OF METASTASIS IN HIGH-RISK LOCALIZED UPS/MFS
Rebecca Gladdy
Favorite
Glade Bender, Julia

Memorial Sloan Kettering Cancer Center
(P 50) ANALYSIS OF CLINICAL FEATURES AND OUTCOMES FOR PATIENTS WITH MULTIFOCAL OSTEOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Julia Glade Bender
Favorite
Glod, John

Center for Cancer Research/National Cancer Institute
(P 163) CHARACTERIZATION OF INTRAHEPATIC RECURRENCE FOLLOWING LIVER-DIRECTED SURGERY IN PATIENTS WITH METASTATIC SDH-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST): RISE AND STABILIZATION OF THE GISTLETS
John Glod
Favorite
Goh, Megan H.

Massachusetts General Hospital
(P 107) DOES THE USE OF ADJUVANT CHEMOTHERAPY IN LOCALIZED, RESECTABLE SOFT TISSUE SARCOMA LEAD TO BETTER SURVIVAL OUTCOMES? - A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Megan H. Goh
Favorite
Gokgoz, Nalan

The Lunenfeld-Tanenbaum Research Institute
(P 225) DETERMINING THE CONTRIBUTIONS OF STAT1 AND THE Y701 PHOSPHORYLATION TO THE UPS ANTI-TUMOR MICROENVIRONMENT
Nalan Gokgoz
Favorite
Gokgoz, Nalan

Lunenfeld Research Institute
(P 238) INTRA-TUMORAL DC-LAMP EXPRESSION IS ASSOCIATED WITH PROGNOSIS IN SOFT TISSUE SARCOMA
Nalan Gokgoz
Favorite
Golden, Lexi

University of Michigan
(P 131) HETEROGENEITY OF THE IMMUNE MICROENVIRONMENT AND IMMUNOTHERAPY RESPONSE IN A DEDIFFERENTIATED LIPOSARCOMA MOUSE MODEL
Lexi Golden
Favorite
(P 341) THE EFFECTS OF ULTRASOUND-GUIDED HISTOTRIPSY ON SOFT TISSUE SARCOMA
Lexi Golden
Favorite
Goldsby, Robert

UCSF Benioff Children's Hospital Oakland
(P 50) ANALYSIS OF CLINICAL FEATURES AND OUTCOMES FOR PATIENTS WITH MULTIFOCAL OSTEOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Robert Goldsby
Favorite
Golik, Paweł

Institute of Genetics and Biotechnology, Faculty of Biology, University of Warsaw, Warsaw, Poland & Institute of Biochemistry and Biophysics Polish Academy of Science, Warsaw, Poland
(P 77) MULTI-PARAMETRICAL PROFILING OF CHONDROSARCOMA
Paweł Golik
Favorite
González Woge, Miguel Angel

Centro Médico ABC
(P 213) REGIONAL KNOWLEDGE TRANSLATION IN RETROPERITONEAL SARCOMAS: IMPACT OF AN EDUCATIONAL WEBINAR SERIES BY THE MEXICAN SARCOMA GROUP
Miguel Angel González Woge
Favorite
Gonzalez-Billalabeitia, Enrique

HU Doce de Octubre
(P 234) IMMUNOSARC II MASTER TRIAL (PHASE II OF SUNITINIB AND NIVOLUMAB): RESULTS FROM THE CLEAR CELL SARCOMA (CCS) COHORT. A GEIS, ISG, AND UCL STUDY
Enrique Gonzalez-Billalabeitia
Favorite
González, Macarena

Vall d´Hebrón University Hospital, Vall d´Hebrón Institute of Oncology
(P 408) OSTEOMYC: A PHASE 2 PILOT STUDY TO EVALIATE THE SAFETY AND THE ANTITUMOR ACTIVITY OF THE MYC INHIBITOR OMO-103 ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH ADVANCED HIGH GRADE OSTEOSARCOMA
Macarena González
Favorite
Gonzalez, Marcos

Massachusetts General Hospital
(P 63) DOES TUMOR NECROSIS IMPACT PROGNOSIS IN CHONDROBLASTIC AND OSTEOBLASTIC OSTEOSARCOMA? A STUDY FROM A LARGE TERTIARY CARE ACADEMIC CENTER
Marcos Gonzalez
Favorite
(P 100) ADVANCING PROGNOSTICS IN ONCOLOGY: MACHINE LEARNING MODELS FOR PREDICTING 2-YEAR AND 5-YEAR SURVIVAL RATES IN PATIENTS WITH UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Marcos Gonzalez
Favorite
(P 107) DOES THE USE OF ADJUVANT CHEMOTHERAPY IN LOCALIZED, RESECTABLE SOFT TISSUE SARCOMA LEAD TO BETTER SURVIVAL OUTCOMES? - A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Marcos Gonzalez
Favorite
(P 108) FIXATION OF IMPENDING OR PATHOLOGIC FRACTURES DUE TO METASTATIC DISEASE WITH CARBON FIBER INTRAMEDULLARY NAILS-A PROPENSITY-SCORE MATCHED COST ANALYSIS
Marcos Gonzalez
Favorite
(P 284) WOUND VAC TEMPORIZATION AFTER TUMOR RESECTION OF SOFT TISSUE SARCOMAS - A COST ANALYSIS IN A PROPENSITY-SCORE MATCHED POPULATION
Marcos Gonzalez
Favorite
Gonzalez, Ricardo

Moffitt Cancer Center
(P 237) INTRALESIONAL ADMINISTRATION OF TALIMOGENE LAHERPAREPVEC (T-VEC) INDUCES TUMOR REGRESSION IN PATIENTS WITH CUTANEOUS ANGIOSARCOMA
Ricardo Gonzalez
Favorite
Goodman, Mark

UPMC
(P 256) CHARACTERIZING ORTHOPAEDIC ONCOLOGIC POLYTRAUMAS: A COMPARISON OF PATIENTS UNDERGOING OPERATIVE FIXATION OF MULTIPLE LESIONS WITH THOSE WITH SOLITARY LESIONS
Mark Goodman
Favorite
(P 258) COMPARING OUTCOMES FOLLOWING INTRALESIONAL VERSUS WIDE RESECTION PROCEDURES IN THE TREATMENT OF RENAL CELL CARCINOMA BONE METASTASES
Mark Goodman
Favorite
Goodspeed, Andrew

University of Colorado Cancer Center
(P 88) SPATIAL TRANSCRIPTOMICS OF EWING SARCOMA: EVOLUTION OF TUMOR MICROENVIRONMENT ASSOCIATED EXTRACELLULAR MATRIX FROM LOCALIZED TO METASTASIS-ASSOCIATED PRIMARY TUMORS
Andrew Goodspeed
Favorite
Gordon, David

University of Iowa
(P 14) HDAC INHIBITORS DOWNREGULATE THE EXPRESSION LEVELS OF THE MINI-CHROMOSOME MAINTENANCE PROTEINS, AND INHIBIT DNA REPLICATION, IN EWING SARCOMA CELLS
David Gordon
Favorite
Gordon, Erlinda

Sarcoma Oncology Research Center
(P 106) DELTAREX-G, A TUMOR TARGETED CCNG1 INHIBITOR, DEMONSTRATES CLINICAL BENEFIT IN ADVANCED CHEMORESISTANT SARCOMA FOLLOWING FDA CBER AUTHORIZATION FOR USE AS PLATFORM THERAPY WITH FDA APPROVED DRUGS
Erlinda Gordon
Favorite
(P 241) LINNOVATE: A PHASE 1/2 STUDY OF SAFETY/EFFICACY USING LURBINECTEDIN COMBINED WITH IPILUMUMAB AND NIVOLUMAB FOR ADVANCED SOFT TISSUE SARCOMA (NCT05876715)
Erlinda Gordon
Favorite
(P 248) TNT: A PHASE 2 STUDY USING TALIMOGENE LAHERPAREPVEC, NIVOLUMAB, AND TRABECTEDIN FOR ADVANCED LEIOMYOSARCOMA AND LIPOSARCOMA (NCT # 03886311)
Erlinda Gordon
Favorite
(P 250) UPDATE ON GALLANT: A PHASE 2 STUDY USING METRONOMIC GEMCITABINE, DOXORUBICIN AND DOCETAXEL PLUS NIVOLUMAB IN PREVIOUSLY TREATED SARCOMA (NCT04535713)
Erlinda Gordon
Favorite
(P 251) UPDATE ON SAINT: A PHASE 2 STUDY USING TRABECTEDIN (T) IN COMBINATION WITH IPILIMUMAB (L) AND NIVOLUMAB (N) IN PREVIOUSLY TREATED SOFT TISSUE SARCOMA (NCT03138161)
Erlinda Gordon
Favorite
Gordon, Michael

HonorHealth Research Institute
(P 37) HEALTH-RELATED QUALITY OF LIFE FROM A PHASE 4 STUDY TO EVALUATE DISCONTINUATION AND RECHALLENGE OF PEXIDARTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR PREVIOUSLY TREATED WITH PEXIDARTINIB
Michael Gordon
Favorite
Gorgels, Daniël

Laboratory of Experimental Oncology, KU Leuven
(P 334) EXPANDING THE LANDSCAPE OF PRECLINICAL MODELS OF SYNOVIAL SARCOMA: FROM 2-DIMENSIONS TO 3-DIMENSIONS TO MICE
Daniël Gorgels
Favorite
(P 340) THE DNA MINOR GROOVE BINDING AGENTS ECUBECTEDIN AND PM54 DEMONSTRATE ANTITUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT MODELS OF SOFT TISSUE SARCOMA
Daniël Gorgels
Favorite
Gorgone, Pierangelo

Fondazione Policlinico Campus Bio-Medico of Rome
(P 178) PREDICTION OF PRIMARY IMATINIB-REFRACTORY PATIENTS WITH LOCALLY ADVANCED OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) USING RADIOMICS AND ARTIFICIAL INTELLIGENCE (AI)
Pierangelo Gorgone
Favorite
Gorlick, Richard

The University of Texas MD Anderson Cancer Center
(P 49) A WORKING GROUP FOR THE DEVELOPMENT OF A CLINICAL FRAMEWORK THAT STRATIFIES OSTEOSARCOMA PATIENTS USING BIOMARKERS OF CLINICAL RISK AND BIOLOGY
Richard Gorlick
Favorite
Goryunova, Marina

The Ohio State University
(P 136) TARGETING MIR-138-5P TO TREAT DEDIFFERENTIATED LIPOSARCOMA
Marina Goryunova
Favorite
Gorzeń, Aleksander

Maria Sklodowska-Curie National Research Institute of Oncology
(P 46) A NEED FOR STANDARDIZATION IN TRIAL DESIGN AND DATA REPORTING IN PHASE II TRIALS IN RARE TUMORS. LESSONS LEARNED FROM PHASE II TRIALS IN BONE SARCOMAS
Aleksander Gorzeń
Favorite
Gounder, Mrinal

Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College
(P 121) ACQUIRED CYCLIN D AMPLIFICATION IS A MECHANISM FOR RESISTANCE TO CDK4/6 INHIBITORS IN DEDIFFERENTIATED LIPOSARCOMA
Mrinal Gounder
Favorite
(P 229) EXPRESSION OF TRANSPOSABLE ELEMENTS AND IKZF1 PREDICTS IMMUNE INFILTRATES IN SARCOMAS AND CORRELATES WITH OUTCOMES AFTER IMMUNE CHECKPOINT INHIBITION
Mrinal Gounder
Favorite
Gouveia, Emanuel

Instituto Português de Oncologia de Lisboa
(P 128) DYNAMIC HETEROGENEITY AMONGST LIPOSARCOMAS
Emanuel Gouveia
Favorite
Gozo, Maricel

Deciphera Pharmaceuticals, LLC
(P 403) DCC-3116 IN COMBINATION WITH RIPRETINIB FOR PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A PHASE 1/2 STUDY
Maricel Gozo
Favorite
Grabowski, Katherine

The Univeristy of Kansas Medical Center General Surgery Residency
(P 36) EARLY REAL-WORLD EXPERIENCE WITH THE USE OF NIROGACESTAT FOR THE TREATMENT OF DESMOID FIBROMATOSIS
Katherine Grabowski
Favorite
Graham, Jess

Yale University
(P 98) A MULTIEPITOPE MRNA VACCINE FOR KAPOSI SARCOMA: AN IMMUNOINFORMATIC APPROACH
Jess Graham
Favorite
Grandhi, Nikhil

Washington University School of Medicine
(P 81) OUTCOMES DATA FOR OSTEOSARCOMA PATIENTS OVER AGE 60
Nikhil Grandhi
Favorite
Graves, Laurie

Department of Pediatrics, Division of Pediatric Hematology/Oncology, Duke University
(P 54) CHONDROBLASTIC OSTEOSARCOMA IS A RISK FACTOR FOR LOCAL RECURRENCE IN PATIENTS WITH SKELETAL OSTEOSARCOMA
Laurie Graves
Favorite
Grbic, Dimitrije

ZRx Outcomes Research Inc.
(P 55) CHONDROSARCOMA PATIENT CHARACTERISTICS AND DIAGNOSTIC AND TREATMENT PATHWAYS: GLOBAL CHONDROSARCOMA PATIENT REGISTRY
Dimitrije Grbic
Favorite
Greco, Francesca

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 429) PATIENTS WITH ADVANCED EPITHELIOID HEMANGIOENDOTHELIOMA TREATED WITH SIROLIMUS: OUTCOME FOLLOWING SIROLIMUS DISCONTINUATION.
Francesca Greco
Favorite
Greco, Gabriella

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 368) AGGRESSIVE PERINEAL ANGIOMYXOMA UNDERGOING SYSTEMIC TREATMENT: AN UPDATED REPORT OF 8-YEARS' EXPERIENCE IN A REFERRAL CENTER
Gabriella Greco
Favorite
Griffin, Anthony

Mount Sinai Hospital- Orthopaedics
(P 71) LIMB-SALVAGE SURGERY AFTER UNPLANNED SURGERY FOR EXTREMITY BONE SARCOMAS: 30-YEAR EXPERIENCE AT A TERTIARY REFERRAL CENTER
Anthony Griffin
Favorite
(P 238) INTRA-TUMORAL DC-LAMP EXPRESSION IS ASSOCIATED WITH PROGNOSIS IN SOFT TISSUE SARCOMA
Anthony Griffin
Favorite
(P 281) THE UTILITY OF INTRAOPERATIVE MARROW MARGIN FROZEN SECTION IN EXTREMITY BONE SARCOMA RESECTION
Anthony Griffin
Favorite
Griffin, Jacob

University of Miami, Sylvester Comprehensive Cancer Center
(P 358) RADIOMIC EVALUATION OF MRIS IN PATIENTS WITH SOFT TISSUE SARCOMA TREATED WITH STEREOTACTIC BOSY RADIATION THERAPY
Jacob Griffin
Favorite
Grignani, Giovanni

Città della Salute e della Scienza di Torino
(P 234) IMMUNOSARC II MASTER TRIAL (PHASE II OF SUNITINIB AND NIVOLUMAB): RESULTS FROM THE CLEAR CELL SARCOMA (CCS) COHORT. A GEIS, ISG, AND UCL STUDY
Giovanni Grignani
Favorite
(P 345) TRANSCRIPTOMIC AND PHENOTYPIC CHARACTERIZATION OF AN IMMUNOCOMPETENT LEIOMYOSARCOMA MOUSE MODEL.
Giovanni Grignani
Favorite
(P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Giovanni Grignani
Favorite
Grignol, Valerie

The Ohio State University James Cancer Hospital
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Valerie Grignol
Favorite
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Valerie Grignol
Favorite
Grilley-Olson, Juneko

Duke University
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Juneko Grilley-Olson
Favorite
Grimaudo, Maria Susanna

Medical Oncology and Hematology Unit, Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, 20089, Italy
(P 124) ASSESSMENT OF THE MECHANISMS OF ACTION OF ERIBULIN IN PATIENTS WITH ADVANCED LIPOSARCOMA THROUGH THE EVALUATION OF THE RADIOLOGICAL, FUNCTIONAL AND TISSUE RESPONSE: A MONOCENTRIC PROSPECTIVE STUDY
Maria Susanna Grimaudo
Favorite
Grimaudo, Maria Susanna

Humanitas Research Hospital
(P 155) PRIMARY MESENCHYMAL TUMORS OF THE HEART: A 8-YEARS, SINGLE INSTITUTION EXPERIENCE
Maria Susanna Grimaudo
Favorite
(P 290) ARTIFICIAL INTELLIGENCE-BASED COMPARISON OF ADULT AND ADOLESCENT AND YOUNG ADULTS (AYA) SARCOMAS: A PILOT STUDY
Maria Susanna Grimaudo
Favorite
(P 431) REAL-WORLD EXPERIENCE OF EFFICACY AND TOLERABILITY OF CONTINUOS INFUSION IFOSFAMIDE AMONG ADVANCED SOFT TISSUE AND BONE SARCOMAS PATIENTS: A SINGLE CENTRE RETROSPECTIVE COHORT.
Maria Susanna Grimaudo
Favorite
Grimison, Peter

Chris O'Brien Lifehouse
(P 37) HEALTH-RELATED QUALITY OF LIFE FROM A PHASE 4 STUDY TO EVALUATE DISCONTINUATION AND RECHALLENGE OF PEXIDARTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR PREVIOUSLY TREATED WITH PEXIDARTINIB
Peter Grimison
Favorite
(P 325) CAN PROTEOMICS PREDICT METASTATIC RELAPSE IN LEIOMYOSARCOMA? DEVELOPMENT OF AN 8 PROTEIN SIGNATURE IN A >350 SAMPLE STUDY INCLUDING A VALIDATION COHORT
Peter Grimison
Favorite
Grobler, Maryke

University of California Santa Cruz, Molecular Cell and Developmental Biology, Genomics Institute
(P 147) INVESTIGATING THE POTENTIAL OF EXTRACELLULAR VESICLE BIOMARKERS IN SYNOVIAL SARCOMA DETECTION
Maryke Grobler
Favorite
(P 156) PROFILING SYNOVIAL SARCOMA EXTRACELLULAR VESICLES FOR DIAGNOSTIC RNA BIOMARKERS
Maryke Grobler
Favorite
Groisberg, Roman

Rutgers Cancer Institute of New Jersey
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Roman Groisberg
Favorite
Gronchi, Alessandro

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Alessandro Gronchi
Favorite
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Alessandro Gronchi
Favorite
(P 137) TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS
Alessandro Gronchi
Favorite
(P 160) UTERINE PECOMA: REPORT OF MOLECULAR AND CLINICAL FEATURES IN A SERIES OF PATIENTS TREATED AT A REFERRAL INSTITUTION
Alessandro Gronchi
Favorite
(P 171) GASTROINTESTINAL STROMAL TUMOURS (GISTS) IN NEUROFIBROMATOSIS TYPE (NF1): A SINGLE-CENTER OBSERVATIONAL RETROSPECTIVE STUDY
Alessandro Gronchi
Favorite
(P 368) AGGRESSIVE PERINEAL ANGIOMYXOMA UNDERGOING SYSTEMIC TREATMENT: AN UPDATED REPORT OF 8-YEARS' EXPERIENCE IN A REFERRAL CENTER
Alessandro Gronchi
Favorite
(P 376) IMPACT OF SITE OF ORIGIN ON THE PROGNOSIS OF PATIENTS WITH PRIMARY RESECTABLE NON-UTERINE ABDOMINAL LEIOMYOSARCOMA
Alessandro Gronchi
Favorite
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Alessandro Gronchi
Favorite
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Alessandro Gronchi
Favorite
(P 420) CELLULARITY DEGREES IN PRIMARY MYXOID LIPOSARCOMA: ASSOCIATION WITH TUMOR IMMUNE INFILTRATE AND PATIENT OUTCOMES
Alessandro Gronchi
Favorite
(P 429) PATIENTS WITH ADVANCED EPITHELIOID HEMANGIOENDOTHELIOMA TREATED WITH SIROLIMUS: OUTCOME FOLLOWING SIROLIMUS DISCONTINUATION.
Alessandro Gronchi
Favorite
GROSIBERG, ROMAN

Rutgers Cancer Institute of New Jersey
(P 87) SAFETY AND EFFICACY OF OLUTASIDENIB, AN IDH1 MUTANT INHIBITOR, FOR THE TREATMENT OF RECURRENT/ RELAPSED LOCALLY ADVANCED OR METASTATIC IDH1 MUTATED CHONDROSARCOMA
ROMAN GROSIBERG
Favorite
Gross, John

Johns hopkins
(P 152) NOVEL PAX3::MAML3 FUSION IDENTIFIED IN ALVEOLAR RHABDOMYOSARCOMA: USING DNA METHYLATION TO EXPANDE THE GENETIC SPECTRUM OF "FUSION POSITIVE" CASES
John Gross
Favorite
Grossman, Julie

University of Miami
(P 246) THE GENOMIC AND IMMUNE LANDSCAPE OF LIPOSARCOMA AND ITS SUBTYPES
Julie Grossman
Favorite
Groundland, John

Huntsman Cancer Institute
(P 91) THE EFFECT OF CHEMOTHERAPY AND SURGERY TIMING ON MORTALITY IN THE TREATMENT OF UPPER AND LOWER EXTREMITY OSTEOSARCOMA: A DATABASE STUDY
John Groundland
Favorite
Grunn, Adina

Columbia University Irving Medical Center
(P 418) A SYSTEMS BIOLOGY APPROACH FOR CHARACTERIZING TUMOR HETEROGENEITY AND CELL STATE-SPECIFIC THERAPEUTIC VULNERABILITIES FROM SINGLE NUCLEUS RNA-SEQ PROFILING OF DESMOPLASTIC SMALL ROUND CELL TUMORS
Adina Grunn
Favorite
Guadagnolo, B. Ashleigh

The University of Texas MD Anderson Cancer Center
(P 360) TREATMENT OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR WITH BROMODOMAIN EXTRA TERMINAL INHIBITOR (BETI) IN COMBINATION WITH RADIOTHERAPY
B. Ashleigh Guadagnolo
Favorite
Guardado, Ashley

MD Anderson Cancer Center
(P 130) HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RESECTABLE RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA (DDLPS) TREATED WITH NEOADJUVANT CHECKPOINT BLOCKADE IN A RANDOMIZED PHASE II CLINICAL TRIAL.
Ashley Guardado
Favorite
Guardino, Nicholas

Duke University
(P 15) HISTONE DEACETYLASE-3 PLAYS A ROLE IN THE METASTATIC POTENTIAL OF A SUBPOPULATION OF CELLS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Nicholas Guardino
Favorite
Guerrieri, Ania Naila

Istituto Ortopedico Rizzoli IRCCS, Osteoncology- Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, Bologna, Italy
(P 336) IMPROVEMENT OF PHOTODYNAMIC THERAPY IN SARCOMA: IN VITRO VALIDATION ON OSTEOSARCOMA AND MYXOFIBROSARCOMA
Ania Naila Guerrieri
Favorite
gui, jianping

The First Hospital of Jilin University
(P 119) UPDATED RESULTS OF A SINGLE-ARM,MULTI-CENTER STUDY OF ANLOTINIB COMBINED WITH TORIPALIMAB IN FIRST-LINE TREATMENT OF UNRESECTABLE OR METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA
jianping gui
Favorite
Guillan, Kristina

Memorial Sloan Kettering Cancer Center
(P 338) PRECLINICAL EFFICACY OF DAN-222, A NOVEL POLYMERIC NANOPARTICLE, IN PEDIATRIC SOLID TUMOR MODELS
Kristina Guillan
Favorite
Guillén, María José

Research Department, PharmaMar S.A.
(P 340) THE DNA MINOR GROOVE BINDING AGENTS ECUBECTEDIN AND PM54 DEMONSTRATE ANTITUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT MODELS OF SOFT TISSUE SARCOMA
María José Guillén
Favorite
Gularte Mérida, Rodrigo

Memorial Sloan Kettering Cancer Center
(P 129) ELUCIDATING THE EVOLUTIONARY DYNAMICS OF DDLS LIPOSARCOMA USING SINGLE-CELL SEQUENCING AND MATHEMATICAL LINEAGE TRACING
Rodrigo Gularte Mérida
Favorite
Gulia, Aashish

Tata Memorial Centre
(P 32) CURRENT INDICATIONS OF OPEN SURGERY IN PRIMARY APPENDICULAR/ PELVIC ANEURYSMAL BONE CYSTS
Aashish Gulia
Favorite
(P 306) LONG TERM OUTCOMES OF TYPE BIIIA ROTATIONPLASTY AFTER TOTAL FEMUR EXCISION IN CHILDREN
Aashish Gulia
Favorite
Gundle, Kenneth

Oregon Health & Science University
(P 34) DESMOID TUMOR COHORT CREATION AND CHARACTERISTICS IN THE VETERANS AFFAIRS (VA) NATIONAL DATABASE
Kenneth Gundle
Favorite
(P 223) ASSOCIATION OF POSTOPERATIVE INFECTION (POI) WITH SOFT TISSUE SARCOMA (STS) RESECTION OUTCOMES
Kenneth Gundle
Favorite
(P 285) A NOVEL METHOD TO PREDICT HEIGHT AT SKELETAL MATURITY IN PEDIATRIC SARCOMA PATIENTS
Kenneth Gundle
Favorite
Gunnesson, Lisa

University of Gothenburg/Institute of Clinical Sciences
(P 20) LEIOMYOSARCOMA OF THE THORACIC AORTA - A RARE CASE REPORT
Lisa Gunnesson
Favorite
(P 382) PARAGANGLIOMA AND CONGENITAL HEART DISEASE - A RARE CASE REPORT
Lisa Gunnesson
Favorite
Guo, Hong-fen

Memorial Sloan Kettering Cancer Center
(P 302) HER2 PRETARGETED ALPHA PARTICLE RADIOIMMUNOTHERAPY FOR DESMOPLASTIC SMALL ROUND CELL TUMORS
Hong-fen Guo
Favorite
Guo, Jinhong

Ontada
(P 133) REAL-WORLD ANALYSIS OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS) IN A US COMMUNITY ONCOLOGY SETTING
Jinhong Guo
Favorite
Guo, Qiuxiang

Abbisko Therapeutics Co., Ltd
(P 407) LONG-TERM EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): PHASE 1B UPDATE.
Qiuxiang Guo
Favorite
Guo, Xi

Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
(P 416) TRIPLR COMNINATION THERAPY IN THE FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA WITH HIGH TUMOR BURDEN: INTERIM ANALYSIS FROM ALTER-S007 STUDY
Xi Guo
Favorite
guo, Zhen

The First Hospital of Jilin University
(P 119) UPDATED RESULTS OF A SINGLE-ARM,MULTI-CENTER STUDY OF ANLOTINIB COMBINED WITH TORIPALIMAB IN FIRST-LINE TREATMENT OF UNRESECTABLE OR METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Zhen guo
Favorite
Gupta, Abha

Princess Margaret Cancer Centre, Hospital for Sick Children, AYA, CanSaRCC
(P 153) PATTERNS, MANAGEMENT AND SURVIVAL OUTCOMES OF PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA: A NATIONWIDE ANALYSIS FROM THE CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION DATABASE
Abha Gupta
Favorite
(P 293) CIC-REARRANGED SOFT TISSUE SARCOMAS: DOES CHEMOTHERAPY CHANGE NATURAL HISTORY AND PROGNOSIS? A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Abha Gupta
Favorite
Gupta, Abha

Hospital for Sick Children
(P 304) LOCAL CONTROL FOR PEDIATRIC RHABDOMYOSARCOMA OF THE EXTREMITIES. IS RADIOTHERAPY ALWAYS REQUIRED AFTER ADEQUATE SURGICAL RESECTION?
Abha Gupta
Favorite
(P 315) SALVAGE THERAPY EFFICACY IS MODIFIED BY RISK GROUP AT DIAGNOSIS IN PATIENTS WITH RELAPSED RHABDOMYOSARCOMA
Abha Gupta
Favorite
Gupta, Abha

Princess Margaret Cancer Centre, Hospital for Sick Children, AYA, CanSaRCC
(P 320) WHAT IS THE ROLE OF CHEMOTHERAPY IN PATIENTS (PTS) WITH SPINDLE CELL/SCLEROSING RHABDOMYOSARCOMA (SCRMS): A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Abha Gupta
Favorite
Gupta, Abha

Hospital for Sick Children
(P 321) WHOLE ABDOMINAL RADIOTHERAPY IN CHILDREN AND YOUNG ADULTS WITH SARCOMA: A CANADIAN SARCOMA AND CLINICAL COLLABORATION (CANSARCC) STUDY
Abha Gupta
Favorite
(P 329) DEVELOPING ARMS METASTATIC MODELS TO RECAPITULATE THE TUMOR MICROENVIRONMENTS OF THE AXILLA/LYMPH NODE AND LUNGS
Abha Gupta
Favorite
Gupta, Ajay

Roswell Park Comprehensive Cancer Center
(P 35) EARLY REAL WORLD EXPERIENCE WITH NIROGACESTAT IN PATIENTS WITH DESMOID FIBROMATOSIS
Ajay Gupta
Favorite
Gupta, Karan

Chris O'Brien Lifehouse
(P 157) REAL WORLD CLINICAL UTILITY OF NEXT GENERATION SEQUENCING IN ADOLESCENT AND YOUNG ADULT SARCOMA PATIENTS
Karan Gupta
Favorite
Gupta, Nishith

Narayana Hospital
(P 32) CURRENT INDICATIONS OF OPEN SURGERY IN PRIMARY APPENDICULAR/ PELVIC ANEURYSMAL BONE CYSTS
Nishith Gupta
Favorite
Gupta, Vandana

V Care Foundation
(P 201) GLOBAL CROSS-SECTIONAL SURVEY ON SARCOMA DIAGNOSIS PATHWAY: A CURRENT STATE ANALYSIS
Vandana Gupta
Favorite
Gupta, Varsha

Roswell Park Comprehensive Cancer Center
(P 35) EARLY REAL WORLD EXPERIENCE WITH NIROGACESTAT IN PATIENTS WITH DESMOID FIBROMATOSIS
Varsha Gupta
Favorite
Gurrieri, Lorena

Clinical and Experimental Oncology, Immunotherapy, Rare Cancers and Biological Resource Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy
(P 144) EXPLORATORY ANALYSIS OF 68GA-FAPI-46 PET-CT IN SOFT TISSUE SARCOMA
Lorena Gurrieri
Favorite
(P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Lorena Gurrieri
Favorite
Guryeva, Valeria

Sarcoma Oncology Center
(P 106) DELTAREX-G, A TUMOR TARGETED CCNG1 INHIBITOR, DEMONSTRATES CLINICAL BENEFIT IN ADVANCED CHEMORESISTANT SARCOMA FOLLOWING FDA CBER AUTHORIZATION FOR USE AS PLATFORM THERAPY WITH FDA APPROVED DRUGS
Valeria Guryeva
Favorite
(P 250) UPDATE ON GALLANT: A PHASE 2 STUDY USING METRONOMIC GEMCITABINE, DOXORUBICIN AND DOCETAXEL PLUS NIVOLUMAB IN PREVIOUSLY TREATED SARCOMA (NCT04535713)
Valeria Guryeva
Favorite
Gustafson, Alexandra

Surgery Branch, NCI, NIH
(P 231) IDENTIFICATION OF NEOANTIGEN FROM PECOMA-LIKE NEOPLASM PROVIDES RATIONALE FOR TREATMENT WITH CELLULAR THERAPY
Alexandra Gustafson
Favorite
Gutiérrez, Natalia

Hospital General Universitario Gregorio Marañón
(P 432) THE ROLE OF SYSTEMIC TREATMENT IN ADVANCED SOLITARY FIBROUS TUMORS: EXPERIENCE AT A REFERRAL CENTER.
Natalia Gutiérrez
Favorite
Gutiérrez, Ana

Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
(P 432) THE ROLE OF SYSTEMIC TREATMENT IN ADVANCED SOLITARY FIBROUS TUMORS: EXPERIENCE AT A REFERRAL CENTER.
Ana Gutiérrez
Favorite
Gutierrez, Antonio

HU Son Espases
(P 234) IMMUNOSARC II MASTER TRIAL (PHASE II OF SUNITINIB AND NIVOLUMAB): RESULTS FROM THE CLEAR CELL SARCOMA (CCS) COHORT. A GEIS, ISG, AND UCL STUDY
Antonio Gutierrez
Favorite
Gutierrez, Wade

University of Iowa
(P 12) GENETIC LANDSCAPE OF MPNST DETERMINES METABOLIC STRATEGIES AND THERAPEUTIC OPPORTUNITIES FOR COPING WITH REDOX STRESS
Wade Gutierrez
Favorite
Gutstein, Lauren

Children's Hospital of Philadelphia
(P 318) SYNOVIAL SARCOMA REGISTRY AND BIOSPECIMEN REPOSITORY: DESCRIBING THE COHORT AND SURVIVAL OUTCOMES TO DATE
Lauren Gutstein
Favorite
Gyorki, David

Peter MacCallum Cancer Centre
(P 151) MOLECULAR ANALYSIS OF CUTANEOUS SARCOMATOID NEOPLASMS FREQUENTLY IDENTIFIES MELANOMA DRIVER VARIANTS
David Gyorki
Favorite
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
David Gyorki
Favorite
H
H.A. Bemelmans, Marc

Department of Surgery, Maastricht University Medical Center+, Maastricht
(P 361) WOUND COMPLICATIONS AFTER SOFT TISSUE SARCOMA RESECTION: A SINGLE-CENTER RETROSPECTIVE ANALYSIS
Marc H.A. Bemelmans
Favorite
Hårklau, Lisbeth

Oslo University Hospital
(P 40) PEGYLATED LIPOSOMAL DOXORUBICIN IN SYMPTOMATIC DESMOID TUMOR
Lisbeth Hårklau
Favorite
Haarberg, Sasha

Washington University School of Medicine
(P 81) OUTCOMES DATA FOR OSTEOSARCOMA PATIENTS OVER AGE 60
Sasha Haarberg
Favorite
Haas, R.L.M.

Netherlands Cancer Institute
(P 24) NEOADJUVANT CHEMOTHERAPY FOR RADIOTHERAPY ASSOCIATED ANGIOSARCOMA (RAAS) OF THE BREAST IMPROVES ONCOLOGICAL OUTCOMES
R.L.M. Haas
Favorite
(P 194) EFFECTIVENESS OF A RISK PREDICTION TOOL (PERSARC) ON THE QUALITY OF TREATMENT DECISIONS IN SOFT-TISSUE SARCOMA PATIENTS (VALUE-PERSARC TRIAL)
R.L.M. Haas
Favorite
(P 317) SMARCB1-DEFICIENT SARCOMA OF THE GENITAL REGION/EPITHELIOID SARCOMA OF THE PROXIMAL TYPE VS EPITHELIOID SARCOMA OF THE DISTAL TYPE
R.L.M. Haas
Favorite
(P 349) LONG-TERM SURVIVAL OF PARTICIPANTS IN THE PASART-1 AND PASART-2 TRIALS OF NEO-ADJUVANT PAZOPANIB AND RADIOTHERAPY IN SOFT TISSUE SARCOMA
R.L.M. Haas
Favorite
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
R.L.M. Haas
Favorite
Haddox, Candace

Dana Farber Cancer Institute
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Candace Haddox
Favorite
(P 412) SARC044: A PHASE II TRIAL OF BEZUCLASTINIB IN COMBINATION WITH SUNITINIB IN PATIENTS WITH GIST WHO PROGRESSED ON SUNITINIB MONOTHERAPY
Candace Haddox
Favorite
Hadley, Abigail

University of Michigan
(P 423) COMPARISON OF CLINICAL COURSE AND FEATURES BETWEEN SCLEROSING EPITHELOID FIBROSARCOMA AND LOW-GRADE FIBROMYXOID SARCOMA
Abigail Hadley
Favorite
HAGIWARA, Yoko

Chiba Cancer center
(P 275) RECONSTRUCTION WITH A BURCH-SCHNEIDER CAGE AFTER BONE AND SOFT TISSUUE TUMOR SURGERY
Yoko HAGIWARA
Favorite
Haglund de Flon, Felix

Karolinska University Hospital
(P 03) CDK4 IS CO-AMPLIFIED WITH EITHER TP53 PROMOTER GENE FUSIONS OR MDM2 THROUGH DISTINCT MECHANISMS IN OSTEOSARCOMA
Felix Haglund de Flon
Favorite
(P 26) SARCDBASE: A TOOL FOR DETECTION OF GENETIC ALTERATIONS IN SARCOMA
Felix Haglund de Flon
Favorite
Haibe-Kains, Benjamin

Princess Margaret Cancer Centre, University Health Network
(P 399) SIMILARITY NETWORK FUSION IDENTIFIES DNA METHYLATION SUBTYPES OF LEIOMYOSARCOMA ASSOCIATED WITH CLINICAL OUTCOME
Benjamin Haibe-Kains
Favorite
(P 427) MULTI-OMIC AND MULTI-REGION PROFILING OF DESMOID TUMORS REVEALS INTRA- AND INTER-TUMOR HETEROGENEITY
Benjamin Haibe-Kains
Favorite
Hains, Peter

ProCan®, Children’s Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, NSW, Australia
(P 325) CAN PROTEOMICS PREDICT METASTATIC RELAPSE IN LEIOMYOSARCOMA? DEVELOPMENT OF AN 8 PROTEIN SIGNATURE IN A >350 SAMPLE STUDY INCLUDING A VALIDATION COHORT
Peter Hains
Favorite
Hajdu, Katherine

Vanderbilt University Medical Center
(P 265) IS THERE AN IDEAL STEM TO CANAL RATIO IN LOWER EXTREMITY ONCOLOGIC ENDOPROSTHESIS RECONSTRUCTION?
Katherine Hajdu
Favorite
(P 404) ENHANCED RECOVERY AFTER SURGERY (ERAS) PROTOCOL FOR PATENTS WITH SOFT TISSUE SARCOMA OF THE EXTREMITY: A PROSPECTIVE, NON-RANDOMIZED, CONSECUTIVELY ENROLLED TRIAL
Katherine Hajdu
Favorite
Hall, Frederick

Aveni Foundation
(P 106) DELTAREX-G, A TUMOR TARGETED CCNG1 INHIBITOR, DEMONSTRATES CLINICAL BENEFIT IN ADVANCED CHEMORESISTANT SARCOMA FOLLOWING FDA CBER AUTHORIZATION FOR USE AS PLATFORM THERAPY WITH FDA APPROVED DRUGS
Frederick Hall
Favorite
Hall, Timothy

University of Michigan
(P 341) THE EFFECTS OF ULTRASOUND-GUIDED HISTOTRIPSY ON SOFT TISSUE SARCOMA
Timothy Hall
Favorite
Halpern, Jennifer

Vanderbilt University Medical Center
(P 73) LONGER TIME INTERVAL BETWEEN NEOADJUVANT CHEMOTHERAPY AND SURGERY IS ASSOCIATED WITH DECREASED TUMOR PERCENT NECROSIS IN OSTEOSARCOMA
Jennifer Halpern
Favorite
(P 199) FINANCIAL TOXICITY AMONG SARCOMA PATIENTS AND ASSOCIATED FACTORS
Jennifer Halpern
Favorite
(P 264) INTRAOPERATIVE FROZEN BONE MARROW MARGINS: A HELP OR A HINDRANCE IN EWING SARCOMA RESECTION?
Jennifer Halpern
Favorite
(P 265) IS THERE AN IDEAL STEM TO CANAL RATIO IN LOWER EXTREMITY ONCOLOGIC ENDOPROSTHESIS RECONSTRUCTION?
Jennifer Halpern
Favorite
(P 268) LOWER TUMOR PERCENT NECROSIS IS ASSOCIATED WITH POSITIVE FINAL SURGICAL MARGINS IN OSTEOSARCOMA
Jennifer Halpern
Favorite
(P 297) ESTABLISHING A PEDIATRIC, ADOLESCENT AND YOUNG ADULT COHORT OF SARCOMA PATIENTS TO STUDY ONCOLOGIC AND NON-ONCOLOGIC OUTCOMES
Jennifer Halpern
Favorite
(P 404) ENHANCED RECOVERY AFTER SURGERY (ERAS) PROTOCOL FOR PATENTS WITH SOFT TISSUE SARCOMA OF THE EXTREMITY: A PROSPECTIVE, NON-RANDOMIZED, CONSECUTIVELY ENROLLED TRIAL
Jennifer Halpern
Favorite
Hameed, Meera

Memorial Sloan Kettering Cancer Center
(P 380) MULTIDISCIPLINARY MANAGEMENT OF INTRA-ABDOMINAL DESMOID-TYPE FIBROMATOSIS: A 30-YEARS EXPERIENCE
Meera Hameed
Favorite
Hanada, Masuo

Kyushu Rosai Hospital
(P 203) IMPACT OF COVID-19 PANDEMIC ON BONE AND SOFT TISSUE SARCOMA PATIENTS' CONSULTATION AND DIAGNOSIS
Masuo Hanada
Favorite
Hanen, Simon

Portland Va Health Care System and OHSU Knight Cancer Institute
(P 173) IN VITRO PROFILING OF IDRX-42 AGAINST SECONDARY MUTATIONS FOUND IN TKI-RESISTANT GIST
Simon Hanen
Favorite
Hanff, David

Erasmus Medical Center
(P 154) PREOPERATIVE CLASSIFICATION OF NERVE SHEATH TUMORS USING RADIOMICS-BASED MACHINE LEARNING
David Hanff
Favorite
Hanif, Muhammad Rashid

SQCCCRC
(P 193) DISTRIBUTION OF CONNECTIVE TISSUE TUMORS BY HISTOLOGY AND DEGREE OF MALIGNANCY IN A SINGLE INSTITUTION IN OMAN
Muhammad Rashid Hanif
Favorite
Hanif, Rashid

SQCCCRC
(P 68) FEASIBILITY OF FIVE-DRUG INTERVAL-COMPRESSED CHEMOTHERAPY FOR ADOLESCENTS AND YOUNG ADULTS WITH EWING SARCOMA FAMILY TUMORS IN THE REAL-WORLD SETTING IN OMAN
Rashid Hanif
Favorite
Han, Ilkyu

Seoul National University Hospital
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Ilkyu Han
Favorite
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Ilkyu Han
Favorite
(P 127) DEDIFFERENTIATED LIPOSARCOMA OF THE EXTREMITIES: A KOREAN MULTI-CENTER STUDY OF 107 CASES
Ilkyu Han
Favorite
(P 428) OLIGOMETASTASES IN EXTREMITY SOFT TISSUE SARCOMA : SUBTYPE-SPECIFIC ANALYSES OF CHARACTERISTICS AND OUTCOMES
Ilkyu Han
Favorite
Han, Jennifer

Boehringer Ingelheim Pharmaceuticals, Inc.
(P 133) REAL-WORLD ANALYSIS OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS) IN A US COMMUNITY ONCOLOGY SETTING
Jennifer Han
Favorite
(P 206) PATIENT PERSPECTIVE ON LIPOSARCOMA DIAGNOSTIC JOURNEY: INTERIM PATIENT SURVEY RESULTS
Jennifer Han
Favorite
Han, Jing

Department of Orthopedic Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Bone Tumor Institution, Shanghai, China
(P 48) A SINGLE-ARM, OPEN-LABEL CLINICAL STUDY OF OVV-01 ONCOLYTIC VIRUS INJECTION AS MONOTHERAPY OR IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR ADVANCED SOLID TUMOR PATIENTS
Jing Han
Favorite
Hanna, Andrew

Memorial Sloan Kettering Cancer Center
(P 380) MULTIDISCIPLINARY MANAGEMENT OF INTRA-ABDOMINAL DESMOID-TYPE FIBROMATOSIS: A 30-YEARS EXPERIENCE
Andrew Hanna
Favorite
Hannah, Cathleen

Surgical Oncology Program, National Cancer Institute/National Institutes of Health
(P 163) CHARACTERIZATION OF INTRAHEPATIC RECURRENCE FOLLOWING LIVER-DIRECTED SURGERY IN PATIENTS WITH METASTATIC SDH-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST): RISE AND STABILIZATION OF THE GISTLETS
Cathleen Hannah
Favorite
Hannour, Saloi

CENTRE LEON BERARD
(P 169) FRENCH LONG TERM REGISTRY WITH LONGITUDINAL FOLLOW UP OF PDGFRA D842V GIST PATIENTS (AVIATOR2020)
Saloi Hannour
Favorite
Han, Ruxu

Childrens Oncology Group
(P 50) ANALYSIS OF CLINICAL FEATURES AND OUTCOMES FOR PATIENTS WITH MULTIFOCAL OSTEOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Ruxu Han
Favorite
Hansén Nord, Karolin

Lund University
(P 03) CDK4 IS CO-AMPLIFIED WITH EITHER TP53 PROMOTER GENE FUSIONS OR MDM2 THROUGH DISTINCT MECHANISMS IN OSTEOSARCOMA
Karolin Hansén Nord
Favorite
(P 26) SARCDBASE: A TOOL FOR DETECTION OF GENETIC ALTERATIONS IN SARCOMA
Karolin Hansén Nord
Favorite
Hansen, Jolanta

Department of Oncology Medical Physics, Aarhus University Hospital
(P 357) RADIATION THERAPY OF EXTREMITY SOFT TISSUE SARCOMAS: A NATIONWIDE COHORT STUDY OF LATE SIDE EFFECTS - TRIAL IN PROGRESS
Jolanta Hansen
Favorite
Hansotia, Kyle

The Ohio State University College of Medicine
(P 244) PREDICTIVE VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO IN IMMUNOTHERAPY OUTCOMES IN ADVANCED SARCOMA
Kyle Hansotia
Favorite
Han, Yiqun

Mayo Clinic
(P 190) CLINICAL FEATURES ASSOCIATED WITH DIFFERENT HISTOLOGICAL SUBTYPES OF SARCOMA: A POPULATION-BASED STUDY OF 97062 CASES
Yiqun Han
Favorite
(P 210) RADIATION-ASSOCIATED ANGIOSARCOMA OF THE BREAST (RAASB): A NOMOGRAM FOR PREDICTING RECURRENCE AND PROGNOSIS
Yiqun Han
Favorite
Hao, Binbin

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
(P 93) THE PROTEOGENOMIC SUBTYPING OF OSTEOSARCOMA
Binbin Hao
Favorite
Hao, Clara

Stanford University School of Medicine
(P 143) EARLY ASSESSMENT OF DISEASE RESPONSE TO IMMUNOTHERAPY VIA CIRCULATING TUMOR DNA IN ADVANCED SOFT TISSUE SARCOMAS
Clara Hao
Favorite
Haramiova, Zuzana

Thermosome GmbH
(P 410) PHASE I STUDY OF THE001 (DPPG2-TSL-DOX) COMBINED WITH REGIONAL HYPERTHERMIA IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Zuzana Haramiova
Favorite
Harley, Brendan

University of Illinois Urbana-Champaign
(P 419) BONE MECHANICS INFLUENCE CANCER STEM CELL FORMATION IN OSTEOSARCOMA
Brendan Harley
Favorite
Haro Varas, Juan Carlos

Instituto Nacional de Enfermedades Neoplasicas
(P 192) CURRENT SCENARIO OF SARCOMA CLINICAL TRIALS IN SOUTH AMERICA: A REPORT BY THE LACOG SARCOMA GROUP
Juan Carlos Haro Varas
Favorite
(P 216) SARCOMA CARE PATHWAYS AND MULTIDISCIPLINARY TUMOR BOARDS IN LATIN AMERICA: AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Juan Carlos Haro Varas
Favorite
(P 217) SARCOMA DRUG APPROVALS IN LATIN AMERICA COMPARED TO THE FDA AND EMA: AN ANALYSIS BY THE LACOG SARCOMA GROUP
Juan Carlos Haro Varas
Favorite
(P 219) SOCIAL MEDIA USE AMONG MEDICAL PROFESSIONALS THAT TREAT PATIENTS WITH SARCOMA IN LATIN AMERICA: RESULTS OF AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Juan Carlos Haro Varas
Favorite
Haroun, Grace

Sarcoma Oncology Center
(P 106) DELTAREX-G, A TUMOR TARGETED CCNG1 INHIBITOR, DEMONSTRATES CLINICAL BENEFIT IN ADVANCED CHEMORESISTANT SARCOMA FOLLOWING FDA CBER AUTHORIZATION FOR USE AS PLATFORM THERAPY WITH FDA APPROVED DRUGS
Grace Haroun
Favorite
Harrow, Brooke

Deciphera Pharmaceuticals, LLC
(P 43) SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
Brooke Harrow
Favorite
Hartner, Lee

Abramson Cancer Center
(P 95) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN PATIENTS WITH CHONDROSARCOMA: UPDATED RESULTS FROM A PHASE 1 STUDY
Lee Hartner
Favorite
Harvard, Hayden

Mercer University School of Medicine
(P 142) CORE NEEDLE BIOPSY OF PERIACETABULAR CHONDROSARCOMA OFTEN RESULTS IN UNDER-GRADING BUT DOES NOT CHANGE MANAGEMENT BY EXPERIENCED ORTHOPAEDIC ONCOLOGISTS.
Hayden Harvard
Favorite
Harwood, Catherine

Royal London Hospital
(P 98) A MULTIEPITOPE MRNA VACCINE FOR KAPOSI SARCOMA: AN IMMUNOINFORMATIC APPROACH
Catherine Harwood
Favorite
Haskins, Kate

Roswell Park Comprehensive Cancer Center
(P 35) EARLY REAL WORLD EXPERIENCE WITH NIROGACESTAT IN PATIENTS WITH DESMOID FIBROMATOSIS
Kate Haskins
Favorite
Hastings, Reuben

NHS England, UCL Cancer Institute
(P 60) DIAGNOSIS AND MANAGEMENT OF PAEDIATRIC EWING SARCOMA PATIENTS IN ENGLAND 2014-2017: A COMPARISON OF NATIONAL DATA WITH THE EURO-EWING 2012 CLINICAL TRIAL
Reuben Hastings
Favorite
Haveman, Lianne

Princess Máxima Center for Pediatric Oncology
(P 319) THE SURVIVAL DISPARITY BETWEEN CHILDREN AND ADOLESCENTS & YOUNG ADULTS WITH EWING SARCOMA IN THE NETHERLANDS DID NOT CHANGE SINCE THE 1990S DESPITE IMPROVED SURVIVAL: A POPULATION-BASED STUDY
Lianne Haveman
Favorite
Hawkins, Douglas

Seattle Children’s Hospital, University of Washington
(P 315) SALVAGE THERAPY EFFICACY IS MODIFIED BY RISK GROUP AT DIAGNOSIS IN PATIENTS WITH RELAPSED RHABDOMYOSARCOMA
Douglas Hawkins
Favorite
Hayashi, Masanori

University of Colorado Cancer Center
(P 88) SPATIAL TRANSCRIPTOMICS OF EWING SARCOMA: EVOLUTION OF TUMOR MICROENVIRONMENT ASSOCIATED EXTRACELLULAR MATRIX FROM LOCALIZED TO METASTASIS-ASSOCIATED PRIMARY TUMORS
Masanori Hayashi
Favorite
Hayden, James

Oregon Health & Science University
(P 223) ASSOCIATION OF POSTOPERATIVE INFECTION (POI) WITH SOFT TISSUE SARCOMA (STS) RESECTION OUTCOMES
James Hayden
Favorite
(P 285) A NOVEL METHOD TO PREDICT HEIGHT AT SKELETAL MATURITY IN PEDIATRIC SARCOMA PATIENTS
James Hayden
Favorite
Heath, Emily

Cumming School of Medicine, University of Calgary
(P 174) INCIDENCE, TREATMENT PATTERNS, AND SURVIVAL OUTCOMES FOR ADULT PATIENTS WITH GASTROINTESTINAL STROMAL TUMOURS (GIST) IN ALBERTA, CANADA FROM 2008 - 2022.
Emily Heath
Favorite
Heer, Collin

University of Iowa
(P 12) GENETIC LANDSCAPE OF MPNST DETERMINES METABOLIC STRATEGIES AND THERAPEUTIC OPPORTUNITIES FOR COPING WITH REDOX STRESS
Collin Heer
Favorite
Heeren, Amanda

Mayo Clinic
(P 200) FRAILTY ASSESSMENT IN OLDER PATIENTS RECEIVING SARCOMA THERAPY
Amanda Heeren
Favorite
Heesen, Philip

SwissSarcomaNetwork
(P 184) A SYSTEMATIC REVIEW ABOUT CLINICAL PROGNOSTIC MODELS FOR SARCOMAS
Philip Heesen
Favorite
(P 204) IMPACT OF UNPéLANNED EXCISION ON THE SURVIVAL OF SARCOMA PATIENTS - A TARGET TRIAL EMULATION
Philip Heesen
Favorite
Heiling, Hilary

Dana-Farber Cancer Institute
(P 107) DOES THE USE OF ADJUVANT CHEMOTHERAPY IN LOCALIZED, RESECTABLE SOFT TISSUE SARCOMA LEAD TO BETTER SURVIVAL OUTCOMES? - A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Hilary Heiling
Favorite
Heilshorn, Sarah

Stanford University
(P 74) MATRIX DENSITY INDUCES CHEMORESISTANCE WITHIN A TISSUE-ENGINEERED MODEL OF OSTEOSARCOMA
Sarah Heilshorn
Favorite
Heimans, L

Netherlands Cancer Institute
(P 24) NEOADJUVANT CHEMOTHERAPY FOR RADIOTHERAPY ASSOCIATED ANGIOSARCOMA (RAAS) OF THE BREAST IMPROVES ONCOLOGICAL OUTCOMES
L Heimans
Favorite
(P 349) LONG-TERM SURVIVAL OF PARTICIPANTS IN THE PASART-1 AND PASART-2 TRIALS OF NEO-ADJUVANT PAZOPANIB AND RADIOTHERAPY IN SOFT TISSUE SARCOMA
L Heimans
Favorite
Heim, Tanya

University of Pittsburgh
(P 51) ASSESSING THE IN VIRTO EFFICACY OF DISULFIRAM AND ENZALUTAMIDE COMBINATION THERAPY IN METASTATIC OSTEOSARCOMA
Tanya Heim
Favorite
Heim, Tanya

UPMC Hillman Cancer Center
(P 240) INVESTIGATING MACROPHAGE POPULATION VARIABILITY IN METASTATIC SARCOMA SAMPLES
Tanya Heim
Favorite
(P 256) CHARACTERIZING ORTHOPAEDIC ONCOLOGIC POLYTRAUMAS: A COMPARISON OF PATIENTS UNDERGOING OPERATIVE FIXATION OF MULTIPLE LESIONS WITH THOSE WITH SOLITARY LESIONS
Tanya Heim
Favorite
(P 353) PREDICTING WOUND COMPLICATIONS FOLLOWING SOFT-TISSUE SARCOMA RESECTION AMONG PATIENTS WHO RECEIVED PRE-OPERATIVE RADIATION
Tanya Heim
Favorite
Heinrich, Michael

Portland VA Health Care System and OHSU Knight Cancer Institute
(P 173) IN VITRO PROFILING OF IDRX-42 AGAINST SECONDARY MUTATIONS FOUND IN TKI-RESISTANT GIST
Michael Heinrich
Favorite
(P 177) PREDICTING THE IMATINIB RESPONSE OF PDGFRA EXON 18-MUTANT GASTROINTESTINAL STROMAL TUMOR USING IN VITRO MODELS
Michael Heinrich
Favorite
(P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE
Michael Heinrich
Favorite
(P 227) EFFICACY OF IMMUNOTHERAPY IN TREATING METASTATIC MALIGNANT MYOPERICYTOMA: A CASE REPORT AND RIVEW OF LITERATURE
Michael Heinrich
Favorite
(P 403) DCC-3116 IN COMBINATION WITH RIPRETINIB FOR PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A PHASE 1/2 STUDY
Michael Heinrich
Favorite
(P 412) SARC044: A PHASE II TRIAL OF BEZUCLASTINIB IN COMBINATION WITH SUNITINIB IN PATIENTS WITH GIST WHO PROGRESSED ON SUNITINIB MONOTHERAPY
Michael Heinrich
Favorite
Heintz, Dimitri

Plant Imaging & Mass Spectrometry, PIMS- Institute of Plant Molecular Biology (IBMP), CNRS
(P 75) METABOLIC EVALUATION OF THE RELATIONSHIP BETWEEN MACROPHAGES AND OSTEOSARCOMA TUMOR CELLS
Dimitri Heintz
Favorite
Heise, Rachel

Weill Cornell Medicine
(P 102) ANALYSIS OF BLOOD-BASED BIOMARKERS AS PROGNOSTIC FACTORS IN PATIENTS WITH EHE TREATED WITH TRAMETINIB IN SARC033
Rachel Heise
Favorite
He, Kevin

Washington University in St. Louis
(P 145) EXPLORING L-TYPE AMINO ACID TRANSPORTER 1 (LAT1) AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)
Kevin He
Favorite
Helman, Lee

The Osteosarcoma Institute, Inc.
(P 408) OSTEOMYC: A PHASE 2 PILOT STUDY TO EVALIATE THE SAFETY AND THE ANTITUMOR ACTIVITY OF THE MYC INHIBITOR OMO-103 ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH ADVANCED HIGH GRADE OSTEOSARCOMA
Lee Helman
Favorite
Helmig, Sara

St. Jude Children’s Research Hospital
(P 288) ANGIOA: A SAFETY AND TOLERABILITY STUDY OF TRIPLE ANTI-ANGIOGENIC THERAPY COMBINED WITH PD-L1 BLOCKADE IN PEDIATRIC, ADOLESCENT AND YOUNG ADULT RECURRENT/REFRACTORY SOLID TUMORS
Sara Helmig
Favorite
Hendrickson, Peter

Duke Univeristy
(P 301) GENOME-WIDE CRISPR/CAS9 VIABILITY SCREENS UNCOVER NOVEL GENETIC DEPENDENCIES IN CIC::DUX4 SARCOMA
Peter Hendrickson
Favorite
(P 303) INVESTIGATING THE THERAPEUTIC POTENTIAL OF TRIPTOLIDE PRODRUG, MINNELIDE, AS A TREATMENT ALTERNATIVE FOR CIC-DUX4 SARCOMA
Peter Hendrickson
Favorite
Henning, Jan-Willem

Tom Baker Cancer Center
(P 174) INCIDENCE, TREATMENT PATTERNS, AND SURVIVAL OUTCOMES FOR ADULT PATIENTS WITH GASTROINTESTINAL STROMAL TUMOURS (GIST) IN ALBERTA, CANADA FROM 2008 - 2022.
Jan-Willem Henning
Favorite
Hensel, Jonathan

Moffitt Cancer Center
(P 237) INTRALESIONAL ADMINISTRATION OF TALIMOGENE LAHERPAREPVEC (T-VEC) INDUCES TUMOR REGRESSION IN PATIENTS WITH CUTANEOUS ANGIOSARCOMA
Jonathan Hensel
Favorite
Henshaw, Robert

Washington Hospital Center
(P 38) LOCAL RECURRENCE OF DIFFUSE PIGMENTED VILLONODULAR SYNOVITIS IN MAJOR JOINTS: A 15 YEAR-LONG CASE SERIES AT A SINGLE INSTITUTION
Robert Henshaw
Favorite
(P 39) PATIENT OUTCOMES FOLLOWING MINIMALLY INVASIVE TREATMENT OF ANEURYSMAL BONE CYSTS USING DOXYCYCLINE
Robert Henshaw
Favorite
(P 401) A PHASE 3 MULTI-CENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO ASSESS THE EFFICACY AND SAFETY OF EMACTUZUMAB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR (TANGENT)
Robert Henshaw
Favorite
(P 406) LONG-TERM DENOSUMAB THERAPY IN GIANT CELL TUMOR PATIENTS MAY POTENTIALLY LEAD TO THE DEVELOPMENT OF OTHER PRIMARY TUMORS: AN INITIAL OBSERVATION
Robert Henshaw
Favorite
Hensley, Martee

Memorial Sloan Kettering Cancer Center
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Martee Hensley
Favorite
Heredia Nieto, Omar

University of Miami/Jackson Health System
(P 314) RETROSPECTIVE EVALUATION OF DISPARITIES IN ADOLESCENT AND YOUNG ADULT (AYA) PATIENTS WITH SYNOVIAL SARCOMA: A SINGLE INSTITUTION STUDY
Omar Heredia Nieto
Favorite
Hergenrother, Paul

University of Illinois Urbana-Champaign
(P 79) NOVEL THERAPEUTIC POTENTIAL THROUGH HYPERACTIVATION OF THE ANTICIPATORY UNFOLDED PROTEIN RESPONSE PATHWAY IN BONE CANCER TREATMENT
Paul Hergenrother
Favorite
Hermann, Frank

Thermosome GmbH
(P 410) PHASE I STUDY OF THE001 (DPPG2-TSL-DOX) COMBINED WITH REGIONAL HYPERTHERMIA IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Frank Hermann
Favorite
Hermoso, Luis

Complejo Hospitalario Universitario de Albacete
(P 432) THE ROLE OF SYSTEMIC TREATMENT IN ADVANCED SOLITARY FIBROUS TUMORS: EXPERIENCE AT A REFERRAL CENTER.
Luis Hermoso
Favorite
Herms, Lisa

Ontada
(P 133) REAL-WORLD ANALYSIS OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS) IN A US COMMUNITY ONCOLOGY SETTING
Lisa Herms
Favorite
Hernandez, Jonathan

Surgical Oncology Program, National Cancer Institute/National Institutes of Health
(P 163) CHARACTERIZATION OF INTRAHEPATIC RECURRENCE FOLLOWING LIVER-DIRECTED SURGERY IN PATIENTS WITH METASTATIC SDH-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST): RISE AND STABILIZATION OF THE GISTLETS
Jonathan Hernandez
Favorite
(P 231) IDENTIFICATION OF NEOANTIGEN FROM PECOMA-LIKE NEOPLASM PROVIDES RATIONALE FOR TREATMENT WITH CELLULAR THERAPY
Jonathan Hernandez
Favorite
Hernando, Florentino

Hospital Clínico San Carlos
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Florentino Hernando
Favorite
Herrmann, Joerg

Mayo Clinic
(P 120) USING AI PREDICTIONS FROM ECG TRACINGS TO PREDICT TOLERANCE TO ANTHRACYCLINE CHEMOTHERAPY IN SARCOMA
Joerg Herrmann
Favorite
Hershenhouse, Tyler

Ann & Robert H Lurie Children's Hospital of Chicago
(P 04) CHROMOSOME SPECIFIC ORGANIZATIONAL CHARACTERISTICS IN RHABDOMYOSARCOMA AND NORMAL MYOGENIC CELLS
Tyler Hershenhouse
Favorite
Hettmer, Simone

Faculty of Medicine at Martin Luther University Halle-Wittenberg (MLU)
(P 287) AN INTERNATIONAL SURVEY OF PROVIDER PRACTICES REGARDING BONE MARROW SAMPLING VERSUS [18F] FDG PET/CT IN THE DIAGNOSTIC EVALUATION OF BONE MARROW METASTASIS IN PEDIATRIC RHABDOMYOSARCOMA
Simone Hettmer
Favorite
Hiemcke-Jiwa, Laura

Princess Maxima Center for Pediatric Oncology, The Netherlands
(P 319) THE SURVIVAL DISPARITY BETWEEN CHILDREN AND ADOLESCENTS & YOUNG ADULTS WITH EWING SARCOMA IN THE NETHERLANDS DID NOT CHANGE SINCE THE 1990S DESPITE IMPROVED SURVIVAL: A POPULATION-BASED STUDY
Laura Hiemcke-Jiwa
Favorite
Higazy, Randa

University Health Network
(P 433) TUMOR HYPOXIA AND THE RISK OF METASTASIS IN HIGH-RISK LOCALIZED UPS/MFS
Randa Higazy
Favorite
Hikmet, Ramsen

Department of Oncology, Aarhus University Hospital.
(P 357) RADIATION THERAPY OF EXTREMITY SOFT TISSUE SARCOMAS: A NATIONWIDE COHORT STUDY OF LATE SIDE EFFECTS - TRIAL IN PROGRESS
Ramsen Hikmet
Favorite
Hildebrand, Karys

University of Calgary
(P 236) INTERFERON STIMULATED GENE SCORES ARE ELEVATED IN THE MYELOID COMPARTMENT OF MURINE KP UNDIFFERENTIATED PLEOMORPHIC TUMORS TREATED WITH TRANSLATIONAL STING AGONISTS
Karys Hildebrand
Favorite
(P 239) INVESTIGATING HOW TUMOUR ASSOCIATED MACROPHAGES INFLUENCE THE EFFICACY OF CAR T THERAPY IN A MURINE MODEL OF SOFT TISSUE SARCOMA
Karys Hildebrand
Favorite
(P 327) CHARACTERIZATION OF TWO NOVEL IMMUNE COMPETENT, MURINE MODELS OF SOFT TISSUE SARCOMA
Karys Hildebrand
Favorite
(P 333) ESTIMATING IMMUNE INFILTRATES OF NOVEL GENETICALLY ENGINEERED MOUSE MODELS OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Karys Hildebrand
Favorite
Hildebrand, Kurt

University of Calgary
(P 236) INTERFERON STIMULATED GENE SCORES ARE ELEVATED IN THE MYELOID COMPARTMENT OF MURINE KP UNDIFFERENTIATED PLEOMORPHIC TUMORS TREATED WITH TRANSLATIONAL STING AGONISTS
Kurt Hildebrand
Favorite
(P 239) INVESTIGATING HOW TUMOUR ASSOCIATED MACROPHAGES INFLUENCE THE EFFICACY OF CAR T THERAPY IN A MURINE MODEL OF SOFT TISSUE SARCOMA
Kurt Hildebrand
Favorite
(P 327) CHARACTERIZATION OF TWO NOVEL IMMUNE COMPETENT, MURINE MODELS OF SOFT TISSUE SARCOMA
Kurt Hildebrand
Favorite
(P 333) ESTIMATING IMMUNE INFILTRATES OF NOVEL GENETICALLY ENGINEERED MOUSE MODELS OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Kurt Hildebrand
Favorite
Hindi, Nadia

Fundacion Jimenez Diaz University Hospital
(P 234) IMMUNOSARC II MASTER TRIAL (PHASE II OF SUNITINIB AND NIVOLUMAB): RESULTS FROM THE CLEAR CELL SARCOMA (CCS) COHORT. A GEIS, ISG, AND UCL STUDY
Nadia Hindi
Favorite
Hiniker, Susan

Stanford University
(P 356) RADIATION PRACTICE PATTERNS AND OUTCOMES IN ADOLESCENT YOUNG ADULT PATIENTS WITH VISCERAL NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA
Susan Hiniker
Favorite
Hirai, Toshihide

National Cancer Center Institute
(P 103) BRAF MUTATIONS AND CONCURRENT ALTERATIONS IN PATIENTS WITH SOFT TISSUE SARCOMA
Toshihide Hirai
Favorite
Hirbe, Angela

Washington University in St. Louis School of Medicine, Division of Oncology
(P 10) GENERATION OF A CHROMOSOME 8 GAIN;NF1-/- HUMAN INDUCED PLURIPOTENT STEM CELL DERIVED SCHWANN CELL PRECURSOR MODEL
Angela Hirbe
Favorite
(P 145) EXPLORING L-TYPE AMINO ACID TRANSPORTER 1 (LAT1) AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)
Angela Hirbe
Favorite
(P 149) LACK OF CORRELATION OF FDG-PET/CT SUV MAXIMUM AND MALIGNANT TRANSFORMATION IN NEUROFIBROMATOSIS TYPE 1-RELATED PLEXIFORM NEUROFIBROMAS
Angela Hirbe
Favorite
(P 187) BRIDGING THE GAP: UNDERSTANDING THE CURRENT TREATMENT RESPONSES TO ENHANCE THE STANDARD OF CARE AND OUTCOMES FOR MALIGNANT PERIPHERAL NERVE SHEATH TUMORS
Angela Hirbe
Favorite
(P 335) FOCAL ADHESION KINASE (FAK) IS A THERPEUTIC TARGET IN CHROMOSOME 8 GAIN-ASSOCIATED MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)
Angela Hirbe
Favorite
Hirose, Takeshi

Memorial Sloan Kettering Cancer Center
(P 203) IMPACT OF COVID-19 PANDEMIC ON BONE AND SOFT TISSUE SARCOMA PATIENTS' CONSULTATION AND DIAGNOSIS
Takeshi Hirose
Favorite
Hirozane, Toru

Department of Orthopaedic Surgery, Kyorin University Faculty of Medicine
(P 18) IMMUNOHISTOCHEMICAL ANALYSIS OF NUCLEAR β-CATENIN IN BONE AND SOFT TISSUE TUMOR MICROARRAYS
Toru Hirozane
Favorite
HOANG, BANG

Montefiore Medical Center
(P 59) COMPREHENSIVE SINGLE CELL TRANSCRIPTOMICS ANALYSIS OF MURINE OSTEOSARCOMA UNCOVERS SKP2 FUNCTION IN METASTASIS, GENOMIC INSTABILITY AND IMMUNE ACTIVATION AND REALS ADDITIONAL TARGET PATHWAYS
BANG HOANG
Favorite
(P 147) INVESTIGATING THE POTENTIAL OF EXTRACELLULAR VESICLE BIOMARKERS IN SYNOVIAL SARCOMA DETECTION
BANG HOANG
Favorite
(P 156) PROFILING SYNOVIAL SARCOMA EXTRACELLULAR VESICLES FOR DIAGNOSTIC RNA BIOMARKERS
BANG HOANG
Favorite
Hobson, Jared

Mayo Clinic
(P 210) RADIATION-ASSOCIATED ANGIOSARCOMA OF THE BREAST (RAASB): A NOMOGRAM FOR PREDICTING RECURRENCE AND PROGNOSIS
Jared Hobson
Favorite
Hodo, Thomas

Massachusetts General Hospital
(P 108) FIXATION OF IMPENDING OR PATHOLOGIC FRACTURES DUE TO METASTATIC DISEASE WITH CARBON FIBER INTRAMEDULLARY NAILS-A PROPENSITY-SCORE MATCHED COST ANALYSIS
Thomas Hodo
Favorite
Hohenberger, Peter

Div.of Surgical Oncology and Thoracic surgery, Mannheim University Medical Center, University of Heidelberg, Germany
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Peter Hohenberger
Favorite
Hojo, Hidehiro

National Cancer Center Hospital East
(P 354) PROTON BEAM THERAPY FOR PEDIATRIC AND ADOLESCENT SARCOMA FROM OVERSEAS
Hidehiro Hojo
Favorite
Holloway, Caroline

BC Cancer
(P 153) PATTERNS, MANAGEMENT AND SURVIVAL OUTCOMES OF PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA: A NATIONWIDE ANALYSIS FROM THE CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION DATABASE
Caroline Holloway
Favorite
(P 293) CIC-REARRANGED SOFT TISSUE SARCOMAS: DOES CHEMOTHERAPY CHANGE NATURAL HISTORY AND PROGNOSIS? A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Caroline Holloway
Favorite
(P 321) WHOLE ABDOMINAL RADIOTHERAPY IN CHILDREN AND YOUNG ADULTS WITH SARCOMA: A CANADIAN SARCOMA AND CLINICAL COLLABORATION (CANSARCC) STUDY
Caroline Holloway
Favorite
Holt, Ginger

Vanderbilt University Medical Center
(P 73) LONGER TIME INTERVAL BETWEEN NEOADJUVANT CHEMOTHERAPY AND SURGERY IS ASSOCIATED WITH DECREASED TUMOR PERCENT NECROSIS IN OSTEOSARCOMA
Ginger Holt
Favorite
(P 265) IS THERE AN IDEAL STEM TO CANAL RATIO IN LOWER EXTREMITY ONCOLOGIC ENDOPROSTHESIS RECONSTRUCTION?
Ginger Holt
Favorite
(P 268) LOWER TUMOR PERCENT NECROSIS IS ASSOCIATED WITH POSITIVE FINAL SURGICAL MARGINS IN OSTEOSARCOMA
Ginger Holt
Favorite
(P 404) ENHANCED RECOVERY AFTER SURGERY (ERAS) PROTOCOL FOR PATENTS WITH SOFT TISSUE SARCOMA OF THE EXTREMITY: A PROSPECTIVE, NON-RANDOMIZED, CONSECUTIVELY ENROLLED TRIAL
Ginger Holt
Favorite
Hompes, Daphne

University Hospitals Gasthuisberg Leuven
(P 291) CASE REPORT: RADICAL EN BLOC MULTI-LEVEL SPONDYLECTOMY FOR A LOCALLY RECURRENT OSTEOSARCOMA
Daphne Hompes
Favorite
(P 334) EXPANDING THE LANDSCAPE OF PRECLINICAL MODELS OF SYNOVIAL SARCOMA: FROM 2-DIMENSIONS TO 3-DIMENSIONS TO MICE
Daphne Hompes
Favorite
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Daphne Hompes
Favorite
Hompland, Ivar

Oslo University Hospital
(P 40) PEGYLATED LIPOSOMAL DOXORUBICIN IN SYMPTOMATIC DESMOID TUMOR
Ivar Hompland
Favorite
Hompland, Tord

Oslo University Hospital
(P 40) PEGYLATED LIPOSOMAL DOXORUBICIN IN SYMPTOMATIC DESMOID TUMOR
Tord Hompland
Favorite
Hong, Angela

Royal Prince Alfred Hospital
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Angela Hong
Favorite
Hong, David

The University of Texas MD Anderson Cancer Center
(P 95) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN PATIENTS WITH CHONDROSARCOMA: UPDATED RESULTS FROM A PHASE 1 STUDY
David Hong
Favorite
(P 396) LONG-TERM FOLLOW-UP EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
David Hong
Favorite
Honoki, Kanya

Nara Medical University
(P 85) PTEROSTILBENE SENSITIZES OSTEOSARCOMA CELLS TO KILLING BY C-MYC INHIBITORS
Kanya Honoki
Favorite
(P 313) RELATION BETWEEN NUTRITIONAL/INFLAMMATORY PARAMETERS AND PROGNOSIS IN CHILDHOOD SARCOMA PATIENTS
Kanya Honoki
Favorite
Honore, Lesly

Rush University Medical Center
(P 31) CLINICAL CHALLENGES AND EVOLVING TREATMENT STRATEGIES IN DESMOID FIBROMATOSIS: A SINGLE INSTITUTION EXPERIENCE
Lesly Honore
Favorite
(P 126) CHARACTERIZING THE TRANSFORMATION AND DIAGNOSIS OF ATYPICAL LIPOMATOUS TUMOR OF THE EXTREMITIES TO DEDIFFERENTIATED LIPOSARCOMA: SINGLE INSTITUTIONAL OUTCOMES
Lesly Honore
Favorite
Hopyan, Sevan

Hospital for Sick Children and University of Toronto
(P 304) LOCAL CONTROL FOR PEDIATRIC RHABDOMYOSARCOMA OF THE EXTREMITIES. IS RADIOTHERAPY ALWAYS REQUIRED AFTER ADEQUATE SURGICAL RESECTION?
Sevan Hopyan
Favorite
Horgan, Santiago

University of California, San Diego
(P 167) DEFINING TEXTBOOK OUTCOMES FOR MINIMALLY INVASIVE SURGICAL RESECTION OF SMALL GASTROINTESTINAL STROMAL TUMORS (GIST) OF THE STOMACH
Santiago Horgan
Favorite
Hornicek, Francis

University of Miami
(P 58) COMBINATORY THERAPIES UTILIZING INHIBITION OF CARBONIC ANHYDRASE IX TO POTENTIATE RESPONSE IN RELAPSED/REFRACTORY OSTEOSARCOMA
Francis Hornicek
Favorite
(P 346) BRACHYTHERAPY FOR SOFT TISSUE SARCOMA: MAINTAINING LOCAL CONTROL WHILE MINIMIZING COMPLICATIONS
Francis Hornicek
Favorite
Horonjeff, Jen

Savvy Cooperative
(P 206) PATIENT PERSPECTIVE ON LIPOSARCOMA DIAGNOSTIC JOURNEY: INTERIM PATIENT SURVEY RESULTS
Jen Horonjeff
Favorite
Horvath, Lisa

Chris O'Brien Lifehouse
(P 325) CAN PROTEOMICS PREDICT METASTATIC RELAPSE IN LEIOMYOSARCOMA? DEVELOPMENT OF AN 8 PROTEIN SIGNATURE IN A >350 SAMPLE STUDY INCLUDING A VALIDATION COHORT
Lisa Horvath
Favorite
Hoskin, Tyler

Atlantic Health System
(P 405) LIPOSOMAL BUPIVACAINE DOESN'T REDUCE NARCOTIC USE OR PAIN SCORES COMPARED TO A MULTIDRUG COCKTAIL FOLLOWING SOFT TISSUE TUMOR REMOVAL: PRELIM RESULTS OF A PROSPECTIVE, RANDOMIZED DOUBLE-BLINDED STUDY
Tyler Hoskin
Favorite
Hosogane, Naobumi

Kyorin University
(P 18) IMMUNOHISTOCHEMICAL ANALYSIS OF NUCLEAR β-CATENIN IN BONE AND SOFT TISSUE TUMOR MICROARRAYS
Naobumi Hosogane
Favorite
Hosono, AKO

National Cancer Center Hospital East
(P 354) PROTON BEAM THERAPY FOR PEDIATRIC AND ADOLESCENT SARCOMA FROM OVERSEAS
AKO Hosono
Favorite
Hosseini, Mojgan

University of California San Diego
(P 175) KIT AND DOG-1 EXPRESSING GASTROINTESTINAL STROMAL TUMORS HARBORING ETV6-NTRK3 FUSIONS DO EXIST, CASE OF NEAR COMPLETE PATHOLOGIC RESPONSE FOLLOWING LAROTRECTINIB AND REVIEW OF THE LITERATURE
Mojgan Hosseini
Favorite
Ho, Thanh

Mayo Clinic
(P 120) USING AI PREDICTIONS FROM ECG TRACINGS TO PREDICT TOLERANCE TO ANTHRACYCLINE CHEMOTHERAPY IN SARCOMA
Thanh Ho
Favorite
(P 200) FRAILTY ASSESSMENT IN OLDER PATIENTS RECEIVING SARCOMA THERAPY
Thanh Ho
Favorite
Houdek, Matthew

Mayo Clinic
(P 210) RADIATION-ASSOCIATED ANGIOSARCOMA OF THE BREAST (RAASB): A NOMOGRAM FOR PREDICTING RECURRENCE AND PROGNOSIS
Matthew Houdek
Favorite
(P 267) LONG-TERM FUNCTIONAL OUTCOMES OF SHOULDER ARTHRODESIS FOR TUMOR RESECTION
Matthew Houdek
Favorite
(P 278) ROTATIONPLASTY AS AN EFFECTIVE LIMB SALVAGE OPTION IN THE ADULT POPULATION
Matthew Houdek
Favorite
(P 294) COMPARING HIGH-GRADE NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA IN ADULT AND PEDIATRIC POPULATIONS
Matthew Houdek
Favorite
(P 307) OUTCOMES OF PEDIATRIC NON-RHABDOMYOSARCOMA SOFT-TISSUE SARCOMAS OF THE EXTREMITIES
Matthew Houdek
Favorite
Hounschell, Corey

University of Kansas, Department of Surgery
(P 36) EARLY REAL-WORLD EXPERIENCE WITH THE USE OF NIROGACESTAT FOR THE TREATMENT OF DESMOID FIBROMATOSIS
Corey Hounschell
Favorite
house, Michael

Indiana University School of Medicine
(P 384) REAL WORLD EXPERIENCE IN TREATING HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA: AN ULTRA-RARE VASCULAR TUMOR
Michael house
Favorite
Hsu, Che-Yu

National Taiwan University Hospital
(P 348) EVALUATING THE IMPACT OF BIOLOGICAL EFFECTIVE DOSE AND DELAYED RADIOTHERAPY ON THE SYNERGISTIC EFFICACY OF TRABECTEDIN IN METASTATIC SOFT TISSUE SARCOMA PATIENTS
Che-Yu Hsu
Favorite
Huang, Elise

University of California Santa Cruz, Molecular Cell and Developmental Biology, Genomics Institute
(P 147) INVESTIGATING THE POTENTIAL OF EXTRACELLULAR VESICLE BIOMARKERS IN SYNOVIAL SARCOMA DETECTION
Elise Huang
Favorite
(P 156) PROFILING SYNOVIAL SARCOMA EXTRACELLULAR VESICLES FOR DIAGNOSTIC RNA BIOMARKERS
Elise Huang
Favorite
Huang, Karen

Children's Hospital of Philadelphia
(P 318) SYNOVIAL SARCOMA REGISTRY AND BIOSPECIMEN REPOSITORY: DESCRIBING THE COHORT AND SURVIVAL OUTCOMES TO DATE
Karen Huang
Favorite
Huang, Michelle

Stanford University
(P 74) MATRIX DENSITY INDUCES CHEMORESISTANCE WITHIN A TISSUE-ENGINEERED MODEL OF OSTEOSARCOMA
Michelle Huang
Favorite
Huang, Paul

ICR
(P 17) IDENTIFICATION OF MARKERS PREDICTIVE OF RESPONSE TO GEMCITABINE AND DOCETAXEL IN LEIOMYOSARCOMA THROUGH MIRNA SEQUENCING
Paul Huang
Favorite
Huang, Rui

Beckman Research Institute at City of Hope
(P 07) DIRECTLY TARGETING CIC-DUX4 FUSION AND MYC ONCOPROTEINS FOR UNDIFFERENTIATED ROUND CELL SARCOMAS
Rui Huang
Favorite
Huang, Wei

OHSU
(P 364) A PHASE 1B TRIAL OF PREOPERATIVE ERIBULIN AND RADIATION FOR RETROPERITONEAL LIPOSARCOMA
Wei Huang
Favorite
Huang, Wenjun

Seattle Children's Research Institute
(P 226) EARLY EXPERIENCE ON ENLIGHTEN-01: A PHASE 1 STUDY OF BISPECIFIC ADAPTER MOLECULE- CONTROLLED FOLATE RECEPTOR CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY OSTEOSARCOMA
Wenjun Huang
Favorite
Hua, Yingqi

Department of Orthopedic Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
(P 48) A SINGLE-ARM, OPEN-LABEL CLINICAL STUDY OF OVV-01 ONCOLYTIC VIRUS INJECTION AS MONOTHERAPY OR IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR ADVANCED SOLID TUMOR PATIENTS
Yingqi Hua
Favorite
(P 83) PREDICTION OF HIGH-RISK OSTEOSARCOMA PATIENTS BASED ON MACHINE LEARNING USING TRANSCRIPTOME AND METHYLATION DATA FROM SGH-COHORT
Yingqi Hua
Favorite
(P 90) TARGETING HIGH RISK MYC- AMPLIFIED OSTEOSARCOMA BY AURORA KINASE INHIBITOR--RESULT FROM A NGS BASED UMBRELLA TRIAL
Yingqi Hua
Favorite
(P 93) THE PROTEOGENOMIC SUBTYPING OF OSTEOSARCOMA
Yingqi Hua
Favorite
Hubbard, Ryan

University of Michigan
(P 341) THE EFFECTS OF ULTRASOUND-GUIDED HISTOTRIPSY ON SOFT TISSUE SARCOMA
Ryan Hubbard
Favorite
Hubsch, Clémence

UMR7021 CNRS -Laboratory of Bioimaging and Pathologies
(P 75) METABOLIC EVALUATION OF THE RELATIONSHIP BETWEEN MACROPHAGES AND OSTEOSARCOMA TUMOR CELLS
Clémence Hubsch
Favorite
(P 89) TARGETED THERAPY OF MET, TYROSINE KINASE RECEPTOR, IN PEDIATRIC HIGH-GRADE OSTEOSARCOMAS : A NEW WAY TO TREAT PATIENTS ?
Clémence Hubsch
Favorite
(P 426) GD2 HETEROGENEIC EXPRESSION IN OSTEOSARCOMAS AND EWING SARCOMAS UNDERLYING A WORST PROGNOSIS
Clémence Hubsch
Favorite
Huerta-Lopez, Carla

Stanford University
(P 74) MATRIX DENSITY INDUCES CHEMORESISTANCE WITHIN A TISSUE-ENGINEERED MODEL OF OSTEOSARCOMA
Carla Huerta-Lopez
Favorite
Hui, Gavin

Atropos Health
(P 209) RACE AND ETHNICITY ON DIAGNOSIS, METASTASIS, AND MORTALITY OF SOFT TISSUE SARCOMAS IN RETROSPECTIVE COHORT STUDY
Gavin Hui
Favorite
Hu, James

University of Southern California, Norris Comprehensive Cancer Center
(P 158) RECURRENT RADIATION-INDUCED SARCOMA IN A PATIENT WITH HEREDITARY RETINOBLASTOMA: PRESENTATION AND OUTCOME
James Hu
Favorite
Hu, James

University of Southern California Norris Comprehensive Cancer Center
(P 413) SUSTAINED EFFICACY DURING DRUG HOLIDAY ON ATEZOLIZUMAB IN PATIENTS WITH ALVEOLAR SOFT PART SARCOMA (ASPS)
James Hu
Favorite
Hung, Arthur

Oregon Health & Science University
(P 359) RAPIDLY PROGRESSIVE, NON-METASTATIC, CUTANEOUS ANGIOSARCOMA OF FACE AND SCALP TREATED WITH HYPOFRACTIONATED RADIATION THERAPY: A CASE SERIES
Arthur Hung
Favorite
(P 364) A PHASE 1B TRIAL OF PREOPERATIVE ERIBULIN AND RADIATION FOR RETROPERITONEAL LIPOSARCOMA
Arthur Hung
Favorite
Hung, Yin

Massachusetts General Hospital
(P 63) DOES TUMOR NECROSIS IMPACT PROGNOSIS IN CHONDROBLASTIC AND OSTEOBLASTIC OSTEOSARCOMA? A STUDY FROM A LARGE TERTIARY CARE ACADEMIC CENTER
Yin Hung
Favorite
Hunt, Kelly

MD Anderson Cancer Center
(P 130) HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RESECTABLE RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA (DDLPS) TREATED WITH NEOADJUVANT CHECKPOINT BLOCKADE IN A RANDOMIZED PHASE II CLINICAL TRIAL.
Kelly Hunt
Favorite
(P 360) TREATMENT OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR WITH BROMODOMAIN EXTRA TERMINAL INHIBITOR (BETI) IN COMBINATION WITH RADIOTHERAPY
Kelly Hunt
Favorite
Hurley, Rachel

Children's Hospital of Philadelphia
(P 318) SYNOVIAL SARCOMA REGISTRY AND BIOSPECIMEN REPOSITORY: DESCRIBING THE COHORT AND SURVIVAL OUTCOMES TO DATE
Rachel Hurley
Favorite
Hurtt, Jo

National Cancer Institute
(P 414) TENOSYNOVIAL GIANT CELL TUMOR IN CHILDREN: INTERIM RESULTS FROM A PHASE 1 STUDY OF TURALIO®
Jo Hurtt
Favorite
Husain, Marium

The Ohio State University
(P 207) PATIENT-REPORTED GLOBAL HEALTH PREDICTS ADVERSE HEALTH OUTCOMES IN PATIENTS WITH ADVANCED SARCOMA
Marium Husain
Favorite
(P 244) PREDICTIVE VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO IN IMMUNOTHERAPY OUTCOMES IN ADVANCED SARCOMA
Marium Husain
Favorite
(P 328) DETERMINING BIOMARKERS FOR GEMCITABINE RESPONSE IN SOFT TISSUE SARCOMAS: LESSONS LEARNED FROM PANCREATIC CANCER
Marium Husain
Favorite
Hussain, Ahmed

The Ohio State University James Comprehensive Cancer Center
(P 207) PATIENT-REPORTED GLOBAL HEALTH PREDICTS ADVERSE HEALTH OUTCOMES IN PATIENTS WITH ADVANCED SARCOMA
Ahmed Hussain
Favorite
Huynh, Thien Huong

University of South Florida Morsani College of Medicine
(P 257) COMPARATIVE OUTCOMES OF CONSTRAINED ACETABULAR LINERS VS. DUAL MOBILITY CUPS IN COMPLEX HIP RECONSTURCTION FOR METASTATIC BONE DISEASE
Thien Huong Huynh
Favorite
(P 262) EVALUATION OF STAGED RESECTION WITH TEMPORIZING VAC OF SOFT TISSUE SARCOMAS
Thien Huong Huynh
Favorite
(P 279) SIGNIFICANCE OF TIP-APEX DISTANCE IN ACTUAL AND IMPENDING PATHOLOGICAL FRACTURES OF THE PROXIMAL FEMUR
Thien Huong Huynh
Favorite
Hyder Junejo, Muhammad

Yale University
(P 98) A MULTIEPITOPE MRNA VACCINE FOR KAPOSI SARCOMA: AN IMMUNOINFORMATIC APPROACH
Muhammad Hyder Junejo
Favorite
I
Ibáñez del Prado, Celia

Complutense University
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Celia Ibáñez del Prado
Favorite
Ibanez, Glorymar

Memorial Sloan Kettering Cancer Center
(P 338) PRECLINICAL EFFICACY OF DAN-222, A NOVEL POLYMERIC NANOPARTICLE, IN PEDIATRIC SOLID TUMOR MODELS
Glorymar Ibanez
Favorite
Ibarra, Joe

Ann & Robert H Lurie Children's Hospital of Chicago
(P 04) CHROMOSOME SPECIFIC ORGANIZATIONAL CHARACTERISTICS IN RHABDOMYOSARCOMA AND NORMAL MYOGENIC CELLS
Joe Ibarra
Favorite
Ibrahim, Toni

Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies, IRCCS, Istituto Ortopedico Rizzoli, Bologna, Italy
(P 77) MULTI-PARAMETRICAL PROFILING OF CHONDROSARCOMA
Toni Ibrahim
Favorite
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Toni Ibrahim
Favorite
(P 336) IMPROVEMENT OF PHOTODYNAMIC THERAPY IN SARCOMA: IN VITRO VALIDATION ON OSTEOSARCOMA AND MYXOFIBROSARCOMA
Toni Ibrahim
Favorite
Id Said, Badr

MD Anderson Cancer Centre
(P 326) CELL-FREE DNA AS A BIOMARKER FOR CELL DEATH AND TREATMENT RESPONSE IN ON-CHIP THREE-DIMENSIONAL SARCOMA TUMOR MODELS
Badr Id Said
Favorite
Ignar, Diane

Chordoma Foundation
(P 02) A PRECLINICAL ASSAY PIPELINE TO IDENTIFY AND OPTIMIZE BRACHYURY-TARGETED THERAPIES IN CHORDOMA AND OTHER SOLID TUMORS
Diane Ignar
Favorite
Ikegami, Masachika

Division of Cellular Signaling, National Cancer Center Research Institute
(P 103) BRAF MUTATIONS AND CONCURRENT ALTERATIONS IN PATIENTS WITH SOFT TISSUE SARCOMA
Masachika Ikegami
Favorite
Ikeuchi, Kyoko

Hyogo Cancer Center
(P 168) EFFICACY OF LOW-DOSE IMATINIB IN A PATIENT WITH A GIST WITH KIT EXON 11 W557_K558 DELETION
Kyoko Ikeuchi
Favorite
Ikuta, Kunihiro

Nagoya university
(P 280) SURGICAL OUTCOMES OF PELVIC CHONDROSARCOMA WITH A FOCUS ON WALKING ABILITY
Kunihiro Ikuta
Favorite
Imagama, Shiro

Nagoya university hospital
(P 280) SURGICAL OUTCOMES OF PELVIC CHONDROSARCOMA WITH A FOCUS ON WALKING ABILITY
Shiro Imagama
Favorite
Imura, Yoshinori

Osaka University Graduate School of Medicine/Orthopaedic Surgery
(P 05) DEVELOPMENT OF SARCOMA ORGANOID MODELS WITH AIR-LIQUID INTERFACE ORGANOID CULTURES
Yoshinori Imura
Favorite
(P 324) BENZIMIDAZOLE DERIVATIVES AS NOVEL THERAPEUTIC AGENTS FOR INI1-DEFICIENT EPITHELIOID SARCOMA
Yoshinori Imura
Favorite
(P 387) SUCCESSFUL PAZOPANIB TREATMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA WITH COAMPLIFICATION OF PDGFRA, VEGFR2, AND KIT: A CASE REPORT
Yoshinori Imura
Favorite
Ingley, Katrina

University College London Hospital
(P 185) ADDRESSING THE GAP FOR SYMPTOM CONTROL THROUGH THE IMPLEMENTATION OF ENHANCED SUPPORTIVE CARE AT THE LONDON SARCOMA SERVICE
Katrina Ingley
Favorite
Ingram, Davis

MD Anderson Cancer Center
(P 325) CAN PROTEOMICS PREDICT METASTATIC RELAPSE IN LEIOMYOSARCOMA? DEVELOPMENT OF AN 8 PROTEIN SIGNATURE IN A >350 SAMPLE STUDY INCLUDING A VALIDATION COHORT
Davis Ingram
Favorite
(P 398) PREDICTORS OF EFFICACY IN PATIENTS WITH SOFT TISSUE SARCOMAS TREATED WITH PAZOPANIB
Davis Ingram
Favorite
Inoue, Akitomo

Osaka University Graduate School of Medicine/Orthopaedic Surgery
(P 324) BENZIMIDAZOLE DERIVATIVES AS NOVEL THERAPEUTIC AGENTS FOR INI1-DEFICIENT EPITHELIOID SARCOMA
Akitomo Inoue
Favorite
Inoue, Satoru

Daiichi Sankyo Co., LTD.
(P 44) TUMOR RESPONSE AND REGROWTH IN RELATION TO CLINICAL EVENTS AMONG PEXIDARTINIB-TREATED SUBJECTS IN THE PHASE 3 ENLIVEN TRIAL
Satoru Inoue
Favorite
(P 400) A LONG-TERM PHASE 4 STUDY TO EVALUATE THE RISK OF HEPATOTOXICITY ASSOCIATED WITH PEXIDARTINIB TREATMENT
Satoru Inoue
Favorite
Iranpur, Khurshid

Division of Surgical Oncology, Department of Surgery, University of California Davis
(P 230) HIGHER BODY MASS INDEX IS ASSOCIATED WITH DECREASED CIRCULATING AND INTRATUMORAL NATURAL KILLER CELLS IN SOFT TISSUE SARCOMA
Khurshid Iranpur
Favorite
Irudayaraj, Joseph

University of Illinois Urbana-Champaign
(P 419) BONE MECHANICS INFLUENCE CANCER STEM CELL FORMATION IN OSTEOSARCOMA
Joseph Irudayaraj
Favorite
Irvin, Boston

University of Miami Miller School of Medicine
(P 296) DISPARITIES IN OVERALL SURVIVAL FOR AYA PATIENTS WITH EWINGS SARCOMA: A RETROSPECTIVE COHORT STUDY AT A SINGLE SARCOMA CENTER
Boston Irvin
Favorite
Isakoff, Michael

Connecticut Children's Medical Center
(P 309) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT SOFT TISSUE SARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Michael Isakoff
Favorite
Ishibashi, Yuki

The University of Tokyo, Department of Orthopaedic Surgery
(P 57) CLINICAL GENOMIC PROFILING OF MALIGNANT GIANT CELL TUMOR OF BONE: A RETROSPECTIVE ANALYSIS USING A REAL-WORLD DATABASE
Yuki Ishibashi
Favorite
(P 103) BRAF MUTATIONS AND CONCURRENT ALTERATIONS IN PATIENTS WITH SOFT TISSUE SARCOMA
Yuki Ishibashi
Favorite
Ishihara, Shin

University of British Columbia
(P 203) IMPACT OF COVID-19 PANDEMIC ON BONE AND SOFT TISSUE SARCOMA PATIENTS' CONSULTATION AND DIAGNOSIS
Shin Ishihara
Favorite
Ishizuka, Jeffrey

Yale New Haven Health
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Jeffrey Ishizuka
Favorite
(P 98) A MULTIEPITOPE MRNA VACCINE FOR KAPOSI SARCOMA: AN IMMUNOINFORMATIC APPROACH
Jeffrey Ishizuka
Favorite
Isler, Marc

CIUSSS Est-de-l'Île-de-Montréal
(P 212) REFERENCE SYSTEM OPTIMIZATION, ANALYSES OF THE IMPLEMENTATION OF A PROVINCIAL MULTIDISCIPLINARY SARCOMA NETWORK
Marc Isler
Favorite
Italiano, Antione

Bergonié Institute
(P 125) CHARACTERISTICS, MANAGEMENT AND SURVIVAL OF N=7314 LIPOSARCOMAS FROM THE NATIONWIDE NETSARC REGISTRY IN FRANCE SINCE 2010
Antione Italiano
Favorite
Itkin, Boris

SQCCCRC
(P 68) FEASIBILITY OF FIVE-DRUG INTERVAL-COMPRESSED CHEMOTHERAPY FOR ADOLESCENTS AND YOUNG ADULTS WITH EWING SARCOMA FAMILY TUMORS IN THE REAL-WORLD SETTING IN OMAN
Boris Itkin
Favorite
(P 193) DISTRIBUTION OF CONNECTIVE TISSUE TUMORS BY HISTOLOGY AND DEGREE OF MALIGNANCY IN A SINGLE INSTITUTION IN OMAN
Boris Itkin
Favorite
Iwata, Shintaro

National Cancer Center Hospital Japan
(P 134) REAL-WORLD CLINICAL OUTCOME OF NEOADJUVANT CHEMOTHERAPY FOR RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA
Shintaro Iwata
Favorite
(P 220) SPORTS ACTIVITIES IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT SURVIVORS OF MALIGNANT BONE SARCOMAS
Shintaro Iwata
Favorite
(P 249) TUMOR CELL DISAPPEARANCE FOLLOWING COVID-19 INFECTION IN A PATIENT WITH PLEOMORPHIC SPINDLE CELL SARCOMA: A CASE REPORT
Shintaro Iwata
Favorite
Ixtlamati-Nava, Diana

Texas Tech University Health Sciences Center
(P 292) CHARACTERIZATION OF TELOMERE MAINTENANCE MECHANISMS IN OSTEOSARCOMA PATIENT-DERIVED LABORATORY MODELS
Diana Ixtlamati-Nava
Favorite
Iyer, Rema

National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
(P 27) SUMO2 INHIBITION REVERSES ABERRANT EPIGENETIC REWIRING DRIVEN BY SYNOVIAL SARCOMA FUSION ONCOPROTEINS AND IMPAIRS SARCOMAGENESIS
Rema Iyer
Favorite
J
Jabado, Nada

McGill University
(P 69) H3.3G34W ONCOHISTONE IN OSTEOSARCOMA
Nada Jabado
Favorite
(P 78) NOVEL EPIGENETIC MECHANISMS DRIVE AGGRESSIVE OSTEOSARCOMA PATHOGENESIS AND DRUG RESISTANCE
Nada Jabado
Favorite
Jacene, Heather

Dana-Farber Cancer Institute
(P 412) SARC044: A PHASE II TRIAL OF BEZUCLASTINIB IN COMBINATION WITH SUNITINIB IN PATIENTS WITH GIST WHO PROGRESSED ON SUNITINIB MONOTHERAPY
Heather Jacene
Favorite
Jackett, Louise

Peter MacCallum Cancer Centre
(P 151) MOLECULAR ANALYSIS OF CUTANEOUS SARCOMATOID NEOPLASMS FREQUENTLY IDENTIFIES MELANOMA DRIVER VARIANTS
Louise Jackett
Favorite
Jadhav, Priyanka

University of California, San Diego
(P 167) DEFINING TEXTBOOK OUTCOMES FOR MINIMALLY INVASIVE SURGICAL RESECTION OF SMALL GASTROINTESTINAL STROMAL TUMORS (GIST) OF THE STOMACH
Priyanka Jadhav
Favorite
Jagodzińska-Mucha, Paulina

Department of Soft Tissue, Bone/Sarcoma, and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
(P 245) PRELIMINARY RESULTS FROM A PHASE 2 EFTISARC-NEO TRIAL OF NEOADJUVANT SOUBLE LAG-3 PROTEIN EFTILAGIMOD ALPHA, PEMBROLIZUMAB, AND CONCURRENT RADIOTHERAPY IN PATIENTS WITH RESECTABLE SOFT TISSUE SARCOMA
Paulina Jagodzińska-Mucha
Favorite
Jagosky, Megan

Levine Cancer Institute
(P 430) QUANTITATIVE EMT GENE SCORES AT DIAGNOSIS INDICATE METASTASIS RISK AND SURVIVAL IN SYNOVIAL SARCOMA
Megan Jagosky
Favorite
Janeway, Katherine

Department of Pediatrics, Dana-Farber / Boston Children’s Cancer and Blood Disorders Center Harvard Medical School
(P 49) A WORKING GROUP FOR THE DEVELOPMENT OF A CLINICAL FRAMEWORK THAT STRATIFIES OSTEOSARCOMA PATIENTS USING BIOMARKERS OF CLINICAL RISK AND BIOLOGY
Katherine Janeway
Favorite
(P 50) ANALYSIS OF CLINICAL FEATURES AND OUTCOMES FOR PATIENTS WITH MULTIFOCAL OSTEOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Katherine Janeway
Favorite
(P 195) ENHANCING PARTICIPANT ENGAGEMENT IN A NOVEL PATIENT-PARTNERED CANCER GENOMICS RESEARCH EFFORT FOR RARE AND AGGRESSIVE SARCOMAS
Katherine Janeway
Favorite
(P 408) OSTEOMYC: A PHASE 2 PILOT STUDY TO EVALIATE THE SAFETY AND THE ANTITUMOR ACTIVITY OF THE MYC INHIBITOR OMO-103 ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH ADVANCED HIGH GRADE OSTEOSARCOMA
Katherine Janeway
Favorite
Jansen, Katrien

UZ Leuven
(P 291) CASE REPORT: RADICAL EN BLOC MULTI-LEVEL SPONDYLECTOMY FOR A LOCALLY RECURRENT OSTEOSARCOMA
Katrien Jansen
Favorite
Jansen, Yanina

UZ Leuven
(P 291) CASE REPORT: RADICAL EN BLOC MULTI-LEVEL SPONDYLECTOMY FOR A LOCALLY RECURRENT OSTEOSARCOMA
Yanina Jansen
Favorite
Jansma, Christianne

Erasmus Medical Center and UMC Utrecht
(P 154) PREOPERATIVE CLASSIFICATION OF NERVE SHEATH TUMORS USING RADIOMICS-BASED MACHINE LEARNING
Christianne Jansma
Favorite
Jarutat, Tiantom

iOmx AG
(P 337) OMX-0407 A NOVEL SPECTRUM-SELECTIVE SMALL MOLECULE KINASE INHIBITOR IS ACTIVE IN THE TREATMENT OF ANGIOSARCOMA
Tiantom Jarutat
Favorite
Jawhar, Wajih

Research Institute of the McGill University Health Center
(P 69) H3.3G34W ONCOHISTONE IN OSTEOSARCOMA
Wajih Jawhar
Favorite
(P 78) NOVEL EPIGENETIC MECHANISMS DRIVE AGGRESSIVE OSTEOSARCOMA PATHOGENESIS AND DRUG RESISTANCE
Wajih Jawhar
Favorite
Jean-Denis, Myriam

Department of Biopathology, CLCC Léon Bérard, Lyon University, Lyon, France & CRCL, University Claude Bernard Lyon 1, Lyon, France
(P 77) MULTI-PARAMETRICAL PROFILING OF CHONDROSARCOMA
Myriam Jean-Denis
Favorite
Jee, Yeseob

Dankook University College of Medicine, Cheonan, Chungnam, Korea
(P 162) ANALYSIS OF 3,144 CASE REPORTS IN THE GASTROINTESTINAL STROMAL TUMOR LITERATURE: IDENTIFICATION OF UNDERAPPRECIATED DEMOGRAPHICS, CLINICAL PRESENTATIONS, AND BIOLOGY
Yeseob Jee
Favorite
Jeffrey, Samantha

Sarcoma Oncology Center
(P 106) DELTAREX-G, A TUMOR TARGETED CCNG1 INHIBITOR, DEMONSTRATES CLINICAL BENEFIT IN ADVANCED CHEMORESISTANT SARCOMA FOLLOWING FDA CBER AUTHORIZATION FOR USE AS PLATFORM THERAPY WITH FDA APPROVED DRUGS
Samantha Jeffrey
Favorite
(P 241) LINNOVATE: A PHASE 1/2 STUDY OF SAFETY/EFFICACY USING LURBINECTEDIN COMBINED WITH IPILUMUMAB AND NIVOLUMAB FOR ADVANCED SOFT TISSUE SARCOMA (NCT05876715)
Samantha Jeffrey
Favorite
(P 248) TNT: A PHASE 2 STUDY USING TALIMOGENE LAHERPAREPVEC, NIVOLUMAB, AND TRABECTEDIN FOR ADVANCED LEIOMYOSARCOMA AND LIPOSARCOMA (NCT # 03886311)
Samantha Jeffrey
Favorite
(P 250) UPDATE ON GALLANT: A PHASE 2 STUDY USING METRONOMIC GEMCITABINE, DOXORUBICIN AND DOCETAXEL PLUS NIVOLUMAB IN PREVIOUSLY TREATED SARCOMA (NCT04535713)
Samantha Jeffrey
Favorite
(P 251) UPDATE ON SAINT: A PHASE 2 STUDY USING TRABECTEDIN (T) IN COMBINATION WITH IPILIMUMAB (L) AND NIVOLUMAB (N) IN PREVIOUSLY TREATED SOFT TISSUE SARCOMA (NCT03138161)
Samantha Jeffrey
Favorite
Jennische, Eva

University of Gothenburg, Department of Medical Biochemistry and Cell Biology
(P 139) CHARACTERIZATION OF GLYCOSPHINGOLIPIDS IN HUMAN LEIOMYOSARCOMA
Eva Jennische
Favorite
Jensen, Michael

BrainChild Bio
(P 226) EARLY EXPERIENCE ON ENLIGHTEN-01: A PHASE 1 STUDY OF BISPECIFIC ADAPTER MOLECULE- CONTROLLED FOLATE RECEPTOR CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY OSTEOSARCOMA
Michael Jensen
Favorite
Jesus-Garcia, Reynaldo

Hospital Israelita Albert Einstein
(P 122) ACTIONABLE FUSIONS IN DEDIFFERENTIATED LIPOSARCOMA: AN ANALYSIS OF 402 CASES IN THE AACR GENIE DATABASE
Reynaldo Jesus-Garcia
Favorite
(P 141) COMPREHENSIVE GENOMIC PROFILING OF PATIENTS DIAGNOSED WITH SARCOMA IN BRAZIL: MOLECULAR PROFILE AND ACTIONABILITY
Reynaldo Jesus-Garcia
Favorite
(P 192) CURRENT SCENARIO OF SARCOMA CLINICAL TRIALS IN SOUTH AMERICA: A REPORT BY THE LACOG SARCOMA GROUP
Reynaldo Jesus-Garcia
Favorite
(P 216) SARCOMA CARE PATHWAYS AND MULTIDISCIPLINARY TUMOR BOARDS IN LATIN AMERICA: AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Reynaldo Jesus-Garcia
Favorite
(P 217) SARCOMA DRUG APPROVALS IN LATIN AMERICA COMPARED TO THE FDA AND EMA: AN ANALYSIS BY THE LACOG SARCOMA GROUP
Reynaldo Jesus-Garcia
Favorite
(P 219) SOCIAL MEDIA USE AMONG MEDICAL PROFESSIONALS THAT TREAT PATIENTS WITH SARCOMA IN LATIN AMERICA: RESULTS OF AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Reynaldo Jesus-Garcia
Favorite
(P 232) IMMUNE CHECKPOINT INHIBITORS COMBINED WITH TYROSINE KINASE INHIBITORS FOR SOFT-TISSUE SARCOMAS: A SYSTEMATIC REVIEW AND SINGLE-ARM META-ANALYSIS
Reynaldo Jesus-Garcia
Favorite
(P 242) MICROSATELLITE INSTABILITY AND CLINICAL USE IN SARCOMAS: A SYSTEMATIC REVIEW
Reynaldo Jesus-Garcia
Favorite
Jiang, Yafei

Department of Orthopedic Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
(P 48) A SINGLE-ARM, OPEN-LABEL CLINICAL STUDY OF OVV-01 ONCOLYTIC VIRUS INJECTION AS MONOTHERAPY OR IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR ADVANCED SOLID TUMOR PATIENTS
Yafei Jiang
Favorite
(P 83) PREDICTION OF HIGH-RISK OSTEOSARCOMA PATIENTS BASED ON MACHINE LEARNING USING TRANSCRIPTOME AND METHYLATION DATA FROM SGH-COHORT
Yafei Jiang
Favorite
(P 90) TARGETING HIGH RISK MYC- AMPLIFIED OSTEOSARCOMA BY AURORA KINASE INHIBITOR--RESULT FROM A NGS BASED UMBRELLA TRIAL
Yafei Jiang
Favorite
(P 93) THE PROTEOGENOMIC SUBTYPING OF OSTEOSARCOMA
Yafei Jiang
Favorite
Jimenez, Marta

Unicancer
(P 82) PLASMA CIRCULATING PROTEOMIC MARKERS ARE ASSOCIATED WITH METASTATIC SPREAD AND OUTCOME IN OSTEOSARCOMA
Marta Jimenez
Favorite
Jin, Chunsheng

University of Gothenburg, Department of Medical Biochemistry and Cell Biology
(P 139) CHARACTERIZATION OF GLYCOSPHINGOLIPIDS IN HUMAN LEIOMYOSARCOMA
Chunsheng Jin
Favorite
Jin, Guangxu

Wake Forest
(P 430) QUANTITATIVE EMT GENE SCORES AT DIAGNOSIS INDICATE METASTASIS RISK AND SURVIVAL IN SYNOVIAL SARCOMA
Guangxu Jin
Favorite
Jing, Weiqing

Northwestern University, Feinberg School of Medicine
(P 222) ANALYSIS OF THE CITN-13 SARCOMA ARM: PEMBROLIZUMAB AND INTERFERON GAMMA FOR SYNOVIAL SARCOMA AND MYXOID/ ROUND CELL LIPOSARCOMA
Weiqing Jing
Favorite
(P 235) INFILTRATION OF MUCOSAL-ASSOCIATED INVARIANT T CELLS (MAITS) INTO CHONDROSARCOMA TUMORS
Weiqing Jing
Favorite
Jin, JinJi

Department of Gastrointestinal Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
(P 164) CLINICAL BENEFITS OF RIPRETINIB AND CYTOREDUCTIVE SURGERY IN IMATINIB-RESISTANT ADVANCED GASTROINTESTINAL STROMAL TUMORS (GISTS): A RETROSPECTIVE DUAL-CENTER STUDY
JinJi Jin
Favorite
Johnson, Daniel

Vanderbilt University Medical Center
(P 265) IS THERE AN IDEAL STEM TO CANAL RATIO IN LOWER EXTREMITY ONCOLOGIC ENDOPROSTHESIS RECONSTRUCTION?
Daniel Johnson
Favorite
Johnson, Shavaughn

Cleveland Clinic
(P 351) OSTEOSARCOMA STEREOTACTIC BODY RADIOTHERAPY: OUTCOMES AND PATTERN OF FAILURE
Shavaughn Johnson
Favorite
Johnson, Shelby

Medical Research Scholars Program (MRSP), National Institutes of Health
(P 163) CHARACTERIZATION OF INTRAHEPATIC RECURRENCE FOLLOWING LIVER-DIRECTED SURGERY IN PATIENTS WITH METASTATIC SDH-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST): RISE AND STABILIZATION OF THE GISTLETS
Shelby Johnson
Favorite
Johnstone, Sarah

Dana-Farber Cancer Institute
(P 371) ELUCIDATING THE CLINICAL UTILITY OF TARGETED GENE EXPRESSION PROFILING IN RETROPERITONEAL LIPOSARCOMA
Sarah Johnstone
Favorite
Jolivet, Philippe

McGill University
(P 17) IDENTIFICATION OF MARKERS PREDICTIVE OF RESPONSE TO GEMCITABINE AND DOCETAXEL IN LEIOMYOSARCOMA THROUGH MIRNA SEQUENCING
Philippe Jolivet
Favorite
Jonczak, Emily

University of Miami, Sylvester Comprehensive Cancer Center
(P 224) COMPREHENSIVE EVALUATION OF DNA DAMAGE RESPONSE PATHWAY ALTERATIONS AND ASSOCIATED IMMUNOTHERAPY-RESPONSE BIOMARKERS IN SARCOMAS
Emily Jonczak
Favorite
(P 253) ASSESSING THE LINK BETWEEN MYXOFIBROSARCOMA RECURRENCE AND TREATMENT ORDER: A MULTIDISCIPLINARY RETROSPECTIVE COHORT STUDY
Emily Jonczak
Favorite
(P 296) DISPARITIES IN OVERALL SURVIVAL FOR AYA PATIENTS WITH EWINGS SARCOMA: A RETROSPECTIVE COHORT STUDY AT A SINGLE SARCOMA CENTER
Emily Jonczak
Favorite
Jonczak, Emily

Sylvester Comprehensive Cancer Center / University of Miami Hospital and Clinics
(P 314) RETROSPECTIVE EVALUATION OF DISPARITIES IN ADOLESCENT AND YOUNG ADULT (AYA) PATIENTS WITH SYNOVIAL SARCOMA: A SINGLE INSTITUTION STUDY
Emily Jonczak
Favorite
Jonczak, Emily

University of Miami, Sylvester Comprehensive Cancer Center
(P 358) RADIOMIC EVALUATION OF MRIS IN PATIENTS WITH SOFT TISSUE SARCOMA TREATED WITH STEREOTACTIC BOSY RADIATION THERAPY
Emily Jonczak
Favorite
(P 381) OLIGOMETASTATIC LEIOMYOSARCOMA: ASSOCIATION BETWEEN TREATMENT TYPE, METASTATIC PATTERN AND SURVIVAL
Emily Jonczak
Favorite
Jones, Conor

Rush University Medical Center
(P 270) OPIOID USE IN IMPENDING VERSUS PATHOLOGIC PROXIMAL FEMUR FRACTURES
Conor Jones
Favorite
Jones, Emily

National Disease Registration Service, NHS England
(P 60) DIAGNOSIS AND MANAGEMENT OF PAEDIATRIC EWING SARCOMA PATIENTS IN ENGLAND 2014-2017: A COMPARISON OF NATIONAL DATA WITH THE EURO-EWING 2012 CLINICAL TRIAL
Emily Jones
Favorite
Jones, Kevin

Department of Orthopaedics, University of Utah
(P 332) ENHANCING THERAPEUTIC EFFICACY IN SYNOVIAL SARCOMA BY TARGETING P53-MDM2 AXIS AND HDAC PATHWAYS
Kevin Jones
Favorite
(P 343) TLE1 DISRUPTION DOES NOT IMPEDE SYNOVIAL SARCOMAGENESIS
Kevin Jones
Favorite
Jones, Paul

Washington University
(P 149) LACK OF CORRELATION OF FDG-PET/CT SUV MAXIMUM AND MALIGNANT TRANSFORMATION IN NEUROFIBROMATOSIS TYPE 1-RELATED PLEXIFORM NEUROFIBROMAS
Paul Jones
Favorite
Jones, Robin

Sarcoma Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research
(P 23) METASTATIC ALVEOLAR SOFT PART SARCOMA: PREGNANCY-RELATED WORSENING AND SPONTANEOUS EXCEPTIONAL REMISSION POSTPARTUM- A CASE REPORT.
Robin Jones
Favorite
(P 87) SAFETY AND EFFICACY OF OLUTASIDENIB, AN IDH1 MUTANT INHIBITOR, FOR THE TREATMENT OF RECURRENT/ RELAPSED LOCALLY ADVANCED OR METASTATIC IDH1 MUTATED CHONDROSARCOMA
Robin Jones
Favorite
(P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE
Robin Jones
Favorite
(P 183) A RETROSPECTIVE STUDY OF THE EFFECTS OF PATIENT, DISEASE, AND TREATMENT FACTORS ON SURVIVAL OUTCOMES IN PATIENTS WITH SOFT TISSUE SARCOMA BRAIN METASTASES
Robin Jones
Favorite
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Robin Jones
Favorite
(P 401) A PHASE 3 MULTI-CENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO ASSESS THE EFFICACY AND SAFETY OF EMACTUZUMAB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR (TANGENT)
Robin Jones
Favorite
(P 429) PATIENTS WITH ADVANCED EPITHELIOID HEMANGIOENDOTHELIOMA TREATED WITH SIROLIMUS: OUTCOME FOLLOWING SIROLIMUS DISCONTINUATION.
Robin Jones
Favorite
Joo, Min Wook

The Catholic University of Korea
(P 218) SEX DIFFERENCES IN THE ASSOCIATION OF ALCOHOL INTAKE WITH THE RISK OF SOFT-TISSUE SARCOMA: A NATIONWIDE POPULATION-BASED RETROSPECTIVE COHORT STUDY
Min Wook Joo
Favorite
Joyce, David

Moffitt Cancer Center
(P 150) MODERN BIOPSY PRACTICE PATTERNS: A SURVEY OF THE MSTS MEMBERSHIP
David Joyce
Favorite
(P 257) COMPARATIVE OUTCOMES OF CONSTRAINED ACETABULAR LINERS VS. DUAL MOBILITY CUPS IN COMPLEX HIP RECONSTURCTION FOR METASTATIC BONE DISEASE
David Joyce
Favorite
(P 262) EVALUATION OF STAGED RESECTION WITH TEMPORIZING VAC OF SOFT TISSUE SARCOMAS
David Joyce
Favorite
(P 279) SIGNIFICANCE OF TIP-APEX DISTANCE IN ACTUAL AND IMPENDING PATHOLOGICAL FRACTURES OF THE PROXIMAL FEMUR
David Joyce
Favorite
(P 347) CAN UPFRONT RADIOTHERAPY PRECLUDE THE NEED FOR OPERATIVE STABILIZATION IN IMPENDING EXTREMITY FRACTURES FROM LUNG CANCER METASTASES?
David Joyce
Favorite
Joyce, Molly

Oregon Health & Science University
(P 223) ASSOCIATION OF POSTOPERATIVE INFECTION (POI) WITH SOFT TISSUE SARCOMA (STS) RESECTION OUTCOMES
Molly Joyce
Favorite
Jude Michael, Michelle

Princess Margaret Cancer Center
(P 153) PATTERNS, MANAGEMENT AND SURVIVAL OUTCOMES OF PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA: A NATIONWIDE ANALYSIS FROM THE CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION DATABASE
Michelle Jude Michael
Favorite
Judge, Charlotte

National Disease Registration Service, NHS England
(P 60) DIAGNOSIS AND MANAGEMENT OF PAEDIATRIC EWING SARCOMA PATIENTS IN ENGLAND 2014-2017: A COMPARISON OF NATIONAL DATA WITH THE EURO-EWING 2012 CLINICAL TRIAL
Charlotte Judge
Favorite
Judge, Sean

Department of Surgery, Memorial Sloan Kettering Cancer Center
(P 230) HIGHER BODY MASS INDEX IS ASSOCIATED WITH DECREASED CIRCULATING AND INTRATUMORAL NATURAL KILLER CELLS IN SOFT TISSUE SARCOMA
Sean Judge
Favorite
Jung, Wonkyung

Lunit
(P 123) ARTIFICIAL INTELLIGENCE-POWERED MITOSIS EVALUATION TO COMPLEMENT HUMAN MITOTIC RATE INTERPRETATION IN PREDICTING PROGNOSIS IN LIPOSARCOMA
Wonkyung Jung
Favorite
Junker, Niels

Department of Oncology, Copenhagen University Hospital, Herlev & Gentofte Hospital
(P 104) CIRQUESARC: A NATIONAL PROSPECTIVE OBSERVATIONAL STUDY OF CIRCULATING TUMOR DNA AND QUALITY OF LIFE IN PATIENTS WITH SARCOMA – PRELIMINARY RESULTS FROM THE SURGICAL COHORT
Niels Junker
Favorite
(P 243) MYELOSUPPRESSION FOLLOWING LYMPHODEPLETING CHEMOTHERAPY AS PART OF ADOPTIVE CELL THERAPY FOR PATIENTS WITH PROGRESSIVE SOFT TISSUE SARCOMA AFTER STANDARD CHEMOTHERAPY
Niels Junker
Favorite
(P 411) PROPANE AN OPEN LABEL PHASE 2 STUDY ON PROPRANOLOL AND PEMBROLIZUMAB IN ADVANCED ANGIOSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA A SCANDINAVIAN SARCOMA GROUP COLLABORATION
Niels Junker
Favorite
Just, Marissa

Division of Pediatric Hematology/Oncology, Riley Hospital for Children
(P 287) AN INTERNATIONAL SURVEY OF PROVIDER PRACTICES REGARDING BONE MARROW SAMPLING VERSUS [18F] FDG PET/CT IN THE DIAGNOSTIC EVALUATION OF BONE MARROW METASTASIS IN PEDIATRIC RHABDOMYOSARCOMA
Marissa Just
Favorite
Jutte, Paul

University Medical Center Groningen
(P 274) PROXIMAL HUMERAL ENDOPROSTHETIC RECONSTRUCTION: RESULTS FROM THE MUTARS ORTHOPEDIC REGISTRY EUROPE (MORE)
Paul Jutte
Favorite
(P 319) THE SURVIVAL DISPARITY BETWEEN CHILDREN AND ADOLESCENTS & YOUNG ADULTS WITH EWING SARCOMA IN THE NETHERLANDS DID NOT CHANGE SINCE THE 1990S DESPITE IMPROVED SURVIVAL: A POPULATION-BASED STUDY
Paul Jutte
Favorite
K
Kaal, Suzanne

Radboud University Medical Center
(P 319) THE SURVIVAL DISPARITY BETWEEN CHILDREN AND ADOLESCENTS & YOUNG ADULTS WITH EWING SARCOMA IN THE NETHERLANDS DID NOT CHANGE SINCE THE 1990S DESPITE IMPROVED SURVIVAL: A POPULATION-BASED STUDY
Suzanne Kaal
Favorite
Kaczkofsky, Brynn

University of Michigan
(P 131) HETEROGENEITY OF THE IMMUNE MICROENVIRONMENT AND IMMUNOTHERAPY RESPONSE IN A DEDIFFERENTIATED LIPOSARCOMA MOUSE MODEL
Brynn Kaczkofsky
Favorite
(P 341) THE EFFECTS OF ULTRASOUND-GUIDED HISTOTRIPSY ON SOFT TISSUE SARCOMA
Brynn Kaczkofsky
Favorite
Kage, Hidenori

The University of Tokyo, Department of Respiratory Medicine
(P 103) BRAF MUTATIONS AND CONCURRENT ALTERATIONS IN PATIENTS WITH SOFT TISSUE SARCOMA
Hidenori Kage
Favorite
Kahraman, Abdullah

SwissSarcomaNetwork
(P 184) A SYSTEMATIC REVIEW ABOUT CLINICAL PROGNOSTIC MODELS FOR SARCOMAS
Abdullah Kahraman
Favorite
Kakunaga, Shigeki

Osaka International Cancer Institute
(P 05) DEVELOPMENT OF SARCOMA ORGANOID MODELS WITH AIR-LIQUID INTERFACE ORGANOID CULTURES
Shigeki Kakunaga
Favorite
(P 96) TRACP-5B AS A BIOMARKER FOR LONG-TERM DENOSUMAB TREATMENT OF UNRESECTABLE GIANT CELL TUMOR OF BONE
Shigeki Kakunaga
Favorite
(P 272) OUTCOMES OF FOUR CASES OF TOTAL HIP ARTHROPLASTY (THA) WITH POROUS TANTALUM IMPLANT AFTER PARTIAL ACETABULAR RESECTION USING 3D PREOPERATIVE PLANNING FOR PELVIC BONE TUMORS
Shigeki Kakunaga
Favorite
(P 283) USE OF MIXED REALITY IN PELVIC BONE TUMOR RESECTION: FIVE CASE STUDY
Shigeki Kakunaga
Favorite
(P 387) SUCCESSFUL PAZOPANIB TREATMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA WITH COAMPLIFICATION OF PDGFRA, VEGFR2, AND KIT: A CASE REPORT
Shigeki Kakunaga
Favorite
Kalabus, James

Inhibrx Biosciences, Inc
(P 95) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN PATIENTS WITH CHONDROSARCOMA: UPDATED RESULTS FROM A PHASE 1 STUDY
James Kalabus
Favorite
Kamal, Kousha

University of Toronto
(P 326) CELL-FREE DNA AS A BIOMARKER FOR CELL DEATH AND TREATMENT RESPONSE IN ON-CHIP THREE-DIMENSIONAL SARCOMA TUMOR MODELS
Kousha Kamal
Favorite
KAMODA, Hiroto

Chiba Cancer Center
(P 275) RECONSTRUCTION WITH A BURCH-SCHNEIDER CAGE AFTER BONE AND SOFT TISSUUE TUMOR SURGERY
Hiroto KAMODA
Favorite
Kanahori, Masaya

Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University
(P 203) IMPACT OF COVID-19 PANDEMIC ON BONE AND SOFT TISSUE SARCOMA PATIENTS' CONSULTATION AND DIAGNOSIS
Masaya Kanahori
Favorite
Kane, Kathleen

Bone Cancer Research Trust
(P 196) ESTABLISHING THE BONE CANCER RESEARCH TRUST'S PATIENT & PUBLIC INVOLVEMENT PANEL
Kathleen Kane
Favorite
Kang, H. Paco

Department of Orthopaedic Surgery, Keck School of Medicine of the University of Southern California
(P 197) EVALUATION OF REVIEWS OF ORTHOPAEDIC ONCOLOGISTS ON INSTITUITIONAL AND PATIENT REVIEW WEBSITES
H. Paco Kang
Favorite
Kang, Hakmook

Vanderbilt University Medical Center
(P 73) LONGER TIME INTERVAL BETWEEN NEOADJUVANT CHEMOTHERAPY AND SURGERY IS ASSOCIATED WITH DECREASED TUMOR PERCENT NECROSIS IN OSTEOSARCOMA
Hakmook Kang
Favorite
(P 264) INTRAOPERATIVE FROZEN BONE MARROW MARGINS: A HELP OR A HINDRANCE IN EWING SARCOMA RESECTION?
Hakmook Kang
Favorite
(P 265) IS THERE AN IDEAL STEM TO CANAL RATIO IN LOWER EXTREMITY ONCOLOGIC ENDOPROSTHESIS RECONSTRUCTION?
Hakmook Kang
Favorite
(P 268) LOWER TUMOR PERCENT NECROSIS IS ASSOCIATED WITH POSITIVE FINAL SURGICAL MARGINS IN OSTEOSARCOMA
Hakmook Kang
Favorite
(P 404) ENHANCED RECOVERY AFTER SURGERY (ERAS) PROTOCOL FOR PATENTS WITH SOFT TISSUE SARCOMA OF THE EXTREMITY: A PROSPECTIVE, NON-RANDOMIZED, CONSECUTIVELY ENROLLED TRIAL
Hakmook Kang
Favorite
Kang, Mingu

Lunit
(P 123) ARTIFICIAL INTELLIGENCE-POWERED MITOSIS EVALUATION TO COMPLEMENT HUMAN MITOTIC RATE INTERPRETATION IN PREDICTING PROGNOSIS IN LIPOSARCOMA
Mingu Kang
Favorite
Kang, Yoon-Koo

Asan Medical Center, University of Ulsan College of Medicine
(P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE
Yoon-Koo Kang
Favorite
Kaplan, Rosandra

National Cancer Institute
(P 414) TENOSYNOVIAL GIANT CELL TUMOR IN CHILDREN: INTERIM RESULTS FROM A PHASE 1 STUDY OF TURALIO®
Rosandra Kaplan
Favorite
Karadimas, Thomas

USF Health Morsani College of Medicine
(P 262) EVALUATION OF STAGED RESECTION WITH TEMPORIZING VAC OF SOFT TISSUE SARCOMAS
Thomas Karadimas
Favorite
Karadimas, Thomas

University of South Florida Morsani College of Medicine
(P 263) HEMI- VS. REVERSE SHOULDER ARTHROPLASTY OUTCOMES FOLLOWING PROXIMAL HUMERAL ONCOLOGIC RESECTION
Thomas Karadimas
Favorite
(P 347) CAN UPFRONT RADIOTHERAPY PRECLUDE THE NEED FOR OPERATIVE STABILIZATION IN IMPENDING EXTREMITY FRACTURES FROM LUNG CANCER METASTASES?
Thomas Karadimas
Favorite
Karakis, Carson

The Ohio State University
(P 136) TARGETING MIR-138-5P TO TREAT DEDIFFERENTIATED LIPOSARCOMA
Carson Karakis
Favorite
Karim-Kos, Henrike

Princess Máxima Center for pediatric oncology
(P 319) THE SURVIVAL DISPARITY BETWEEN CHILDREN AND ADOLESCENTS & YOUNG ADULTS WITH EWING SARCOMA IN THE NETHERLANDS DID NOT CHANGE SINCE THE 1990S DESPITE IMPROVED SURVIVAL: A POPULATION-BASED STUDY
Henrike Karim-Kos
Favorite
Karim, Rooshdiya

Royal Prince Alfred Hospital-Labs-Anatomical Pathology
(P 325) CAN PROTEOMICS PREDICT METASTATIC RELAPSE IN LEIOMYOSARCOMA? DEVELOPMENT OF AN 8 PROTEIN SIGNATURE IN A >350 SAMPLE STUDY INCLUDING A VALIDATION COHORT
Rooshdiya Karim
Favorite
Kashyap, Jayanth

University of Pittsburgh School of Medicine
(P 256) CHARACTERIZING ORTHOPAEDIC ONCOLOGIC POLYTRAUMAS: A COMPARISON OF PATIENTS UNDERGOING OPERATIVE FIXATION OF MULTIPLE LESIONS WITH THOSE WITH SOLITARY LESIONS
Jayanth Kashyap
Favorite
(P 258) COMPARING OUTCOMES FOLLOWING INTRALESIONAL VERSUS WIDE RESECTION PROCEDURES IN THE TREATMENT OF RENAL CELL CARCINOMA BONE METASTASES
Jayanth Kashyap
Favorite
(P 353) PREDICTING WOUND COMPLICATIONS FOLLOWING SOFT-TISSUE SARCOMA RESECTION AMONG PATIENTS WHO RECEIVED PRE-OPERATIVE RADIATION
Jayanth Kashyap
Favorite
Kasper, Bernd

University of Heidelberg, Mannheim University Medical Center, Mannheim Cancer Center (MCC)
(P 33) DESCRIPTIVE EVALUATION OF PATIENTS WITH DESMOID TUMOR AND CO-OCCURRING SOMATIC MUTATIONS OF CTNNB1 AND APC IN THE PHASE 3 DEFI TRIAL
Bernd Kasper
Favorite
Kasper, Bernd

Mannheim University Medical Center
(P 201) GLOBAL CROSS-SECTIONAL SURVEY ON SARCOMA DIAGNOSIS PATHWAY: A CURRENT STATE ANALYSIS
Bernd Kasper
Favorite
Kaths, Moritz

University Hospital Essen, Sarcoma Centre
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Moritz Kaths
Favorite
Kawaguchi, Kengo

Kyushu University
(P 203) IMPACT OF COVID-19 PANDEMIC ON BONE AND SOFT TISSUE SARCOMA PATIENTS' CONSULTATION AND DIAGNOSIS
Kengo Kawaguchi
Favorite
Kawai, Akira

National Cancer Center Hospital Japan
(P 134) REAL-WORLD CLINICAL OUTCOME OF NEOADJUVANT CHEMOTHERAPY FOR RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA
Akira Kawai
Favorite
(P 220) SPORTS ACTIVITIES IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT SURVIVORS OF MALIGNANT BONE SARCOMAS
Akira Kawai
Favorite
(P 249) TUMOR CELL DISAPPEARANCE FOLLOWING COVID-19 INFECTION IN A PATIENT WITH PLEOMORPHIC SPINDLE CELL SARCOMA: A CASE REPORT
Akira Kawai
Favorite
Kawamura, Miyuki

Hyogo Cancer Center
(P 168) EFFICACY OF LOW-DOSE IMATINIB IN A PATIENT WITH A GIST WITH KIT EXON 11 W557_K558 DELETION
Miyuki Kawamura
Favorite
Kazemi, Mobina

Arnie Charbonneau Cancer Institute
(P 422) COMPARISON OF ANNOTATION METHODS FOR PAN-SARCOMA SINGLE CELL DATA
Mobina Kazemi
Favorite
Keedy, Vicki

Vanderbilt Ingram Cancer Center
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Vicki Keedy
Favorite
Keedy, Vicki

Vanderbilt University Medical Center
(P 199) FINANCIAL TOXICITY AMONG SARCOMA PATIENTS AND ASSOCIATED FACTORS
Vicki Keedy
Favorite
(P 297) ESTABLISHING A PEDIATRIC, ADOLESCENT AND YOUNG ADULT COHORT OF SARCOMA PATIENTS TO STUDY ONCOLOGIC AND NON-ONCOLOGIC OUTCOMES
Vicki Keedy
Favorite
Keegan, Theresa

University of California Davis
(P 205) MULTI-MODAL TREATMENT IS ASSOCIATED WITH IMPROVED SURVIVAL IN AYA PATIENTS WITH METASTATIC NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA
Theresa Keegan
Favorite
(P 356) RADIATION PRACTICE PATTERNS AND OUTCOMES IN ADOLESCENT YOUNG ADULT PATIENTS WITH VISCERAL NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA
Theresa Keegan
Favorite
Keisch, Martin

University of Miami
(P 346) BRACHYTHERAPY FOR SOFT TISSUE SARCOMA: MAINTAINING LOCAL CONTROL WHILE MINIMIZING COMPLICATIONS
Martin Keisch
Favorite
Keit, Emily

Moffitt Cancer Center
(P 347) CAN UPFRONT RADIOTHERAPY PRECLUDE THE NEED FOR OPERATIVE STABILIZATION IN IMPENDING EXTREMITY FRACTURES FROM LUNG CANCER METASTASES?
Emily Keit
Favorite
Kelany, Mohamed

Ain Shams University Faculty of Medicine
(P 191) CLINICOPATHOLOGICAL CHARACTERISTICS OF ANGIOSARCOMA AND THE RISK OF MULTIPLE PRIMARY MALIGNANCIES
Mohamed Kelany
Favorite
Kelly, Ciara

Memorial Sloan Kettering Cancer Center
(P 101) AN OPEN LABEL PHASE IIA STUDY EVALUATING THE PRELIMINARY EFFICACY OF INTRATUMORAL TIGILANOL TIGLATE (TT) IN ADVANCED AND/OR METASTATIC SOFT TISSUE SARCOMA (STS, NCT05755113)
Ciara Kelly
Favorite
(P 121) ACQUIRED CYCLIN D AMPLIFICATION IS A MECHANISM FOR RESISTANCE TO CDK4/6 INHIBITORS IN DEDIFFERENTIATED LIPOSARCOMA
Ciara Kelly
Favorite
(P 229) EXPRESSION OF TRANSPOSABLE ELEMENTS AND IKZF1 PREDICTS IMMUNE INFILTRATES IN SARCOMAS AND CORRELATES WITH OUTCOMES AFTER IMMUNE CHECKPOINT INHIBITION
Ciara Kelly
Favorite
Kenna, Emma

University of Michigan
(P 131) HETEROGENEITY OF THE IMMUNE MICROENVIRONMENT AND IMMUNOTHERAPY RESPONSE IN A DEDIFFERENTIATED LIPOSARCOMA MOUSE MODEL
Emma Kenna
Favorite
(P 341) THE EFFECTS OF ULTRASOUND-GUIDED HISTOTRIPSY ON SOFT TISSUE SARCOMA
Emma Kenna
Favorite
Keohan, Mary Lou

Memorial Sloan Kettering Cancer Center
(P 121) ACQUIRED CYCLIN D AMPLIFICATION IS A MECHANISM FOR RESISTANCE TO CDK4/6 INHIBITORS IN DEDIFFERENTIATED LIPOSARCOMA
Mary Lou Keohan
Favorite
(P 229) EXPRESSION OF TRANSPOSABLE ELEMENTS AND IKZF1 PREDICTS IMMUNE INFILTRATES IN SARCOMAS AND CORRELATES WITH OUTCOMES AFTER IMMUNE CHECKPOINT INHIBITION
Mary Lou Keohan
Favorite
Kephart, Ellen

University of California- Santa Cruz
(P 295) DEFINING OSTEOSARCOMA HETEROGENEITY: CONSENSUS CLUSTERING REVEALS GENE EXPRESSION SUBTYPES
Ellen Kephart
Favorite
Kersch, Cymon

Oregon Health and Science University
(P 359) RAPIDLY PROGRESSIVE, NON-METASTATIC, CUTANEOUS ANGIOSARCOMA OF FACE AND SCALP TREATED WITH HYPOFRACTIONATED RADIATION THERAPY: A CASE SERIES
Cymon Kersch
Favorite
Kessler, Peter

Maastricht University Medical Center
(P 42) RANKL-INHIBITION FOR GIANT CELL LESIONS OF THE JAW: A RETROSPECTIVE COHORT ANALYSIS
Peter Kessler
Favorite
Keung, Emily

MD Anderson Cancer Center
(P 130) HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RESECTABLE RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA (DDLPS) TREATED WITH NEOADJUVANT CHECKPOINT BLOCKADE IN A RANDOMIZED PHASE II CLINICAL TRIAL.
Emily Keung
Favorite
(P 233) IMMUNE CLASSES OF LEIOMYOSARCOMA DRIVEN BY B CELL INFILTRATE AND CTLA4 EXPRESSION
Emily Keung
Favorite
(P 360) TREATMENT OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR WITH BROMODOMAIN EXTRA TERMINAL INHIBITOR (BETI) IN COMBINATION WITH RADIOTHERAPY
Emily Keung
Favorite
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Emily Keung
Favorite
Keymeulen, Kristien

Maastricht University Medical Center
(P 361) WOUND COMPLICATIONS AFTER SOFT TISSUE SARCOMA RESECTION: A SINGLE-CENTER RETROSPECTIVE ANALYSIS
Kristien Keymeulen
Favorite
Khalaj, Andrew

Dana-Farber Cancer Institute
(P 195) ENHANCING PARTICIPANT ENGAGEMENT IN A NOVEL PATIENT-PARTNERED CANCER GENOMICS RESEARCH EFFORT FOR RARE AND AGGRESSIVE SARCOMAS
Andrew Khalaj
Favorite
Khalili, Korosh

Princess Margaret Cancer Centre
(P 376) IMPACT OF SITE OF ORIGIN ON THE PROGNOSIS OF PATIENTS WITH PRIMARY RESECTABLE NON-UTERINE ABDOMINAL LEIOMYOSARCOMA
Korosh Khalili
Favorite
Khalil, Moustafa

Hospital Maisonneuve-Rosment, University of Montreal
(P 394) IDENTIFYING THE INTERACTOME OF THE ONCOGENIC FUSIONS OF SARCOMAS TO REVEAL NOVEL THERAPEUTIC TARGETS
Moustafa Khalil
Favorite
Khanna, Chand

Ethos Discovery
(P 115) PROSPECTIVE EVALUATION OF THORACOSCOPIC METASTASECTOMY IN DOGS: A NOVEL TRANSLATIONAL DRUG DEVELOPMENT PIPELINE TAGETING METASTATIC OSTEOSARCOMA
Chand Khanna
Favorite
(P 408) OSTEOMYC: A PHASE 2 PILOT STUDY TO EVALIATE THE SAFETY AND THE ANTITUMOR ACTIVITY OF THE MYC INHIBITOR OMO-103 ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH ADVANCED HIGH GRADE OSTEOSARCOMA
Chand Khanna
Favorite
Khan, Omar

Cumming School of Medicine, University of Calgary
(P 174) INCIDENCE, TREATMENT PATTERNS, AND SURVIVAL OUTCOMES FOR ADULT PATIENTS WITH GASTROINTESTINAL STROMAL TUMOURS (GIST) IN ALBERTA, CANADA FROM 2008 - 2022.
Omar Khan
Favorite
Khan, Omar

Tom Baker Cancer Center
(P 293) CIC-REARRANGED SOFT TISSUE SARCOMAS: DOES CHEMOTHERAPY CHANGE NATURAL HISTORY AND PROGNOSIS? A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Omar Khan
Favorite
Khare, Mansi

University of California Santa Cruz, Molecular Cell and Developmental Biology, Genomics Institute
(P 156) PROFILING SYNOVIAL SARCOMA EXTRACELLULAR VESICLES FOR DIAGNOSTIC RNA BIOMARKERS
Mansi Khare
Favorite
KHNEISSER, Pierre

Gustave Roussy
(P 53) CHARACTERIZING THE SPATIAL TRANSCRIPTOMIC LANDSCAPE OF OSTEOSARCOMA FROM DIAGNOSIS TO RELAPSE
Pierre KHNEISSER
Favorite
Kholodovsky, Eric

University of Miami
(P 282) UNPLANNED RESECTION OF SOFT TISSUE SARCOMA: THE IMPACT OF RESIDUAL DISEASE IN RE-RESECTION SPECIMEN
Eric Kholodovsky
Favorite
(P 346) BRACHYTHERAPY FOR SOFT TISSUE SARCOMA: MAINTAINING LOCAL CONTROL WHILE MINIMIZING COMPLICATIONS
Eric Kholodovsky
Favorite
Khosroyani, Homma

OHSU Knight Cancer Institute
(P 177) PREDICTING THE IMATINIB RESPONSE OF PDGFRA EXON 18-MUTANT GASTROINTESTINAL STROMAL TUMOR USING IN VITRO MODELS
Homma Khosroyani
Favorite
Kim, Hak Jae

Seoul National University Hospital
(P 428) OLIGOMETASTASES IN EXTREMITY SOFT TISSUE SARCOMA : SUBTYPE-SPECIFIC ANALYSES OF CHARACTERISTICS AND OUTCOMES
Hak Jae Kim
Favorite
Kim, Han-soo

Seoul National University Hospital
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Han-soo Kim
Favorite
(P 127) DEDIFFERENTIATED LIPOSARCOMA OF THE EXTREMITIES: A KOREAN MULTI-CENTER STUDY OF 107 CASES
Han-soo Kim
Favorite
(P 428) OLIGOMETASTASES IN EXTREMITY SOFT TISSUE SARCOMA : SUBTYPE-SPECIFIC ANALYSES OF CHARACTERISTICS AND OUTCOMES
Han-Soo Kim
Favorite
Kim, Jae-Weon

, Seoul National University College of Medicine, Seoul (Republic of Korea);
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Jae-Weon Kim
Favorite
Kim, June Hyuk

National Cancer Center
(P 127) DEDIFFERENTIATED LIPOSARCOMA OF THE EXTREMITIES: A KOREAN MULTI-CENTER STUDY OF 107 CASES
June Hyuk Kim
Favorite
Kim, Kyung Soo

Seoul National University Hospital
(P 428) OLIGOMETASTASES IN EXTREMITY SOFT TISSUE SARCOMA : SUBTYPE-SPECIFIC ANALYSES OF CHARACTERISTICS AND OUTCOMES
Kyung Soo Kim
Favorite
Kim, Miso

Seoul National University Hospital
(P 428) OLIGOMETASTASES IN EXTREMITY SOFT TISSUE SARCOMA : SUBTYPE-SPECIFIC ANALYSES OF CHARACTERISTICS AND OUTCOMES
Miso Kim
Favorite
Kim, Taehee

David Geffen School of Medicine, University of California, Los Angeles
(P 27) SUMO2 INHIBITION REVERSES ABERRANT EPIGENETIC REWIRING DRIVEN BY SYNOVIAL SARCOMA FUSION ONCOPROTEINS AND IMPAIRS SARCOMAGENESIS
Taehee Kim
Favorite
Kim, Wanlim

Asan Medical Center
(P 127) DEDIFFERENTIATED LIPOSARCOMA OF THE EXTREMITIES: A KOREAN MULTI-CENTER STUDY OF 107 CASES
Wanlim Kim
Favorite
Kim, Yongsung

Seoul National University Bundang Hospital
(P 127) DEDIFFERENTIATED LIPOSARCOMA OF THE EXTREMITIES: A KOREAN MULTI-CENTER STUDY OF 107 CASES
Yongsung Kim
Favorite
King, Caitlin

Chordoma Foundation
(P 425) EXPLORING MECHANISMS OF EGFR INHIBITOR RESISTANCE IN CHORDOMA
Caitlin King
Favorite
KINOSHITA, Hideyuki

Chiba Cancer Center
(P 275) RECONSTRUCTION WITH A BURCH-SCHNEIDER CAGE AFTER BONE AND SOFT TISSUUE TUMOR SURGERY
Hideyuki KINOSHITA
Favorite
Kirsch, David

Princess Margaret Cancer Centre
(P 15) HISTONE DEACETYLASE-3 PLAYS A ROLE IN THE METASTATIC POTENTIAL OF A SUBPOPULATION OF CELLS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA
David Kirsch
Favorite
(P 301) GENOME-WIDE CRISPR/CAS9 VIABILITY SCREENS UNCOVER NOVEL GENETIC DEPENDENCIES IN CIC::DUX4 SARCOMA
David Kirsch
Favorite
(P 303) INVESTIGATING THE THERAPEUTIC POTENTIAL OF TRIPTOLIDE PRODRUG, MINNELIDE, AS A TREATMENT ALTERNATIVE FOR CIC-DUX4 SARCOMA
David Kirsch
Favorite
(P 352) OUTCOMES OF PRIMARY INTRATHORACIC SOFT TISSUE SARCOMA
David Kirsch
Favorite
Kirton, Laura

University of Birmingham
(P 60) DIAGNOSIS AND MANAGEMENT OF PAEDIATRIC EWING SARCOMA PATIENTS IN ENGLAND 2014-2017: A COMPARISON OF NATIONAL DATA WITH THE EURO-EWING 2012 CLINICAL TRIAL
Laura Kirton
Favorite
Kishi, Shingo

Nozaki Tokushukai Hospital
(P 85) PTEROSTILBENE SENSITIZES OSTEOSARCOMA CELLS TO KILLING BY C-MYC INHIBITORS
Shingo Kishi
Favorite
Kiyotani, Chikako

National Center for Child Health and Development
(P 220) SPORTS ACTIVITIES IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT SURVIVORS OF MALIGNANT BONE SARCOMAS
Chikako Kiyotani
Favorite
Klein, Alyssa

Boehringer Ingelheim Pharmaceuticals Inc
(P 133) REAL-WORLD ANALYSIS OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS) IN A US COMMUNITY ONCOLOGY SETTING
Alyssa Klein
Favorite
Klein, Jessica

Vanderbilt University School of Medicine
(P 73) LONGER TIME INTERVAL BETWEEN NEOADJUVANT CHEMOTHERAPY AND SURGERY IS ASSOCIATED WITH DECREASED TUMOR PERCENT NECROSIS IN OSTEOSARCOMA
Jessica Klein
Favorite
(P 268) LOWER TUMOR PERCENT NECROSIS IS ASSOCIATED WITH POSITIVE FINAL SURGICAL MARGINS IN OSTEOSARCOMA
Jessica Klein
Favorite
Kleinman, Claudia

McGill university
(P 78) NOVEL EPIGENETIC MECHANISMS DRIVE AGGRESSIVE OSTEOSARCOMA PATHOGENESIS AND DRUG RESISTANCE
Claudia Kleinman
Favorite
Klein, Stefan

Erasmus Medical Center
(P 154) PREOPERATIVE CLASSIFICATION OF NERVE SHEATH TUMORS USING RADIOMICS-BASED MACHINE LEARNING
Stefan Klein
Favorite
Klemen, Nicholas

Surgery Branch, NCI, NIH
(P 231) IDENTIFICATION OF NEOANTIGEN FROM PECOMA-LIKE NEOPLASM PROVIDES RATIONALE FOR TREATMENT WITH CELLULAR THERAPY
Nicholas Klemen
Favorite
Klimeš Lipánová, Michaela

Department of Oncology, 2nd Medical Faculty, Charles University and University Hospital Motol Proton Therapy Center Czech, s.r.o.
(P 355) PROTON RADIOTHERAPY FOR DESMOID TUMORS: A SINGLE-CENTER EXPERIENCE
Michaela Klimeš Lipánová
Favorite
KLop, Cornelis

Amsterdam University Medical Center
(P 42) RANKL-INHIBITION FOR GIANT CELL LESIONS OF THE JAW: A RETROSPECTIVE COHORT ANALYSIS
Cornelis KLop
Favorite
Klymchenko, Andrey

UMR7021 CNRS -Laboratory of Bioimaging and Pathologies
(P 75) METABOLIC EVALUATION OF THE RELATIONSHIP BETWEEN MACROPHAGES AND OSTEOSARCOMA TUMOR CELLS
Andrey Klymchenko
Favorite
Knab, Tim

Metrum Research Group
(P 116) QUANTITATIVE SYSTEMS PHARMACOLOGY MODELING OF MIPASETAMAB UZOPTERINE INTEGRATES KNOWLEDGE AND DEFINES DOSING STRATEGY FOR PATIENTS WITH SARCOMA
Tim Knab
Favorite
Knight, James

School of Natural and Environmental Sciences, Newcastle University, UK
(P 22) MECHANISMS OF PREFERENTIAL TUMOUR UPTAKE OF INDOCYANINE GREEN IN SARCOMA
James Knight
Favorite
Kobayashi, Eisuke

Department of Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital
(P 134) REAL-WORLD CLINICAL OUTCOME OF NEOADJUVANT CHEMOTHERAPY FOR RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA
Eisuke Kobayashi
Favorite
(P 249) TUMOR CELL DISAPPEARANCE FOLLOWING COVID-19 INFECTION IN A PATIENT WITH PLEOMORPHIC SPINDLE CELL SARCOMA: A CASE REPORT
Eisuke Kobayashi
Favorite
Kobayashi, Hiroshi

The University of Tokyo Hospital
(P 57) CLINICAL GENOMIC PROFILING OF MALIGNANT GIANT CELL TUMOR OF BONE: A RETROSPECTIVE ANALYSIS USING A REAL-WORLD DATABASE
Hiroshi Kobayashi
Favorite
(P 103) BRAF MUTATIONS AND CONCURRENT ALTERATIONS IN PATIENTS WITH SOFT TISSUE SARCOMA
Hiroshi Kobayashi
Favorite
(P 220) SPORTS ACTIVITIES IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT SURVIVORS OF MALIGNANT BONE SARCOMAS
Hiroshi Kobayashi
Favorite
Kobbeltvedt, Marthe Rosvoll

Oslo University Hospital
(P 40) PEGYLATED LIPOSOMAL DOXORUBICIN IN SYMPTOMATIC DESMOID TUMOR
Marthe Rosvoll Kobbeltvedt
Favorite
Koch, Regina

Mayo Clinic
(P 120) USING AI PREDICTIONS FROM ECG TRACINGS TO PREDICT TOLERANCE TO ANTHRACYCLINE CHEMOTHERAPY IN SARCOMA
Regina Koch
Favorite
Ko, Christine

Yale University
(P 98) A MULTIEPITOPE MRNA VACCINE FOR KAPOSI SARCOMA: AN IMMUNOINFORMATIC APPROACH
Christine Ko
Favorite
Kocsis, Jenna

Cleveland Clinic
(P 351) OSTEOSARCOMA STEREOTACTIC BODY RADIOTHERAPY: OUTCOMES AND PATTERN OF FAILURE
Jenna Kocsis
Favorite
Koh, Andrew

University of Texas Southwestern Medical Center
(P 417) VITAS: ATEZOLIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY SOLID TUMORS: AN OPEN-LABEL, PHASE I/II, SINGLE-ARM, MULTI-CENTER TRIAL IN PROGRESS
Andrew Koh
Favorite
Koh, Jennifer

ProCan, Children’s Medical Research Institute
(P 325) CAN PROTEOMICS PREDICT METASTATIC RELAPSE IN LEIOMYOSARCOMA? DEVELOPMENT OF AN 8 PROTEIN SIGNATURE IN A >350 SAMPLE STUDY INCLUDING A VALIDATION COHORT
Jennifer Koh
Favorite
Koike, Hiroshi

Nagoya University Hospital
(P 280) SURGICAL OUTCOMES OF PELVIC CHONDROSARCOMA WITH A FOCUS ON WALKING ABILITY
Hiroshi Koike
Favorite
KOLLENDER, YEHUDA

The Israeli Orthopedic Oncology Center
(P 182) A NOVEL MODEL FOR THE DIRECT REFERRAL OF ONCOLOGIC PATIENTS IN A PUBLIC HEALTH CARE SYSTEM
YEHUDA KOLLENDER
Favorite
(P 252) A NOVEL MULTIDISCIPLINARY SURGICAL APPROACH TO PERIPHERAL NERVE SHEATH TUMORS AND SOFT TISSUE SARCOMAS.
YEHUDA KOLLENDER
Favorite
Komiyama, Motokiyo

Department of Urology, National Cancer Center Hospital, Tokyo, Japan
(P 134) REAL-WORLD CLINICAL OUTCOME OF NEOADJUVANT CHEMOTHERAPY FOR RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA
Motokiyo Komiyama
Favorite
Kondo, Hiroya

National Cancer Center Hospital
(P 249) TUMOR CELL DISAPPEARANCE FOLLOWING COVID-19 INFECTION IN A PATIENT WITH PLEOMORPHIC SPINDLE CELL SARCOMA: A CASE REPORT
Hiroya Kondo
Favorite
Koneru, Balakrishna

Texas Tech University Health Sciences Center
(P 292) CHARACTERIZATION OF TELOMERE MAINTENANCE MECHANISMS IN OSTEOSARCOMA PATIENT-DERIVED LABORATORY MODELS
Balakrishna Koneru
Favorite
Koo, Selene

St. Jude Children's Research Hospital
(P 288) ANGIOA: A SAFETY AND TOLERABILITY STUDY OF TRIPLE ANTI-ANGIOGENIC THERAPY COMBINED WITH PD-L1 BLOCKADE IN PEDIATRIC, ADOLESCENT AND YOUNG ADULT RECURRENT/REFRACTORY SOLID TUMORS
Selene Koo
Favorite
Kopečková, Kateřina

2nd Medical Faculty, Charles University and University Hospital Motol
(P 355) PROTON RADIOTHERAPY FOR DESMOID TUMORS: A SINGLE-CENTER EXPERIENCE
Kateřina Kopečková
Favorite
Kopeld, Jacob

Atlantic Health System
(P 255) CAN LARGE, LIPOMATOUS LESIONS ADJACENT TO THE SUPINATOR MUSCLE BE REMOVED WITHOUT INJURING THE POSTERIOR INTEROSSEOUS NERVE? A RETROSPECTIVE REVIEW
Jacob Kopeld
Favorite
(P 260) EMERGING TECHNOLOGY IN ORTHOPEDIC ONCOLOGY: ROBOTIC ARM-ASSISTED TOTAL KNEE ARTHROPLASTY HAS EXCEPTIONAL FUNCTION OUTCOMES FOR PATIENTS WITH BENIGN AND MALIGNANT MUSCULOSKELETAL DISEASE
Jacob Kopeld
Favorite
(P 266) LONG STEM CEMENTED ROBTIC ARM-ASSISTED TOTAL HIP ARTHROPLASTY: OUTCOMES IN PATIENTS WITH PRIOR ONCOLOGIC DISEASE
Jacob Kopeld
Favorite
(P 277) REVERSE TOTAL SHOULDER ARTHROPLASTY MAINTAINS GLOBAL FUNCTION OF THE UPPER EXTREMITY IN PATIENTS WITH ONCOLOGIC DISEASE OF THE PROXIMAL HUMERUS
Jacob Kopeld
Favorite
(P 405) LIPOSOMAL BUPIVACAINE DOESN'T REDUCE NARCOTIC USE OR PAIN SCORES COMPARED TO A MULTIDRUG COCKTAIL FOLLOWING SOFT TISSUE TUMOR REMOVAL: PRELIM RESULTS OF A PROSPECTIVE, RANDOMIZED DOUBLE-BLINDED STUDY
Jacob Kopeld
Favorite
Koppenhafer, Stacia

University of Iowa
(P 14) HDAC INHIBITORS DOWNREGULATE THE EXPRESSION LEVELS OF THE MINI-CHROMOSOME MAINTENANCE PROTEINS, AND INHIBIT DNA REPLICATION, IN EWING SARCOMA CELLS
Stacia Koppenhafer
Favorite
Korleski, John

Mayo Clinic
(P 120) USING AI PREDICTIONS FROM ECG TRACINGS TO PREDICT TOLERANCE TO ANTHRACYCLINE CHEMOTHERAPY IN SARCOMA
John Korleski
Favorite
Koyama, Tatsuki

Vanderbilt University Medical Center
(P 199) FINANCIAL TOXICITY AMONG SARCOMA PATIENTS AND ASSOCIATED FACTORS
Tatsuki Koyama
Favorite
(P 297) ESTABLISHING A PEDIATRIC, ADOLESCENT AND YOUNG ADULT COHORT OF SARCOMA PATIENTS TO STUDY ONCOLOGIC AND NON-ONCOLOGIC OUTCOMES
Tatsuki Koyama
Favorite
Kozak, Katarzyna

Maria Sklodowska-Curie National Research Institute of Oncology
(P 245) PRELIMINARY RESULTS FROM A PHASE 2 EFTISARC-NEO TRIAL OF NEOADJUVANT SOUBLE LAG-3 PROTEIN EFTILAGIMOD ALPHA, PEMBROLIZUMAB, AND CONCURRENT RADIOTHERAPY IN PATIENTS WITH RESECTABLE SOFT TISSUE SARCOMA
Katarzyna Kozak
Favorite
Kozlowski, Erin

SARC
(P 102) ANALYSIS OF BLOOD-BASED BIOMARKERS AS PROGNOSTIC FACTORS IN PATIENTS WITH EHE TREATED WITH TRAMETINIB IN SARC033
Erin Kozlowski
Favorite
Kozlowski, Konrad

University of Miami Miller School of Medicine
(P 369) BLAND EMBOLIZATION AS ADJUNCT TREATMENT FOR HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA
Konrad Kozlowski
Favorite
Krailo, Mark

Keck School of Medicine of the University of Southern California
(P 06) DIFFICULTIES IN ASSESSING THE PROGNOSTIC SIGNIFICANCE OF A NOVEL BIOMARKER IN THE CONTEXT OF A TISSUE BANKING STUDY
Mark Krailo
Favorite
Krailo, Mark

Childrens Oncology Group
(P 50) ANALYSIS OF CLINICAL FEATURES AND OUTCOMES FOR PATIENTS WITH MULTIFOCAL OSTEOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Mark Krailo
Favorite
Kramer, Jeffrey

Chondrosarcoma Foundation
(P 55) CHONDROSARCOMA PATIENT CHARACTERISTICS AND DIAGNOSTIC AND TREATMENT PATHWAYS: GLOBAL CHONDROSARCOMA PATIENT REGISTRY
Jeffrey Kramer
Favorite
Krarup-Hansen, Anders

Department of Oncology, Copenhagen University Hospital, Herlev & Gentofte Hospital
(P 29) ABDOMINAL LYMPHANGIOMA CAUSING EXCESSIVE GASTROINTESTINAL BLEEDING FOR MORE THAN TWO DECADES
Anders Krarup-Hansen
Favorite
(P 104) CIRQUESARC: A NATIONAL PROSPECTIVE OBSERVATIONAL STUDY OF CIRCULATING TUMOR DNA AND QUALITY OF LIFE IN PATIENTS WITH SARCOMA – PRELIMINARY RESULTS FROM THE SURGICAL COHORT
Anders Krarup-Hansen
Favorite
(P 243) MYELOSUPPRESSION FOLLOWING LYMPHODEPLETING CHEMOTHERAPY AS PART OF ADOPTIVE CELL THERAPY FOR PATIENTS WITH PROGRESSIVE SOFT TISSUE SARCOMA AFTER STANDARD CHEMOTHERAPY
Anders Krarup-Hansen
Favorite
(P 411) PROPANE AN OPEN LABEL PHASE 2 STUDY ON PROPRANOLOL AND PEMBROLIZUMAB IN ADVANCED ANGIOSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA A SCANDINAVIAN SARCOMA GROUP COLLABORATION
Anders Krarup-Hansen
Favorite
Krawetz, Roman

McCaig Institute for Bone and Joint Health
(P 327) CHARACTERIZATION OF TWO NOVEL IMMUNE COMPETENT, MURINE MODELS OF SOFT TISSUE SARCOMA
Roman Krawetz
Favorite
Krez, Alexandra

Duke University School of Medicine
(P 54) CHONDROBLASTIC OSTEOSARCOMA IS A RISK FACTOR FOR LOCAL RECURRENCE IN PATIENTS WITH SKELETAL OSTEOSARCOMA
Alexandra Krez
Favorite
Krishnan, Chandra Kumar

Cancer Institute (WIA)
(P 61) DOES CLINICAL PROGRESSION PORTEND POOR ONCOLOGICAL OUTCOMES IN PATIENTS RECEIVING NEOADJUVANT CHEMOTHERAPY
Chandra Kumar Krishnan
Favorite
(P 67) EXTERMITY SOFT TISSUE SARCOMA -RETROSPECTIVE ANALYSIS OF 21YEARS EXPERIENCE IN A TERTITARY CARE CENTRE.
Chandra Kumar Krishnan
Favorite
(P 84) PROGNOSTIC IMPLICATIONS OF PATHOLOGICAL FRACTURES IN EXTREMITY OSTEOSARCOMA: A RETROSPECTIVE ANALYSIS OF SURVIVAL OUTCOMES AND LIMB-SALVAGE FEASIBILITY
Chandra Kumar Krishnan
Favorite
(P 105) CLINICAL OUTCOMES OF SUB-CENTIMETRIC LUNG NODULES IN PATIENTS WITH EXTREMITY OSTEOSARCOMA: A RETROSPECTIEV COHORT STUDY
Chandra Kumar Krishnan
Favorite
(P 198) FACTORS INFLUENCING TIME TO TREATMENT INITIATION IN PROMARY EXTREMITY SARCOMA: A RETROSPECTIVE ANALYSIS
Chandra Kumar Krishnan
Favorite
Kristiansson, Ingvar

Dpt of Radiology, Skane University Hospital, Lund, Sweden
(P 286) ADAMANTINOMA - LIKE EWING SARCOMA WITH ATYPICAL PRESENTATION AND FATAL OUTCOME IN 20-YEAR-OLD WOMAN - A CASE REPORT
Ingvar Kristiansson
Favorite
Kruiswijk, Anouk

Leiden University Medical Center
(P 194) EFFECTIVENESS OF A RISK PREDICTION TOOL (PERSARC) ON THE QUALITY OF TREATMENT DECISIONS IN SOFT-TISSUE SARCOMA PATIENTS (VALUE-PERSARC TRIAL)
Anouk Kruiswijk
Favorite
Kubeš, Jiří

Proton Therapy Center Czech, s.r.o.
(P 355) PROTON RADIOTHERAPY FOR DESMOID TUMORS: A SINGLE-CENTER EXPERIENCE
Jiří Kubeš
Favorite
Kubicki, Natalie

Duke University
(P 16) HOW TO GROW A BONE IN 60 DAYS: EXPLORING THE UNIQUE PRO-GROWTH, ANTI-CANCER ENVIRONMENT IN ELK ANTLERS
Natalie Kubicki
Favorite
Kucharik, Michael

USF Morsani College of Medicine
(P 263) HEMI- VS. REVERSE SHOULDER ARTHROPLASTY OUTCOMES FOLLOWING PROXIMAL HUMERAL ONCOLOGIC RESECTION
Michael Kucharik
Favorite
Kuijpers, Anke

Netherlands Cancer Institute/ Antoni van Leeuwenhoek
(P 24) NEOADJUVANT CHEMOTHERAPY FOR RADIOTHERAPY ASSOCIATED ANGIOSARCOMA (RAAS) OF THE BREAST IMPROVES ONCOLOGICAL OUTCOMES
Anke Kuijpers
Favorite
Kuleshov, Nikol

CHU de Québec - Université Laval
(P 153) PATTERNS, MANAGEMENT AND SURVIVAL OUTCOMES OF PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA: A NATIONWIDE ANALYSIS FROM THE CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION DATABASE
Nikol Kuleshov
Favorite
(P 320) WHAT IS THE ROLE OF CHEMOTHERAPY IN PATIENTS (PTS) WITH SPINDLE CELL/SCLEROSING RHABDOMYOSARCOMA (SCRMS): A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Nikol Kuleshov
Favorite
Kumar, Anand

6Department of Radiology, Massachusetts General Hospital
(P 22) MECHANISMS OF PREFERENTIAL TUMOUR UPTAKE OF INDOCYANINE GREEN IN SARCOMA
Anand Kumar
Favorite
Kumar, Jessica

University of Miami Miller School of Medicine
(P 369) BLAND EMBOLIZATION AS ADJUNCT TREATMENT FOR HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA
Jessica Kumar
Favorite
Kumar, Sonia

IRCCS Humanitas Research Hospital
(P 373) EVALUATION OF HISTOLOGIC ORGAN INFILTRATION (HOI) AND VISCERAL RESECTION MARGINS (VRM) IN PRIMARY RETROPERITONEAL SARCOMAS: PROGNOSTIC IMPLICATIONS FOR LOCAL RECURRENCE
Sonia Kumar
Favorite
(P 389) THE ROLE OF NUTRITIONAL STATUS ON POSTOPERATIVE AND ONCOLOGICAL OUTCOMES IN RETROPERITONEAL SARCOMA
Sonia Kumar
Favorite
Kummar, Shivaani

Oregon Health & Science University
(P 396) LONG-TERM FOLLOW-UP EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Shivaani Kummar
Favorite
Kung, Andrew

Memorial Sloan Kettering Cancer Center
(P 338) PRECLINICAL EFFICACY OF DAN-222, A NOVEL POLYMERIC NANOPARTICLE, IN PEDIATRIC SOLID TUMOR MODELS
Andrew Kung
Favorite
(P 418) A SYSTEMS BIOLOGY APPROACH FOR CHARACTERIZING TUMOR HETEROGENEITY AND CELL STATE-SPECIFIC THERAPEUTIC VULNERABILITIES FROM SINGLE NUCLEUS RNA-SEQ PROFILING OF DESMOPLASTIC SMALL ROUND CELL TUMORS
Andrew Kung
Favorite
Kuniyasu, Hiroki

Nara Medical University
(P 85) PTEROSTILBENE SENSITIZES OSTEOSARCOMA CELLS TO KILLING BY C-MYC INHIBITORS
Hiroki Kuniyasu
Favorite
Kunning, Sheryl

UPMC Department of Immunology and Hillman Cancer Center
(P 240) INVESTIGATING MACROPHAGE POPULATION VARIABILITY IN METASTATIC SARCOMA SAMPLES
Sheryl Kunning
Favorite
Kuo, Christopher

Children's Hospital Los Angeles
(P 76) MOLECULAR AND CHROMOSOMAL MICROARRAY PROFILING OF OSTEOSARCOMA IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS: A SINGLE INSTITUTION REPORT
Christopher Kuo
Favorite
(P 88) SPATIAL TRANSCRIPTOMICS OF EWING SARCOMA: EVOLUTION OF TUMOR MICROENVIRONMENT ASSOCIATED EXTRACELLULAR MATRIX FROM LOCALIZED TO METASTASIS-ASSOCIATED PRIMARY TUMORS
Christopher Kuo
Favorite
Kuruvilla, Davis

University of South Florida Morsani College of Medicine
(P 257) COMPARATIVE OUTCOMES OF CONSTRAINED ACETABULAR LINERS VS. DUAL MOBILITY CUPS IN COMPLEX HIP RECONSTURCTION FOR METASTATIC BONE DISEASE
Davis Kuruvilla
Favorite
(P 279) SIGNIFICANCE OF TIP-APEX DISTANCE IN ACTUAL AND IMPENDING PATHOLOGICAL FRACTURES OF THE PROXIMAL FEMUR
Davis Kuruvilla
Favorite
Kusakawa, Halu

Sarcoma Oncology Center
(P 106) DELTAREX-G, A TUMOR TARGETED CCNG1 INHIBITOR, DEMONSTRATES CLINICAL BENEFIT IN ADVANCED CHEMORESISTANT SARCOMA FOLLOWING FDA CBER AUTHORIZATION FOR USE AS PLATFORM THERAPY WITH FDA APPROVED DRUGS
Halu Kusakawa
Favorite
Kyrysyuk, Sasha

Yale University
(P 98) A MULTIEPITOPE MRNA VACCINE FOR KAPOSI SARCOMA: AN IMMUNOINFORMATIC APPROACH
Sasha Kyrysyuk
Favorite
L
L. Zapata, Maycos

Latin American Cooperative Oncology Group
(P 192) CURRENT SCENARIO OF SARCOMA CLINICAL TRIALS IN SOUTH AMERICA: A REPORT BY THE LACOG SARCOMA GROUP
Maycos L. Zapata
Favorite
(P 216) SARCOMA CARE PATHWAYS AND MULTIDISCIPLINARY TUMOR BOARDS IN LATIN AMERICA: AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Maycos L. Zapata
Favorite
(P 219) SOCIAL MEDIA USE AMONG MEDICAL PROFESSIONALS THAT TREAT PATIENTS WITH SARCOMA IN LATIN AMERICA: RESULTS OF AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Maycos L. Zapata
Favorite
La Ferlita, Alessandro

The Ohio State University
(P 136) TARGETING MIR-138-5P TO TREAT DEDIFFERENTIATED LIPOSARCOMA
Alessandro La Ferlita
Favorite
López Pousa, Antonio

Hospital Santa Creu Y Sant Pau
(P 37) HEALTH-RELATED QUALITY OF LIFE FROM A PHASE 4 STUDY TO EVALUATE DISCONTINUATION AND RECHALLENGE OF PEXIDARTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR PREVIOUSLY TREATED WITH PEXIDARTINIB
Antonio López Pousa
Favorite
Laetsch, Theodore

The Children’s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA
(P 318) SYNOVIAL SARCOMA REGISTRY AND BIOSPECIMEN REPOSITORY: DESCRIBING THE COHORT AND SURVIVAL OUTCOMES TO DATE
Theodore Laetsch
Favorite
(P 393) EFFICACY AND SAFETY OF LAROTRECTINIB AS FIRST-LINE TREATMENT IN PATIENTS WITH TRK FUSION SARCOMAS
Theodore Laetsch
Favorite
(P 417) VITAS: ATEZOLIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY SOLID TUMORS: AN OPEN-LABEL, PHASE I/II, SINGLE-ARM, MULTI-CENTER TRIAL IN PROGRESS
Theodore Laetsch
Favorite
Laffi, Alice

Humanitas Research Hospital
(P 124) ASSESSMENT OF THE MECHANISMS OF ACTION OF ERIBULIN IN PATIENTS WITH ADVANCED LIPOSARCOMA THROUGH THE EVALUATION OF THE RADIOLOGICAL, FUNCTIONAL AND TISSUE RESPONSE: A MONOCENTRIC PROSPECTIVE STUDY
Alice Laffi
Favorite
(P 155) PRIMARY MESENCHYMAL TUMORS OF THE HEART: A 8-YEARS, SINGLE INSTITUTION EXPERIENCE
Alice Laffi
Favorite
(P 290) ARTIFICIAL INTELLIGENCE-BASED COMPARISON OF ADULT AND ADOLESCENT AND YOUNG ADULTS (AYA) SARCOMAS: A PILOT STUDY
Alice Laffi
Favorite
(P 431) REAL-WORLD EXPERIENCE OF EFFICACY AND TOLERABILITY OF CONTINUOS INFUSION IFOSFAMIDE AMONG ADVANCED SOFT TISSUE AND BONE SARCOMAS PATIENTS: A SINGLE CENTRE RETROSPECTIVE COHORT.
Alice Laffi
Favorite
Lafontaine, Julie

Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), Montréal, Canada; Institut du Cancer de Montréal (ICM), Montréal, Canada
(P 326) CELL-FREE DNA AS A BIOMARKER FOR CELL DEATH AND TREATMENT RESPONSE IN ON-CHIP THREE-DIMENSIONAL SARCOMA TUMOR MODELS
Julie Lafontaine
Favorite
Laginestra, Maria Antonella

IRCCS Istituto Ortopedico Rizzoli
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Maria Antonella Laginestra
Favorite
Lagmay, Joanne

Shand's Hospital for Children at the University of Florida
(P 309) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT SOFT TISSUE SARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Joanne Lagmay
Favorite
Lake, Jessica

National Cancer Institute
(P 414) TENOSYNOVIAL GIANT CELL TUMOR IN CHILDREN: INTERIM RESULTS FROM A PHASE 1 STUDY OF TURALIO®
Jessica Lake
Favorite
Lakhani, Nehal

START Midwest
(P 95) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN PATIENTS WITH CHONDROSARCOMA: UPDATED RESULTS FROM A PHASE 1 STUDY
Nehal Lakhani
Favorite
Lalezari, Jacob

Quest Clinical Research
(P 106) DELTAREX-G, A TUMOR TARGETED CCNG1 INHIBITOR, DEMONSTRATES CLINICAL BENEFIT IN ADVANCED CHEMORESISTANT SARCOMA FOLLOWING FDA CBER AUTHORIZATION FOR USE AS PLATFORM THERAPY WITH FDA APPROVED DRUGS
Jacob Lalezari
Favorite
Lalli, Luca

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 420) CELLULARITY DEGREES IN PRIMARY MYXOID LIPOSARCOMA: ASSOCIATION WITH TUMOR IMMUNE INFILTRATE AND PATIENT OUTCOMES
Luca Lalli
Favorite
Lammers, Marshall

Division of Surgical Oncology, Department of Surgery, University of California Davis
(P 230) HIGHER BODY MASS INDEX IS ASSOCIATED WITH DECREASED CIRCULATING AND INTRATUMORAL NATURAL KILLER CELLS IN SOFT TISSUE SARCOMA
Marshall Lammers
Favorite
Landers, Sharon

The University of Texas MD Anderson Cancer Center
(P 360) TREATMENT OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR WITH BROMODOMAIN EXTRA TERMINAL INHIBITOR (BETI) IN COMBINATION WITH RADIOTHERAPY
Sharon Landers
Favorite
Lan, shijie

The First Hospital of Jilin University
(P 119) UPDATED RESULTS OF A SINGLE-ARM,MULTI-CENTER STUDY OF ANLOTINIB COMBINED WITH TORIPALIMAB IN FIRST-LINE TREATMENT OF UNRESECTABLE OR METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA
shijie Lan
Favorite
Lanza, Ezio

IRCCS Humanitas Research Hospital
(P 124) ASSESSMENT OF THE MECHANISMS OF ACTION OF ERIBULIN IN PATIENTS WITH ADVANCED LIPOSARCOMA THROUGH THE EVALUATION OF THE RADIOLOGICAL, FUNCTIONAL AND TISSUE RESPONSE: A MONOCENTRIC PROSPECTIVE STUDY
Ezio Lanza
Favorite
Lapp, Sean

USF Health Morsani College of Medicine
(P 257) COMPARATIVE OUTCOMES OF CONSTRAINED ACETABULAR LINERS VS. DUAL MOBILITY CUPS IN COMPLEX HIP RECONSTURCTION FOR METASTATIC BONE DISEASE
Sean Lapp
Favorite
(P 262) EVALUATION OF STAGED RESECTION WITH TEMPORIZING VAC OF SOFT TISSUE SARCOMAS
Sean Lapp
Favorite
Lara, Camila

Hospital Israelita Albert Einstein
(P 141) COMPREHENSIVE GENOMIC PROFILING OF PATIENTS DIAGNOSED WITH SARCOMA IN BRAZIL: MOLECULAR PROFILE AND ACTIONABILITY
Camila Lara
Favorite
Lara, Kristi

Department of Internal Medicine, Keck School of Medicine of USC Division of Medical Oncology
(P 158) RECURRENT RADIATION-INDUCED SARCOMA IN A PATIENT WITH HEREDITARY RETINOBLASTOMA: PRESENTATION AND OUTCOME
Kristi Lara
Favorite
Latour, Emile

OHSU
(P 364) A PHASE 1B TRIAL OF PREOPERATIVE ERIBULIN AND RADIATION FOR RETROPERITONEAL LIPOSARCOMA
Emile Latour
Favorite
Lau, Ching

The Jackson Laboratory for Genomic Medicine
(P 70) IDENTIFICATION OF NOVEL PROTEIN VARIANTS IN OSTEOSARCOMA TUMORS THROUGH LONG-READ RNA SEQUENCING
Ching Lau
Favorite
Lawlor, Elizabeth

Seattle Children's Research Institute
(P 330) EFFICACY OF NON-CARDIOTOXIC ANTHRACYCLINES IN EWING SARCOMA
Elizabeth Lawlor
Favorite
Lawrenz, Joshua

Vanderbilt University Medical Center
(P 73) LONGER TIME INTERVAL BETWEEN NEOADJUVANT CHEMOTHERAPY AND SURGERY IS ASSOCIATED WITH DECREASED TUMOR PERCENT NECROSIS IN OSTEOSARCOMA
Joshua Lawrenz
Favorite
(P 199) FINANCIAL TOXICITY AMONG SARCOMA PATIENTS AND ASSOCIATED FACTORS
Joshua Lawrenz
Favorite
(P 264) INTRAOPERATIVE FROZEN BONE MARROW MARGINS: A HELP OR A HINDRANCE IN EWING SARCOMA RESECTION?
Joshua Lawrenz
Favorite
(P 265) IS THERE AN IDEAL STEM TO CANAL RATIO IN LOWER EXTREMITY ONCOLOGIC ENDOPROSTHESIS RECONSTRUCTION?
Joshua Lawrenz
Favorite
(P 268) LOWER TUMOR PERCENT NECROSIS IS ASSOCIATED WITH POSITIVE FINAL SURGICAL MARGINS IN OSTEOSARCOMA
Joshua Lawrenz
Favorite
(P 297) ESTABLISHING A PEDIATRIC, ADOLESCENT AND YOUNG ADULT COHORT OF SARCOMA PATIENTS TO STUDY ONCOLOGIC AND NON-ONCOLOGIC OUTCOMES
Joshua Lawrenz
Favorite
(P 404) ENHANCED RECOVERY AFTER SURGERY (ERAS) PROTOCOL FOR PATENTS WITH SOFT TISSUE SARCOMA OF THE EXTREMITY: A PROSPECTIVE, NON-RANDOMIZED, CONSECUTIVELY ENROLLED TRIAL
Joshua Lawrenz
Favorite
Lazar, Alexander

MD Anderson Cancer Center
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Alexander Lazar
Favorite
(P 233) IMMUNE CLASSES OF LEIOMYOSARCOMA DRIVEN BY B CELL INFILTRATE AND CTLA4 EXPRESSION
Alexander Lazar
Favorite
(P 325) CAN PROTEOMICS PREDICT METASTATIC RELAPSE IN LEIOMYOSARCOMA? DEVELOPMENT OF AN 8 PROTEIN SIGNATURE IN A >350 SAMPLE STUDY INCLUDING A VALIDATION COHORT
Alexander Lazar
Favorite
(P 360) TREATMENT OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR WITH BROMODOMAIN EXTRA TERMINAL INHIBITOR (BETI) IN COMBINATION WITH RADIOTHERAPY
Alexander Lazar
Favorite
(P 398) PREDICTORS OF EFFICACY IN PATIENTS WITH SOFT TISSUE SARCOMAS TREATED WITH PAZOPANIB
Alexander Lazar
Favorite
Lazarides, Alexander

Moffitt Cancer Center
(P 150) MODERN BIOPSY PRACTICE PATTERNS: A SURVEY OF THE MSTS MEMBERSHIP
Alexander Lazarides
Favorite
(P 257) COMPARATIVE OUTCOMES OF CONSTRAINED ACETABULAR LINERS VS. DUAL MOBILITY CUPS IN COMPLEX HIP RECONSTURCTION FOR METASTATIC BONE DISEASE
Alexander Lazarides
Favorite
(P 262) EVALUATION OF STAGED RESECTION WITH TEMPORIZING VAC OF SOFT TISSUE SARCOMAS
Alexander Lazarides
Favorite
(P 263) HEMI- VS. REVERSE SHOULDER ARTHROPLASTY OUTCOMES FOLLOWING PROXIMAL HUMERAL ONCOLOGIC RESECTION
Alexander Lazarides
Favorite
(P 279) SIGNIFICANCE OF TIP-APEX DISTANCE IN ACTUAL AND IMPENDING PATHOLOGICAL FRACTURES OF THE PROXIMAL FEMUR
Alexander Lazarides
Favorite
(P 347) CAN UPFRONT RADIOTHERAPY PRECLUDE THE NEED FOR OPERATIVE STABILIZATION IN IMPENDING EXTREMITY FRACTURES FROM LUNG CANCER METASTASES?
Alexander Lazarides
Favorite
Lazcano, Rossana

MD Anderson Cancer Center
(P 233) IMMUNE CLASSES OF LEIOMYOSARCOMA DRIVEN BY B CELL INFILTRATE AND CTLA4 EXPRESSION
Rossana Lazcano
Favorite
Le Cesne, Axel

Gustave Roussy
(P 43) SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
Axel Le Cesne
Favorite
(P 125) CHARACTERISTICS, MANAGEMENT AND SURVIVAL OF N=7314 LIPOSARCOMAS FROM THE NATIONWIDE NETSARC REGISTRY IN FRANCE SINCE 2010
Axel Le Cesne
Favorite
(P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE
Axel Le Cesne
Favorite
Le Moli, Marialudovica

Humanitas University/IRCCS Humanitas Research Hospital
(P 124) ASSESSMENT OF THE MECHANISMS OF ACTION OF ERIBULIN IN PATIENTS WITH ADVANCED LIPOSARCOMA THROUGH THE EVALUATION OF THE RADIOLOGICAL, FUNCTIONAL AND TISSUE RESPONSE: A MONOCENTRIC PROSPECTIVE STUDY
Marialudovica Le Moli
Favorite
(P 155) PRIMARY MESENCHYMAL TUMORS OF THE HEART: A 8-YEARS, SINGLE INSTITUTION EXPERIENCE
Marialudovica Le Moli
Favorite
LeBrasseur, Nathan

Mayo Clinic
(P 200) FRAILTY ASSESSMENT IN OLDER PATIENTS RECEIVING SARCOMA THERAPY
Nathan LeBrasseur
Favorite
Ledesma, Patricio

Sofpromed
(P 234) IMMUNOSARC II MASTER TRIAL (PHASE II OF SUNITINIB AND NIVOLUMAB): RESULTS FROM THE CLEAR CELL SARCOMA (CCS) COHORT. A GEIS, ISG, AND UCL STUDY
Patricio Ledesma
Favorite
Lee, Alex

UCSF
(P 65) EPIGENETIC HETEROGENEITY AND STATE SPECIFIC TRANSCRIPTIONAL PROGRAMS DRIVE DRUG RESPONSE IN OSTEOSARCOMA
Alex Lee
Favorite
Lee, Alex

Stanford University School of Medicine
(P 143) EARLY ASSESSMENT OF DISEASE RESPONSE TO IMMUNOTHERAPY VIA CIRCULATING TUMOR DNA IN ADVANCED SOFT TISSUE SARCOMAS
Alex Lee
Favorite
lee, Dasom

Lunit
(P 123) ARTIFICIAL INTELLIGENCE-POWERED MITOSIS EVALUATION TO COMPLEMENT HUMAN MITOTIC RATE INTERPRETATION IN PREDICTING PROGNOSIS IN LIPOSARCOMA
Dasom lee
Favorite
Lee, Jinhee

Lunit
(P 123) ARTIFICIAL INTELLIGENCE-POWERED MITOSIS EVALUATION TO COMPLEMENT HUMAN MITOTIC RATE INTERPRETATION IN PREDICTING PROGNOSIS IN LIPOSARCOMA
Jinhee Lee
Favorite
Lee, Kyoung Bun

Seoul National University Hospital
(P 428) OLIGOMETASTASES IN EXTREMITY SOFT TISSUE SARCOMA : SUBTYPE-SPECIFIC ANALYSES OF CHARACTERISTICS AND OUTCOMES
Kyoung Bun Lee
Favorite
Lee, Kyu Sang

Seoul National University Bundang Hospital
(P 123) ARTIFICIAL INTELLIGENCE-POWERED MITOSIS EVALUATION TO COMPLEMENT HUMAN MITOTIC RATE INTERPRETATION IN PREDICTING PROGNOSIS IN LIPOSARCOMA
Kyu Sang Lee
Favorite
Lee, Ming-Jing

National Taiwan University Hospital Hsin-Chu Branch
(P 348) EVALUATING THE IMPACT OF BIOLOGICAL EFFECTIVE DOSE AND DELAYED RADIOTHERAPY ON THE SYNERGISTIC EFFICACY OF TRABECTEDIN IN METASTATIC SOFT TISSUE SARCOMA PATIENTS
Ming-Jing Lee
Favorite
Lee, Minjae

University of Texas Southwestern Medical Center
(P 417) VITAS: ATEZOLIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY SOLID TUMORS: AN OPEN-LABEL, PHASE I/II, SINGLE-ARM, MULTI-CENTER TRIAL IN PROGRESS
Minjae Lee
Favorite
Lee, Sang Gyu

Memorial Sloan Kettering Cancer Center
(P 302) HER2 PRETARGETED ALPHA PARTICLE RADIOIMMUNOTHERAPY FOR DESMOPLASTIC SMALL ROUND CELL TUMORS
Sang Gyu Lee
Favorite
Lee, Stella

UPMC
(P 256) CHARACTERIZING ORTHOPAEDIC ONCOLOGIC POLYTRAUMAS: A COMPARISON OF PATIENTS UNDERGOING OPERATIVE FIXATION OF MULTIPLE LESIONS WITH THOSE WITH SOLITARY LESIONS
Stella Lee
Favorite
(P 258) COMPARING OUTCOMES FOLLOWING INTRALESIONAL VERSUS WIDE RESECTION PROCEDURES IN THE TREATMENT OF RENAL CELL CARCINOMA BONE METASTASES
Stella Lee
Favorite
Lee, Yoongyeong

University of Illinois Urbana-Champaign
(P 79) NOVEL THERAPEUTIC POTENTIAL THROUGH HYPERACTIVATION OF THE ANTICIPATORY UNFOLDED PROTEIN RESPONSE PATHWAY IN BONE CANCER TREATMENT
Yoongyeong Lee
Favorite
Lefler, Daniel

University of Pennsylvania
(P 397) MTOR ACTIVITY: A BIOMARKER FOR CHEMO- AND IMMUNOTHERAPY RESPONSE AND OUTCOMES IN SARCOMAS
Daniel Lefler
Favorite
Leiva, Ana Paula

Hospital Clínico San Carlos
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Ana Paula Leiva
Favorite
Leix, Julia

University of Pittsburgh/UPMC Children's Hospital of Pittsburgh
(P 392) ATRX LOSS IN UTERINE LEIOMYOSARCOMA IS ASSOCIATED WITH WORSE OVERALL SURVIVAL AND A DISTINCT PATTERN OF GENE EXPRESSION ACROSS SUBTYPES
Julia Leix
Favorite
Lemieux, Christopher

CHU de Quebec - Universite Laval
(P 153) PATTERNS, MANAGEMENT AND SURVIVAL OUTCOMES OF PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA: A NATIONWIDE ANALYSIS FROM THE CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION DATABASE
Christopher Lemieux
Favorite
(P 320) WHAT IS THE ROLE OF CHEMOTHERAPY IN PATIENTS (PTS) WITH SPINDLE CELL/SCLEROSING RHABDOMYOSARCOMA (SCRMS): A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Christopher Lemieux
Favorite
Lemos, Maria Manuel

Instituto Português de Oncologia de Lisboa Francisco Gentil
(P 128) DYNAMIC HETEROGENEITY AMONGST LIPOSARCOMAS
Maria Manuel Lemos
Favorite
Leonard, Hugh

Chair of Trustees of the EHE Rare Cancer Charity UK, Charity Number 1162472
(P 429) PATIENTS WITH ADVANCED EPITHELIOID HEMANGIOENDOTHELIOMA TREATED WITH SIROLIMUS: OUTCOME FOLLOWING SIROLIMUS DISCONTINUATION.
Hugh Leonard
Favorite
Letson, Douglas

Moffitt Cancer Center
(P 150) MODERN BIOPSY PRACTICE PATTERNS: A SURVEY OF THE MSTS MEMBERSHIP
Douglas Letson
Favorite
(P 257) COMPARATIVE OUTCOMES OF CONSTRAINED ACETABULAR LINERS VS. DUAL MOBILITY CUPS IN COMPLEX HIP RECONSTURCTION FOR METASTATIC BONE DISEASE
Douglas Letson
Favorite
(P 263) HEMI- VS. REVERSE SHOULDER ARTHROPLASTY OUTCOMES FOLLOWING PROXIMAL HUMERAL ONCOLOGIC RESECTION
Douglas Letson
Favorite
(P 347) CAN UPFRONT RADIOTHERAPY PRECLUDE THE NEED FOR OPERATIVE STABILIZATION IN IMPENDING EXTREMITY FRACTURES FROM LUNG CANCER METASTASES?
Douglas Letson
Favorite
Levine, Nicole

Duke University Hospital
(P 16) HOW TO GROW A BONE IN 60 DAYS: EXPLORING THE UNIQUE PRO-GROWTH, ANTI-CANCER ENVIRONMENT IN ELK ANTLERS
Nicole Levine
Favorite
(P 54) CHONDROBLASTIC OSTEOSARCOMA IS A RISK FACTOR FOR LOCAL RECURRENCE IN PATIENTS WITH SKELETAL OSTEOSARCOMA
Nicole Levine
Favorite
(P 142) CORE NEEDLE BIOPSY OF PERIACETABULAR CHONDROSARCOMA OFTEN RESULTS IN UNDER-GRADING BUT DOES NOT CHANGE MANAGEMENT BY EXPERIENCED ORTHOPAEDIC ONCOLOGISTS.
Nicole Levine
Favorite
(P 148) ISOCITRATE DEHYDROGENASE MUTATIONS IN CHONDROSARCOMA: A META-ANALYSIS
Nicole Levine
Favorite
Levy, Joan

Melanoma Research Alliance
(P 425) EXPLORING MECHANISMS OF EGFR INHIBITOR RESISTANCE IN CHORDOMA
Joan Levy
Favorite
Lewandowski, Sara

Pyxis Oncology
(P 339) SARCOMAS EXPRESS EXTRA DOMAIN B OF FIBRONECTIN AND PRECLINICAL PATIENT-DERIVED XENOGRAFT MODELS OF SEVERAL SARCOMA SUBTYPES ARE SENSITIVE TO THE STROMA TARGETING ANTIBODY DRUG CONJUGATE PYX-201
Sara Lewandowski
Favorite
Lhermitte, Benoit

University Hospital of Strasbourg and UMR CNRS 7021
(P 89) TARGETED THERAPY OF MET, TYROSINE KINASE RECEPTOR, IN PEDIATRIC HIGH-GRADE OSTEOSARCOMAS : A NEW WAY TO TREAT PATIENTS ?
Benoit Lhermitte
Favorite
(P 426) GD2 HETEROGENEIC EXPRESSION IN OSTEOSARCOMAS AND EWING SARCOMAS UNDERLYING A WORST PROGNOSIS
Benoit Lhermitte
Favorite
Liang, Han

Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer; Tianjin Key Laboratory of Digestive Cancer, Tianjin; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, P. R. China
(P 180) TUMOR VASCULAR SIGN IN THE RESPONSE ASSESSMENT OF GASTROINTESTINAL STROMAL TUMOR TREATED WITH RIPRETINIB: A MULTICENTER STUDY
Han Liang
Favorite
Li, Binghao

Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University School of Medicine
(P 407) LONG-TERM EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): PHASE 1B UPDATE.
Binghao Li
Favorite
Li, Chia-Chen

National Taiwan University Cancer Center
(P 348) EVALUATING THE IMPACT OF BIOLOGICAL EFFECTIVE DOSE AND DELAYED RADIOTHERAPY ON THE SYNERGISTIC EFFICACY OF TRABECTEDIN IN METASTATIC SOFT TISSUE SARCOMA PATIENTS
Chia-Chen Li
Favorite
Li, Duan

Memorial Sloan Kettering Cancer Center
(P 101) AN OPEN LABEL PHASE IIA STUDY EVALUATING THE PRELIMINARY EFFICACY OF INTRATUMORAL TIGILANOL TIGLATE (TT) IN ADVANCED AND/OR METASTATIC SOFT TISSUE SARCOMA (STS, NCT05755113)
Duan Li
Favorite
Liebner, David

The Ohio State University Comprehensive Cancer Center
(P 207) PATIENT-REPORTED GLOBAL HEALTH PREDICTS ADVERSE HEALTH OUTCOMES IN PATIENTS WITH ADVANCED SARCOMA
David Liebner
Favorite
(P 244) PREDICTIVE VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO IN IMMUNOTHERAPY OUTCOMES IN ADVANCED SARCOMA
David Liebner
Favorite
(P 328) DETERMINING BIOMARKERS FOR GEMCITABINE RESPONSE IN SOFT TISSUE SARCOMAS: LESSONS LEARNED FROM PANCREATIC CANCER
David Liebner
Favorite
Lieu, Christopher

University of Colorado
(P 95) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN PATIENTS WITH CHONDROSARCOMA: UPDATED RESULTS FROM A PHASE 1 STUDY
Christopher Lieu
Favorite
Li, George

Memorial Sloan Kettering Cancer Center
(P 101) AN OPEN LABEL PHASE IIA STUDY EVALUATING THE PRELIMINARY EFFICACY OF INTRATUMORAL TIGILANOL TIGLATE (TT) IN ADVANCED AND/OR METASTATIC SOFT TISSUE SARCOMA (STS, NCT05755113)
George Li
Favorite
Li, Hui

Fujian Cancer Hospital
(P 409) PHASE 2 STUDY EVALUATING SURUFATINIB IN PATIENTS WITH OSTEOSARCOMA AND SOFT TISSUE SARCOMA WHO HAVE FAILED STANDARD CHEMOTHERAPY
Hui Li
Favorite
Li, Jian

Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute Beijing 100142, P. R. China
(P 180) TUMOR VASCULAR SIGN IN THE RESPONSE ASSESSMENT OF GASTROINTESTINAL STROMAL TUMOR TREATED WITH RIPRETINIB: A MULTICENTER STUDY
Jian Li
Favorite
li, jiazheng

Peking University Cancer Hospital
(P 180) TUMOR VASCULAR SIGN IN THE RESPONSE ASSESSMENT OF GASTROINTESTINAL STROMAL TUMOR TREATED WITH RIPRETINIB: A MULTICENTER STUDY
jiazheng li
Favorite
Li, Jing

Karmanos Cancer Institute
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Jing Li
Favorite
Li, Jing

Department of Bioinformatics and Biostatistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China
(P 93) THE PROTEOGENOMIC SUBTYPING OF OSTEOSARCOMA
Jing Li
Favorite
Li, Jinxiu

University of Utah
(P 332) ENHANCING THERAPEUTIC EFFICACY IN SYNOVIAL SARCOMA BY TARGETING P53-MDM2 AXIS AND HDAC PATHWAYS
Jinxiu Li
Favorite
(P 343) TLE1 DISRUPTION DOES NOT IMPEDE SYNOVIAL SARCOMAGENESIS
Jinxiu Li
Favorite
Li, Li

Department of Orthopaedics, University of Utah
(P 332) ENHANCING THERAPEUTIC EFFICACY IN SYNOVIAL SARCOMA BY TARGETING P53-MDM2 AXIS AND HDAC PATHWAYS
Li Li
Favorite
(P 343) TLE1 DISRUPTION DOES NOT IMPEDE SYNOVIAL SARCOMAGENESIS
Li Li
Favorite
Lillemoe, Heather

MD Anderson Cancer Center
(P 360) TREATMENT OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR WITH BROMODOMAIN EXTRA TERMINAL INHIBITOR (BETI) IN COMBINATION WITH RADIOTHERAPY
Heather Lillemoe
Favorite
Li, Luyuan

University of Miami
(P 58) COMBINATORY THERAPIES UTILIZING INHIBITION OF CARBONIC ANHYDRASE IX TO POTENTIATE RESPONSE IN RELAPSED/REFRACTORY OSTEOSARCOMA
Luyuan Li
Favorite
Lim, Allison

SpringWorks Therapeutics, Inc.
(P 33) DESCRIPTIVE EVALUATION OF PATIENTS WITH DESMOID TUMOR AND CO-OCCURRING SOMATIC MUTATIONS OF CTNNB1 AND APC IN THE PHASE 3 DEFI TRIAL
Allison Lim
Favorite
Lim, Ratana

WEHI - Walter and Eliza Hall Institute of Medical Research
(P 325) CAN PROTEOMICS PREDICT METASTATIC RELAPSE IN LEIOMYOSARCOMA? DEVELOPMENT OF AN 8 PROTEIN SIGNATURE IN A >350 SAMPLE STUDY INCLUDING A VALIDATION COHORT
Ratana Lim
Favorite
Lim, Terry

Monash University
(P 299) EXPLORING THE POTENTIAL OF PHOSPHOPROTEOMIC PROFILING FOR TARGET DISCOVERY IN HIGH-RISK OSTEOSARCOMA: A PATHWAY TO NOVEL THERAPIES?
Terry Lim
Favorite
Linardic, Corinne

Duke University School of Medicine
(P 287) AN INTERNATIONAL SURVEY OF PROVIDER PRACTICES REGARDING BONE MARROW SAMPLING VERSUS [18F] FDG PET/CT IN THE DIAGNOSTIC EVALUATION OF BONE MARROW METASTASIS IN PEDIATRIC RHABDOMYOSARCOMA
Corinne Linardic
Favorite
Lin, Chia-Chi

National Taiwan University Hospital
(P 37) HEALTH-RELATED QUALITY OF LIFE FROM A PHASE 4 STUDY TO EVALUATE DISCONTINUATION AND RECHALLENGE OF PEXIDARTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR PREVIOUSLY TREATED WITH PEXIDARTINIB
Chia-Chi Lin
Favorite
Lind Nielsen, Christian

Department of Orthopedics, Aarhus University Hospital
(P 104) CIRQUESARC: A NATIONAL PROSPECTIVE OBSERVATIONAL STUDY OF CIRCULATING TUMOR DNA AND QUALITY OF LIFE IN PATIENTS WITH SARCOMA – PRELIMINARY RESULTS FROM THE SURGICAL COHORT
Christian Lind Nielsen
Favorite
Lindner, Lars

Department of Medicine III, LMU University Hospital, LMU Munich
(P 410) PHASE I STUDY OF THE001 (DPPG2-TSL-DOX) COMBINED WITH REGIONAL HYPERTHERMIA IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Lars Lindner
Favorite
Lindsay, Sarah

Oregon Health & Science University
(P 34) DESMOID TUMOR COHORT CREATION AND CHARACTERISTICS IN THE VETERANS AFFAIRS (VA) NATIONAL DATABASE
Sarah Lindsay
Favorite
(P 223) ASSOCIATION OF POSTOPERATIVE INFECTION (POI) WITH SOFT TISSUE SARCOMA (STS) RESECTION OUTCOMES
Sarah Lindsay
Favorite
(P 285) A NOVEL METHOD TO PREDICT HEIGHT AT SKELETAL MATURITY IN PEDIATRIC SARCOMA PATIENTS
Sarah Lindsay
Favorite
Lindskog, Stefan

Sahlgrenska University Hospital
(P 170) GASTRIN RELEASING PEPTIDE RECEPTOR EXPRESSION IN GASTROINTESTINAL STROMAL TUMORS (GIST)
Stefan Lindskog
Favorite
Lingad, Allyssa

Sarcoma Oncology Center
(P 248) TNT: A PHASE 2 STUDY USING TALIMOGENE LAHERPAREPVEC, NIVOLUMAB, AND TRABECTEDIN FOR ADVANCED LEIOMYOSARCOMA AND LIPOSARCOMA (NCT # 03886311)
Allyssa Lingad
Favorite
Lin, Jian-Hua

The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
(P 132) PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND DISEASE BURDEN OF DEDIFFERENTIATED LIPOSARCOMA IN CHINA: A REAL-WORLD STUDY BASED ON NATIONAL CANCER REGISTRY
Jian-Hua Lin
Favorite
Lin, Ran

Tel Aviv Soursky medical center
(P 350) MONITORING CHANGES IN FEMORAL BONE STRENGTH IN PATIENTS WITH METASTATIC BONE DISEASE TREATED WITH RADIATION THERAPY
Ran Lin
Favorite
Lipplaa, Astrid

Leiden University Medical Center
(P 42) RANKL-INHIBITION FOR GIANT CELL LESIONS OF THE JAW: A RETROSPECTIVE COHORT ANALYSIS
Astrid Lipplaa
Favorite
Li, Qian

University of California Davis School Medicine
(P 205) MULTI-MODAL TREATMENT IS ASSOCIATED WITH IMPROVED SURVIVAL IN AYA PATIENTS WITH METASTATIC NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA
Qian Li
Favorite
(P 356) RADIATION PRACTICE PATTERNS AND OUTCOMES IN ADOLESCENT YOUNG ADULT PATIENTS WITH VISCERAL NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA
Qian Li
Favorite
Liu, Hongrui

University of Calgary
(P 289) APPLICATION AND ANALYSIS OF SPATIAL TRANSCRIPTOMIC PROFILING TO CLINICAL ALVEOLAR SOFT PART SARCOMA SAMPLES TO UNDERSTAND IMMUNOTHERAPY-RELEVANT VARIABLES
Hongrui Liu
Favorite
Liu, Kunpeng

Department of Anesthesiology, Peking University International Hospital
(P 186) ANALYSIS OF FACTORS INFLUENCING POSTOPERATIVE VENOUS THROMBOEMBOLISM FORMATION IN PATIENTS WITH MASSIVE BLOOD LOSS DURING RETROPERITONEAL TUMOR RESECTION
Kunpeng Liu
Favorite
(P 377) INCIDENCE, RISK FACTORS, AND EFFECT ON 60-DAYS SURVIVAL OF ACUTE KIDNEY INJURY OCCURRED WITHIN 7 DAYS AFTER SURGERY IN ELDERLY PATIENTS WITH RETROPERITONEALL TUMORS: A RETROSPECTIVE COHORT STUDY
Kunpeng Liu
Favorite
(P 379) KEY POINTS OF ANESTHESIA MANAGEMENT AND PROGNOSIS ANALYSIS OF ELDERLY PATIENTS WITH RETROPERITONEAL TUMOR
Kunpeng Liu
Favorite
Liu, Renyan

Dana-Farber Cancer Institute
(P 402) A PILOT STUDY OF BTX-A51 IN PATIENTS WITH METASTATIC AND/OR RECURRENT LIPOSARCOMAS CHARACTERIZED BY MDM2 AMPLIFICATIONS
Renyan Liu
Favorite
Liu, Tracy

West Virginia University
(P 342) THE ROLE OF MYELOPEROXIDASE IN SARCOMA TREATMENT
Tracy Liu
Favorite
Liu, Yu-Tao

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
(P 132) PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND DISEASE BURDEN OF DEDIFFERENTIATED LIPOSARCOMA IN CHINA: A REAL-WORLD STUDY BASED ON NATIONAL CANCER REGISTRY
Yu-Tao Liu
Favorite
Liverani, Chiara

Istituto Romagnolo per lo studio dei Tumori "Dino Amadori" IRST IRCCS, Preclinic and Osteoncology Unit, Meldola, Italy
(P 336) IMPROVEMENT OF PHOTODYNAMIC THERAPY IN SARCOMA: IN VITRO VALIDATION ON OSTEOSARCOMA AND MYXOFIBROSARCOMA
Chiara Liverani
Favorite
Livingston, J. Andrew

The University of Texas MD Anderson Cancer Center, Houston, TX, USA
(P 49) A WORKING GROUP FOR THE DEVELOPMENT OF A CLINICAL FRAMEWORK THAT STRATIFIES OSTEOSARCOMA PATIENTS USING BIOMARKERS OF CLINICAL RISK AND BIOLOGY
J. Andrew Livingston
Favorite
(P 233) IMMUNE CLASSES OF LEIOMYOSARCOMA DRIVEN BY B CELL INFILTRATE AND CTLA4 EXPRESSION
J. Andrew Livingston
Favorite
(P 360) TREATMENT OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR WITH BROMODOMAIN EXTRA TERMINAL INHIBITOR (BETI) IN COMBINATION WITH RADIOTHERAPY
J. Andrew Livingston
Favorite
(P 396) LONG-TERM FOLLOW-UP EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
J. Andrew Livingston
Favorite
Li, Wei

Department of Medical Oncology, Zhongshan Hospital, Fudan University,Shanghai, China
(P 416) TRIPLR COMNINATION THERAPY IN THE FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA WITH HIGH TUMOR BURDEN: INTERIM ANALYSIS FROM ALTER-S007 STUDY
Wei Li
Favorite
Li, William

University of Pittsburgh Medical Center
(P 117) THE TUMOR IMMUNE MICROENVIRONMENT OF DEDIFFERENTIATED SARCOMAS: DIGITAL SPATIAL PROFILING SHOWS IMMUNE TRANSCRIPTIONAL DIFFERENCES BETWEEN DEDIFFERENTIATED LIPOSARCOMA AND CHONDROSARCOMA
William Li
Favorite
Li, Yi Xin

Singapore General Hospital
(P 370) DEFYING NORMS - CENTRALIZATION OF SARCOMA CARE ON AN ISLAND NATION
Yi Xin Li
Favorite
Li, Yi Xin

Duke NUS Medical School
(P 375) FROM SAPLING TO SHADE: GROWTH OF A HIGH VOLUME ASIAN TERTIARY SARCOMA SPECIALISED CENTRE
Yi Xin Li
Favorite
Li, Yi-Jia

Beckman Research Institute at City of Hope Cancer Center
(P 07) DIRECTLY TARGETING CIC-DUX4 FUSION AND MYC ONCOPROTEINS FOR UNDIFFERENTIATED ROUND CELL SARCOMAS
Yi-Jia Li
Favorite
Li, Yuan

Beijing Jishuitan Hospital, Capital Medical University
(P 407) LONG-TERM EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): PHASE 1B UPDATE.
Yuan Li
Favorite
Li, Yuezhe

Metrum Research Group
(P 116) QUANTITATIVE SYSTEMS PHARMACOLOGY MODELING OF MIPASETAMAB UZOPTERINE INTEGRATES KNOWLEDGE AND DEFINES DOSING STRATEGY FOR PATIENTS WITH SARCOMA
Yuezhe Li
Favorite
Ljevar, Silva

Unit of Biostatistics for Clinical Research Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Silva Ljevar
Favorite
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Silva Ljevar
Favorite
Ljevar, Silva

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 429) PATIENTS WITH ADVANCED EPITHELIOID HEMANGIOENDOTHELIOMA TREATED WITH SIROLIMUS: OUTCOME FOLLOWING SIROLIMUS DISCONTINUATION.
Silva Ljevar
Favorite
Lobmaier, Ingvild

Oslo University Hospital
(P 40) PEGYLATED LIPOSOMAL DOXORUBICIN IN SYMPTOMATIC DESMOID TUMOR
Ingvild Lobmaier
Favorite
Lobner, Amy

The Osteosarcoma Institute
(P 408) OSTEOMYC: A PHASE 2 PILOT STUDY TO EVALIATE THE SAFETY AND THE ANTITUMOR ACTIVITY OF THE MYC INHIBITOR OMO-103 ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH ADVANCED HIGH GRADE OSTEOSARCOMA
Amy Lobner
Favorite
Locatelli, Franco

Ospedale Pediatrico Bambino Gesù
(P 311) QUANTIFICATION OF TUMOUR-INFILTRATING IMMUNE CELLS THROUGH DECONVOLUTION OF DNA METHYLATION DATA IN EWING SARCOMAS
Franco Locatelli
Favorite
Loferer, Hannes

iOmx AG
(P 337) OMX-0407 A NOVEL SPECTRUM-SELECTIVE SMALL MOLECULE KINASE INHIBITOR IS ACTIVE IN THE TREATMENT OF ANGIOSARCOMA
Hannes Loferer
Favorite
Logie, Natalie

Tom Baker Cancer Center
(P 321) WHOLE ABDOMINAL RADIOTHERAPY IN CHILDREN AND YOUNG ADULTS WITH SARCOMA: A CANADIAN SARCOMA AND CLINICAL COLLABORATION (CANSARCC) STUDY
Natalie Logie
Favorite
Lohse, Ines

University of Pittsburgh
(P 51) ASSESSING THE IN VIRTO EFFICACY OF DISULFIRAM AND ENZALUTAMIDE COMBINATION THERAPY IN METASTATIC OSTEOSARCOMA
Ines Lohse
Favorite
(P 117) THE TUMOR IMMUNE MICROENVIRONMENT OF DEDIFFERENTIATED SARCOMAS: DIGITAL SPATIAL PROFILING SHOWS IMMUNE TRANSCRIPTIONAL DIFFERENCES BETWEEN DEDIFFERENTIATED LIPOSARCOMA AND CHONDROSARCOMA
Ines Lohse
Favorite
(P 240) INVESTIGATING MACROPHAGE POPULATION VARIABILITY IN METASTATIC SARCOMA SAMPLES
Ines Lohse
Favorite
(P 256) CHARACTERIZING ORTHOPAEDIC ONCOLOGIC POLYTRAUMAS: A COMPARISON OF PATIENTS UNDERGOING OPERATIVE FIXATION OF MULTIPLE LESIONS WITH THOSE WITH SOLITARY LESIONS
Ines Lohse
Favorite
(P 258) COMPARING OUTCOMES FOLLOWING INTRALESIONAL VERSUS WIDE RESECTION PROCEDURES IN THE TREATMENT OF RENAL CELL CARCINOMA BONE METASTASES
Ines Lohse
Favorite
(P 353) PREDICTING WOUND COMPLICATIONS FOLLOWING SOFT-TISSUE SARCOMA RESECTION AMONG PATIENTS WHO RECEIVED PRE-OPERATIVE RADIATION
Ines Lohse
Favorite
Loidl, Verena

Institute for Medical Information Processing, Biometry, and Epidemiology (IBE), Faculty of Medicine, LMU Munich, MPH
(P 201) GLOBAL CROSS-SECTIONAL SURVEY ON SARCOMA DIAGNOSIS PATHWAY: A CURRENT STATE ANALYSIS
Verena Loidl
Favorite
Lokshin, Anna
(P 353) PREDICTING WOUND COMPLICATIONS FOLLOWING SOFT-TISSUE SARCOMA RESECTION AMONG PATIENTS WHO RECEIVED PRE-OPERATIVE RADIATION
Anna Lokshin
Favorite
Long, Chris

Stanford University
(P 74) MATRIX DENSITY INDUCES CHEMORESISTANCE WITHIN A TISSUE-ENGINEERED MODEL OF OSTEOSARCOMA
Chris Long
Favorite
Lopez, Ann

Clear Cell Sarcoma Foundation
(P 189) CLEAR CELL SARCOMA - REAL WORLD DATA ANALYSIS
Ann Lopez
Favorite
Lopez-Fuentes, Eunice

UCSF
(P 65) EPIGENETIC HETEROGENEITY AND STATE SPECIFIC TRANSCRIPTIONAL PROGRAMS DRIVE DRUG RESPONSE IN OSTEOSARCOMA
Eunice Lopez-Fuentes
Favorite
LoRusso, Patricia

Yale University School of Medicine, Yale Cancer Center
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Patricia LoRusso
Favorite
LOZANO LOMINCHAR, PABLO

Memorial Sloan Kettering Cancer Center
(P 380) MULTIDISCIPLINARY MANAGEMENT OF INTRA-ABDOMINAL DESMOID-TYPE FIBROMATOSIS: A 30-YEARS EXPERIENCE
PABLO LOZANO LOMINCHAR
Favorite
Lozano-Calderon, Santiago A.

Massachusetts General Hospital, Harvard Medical School
(P 63) DOES TUMOR NECROSIS IMPACT PROGNOSIS IN CHONDROBLASTIC AND OSTEOBLASTIC OSTEOSARCOMA? A STUDY FROM A LARGE TERTIARY CARE ACADEMIC CENTER
Santiago A. Lozano-Calderon
Favorite
(P 100) ADVANCING PROGNOSTICS IN ONCOLOGY: MACHINE LEARNING MODELS FOR PREDICTING 2-YEAR AND 5-YEAR SURVIVAL RATES IN PATIENTS WITH UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Santiago A. Lozano-Calderon
Favorite
(P 107) DOES THE USE OF ADJUVANT CHEMOTHERAPY IN LOCALIZED, RESECTABLE SOFT TISSUE SARCOMA LEAD TO BETTER SURVIVAL OUTCOMES? - A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Santiago A. Lozano-Calderon
Favorite
(P 108) FIXATION OF IMPENDING OR PATHOLOGIC FRACTURES DUE TO METASTATIC DISEASE WITH CARBON FIBER INTRAMEDULLARY NAILS-A PROPENSITY-SCORE MATCHED COST ANALYSIS
Santiago A. Lozano-Calderon
Favorite
(P 284) WOUND VAC TEMPORIZATION AFTER TUMOR RESECTION OF SOFT TISSUE SARCOMAS - A COST ANALYSIS IN A PROPENSITY-SCORE MATCHED POPULATION
Santiago A. Lozano-Calderon
Favorite
Lubovsky, Omri

Orthopedics, Barzilai Medical Center
(P 182) A NOVEL MODEL FOR THE DIRECT REFERRAL OF ONCOLOGIC PATIENTS IN A PUBLIC HEALTH CARE SYSTEM
Omri Lubovsky
Favorite
Lucarelli, Enrico

Istituto Ortopedico Rizzoli IRCCS, Osteoncology- Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, Bologna, Italy
(P 336) IMPROVEMENT OF PHOTODYNAMIC THERAPY IN SARCOMA: IN VITRO VALIDATION ON OSTEOSARCOMA AND MYXOFIBROSARCOMA
Enrico Lucarelli
Favorite
Lucatelli, Maria Victoria

Pharmacology Unit, Humanitas Clinical and Research Center, IRCCS, Rozzano, 20089, Italy
(P 431) REAL-WORLD EXPERIENCE OF EFFICACY AND TOLERABILITY OF CONTINUOS INFUSION IFOSFAMIDE AMONG ADVANCED SOFT TISSUE AND BONE SARCOMAS PATIENTS: A SINGLE CENTRE RETROSPECTIVE COHORT.
Maria Victoria Lucatelli
Favorite
Lui, Darren

St. George’s Hospital
(P 261) EVALUATION OF CT ARTIFACTS AFTER SPINAL OLIGOMETASTATIC DISEASE RESECTION AND RECONSTRUCTION: A COMPARATIVE STUDY OF CARBON-FIBER VS. TITANIUM IMPLANTS
Darren Lui
Favorite
Luiz Cunha Martins, Cicero

Latin American Cooperative Oncology Group
(P 192) CURRENT SCENARIO OF SARCOMA CLINICAL TRIALS IN SOUTH AMERICA: A REPORT BY THE LACOG SARCOMA GROUP
Cicero Luiz Cunha Martins
Favorite
(P 216) SARCOMA CARE PATHWAYS AND MULTIDISCIPLINARY TUMOR BOARDS IN LATIN AMERICA: AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Cicero Luiz Cunha Martins
Favorite
(P 217) SARCOMA DRUG APPROVALS IN LATIN AMERICA COMPARED TO THE FDA AND EMA: AN ANALYSIS BY THE LACOG SARCOMA GROUP
Cicero Luiz Cunha Martins
Favorite
(P 219) SOCIAL MEDIA USE AMONG MEDICAL PROFESSIONALS THAT TREAT PATIENTS WITH SARCOMA IN LATIN AMERICA: RESULTS OF AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Cicero Luiz Cunha Martins
Favorite
Lum, Lotus

Yale University
(P 98) A MULTIEPITOPE MRNA VACCINE FOR KAPOSI SARCOMA: AN IMMUNOINFORMATIC APPROACH
Lotus Lum
Favorite
Lunt, Colin

Adaptimmune
(P 202) IMPACT OF AFAMI-CEL ON THE HEALTH STATE OF PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR MYXOID/ROUND CELL LIPOSARCOMA: COHORT 1 OF SPEARHEAD-1
Colin Lunt
Favorite
Luo, Cheng-Hua

Peking University People's Hospital
(P 186) ANALYSIS OF FACTORS INFLUENCING POSTOPERATIVE VENOUS THROMBOEMBOLISM FORMATION IN PATIENTS WITH MASSIVE BLOOD LOSS DURING RETROPERITONEAL TUMOR RESECTION
Cheng-Hua Luo
Favorite
(P 377) INCIDENCE, RISK FACTORS, AND EFFECT ON 60-DAYS SURVIVAL OF ACUTE KIDNEY INJURY OCCURRED WITHIN 7 DAYS AFTER SURGERY IN ELDERLY PATIENTS WITH RETROPERITONEALL TUMORS: A RETROSPECTIVE COHORT STUDY
Cheng-Hua Luo
Favorite
Luo, Chongliang

Washington University in St Louis
(P 81) OUTCOMES DATA FOR OSTEOSARCOMA PATIENTS OVER AGE 60
Chongliang Luo
Favorite
(P 187) BRIDGING THE GAP: UNDERSTANDING THE CURRENT TREATMENT RESPONSES TO ENHANCE THE STANDARD OF CARE AND OUTCOMES FOR MALIGNANT PERIPHERAL NERVE SHEATH TUMORS
Chongliang Luo
Favorite
Luo, Leo

Vanderbilt University Medical Center
(P 199) FINANCIAL TOXICITY AMONG SARCOMA PATIENTS AND ASSOCIATED FACTORS
Leo Luo
Favorite
(P 297) ESTABLISHING A PEDIATRIC, ADOLESCENT AND YOUNG ADULT COHORT OF SARCOMA PATIENTS TO STUDY ONCOLOGIC AND NON-ONCOLOGIC OUTCOMES
Leo Luo
Favorite
Luo, Rong-Kui

Zhongshan Hospital, Fudan University, Shanghai, China
(P 416) TRIPLR COMNINATION THERAPY IN THE FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA WITH HIGH TUMOR BURDEN: INTERIM ANALYSIS FROM ALTER-S007 STUDY
Rong-Kui Luo
Favorite
Lupo, Philip

Texas Children's Cancer Center, Epidemiology Program, Baylor College of Medicine
(P 315) SALVAGE THERAPY EFFICACY IS MODIFIED BY RISK GROUP AT DIAGNOSIS IN PATIENTS WITH RELAPSED RHABDOMYOSARCOMA
Philip Lupo
Favorite
Lusi, Stefano

IRCCS Humanitas Research Hospital
(P 290) ARTIFICIAL INTELLIGENCE-BASED COMPARISON OF ADULT AND ADOLESCENT AND YOUNG ADULTS (AYA) SARCOMAS: A PILOT STUDY
Stefano Lusi
Favorite
Lu, Weiqi

Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
(P 416) TRIPLR COMNINATION THERAPY IN THE FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA WITH HIGH TUMOR BURDEN: INTERIM ANALYSIS FROM ALTER-S007 STUDY
Weiqi Lu
Favorite
lv, yu

Shanghai General Hospital, School of Medicine Shanghai Jiao Tong University
(P 48) A SINGLE-ARM, OPEN-LABEL CLINICAL STUDY OF OVV-01 ONCOLYTIC VIRUS INJECTION AS MONOTHERAPY OR IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR ADVANCED SOLID TUMOR PATIENTS
yu lv
Favorite
(P 90) TARGETING HIGH RISK MYC- AMPLIFIED OSTEOSARCOMA BY AURORA KINASE INHIBITOR--RESULT FROM A NGS BASED UMBRELLA TRIAL
yu lv
Favorite
Lyle, Alfred

University of California- Santa Cruz
(P 295) DEFINING OSTEOSARCOMA HETEROGENEITY: CONSENSUS CLUSTERING REVEALS GENE EXPRESSION SUBTYPES
Alfred Lyle
Favorite
Lynch, Carmel

Adcendo ApS
(P 331) EFFICACY OF NOVEL UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN TARGETED ANTIBODY-DRUG CONJUGATES IN PATIENT-DERIVED XENOGRAFTS OF SOFT TISSUE SARCOMA
Carmel Lynch
Favorite
Lyu, Heather

MD Anderson Cancer Center
(P 130) HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RESECTABLE RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA (DDLPS) TREATED WITH NEOADJUVANT CHECKPOINT BLOCKADE IN A RANDOMIZED PHASE II CLINICAL TRIAL.
Heather Lyu
Favorite
(P 360) TREATMENT OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR WITH BROMODOMAIN EXTRA TERMINAL INHIBITOR (BETI) IN COMBINATION WITH RADIOTHERAPY
Heather Lyu
Favorite
M
Møller, Ditte

Department of Oncology Medical Physics, Aarhus University Hospital
(P 357) RADIATION THERAPY OF EXTREMITY SOFT TISSUE SARCOMAS: A NATIONWIDE COHORT STUDY OF LATE SIDE EFFECTS - TRIAL IN PROGRESS
Ditte Møller
Favorite
Mühlenberg, Thomas

Department of Medical Oncology, Sarcoma Center, West German Cancer Center, University Duisburg-Essen, Medical School, Essen, Germany
(P 173) IN VITRO PROFILING OF IDRX-42 AGAINST SECONDARY MUTATIONS FOUND IN TKI-RESISTANT GIST
Thomas Mühlenberg
Favorite
Mack, Jennifer W

Boston Children's/DFCI
(P 195) ENHANCING PARTICIPANT ENGAGEMENT IN A NOVEL PATIENT-PARTNERED CANCER GENOMICS RESEARCH EFFORT FOR RARE AND AGGRESSIVE SARCOMAS
Jennifer W Mack
Favorite
Mack, Lloyd

University of Calgary
(P 174) INCIDENCE, TREATMENT PATTERNS, AND SURVIVAL OUTCOMES FOR ADULT PATIENTS WITH GASTROINTESTINAL STROMAL TUMOURS (GIST) IN ALBERTA, CANADA FROM 2008 - 2022.
Lloyd Mack
Favorite
MacQuarrie, Kyle

Northwestern University Feinberg School of Medicine/Ann & Robert H Lurie Children's Hospital of Chicago
(P 04) CHROMOSOME SPECIFIC ORGANIZATIONAL CHARACTERISTICS IN RHABDOMYOSARCOMA AND NORMAL MYOGENIC CELLS
Kyle MacQuarrie
Favorite
Madison, Cecelia

Portland VA Medical Center
(P 34) DESMOID TUMOR COHORT CREATION AND CHARACTERISTICS IN THE VETERANS AFFAIRS (VA) NATIONAL DATABASE
Cecelia Madison
Favorite
Maejima, Aiko

Department of Medical Oncology/Urology, National Cancer Center Hospital, Tokyo, Japan
(P 134) REAL-WORLD CLINICAL OUTCOME OF NEOADJUVANT CHEMOTHERAPY FOR RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA
Aiko Maejima
Favorite
Maekawa, Akira

Kyushu Rosai Hospital
(P 203) IMPACT OF COVID-19 PANDEMIC ON BONE AND SOFT TISSUE SARCOMA PATIENTS' CONSULTATION AND DIAGNOSIS
Akira Maekawa
Favorite
Magagnoli, Giovanna

Deapartment of Pathology, IRCCS, Istituto Ortopedico Rizzoli, Bologna, Italy
(P 77) MULTI-PARAMETRICAL PROFILING OF CHONDROSARCOMA
Giovanna Magagnoli
Favorite
Maggs, Rebecca

Newcastle University
(P 323) AN IN-VITRO INVESTIGATION OF 5-AMINOLEVULINIC ACID MEDIATED PHOTODYNAMIC THERAPY IN SOFT-TISSUE SARCOMA
Rebecca Maggs
Favorite
Magnelli, Anthony

Cleveland Clinic
(P 351) OSTEOSARCOMA STEREOTACTIC BODY RADIOTHERAPY: OUTCOMES AND PATTERN OF FAILURE
Anthony Magnelli
Favorite
Magnusson, Linda

Lund University
(P 03) CDK4 IS CO-AMPLIFIED WITH EITHER TP53 PROMOTER GENE FUSIONS OR MDM2 THROUGH DISTINCT MECHANISMS IN OSTEOSARCOMA
Linda Magnusson
Favorite
Maguire, Frances

University of California Davis
(P 205) MULTI-MODAL TREATMENT IS ASSOCIATED WITH IMPROVED SURVIVAL IN AYA PATIENTS WITH METASTATIC NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA
Frances Maguire
Favorite
(P 356) RADIATION PRACTICE PATTERNS AND OUTCOMES IN ADOLESCENT YOUNG ADULT PATIENTS WITH VISCERAL NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA
Frances Maguire
Favorite
Maher, Hanne

KU Leuven
(P 334) EXPANDING THE LANDSCAPE OF PRECLINICAL MODELS OF SYNOVIAL SARCOMA: FROM 2-DIMENSIONS TO 3-DIMENSIONS TO MICE
Hanne Maher
Favorite
Mahoney, Douglas

Arnie Charbonneau Cancer Institute
(P 289) APPLICATION AND ANALYSIS OF SPATIAL TRANSCRIPTOMIC PROFILING TO CLINICAL ALVEOLAR SOFT PART SARCOMA SAMPLES TO UNDERSTAND IMMUNOTHERAPY-RELEVANT VARIABLES
Douglas Mahoney
Favorite
(P 327) CHARACTERIZATION OF TWO NOVEL IMMUNE COMPETENT, MURINE MODELS OF SOFT TISSUE SARCOMA
Douglas Mahoney
Favorite
Makanji, Rikesh

Moffitt
(P 421) CHARACTERIZATION OF INTRA-PATIENT, INTER-LESIONAL RESPONSE AND RESISTANCE DYNAMICS IN METASTATIC, FUSION-POSITIVE RHABDOMYOSARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Rikesh Makanji
Favorite
Maki, Robert

Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College
(P 101) AN OPEN LABEL PHASE IIA STUDY EVALUATING THE PRELIMINARY EFFICACY OF INTRATUMORAL TIGILANOL TIGLATE (TT) IN ADVANCED AND/OR METASTATIC SOFT TISSUE SARCOMA (STS, NCT05755113)
Robert Maki
Favorite
(P 124) ASSESSMENT OF THE MECHANISMS OF ACTION OF ERIBULIN IN PATIENTS WITH ADVANCED LIPOSARCOMA THROUGH THE EVALUATION OF THE RADIOLOGICAL, FUNCTIONAL AND TISSUE RESPONSE: A MONOCENTRIC PROSPECTIVE STUDY
Robert Maki
Favorite
(P 155) PRIMARY MESENCHYMAL TUMORS OF THE HEART: A 8-YEARS, SINGLE INSTITUTION EXPERIENCE
Robert Maki
Favorite
(P 229) EXPRESSION OF TRANSPOSABLE ELEMENTS AND IKZF1 PREDICTS IMMUNE INFILTRATES IN SARCOMAS AND CORRELATES WITH OUTCOMES AFTER IMMUNE CHECKPOINT INHIBITION
Robert Maki
Favorite
(P 246) THE GENOMIC AND IMMUNE LANDSCAPE OF LIPOSARCOMA AND ITS SUBTYPES
Robert Maki
Favorite
(P 290) ARTIFICIAL INTELLIGENCE-BASED COMPARISON OF ADULT AND ADOLESCENT AND YOUNG ADULTS (AYA) SARCOMAS: A PILOT STUDY
Robert Maki
Favorite
(P 431) REAL-WORLD EXPERIENCE OF EFFICACY AND TOLERABILITY OF CONTINUOS INFUSION IFOSFAMIDE AMONG ADVANCED SOFT TISSUE AND BONE SARCOMAS PATIENTS: A SINGLE CENTRE RETROSPECTIVE COHORT.
Robert Maki
Favorite
Makkawi, Rawan

OHSU
(P 72) LIVE-CELL TISSUE MODELS REVEAL SOURCES OF DYNAMIC HETEROGENEITY IN THE OSTEOSARCOMA METASTATIC NICHE
Rawan Makkawi
Favorite
Makri, Stavriani

Johns Hopkins University School of Medicine
(P 187) BRIDGING THE GAP: UNDERSTANDING THE CURRENT TREATMENT RESPONSES TO ENHANCE THE STANDARD OF CARE AND OUTCOMES FOR MALIGNANT PERIPHERAL NERVE SHEATH TUMORS
Stavriani Makri
Favorite
Malhotra, Gunjan

University of Michigan
(P 341) THE EFFECTS OF ULTRASOUND-GUIDED HISTOTRIPSY ON SOFT TISSUE SARCOMA
Gunjan Malhotra
Favorite
Malik, Faizan

st judes
(P 152) NOVEL PAX3::MAML3 FUSION IDENTIFIED IN ALVEOLAR RHABDOMYOSARCOMA: USING DNA METHYLATION TO EXPANDE THE GENETIC SPECTRUM OF "FUSION POSITIVE" CASES
Faizan Malik
Favorite
Malik, Faizan

St. Jude Children’s Research Hospital
(P 288) ANGIOA: A SAFETY AND TOLERABILITY STUDY OF TRIPLE ANTI-ANGIOGENIC THERAPY COMBINED WITH PD-L1 BLOCKADE IN PEDIATRIC, ADOLESCENT AND YOUNG ADULT RECURRENT/REFRACTORY SOLID TUMORS
Faizan Malik
Favorite
Malik, Neha

MD Anderson Cancer Center
(P 130) HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RESECTABLE RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA (DDLPS) TREATED WITH NEOADJUVANT CHECKPOINT BLOCKADE IN A RANDOMIZED PHASE II CLINICAL TRIAL.
Neha Malik
Favorite
Malik, Roshaan

Varna Medical University , Queen Elizabeth Hospital
(P 383) PRE-OPERATIVE SPLIT RENAL FUNCTION RADIONUCLIDE IMAGING IN SURGICAL PLANNING FOR MULTI-VISCERAL RESECTION OF RETROPERITONEAL SARCOMA: A RETROSPECTIVE COHORT STUDY
Roshaan Malik
Favorite
Mallick, Atrayee Basu

Thomas Jefferson University Hospital
(P 344) TRANSCRIPTOMIC ANALYSIS OF DESMOID TUMOR RESPONSE TO NIROGACESTAT: NOVEL MECHANISMS OF RESISTANCE?
Atrayee Basu Mallick
Favorite
(P 397) MTOR ACTIVITY: A BIOMARKER FOR CHEMO- AND IMMUNOTHERAPY RESPONSE AND OUTCOMES IN SARCOMAS
Atrayee Basu Mallick
Favorite
Mallory, Robert

University of California San Diego
(P 165) COMPLETE PERITONEAL CYTOREDUCTIVE SURGERY IN HIGHLY SELECTED PATIENTS WITH AGGRESSIVE METASTATIC SDH-DEFICIENT GIST CAN PROLONG EVENT-FREE SURVIVAL
Robert Mallory
Favorite
(P 175) KIT AND DOG-1 EXPRESSING GASTROINTESTINAL STROMAL TUMORS HARBORING ETV6-NTRK3 FUSIONS DO EXIST, CASE OF NEAR COMPLETE PATHOLOGIC RESPONSE FOLLOWING LAROTRECTINIB AND REVIEW OF THE LITERATURE
Robert Mallory
Favorite
Malogolowkin, Marcio

University of California Davis
(P 205) MULTI-MODAL TREATMENT IS ASSOCIATED WITH IMPROVED SURVIVAL IN AYA PATIENTS WITH METASTATIC NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA
Marcio Malogolowkin
Favorite
(P 356) RADIATION PRACTICE PATTERNS AND OUTCOMES IN ADOLESCENT YOUNG ADULT PATIENTS WITH VISCERAL NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA
Marcio Malogolowkin
Favorite
Malvar, Jemily

Children's Hospital Los Angeles
(P 76) MOLECULAR AND CHROMOSOMAL MICROARRAY PROFILING OF OSTEOSARCOMA IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS: A SINGLE INSTITUTION REPORT
Jemily Malvar
Favorite
Mandel, Anna

University of Toronto
(P 329) DEVELOPING ARMS METASTATIC MODELS TO RECAPITULATE THE TUMOR MICROENVIRONMENTS OF THE AXILLA/LYMPH NODE AND LUNGS
Anna Mandel
Favorite
Mann, Gary

Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Gary Mann
Favorite
Manor Binyamini, Iris

Department of Social Work (Medical Social Work).Tel – Hai College. Israel
(P 182) A NOVEL MODEL FOR THE DIRECT REFERRAL OF ONCOLOGIC PATIENTS IN A PUBLIC HEALTH CARE SYSTEM
Iris Manor Binyamini
Favorite
Manrique, Elena

Hospital Clinico san Carlos
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Elena Manrique
Favorite
Mantero, Maria

University of Miami Miller School of Medicine
(P 296) DISPARITIES IN OVERALL SURVIVAL FOR AYA PATIENTS WITH EWINGS SARCOMA: A RETROSPECTIVE COHORT STUDY AT A SINGLE SARCOMA CENTER
Maria Mantero
Favorite
Mantri, Shilpa

Department of Internal Medicine, University of Southern California
(P 158) RECURRENT RADIATION-INDUCED SARCOMA IN A PATIENT WITH HEREDITARY RETINOBLASTOMA: PRESENTATION AND OUTCOME
Shilpa Mantri
Favorite
Maple, Ellen

Children's Hospital of Philadelphia
(P 318) SYNOVIAL SARCOMA REGISTRY AND BIOSPECIMEN REPOSITORY: DESCRIBING THE COHORT AND SURVIVAL OUTCOMES TO DATE
Ellen Maple
Favorite
Marang-van de Mheen, Perla

Safety & Security Science, Faculty of Technology, Policy & Management, Delft University of Technology
(P 194) EFFECTIVENESS OF A RISK PREDICTION TOOL (PERSARC) ON THE QUALITY OF TREATMENT DECISIONS IN SOFT-TISSUE SARCOMA PATIENTS (VALUE-PERSARC TRIAL)
Perla Marang-van de Mheen
Favorite
Marchais, Antonin

Gustave Roussy
(P 53) CHARACTERIZING THE SPATIAL TRANSCRIPTOMIC LANDSCAPE OF OSTEOSARCOMA FROM DIAGNOSIS TO RELAPSE
Antonin Marchais
Favorite
(P 82) PLASMA CIRCULATING PROTEOMIC MARKERS ARE ASSOCIATED WITH METASTATIC SPREAD AND OUTCOME IN OSTEOSARCOMA
Antonin Marchais
Favorite
Marchiò, Caterina

University of Turin
(P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Caterina Marchiò
Favorite
Marchini, Sergio

IRCCS Humanitas Research Hospital
(P 124) ASSESSMENT OF THE MECHANISMS OF ACTION OF ERIBULIN IN PATIENTS WITH ADVANCED LIPOSARCOMA THROUGH THE EVALUATION OF THE RADIOLOGICAL, FUNCTIONAL AND TISSUE RESPONSE: A MONOCENTRIC PROSPECTIVE STUDY
Sergio Marchini
Favorite
Mariani, Luigi

Unit of Clinical Epidemiology and Trial Organization, IRCCS Fondazione Istituto Nazionale Tumori, Milan, Italy
(P 420) CELLULARITY DEGREES IN PRIMARY MYXOID LIPOSARCOMA: ASSOCIATION WITH TUMOR IMMUNE INFILTRATE AND PATIENT OUTCOMES
Luigi Mariani
Favorite
Mariathasan, Anthony Burton

Oslo University Hospital
(P 40) PEGYLATED LIPOSOMAL DOXORUBICIN IN SYMPTOMATIC DESMOID TUMOR
Anthony Burton Mariathasan
Favorite
Marinoff, Amanda

UCSF
(P 49) A WORKING GROUP FOR THE DEVELOPMENT OF A CLINICAL FRAMEWORK THAT STRATIFIES OSTEOSARCOMA PATIENTS USING BIOMARKERS OF CLINICAL RISK AND BIOLOGY
Amanda Marinoff
Favorite
Mariuk-Jarema, Anna

Maria Sklodowska-Curie National Research Institute of Oncology
(P 245) PRELIMINARY RESULTS FROM A PHASE 2 EFTISARC-NEO TRIAL OF NEOADJUVANT SOUBLE LAG-3 PROTEIN EFTILAGIMOD ALPHA, PEMBROLIZUMAB, AND CONCURRENT RADIOTHERAPY IN PATIENTS WITH RESECTABLE SOFT TISSUE SARCOMA
Anna Mariuk-Jarema
Favorite
Markowitz, Moses

University of Miami Miller School of Medicine
(P 282) UNPLANNED RESECTION OF SOFT TISSUE SARCOMA: THE IMPACT OF RESIDUAL DISEASE IN RE-RESECTION SPECIMEN
Moses Markowitz
Favorite
(P 346) BRACHYTHERAPY FOR SOFT TISSUE SARCOMA: MAINTAINING LOCAL CONTROL WHILE MINIMIZING COMPLICATIONS
Moses Markowitz
Favorite
Marks, Adam

University of Michigan
(P 308) PALLIATIVE CARE INVOLVEMENT FOR ADOLESCENTS AND YOUNG ADULTS WITH BONE AND SOFT TISSUE SARCOMAS
Adam Marks
Favorite
Marques Da Costa, Maria Eugénia

Gustave Roussy
(P 53) CHARACTERIZING THE SPATIAL TRANSCRIPTOMIC LANDSCAPE OF OSTEOSARCOMA FROM DIAGNOSIS TO RELAPSE
Maria Eugénia Marques Da Costa
Favorite
(P 82) PLASMA CIRCULATING PROTEOMIC MARKERS ARE ASSOCIATED WITH METASTATIC SPREAD AND OUTCOME IN OSTEOSARCOMA
Maria Eugénia Marques Da Costa
Favorite
Marques, Bruna

A.C.Camargo Cancer Center
(P 300) GASTROINTESTINAL STROMAL TUMORS (GIST) IN YOUNG ADULTS (YA): A BRAZILIAN COHORT OF PATIENTS
Bruna Marques
Favorite
Marquina, Gloria

Hospital Clínico San Carlos
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Gloria Marquina
Favorite
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Gloria Marquina
Favorite
Martella, Elisa

Institute for the Organic Synthesis and Photoreactivity (ISOF), National Research Council (CNR)
(P 336) IMPROVEMENT OF PHOTODYNAMIC THERAPY IN SARCOMA: IN VITRO VALIDATION ON OSTEOSARCOMA AND MYXOFIBROSARCOMA
Elisa Martella
Favorite
Martin-Antona, Esteban

Hospital Clinico San Carlos
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Esteban Martin-Antona
Favorite
Martin-Broto, Javier

Fundación Jiménez Díaz University Hospital
(P 234) IMMUNOSARC II MASTER TRIAL (PHASE II OF SUNITINIB AND NIVOLUMAB): RESULTS FROM THE CLEAR CELL SARCOMA (CCS) COHORT. A GEIS, ISG, AND UCL STUDY
Javier Martin-Broto
Favorite
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Javier Martin-Broto
Favorite
(P 401) A PHASE 3 MULTI-CENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO ASSESS THE EFFICACY AND SAFETY OF EMACTUZUMAB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR (TANGENT)
Javier Martin-Broto
Favorite
Martin, Elizabeth

West Virginia University
(P 342) THE ROLE OF MYELOPEROXIDASE IN SARCOMA TREATMENT
Elizabeth Martin
Favorite
Martin, Enrico

UMC Utrecht
(P 154) PREOPERATIVE CLASSIFICATION OF NERVE SHEATH TUMORS USING RADIOMICS-BASED MACHINE LEARNING
Enrico Martin
Favorite
Martinez-Font, Esther

Fundació Institutd'InvestigacióSanitàriaIlles Balears –IdISBa
(P 13) GENOMIC PROFILING OF ADULT SOFT TISSUE SARCOMAS FROM A SINGLE CENTER EXPERIENCE
Esther Martinez-Font
Favorite
(P 322) A NEW PLAYER IN SOFT TISSUE SARCOMA PROGRESSION: WNT5A IS A PROGNOSIS BIOMARKER AND A POTENTIAL ACTIONABLE TARGET
Esther Martinez-Font
Favorite
Martinez-Torres, Valerie

University of Miami/ Jackson Health System
(P 58) COMBINATORY THERAPIES UTILIZING INHIBITION OF CARBONIC ANHYDRASE IX TO POTENTIATE RESPONSE IN RELAPSED/REFRACTORY OSTEOSARCOMA
Valerie Martinez-Torres
Favorite
(P 314) RETROSPECTIVE EVALUATION OF DISPARITIES IN ADOLESCENT AND YOUNG ADULT (AYA) PATIENTS WITH SYNOVIAL SARCOMA: A SINGLE INSTITUTION STUDY
Valerie Martinez-Torres
Favorite
Martin, Karla

National Cancer Institute Mexico
(P 213) REGIONAL KNOWLEDGE TRANSLATION IN RETROPERITONEAL SARCOMAS: IMPACT OF AN EDUCATIONAL WEBINAR SERIES BY THE MEXICAN SARCOMA GROUP
Karla Martin
Favorite
Martins, Lívia

A.C.Camargo Cancer Center
(P 300) GASTROINTESTINAL STROMAL TUMORS (GIST) IN YOUNG ADULTS (YA): A BRAZILIAN COHORT OF PATIENTS
Lívia Martins
Favorite
Martin, Sophie

UMR7021 CNRS -Laboratory of Bioimaging and Pathologies
(P 75) METABOLIC EVALUATION OF THE RELATIONSHIP BETWEEN MACROPHAGES AND OSTEOSARCOMA TUMOR CELLS
Sophie Martin
Favorite
(P 89) TARGETED THERAPY OF MET, TYROSINE KINASE RECEPTOR, IN PEDIATRIC HIGH-GRADE OSTEOSARCOMAS : A NEW WAY TO TREAT PATIENTS ?
Sophie Martin
Favorite
(P 426) GD2 HETEROGENEIC EXPRESSION IN OSTEOSARCOMAS AND EWING SARCOMAS UNDERLYING A WORST PROGNOSIS
Sophie Martin
Favorite
Marwa, Bilal

Saskatchewan Cancer Agency
(P 293) CIC-REARRANGED SOFT TISSUE SARCOMAS: DOES CHEMOTHERAPY CHANGE NATURAL HISTORY AND PROGNOSIS? A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Bilal Marwa
Favorite
(P 320) WHAT IS THE ROLE OF CHEMOTHERAPY IN PATIENTS (PTS) WITH SPINDLE CELL/SCLEROSING RHABDOMYOSARCOMA (SCRMS): A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Bilal Marwa
Favorite
Marzullo, Aldo

IRCCS Humanitas Research Hospital
(P 290) ARTIFICIAL INTELLIGENCE-BASED COMPARISON OF ADULT AND ADOLESCENT AND YOUNG ADULTS (AYA) SARCOMAS: A PILOT STUDY
Aldo Marzullo
Favorite
Mascagni, Ilaria

IRCCS Humanitas Research Hospital
(P 124) ASSESSMENT OF THE MECHANISMS OF ACTION OF ERIBULIN IN PATIENTS WITH ADVANCED LIPOSARCOMA THROUGH THE EVALUATION OF THE RADIOLOGICAL, FUNCTIONAL AND TISSUE RESPONSE: A MONOCENTRIC PROSPECTIVE STUDY
Ilaria Mascagni
Favorite
(P 431) REAL-WORLD EXPERIENCE OF EFFICACY AND TOLERABILITY OF CONTINUOS INFUSION IFOSFAMIDE AMONG ADVANCED SOFT TISSUE AND BONE SARCOMAS PATIENTS: A SINGLE CENTRE RETROSPECTIVE COHORT.
Ilaria Mascagni
Favorite
Mascarenhas, Leo

Cedars-Sinai Medical Center, California, CA, USA
(P 76) MOLECULAR AND CHROMOSOMAL MICROARRAY PROFILING OF OSTEOSARCOMA IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS: A SINGLE INSTITUTION REPORT
Leo Mascarenhas
Favorite
(P 140) CIRCULATING TUMOR DNA AS A TOOL OF SURVEILLANCE AND EARLY INDICATOR OF RELAPSE IN SARCOMA PATIENTS
Leo Mascarenhas
Favorite
(P 309) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT SOFT TISSUE SARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Leo Mascarenhas
Favorite
(P 393) EFFICACY AND SAFETY OF LAROTRECTINIB AS FIRST-LINE TREATMENT IN PATIENTS WITH TRK FUSION SARCOMAS
Leo Mascarenhas
Favorite
Maser, Petra

IOmx AG
(P 337) OMX-0407 A NOVEL SPECTRUM-SELECTIVE SMALL MOLECULE KINASE INHIBITOR IS ACTIVE IN THE TREATMENT OF ANGIOSARCOMA
Petra Maser
Favorite
Ma, Shuang

Cleveland Clinic
(P 102) ANALYSIS OF BLOOD-BASED BIOMARKERS AS PROGNOSTIC FACTORS IN PATIENTS WITH EHE TREATED WITH TRAMETINIB IN SARC033
Shuang Ma
Favorite
MASSARD, CHRISOPHE

Institut Gustave Roussy
(P 87) SAFETY AND EFFICACY OF OLUTASIDENIB, AN IDH1 MUTANT INHIBITOR, FOR THE TREATMENT OF RECURRENT/ RELAPSED LOCALLY ADVANCED OR METASTATIC IDH1 MUTATED CHONDROSARCOMA
CHRISOPHE MASSARD
Favorite
Massa, Simona

Azienda Ospedaliera Specialistica dei Colli
(P 420) CELLULARITY DEGREES IN PRIMARY MYXOID LIPOSARCOMA: ASSOCIATION WITH TUMOR IMMUNE INFILTRATE AND PATIENT OUTCOMES
Simona Massa
Favorite
mastronuzzi, angela

BAMBINO GESU CHILDREN HOSPITAL
(P 298) EWING SARCOMA OF MAXILLOFACIAL REGION AND SKULL: A RETROSPECTIVE MONOINSTITUTIONAL PEDIATRIC SERIES
angela mastronuzzi
Favorite
(P 311) QUANTIFICATION OF TUMOUR-INFILTRATING IMMUNE CELLS THROUGH DECONVOLUTION OF DNA METHYLATION DATA IN EWING SARCOMAS
angela mastronuzzi
Favorite
Masunaga, Tomoya

Nara Medical University
(P 85) PTEROSTILBENE SENSITIZES OSTEOSARCOMA CELLS TO KILLING BY C-MYC INHIBITORS
Tomoya Masunaga
Favorite
(P 313) RELATION BETWEEN NUTRITIONAL/INFLAMMATORY PARAMETERS AND PROGNOSIS IN CHILDHOOD SARCOMA PATIENTS
Tomoya Masunaga
Favorite
Masztalerz, Jan

Maria Sklodowska-Curie National Research Institute of Oncology
(P 46) A NEED FOR STANDARDIZATION IN TRIAL DESIGN AND DATA REPORTING IN PHASE II TRIALS IN RARE TUMORS. LESSONS LEARNED FROM PHASE II TRIALS IN BONE SARCOMAS
Jan Masztalerz
Favorite
Matalon, Julia

Atlantic Health System
(P 405) LIPOSOMAL BUPIVACAINE DOESN'T REDUCE NARCOTIC USE OR PAIN SCORES COMPARED TO A MULTIDRUG COCKTAIL FOLLOWING SOFT TISSUE TUMOR REMOVAL: PRELIM RESULTS OF A PROSPECTIVE, RANDOMIZED DOUBLE-BLINDED STUDY
Julia Matalon
Favorite
Matsumoto, Koji

Hyogo Cancer Center
(P 168) EFFICACY OF LOW-DOSE IMATINIB IN A PATIENT WITH A GIST WITH KIT EXON 11 W557_K558 DELETION
Koji Matsumoto
Favorite
Matsumoto, Yoshihiro

Fukushima Medical University
(P 203) IMPACT OF COVID-19 PANDEMIC ON BONE AND SOFT TISSUE SARCOMA PATIENTS' CONSULTATION AND DIAGNOSIS
Yoshihiro Matsumoto
Favorite
Matsunobu, Tomoya

Kyushu Rosai Hospital
(P 203) IMPACT OF COVID-19 PANDEMIC ON BONE AND SOFT TISSUE SARCOMA PATIENTS' CONSULTATION AND DIAGNOSIS
Tomoya Matsunobu
Favorite
Matsuoka, Haruki

Osaka International Cancer Institute
(P 283) USE OF MIXED REALITY IN PELVIC BONE TUMOR RESECTION: FIVE CASE STUDY
Haruki Matsuoka
Favorite
(P 387) SUCCESSFUL PAZOPANIB TREATMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA WITH COAMPLIFICATION OF PDGFRA, VEGFR2, AND KIT: A CASE REPORT
Haruki Matsuoka
Favorite
Matsuyama, Arata

University of Saskatchewan
(P 01) A PILOT STUDY ON SINGLE-NUCLEUS RNA SEQUENCING IN CANINE SOFT TISSUE SARCOMAS
Arata Matsuyama
Favorite
Matteucci, Federica

IRST - Meldola
(P 144) EXPLORATORY ANALYSIS OF 68GA-FAPI-46 PET-CT IN SOFT TISSUE SARCOMA
Federica Matteucci
Favorite
Matui, Yoshiyuki

Department of Urology, National Cancer Center Hospital, Tokyo, Japan
(P 134) REAL-WORLD CLINICAL OUTCOME OF NEOADJUVANT CHEMOTHERAPY FOR RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA
Yoshiyuki Matui
Favorite
Matyas, John

McCaig Institute for Bone and Joint Health
(P 327) CHARACTERIZATION OF TWO NOVEL IMMUNE COMPETENT, MURINE MODELS OF SOFT TISSUE SARCOMA
John Matyas
Favorite
Mayo, Skye

OHSU Knight Cancer Institute
(P 364) A PHASE 1B TRIAL OF PREOPERATIVE ERIBULIN AND RADIATION FOR RETROPERITONEAL LIPOSARCOMA
Skye Mayo
Favorite
Mazzeo, Filomena

Clinic St Luc Bussells
(P 337) OMX-0407 A NOVEL SPECTRUM-SELECTIVE SMALL MOLECULE KINASE INHIBITOR IS ACTIVE IN THE TREATMENT OF ANGIOSARCOMA
Filomena Mazzeo
Favorite
Mazzocca, Alessandro

Fondazione Policlinico Universitario Campus Bio-Medico
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Alessandro Mazzocca
Favorite
(P 178) PREDICTION OF PRIMARY IMATINIB-REFRACTORY PATIENTS WITH LOCALLY ADVANCED OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) USING RADIOMICS AND ARTIFICIAL INTELLIGENCE (AI)
Alessandro Mazzocca
Favorite
Mazzola, Emanuele

Dana-Farber Cancer Institute
(P 107) DOES THE USE OF ADJUVANT CHEMOTHERAPY IN LOCALIZED, RESECTABLE SOFT TISSUE SARCOMA LEAD TO BETTER SURVIVAL OUTCOMES? - A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Emanuele Mazzola
Favorite
(P 402) A PILOT STUDY OF BTX-A51 IN PATIENTS WITH METASTATIC AND/OR RECURRENT LIPOSARCOMAS CHARACTERIZED BY MDM2 AMPLIFICATIONS
Emanuele Mazzola
Favorite
McCabe, Martin

University of Manchester
(P 60) DIAGNOSIS AND MANAGEMENT OF PAEDIATRIC EWING SARCOMA PATIENTS IN ENGLAND 2014-2017: A COMPARISON OF NATIONAL DATA WITH THE EURO-EWING 2012 CLINICAL TRIAL
Martin McCabe
Favorite
McCadden, Meagan

Massachusetts General Hospital
(P 63) DOES TUMOR NECROSIS IMPACT PROGNOSIS IN CHONDROBLASTIC AND OSTEOBLASTIC OSTEOSARCOMA? A STUDY FROM A LARGE TERTIARY CARE ACADEMIC CENTER
Meagan McCadden
Favorite
McCarville, M.

Vanderbilt University School of Medicine
(P 288) ANGIOA: A SAFETY AND TOLERABILITY STUDY OF TRIPLE ANTI-ANGIOGENIC THERAPY COMBINED WITH PD-L1 BLOCKADE IN PEDIATRIC, ADOLESCENT AND YOUNG ADULT RECURRENT/REFRACTORY SOLID TUMORS
M. McCarville
Favorite
McCormack, Thomas

University of Kansas Medical Center
(P 271) OUTCOMES OF DISTAL FEMORAL REPLACEMENT VS INTERNAL FIXATION FOR METASTATIC BONE DISEASE OF THE DISTAL FEMUR
Thomas McCormack
Favorite
McCoy, Kristyn

Texas Tech University Health Sciences Center
(P 292) CHARACTERIZATION OF TELOMERE MAINTENANCE MECHANISMS IN OSTEOSARCOMA PATIENT-DERIVED LABORATORY MODELS
Kristyn McCoy
Favorite
McCoy, Michaella

University College London Hospital
(P 185) ADDRESSING THE GAP FOR SYMPTOM CONTROL THROUGH THE IMPLEMENTATION OF ENHANCED SUPPORTIVE CARE AT THE LONDON SARCOMA SERVICE
Michaella McCoy
Favorite
McCutcheon, Ian

The University of Texas MD Anderson Cancer Center
(P 360) TREATMENT OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR WITH BROMODOMAIN EXTRA TERMINAL INHIBITOR (BETI) IN COMBINATION WITH RADIOTHERAPY
Ian McCutcheon
Favorite
McDermott, Ray

St. Vincent’s University Hospital and University College Dublin
(P 396) LONG-TERM FOLLOW-UP EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Ray McDermott
Favorite
McDuffie, Keasya

University of Pittsburgh
(P 64) ENTINOSTAT ENHANCES PRO-INFLAMMATORY CHEMOKINE PRODUCTION AND INCREASES RADIATION-INDUCED APOPTOSIS IN EWING SARCOMA
Keasya McDuffie
Favorite
McGivney, Gavin

University of Iowa
(P 12) GENETIC LANDSCAPE OF MPNST DETERMINES METABOLIC STRATEGIES AND THERAPEUTIC OPPORTUNITIES FOR COPING WITH REDOX STRESS
Gavin McGivney
Favorite
McGough, Richard

UPMC
(P 256) CHARACTERIZING ORTHOPAEDIC ONCOLOGIC POLYTRAUMAS: A COMPARISON OF PATIENTS UNDERGOING OPERATIVE FIXATION OF MULTIPLE LESIONS WITH THOSE WITH SOLITARY LESIONS
Richard McGough
Favorite
(P 258) COMPARING OUTCOMES FOLLOWING INTRALESIONAL VERSUS WIDE RESECTION PROCEDURES IN THE TREATMENT OF RENAL CELL CARCINOMA BONE METASTASES
Richard McGough
Favorite
McMahon, Alyson

The Ohio State University James Comprehensive Cancer Center
(P 244) PREDICTIVE VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO IN IMMUNOTHERAPY OUTCOMES IN ADVANCED SARCOMA
Alyson McMahon
Favorite
Meazza, Cristina

Pediatric Oncology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori,
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Cristina Meazza
Favorite
Mebrahtu, Aron

Duke University School of Medicine
(P 54) CHONDROBLASTIC OSTEOSARCOMA IS A RISK FACTOR FOR LOCAL RECURRENCE IN PATIENTS WITH SKELETAL OSTEOSARCOMA
Aron Mebrahtu
Favorite
Medina-Franco, Heriberto

Centro Estatal de Atención Oncológica de Morelia
(P 213) REGIONAL KNOWLEDGE TRANSLATION IN RETROPERITONEAL SARCOMAS: IMPACT OF AN EDUCATIONAL WEBINAR SERIES BY THE MEXICAN SARCOMA GROUP
Heriberto Medina-Franco
Favorite
Mehnert, Janice

Perlmutter Cancer Center of New York University Langone Health/New York University Grossman School of Medicine
(P 403) DCC-3116 IN COMBINATION WITH RIPRETINIB FOR PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A PHASE 1/2 STUDY
Janice Mehnert
Favorite
Meijer, Debora

LUMC
(P 114) METHYLOME PROFILING OF CARTILAGE TUMOURS: A PROMISING NEW TOOL FOR BIOPSY MATERIAL?
Debora Meijer
Favorite
meldolesi, elisa

POLICLINO AGOSTINO GEMELLI
(P 298) EWING SARCOMA OF MAXILLOFACIAL REGION AND SKULL: A RETROSPECTIVE MONOINSTITUTIONAL PEDIATRIC SERIES
elisa meldolesi
Favorite
Melendez-Fernandez, Ana

Instituto Nacional de Cancerología (Mexico)
(P 374) FACTORS ASSOCIATED WITH RECURRENCE IN DEDIFFERENTIATED RETROPERITONEAL LIPOSARCOMA: ANALYSIS AT A REFERENCE CENTER
Ana Melendez-Fernandez
Favorite
Mendez, Ramiro

HU Clínico San Carlos
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Ramiro Mendez
Favorite
Mercatali, Laura

Istituto Ortopedico Rizzoli IRCCS, Osteoncology- Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, Bologna, Italy ; Istituto Scientifico Romagnolo per lo studio dei Tumori "Dino Amadori", Preclinic and Osteoncology Unit, Meldola, Italy
(P 336) IMPROVEMENT OF PHOTODYNAMIC THERAPY IN SARCOMA: IN VITRO VALIDATION ON OSTEOSARCOMA AND MYXOFIBROSARCOMA
Laura Mercatali
Favorite
Mercolini, Federico

"Lalla Seràgnoli", Istituto di Ricovero e Cura a Carattere Scientifico, Azienda Ospedaliero-Universitaria di Bologna,
(P 287) AN INTERNATIONAL SURVEY OF PROVIDER PRACTICES REGARDING BONE MARROW SAMPLING VERSUS [18F] FDG PET/CT IN THE DIAGNOSTIC EVALUATION OF BONE MARROW METASTASIS IN PEDIATRIC RHABDOMYOSARCOMA
Federico Mercolini
Favorite
Meredith, Amanda

Research Institute McGill University Health Center
(P 69) H3.3G34W ONCOHISTONE IN OSTEOSARCOMA
Amanda Meredith
Favorite
Merks, Johannes

Princess Máxima Center for pediatric oncology
(P 319) THE SURVIVAL DISPARITY BETWEEN CHILDREN AND ADOLESCENTS & YOUNG ADULTS WITH EWING SARCOMA IN THE NETHERLANDS DID NOT CHANGE SINCE THE 1990S DESPITE IMPROVED SURVIVAL: A POPULATION-BASED STUDY
Johannes Merks
Favorite
Merlini, Alessandra

Department of Oncology, University of Turin
(P 345) TRANSCRIPTOMIC AND PHENOTYPIC CHARACTERIZATION OF AN IMMUNOCOMPETENT LEIOMYOSARCOMA MOUSE MODEL.
Alessandra Merlini
Favorite
(P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Alessandra Merlini
Favorite
Mersfelder, Rachel

Vanderbilt University School of Medicine
(P 73) LONGER TIME INTERVAL BETWEEN NEOADJUVANT CHEMOTHERAPY AND SURGERY IS ASSOCIATED WITH DECREASED TUMOR PERCENT NECROSIS IN OSTEOSARCOMA
Rachel Mersfelder
Favorite
Mersfelder, Rachel

Vanderbilt University Medical Center
(P 264) INTRAOPERATIVE FROZEN BONE MARROW MARGINS: A HELP OR A HINDRANCE IN EWING SARCOMA RESECTION?
Rachel Mersfelder
Favorite
Mersfelder, Rachel

Vanderbilt University School of Medicine
(P 268) LOWER TUMOR PERCENT NECROSIS IS ASSOCIATED WITH POSITIVE FINAL SURGICAL MARGINS IN OSTEOSARCOMA
Rachel Mersfelder
Favorite
Mesko, Nathan

Cleveland Clinic
(P 150) MODERN BIOPSY PRACTICE PATTERNS: A SURVEY OF THE MSTS MEMBERSHIP
Nathan Mesko
Favorite
Messina, James

University of Michigan
(P 341) THE EFFECTS OF ULTRASOUND-GUIDED HISTOTRIPSY ON SOFT TISSUE SARCOMA
James Messina
Favorite
Met, Özcan

National Center for Cancer Immune Therapy, Department of Oncology, Herlev Hospital
(P 243) MYELOSUPPRESSION FOLLOWING LYMPHODEPLETING CHEMOTHERAPY AS PART OF ADOPTIVE CELL THERAPY FOR PATIENTS WITH PROGRESSIVE SOFT TISSUE SARCOMA AFTER STANDARD CHEMOTHERAPY
Özcan Met
Favorite
Metts, Jonathan

Moffitt Cancer Center
(P 113) METASTATIC EWING'S TRAIL TESTING SCHEDULE ENHANCEMENT TO IMPROVE OUTCOMES (METTSEO)
Jonathan Metts
Favorite
(P 316) SECONDARY RHABDOMYOSARCOMA IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS
Jonathan Metts
Favorite
(P 421) CHARACTERIZATION OF INTRA-PATIENT, INTER-LESIONAL RESPONSE AND RESISTANCE DYNAMICS IN METASTATIC, FUSION-POSITIVE RHABDOMYOSARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Jonathan Metts
Favorite
Meydanli, Mehmet Mutlu

, Medical Point Hospital, Gaziantep (Turkey
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Mehmet Mutlu Meydanli
Favorite
Meyer, Andres

The University of Kansas Medical Center
(P 36) EARLY REAL-WORLD EXPERIENCE WITH THE USE OF NIROGACESTAT FOR THE TREATMENT OF DESMOID FIBROMATOSIS
Andres Meyer
Favorite
Meyers, Paul

Memorial Sloan Kettering Cancer Center
(P 50) ANALYSIS OF CLINICAL FEATURES AND OUTCOMES FOR PATIENTS WITH MULTIFOCAL OSTEOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Paul Meyers
Favorite
Mgebroff, Stephanie

Seattle Children's Research Institute
(P 226) EARLY EXPERIENCE ON ENLIGHTEN-01: A PHASE 1 STUDY OF BISPECIFIC ADAPTER MOLECULE- CONTROLLED FOLATE RECEPTOR CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY OSTEOSARCOMA
Stephanie Mgebroff
Favorite
Miah, Aisha

The Royal Marsden hospital
(P 183) A RETROSPECTIVE STUDY OF THE EFFECTS OF PATIENT, DISEASE, AND TREATMENT FACTORS ON SURVIVAL OUTCOMES IN PATIENTS WITH SOFT TISSUE SARCOMA BRAIN METASTASES
Aisha Miah
Favorite
(P 349) LONG-TERM SURVIVAL OF PARTICIPANTS IN THE PASART-1 AND PASART-2 TRIALS OF NEO-ADJUVANT PAZOPANIB AND RADIOTHERAPY IN SOFT TISSUE SARCOMA
Aisha Miah
Favorite
MIALLOT, Richard

Research Institute McGill University Health Centre
(P 19) INVOLVEMENT OF O-GLCNAC TRANSFERASE IN RESISTANCE TO DOXORUBICIN AND CELL DEATH IN PRECLINICAL MODELS OF LEIOMYOSARCOMA AND DESMOID TUMORS
Richard MIALLOT
Favorite
Miceli, Rosalba

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Rosalba Miceli
Favorite
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Rosalba Miceli
Favorite
(P 429) PATIENTS WITH ADVANCED EPITHELIOID HEMANGIOENDOTHELIOMA TREATED WITH SIROLIMUS: OUTCOME FOLLOWING SIROLIMUS DISCONTINUATION.
Rosalba Miceli
Favorite
Michel Zwaan, Christian

Prinses Maxima Centrum, Utrecht, the Netherlands and Erasmus MC-Sophia Children’s Hospital, Rotterdam, Netherlands
(P 393) EFFICACY AND SAFETY OF LAROTRECTINIB AS FIRST-LINE TREATMENT IN PATIENTS WITH TRK FUSION SARCOMAS
Christian Michel Zwaan
Favorite
miele, evelina

BAMBINO GESU CHILDREN HOSPITAL
(P 298) EWING SARCOMA OF MAXILLOFACIAL REGION AND SKULL: A RETROSPECTIVE MONOINSTITUTIONAL PEDIATRIC SERIES
evelina miele
Favorite
(P 311) QUANTIFICATION OF TUMOUR-INFILTRATING IMMUNE CELLS THROUGH DECONVOLUTION OF DNA METHYLATION DATA IN EWING SARCOMAS
evelina miele
Favorite
Miettinen, Markku

Laboratory of Pathology, National Cancer Institute/National Institutes of Health
(P 163) CHARACTERIZATION OF INTRAHEPATIC RECURRENCE FOLLOWING LIVER-DIRECTED SURGERY IN PATIENTS WITH METASTATIC SDH-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST): RISE AND STABILIZATION OF THE GISTLETS
Markku Miettinen
Favorite
Milano, Giuseppe

Bambino Gesù Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCSS)
(P 298) EWING SARCOMA OF MAXILLOFACIAL REGION AND SKULL: A RETROSPECTIVE MONOINSTITUTIONAL PEDIATRIC SERIES
Giuseppe Milano
Favorite
(P 311) QUANTIFICATION OF TUMOUR-INFILTRATING IMMUNE CELLS THROUGH DECONVOLUTION OF DNA METHYLATION DATA IN EWING SARCOMAS
Giuseppe Milano
Favorite
Milan, Raymond

Boehringer Ingelheim Canada Ltd
(P 135) SURVIVAL OUTCOMES AND TREATMENT PATTERNS FOR PATIENTS WITH DEDIFFERENTIATED LIPOSARCOMA: A RETROSPECTIVE COHORT STUDY IN ONTARIO, CANADA
Raymond Milan
Favorite
Milhem, Mo

University of Iowa
(P 395) INTEGRATED EPIGENETIC ANALYSES IDENTIFY A MULTI-SARCOMA DNA METHYLATION SIGNATURE OF TUMOR PROGRESSION AND METASTASIS
Mo Milhem
Favorite
Milhem, Mohammed

University of Iowa
(P 87) SAFETY AND EFFICACY OF OLUTASIDENIB, AN IDH1 MUTANT INHIBITOR, FOR THE TREATMENT OF RECURRENT/ RELAPSED LOCALLY ADVANCED OR METASTATIC IDH1 MUTATED CHONDROSARCOMA
Mohammed Milhem
Favorite
(P 413) SUSTAINED EFFICACY DURING DRUG HOLIDAY ON ATEZOLIZUMAB IN PATIENTS WITH ALVEOLAR SOFT PART SARCOMA (ASPS)
Mohammed Milhem
Favorite
Miller, Ira

Rush University Medical Center
(P 126) CHARACTERIZING THE TRANSFORMATION AND DIAGNOSIS OF ATYPICAL LIPOMATOUS TUMOR OF THE EXTREMITIES TO DEDIFFERENTIATED LIPOSARCOMA: SINGLE INSTITUTIONAL OUTCOMES
Ira Miller
Favorite
Million, Lynn

Stanford University School of Medicine
(P 356) RADIATION PRACTICE PATTERNS AND OUTCOMES IN ADOLESCENT YOUNG ADULT PATIENTS WITH VISCERAL NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA
Lynn Million
Favorite
Mintemur, Ömer

IRCCS Humanitas Research Hospital
(P 373) EVALUATION OF HISTOLOGIC ORGAN INFILTRATION (HOI) AND VISCERAL RESECTION MARGINS (VRM) IN PRIMARY RETROPERITONEAL SARCOMAS: PROGNOSTIC IMPLICATIONS FOR LOCAL RECURRENCE
Ömer Mintemur
Favorite
Miserocchi, Giacomo

Istituto Romagnolo per lo studio dei Tumori "Dino Amadori" IRST IRCCS, Preclinic and Osteoncology Unit, Meldola, Italy
(P 336) IMPROVEMENT OF PHOTODYNAMIC THERAPY IN SARCOMA: IN VITRO VALIDATION ON OSTEOSARCOMA AND MYXOFIBROSARCOMA
Giacomo Miserocchi
Favorite
Mitchell, Catherine

Peter MacCallum Cancer Centre
(P 151) MOLECULAR ANALYSIS OF CUTANEOUS SARCOMATOID NEOPLASMS FREQUENTLY IDENTIFIES MELANOMA DRIVER VARIANTS
Catherine Mitchell
Favorite
Mitra, Akash

Tempus Labs
(P 398) PREDICTORS OF EFFICACY IN PATIENTS WITH SOFT TISSUE SARCOMAS TREATED WITH PAZOPANIB
Akash Mitra
Favorite
Miyagi, Ryo

Department of Orthopaedic Surgery, Tokushima Prefectural Central Hospital
(P 138) ACCURACY AND COMPLICATIONS OF CORE NEEDLE BIOPSY OF PERIPHERAL NERVE TUMORS
Ryo Miyagi
Favorite
Miyaki, Aya

Seattle Children's Research Institute
(P 330) EFFICACY OF NON-CARDIOTOXIC ANTHRACYCLINES IN EWING SARCOMA
Aya Miyaki
Favorite
Moding, Everett

Stanford University
(P 356) RADIATION PRACTICE PATTERNS AND OUTCOMES IN ADOLESCENT YOUNG ADULT PATIENTS WITH VISCERAL NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA
Everett Moding
Favorite
(P 397) MTOR ACTIVITY: A BIOMARKER FOR CHEMO- AND IMMUNOTHERAPY RESPONSE AND OUTCOMES IN SARCOMAS
Everett Moding
Favorite
Mollard, Coralie

UPR3572 CNRS Laboratory Institute of Molecular and Cellular Biology
(P 75) METABOLIC EVALUATION OF THE RELATIONSHIP BETWEEN MACROPHAGES AND OSTEOSARCOMA TUMOR CELLS
Coralie Mollard
Favorite
Moloney, Brendan

Oregon Health & Science University
(P 364) A PHASE 1B TRIAL OF PREOPERATIVE ERIBULIN AND RADIATION FOR RETROPERITONEAL LIPOSARCOMA
Brendan Moloney
Favorite
Momoli, Carolina

Institute for the Organic Synthesis and Photoreactivity (ISOF), National Research Council (CNR)
(P 336) IMPROVEMENT OF PHOTODYNAMIC THERAPY IN SARCOMA: IN VITRO VALIDATION ON OSTEOSARCOMA AND MYXOFIBROSARCOMA
Carolina Momoli
Favorite
Monberg, Tine

National Center for Cancer Immune Therapy, Department of Oncology, Herlev Hospital
(P 243) MYELOSUPPRESSION FOLLOWING LYMPHODEPLETING CHEMOTHERAPY AS PART OF ADOPTIVE CELL THERAPY FOR PATIENTS WITH PROGRESSIVE SOFT TISSUE SARCOMA AFTER STANDARD CHEMOTHERAPY
Tine Monberg
Favorite
Monga, Varun

University of California San Francisco
(P 395) INTEGRATED EPIGENETIC ANALYSES IDENTIFY A MULTI-SARCOMA DNA METHYLATION SIGNATURE OF TUMOR PROGRESSION AND METASTASIS
Varun Monga
Favorite
Monjazeb, Arta

Radiation Oncology, University of California Davis, Sacramento
(P 230) HIGHER BODY MASS INDEX IS ASSOCIATED WITH DECREASED CIRCULATING AND INTRATUMORAL NATURAL KILLER CELLS IN SOFT TISSUE SARCOMA
Arta Monjazeb
Favorite
Monteleone, Laura

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 429) PATIENTS WITH ADVANCED EPITHELIOID HEMANGIOENDOTHELIOMA TREATED WITH SIROLIMUS: OUTCOME FOLLOWING SIROLIMUS DISCONTINUATION.
Laura Monteleone
Favorite
Montgomery, Elizabeth

University of Miami
(P 224) COMPREHENSIVE EVALUATION OF DNA DAMAGE RESPONSE PATHWAY ALTERATIONS AND ASSOCIATED IMMUNOTHERAPY-RESPONSE BIOMARKERS IN SARCOMAS
Elizabeth Montgomery
Favorite
Monti, Lorenzo

IRCCS, Humanitas Research Hospital
(P 155) PRIMARY MESENCHYMAL TUMORS OF THE HEART: A 8-YEARS, SINGLE INSTITUTION EXPERIENCE
Lorenzo Monti
Favorite
Montreuil, Julien

University of Miami
(P 282) UNPLANNED RESECTION OF SOFT TISSUE SARCOMA: THE IMPACT OF RESIDUAL DISEASE IN RE-RESECTION SPECIMEN
Julien Montreuil
Favorite
(P 346) BRACHYTHERAPY FOR SOFT TISSUE SARCOMA: MAINTAINING LOCAL CONTROL WHILE MINIMIZING COMPLICATIONS
Julien Montreuil
Favorite
Monument, Michael

University of Calgary
(P 236) INTERFERON STIMULATED GENE SCORES ARE ELEVATED IN THE MYELOID COMPARTMENT OF MURINE KP UNDIFFERENTIATED PLEOMORPHIC TUMORS TREATED WITH TRANSLATIONAL STING AGONISTS
Michael Monument
Favorite
(P 327) CHARACTERIZATION OF TWO NOVEL IMMUNE COMPETENT, MURINE MODELS OF SOFT TISSUE SARCOMA
Michael Monument
Favorite
(P 333) ESTIMATING IMMUNE INFILTRATES OF NOVEL GENETICALLY ENGINEERED MOUSE MODELS OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Michael Monument
Favorite
(P 422) COMPARISON OF ANNOTATION METHODS FOR PAN-SARCOMA SINGLE CELL DATA
Michael Monument
Favorite
(P 424) CROSS-COHORT INTEGRATION AS A STRATEGY TO CLASSIFY IMMUNE CHECKPOINT BLOCKADE RESPONSE IN SARCOMA
Michael Monument
Favorite
Moore, Nancy

National Institutes of Health
(P 413) SUSTAINED EFFICACY DURING DRUG HOLIDAY ON ATEZOLIZUMAB IN PATIENTS WITH ALVEOLAR SOFT PART SARCOMA (ASPS)
Nancy Moore
Favorite
Moquin-Baudry, Gael

Gustave Roussy
(P 82) PLASMA CIRCULATING PROTEOMIC MARKERS ARE ASSOCIATED WITH METASTATIC SPREAD AND OUTCOME IN OSTEOSARCOMA
Gael Moquin-Baudry
Favorite
Moquin-Beaudry,, Gael

Gustave Roussy
(P 53) CHARACTERIZING THE SPATIAL TRANSCRIPTOMIC LANDSCAPE OF OSTEOSARCOMA FROM DIAGNOSIS TO RELAPSE
Gael Moquin-Beaudry,
Favorite
Moradkhani, Ania

Sarcoma Oncology Center
(P 241) LINNOVATE: A PHASE 1/2 STUDY OF SAFETY/EFFICACY USING LURBINECTEDIN COMBINED WITH IPILUMUMAB AND NIVOLUMAB FOR ADVANCED SOFT TISSUE SARCOMA (NCT05876715)
Ania Moradkhani
Favorite
Morales, Pepi

Peptomycs S.L
(P 408) OSTEOMYC: A PHASE 2 PILOT STUDY TO EVALIATE THE SAFETY AND THE ANTITUMOR ACTIVITY OF THE MYC INHIBITOR OMO-103 ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH ADVANCED HIGH GRADE OSTEOSARCOMA
Pepi Morales
Favorite
Moran, Steven

Mayo Clinic
(P 267) LONG-TERM FUNCTIONAL OUTCOMES OF SHOULDER ARTHRODESIS FOR TUMOR RESECTION
Steven Moran
Favorite
Morelle, Magali

Centre Leon Berard
(P 125) CHARACTERISTICS, MANAGEMENT AND SURVIVAL OF N=7314 LIPOSARCOMAS FROM THE NATIONWIDE NETSARC REGISTRY IN FRANCE SINCE 2010
Magali Morelle
Favorite
Moreno, Maria Jose

Hospital Clinico san Carlos
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Maria Jose Moreno
Favorite
Moreno, Victor

START MADRID-FJD, Hospital Universitario Fundación Jiménez Díaz
(P 337) OMX-0407 A NOVEL SPECTRUM-SELECTIVE SMALL MOLECULE KINASE INHIBITOR IS ACTIVE IN THE TREATMENT OF ANGIOSARCOMA
Victor Moreno
Favorite
(P 393) EFFICACY AND SAFETY OF LAROTRECTINIB AS FIRST-LINE TREATMENT IN PATIENTS WITH TRK FUSION SARCOMAS
Victor Moreno
Favorite
Morey, Rohini

The University of Texas MD Anderson Cancer Center -
(P 325) CAN PROTEOMICS PREDICT METASTATIC RELAPSE IN LEIOMYOSARCOMA? DEVELOPMENT OF AN 8 PROTEIN SIGNATURE IN A >350 SAMPLE STUDY INCLUDING A VALIDATION COHORT
Rohini Morey
Favorite
Morii, Takeshi

Kyorin University
(P 18) IMMUNOHISTOCHEMICAL ANALYSIS OF NUCLEAR β-CATENIN IN BONE AND SOFT TISSUE TUMOR MICROARRAYS
Takeshi Morii
Favorite
Morita, Mitsunori

Hyogo Cancer Center
(P 168) EFFICACY OF LOW-DOSE IMATINIB IN A PATIENT WITH A GIST WITH KIT EXON 11 W557_K558 DELETION
Mitsunori Morita
Favorite
Moritani, Konosuke

Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan
(P 134) REAL-WORLD CLINICAL OUTCOME OF NEOADJUVANT CHEMOTHERAPY FOR RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA
Konosuke Moritani
Favorite
Morosi, Carlo

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 171) GASTROINTESTINAL STROMAL TUMOURS (GISTS) IN NEUROFIBROMATOSIS TYPE (NF1): A SINGLE-CENTER OBSERVATIONAL RETROSPECTIVE STUDY
Carlo Morosi
Favorite
(P 368) AGGRESSIVE PERINEAL ANGIOMYXOMA UNDERGOING SYSTEMIC TREATMENT: AN UPDATED REPORT OF 8-YEARS' EXPERIENCE IN A REFERRAL CENTER
Carlo Morosi
Favorite
(P 376) IMPACT OF SITE OF ORIGIN ON THE PROGNOSIS OF PATIENTS WITH PRIMARY RESECTABLE NON-UTERINE ABDOMINAL LEIOMYOSARCOMA
Carlo Morosi
Favorite
(P 429) PATIENTS WITH ADVANCED EPITHELIOID HEMANGIOENDOTHELIOMA TREATED WITH SIROLIMUS: OUTCOME FOLLOWING SIROLIMUS DISCONTINUATION.
Carlo Morosi
Favorite
Morrison, John

Division of Pediatric Hospital Medicine, Johns Hopkins All Children’s Hospital
(P 316) SECONDARY RHABDOMYOSARCOMA IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS
John Morrison
Favorite
Morrison, Linda

University of Utah
(P 332) ENHANCING THERAPEUTIC EFFICACY IN SYNOVIAL SARCOMA BY TARGETING P53-MDM2 AXIS AND HDAC PATHWAYS
Linda Morrison
Favorite
Morrissy, A. Sorana

Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary
(P 236) INTERFERON STIMULATED GENE SCORES ARE ELEVATED IN THE MYELOID COMPARTMENT OF MURINE KP UNDIFFERENTIATED PLEOMORPHIC TUMORS TREATED WITH TRANSLATIONAL STING AGONISTS
A. Sorana Morrissy
Favorite
(P 289) APPLICATION AND ANALYSIS OF SPATIAL TRANSCRIPTOMIC PROFILING TO CLINICAL ALVEOLAR SOFT PART SARCOMA SAMPLES TO UNDERSTAND IMMUNOTHERAPY-RELEVANT VARIABLES
A. Sorana Morrissy
Favorite
(P 327) CHARACTERIZATION OF TWO NOVEL IMMUNE COMPETENT, MURINE MODELS OF SOFT TISSUE SARCOMA
A. Sorana Morrissy
Favorite
(P 333) ESTIMATING IMMUNE INFILTRATES OF NOVEL GENETICALLY ENGINEERED MOUSE MODELS OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA
A. Sorana Morrissy
Favorite
(P 422) COMPARISON OF ANNOTATION METHODS FOR PAN-SARCOMA SINGLE CELL DATA
A. Sorana Morrissy
Favorite
(P 424) CROSS-COHORT INTEGRATION AS A STRATEGY TO CLASSIFY IMMUNE CHECKPOINT BLOCKADE RESPONSE IN SARCOMA
A. Sorana Morrissy
Favorite
Morse, Ashlyn

Massachusetts General Hospital
(P 108) FIXATION OF IMPENDING OR PATHOLOGIC FRACTURES DUE TO METASTATIC DISEASE WITH CARBON FIBER INTRAMEDULLARY NAILS-A PROPENSITY-SCORE MATCHED COST ANALYSIS
Ashlyn Morse
Favorite
(P 284) WOUND VAC TEMPORIZATION AFTER TUMOR RESECTION OF SOFT TISSUE SARCOMAS - A COST ANALYSIS IN A PROPENSITY-SCORE MATCHED POPULATION
Ashlyn Morse
Favorite
Mosam, Anisa

University of KwaZulu-Natal
(P 98) A MULTIEPITOPE MRNA VACCINE FOR KAPOSI SARCOMA: AN IMMUNOINFORMATIC APPROACH
Anisa Mosam
Favorite
Mosher, Hannah

University of Miami Miller School of Medicine
(P 253) ASSESSING THE LINK BETWEEN MYXOFIBROSARCOMA RECURRENCE AND TREATMENT ORDER: A MULTIDISCIPLINARY RETROSPECTIVE COHORT STUDY
Hannah Mosher
Favorite
Moskwa, Arkadiusz

Maria Sklodowska-Curie National Research Institute of Oncology
(P 46) A NEED FOR STANDARDIZATION IN TRIAL DESIGN AND DATA REPORTING IN PHASE II TRIALS IN RARE TUMORS. LESSONS LEARNED FROM PHASE II TRIALS IN BONE SARCOMAS
Arkadiusz Moskwa
Favorite
Mottard, Sophie

CEMTL
(P 212) REFERENCE SYSTEM OPTIMIZATION, ANALYSES OF THE IMPLEMENTATION OF A PROVINCIAL MULTIDISCIPLINARY SARCOMA NETWORK
Sophie Mottard
Favorite
Moura, David da Silva

Instituto de Investigación Sanitaria Fundación Jimenez Díaz (IIS-FJD)
(P 234) IMMUNOSARC II MASTER TRIAL (PHASE II OF SUNITINIB AND NIVOLUMAB): RESULTS FROM THE CLEAR CELL SARCOMA (CCS) COHORT. A GEIS, ISG, AND UCL STUDY
David da Silva Moura
Favorite
Moura, Fernando

Hospital Israelita Albert Einstein
(P 122) ACTIONABLE FUSIONS IN DEDIFFERENTIATED LIPOSARCOMA: AN ANALYSIS OF 402 CASES IN THE AACR GENIE DATABASE
Fernando Moura
Favorite
(P 141) COMPREHENSIVE GENOMIC PROFILING OF PATIENTS DIAGNOSED WITH SARCOMA IN BRAZIL: MOLECULAR PROFILE AND ACTIONABILITY
Fernando Moura
Favorite
(P 232) IMMUNE CHECKPOINT INHIBITORS COMBINED WITH TYROSINE KINASE INHIBITORS FOR SOFT-TISSUE SARCOMAS: A SYSTEMATIC REVIEW AND SINGLE-ARM META-ANALYSIS
Fernando Moura
Favorite
(P 242) MICROSATELLITE INSTABILITY AND CLINICAL USE IN SARCOMAS: A SYSTEMATIC REVIEW
Fernando Moura
Favorite
Movva, Sujana

Memorial Sloan Kettering Cancer Center
(P 229) EXPRESSION OF TRANSPOSABLE ELEMENTS AND IKZF1 PREDICTS IMMUNE INFILTRATES IN SARCOMAS AND CORRELATES WITH OUTCOMES AFTER IMMUNE CHECKPOINT INHIBITION
Sujana Movva
Favorite
Mo, Xiaokui

The Ohio State University James Comprehensive Cancer Center
(P 244) PREDICTIVE VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO IN IMMUNOTHERAPY OUTCOMES IN ADVANCED SARCOMA
Xiaokui Mo
Favorite
Mukherjee, Elina

University of Pittsburgh
(P 64) ENTINOSTAT ENHANCES PRO-INFLAMMATORY CHEMOKINE PRODUCTION AND INCREASES RADIATION-INDUCED APOPTOSIS IN EWING SARCOMA
Elina Mukherjee
Favorite
(P 66) EWING TUMORS WITH STAG2 LOSS DEMOSNTRATE ALTERED INTERFERON SIGNATURES AND IMPAIRED CXCL10 EXPRESSION
Elina Mukherjee
Favorite
Mukouhara, Toru

National Cancer Center Hospital East
(P 354) PROTON BEAM THERAPY FOR PEDIATRIC AND ADOLESCENT SARCOMA FROM OVERSEAS
Toru Mukouhara
Favorite
Mulherkar, Ria

UPMC
(P 353) PREDICTING WOUND COMPLICATIONS FOLLOWING SOFT-TISSUE SARCOMA RESECTION AMONG PATIENTS WHO RECEIVED PRE-OPERATIVE RADIATION
Ria Mulherkar
Favorite
Mullen, John

Massachusetts General Hospital
(P 371) ELUCIDATING THE CLINICAL UTILITY OF TARGETED GENE EXPRESSION PROFILING IN RETROPERITONEAL LIPOSARCOMA
John Mullen
Favorite
Mulligan, Dan

Patient Advocate
(P 206) PATIENT PERSPECTIVE ON LIPOSARCOMA DIAGNOSTIC JOURNEY: INTERIM PATIENT SURVEY RESULTS
Dan Mulligan
Favorite
Mulligan, Michael

University of Illinois Urbana-Champaign
(P 79) NOVEL THERAPEUTIC POTENTIAL THROUGH HYPERACTIVATION OF THE ANTICIPATORY UNFOLDED PROTEIN RESPONSE PATHWAY IN BONE CANCER TREATMENT
Michael Mulligan
Favorite
Mullinax, John

Moffitt Cancer Center
(P 237) INTRALESIONAL ADMINISTRATION OF TALIMOGENE LAHERPAREPVEC (T-VEC) INDUCES TUMOR REGRESSION IN PATIENTS WITH CUTANEOUS ANGIOSARCOMA
John Mullinax
Favorite
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
John Mullinax
Favorite
MUNAKATA, Yutaro

Tokyo Women’s Medical University
(P 275) RECONSTRUCTION WITH A BURCH-SCHNEIDER CAGE AFTER BONE AND SOFT TISSUUE TUMOR SURGERY
Yutaro MUNAKATA
Favorite
Munoz, Maria

University of California Davis
(P 08) ELUCIDATING THE ROLE OF YAP IN SARCOMA DEVELOPMENT
Maria Munoz
Favorite
Murad, Rabi

Sanford Burnham Prebys Medical Discovery Institute
(P 27) SUMO2 INHIBITION REVERSES ABERRANT EPIGENETIC REWIRING DRIVEN BY SYNOVIAL SARCOMA FUSION ONCOPROTEINS AND IMPAIRS SARCOMAGENESIS
Rabi Murad
Favorite
Murphy, Erin

Cleveland Clinic
(P 351) OSTEOSARCOMA STEREOTACTIC BODY RADIOTHERAPY: OUTCOMES AND PATTERN OF FAILURE
Erin Murphy
Favorite
Murphy, William

Department of Dermatology, University of California Davis
(P 230) HIGHER BODY MASS INDEX IS ASSOCIATED WITH DECREASED CIRCULATING AND INTRATUMORAL NATURAL KILLER CELLS IN SOFT TISSUE SARCOMA
William Murphy
Favorite
Mussi, Chiara

Bayer HealthCare Pharmaceuticals
(P 396) LONG-TERM FOLLOW-UP EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Chiara Mussi
Favorite
Muth, Andreas

Sahlgrenska University Hospital
(P 170) GASTRIN RELEASING PEPTIDE RECEPTOR EXPRESSION IN GASTROINTESTINAL STROMAL TUMORS (GIST)
Andreas Muth
Favorite
Muthusamy, Bharathi

Indiana University School of Medicine
(P 365) A SINGLE INSTITUTION COMPARISON OF OUTCOMES IN PEDIATRIC AND ADULT PATIENTS WITH GYNECOLOGIC ORIGIN RHABDOMYOSARCOMA
Bharathi Muthusamy
Favorite
Mutter, Robert

Mayo Clinic
(P 210) RADIATION-ASSOCIATED ANGIOSARCOMA OF THE BREAST (RAASB): A NOMOGRAM FOR PREDICTING RECURRENCE AND PROGNOSIS
Robert Mutter
Favorite
N
Nabeshima, Akira

Kyushu University
(P 203) IMPACT OF COVID-19 PANDEMIC ON BONE AND SOFT TISSUE SARCOMA PATIENTS' CONSULTATION AND DIAGNOSIS
Akira Nabeshima
Favorite
Nacev, Benjamin

University of Pittsburgh Hillman Cancer Center
(P 229) EXPRESSION OF TRANSPOSABLE ELEMENTS AND IKZF1 PREDICTS IMMUNE INFILTRATES IN SARCOMAS AND CORRELATES WITH OUTCOMES AFTER IMMUNE CHECKPOINT INHIBITION
Benjamin Nacev
Favorite
(P 392) ATRX LOSS IN UTERINE LEIOMYOSARCOMA IS ASSOCIATED WITH WORSE OVERALL SURVIVAL AND A DISTINCT PATTERN OF GENE EXPRESSION ACROSS SUBTYPES
Benjamin Nacev
Favorite
Nadesan, Puvi

Duke University
(P 15) HISTONE DEACETYLASE-3 PLAYS A ROLE IN THE METASTATIC POTENTIAL OF A SUBPOPULATION OF CELLS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Puvi Nadesan
Favorite
Nafii, Yosef

USF Morsani College of Medicine
(P 263) HEMI- VS. REVERSE SHOULDER ARTHROPLASTY OUTCOMES FOLLOWING PROXIMAL HUMERAL ONCOLOGIC RESECTION
Yosef Nafii
Favorite
Nakahara, Ichiro

National Hospital Organization Osaka Minami Medical Center
(P 272) OUTCOMES OF FOUR CASES OF TOTAL HIP ARTHROPLASTY (THA) WITH POROUS TANTALUM IMPLANT AFTER PARTIAL ACETABULAR RESECTION USING 3D PREOPERATIVE PLANNING FOR PELVIC BONE TUMORS
Ichiro Nakahara
Favorite
Nakai, Sho

Osaka International Cancer Institute
(P 324) BENZIMIDAZOLE DERIVATIVES AS NOVEL THERAPEUTIC AGENTS FOR INI1-DEFICIENT EPITHELIOID SARCOMA
Sho Nakai
Favorite
Nakai, Sho

Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine
(P 387) SUCCESSFUL PAZOPANIB TREATMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA WITH COAMPLIFICATION OF PDGFRA, VEGFR2, AND KIT: A CASE REPORT
Sho Nakai
Favorite
Nakashima, Yasuharu

Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University
(P 203) IMPACT OF COVID-19 PANDEMIC ON BONE AND SOFT TISSUE SARCOMA PATIENTS' CONSULTATION AND DIAGNOSIS
Yasuharu Nakashima
Favorite
Nakayama, Robert

Department of Orthopaedic Surgery, Keio University School of Medicine
(P 220) SPORTS ACTIVITIES IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT SURVIVORS OF MALIGNANT BONE SARCOMAS
Robert Nakayama
Favorite
Nakazawa, Michael

MD Anderson Cancer Center
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Michael Nakazawa
Favorite
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Michael Nakazawa
Favorite
(P 233) IMMUNE CLASSES OF LEIOMYOSARCOMA DRIVEN BY B CELL INFILTRATE AND CTLA4 EXPRESSION
Michael Nakazawa
Favorite
Namciu, Stephanie

Seattle Children's Research Institute
(P 330) EFFICACY OF NON-CARDIOTOXIC ANTHRACYCLINES IN EWING SARCOMA
Stephanie Namciu
Favorite
Namer, Izzie-Jacques

iCube UMR 7357 - Laboratory for Engineering, Computer Science and Imaging- University Hospital of Strasbourg
(P 75) METABOLIC EVALUATION OF THE RELATIONSHIP BETWEEN MACROPHAGES AND OSTEOSARCOMA TUMOR CELLS
Izzie-Jacques Namer
Favorite
(P 89) TARGETED THERAPY OF MET, TYROSINE KINASE RECEPTOR, IN PEDIATRIC HIGH-GRADE OSTEOSARCOMAS : A NEW WAY TO TREAT PATIENTS ?
Izzie-Jacques Namer
Favorite
Napolitano, Andrea

The Royal Marsden NHS Foundation Trust
(P 183) A RETROSPECTIVE STUDY OF THE EFFECTS OF PATIENT, DISEASE, AND TREATMENT FACTORS ON SURVIVAL OUTCOMES IN PATIENTS WITH SOFT TISSUE SARCOMA BRAIN METASTASES
Andrea Napolitano
Favorite
Nara, Satoshi

Department of Hepatoibiliary and Pancreatic Surgery, National Cancer Center Hospital, Tokyo, Japan
(P 134) REAL-WORLD CLINICAL OUTCOME OF NEOADJUVANT CHEMOTHERAPY FOR RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA
Satoshi Nara
Favorite
Narasimhan, Supraja

Deciphera Pharmaceuticals, A member of ONO Pharma
(P 43) SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
Supraja Narasimhan
Favorite
Narayanaswamy, Prabha

Seattle Children's Research Institute
(P 226) EARLY EXPERIENCE ON ENLIGHTEN-01: A PHASE 1 STUDY OF BISPECIFIC ADAPTER MOLECULE- CONTROLLED FOLATE RECEPTOR CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY OSTEOSARCOMA
Prabha Narayanaswamy
Favorite
Narayan, Raja

Loma Linda University
(P 371) ELUCIDATING THE CLINICAL UTILITY OF TARGETED GENE EXPRESSION PROFILING IN RETROPERITONEAL LIPOSARCOMA
Raja Narayan
Favorite
Nardini, Claudia

Ospedale Pediatrico Bambino Gesù
(P 311) QUANTIFICATION OF TUMOUR-INFILTRATING IMMUNE CELLS THROUGH DECONVOLUTION OF DNA METHYLATION DATA IN EWING SARCOMAS
Claudia Nardini
Favorite
Nardi, Walter

Buenos Aires British Hospital
(P 25) PRIMARY TREATED VERSUS REFERRED TRUNK AND EXTREMITIES SOFT TISSUE SARCOMAS: ANALYSIS OF TREATMENT IMPACT IN A SPECIALIZED CENTER IN ARGENTINA.
Walter Nardi
Favorite
(P 366) ABDOMINAL AORTA RESECTION EN-BLOC WITH PRIMARY RETROPERITONEAL SOFT-TISSUE SARCOMA AND BI-ILIAC GRAFT RECONSTRUCTION.
Walter Nardi
Favorite
Narta, Kiran

University of Calgary
(P 236) INTERFERON STIMULATED GENE SCORES ARE ELEVATED IN THE MYELOID COMPARTMENT OF MURINE KP UNDIFFERENTIATED PLEOMORPHIC TUMORS TREATED WITH TRANSLATIONAL STING AGONISTS
Kiran Narta
Favorite
(P 327) CHARACTERIZATION OF TWO NOVEL IMMUNE COMPETENT, MURINE MODELS OF SOFT TISSUE SARCOMA
Kiran Narta
Favorite
(P 333) ESTIMATING IMMUNE INFILTRATES OF NOVEL GENETICALLY ENGINEERED MOUSE MODELS OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Kiran Narta
Favorite
(P 422) COMPARISON OF ANNOTATION METHODS FOR PAN-SARCOMA SINGLE CELL DATA
Kiran Narta
Favorite
Nash, Joshua

The Hospital for Sick Children
(P 159) USING THE TRANSCRIPTIONAL SPECTRUM OF UTERINE SMOOTH MUSCLE TUMORS TO IDENTIFY PROGNOSTIC SIGNATURES FOR ABNORMAL LEIOMYOMAS AND SMOOTH MUSCLE TUMOURS OF UNCERTAIN MALIGNANT POTENTIAL
Joshua Nash
Favorite
(P 329) DEVELOPING ARMS METASTATIC MODELS TO RECAPITULATE THE TUMOR MICROENVIRONMENTS OF THE AXILLA/LYMPH NODE AND LUNGS
Joshua Nash
Favorite
Nassif Haddad, Elise

The University of Texas MD Anderson Cancer Center
(P 130) HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RESECTABLE RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA (DDLPS) TREATED WITH NEOADJUVANT CHECKPOINT BLOCKADE IN A RANDOMIZED PHASE II CLINICAL TRIAL.
Elise Nassif Haddad
Favorite
(P 233) IMMUNE CLASSES OF LEIOMYOSARCOMA DRIVEN BY B CELL INFILTRATE AND CTLA4 EXPRESSION
Elise Nassif Haddad
Favorite
(P 325) CAN PROTEOMICS PREDICT METASTATIC RELAPSE IN LEIOMYOSARCOMA? DEVELOPMENT OF AN 8 PROTEIN SIGNATURE IN A >350 SAMPLE STUDY INCLUDING A VALIDATION COHORT
Elise Nassif Haddad
Favorite
Natale, Jordan

Roswell Park Comprehensive Cancer Center
(P 35) EARLY REAL WORLD EXPERIENCE WITH NIROGACESTAT IN PATIENTS WITH DESMOID FIBROMATOSIS
Jordan Natale
Favorite
Nathrath, Michaela

Klinikum Kassel
(P 03) CDK4 IS CO-AMPLIFIED WITH EITHER TP53 PROMOTER GENE FUSIONS OR MDM2 THROUGH DISTINCT MECHANISMS IN OSTEOSARCOMA
Michaela Nathrath
Favorite
(P 26) SARCDBASE: A TOOL FOR DETECTION OF GENETIC ALTERATIONS IN SARCOMA
Michaela Nathrath
Favorite
Nations, Troy

Texas Tech University Health Sciences Center
(P 292) CHARACTERIZATION OF TELOMERE MAINTENANCE MECHANISMS IN OSTEOSARCOMA PATIENT-DERIVED LABORATORY MODELS
Troy Nations
Favorite
Navai, Shoba

Baylor College of Medicine
(P 417) VITAS: ATEZOLIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY SOLID TUMORS: AN OPEN-LABEL, PHASE I/II, SINGLE-ARM, MULTI-CENTER TRIAL IN PROGRESS
Shoba Navai
Favorite
Navarria, Pierina

Humanitas Research Hospital
(P 155) PRIMARY MESENCHYMAL TUMORS OF THE HEART: A 8-YEARS, SINGLE INSTITUTION EXPERIENCE
Pierina Navarria
Favorite
(P 431) REAL-WORLD EXPERIENCE OF EFFICACY AND TOLERABILITY OF CONTINUOS INFUSION IFOSFAMIDE AMONG ADVANCED SOFT TISSUE AND BONE SARCOMAS PATIENTS: A SINGLE CENTRE RETROSPECTIVE COHORT.
Pierina Navarria
Favorite
Navid, Fariba

Children's Hospital Los Angeles
(P 76) MOLECULAR AND CHROMOSOMAL MICROARRAY PROFILING OF OSTEOSARCOMA IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS: A SINGLE INSTITUTION REPORT
Fariba Navid
Favorite
Nayak, Prakash

Tata Memorial Hospital
(P 32) CURRENT INDICATIONS OF OPEN SURGERY IN PRIMARY APPENDICULAR/ PELVIC ANEURYSMAL BONE CYSTS
Prakash Nayak
Favorite
(P 306) LONG TERM OUTCOMES OF TYPE BIIIA ROTATIONPLASTY AFTER TOTAL FEMUR EXCISION IN CHILDREN
Prakash Nayak
Favorite
Nazon, Charlotte

University Hospital of Strasbourg
(P 426) GD2 HETEROGENEIC EXPRESSION IN OSTEOSARCOMAS AND EWING SARCOMAS UNDERLYING A WORST PROGNOSIS
Charlotte Nazon
Favorite
Ndengu, Andoyo

Memorial Sloan Kettering Cancer Center
(P 338) PRECLINICAL EFFICACY OF DAN-222, A NOVEL POLYMERIC NANOPARTICLE, IN PEDIATRIC SOLID TUMOR MODELS
Andoyo Ndengu
Favorite
Neal, Jill

Clear Cell Sarcoma Foundation
(P 189) CLEAR CELL SARCOMA - REAL WORLD DATA ANALYSIS
Jill Neal
Favorite
Neefjes, Jacques

Leiden University Medical Center
(P 330) EFFICACY OF NON-CARDIOTOXIC ANTHRACYCLINES IN EWING SARCOMA
Jacques Neefjes
Favorite
Negrón-Lomas, Claudia

Research Institute McGill University Health Center
(P 69) H3.3G34W ONCOHISTONE IN OSTEOSARCOMA
Claudia Negrón-Lomas
Favorite
Neilson, Amber

Genome Engineering & Stem Cell Center (GESC@MGI) Dept. of Genetics, Washington University in St. Louis School of Medicine
(P 10) GENERATION OF A CHROMOSOME 8 GAIN;NF1-/- HUMAN INDUCED PLURIPOTENT STEM CELL DERIVED SCHWANN CELL PRECURSOR MODEL
Amber Neilson
Favorite
Nepal, Bal

Ontada
(P 133) REAL-WORLD ANALYSIS OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS) IN A US COMMUNITY ONCOLOGY SETTING
Bal Nepal
Favorite
Nessim, Carolyn

Ottawa Hospital Research Institute
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Carolyn Nessim
Favorite
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Carolyn Nessim
Favorite
Nester, Matthew

USF Health Morsani College of Medicine
(P 257) COMPARATIVE OUTCOMES OF CONSTRAINED ACETABULAR LINERS VS. DUAL MOBILITY CUPS IN COMPLEX HIP RECONSTURCTION FOR METASTATIC BONE DISEASE
Matthew Nester
Favorite
(P 262) EVALUATION OF STAGED RESECTION WITH TEMPORIZING VAC OF SOFT TISSUE SARCOMAS
Matthew Nester
Favorite
Nester, Matthew

University of South Florida Morsani College of Medicine
(P 279) SIGNIFICANCE OF TIP-APEX DISTANCE IN ACTUAL AND IMPENDING PATHOLOGICAL FRACTURES OF THE PROXIMAL FEMUR
Matthew Nester
Favorite
Neu, Natascha

Chrestos Concept GmbH & Co. KG, Essen, Germany
(P 393) EFFICACY AND SAFETY OF LAROTRECTINIB AS FIRST-LINE TREATMENT IN PATIENTS WITH TRK FUSION SARCOMAS
Natascha Neu
Favorite
(P 396) LONG-TERM FOLLOW-UP EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Natascha Neu
Favorite
Nevens, Thomas

UZ Leuven
(P 291) CASE REPORT: RADICAL EN BLOC MULTI-LEVEL SPONDYLECTOMY FOR A LOCALLY RECURRENT OSTEOSARCOMA
Thomas Nevens
Favorite
Nezu, Yutaka

Kanagawa Cancer Center
(P 220) SPORTS ACTIVITIES IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT SURVIVORS OF MALIGNANT BONE SARCOMAS
Yutaka Nezu
Favorite
Ng, Deanna

University of Toronto
(P 376) IMPACT OF SITE OF ORIGIN ON THE PROGNOSIS OF PATIENTS WITH PRIMARY RESECTABLE NON-UTERINE ABDOMINAL LEIOMYOSARCOMA
Deanna Ng
Favorite
Ng, Juliana

Northwestern University, Feinberg School of Medicine
(P 222) ANALYSIS OF THE CITN-13 SARCOMA ARM: PEMBROLIZUMAB AND INTERFERON GAMMA FOR SYNOVIAL SARCOMA AND MYXOID/ ROUND CELL LIPOSARCOMA
Juliana Ng
Favorite
(P 235) INFILTRATION OF MUCOSAL-ASSOCIATED INVARIANT T CELLS (MAITS) INTO CHONDROSARCOMA TUMORS
Juliana Ng
Favorite
Nguyen, Gia Hoang Nam

Oslo University Hospital
(P 40) PEGYLATED LIPOSOMAL DOXORUBICIN IN SYMPTOMATIC DESMOID TUMOR
Gia Hoang Nam Nguyen
Favorite
Nguyen, Sa

University of Texas MD Anderson Cancer Center
(P 130) HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RESECTABLE RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA (DDLPS) TREATED WITH NEOADJUVANT CHECKPOINT BLOCKADE IN A RANDOMIZED PHASE II CLINICAL TRIAL.
Sa Nguyen
Favorite
Nguyen, Sang

Vanderbilt University Medical Center
(P 199) FINANCIAL TOXICITY AMONG SARCOMA PATIENTS AND ASSOCIATED FACTORS
Sang Nguyen
Favorite
Nguyen, Trang

Washington University, St. Louis
(P 384) REAL WORLD EXPERIENCE IN TREATING HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA: AN ULTRA-RARE VASCULAR TUMOR
Trang Nguyen
Favorite
Nicholls, Lauren

Baylor College of Medicine
(P 315) SALVAGE THERAPY EFFICACY IS MODIFIED BY RISK GROUP AT DIAGNOSIS IN PATIENTS WITH RELAPSED RHABDOMYOSARCOMA
Lauren Nicholls
Favorite
Nicoli, Fabio

Northumbria Healthcare NHS Foundation Trust
(P 269) LYMPHOEDEMA FOLLOWING LIMB SALVAGE SURGERY FOR EXTREMITY SARCOMA: A RETROSPECTIVE ANALYSIS OF 282 PATIENTS
Fabio Nicoli
Favorite
Nielsen, Morten

National Center for Cancer Immune Therapy, Department of Oncology, Herlev Hospital
(P 243) MYELOSUPPRESSION FOLLOWING LYMPHODEPLETING CHEMOTHERAPY AS PART OF ADOPTIVE CELL THERAPY FOR PATIENTS WITH PROGRESSIVE SOFT TISSUE SARCOMA AFTER STANDARD CHEMOTHERAPY
Morten Nielsen
Favorite
Nielsen, Petur
(P 63) DOES TUMOR NECROSIS IMPACT PROGNOSIS IN CHONDROBLASTIC AND OSTEOBLASTIC OSTEOSARCOMA? A STUDY FROM A LARGE TERTIARY CARE ACADEMIC CENTER
Petur Nielsen
Favorite
Nielsen, Torsten

University of British Columbia
(P 343) TLE1 DISRUPTION DOES NOT IMPEDE SYNOVIAL SARCOMAGENESIS
Torsten Nielsen
Favorite
Niewel, Manuela

Peptomyc, S.L.
(P 408) OSTEOMYC: A PHASE 2 PILOT STUDY TO EVALIATE THE SAFETY AND THE ANTITUMOR ACTIVITY OF THE MYC INHIBITOR OMO-103 ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH ADVANCED HIGH GRADE OSTEOSARCOMA
Manuela Niewel
Favorite
Nilsson, Jenny

Lund University
(P 03) CDK4 IS CO-AMPLIFIED WITH EITHER TP53 PROMOTER GENE FUSIONS OR MDM2 THROUGH DISTINCT MECHANISMS IN OSTEOSARCOMA
Jenny Nilsson
Favorite
Nirgudkar, Neel

University of Miami Miller School of Medicine
(P 369) BLAND EMBOLIZATION AS ADJUNCT TREATMENT FOR HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA
Neel Nirgudkar
Favorite
Nishida, Yoshihiro

Nagoya university hospital
(P 280) SURGICAL OUTCOMES OF PELVIC CHONDROSARCOMA WITH A FOCUS ON WALKING ABILITY
Yoshihiro Nishida
Favorite
Nishisho, Toshihiko

Department of Orthopedics, Institute of Biomedical Sciences, Tokushima University Graduate School
(P 138) ACCURACY AND COMPLICATIONS OF CORE NEEDLE BIOPSY OF PERIPHERAL NERVE TUMORS
Toshihiko Nishisho
Favorite
Nitzan - Luques, Adi

SickKids hospital
(P 304) LOCAL CONTROL FOR PEDIATRIC RHABDOMYOSARCOMA OF THE EXTREMITIES. IS RADIOTHERAPY ALWAYS REQUIRED AFTER ADEQUATE SURGICAL RESECTION?
Adi Nitzan - Luques
Favorite
Niu, Ningning

The First Hospital of Jilin University
(P 119) UPDATED RESULTS OF A SINGLE-ARM,MULTI-CENTER STUDY OF ANLOTINIB COMBINED WITH TORIPALIMAB IN FIRST-LINE TREATMENT OF UNRESECTABLE OR METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Ningning Niu
Favorite
Niu, Xiaohui

Beijing Jishuitan Hospital, Capital Medical University
(P 407) LONG-TERM EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): PHASE 1B UPDATE.
Xiaohui Niu
Favorite
Niu, Xiao-Hui

Beijing Jishuitan Hospital, Capital Medical University, Beijing, China
(P 132) PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND DISEASE BURDEN OF DEDIFFERENTIATED LIPOSARCOMA IN CHINA: A REAL-WORLD STUDY BASED ON NATIONAL CANCER REGISTRY
Xiao-Hui Niu
Favorite
Nizri, Eran

Tel-Aviv Sourasky Medical Center and Sackler Faculty of Medicine
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Eran Nizri
Favorite
Nizri, Eran

Tel-Aviv Sourasky Medical Center
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Eran Nizri
Favorite
Nordan, Taylor

Brigham and Women's Hospital
(P 167) DEFINING TEXTBOOK OUTCOMES FOR MINIMALLY INVASIVE SURGICAL RESECTION OF SMALL GASTROINTESTINAL STROMAL TUMORS (GIST) OF THE STOMACH
Taylor Nordan
Favorite
Norry, Elliot

Adaptimmune
(P 202) IMPACT OF AFAMI-CEL ON THE HEALTH STATE OF PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR MYXOID/ROUND CELL LIPOSARCOMA: COHORT 1 OF SPEARHEAD-1
Elliot Norry
Favorite
Noujaim, Jonathan

Hôpital Maisonneuve-Rosemont
(P 153) PATTERNS, MANAGEMENT AND SURVIVAL OUTCOMES OF PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA: A NATIONWIDE ANALYSIS FROM THE CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION DATABASE
Jonathan Noujaim
Favorite
(P 212) REFERENCE SYSTEM OPTIMIZATION, ANALYSES OF THE IMPLEMENTATION OF A PROVINCIAL MULTIDISCIPLINARY SARCOMA NETWORK
Jonathan Noujaim
Favorite
(P 293) CIC-REARRANGED SOFT TISSUE SARCOMAS: DOES CHEMOTHERAPY CHANGE NATURAL HISTORY AND PROGNOSIS? A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Jonathan Noujaim
Favorite
(P 320) WHAT IS THE ROLE OF CHEMOTHERAPY IN PATIENTS (PTS) WITH SPINDLE CELL/SCLEROSING RHABDOMYOSARCOMA (SCRMS): A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Jonathan Noujaim
Favorite
(P 394) IDENTIFYING THE INTERACTOME OF THE ONCOGENIC FUSIONS OF SARCOMAS TO REVEAL NOVEL THERAPEUTIC TARGETS
Jonathan Noujaim
Favorite
Novak, Marko

Institute of Oncology Ljubljana
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Marko Novak
Favorite
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Marko Novak
Favorite
Nunez, Osvaldo

University of Miami Miller School of Medicine
(P 253) ASSESSING THE LINK BETWEEN MYXOFIBROSARCOMA RECURRENCE AND TREATMENT ORDER: A MULTIDISCIPLINARY RETROSPECTIVE COHORT STUDY
Osvaldo Nunez
Favorite
Nuss, Kalie

University of South Florida Morsani College of Medicine
(P 263) HEMI- VS. REVERSE SHOULDER ARTHROPLASTY OUTCOMES FOLLOWING PROXIMAL HUMERAL ONCOLOGIC RESECTION
Kalie Nuss
Favorite
Nyeng, Tine

Department of Oncology Medical Physics, Aarhus University Hospital
(P 357) RADIATION THERAPY OF EXTREMITY SOFT TISSUE SARCOMAS: A NATIONWIDE COHORT STUDY OF LATE SIDE EFFECTS - TRIAL IN PROGRESS
Tine Nyeng
Favorite
Nystrom, Lukas

Cleveland Clinic
(P 150) MODERN BIOPSY PRACTICE PATTERNS: A SURVEY OF THE MSTS MEMBERSHIP
Lukas Nystrom
Favorite
O
Obeidin, Farres

Northwestern University, Feinberg School of Medicine, Department of Pathology
(P 179) PRIMARY MANAGEMENT OF LOCALIZED GASTROINTESTINAL STROMAL TUMORS WITH IMATINIB MONOTHERAPY: AN ALTERNATIVE TO RESECTION FOR PATIENTS PRECLUDED FROM SURGERY
Farres Obeidin
Favorite
(P 222) ANALYSIS OF THE CITN-13 SARCOMA ARM: PEMBROLIZUMAB AND INTERFERON GAMMA FOR SYNOVIAL SARCOMA AND MYXOID/ ROUND CELL LIPOSARCOMA
Farres Obeidin
Favorite
(P 235) INFILTRATION OF MUCOSAL-ASSOCIATED INVARIANT T CELLS (MAITS) INTO CHONDROSARCOMA TUMORS
Farres Obeidin
Favorite
Obergfell, Timo

SwissSarcomaNetwork
(P 204) IMPACT OF UNPéLANNED EXCISION ON THE SURVIVAL OF SARCOMA PATIENTS - A TARGET TRIAL EMULATION
Timo Obergfell
Favorite
Oberley, Matthew

Caris Life Sciences
(P 224) COMPREHENSIVE EVALUATION OF DNA DAMAGE RESPONSE PATHWAY ALTERATIONS AND ASSOCIATED IMMUNOTHERAPY-RESPONSE BIOMARKERS IN SARCOMAS
Matthew Oberley
Favorite
(P 246) THE GENOMIC AND IMMUNE LANDSCAPE OF LIPOSARCOMA AND ITS SUBTYPES
Matthew Oberley
Favorite
Oberoi, Sapna

CancerCare Manitoba
(P 293) CIC-REARRANGED SOFT TISSUE SARCOMAS: DOES CHEMOTHERAPY CHANGE NATURAL HISTORY AND PROGNOSIS? A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Sapna Oberoi
Favorite
Obrador-Hevia, Antonia

Fundació Institutd'InvestigacióSanitàriaIlles Balears –IdISBa
(P 13) GENOMIC PROFILING OF ADULT SOFT TISSUE SARCOMAS FROM A SINGLE CENTER EXPERIENCE
Antonia Obrador-Hevia
Favorite
(P 322) A NEW PLAYER IN SOFT TISSUE SARCOMA PROGRESSION: WNT5A IS A PROGNOSIS BIOMARKER AND A POTENTIAL ACTIONABLE TARGET
Antonia Obrador-Hevia
Favorite
O'Brien Cox, Anderson

Wake Forest
(P 430) QUANTITATIVE EMT GENE SCORES AT DIAGNOSIS INDICATE METASTASIS RISK AND SURVIVAL IN SYNOVIAL SARCOMA
Anderson O'Brien Cox
Favorite
Oda, Katsutoshi

The University of Tokyo, Division of Integrative Genomics
(P 103) BRAF MUTATIONS AND CONCURRENT ALTERATIONS IN PATIENTS WITH SOFT TISSUE SARCOMA
Katsutoshi Oda
Favorite
O'Donnell, edmond

university of california davis
(P 11) GENETIC AND EPIGENETIC CHARACTERIZATION OF SARCOMA STEM CELLS ACROSS SUBTYPES IDENTIFIES EZH2 AS A THERAPEUTIC TARGET
edmond O'Donnell
Favorite
Oesterheld, Javier

Atrium Health Levine Children's Hospital
(P 309) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT SOFT TISSUE SARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Javier Oesterheld
Favorite
Ogura, Koichi

National Cancer Center Hospital
(P 249) TUMOR CELL DISAPPEARANCE FOLLOWING COVID-19 INFECTION IN A PATIENT WITH PLEOMORPHIC SPINDLE CELL SARCOMA: A CASE REPORT
Koichi Ogura
Favorite
Okada, Seiji

Osaka University
(P 324) BENZIMIDAZOLE DERIVATIVES AS NOVEL THERAPEUTIC AGENTS FOR INI1-DEFICIENT EPITHELIOID SARCOMA
Seiji Okada
Favorite
Okajima, Koichi

The University of Tokyo, Department of Orthopaedic Surgery
(P 57) CLINICAL GENOMIC PROFILING OF MALIGNANT GIANT CELL TUMOR OF BONE: A RETROSPECTIVE ANALYSIS USING A REAL-WORLD DATABASE
Koichi Okajima
Favorite
(P 103) BRAF MUTATIONS AND CONCURRENT ALTERATIONS IN PATIENTS WITH SOFT TISSUE SARCOMA
Koichi Okajima
Favorite
Okcu, M. Fatih

Baylor College of Medicine
(P 315) SALVAGE THERAPY EFFICACY IS MODIFIED BY RISK GROUP AT DIAGNOSIS IN PATIENTS WITH RELAPSED RHABDOMYOSARCOMA
M. Fatih Okcu
Favorite
Okimoto, Ross

University of California, San Francisco
(P 07) DIRECTLY TARGETING CIC-DUX4 FUSION AND MYC ONCOPROTEINS FOR UNDIFFERENTIATED ROUND CELL SARCOMAS
Ross Okimoto
Favorite
Okuno, Scott

Mayo Clinic
(P 120) USING AI PREDICTIONS FROM ECG TRACINGS TO PREDICT TOLERANCE TO ANTHRACYCLINE CHEMOTHERAPY IN SARCOMA
Scott Okuno
Favorite
(P 200) FRAILTY ASSESSMENT IN OLDER PATIENTS RECEIVING SARCOMA THERAPY
Scott Okuno
Favorite
(P 412) SARC044: A PHASE II TRIAL OF BEZUCLASTINIB IN COMBINATION WITH SUNITINIB IN PATIENTS WITH GIST WHO PROGRESSED ON SUNITINIB MONOTHERAPY
Scott Okuno
Favorite
Olino, Kelly

Yale University
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Kelly Olino
Favorite
Olsen, Mallery

Phoenix Children's Hospital
(P 305) LOCAL THERAPY APPROACHES IN RELAPSED PEDIATRIC SOFT TISSUE SARCOMA AND EWING SARCOMA PATIENTS: A SINGLE INSTITUTION SERIES
Mallery Olsen
Favorite
Olson, Aaron

Seattle Children's Research Institute
(P 330) EFFICACY OF NON-CARDIOTOXIC ANTHRACYCLINES IN EWING SARCOMA
Aaron Olson
Favorite
Olson, Adam

UPMC Hillman Cancer Center
(P 353) PREDICTING WOUND COMPLICATIONS FOLLOWING SOFT-TISSUE SARCOMA RESECTION AMONG PATIENTS WHO RECEIVED PRE-OPERATIVE RADIATION
Adam Olson
Favorite
O'Neill, Brianne

Inhibrx Biosciences, Inc
(P 95) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN PATIENTS WITH CHONDROSARCOMA: UPDATED RESULTS FROM A PHASE 1 STUDY
Brianne O'Neill
Favorite
O'Neill, Francis

The Jackson Laboratory for Genomic Medicine
(P 70) IDENTIFICATION OF NOVEL PROTEIN VARIANTS IN OSTEOSARCOMA TUMORS THROUGH LONG-READ RNA SEQUENCING
Francis O'Neill
Favorite
Ong, Johnny

Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore
(P 370) DEFYING NORMS - CENTRALIZATION OF SARCOMA CARE ON AN ISLAND NATION
Johnny Ong
Favorite
(P 375) FROM SAPLING TO SHADE: GROWTH OF A HIGH VOLUME ASIAN TERTIARY SARCOMA SPECIALISED CENTRE
Johnny Ong
Favorite
Onoe, Takuma

Hyogo Cancer Center
(P 168) EFFICACY OF LOW-DOSE IMATINIB IN A PATIENT WITH A GIST WITH KIT EXON 11 W557_K558 DELETION
Takuma Onoe
Favorite
Orbach, Daniel

SIREDO Oncology Center (Care, Innovation and Research for Children and AYA with Cancer), Institut Curie, and University PSL, Paris, France
(P 393) EFFICACY AND SAFETY OF LAROTRECTINIB AS FIRST-LINE TREATMENT IN PATIENTS WITH TRK FUSION SARCOMAS
Daniel Orbach
Favorite
Organ, Bailey

Lunenefeld Tanenbaum
(P 433) TUMOR HYPOXIA AND THE RISK OF METASTASIS IN HIGH-RISK LOCALIZED UPS/MFS
Bailey Organ
Favorite
Oristian, Kristianne

Duke University
(P 301) GENOME-WIDE CRISPR/CAS9 VIABILITY SCREENS UNCOVER NOVEL GENETIC DEPENDENCIES IN CIC::DUX4 SARCOMA
Kristianne Oristian
Favorite
Orlando, Sarah

Fondazione Policlinico Campus Bio-Medico of Rome
(P 178) PREDICTION OF PRIMARY IMATINIB-REFRACTORY PATIENTS WITH LOCALLY ADVANCED OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) USING RADIOMICS AND ARTIFICIAL INTELLIGENCE (AI)
Sarah Orlando
Favorite
OROSCO TTAMINA, Angel Luis

Clinical Research Facility, University College London NHS Foundation Trust
(P 23) METASTATIC ALVEOLAR SOFT PART SARCOMA: PREGNANCY-RELATED WORSENING AND SPONTANEOUS EXCEPTIONAL REMISSION POSTPARTUM- A CASE REPORT.
Angel Luis OROSCO TTAMINA
Favorite
Ortega, Luis

Hospital Clinico san Carlos
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Luis Ortega
Favorite
Osaki, Shuhei

National Cancer Center Hospital
(P 134) REAL-WORLD CLINICAL OUTCOME OF NEOADJUVANT CHEMOTHERAPY FOR RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA
Shuhei Osaki
Favorite
(P 249) TUMOR CELL DISAPPEARANCE FOLLOWING COVID-19 INFECTION IN A PATIENT WITH PLEOMORPHIC SPINDLE CELL SARCOMA: A CASE REPORT
Shuhei Osaki
Favorite
O'Sullivan-Coyne, Geraldine

Mater Misecordiae University Hospital (MMUH)
(P 413) SUSTAINED EFFICACY DURING DRUG HOLIDAY ON ATEZOLIZUMAB IN PATIENTS WITH ALVEOLAR SOFT PART SARCOMA (ASPS)
Geraldine O'Sullivan-Coyne
Favorite
Otero Norza, Diana

Hospital Dr. Rafael Angel Calderón Guardia
(P 367) AGE AS A PROGNOSTIC FACTOR IN RETROPERITONEAL SARCOMA: A MULTICENTER LATIN AMERICAN STUDY
Diana Otero Norza
Favorite
Outani, Hidetatsu

Osaka University
(P 324) BENZIMIDAZOLE DERIVATIVES AS NOVEL THERAPEUTIC AGENTS FOR INI1-DEFICIENT EPITHELIOID SARCOMA
Hidetatsu Outani
Favorite
(P 387) SUCCESSFUL PAZOPANIB TREATMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA WITH COAMPLIFICATION OF PDGFRA, VEGFR2, AND KIT: A CASE REPORT
Hidetatsu Outani
Favorite
Outilaft, Hassiba

iCube UMR 7357 - Laboratory for Engineering, Computer Science and Imaging- University Hospital of Strasbourg
(P 75) METABOLIC EVALUATION OF THE RELATIONSHIP BETWEEN MACROPHAGES AND OSTEOSARCOMA TUMOR CELLS
Hassiba Outilaft
Favorite
(P 89) TARGETED THERAPY OF MET, TYROSINE KINASE RECEPTOR, IN PEDIATRIC HIGH-GRADE OSTEOSARCOMAS : A NEW WAY TO TREAT PATIENTS ?
Hassiba Outilaft
Favorite
Oyama, Ryunosuke

Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University
(P 203) IMPACT OF COVID-19 PANDEMIC ON BONE AND SOFT TISSUE SARCOMA PATIENTS' CONSULTATION AND DIAGNOSIS
Ryunosuke Oyama
Favorite
Oztosun, Gorkem

Washington University in St. Louis School of Medicine, Division of Oncology
(P 10) GENERATION OF A CHROMOSOME 8 GAIN;NF1-/- HUMAN INDUCED PLURIPOTENT STEM CELL DERIVED SCHWANN CELL PRECURSOR MODEL
Gorkem Oztosun
Favorite
(P 335) FOCAL ADHESION KINASE (FAK) IS A THERPEUTIC TARGET IN CHROMOSOME 8 GAIN-ASSOCIATED MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)
Gorkem Oztosun
Favorite
P
Pacas, Pavel

Department of Oncology, 2nd Medical Faculty, Charles University and University Hospital Motol
(P 355) PROTON RADIOTHERAPY FOR DESMOID TUMORS: A SINGLE-CENTER EXPERIENCE
Pavel Pacas
Favorite
Pacaud, Camille

University Hospitals of Strasbourg
(P 426) GD2 HETEROGENEIC EXPRESSION IN OSTEOSARCOMAS AND EWING SARCOMAS UNDERLYING A WORST PROGNOSIS
Camille Pacaud
Favorite
Pagnano, Maria Elisabetta

Campus Bio-Medico University of Rome
(P 178) PREDICTION OF PRIMARY IMATINIB-REFRACTORY PATIENTS WITH LOCALLY ADVANCED OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) USING RADIOMICS AND ARTIFICIAL INTELLIGENCE (AI)
Maria Elisabetta Pagnano
Favorite
Palmerini, Emanuela

IRCCS Istituto Ortopedico Rizzoli
(P 41) PEXIDARTINIB UPFRONT IN A CASE OF TENOSYNOVIAL GIANT CELL TUMOR: PROOF OF CONCEPT FOR A TREATMENT PARADIGM SHIFT
Emanuela Palmerini
Favorite
(P 43) SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
Emanuela Palmerini
Favorite
Palmerini, Emanuela

Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies Unit IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy
(P 77) MULTI-PARAMETRICAL PROFILING OF CHONDROSARCOMA
Emanuela Palmerini
Favorite
Palmerini, Emanuela

IRCCS Istituto Ortopedico Rizzoli
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Emanuela Palmerini
Favorite
(P 234) IMMUNOSARC II MASTER TRIAL (PHASE II OF SUNITINIB AND NIVOLUMAB): RESULTS FROM THE CLEAR CELL SARCOMA (CCS) COHORT. A GEIS, ISG, AND UCL STUDY
Emanuela Palmerini
Favorite
(P 401) A PHASE 3 MULTI-CENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO ASSESS THE EFFICACY AND SAFETY OF EMACTUZUMAB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR (TANGENT)
Emanuela Palmerini
Favorite
Pal, Rahul

6Department of Radiology, Massachusetts General Hospital
(P 22) MECHANISMS OF PREFERENTIAL TUMOUR UPTAKE OF INDOCYANINE GREEN IN SARCOMA
Rahul Pal
Favorite
Pal, Tuya

Vanderbilt University Medical Center
(P 199) FINANCIAL TOXICITY AMONG SARCOMA PATIENTS AND ASSOCIATED FACTORS
Tuya Pal
Favorite
(P 297) ESTABLISHING A PEDIATRIC, ADOLESCENT AND YOUNG ADULT COHORT OF SARCOMA PATIENTS TO STUDY ONCOLOGIC AND NON-ONCOLOGIC OUTCOMES
Tuya Pal
Favorite
Pan, Irene

United BioSource LLC
(P 211) REAL-WORLD EXPERIENCE OF PATIENTS NEWLY INITIATED ON PEXIDARTINIB FOR TENOSYNOVIAL GIANT CELL TUMOR
Irene Pan
Favorite
Pan, Minggui

Stanford University School of Medicine
(P 143) EARLY ASSESSMENT OF DISEASE RESPONSE TO IMMUNOTHERAPY VIA CIRCULATING TUMOR DNA IN ADVANCED SOFT TISSUE SARCOMAS
Minggui Pan
Favorite
(P 161) UTILITY OF CTDNA MONITORING IN THE ADJUVANT AND METASTATIC SETTING IN SOFT TISSUE SARCOMA
Minggui Pan
Favorite
Pannella, Micaela

Istituto Ortopedico Rizzoli IRCCS, Osteoncology- Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, Bologna, Italy
(P 336) IMPROVEMENT OF PHOTODYNAMIC THERAPY IN SARCOMA: IN VITRO VALIDATION ON OSTEOSARCOMA AND MYXOFIBROSARCOMA
Micaela Pannella
Favorite
Pan, Qiuzhong

Sun Yat-sen University Cancer Center
(P 409) PHASE 2 STUDY EVALUATING SURUFATINIB IN PATIENTS WITH OSTEOSARCOMA AND SOFT TISSUE SARCOMA WHO HAVE FAILED STANDARD CHEMOTHERAPY
Qiuzhong Pan
Favorite
Pantaleo, Maria Abbondanza

Università di Bologna
(P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Maria Abbondanza Pantaleo
Favorite
Paoli, Albit

MedStar Georgetown Cancer Institute
(P 38) LOCAL RECURRENCE OF DIFFUSE PIGMENTED VILLONODULAR SYNOVITIS IN MAJOR JOINTS: A 15 YEAR-LONG CASE SERIES AT A SINGLE INSTITUTION
Albit Paoli
Favorite
Paoluzzi Tomada, Elisa

IRCCS Humanitas Research Hospital
(P 388) THE ROAD TO CURATIVE SURGERY IN RETROPERITONEAL SOFT TISSUE SARCOMA: A DIFFERENT PATH IN THE ELDERLY?
Elisa Paoluzzi Tomada
Favorite
Papagelopoulos, Panayiotis

First Department of orthopaedic surgery, National and Kapodistrian University of Athens, Attikon University General Hospital
(P 274) PROXIMAL HUMERAL ENDOPROSTHETIC RECONSTRUCTION: RESULTS FROM THE MUTARS ORTHOPEDIC REGISTRY EUROPE (MORE)
Panayiotis Papagelopoulos
Favorite
Papai, Emily

Fox Chase Cancer Center
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Emily Papai
Favorite
Papakonstantinou, Andri

Karolinska University Hospital
(P 411) PROPANE AN OPEN LABEL PHASE 2 STUDY ON PROPRANOLOL AND PEMBROLIZUMAB IN ADVANCED ANGIOSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA A SCANDINAVIAN SARCOMA GROUP COLLABORATION
Andri Papakonstantinou
Favorite
Parafioriti, Antonina

Istituto Ortopedico Gaetano Pini
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Antonina Parafioriti
Favorite
Park, Ben

Vanderbilt University Medical Center
(P 199) FINANCIAL TOXICITY AMONG SARCOMA PATIENTS AND ASSOCIATED FACTORS
Ben Park
Favorite
(P 297) ESTABLISHING A PEDIATRIC, ADOLESCENT AND YOUNG ADULT COHORT OF SARCOMA PATIENTS TO STUDY ONCOLOGIC AND NON-ONCOLOGIC OUTCOMES
Ben Park
Favorite
Park, Byung

OHSU
(P 364) A PHASE 1B TRIAL OF PREOPERATIVE ERIBULIN AND RADIATION FOR RETROPERITONEAL LIPOSARCOMA
Byung Park
Favorite
Park, Jay Hoon

Seoul National University Hospital
(P 127) DEDIFFERENTIATED LIPOSARCOMA OF THE EXTREMITIES: A KOREAN MULTI-CENTER STUDY OF 107 CASES
Jay Hoon Park
Favorite
(P 428) OLIGOMETASTASES IN EXTREMITY SOFT TISSUE SARCOMA : SUBTYPE-SPECIFIC ANALYSES OF CHARACTERISTICS AND OUTCOMES
Jay Hoon Park
Favorite
Park, Julie

St. Jude Children's Research Hospital
(P 226) EARLY EXPERIENCE ON ENLIGHTEN-01: A PHASE 1 STUDY OF BISPECIFIC ADAPTER MOLECULE- CONTROLLED FOLATE RECEPTOR CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY OSTEOSARCOMA
Julie Park
Favorite
Parra, Adrian

University of Miami Miller School of Medicine
(P 381) OLIGOMETASTATIC LEIOMYOSARCOMA: ASSOCIATION BETWEEN TREATMENT TYPE, METASTATIC PATTERN AND SURVIVAL
Adrian Parra
Favorite
Pasquali, Sandro

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 137) TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS
Sandro Pasquali
Favorite
(P 420) CELLULARITY DEGREES IN PRIMARY MYXOID LIPOSARCOMA: ASSOCIATION WITH TUMOR IMMUNE INFILTRATE AND PATIENT OUTCOMES
Sandro Pasquali
Favorite
Patel, Abhijit

Yale University School of Medicine
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Abhijit Patel
Favorite
Patel, Anand

St. Jude Children’s Research Hospital
(P 288) ANGIOA: A SAFETY AND TOLERABILITY STUDY OF TRIPLE ANTI-ANGIOGENIC THERAPY COMBINED WITH PD-L1 BLOCKADE IN PEDIATRIC, ADOLESCENT AND YOUNG ADULT RECURRENT/REFRACTORY SOLID TUMORS
Anand Patel
Favorite
Patel, Anmol

University of Miami Miller School of Medicine
(P 369) BLAND EMBOLIZATION AS ADJUNCT TREATMENT FOR HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA
Anmol Patel
Favorite
Patel, Neel

Massachusetts General Hospital
(P 63) DOES TUMOR NECROSIS IMPACT PROGNOSIS IN CHONDROBLASTIC AND OSTEOBLASTIC OSTEOSARCOMA? A STUDY FROM A LARGE TERTIARY CARE ACADEMIC CENTER
Neel Patel
Favorite
Patel, Neil

University of Miami Miller School of Medicine
(P 369) BLAND EMBOLIZATION AS ADJUNCT TREATMENT FOR HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA
Neil Patel
Favorite
Patel, Shalin Shreyaskumar

The University of Texas MD Anderson Cancer Center
(P 233) IMMUNE CLASSES OF LEIOMYOSARCOMA DRIVEN BY B CELL INFILTRATE AND CTLA4 EXPRESSION
Shalin Shreyaskumar Patel
Favorite
Paternostro, Flavia

Fondazione Policlinico Campus Bio-Medico of Rome
(P 178) PREDICTION OF PRIMARY IMATINIB-REFRACTORY PATIENTS WITH LOCALLY ADVANCED OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) USING RADIOMICS AND ARTIFICIAL INTELLIGENCE (AI)
Flavia Paternostro
Favorite
Patrizi, Sara

Ospedale Pediatrico Bambino Gesù
(P 298) EWING SARCOMA OF MAXILLOFACIAL REGION AND SKULL: A RETROSPECTIVE MONOINSTITUTIONAL PEDIATRIC SERIES
Sara Patrizi
Favorite
(P 311) QUANTIFICATION OF TUMOUR-INFILTRATING IMMUNE CELLS THROUGH DECONVOLUTION OF DNA METHYLATION DATA IN EWING SARCOMAS
Sara Patrizi
Favorite
Pattabhi, Sowmya

Seattle Children's Research Institute
(P 226) EARLY EXPERIENCE ON ENLIGHTEN-01: A PHASE 1 STUDY OF BISPECIFIC ADAPTER MOLECULE- CONTROLLED FOLATE RECEPTOR CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY OSTEOSARCOMA
Sowmya Pattabhi
Favorite
Paudel, Amrit

University of Miami Sylvester Comprehensive Cancer Center
(P 253) ASSESSING THE LINK BETWEEN MYXOFIBROSARCOMA RECURRENCE AND TREATMENT ORDER: A MULTIDISCIPLINARY RETROSPECTIVE COHORT STUDY
Amrit Paudel
Favorite
Pauli, Chantal

University Hospital Zurich, Switzerland
(P 99) ACQUIRED NF2 MUTATION CONFERS RESISTANCE TO TRK INHIBITION IN AN EX VIVO LMNA::NTRK1-REARRANGED SOFT TISSUE SARCOMA CELL MODEL
Chantal Pauli
Favorite
(P 118) UNRAVELING HOMOLOGOUS RECOMBINATION REPAIR DEFICIENCY AND THERAPEUTIC OPPORTUNITIES IN SOFT TISSUE AND BONE SARCOMA
Chantal Pauli
Favorite
Pautier, Patricia

Gustave Roussy
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Patricia Pautier
Favorite
Pavisic, Jovana

Memorial Sloan Kettering Cancer Center
(P 49) A WORKING GROUP FOR THE DEVELOPMENT OF A CLINICAL FRAMEWORK THAT STRATIFIES OSTEOSARCOMA PATIENTS USING BIOMARKERS OF CLINICAL RISK AND BIOLOGY
Jovana Pavisic
Favorite
(P 418) A SYSTEMS BIOLOGY APPROACH FOR CHARACTERIZING TUMOR HETEROGENEITY AND CELL STATE-SPECIFIC THERAPEUTIC VULNERABILITIES FROM SINGLE NUCLEUS RNA-SEQ PROFILING OF DESMOPLASTIC SMALL ROUND CELL TUMORS
Jovana Pavisic
Favorite
Peabody, Terrance

Northwestern Memorial Hospital
(P 235) INFILTRATION OF MUCOSAL-ASSOCIATED INVARIANT T CELLS (MAITS) INTO CHONDROSARCOMA TUMORS
Terrance Peabody
Favorite
Peairs, Emily
(P 278) ROTATIONPLASTY AS AN EFFECTIVE LIMB SALVAGE OPTION IN THE ADULT POPULATION
Emily Peairs
Favorite
Pecchia, Leandro

Campus Bio-Medico University of Rome
(P 178) PREDICTION OF PRIMARY IMATINIB-REFRACTORY PATIENTS WITH LOCALLY ADVANCED OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) USING RADIOMICS AND ARTIFICIAL INTELLIGENCE (AI)
Leandro Pecchia
Favorite
Pedace, Lucia

Ospedale Pediatrico Bambino Gesù
(P 311) QUANTIFICATION OF TUMOUR-INFILTRATING IMMUNE CELLS THROUGH DECONVOLUTION OF DNA METHYLATION DATA IN EWING SARCOMAS
Lucia Pedace
Favorite
Pedgaonkar, Aditi

Sanford Burnham Prebys Medical Discovery Institute
(P 27) SUMO2 INHIBITION REVERSES ABERRANT EPIGENETIC REWIRING DRIVEN BY SYNOVIAL SARCOMA FUSION ONCOPROTEINS AND IMPAIRS SARCOMAGENESIS
Aditi Pedgaonkar
Favorite
Pelles, Sharon

Oncology, Barzilai Medical Center, Ashkelon
(P 182) A NOVEL MODEL FOR THE DIRECT REFERRAL OF ONCOLOGIC PATIENTS IN A PUBLIC HEALTH CARE SYSTEM
Sharon Pelles
Favorite
Pendilli, Sebastiano

IRCCS Humanitas Research Hospital
(P 389) THE ROLE OF NUTRITIONAL STATUS ON POSTOPERATIVE AND ONCOLOGICAL OUTCOMES IN RETROPERITONEAL SARCOMA
Sebastiano Pendilli
Favorite
Penel, Nicolas

Centre Oscar Lambret
(P 125) CHARACTERISTICS, MANAGEMENT AND SURVIVAL OF N=7314 LIPOSARCOMAS FROM THE NATIONWIDE NETSARC REGISTRY IN FRANCE SINCE 2010
Nicolas Penel
Favorite
Peng, Ruiqing

Sun Yat-sen University Cancer Center
(P 409) PHASE 2 STUDY EVALUATING SURUFATINIB IN PATIENTS WITH OSTEOSARCOMA AND SOFT TISSUE SARCOMA WHO HAVE FAILED STANDARD CHEMOTHERAPY
Ruiqing Peng
Favorite
Pennacchioli, Elisabetta

Istituto Europeo di Oncologia
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Elisabetta Pennacchioli
Favorite
Penninga, Luit

Department of Surgery and Transplantation, Copenhagen University Hospital, Rigshospitalet
(P 29) ABDOMINAL LYMPHANGIOMA CAUSING EXCESSIVE GASTROINTESTINAL BLEEDING FOR MORE THAN TWO DECADES
Luit Penninga
Favorite
(P 385) SIMULTANEOUS OCCURRENCE OF MANTLE CELL LYMPHOMA AND LIPOSARCOMA IN THE RETROPERITONEUM
Luit Penninga
Favorite
(P 386) SOLITARY FIBROUS TUMOUR: A DANISH SAMPLE FROM 2013 – 2018
Luit Penninga
Favorite
(P 391) VISCERAL ANGIOSARCOMA: A NATIONWIDE STUDY WITH LONG-TERM FOLLOW-UP
Luit Penninga
Favorite
Perano, Vittoria

IRCCS Humanitas Research Hospital
(P 362) A NEW ROCK BAND FOR DIAPHRAGMATIC RECONSTRUCTION IN LEFT RETROPERITONEAL SARCOMA SURGERY
Vittoria Perano
Favorite
Perati, Shruthi

National Institutes of Health, National Cancer Institute, Surgical Oncology Program
(P 163) CHARACTERIZATION OF INTRAHEPATIC RECURRENCE FOLLOWING LIVER-DIRECTED SURGERY IN PATIENTS WITH METASTATIC SDH-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST): RISE AND STABILIZATION OF THE GISTLETS
Shruthi Perati
Favorite
Percio, Stefano

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 137) TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS
Stefano Percio
Favorite
Peretz Soroka, Hagit

Princess Margaret Cancer Centre
(P 153) PATTERNS, MANAGEMENT AND SURVIVAL OUTCOMES OF PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA: A NATIONWIDE ANALYSIS FROM THE CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION DATABASE
Hagit Peretz Soroka
Favorite
(P 293) CIC-REARRANGED SOFT TISSUE SARCOMAS: DOES CHEMOTHERAPY CHANGE NATURAL HISTORY AND PROGNOSIS? A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Hagit Peretz Soroka
Favorite
(P 304) LOCAL CONTROL FOR PEDIATRIC RHABDOMYOSARCOMA OF THE EXTREMITIES. IS RADIOTHERAPY ALWAYS REQUIRED AFTER ADEQUATE SURGICAL RESECTION?
Hagit Peretz Soroka
Favorite
(P 320) WHAT IS THE ROLE OF CHEMOTHERAPY IN PATIENTS (PTS) WITH SPINDLE CELL/SCLEROSING RHABDOMYOSARCOMA (SCRMS): A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Hagit Peretz Soroka
Favorite
(P 321) WHOLE ABDOMINAL RADIOTHERAPY IN CHILDREN AND YOUNG ADULTS WITH SARCOMA: A CANADIAN SARCOMA AND CLINICAL COLLABORATION (CANSARCC) STUDY
Hagit Peretz Soroka
Favorite
Pérez Capó, Marina

Health Research Institute of the Balearic Islands
(P 13) GENOMIC PROFILING OF ADULT SOFT TISSUE SARCOMAS FROM A SINGLE CENTER EXPERIENCE
Marina Pérez Capó
Favorite
(P 322) A NEW PLAYER IN SOFT TISSUE SARCOMA PROGRESSION: WNT5A IS A PROGNOSIS BIOMARKER AND A POTENTIAL ACTIONABLE TARGET
Marina Pérez Capó
Favorite
Pérez-Albert, Maria Paula

Vall d´Hebrón University Hospital
(P 408) OSTEOMYC: A PHASE 2 PILOT STUDY TO EVALIATE THE SAFETY AND THE ANTITUMOR ACTIVITY OF THE MYC INHIBITOR OMO-103 ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH ADVANCED HIGH GRADE OSTEOSARCOMA
Maria Paula Pérez-Albert
Favorite
Perkins, Callum

Children's Cancer Institute
(P 299) EXPLORING THE POTENTIAL OF PHOSPHOPROTEOMIC PROFILING FOR TARGET DISCOVERY IN HIGH-RISK OSTEOSARCOMA: A PATHWAY TO NOVEL THERAPIES?
Callum Perkins
Favorite
Perry, Curtis

Yale University
(P 98) A MULTIEPITOPE MRNA VACCINE FOR KAPOSI SARCOMA: AN IMMUNOINFORMATIC APPROACH
Curtis Perry
Favorite
Perry, Kyle

University of Michigan
(P 131) HETEROGENEITY OF THE IMMUNE MICROENVIRONMENT AND IMMUNOTHERAPY RESPONSE IN A DEDIFFERENTIATED LIPOSARCOMA MOUSE MODEL
Kyle Perry
Favorite
(P 341) THE EFFECTS OF ULTRASOUND-GUIDED HISTOTRIPSY ON SOFT TISSUE SARCOMA
Kyle Perry
Favorite
(P 423) COMPARISON OF CLINICAL COURSE AND FEATURES BETWEEN SCLEROSING EPITHELOID FIBROSARCOMA AND LOW-GRADE FIBROMYXOID SARCOMA
Kyle Perry
Favorite
Pestana, Roberto

Hospital Israelita Albert Einstein
(P 122) ACTIONABLE FUSIONS IN DEDIFFERENTIATED LIPOSARCOMA: AN ANALYSIS OF 402 CASES IN THE AACR GENIE DATABASE
Roberto Pestana
Favorite
(P 141) COMPREHENSIVE GENOMIC PROFILING OF PATIENTS DIAGNOSED WITH SARCOMA IN BRAZIL: MOLECULAR PROFILE AND ACTIONABILITY
Roberto Pestana
Favorite
(P 192) CURRENT SCENARIO OF SARCOMA CLINICAL TRIALS IN SOUTH AMERICA: A REPORT BY THE LACOG SARCOMA GROUP
Roberto Pestana
Favorite
(P 216) SARCOMA CARE PATHWAYS AND MULTIDISCIPLINARY TUMOR BOARDS IN LATIN AMERICA: AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Roberto Pestana
Favorite
(P 217) SARCOMA DRUG APPROVALS IN LATIN AMERICA COMPARED TO THE FDA AND EMA: AN ANALYSIS BY THE LACOG SARCOMA GROUP
Roberto Pestana
Favorite
(P 219) SOCIAL MEDIA USE AMONG MEDICAL PROFESSIONALS THAT TREAT PATIENTS WITH SARCOMA IN LATIN AMERICA: RESULTS OF AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Roberto Pestana
Favorite
(P 232) IMMUNE CHECKPOINT INHIBITORS COMBINED WITH TYROSINE KINASE INHIBITORS FOR SOFT-TISSUE SARCOMAS: A SYSTEMATIC REVIEW AND SINGLE-ARM META-ANALYSIS
Roberto Pestana
Favorite
(P 242) MICROSATELLITE INSTABILITY AND CLINICAL USE IN SARCOMAS: A SYSTEMATIC REVIEW
Roberto Pestana
Favorite
Peta, Giuliano

Radiology, IRCCS Istituto Ortopedico Rizzoli
(P 41) PEXIDARTINIB UPFRONT IN A CASE OF TENOSYNOVIAL GIANT CELL TUMOR: PROOF OF CONCEPT FOR A TREATMENT PARADIGM SHIFT
Giuliano Peta
Favorite
Petersen, Michael

Musculoskeletal Tumor Section, Department of Orthopedic Surgery, Rigshospitalet, Copenhagen University Hospital
(P 104) CIRQUESARC: A NATIONAL PROSPECTIVE OBSERVATIONAL STUDY OF CIRCULATING TUMOR DNA AND QUALITY OF LIFE IN PATIENTS WITH SARCOMA – PRELIMINARY RESULTS FROM THE SURGICAL COHORT
Michael Petersen
Favorite
(P 243) MYELOSUPPRESSION FOLLOWING LYMPHODEPLETING CHEMOTHERAPY AS PART OF ADOPTIVE CELL THERAPY FOR PATIENTS WITH PROGRESSIVE SOFT TISSUE SARCOMA AFTER STANDARD CHEMOTHERAPY
Michael Petersen
Favorite
(P 391) VISCERAL ANGIOSARCOMA: A NATIONWIDE STUDY WITH LONG-TERM FOLLOW-UP
Michael Petersen
Favorite
Peterson, Susan

MD Anderson Cancer Center
(P 130) HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RESECTABLE RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA (DDLPS) TREATED WITH NEOADJUVANT CHECKPOINT BLOCKADE IN A RANDOMIZED PHASE II CLINICAL TRIAL.
Susan Peterson
Favorite
Philibert, Helene

University of Saskatchewan
(P 01) A PILOT STUDY ON SINGLE-NUCLEUS RNA SEQUENCING IN CANINE SOFT TISSUE SARCOMAS
Helene Philibert
Favorite
Phillips, McLeod

Atlantic Health System
(P 277) REVERSE TOTAL SHOULDER ARTHROPLASTY MAINTAINS GLOBAL FUNCTION OF THE UPPER EXTREMITY IN PATIENTS WITH ONCOLOGIC DISEASE OF THE PROXIMAL HUMERUS
McLeod Phillips
Favorite
(P 405) LIPOSOMAL BUPIVACAINE DOESN'T REDUCE NARCOTIC USE OR PAIN SCORES COMPARED TO A MULTIDRUG COCKTAIL FOLLOWING SOFT TISSUE TUMOR REMOVAL: PRELIM RESULTS OF A PROSPECTIVE, RANDOMIZED DOUBLE-BLINDED STUDY
McLeod Phillips
Favorite
Piątkowski, Jakub

Institute of Genetics and Biotechnology, Faculty of Biology, University of Warsaw, Warsaw, Poland
(P 77) MULTI-PARAMETRICAL PROFILING OF CHONDROSARCOMA
Jakub Piątkowski
Favorite
Pierini, Michela

Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies, IRCCS, Istituto Ortopedico Rizzoli, Bologna, Italy
(P 77) MULTI-PARAMETRICAL PROFILING OF CHONDROSARCOMA
Michela Pierini
Favorite
Pignochino, Ymera

University of Turin, School of Medicine,Candiolo Cancer Institute, FPO-IRCCS
(P 345) TRANSCRIPTOMIC AND PHENOTYPIC CHARACTERIZATION OF AN IMMUNOCOMPETENT LEIOMYOSARCOMA MOUSE MODEL.
Ymera Pignochino
Favorite
(P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Ymera Pignochino
Favorite
Pike, William

Atropos Health
(P 209) RACE AND ETHNICITY ON DIAGNOSIS, METASTASIS, AND MORTALITY OF SOFT TISSUE SARCOMAS IN RETROSPECTIVE COHORT STUDY
William Pike
Favorite
Pilat, Mary

Karmanos Cancer Institute
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Mary Pilat
Favorite
Pileri, Stefano

UniversitY of Bologna
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Stefano Pileri
Favorite
Pinkas, Jan

Pyxis Oncology
(P 339) SARCOMAS EXPRESS EXTRA DOMAIN B OF FIBRONECTIN AND PRECLINICAL PATIENT-DERIVED XENOGRAFT MODELS OF SEVERAL SARCOMA SUBTYPES ARE SENSITIVE TO THE STROMA TARGETING ANTIBODY DRUG CONJUGATE PYX-201
Jan Pinkas
Favorite
Pinnaduwage, Dushanthi

University of Toronto
(P 238) INTRA-TUMORAL DC-LAMP EXPRESSION IS ASSOCIATED WITH PROGNOSIS IN SOFT TISSUE SARCOMA
Dushanthi Pinnaduwage
Favorite
Pinto, Navin

Children's Hospital of Colorado
(P 226) EARLY EXPERIENCE ON ENLIGHTEN-01: A PHASE 1 STUDY OF BISPECIFIC ADAPTER MOLECULE- CONTROLLED FOLATE RECEPTOR CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY OSTEOSARCOMA
Navin Pinto
Favorite
Piperno-neumann, Sophie

Institut Curie
(P 125) CHARACTERISTICS, MANAGEMENT AND SURVIVAL OF N=7314 LIPOSARCOMAS FROM THE NATIONWIDE NETSARC REGISTRY IN FRANCE SINCE 2010
Sophie Piperno-neumann
Favorite
Pires de Camargo, Veridiana

Latin American Cooperative Oncology Group
(P 192) CURRENT SCENARIO OF SARCOMA CLINICAL TRIALS IN SOUTH AMERICA: A REPORT BY THE LACOG SARCOMA GROUP
Veridiana Pires de Camargo
Favorite
(P 216) SARCOMA CARE PATHWAYS AND MULTIDISCIPLINARY TUMOR BOARDS IN LATIN AMERICA: AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Veridiana Pires de Camargo
Favorite
(P 217) SARCOMA DRUG APPROVALS IN LATIN AMERICA COMPARED TO THE FDA AND EMA: AN ANALYSIS BY THE LACOG SARCOMA GROUP
Veridiana Pires de Camargo
Favorite
(P 219) SOCIAL MEDIA USE AMONG MEDICAL PROFESSIONALS THAT TREAT PATIENTS WITH SARCOMA IN LATIN AMERICA: RESULTS OF AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Veridiana Pires de Camargo
Favorite
Pischel, Kristin

Sarcoma Oncology Center
(P 241) LINNOVATE: A PHASE 1/2 STUDY OF SAFETY/EFFICACY USING LURBINECTEDIN COMBINED WITH IPILUMUMAB AND NIVOLUMAB FOR ADVANCED SOFT TISSUE SARCOMA (NCT05876715)
Kristin Pischel
Favorite
Planas-Paz, Lara

Department of Pathology and Molecular Pathology USZ
(P 99) ACQUIRED NF2 MUTATION CONFERS RESISTANCE TO TRK INHIBITION IN AN EX VIVO LMNA::NTRK1-REARRANGED SOFT TISSUE SARCOMA CELL MODEL
Lara Planas-Paz
Favorite
(P 118) UNRAVELING HOMOLOGOUS RECOMBINATION REPAIR DEFICIENCY AND THERAPEUTIC OPPORTUNITIES IN SOFT TISSUE AND BONE SARCOMA
Lara Planas-Paz
Favorite
Planchamp, François

Institut Bergonié, Bordeaux (France);
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
François Planchamp
Favorite
Pliego-Mendieta, Alicia

Department of Pathology and Molecular Pathology USZ
(P 118) UNRAVELING HOMOLOGOUS RECOMBINATION REPAIR DEFICIENCY AND THERAPEUTIC OPPORTUNITIES IN SOFT TISSUE AND BONE SARCOMA
Alicia Pliego-Mendieta
Favorite
Pohly Jeppesen Thorn, Andrea

Musculoskeletal Tumor Section, Copenhagen University Hospital, Rigshospitalet
(P 104) CIRQUESARC: A NATIONAL PROSPECTIVE OBSERVATIONAL STUDY OF CIRCULATING TUMOR DNA AND QUALITY OF LIFE IN PATIENTS WITH SARCOMA – PRELIMINARY RESULTS FROM THE SURGICAL COHORT
Andrea Pohly Jeppesen Thorn
Favorite
Pollack, Seth

Northwestern University, Feinberg School of Medicine, Department of Medicine, Division of Oncology, Chicago
(P 179) PRIMARY MANAGEMENT OF LOCALIZED GASTROINTESTINAL STROMAL TUMORS WITH IMATINIB MONOTHERAPY: AN ALTERNATIVE TO RESECTION FOR PATIENTS PRECLUDED FROM SURGERY
Seth Pollack
Favorite
(P 222) ANALYSIS OF THE CITN-13 SARCOMA ARM: PEMBROLIZUMAB AND INTERFERON GAMMA FOR SYNOVIAL SARCOMA AND MYXOID/ ROUND CELL LIPOSARCOMA
Seth Pollack
Favorite
(P 235) INFILTRATION OF MUCOSAL-ASSOCIATED INVARIANT T CELLS (MAITS) INTO CHONDROSARCOMA TUMORS
Seth Pollack
Favorite
Pollock, Raphael

The James Cancer Hospital / The Ohio State University
(P 19) INVOLVEMENT OF O-GLCNAC TRANSFERASE IN RESISTANCE TO DOXORUBICIN AND CELL DEATH IN PRECLINICAL MODELS OF LEIOMYOSARCOMA AND DESMOID TUMORS
Raphael Pollock
Favorite
Pollock, Raphael E.

The Ohio State University
(P 136) TARGETING MIR-138-5P TO TREAT DEDIFFERENTIATED LIPOSARCOMA
Raphael E. Pollock
Favorite
Post, Carl

Oregon Health and Science University
(P 359) RAPIDLY PROGRESSIVE, NON-METASTATIC, CUTANEOUS ANGIOSARCOMA OF FACE AND SCALP TREATED WITH HYPOFRACTIONATED RADIATION THERAPY: A CASE SERIES
Carl Post
Favorite
Postovsky, Sergey

Emek General Hospital
(P 312) RARE CASE OF INTRAOSSEOUS RHABDOMYOSARCOMA IN A YOUNG CHILD
Sergey Postovsky
Favorite
Poulson, Trevor

Rush University Medical Center
(P 80) OUTCOMES AND MANAGEMENT OF POSITIVE MARGINS IN CHONDROSARCOMA WITH SOFT TISSUE EXTENSION: A CASE SERIES AND REVIEW OF LITERATURE
Trevor Poulson
Favorite
(P 92) THE IMPACT OF CHONDROSARCOMA WITH POSITIVE MARGINS AND EXTRAOSSEOUS EXTENSION ON PATIENT OUTCOMES
Trevor Poulson
Favorite
Powers, Benjamin

University of Kansas Cancer Center
(P 36) EARLY REAL-WORLD EXPERIENCE WITH THE USE OF NIROGACESTAT FOR THE TREATMENT OF DESMOID FIBROMATOSIS
Benjamin Powers
Favorite
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Benjamin Powers
Favorite
(P 221) 8+ YEARS OF IMMUNOTHERAPY FOR METASTATIC ALVEOLAR SOFT PART SARCOMA
Benjamin Powers
Favorite
Pozas, Javier

The Royal Marsden NHS Foundation Trust, London- UK
(P 23) METASTATIC ALVEOLAR SOFT PART SARCOMA: PREGNANCY-RELATED WORSENING AND SPONTANEOUS EXCEPTIONAL REMISSION POSTPARTUM- A CASE REPORT.
Javier Pozas
Favorite
Pracha, Sahal

The Ohio State University James Comprehensive Cancer Center
(P 207) PATIENT-REPORTED GLOBAL HEALTH PREDICTS ADVERSE HEALTH OUTCOMES IN PATIENTS WITH ADVANCED SARCOMA
Sahal Pracha
Favorite
Prados, Elena

Son Espases University Hospital
(P 13) GENOMIC PROFILING OF ADULT SOFT TISSUE SARCOMAS FROM A SINGLE CENTER EXPERIENCE
Elena Prados
Favorite
(P 322) A NEW PLAYER IN SOFT TISSUE SARCOMA PROGRESSION: WNT5A IS A PROGNOSIS BIOMARKER AND A POTENTIAL ACTIONABLE TARGET
Elena Prados
Favorite
Pratilas, Christine

Johns Hopkins University School of Medicine
(P 152) NOVEL PAX3::MAML3 FUSION IDENTIFIED IN ALVEOLAR RHABDOMYOSARCOMA: USING DNA METHYLATION TO EXPANDE THE GENETIC SPECTRUM OF "FUSION POSITIVE" CASES
Christine Pratilas
Favorite
(P 187) BRIDGING THE GAP: UNDERSTANDING THE CURRENT TREATMENT RESPONSES TO ENHANCE THE STANDARD OF CARE AND OUTCOMES FOR MALIGNANT PERIPHERAL NERVE SHEATH TUMORS
Christine Pratilas
Favorite
(P 309) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT SOFT TISSUE SARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Christine Pratilas
Favorite
Preisler, Louise

Rigshospitalet
(P 29) ABDOMINAL LYMPHANGIOMA CAUSING EXCESSIVE GASTROINTESTINAL BLEEDING FOR MORE THAN TWO DECADES
Louise Preisler
Favorite
(P 385) SIMULTANEOUS OCCURRENCE OF MANTLE CELL LYMPHOMA AND LIPOSARCOMA IN THE RETROPERITONEUM
Louise Preisler
Favorite
Pretorius, Lauren

Campaigning for Cancer
(P 201) GLOBAL CROSS-SECTIONAL SURVEY ON SARCOMA DIAGNOSIS PATHWAY: A CURRENT STATE ANALYSIS
Lauren Pretorius
Favorite
Price, Lucy

Queen Elizabeth Hospital
(P 383) PRE-OPERATIVE SPLIT RENAL FUNCTION RADIONUCLIDE IMAGING IN SURGICAL PLANNING FOR MULTI-VISCERAL RESECTION OF RETROPERITONEAL SARCOMA: A RETROSPECTIVE COHORT STUDY
Lucy Price
Favorite
Prigmore, Brian

Oregon Health & Science University
(P 285) A NOVEL METHOD TO PREDICT HEIGHT AT SKELETAL MATURITY IN PEDIATRIC SARCOMA PATIENTS
Brian Prigmore
Favorite
Primeaux, Sharon

University of Texas Southwestern Medical Center
(P 417) VITAS: ATEZOLIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY SOLID TUMORS: AN OPEN-LABEL, PHASE I/II, SINGLE-ARM, MULTI-CENTER TRIAL IN PROGRESS
Sharon Primeaux
Favorite
Pringle, Toni

School of Natural and Environmental Sciences, Newcastle University, UK
(P 22) MECHANISMS OF PREFERENTIAL TUMOUR UPTAKE OF INDOCYANINE GREEN IN SARCOMA
Toni Pringle
Favorite
Prosser, Denise
(P 353) PREDICTING WOUND COMPLICATIONS FOLLOWING SOFT-TISSUE SARCOMA RESECTION AMONG PATIENTS WHO RECEIVED PRE-OPERATIVE RADIATION
Denise Prosser
Favorite
Prudhomme, Nicolas

Centre Hospitalier Universitaire Sainte-Justine
(P 293) CIC-REARRANGED SOFT TISSUE SARCOMAS: DOES CHEMOTHERAPY CHANGE NATURAL HISTORY AND PROGNOSIS? A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Nicolas Prudhomme
Favorite
(P 320) WHAT IS THE ROLE OF CHEMOTHERAPY IN PATIENTS (PTS) WITH SPINDLE CELL/SCLEROSING RHABDOMYOSARCOMA (SCRMS): A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Nicolas Prudhomme
Favorite
(P 321) WHOLE ABDOMINAL RADIOTHERAPY IN CHILDREN AND YOUNG ADULTS WITH SARCOMA: A CANADIAN SARCOMA AND CLINICAL COLLABORATION (CANSARCC) STUDY
Nicolas Prudhomme
Favorite
Pruimboom, Tim

Maastricht University Medical Center
(P 361) WOUND COMPLICATIONS AFTER SOFT TISSUE SARCOMA RESECTION: A SINGLE-CENTER RETROSPECTIVE ANALYSIS
Tim Pruimboom
Favorite
Pruthi, Manish

Tata Memorial Hospital
(P 32) CURRENT INDICATIONS OF OPEN SURGERY IN PRIMARY APPENDICULAR/ PELVIC ANEURYSMAL BONE CYSTS
Manish Pruthi
Favorite
(P 306) LONG TERM OUTCOMES OF TYPE BIIIA ROTATIONPLASTY AFTER TOTAL FEMUR EXCISION IN CHILDREN
Manish Pruthi
Favorite
Przybyl, Joanna

McGill University
(P 17) IDENTIFICATION OF MARKERS PREDICTIVE OF RESPONSE TO GEMCITABINE AND DOCETAXEL IN LEIOMYOSARCOMA THROUGH MIRNA SEQUENCING
Joanna Przybyl
Favorite
(P 19) INVOLVEMENT OF O-GLCNAC TRANSFERASE IN RESISTANCE TO DOXORUBICIN AND CELL DEATH IN PRECLINICAL MODELS OF LEIOMYOSARCOMA AND DESMOID TUMORS
Joanna Przybyl
Favorite
(P 112) MACHINE LEARNING ANALYSIS TO DEFINE CELL LINEAGE IN LEIOMYOSARCOMA
Joanna Przybyl
Favorite
(P 159) USING THE TRANSCRIPTIONAL SPECTRUM OF UTERINE SMOOTH MUSCLE TUMORS TO IDENTIFY PROGNOSTIC SIGNATURES FOR ABNORMAL LEIOMYOMAS AND SMOOTH MUSCLE TUMOURS OF UNCERTAIN MALIGNANT POTENTIAL
Joanna Przybyl
Favorite
(P 176) LOSS OF PTEN EXPRESSION IN MINIGISTS AND CLINICALLY RELEVANT GISTS
Joanna Przybyl
Favorite
(P 399) SIMILARITY NETWORK FUSION IDENTIFIES DNA METHYLATION SUBTYPES OF LEIOMYOSARCOMA ASSOCIATED WITH CLINICAL OUTCOME
Joanna Przybyl
Favorite
(P 427) MULTI-OMIC AND MULTI-REGION PROFILING OF DESMOID TUMORS REVEALS INTRA- AND INTER-TUMOR HETEROGENEITY
Joanna Przybyl
Favorite
Psoinos, Charles

Deciphera Pharmaceuticals, LLC
(P 403) DCC-3116 IN COMBINATION WITH RIPRETINIB FOR PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A PHASE 1/2 STUDY
Charles Psoinos
Favorite
Puls, Florian

Sahlgrenska University hospital
(P 170) GASTRIN RELEASING PEPTIDE RECEPTOR EXPRESSION IN GASTROINTESTINAL STROMAL TUMORS (GIST)
Florian Puls
Favorite
Punturi, Nindo

Chordoma Foundation
(P 425) EXPLORING MECHANISMS OF EGFR INHIBITOR RESISTANCE IN CHORDOMA
Nindo Punturi
Favorite
Puri, Ajay

Tata Memorial Hospital
(P 32) CURRENT INDICATIONS OF OPEN SURGERY IN PRIMARY APPENDICULAR/ PELVIC ANEURYSMAL BONE CYSTS
Ajay Puri
Favorite
(P 306) LONG TERM OUTCOMES OF TYPE BIIIA ROTATIONPLASTY AFTER TOTAL FEMUR EXCISION IN CHILDREN
Ajay Puri
Favorite
Pu, Tracey

Surgical Oncology, NCI, NIH
(P 231) IDENTIFICATION OF NEOANTIGEN FROM PECOMA-LIKE NEOPLASM PROVIDES RATIONALE FOR TREATMENT WITH CELLULAR THERAPY
Tracey Pu
Favorite
Puviidran, Vijitha

Duke University
(P 15) HISTONE DEACETYLASE-3 PLAYS A ROLE IN THE METASTATIC POTENTIAL OF A SUBPOPULATION OF CELLS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Vijitha Puviidran
Favorite
Pyczek, Joanna

University of Calgary
(P 422) COMPARISON OF ANNOTATION METHODS FOR PAN-SARCOMA SINGLE CELL DATA
Joanna Pyczek
Favorite
(P 424) CROSS-COHORT INTEGRATION AS A STRATEGY TO CLASSIFY IMMUNE CHECKPOINT BLOCKADE RESPONSE IN SARCOMA
Joanna Pyczek
Favorite
Q
Qian, Meng

Daiichi Sankyo, Inc.
(P 44) TUMOR RESPONSE AND REGROWTH IN RELATION TO CLINICAL EVENTS AMONG PEXIDARTINIB-TREATED SUBJECTS IN THE PHASE 3 ENLIVEN TRIAL
Meng Qian
Favorite
(P 400) A LONG-TERM PHASE 4 STUDY TO EVALUATE THE RISK OF HEPATOTOXICITY ASSOCIATED WITH PEXIDARTINIB TREATMENT
Meng Qian
Favorite
Qi, Lihong

UC Davis Medical Center
(P 230) HIGHER BODY MASS INDEX IS ASSOCIATED WITH DECREASED CIRCULATING AND INTRATUMORAL NATURAL KILLER CELLS IN SOFT TISSUE SARCOMA
Lihong Qi
Favorite
Qi, Peng

Cleveland Clinic
(P 351) OSTEOSARCOMA STEREOTACTIC BODY RADIOTHERAPY: OUTCOMES AND PATTERN OF FAILURE
Peng Qi
Favorite
Quagliuolo, Vittorio

Istituto Clinico Humanitas
(P 290) ARTIFICIAL INTELLIGENCE-BASED COMPARISON OF ADULT AND ADOLESCENT AND YOUNG ADULTS (AYA) SARCOMAS: A PILOT STUDY
Vittorio Quagliuolo
Favorite
(P 362) A NEW ROCK BAND FOR DIAPHRAGMATIC RECONSTRUCTION IN LEFT RETROPERITONEAL SARCOMA SURGERY
Vittorio Quagliuolo
Favorite
(P 363) A NEW SURGICAL TECHNIQUE FOR THE RECONSTRUCTION OF INGUINAL 'NEOLIGAMENT' AFTER SOFT TISSUE SARCOMA RESECTION
Vittorio Quagliuolo
Favorite
(P 373) EVALUATION OF HISTOLOGIC ORGAN INFILTRATION (HOI) AND VISCERAL RESECTION MARGINS (VRM) IN PRIMARY RETROPERITONEAL SARCOMAS: PROGNOSTIC IMPLICATIONS FOR LOCAL RECURRENCE
Vittorio Quagliuolo
Favorite
(P 388) THE ROAD TO CURATIVE SURGERY IN RETROPERITONEAL SOFT TISSUE SARCOMA: A DIFFERENT PATH IN THE ELDERLY?
Vittorio Quagliuolo
Favorite
(P 389) THE ROLE OF NUTRITIONAL STATUS ON POSTOPERATIVE AND ONCOLOGICAL OUTCOMES IN RETROPERITONEAL SARCOMA
Vittorio Quagliuolo
Favorite
Quevillon, Sarah

CIUSSS Est-de-l'Île-de-Montréal
(P 212) REFERENCE SYSTEM OPTIMIZATION, ANALYSES OF THE IMPLEMENTATION OF A PROVINCIAL MULTIDISCIPLINARY SARCOMA NETWORK
Sarah Quevillon
Favorite
Quildrian, Sergio

University of Buenos Aires, Angel H. Roffo Institute of Oncology - Buenos Aires British Hospital
(P 25) PRIMARY TREATED VERSUS REFERRED TRUNK AND EXTREMITIES SOFT TISSUE SARCOMAS: ANALYSIS OF TREATMENT IMPACT IN A SPECIALIZED CENTER IN ARGENTINA.
Sergio Quildrian
Favorite
(P 273) PRIMARY SOFT-TISSUE SARCOMAS OF THE UPPER LIMBS
Sergio Quildrian
Favorite
(P 366) ABDOMINAL AORTA RESECTION EN-BLOC WITH PRIMARY RETROPERITONEAL SOFT-TISSUE SARCOMA AND BI-ILIAC GRAFT RECONSTRUCTION.
Sergio Quildrian
Favorite
(P 367) AGE AS A PROGNOSTIC FACTOR IN RETROPERITONEAL SARCOMA: A MULTICENTER LATIN AMERICAN STUDY
Sergio Quildrian
Favorite
Quirion, Julia

Vanderbilt University Medical Center
(P 265) IS THERE AN IDEAL STEM TO CANAL RATIO IN LOWER EXTREMITY ONCOLOGIC ENDOPROSTHESIS RECONSTRUCTION?
Julia Quirion
Favorite
R
Rabino, Martina

Department of Oncology, University of Turin
(P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Martina Rabino
Favorite
Radaelli, Stefano

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(P 171) GASTROINTESTINAL STROMAL TUMOURS (GISTS) IN NEUROFIBROMATOSIS TYPE (NF1): A SINGLE-CENTER OBSERVATIONAL RETROSPECTIVE STUDY
Stefano Radaelli
Favorite
Rahimizadeh, Pegah

McGill University
(P 17) IDENTIFICATION OF MARKERS PREDICTIVE OF RESPONSE TO GEMCITABINE AND DOCETAXEL IN LEIOMYOSARCOMA THROUGH MIRNA SEQUENCING
Pegah Rahimizadeh
Favorite
(P 176) LOSS OF PTEN EXPRESSION IN MINIGISTS AND CLINICALLY RELEVANT GISTS
Pegah Rahimizadeh
Favorite
Rahul, Ekta

India Institute of Medical Sciences
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Ekta Rahul
Favorite
Raish, Hayden

The Ohio State University
(P 136) TARGETING MIR-138-5P TO TREAT DEDIFFERENTIATED LIPOSARCOMA
Hayden Raish
Favorite
Raja, Anand

Cancer Institute (WIA)
(P 61) DOES CLINICAL PROGRESSION PORTEND POOR ONCOLOGICAL OUTCOMES IN PATIENTS RECEIVING NEOADJUVANT CHEMOTHERAPY
Anand Raja
Favorite
(P 67) EXTERMITY SOFT TISSUE SARCOMA -RETROSPECTIVE ANALYSIS OF 21YEARS EXPERIENCE IN A TERTITARY CARE CENTRE.
Anand Raja
Favorite
(P 84) PROGNOSTIC IMPLICATIONS OF PATHOLOGICAL FRACTURES IN EXTREMITY OSTEOSARCOMA: A RETROSPECTIVE ANALYSIS OF SURVIVAL OUTCOMES AND LIMB-SALVAGE FEASIBILITY
Anand Raja
Favorite
(P 105) CLINICAL OUTCOMES OF SUB-CENTIMETRIC LUNG NODULES IN PATIENTS WITH EXTREMITY OSTEOSARCOMA: A RETROSPECTIEV COHORT STUDY
Anand Raja
Favorite
(P 198) FACTORS INFLUENCING TIME TO TREATMENT INITIATION IN PROMARY EXTREMITY SARCOMA: A RETROSPECTIVE ANALYSIS
Anand Raja
Favorite
Rajper, Abdul

Daiichi Sankyo, Inc.
(P 44) TUMOR RESPONSE AND REGROWTH IN RELATION TO CLINICAL EVENTS AMONG PEXIDARTINIB-TREATED SUBJECTS IN THE PHASE 3 ENLIVEN TRIAL
Abdul Rajper
Favorite
Ramachandran, Smrithi

University of Miami Miller School of Medicine
(P 296) DISPARITIES IN OVERALL SURVIVAL FOR AYA PATIENTS WITH EWINGS SARCOMA: A RETROSPECTIVE COHORT STUDY AT A SINGLE SARCOMA CENTER
Smrithi Ramachandran
Favorite
Ramella Munhoz, Rodrigo

Latin American Cooperative Oncology Group
(P 192) CURRENT SCENARIO OF SARCOMA CLINICAL TRIALS IN SOUTH AMERICA: A REPORT BY THE LACOG SARCOMA GROUP
Rodrigo Ramella Munhoz
Favorite
(P 216) SARCOMA CARE PATHWAYS AND MULTIDISCIPLINARY TUMOR BOARDS IN LATIN AMERICA: AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Rodrigo Ramella Munhoz
Favorite
(P 217) SARCOMA DRUG APPROVALS IN LATIN AMERICA COMPARED TO THE FDA AND EMA: AN ANALYSIS BY THE LACOG SARCOMA GROUP
Rodrigo Ramella Munhoz
Favorite
(P 219) SOCIAL MEDIA USE AMONG MEDICAL PROFESSIONALS THAT TREAT PATIENTS WITH SARCOMA IN LATIN AMERICA: RESULTS OF AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Rodrigo Ramella Munhoz
Favorite
Ramsey, Duncan

Oregon Health & Science University
(P 34) DESMOID TUMOR COHORT CREATION AND CHARACTERISTICS IN THE VETERANS AFFAIRS (VA) NATIONAL DATABASE
Duncan Ramsey
Favorite
(P 223) ASSOCIATION OF POSTOPERATIVE INFECTION (POI) WITH SOFT TISSUE SARCOMA (STS) RESECTION OUTCOMES
Duncan Ramsey
Favorite
(P 285) A NOVEL METHOD TO PREDICT HEIGHT AT SKELETAL MATURITY IN PEDIATRIC SARCOMA PATIENTS
Duncan Ramsey
Favorite
Ranallo, Nicoletta

Irst
(P 144) EXPLORATORY ANALYSIS OF 68GA-FAPI-46 PET-CT IN SOFT TISSUE SARCOMA
Nicoletta Ranallo
Favorite
Randall, R. Lor

University of California Davis School of Medicine
(P 11) GENETIC AND EPIGENETIC CHARACTERIZATION OF SARCOMA STEM CELLS ACROSS SUBTYPES IDENTIFIES EZH2 AS A THERAPEUTIC TARGET
R. Lor Randall
Favorite
(P 205) MULTI-MODAL TREATMENT IS ASSOCIATED WITH IMPROVED SURVIVAL IN AYA PATIENTS WITH METASTATIC NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA
R. Lor Randall
Favorite
(P 356) RADIATION PRACTICE PATTERNS AND OUTCOMES IN ADOLESCENT YOUNG ADULT PATIENTS WITH VISCERAL NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA
R. Lor Randall
Favorite
Ranjbarian, Tannaz

University of California, San Diego (UCSD)
(P 162) ANALYSIS OF 3,144 CASE REPORTS IN THE GASTROINTESTINAL STROMAL TUMOR LITERATURE: IDENTIFICATION OF UNDERAPPRECIATED DEMOGRAPHICS, CLINICAL PRESENTATIONS, AND BIOLOGY
Tannaz Ranjbarian
Favorite
(P 175) KIT AND DOG-1 EXPRESSING GASTROINTESTINAL STROMAL TUMORS HARBORING ETV6-NTRK3 FUSIONS DO EXIST, CASE OF NEAR COMPLETE PATHOLOGIC RESPONSE FOLLOWING LAROTRECTINIB AND REVIEW OF THE LITERATURE
Tannaz Ranjbarian
Favorite
Rankin, Kenneth

The Newcastle upon Tyne Hospitals NHS Foundation Trust
(P 22) MECHANISMS OF PREFERENTIAL TUMOUR UPTAKE OF INDOCYANINE GREEN IN SARCOMA
Kenneth Rankin
Favorite
(P 269) LYMPHOEDEMA FOLLOWING LIMB SALVAGE SURGERY FOR EXTREMITY SARCOMA: A RETROSPECTIVE ANALYSIS OF 282 PATIENTS
Kenneth Rankin
Favorite
(P 323) AN IN-VITRO INVESTIGATION OF 5-AMINOLEVULINIC ACID MEDIATED PHOTODYNAMIC THERAPY IN SOFT-TISSUE SARCOMA
Kenneth Rankin
Favorite
Rao, Rameshwar

Seattle Children's Research Institute
(P 74) MATRIX DENSITY INDUCES CHEMORESISTANCE WITHIN A TISSUE-ENGINEERED MODEL OF OSTEOSARCOMA
Rameshwar Rao
Favorite
Raredon, Micha Sam Brickman

Yale School of Medicine
(P 88) SPATIAL TRANSCRIPTOMICS OF EWING SARCOMA: EVOLUTION OF TUMOR MICROENVIRONMENT ASSOCIATED EXTRACELLULAR MATRIX FROM LOCALIZED TO METASTASIS-ASSOCIATED PRIMARY TUMORS
Micha Sam Brickman Raredon
Favorite
Rask, Galen

Nationwide Children's Hospital
(P 21) LSD1 INHIBITOR SP-2509 DISRUPTS IRON-SULFUR CLUSTER BIOGENESIS
Galen Rask
Favorite
Raspagliesi, Francesco

INT
(P 160) UTERINE PECOMA: REPORT OF MOLECULAR AND CLINICAL FEATURES IN A SERIES OF PATIENTS TREATED AT A REFERRAL INSTITUTION
Francesco Raspagliesi
Favorite
Ratan, Ravin

University of Texas, MD Anderson Cancer Center, Department of Sarcoma Medical Oncology, Division of Cancer Medicine
(P 233) IMMUNE CLASSES OF LEIOMYOSARCOMA DRIVEN BY B CELL INFILTRATE AND CTLA4 EXPRESSION
Ravin Ratan
Favorite
Ratnayake, Gayanie

The Royal Children's Hospital Melbourne,
(P 325) CAN PROTEOMICS PREDICT METASTATIC RELAPSE IN LEIOMYOSARCOMA? DEVELOPMENT OF AN 8 PROTEIN SIGNATURE IN A >350 SAMPLE STUDY INCLUDING A VALIDATION COHORT
Gayanie Ratnayake
Favorite
Rauckhorst, Adam

University of Iowa
(P 12) GENETIC LANDSCAPE OF MPNST DETERMINES METABOLIC STRATEGIES AND THERAPEUTIC OPPORTUNITIES FOR COPING WITH REDOX STRESS
Adam Rauckhorst
Favorite
Raut, Chandrajit

Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School
(P 167) DEFINING TEXTBOOK OUTCOMES FOR MINIMALLY INVASIVE SURGICAL RESECTION OF SMALL GASTROINTESTINAL STROMAL TUMORS (GIST) OF THE STOMACH
Chandrajit Raut
Favorite
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Chandrajit Raut
Favorite
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Chandrajit Raut
Favorite
Ravi, Vinod

The University of Texas MD Anderson Cancer Center
(P 233) IMMUNE CLASSES OF LEIOMYOSARCOMA DRIVEN BY B CELL INFILTRATE AND CTLA4 EXPRESSION
Vinod Ravi
Favorite
(P 398) PREDICTORS OF EFFICACY IN PATIENTS WITH SOFT TISSUE SARCOMAS TREATED WITH PAZOPANIB
Vinod Ravi
Favorite
Rawlings-Rhea, Stephanie

Seattle Children's Research Institute
(P 226) EARLY EXPERIENCE ON ENLIGHTEN-01: A PHASE 1 STUDY OF BISPECIFIC ADAPTER MOLECULE- CONTROLLED FOLATE RECEPTOR CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY OSTEOSARCOMA
Stephanie Rawlings-Rhea
Favorite
Ray-Coquard, Isabelle

Department of Medical Oncology, Centre Léon Bérard,
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Isabelle Ray-Coquard
Favorite
Read, William

Emory University Hospital
(P 413) SUSTAINED EFFICACY DURING DRUG HOLIDAY ON ATEZOLIZUMAB IN PATIENTS WITH ALVEOLAR SOFT PART SARCOMA (ASPS)
William Read
Favorite
Redd, Bernadette

Radiology and Imaging Sciences Department, National Institutes of Health Clinical Center
(P 163) CHARACTERIZATION OF INTRAHEPATIC RECURRENCE FOLLOWING LIVER-DIRECTED SURGERY IN PATIENTS WITH METASTATIC SDH-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST): RISE AND STABILIZATION OF THE GISTLETS
Bernadette Redd
Favorite
Reddel, Roger

ProCan®, Children’s Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, NSW, Australia
(P 325) CAN PROTEOMICS PREDICT METASTATIC RELAPSE IN LEIOMYOSARCOMA? DEVELOPMENT OF AN 8 PROTEIN SIGNATURE IN A >350 SAMPLE STUDY INCLUDING A VALIDATION COHORT
Roger Reddel
Favorite
Reddy, Chandana

Cleveland Clinic
(P 351) OSTEOSARCOMA STEREOTACTIC BODY RADIOTHERAPY: OUTCOMES AND PATTERN OF FAILURE
Chandana Reddy
Favorite
Redondo, Andres

HU La Paz
(P 234) IMMUNOSARC II MASTER TRIAL (PHASE II OF SUNITINIB AND NIVOLUMAB): RESULTS FROM THE CLEAR CELL SARCOMA (CCS) COHORT. A GEIS, ISG, AND UCL STUDY
Andres Redondo
Favorite
Reed, Damon

Memorial Sloan Kettering
(P 49) A WORKING GROUP FOR THE DEVELOPMENT OF A CLINICAL FRAMEWORK THAT STRATIFIES OSTEOSARCOMA PATIENTS USING BIOMARKERS OF CLINICAL RISK AND BIOLOGY
Damon Reed
Favorite
(P 50) ANALYSIS OF CLINICAL FEATURES AND OUTCOMES FOR PATIENTS WITH MULTIFOCAL OSTEOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Damon Reed
Favorite
(P 113) METASTATIC EWING'S TRAIL TESTING SCHEDULE ENHANCEMENT TO IMPROVE OUTCOMES (METTSEO)
Damon Reed
Favorite
(P 309) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT SOFT TISSUE SARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Damon Reed
Favorite
(P 421) CHARACTERIZATION OF INTRA-PATIENT, INTER-LESIONAL RESPONSE AND RESISTANCE DYNAMICS IN METASTATIC, FUSION-POSITIVE RHABDOMYOSARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Damon Reed
Favorite
Reed, Rebecca

Aveni Foundation
(P 106) DELTAREX-G, A TUMOR TARGETED CCNG1 INHIBITOR, DEMONSTRATES CLINICAL BENEFIT IN ADVANCED CHEMORESISTANT SARCOMA FOLLOWING FDA CBER AUTHORIZATION FOR USE AS PLATFORM THERAPY WITH FDA APPROVED DRUGS
Rebecca Reed
Favorite
Regan, Daniel

Colorado State University
(P 94) THE ROLE OF CMYC AMPLIFICATION VERSUS CMYC PROTEIN EXPRESSION AS A PROGNOSTIC BIOMARKER IN OSTEOSARCOMA
Daniel Regan
Favorite
Rehal, Michael

Atlantic Health System
(P 266) LONG STEM CEMENTED ROBTIC ARM-ASSISTED TOTAL HIP ARTHROPLASTY: OUTCOMES IN PATIENTS WITH PRIOR ONCOLOGIC DISEASE
Michael Rehal
Favorite
(P 277) REVERSE TOTAL SHOULDER ARTHROPLASTY MAINTAINS GLOBAL FUNCTION OF THE UPPER EXTREMITY IN PATIENTS WITH ONCOLOGIC DISEASE OF THE PROXIMAL HUMERUS
Michael Rehal
Favorite
Reichardt, Peter

Helios Klinikum Berlin-Buch, Medical School Berlin
(P 33) DESCRIPTIVE EVALUATION OF PATIENTS WITH DESMOID TUMOR AND CO-OCCURRING SOMATIC MUTATIONS OF CTNNB1 AND APC IN THE PHASE 3 DEFI TRIAL
Peter Reichardt
Favorite
Reichardt, Peter

Helios Klinikum Berlin-Buch and Medical School Berlin
(P 410) PHASE I STUDY OF THE001 (DPPG2-TSL-DOX) COMBINED WITH REGIONAL HYPERTHERMIA IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Peter Reichardt
Favorite
Reijers, Sophie

Nederlands Cancer Institute
(P 24) NEOADJUVANT CHEMOTHERAPY FOR RADIOTHERAPY ASSOCIATED ANGIOSARCOMA (RAAS) OF THE BREAST IMPROVES ONCOLOGICAL OUTCOMES
Sophie Reijers
Favorite
Reinke, Denise

University of Michigan Comprehensive Cancer Center
(P 189) CLEAR CELL SARCOMA - REAL WORLD DATA ANALYSIS
Denise Reinke
Favorite
(P 201) GLOBAL CROSS-SECTIONAL SURVEY ON SARCOMA DIAGNOSIS PATHWAY: A CURRENT STATE ANALYSIS
Denise Reinke
Favorite
Reisch, Andréas

UMR7021 CNRS -Laboratory of Bioimaging and Pathologies
(P 75) METABOLIC EVALUATION OF THE RELATIONSHIP BETWEEN MACROPHAGES AND OSTEOSARCOMA TUMOR CELLS
Andréas Reisch
Favorite
Rekdal, Øystein

Lytix Biopharma AS
(P 243) MYELOSUPPRESSION FOLLOWING LYMPHODEPLETING CHEMOTHERAPY AS PART OF ADOPTIVE CELL THERAPY FOR PATIENTS WITH PROGRESSIVE SOFT TISSUE SARCOMA AFTER STANDARD CHEMOTHERAPY
Øystein Rekdal
Favorite
Rekulapelli, Akhil

Vanderbilt University School of Medicine
(P 73) LONGER TIME INTERVAL BETWEEN NEOADJUVANT CHEMOTHERAPY AND SURGERY IS ASSOCIATED WITH DECREASED TUMOR PERCENT NECROSIS IN OSTEOSARCOMA
Akhil Rekulapelli
Favorite
Rekulapelli, Akhil

Vanderbilt University Medical Center
(P 264) INTRAOPERATIVE FROZEN BONE MARROW MARGINS: A HELP OR A HINDRANCE IN EWING SARCOMA RESECTION?
Akhil Rekulapelli
Favorite
(P 265) IS THERE AN IDEAL STEM TO CANAL RATIO IN LOWER EXTREMITY ONCOLOGIC ENDOPROSTHESIS RECONSTRUCTION?
Akhil Rekulapelli
Favorite
Rekulapelli, Akhil

Vanderbilt University School of Medicine
(P 268) LOWER TUMOR PERCENT NECROSIS IS ASSOCIATED WITH POSITIVE FINAL SURGICAL MARGINS IN OSTEOSARCOMA
Akhil Rekulapelli
Favorite
Rekulapelli, Akhil

Vanderbilt University Medical Center
(P 404) ENHANCED RECOVERY AFTER SURGERY (ERAS) PROTOCOL FOR PATENTS WITH SOFT TISSUE SARCOMA OF THE EXTREMITY: A PROSPECTIVE, NON-RANDOMIZED, CONSECUTIVELY ENROLLED TRIAL
Akhil Rekulapelli
Favorite
Renard, Marleen

UZ Leuven
(P 291) CASE REPORT: RADICAL EN BLOC MULTI-LEVEL SPONDYLECTOMY FOR A LOCALLY RECURRENT OSTEOSARCOMA
Marleen Renard
Favorite
Renne, Salvatore Lorenzo

IRCCS Humanitas Research Hospital
(P 124) ASSESSMENT OF THE MECHANISMS OF ACTION OF ERIBULIN IN PATIENTS WITH ADVANCED LIPOSARCOMA THROUGH THE EVALUATION OF THE RADIOLOGICAL, FUNCTIONAL AND TISSUE RESPONSE: A MONOCENTRIC PROSPECTIVE STUDY
Salvatore Lorenzo Renne
Favorite
(P 155) PRIMARY MESENCHYMAL TUMORS OF THE HEART: A 8-YEARS, SINGLE INSTITUTION EXPERIENCE
Salvatore Lorenzo Renne
Favorite
(P 290) ARTIFICIAL INTELLIGENCE-BASED COMPARISON OF ADULT AND ADOLESCENT AND YOUNG ADULTS (AYA) SARCOMAS: A PILOT STUDY
Salvatore Lorenzo Renne
Favorite
(P 373) EVALUATION OF HISTOLOGIC ORGAN INFILTRATION (HOI) AND VISCERAL RESECTION MARGINS (VRM) IN PRIMARY RETROPERITONEAL SARCOMAS: PROGNOSTIC IMPLICATIONS FOR LOCAL RECURRENCE
Salvatore Lorenzo Renne
Favorite
(P 388) THE ROAD TO CURATIVE SURGERY IN RETROPERITONEAL SOFT TISSUE SARCOMA: A DIFFERENT PATH IN THE ELDERLY?
Salvatore Lorenzo Renne
Favorite
(P 389) THE ROLE OF NUTRITIONAL STATUS ON POSTOPERATIVE AND ONCOLOGICAL OUTCOMES IN RETROPERITONEAL SARCOMA
Salvatore Lorenzo Renne
Favorite
(P 431) REAL-WORLD EXPERIENCE OF EFFICACY AND TOLERABILITY OF CONTINUOS INFUSION IFOSFAMIDE AMONG ADVANCED SOFT TISSUE AND BONE SARCOMAS PATIENTS: A SINGLE CENTRE RETROSPECTIVE COHORT.
Salvatore Lorenzo Renne
Favorite
Reu, Frederic

Deciphera Pharmaceuticals, LLC
(P 403) DCC-3116 IN COMBINATION WITH RIPRETINIB FOR PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A PHASE 1/2 STUDY
Frederic Reu
Favorite
Reynolds, C. Patrick

Texas Tech University Health Sciences Center
(P 292) CHARACTERIZATION OF TELOMERE MAINTENANCE MECHANISMS IN OSTEOSARCOMA PATIENT-DERIVED LABORATORY MODELS
C. Patrick Reynolds
Favorite
Riad, Soha

Moffitt Cancer Center
(P 237) INTRALESIONAL ADMINISTRATION OF TALIMOGENE LAHERPAREPVEC (T-VEC) INDUCES TUMOR REGRESSION IN PATIENTS WITH CUTANEOUS ANGIOSARCOMA
Soha Riad
Favorite
Rice, John

University of Michigan
(P 423) COMPARISON OF CLINICAL COURSE AND FEATURES BETWEEN SCLEROSING EPITHELOID FIBROSARCOMA AND LOW-GRADE FIBROMYXOID SARCOMA
John Rice
Favorite
Richard, Alexis

Massachusetts General Hospital
(P 63) DOES TUMOR NECROSIS IMPACT PROGNOSIS IN CHONDROBLASTIC AND OSTEOBLASTIC OSTEOSARCOMA? A STUDY FROM A LARGE TERTIARY CARE ACADEMIC CENTER
Alexis Richard
Favorite
Richards, Allison

Memorial Sloan Kettering Cancer Center
(P 229) EXPRESSION OF TRANSPOSABLE ELEMENTS AND IKZF1 PREDICTS IMMUNE INFILTRATES IN SARCOMAS AND CORRELATES WITH OUTCOMES AFTER IMMUNE CHECKPOINT INHIBITION
Allison Richards
Favorite
Richardson, Kenneth

University of Miami Miller School of Medicine
(P 369) BLAND EMBOLIZATION AS ADJUNCT TREATMENT FOR HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA
Kenneth Richardson
Favorite
Ridolfi, Laura

IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
(P 144) EXPLORATORY ANALYSIS OF 68GA-FAPI-46 PET-CT IN SOFT TISSUE SARCOMA
Laura Ridolfi
Favorite
Riedel, Richard

Duke Cancer Institute
(P 33) DESCRIPTIVE EVALUATION OF PATIENTS WITH DESMOID TUMOR AND CO-OCCURRING SOMATIC MUTATIONS OF CTNNB1 AND APC IN THE PHASE 3 DEFI TRIAL
Richard Riedel
Favorite
(P 246) THE GENOMIC AND IMMUNE LANDSCAPE OF LIPOSARCOMA AND ITS SUBTYPES
Richard Riedel
Favorite
(P 413) SUSTAINED EFFICACY DURING DRUG HOLIDAY ON ATEZOLIZUMAB IN PATIENTS WITH ALVEOLAR SOFT PART SARCOMA (ASPS)
Richard Riedel
Favorite
Righi, Alberto

Department of Pathology, IRCCS, Istituto Ortopedico Rizzoli, Bologna, Italy
(P 77) MULTI-PARAMETRICAL PROFILING OF CHONDROSARCOMA
Alberto Righi
Favorite
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Alberto Righi
Favorite
Rijs, Zeger

Leiden University Medical Center
(P 261) EVALUATION OF CT ARTIFACTS AFTER SPINAL OLIGOMETASTATIC DISEASE RESECTION AND RECONSTRUCTION: A COMPARATIVE STUDY OF CARBON-FIBER VS. TITANIUM IMPLANTS
Zeger Rijs
Favorite
Rios, Maria

Institut de Cancérologie de Lorraine
(P 125) CHARACTERISTICS, MANAGEMENT AND SURVIVAL OF N=7314 LIPOSARCOMAS FROM THE NATIONWIDE NETSARC REGISTRY IN FRANCE SINCE 2010
Maria Rios
Favorite
Risi Ambrogioni, Laura

Fondazione Policlinico Campus Bio-Medico of Rome
(P 178) PREDICTION OF PRIMARY IMATINIB-REFRACTORY PATIENTS WITH LOCALLY ADVANCED OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) USING RADIOMICS AND ARTIFICIAL INTELLIGENCE (AI)
Laura Risi Ambrogioni
Favorite
Riva, Nada

Clinical and Experimental Oncology, Immunotherapy, Rare Cancers and Biological Resource Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"
(P 144) EXPLORATORY ANALYSIS OF 68GA-FAPI-46 PET-CT IN SOFT TISSUE SARCOMA
Nada Riva
Favorite
Rivera, Dyani

Children's Hospital of Philadelphia
(P 318) SYNOVIAL SARCOMA REGISTRY AND BIOSPECIMEN REPOSITORY: DESCRIBING THE COHORT AND SURVIVAL OUTCOMES TO DATE
Dyani Rivera
Favorite
Rizk, Paul

Massachusetts General Hospital
(P 108) FIXATION OF IMPENDING OR PATHOLOGIC FRACTURES DUE TO METASTATIC DISEASE WITH CARBON FIBER INTRAMEDULLARY NAILS-A PROPENSITY-SCORE MATCHED COST ANALYSIS
Paul Rizk
Favorite
Robbins, Paul

Surgery Branch, NCI, NIH
(P 231) IDENTIFICATION OF NEOANTIGEN FROM PECOMA-LIKE NEOPLASM PROVIDES RATIONALE FOR TREATMENT WITH CELLULAR THERAPY
Paul Robbins
Favorite
Roberts, Ryan

Nationwide Children's Hospital
(P 49) A WORKING GROUP FOR THE DEVELOPMENT OF A CLINICAL FRAMEWORK THAT STRATIFIES OSTEOSARCOMA PATIENTS USING BIOMARKERS OF CLINICAL RISK AND BIOLOGY
Ryan Roberts
Favorite
(P 115) PROSPECTIVE EVALUATION OF THORACOSCOPIC METASTASECTOMY IN DOGS: A NOVEL TRANSLATIONAL DRUG DEVELOPMENT PIPELINE TAGETING METASTATIC OSTEOSARCOMA
Ryan Roberts
Favorite
Robinson, James

Children's Hospital of Philadelphia
(P 318) SYNOVIAL SARCOMA REGISTRY AND BIOSPECIMEN REPOSITORY: DESCRIBING THE COHORT AND SURVIVAL OUTCOMES TO DATE
James Robinson
Favorite
Robinson, Michael

Vanderbilt University Medical Center
(P 199) FINANCIAL TOXICITY AMONG SARCOMA PATIENTS AND ASSOCIATED FACTORS
Michael Robinson
Favorite
(P 297) ESTABLISHING A PEDIATRIC, ADOLESCENT AND YOUNG ADULT COHORT OF SARCOMA PATIENTS TO STUDY ONCOLOGIC AND NON-ONCOLOGIC OUTCOMES
Michael Robinson
Favorite
Robinson, Phillip J.

ProCan®, Children’s Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, NSW, Australia
(P 325) CAN PROTEOMICS PREDICT METASTATIC RELAPSE IN LEIOMYOSARCOMA? DEVELOPMENT OF AN 8 PROTEIN SIGNATURE IN A >350 SAMPLE STUDY INCLUDING A VALIDATION COHORT
Phillip J. Robinson
Favorite
Robinson, Steven

Mayo Clinic
(P 120) USING AI PREDICTIONS FROM ECG TRACINGS TO PREDICT TOLERANCE TO ANTHRACYCLINE CHEMOTHERAPY IN SARCOMA
Steven Robinson
Favorite
(P 200) FRAILTY ASSESSMENT IN OLDER PATIENTS RECEIVING SARCOMA THERAPY
Steven Robinson
Favorite
Robledo, Mercedes

Spanish National Cancer Research Center (CNIO)
(P 13) GENOMIC PROFILING OF ADULT SOFT TISSUE SARCOMAS FROM A SINGLE CENTER EXPERIENCE
Mercedes Robledo
Favorite
Rocha, Flavio

OHSU
(P 364) A PHASE 1B TRIAL OF PREOPERATIVE ERIBULIN AND RADIATION FOR RETROPERITONEAL LIPOSARCOMA
Flavio Rocha
Favorite
Roch, Alexandra

Indiana University School of Medicine
(P 384) REAL WORLD EXPERIENCE IN TREATING HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA: AN ULTRA-RARE VASCULAR TUMOR
Alexandra Roch
Favorite
Rochkind, Shimon

The Israeli Orthopedic Oncology center
(P 252) A NOVEL MULTIDISCIPLINARY SURGICAL APPROACH TO PERIPHERAL NERVE SHEATH TUMORS AND SOFT TISSUE SARCOMAS.
Shimon Rochkind
Favorite
Rodier, Francis

Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), Montréal, Canada; Institut du Cancer de Montréal (ICM), Montréal, Canada; Université de Montréal, Montréal, Canada
(P 326) CELL-FREE DNA AS A BIOMARKER FOR CELL DEATH AND TREATMENT RESPONSE IN ON-CHIP THREE-DIMENSIONAL SARCOMA TUMOR MODELS
Francis Rodier
Favorite
Rodon Ahnert, Jordi

MD Anderson Cancer Center
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Jordi Rodon Ahnert
Favorite
Rodriguez-Aguayo, Cristian

UT MD Anderson Cancer Center
(P 360) TREATMENT OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR WITH BROMODOMAIN EXTRA TERMINAL INHIBITOR (BETI) IN COMBINATION WITH RADIOTHERAPY
Cristian Rodriguez-Aguayo
Favorite
Rodriguez-Valentin, Madeline

Moffitt Cancer Center
(P 237) INTRALESIONAL ADMINISTRATION OF TALIMOGENE LAHERPAREPVEC (T-VEC) INDUCES TUMOR REGRESSION IN PATIENTS WITH CUTANEOUS ANGIOSARCOMA
Madeline Rodriguez-Valentin
Favorite
Rogala, Pawel

Maria Sklodowska-Curie National Research Institute of Oncology
(P 245) PRELIMINARY RESULTS FROM A PHASE 2 EFTISARC-NEO TRIAL OF NEOADJUVANT SOUBLE LAG-3 PROTEIN EFTILAGIMOD ALPHA, PEMBROLIZUMAB, AND CONCURRENT RADIOTHERAPY IN PATIENTS WITH RESECTABLE SOFT TISSUE SARCOMA
Pawel Rogala
Favorite
Rogers, Michael

Atlantic Health System
(P 255) CAN LARGE, LIPOMATOUS LESIONS ADJACENT TO THE SUPINATOR MUSCLE BE REMOVED WITHOUT INJURING THE POSTERIOR INTEROSSEOUS NERVE? A RETROSPECTIVE REVIEW
Michael Rogers
Favorite
(P 260) EMERGING TECHNOLOGY IN ORTHOPEDIC ONCOLOGY: ROBOTIC ARM-ASSISTED TOTAL KNEE ARTHROPLASTY HAS EXCEPTIONAL FUNCTION OUTCOMES FOR PATIENTS WITH BENIGN AND MALIGNANT MUSCULOSKELETAL DISEASE
Michael Rogers
Favorite
(P 266) LONG STEM CEMENTED ROBTIC ARM-ASSISTED TOTAL HIP ARTHROPLASTY: OUTCOMES IN PATIENTS WITH PRIOR ONCOLOGIC DISEASE
Michael Rogers
Favorite
(P 277) REVERSE TOTAL SHOULDER ARTHROPLASTY MAINTAINS GLOBAL FUNCTION OF THE UPPER EXTREMITY IN PATIENTS WITH ONCOLOGIC DISEASE OF THE PROXIMAL HUMERUS
Michael Rogers
Favorite
(P 405) LIPOSOMAL BUPIVACAINE DOESN'T REDUCE NARCOTIC USE OR PAIN SCORES COMPARED TO A MULTIDRUG COCKTAIL FOLLOWING SOFT TISSUE TUMOR REMOVAL: PRELIM RESULTS OF A PROSPECTIVE, RANDOMIZED DOUBLE-BLINDED STUDY
Michael Rogers
Favorite
Roland, Christina

The University of Texas MD Anderson Cancer Center
(P 130) HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RESECTABLE RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA (DDLPS) TREATED WITH NEOADJUVANT CHECKPOINT BLOCKADE IN A RANDOMIZED PHASE II CLINICAL TRIAL.
Christina Roland
Favorite
(P 233) IMMUNE CLASSES OF LEIOMYOSARCOMA DRIVEN BY B CELL INFILTRATE AND CTLA4 EXPRESSION
Christina Roland
Favorite
(P 360) TREATMENT OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR WITH BROMODOMAIN EXTRA TERMINAL INHIBITOR (BETI) IN COMBINATION WITH RADIOTHERAPY
Christina Roland
Favorite
Romandini, Davide

Fondazione Policlinico Campus Bio-Medico of Rome
(P 178) PREDICTION OF PRIMARY IMATINIB-REFRACTORY PATIENTS WITH LOCALLY ADVANCED OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) USING RADIOMICS AND ARTIFICIAL INTELLIGENCE (AI)
Davide Romandini
Favorite
Romanelli, Roberta

IRCCS Humanitas Research Hospital
(P 290) ARTIFICIAL INTELLIGENCE-BASED COMPARISON OF ADULT AND ADOLESCENT AND YOUNG ADULTS (AYA) SARCOMAS: A PILOT STUDY
Roberta Romanelli
Favorite
Ropars, Mikael

CHU Rennes
(P 125) CHARACTERISTICS, MANAGEMENT AND SURVIVAL OF N=7314 LIPOSARCOMAS FROM THE NATIONWIDE NETSARC REGISTRY IN FRANCE SINCE 2010
Mikael Ropars
Favorite
Rosales, Nestor

Memorial Sloan Kettering Cancer Center
(P 338) PRECLINICAL EFFICACY OF DAN-222, A NOVEL POLYMERIC NANOPARTICLE, IN PEDIATRIC SOLID TUMOR MODELS
Nestor Rosales
Favorite
Rose, Brandon

University of Miami and Jackson Health Systems
(P 253) ASSESSING THE LINK BETWEEN MYXOFIBROSARCOMA RECURRENCE AND TREATMENT ORDER: A MULTIDISCIPLINARY RETROSPECTIVE COHORT STUDY
Brandon Rose
Favorite
(P 296) DISPARITIES IN OVERALL SURVIVAL FOR AYA PATIENTS WITH EWINGS SARCOMA: A RETROSPECTIVE COHORT STUDY AT A SINGLE SARCOMA CENTER
Brandon Rose
Favorite
(P 314) RETROSPECTIVE EVALUATION OF DISPARITIES IN ADOLESCENT AND YOUNG ADULT (AYA) PATIENTS WITH SYNOVIAL SARCOMA: A SINGLE INSTITUTION STUDY
Brandon Rose
Favorite
(P 369) BLAND EMBOLIZATION AS ADJUNCT TREATMENT FOR HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA
Brandon Rose
Favorite
(P 381) OLIGOMETASTATIC LEIOMYOSARCOMA: ASSOCIATION BETWEEN TREATMENT TYPE, METASTATIC PATTERN AND SURVIVAL
Brandon Rose
Favorite
Rosenbaum, Evan

Memorial Sloan Kettering Cancer Center
(P 229) EXPRESSION OF TRANSPOSABLE ELEMENTS AND IKZF1 PREDICTS IMMUNE INFILTRATES IN SARCOMAS AND CORRELATES WITH OUTCOMES AFTER IMMUNE CHECKPOINT INHIBITION
Evan Rosenbaum
Favorite
Rosenberg, Andrew

University of Miami School of Medicine
(P 224) COMPREHENSIVE EVALUATION OF DNA DAMAGE RESPONSE PATHWAY ALTERATIONS AND ASSOCIATED IMMUNOTHERAPY-RESPONSE BIOMARKERS IN SARCOMAS
Andrew Rosenberg
Favorite
(P 358) RADIOMIC EVALUATION OF MRIS IN PATIENTS WITH SOFT TISSUE SARCOMA TREATED WITH STEREOTACTIC BOSY RADIATION THERAPY
Andrew Rosenberg
Favorite
(P 434) UTILIZATION OF IMAGING MASS CYTOMETRY TO EVALUATE THE IMMUNE LANDSCAPE OF PEDIATRIC AND ADULT PATIENTS WITH SARCOMA TREATED WITH AN AUTOLOGOUS DENDRITIC CELL VACCINE
Andrew Rosenberg
Favorite
Rosenberger, Christina

National Cancer Institute
(P 413) SUSTAINED EFFICACY DURING DRUG HOLIDAY ON ATEZOLIZUMAB IN PATIENTS WITH ALVEOLAR SOFT PART SARCOMA (ASPS)
Christina Rosenberger
Favorite
Rosenberg, Steven

Surgery Branch, NCI, NIH
(P 231) IDENTIFICATION OF NEOANTIGEN FROM PECOMA-LIKE NEOPLASM PROVIDES RATIONALE FOR TREATMENT WITH CELLULAR THERAPY
Steven Rosenberg
Favorite
Rosenfelder, Nicola

The Royal Marsden Hospital
(P 183) A RETROSPECTIVE STUDY OF THE EFFECTS OF PATIENT, DISEASE, AND TREATMENT FACTORS ON SURVIVAL OUTCOMES IN PATIENTS WITH SOFT TISSUE SARCOMA BRAIN METASTASES
Nicola Rosenfelder
Favorite
Rosenheck, Michael

Indiana University School of Medicine
(P 384) REAL WORLD EXPERIENCE IN TREATING HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA: AN ULTRA-RARE VASCULAR TUMOR
Michael Rosenheck
Favorite
Rose, Peter

Mayo Clinic
(P 294) COMPARING HIGH-GRADE NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA IN ADULT AND PEDIATRIC POPULATIONS
Peter Rose
Favorite
Rossing, Caroline Maria

Center for Genomic Medicine, Copenhagen University Hospital, Rigshospitalet
(P 104) CIRQUESARC: A NATIONAL PROSPECTIVE OBSERVATIONAL STUDY OF CIRCULATING TUMOR DNA AND QUALITY OF LIFE IN PATIENTS WITH SARCOMA – PRELIMINARY RESULTS FROM THE SURGICAL COHORT
Caroline Maria Rossing
Favorite
Rothschild, Sara

TGCT Support/Life Raft Group
(P 166) D842V - A TALE OF TWO STAGES: COMPARATIVE ANALYSIS OF OVERALL SURVIVAL AND TREATMENT RESPONSE IN GIST PATIENTS WITH PDGFRA D842V MUTATIONS
Sara Rothschild
Favorite
(P 176) LOSS OF PTEN EXPRESSION IN MINIGISTS AND CLINICALLY RELEVANT GISTS
Sara Rothschild
Favorite
Roux, Audrey

Hôpital Maisonneuve-Rosemont
(P 321) WHOLE ABDOMINAL RADIOTHERAPY IN CHILDREN AND YOUNG ADULTS WITH SARCOMA: A CANADIAN SARCOMA AND CLINICAL COLLABORATION (CANSARCC) STUDY
Audrey Roux
Favorite
Rouzbahman, Marjan

University Hospital Network
(P 159) USING THE TRANSCRIPTIONAL SPECTRUM OF UTERINE SMOOTH MUSCLE TUMORS TO IDENTIFY PROGNOSTIC SIGNATURES FOR ABNORMAL LEIOMYOMAS AND SMOOTH MUSCLE TUMOURS OF UNCERTAIN MALIGNANT POTENTIAL
Marjan Rouzbahman
Favorite
ROXBURGH, PATRICIA

UNIVERSITY OF GLASGOW
(P 87) SAFETY AND EFFICACY OF OLUTASIDENIB, AN IDH1 MUTANT INHIBITOR, FOR THE TREATMENT OF RECURRENT/ RELAPSED LOCALLY ADVANCED OR METASTATIC IDH1 MUTATED CHONDROSARCOMA
PATRICIA ROXBURGH
Favorite
Rubinacci, Maria

Daiichi Sankyo, Inc.
(P 37) HEALTH-RELATED QUALITY OF LIFE FROM A PHASE 4 STUDY TO EVALUATE DISCONTINUATION AND RECHALLENGE OF PEXIDARTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR PREVIOUSLY TREATED WITH PEXIDARTINIB
Maria Rubinacci
Favorite
Rubin, Brian

Cleveland Clinic
(P 102) ANALYSIS OF BLOOD-BASED BIOMARKERS AS PROGNOSTIC FACTORS IN PATIENTS WITH EHE TREATED WITH TRAMETINIB IN SARC033
Brian Rubin
Favorite
Ruiz, Antonio

Hospital Clinico san Carlos
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Antonio Ruiz
Favorite
Ruiz-Soto, Rodrigo

Deciphera Pharmaceuticals, LLC
(P 43) SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
Rodrigo Ruiz-Soto
Favorite
(P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE
Rodrigo Ruiz-Soto
Favorite
(P 403) DCC-3116 IN COMBINATION WITH RIPRETINIB FOR PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A PHASE 1/2 STUDY
Rodrigo Ruiz-Soto
Favorite
Rushing, Daniel

Indiana University Melvin and Bren Simon Cancer Center
(P 384) REAL WORLD EXPERIENCE IN TREATING HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA: AN ULTRA-RARE VASCULAR TUMOR
Daniel Rushing
Favorite
Ruspi, Laura

IRCCS Humanitas Research Hospital
(P 362) A NEW ROCK BAND FOR DIAPHRAGMATIC RECONSTRUCTION IN LEFT RETROPERITONEAL SARCOMA SURGERY
Laura Ruspi
Favorite
(P 363) A NEW SURGICAL TECHNIQUE FOR THE RECONSTRUCTION OF INGUINAL 'NEOLIGAMENT' AFTER SOFT TISSUE SARCOMA RESECTION
Laura Ruspi
Favorite
(P 373) EVALUATION OF HISTOLOGIC ORGAN INFILTRATION (HOI) AND VISCERAL RESECTION MARGINS (VRM) IN PRIMARY RETROPERITONEAL SARCOMAS: PROGNOSTIC IMPLICATIONS FOR LOCAL RECURRENCE
Laura Ruspi
Favorite
(P 388) THE ROAD TO CURATIVE SURGERY IN RETROPERITONEAL SOFT TISSUE SARCOMA: A DIFFERENT PATH IN THE ELDERLY?
Laura Ruspi
Favorite
(P 389) THE ROLE OF NUTRITIONAL STATUS ON POSTOPERATIVE AND ONCOLOGICAL OUTCOMES IN RETROPERITONEAL SARCOMA
Laura Ruspi
Favorite
Russell, Heidi

University of Texas Health Science Center at Houston School of Public Health
(P 315) SALVAGE THERAPY EFFICACY IS MODIFIED BY RISK GROUP AT DIAGNOSIS IN PATIENTS WITH RELAPSED RHABDOMYOSARCOMA
Heidi Russell
Favorite
Russo, Caterina

Research Institute McGill University Health Center
(P 69) H3.3G34W ONCOHISTONE IN OSTEOSARCOMA
Caterina Russo
Favorite
Russo, Ida

BAMBINO GESU CHILDREN HOSPITAL
(P 298) EWING SARCOMA OF MAXILLOFACIAL REGION AND SKULL: A RETROSPECTIVE MONOINSTITUTIONAL PEDIATRIC SERIES
Ida Russo
Favorite
(P 311) QUANTIFICATION OF TUMOUR-INFILTRATING IMMUNE CELLS THROUGH DECONVOLUTION OF DNA METHYLATION DATA IN EWING SARCOMAS
Ida Russo
Favorite
Russo, Luigi

BC Cancer
(P 153) PATTERNS, MANAGEMENT AND SURVIVAL OUTCOMES OF PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA: A NATIONWIDE ANALYSIS FROM THE CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION DATABASE
Luigi Russo
Favorite
Rutkowski, Piotr

Department of Soft Tissue/Bone Sarcoma and Melanoma; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
(P 43) SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
Piotr Rutkowski
Favorite
Rutkowski, Piotr

Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw Poland
(P 46) A NEED FOR STANDARDIZATION IN TRIAL DESIGN AND DATA REPORTING IN PHASE II TRIALS IN RARE TUMORS. LESSONS LEARNED FROM PHASE II TRIALS IN BONE SARCOMAS
Piotr Rutkowski
Favorite
(P 77) MULTI-PARAMETRICAL PROFILING OF CHONDROSARCOMA
Piotr Rutkowski
Favorite
Rutkowski, Piotr

Maria Sklodowska-Curie National Research Institute of Oncology
(P 245) PRELIMINARY RESULTS FROM A PHASE 2 EFTISARC-NEO TRIAL OF NEOADJUVANT SOUBLE LAG-3 PROTEIN EFTILAGIMOD ALPHA, PEMBROLIZUMAB, AND CONCURRENT RADIOTHERAPY IN PATIENTS WITH RESECTABLE SOFT TISSUE SARCOMA
Piotr Rutkowski
Favorite
Rutkowski, Piotr

Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw Poland
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Piotr Rutkowski
Favorite
Ruus, Caroline

BC Children's Hospital
(P 321) WHOLE ABDOMINAL RADIOTHERAPY IN CHILDREN AND YOUNG ADULTS WITH SARCOMA: A CANADIAN SARCOMA AND CLINICAL COLLABORATION (CANSARCC) STUDY
Caroline Ruus
Favorite
Ryan, Christopher

OHSU Knight Cancer Institute
(P 37) HEALTH-RELATED QUALITY OF LIFE FROM A PHASE 4 STUDY TO EVALUATE DISCONTINUATION AND RECHALLENGE OF PEXIDARTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR PREVIOUSLY TREATED WITH PEXIDARTINIB
Christopher Ryan
Favorite
(P 227) EFFICACY OF IMMUNOTHERAPY IN TREATING METASTATIC MALIGNANT MYOPERICYTOMA: A CASE REPORT AND RIVEW OF LITERATURE
Christopher Ryan
Favorite
(P 364) A PHASE 1B TRIAL OF PREOPERATIVE ERIBULIN AND RADIATION FOR RETROPERITONEAL LIPOSARCOMA
Christopher Ryan
Favorite
Rytlewski, Jeffrey

University of Iowa
(P 395) INTEGRATED EPIGENETIC ANALYSES IDENTIFY A MULTI-SARCOMA DNA METHYLATION SIGNATURE OF TUMOR PROGRESSION AND METASTASIS
Jeffrey Rytlewski
Favorite
S
Sánchez Morillas, Raúl

Son Espases University Hospital
(P 13) GENOMIC PROFILING OF ADULT SOFT TISSUE SARCOMAS FROM A SINGLE CENTER EXPERIENCE
Raúl Sánchez Morillas
Favorite
(P 322) A NEW PLAYER IN SOFT TISSUE SARCOMA PROGRESSION: WNT5A IS A PROGNOSIS BIOMARKER AND A POTENTIAL ACTIONABLE TARGET
Raúl Sánchez Morillas
Favorite
Säljö, Karin

University of Gothenburg, Institute of Clinical Scinces
(P 139) CHARACTERIZATION OF GLYCOSPHINGOLIPIDS IN HUMAN LEIOMYOSARCOMA
Karin Säljö
Favorite
Saavedra, Omar

NEXT Oncology Hospital Quionsalud Barcelona
(P 337) OMX-0407 A NOVEL SPECTRUM-SELECTIVE SMALL MOLECULE KINASE INHIBITOR IS ACTIVE IN THE TREATMENT OF ANGIOSARCOMA
Omar Saavedra
Favorite
Saba, Karim

Lund University
(P 03) CDK4 IS CO-AMPLIFIED WITH EITHER TP53 PROMOTER GENE FUSIONS OR MDM2 THROUGH DISTINCT MECHANISMS IN OSTEOSARCOMA
Karim Saba
Favorite
(P 26) SARCDBASE: A TOOL FOR DETECTION OF GENETIC ALTERATIONS IN SARCOMA
Karim Saba
Favorite
Sachdeva, Ishita

Washington University in St Louis
(P 187) BRIDGING THE GAP: UNDERSTANDING THE CURRENT TREATMENT RESPONSES TO ENHANCE THE STANDARD OF CARE AND OUTCOMES FOR MALIGNANT PERIPHERAL NERVE SHEATH TUMORS
Ishita Sachdeva
Favorite
Sachs, Elizabeth

Duke
(P 54) CHONDROBLASTIC OSTEOSARCOMA IS A RISK FACTOR FOR LOCAL RECURRENCE IN PATIENTS WITH SKELETAL OSTEOSARCOMA
Elizabeth Sachs
Favorite
Saeki, Kohei

Okayama University of Science
(P 01) A PILOT STUDY ON SINGLE-NUCLEUS RNA SEQUENCING IN CANINE SOFT TISSUE SARCOMAS
Kohei Saeki
Favorite
Saiduzzaman, S. M.

University of California Santa Cruz, Electrical and Computer Engineering, Genomics Institute
(P 147) INVESTIGATING THE POTENTIAL OF EXTRACELLULAR VESICLE BIOMARKERS IN SYNOVIAL SARCOMA DETECTION
S. M. Saiduzzaman
Favorite
Saigh, Shannon

University of Miami Miller School of Medicine
(P 434) UTILIZATION OF IMAGING MASS CYTOMETRY TO EVALUATE THE IMMUNE LANDSCAPE OF PEDIATRIC AND ADULT PATIENTS WITH SARCOMA TREATED WITH AN AUTOLOGOUS DENDRITIC CELL VACCINE
Shannon Saigh
Favorite
Saint-Yves, Hugo

CEMTL
(P 153) PATTERNS, MANAGEMENT AND SURVIVAL OUTCOMES OF PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA: A NATIONWIDE ANALYSIS FROM THE CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION DATABASE
Hugo Saint-Yves
Favorite
(P 212) REFERENCE SYSTEM OPTIMIZATION, ANALYSES OF THE IMPLEMENTATION OF A PROVINCIAL MULTIDISCIPLINARY SARCOMA NETWORK
Hugo Saint-Yves
Favorite
Sairyo, Koichi

Tokushima University
(P 138) ACCURACY AND COMPLICATIONS OF CORE NEEDLE BIOPSY OF PERIPHERAL NERVE TUMORS
Koichi Sairyo
Favorite
Sakai, Hideki

Hyogo Cancer Center
(P 168) EFFICACY OF LOW-DOSE IMATINIB IN A PATIENT WITH A GIST WITH KIT EXON 11 W557_K558 DELETION
Hideki Sakai
Favorite
Sakai, Tomohisa

Nagoya university hospital
(P 280) SURGICAL OUTCOMES OF PELVIC CHONDROSARCOMA WITH A FOCUS ON WALKING ABILITY
Tomohisa Sakai
Favorite
Salawu, Abdulazeez

Mount Sinai Hospital and Princess Margaret Cancer Centre/University of Toronto
(P 320) WHAT IS THE ROLE OF CHEMOTHERAPY IN PATIENTS (PTS) WITH SPINDLE CELL/SCLEROSING RHABDOMYOSARCOMA (SCRMS): A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Abdulazeez Salawu
Favorite
Salazar-Arcila, Carolina

University of Calgary
(P 236) INTERFERON STIMULATED GENE SCORES ARE ELEVATED IN THE MYELOID COMPARTMENT OF MURINE KP UNDIFFERENTIATED PLEOMORPHIC TUMORS TREATED WITH TRANSLATIONAL STING AGONISTS
Carolina Salazar-Arcila
Favorite
(P 239) INVESTIGATING HOW TUMOUR ASSOCIATED MACROPHAGES INFLUENCE THE EFFICACY OF CAR T THERAPY IN A MURINE MODEL OF SOFT TISSUE SARCOMA
Carolina Salazar-Arcila
Favorite
(P 327) CHARACTERIZATION OF TWO NOVEL IMMUNE COMPETENT, MURINE MODELS OF SOFT TISSUE SARCOMA
Carolina Salazar-Arcila
Favorite
(P 333) ESTIMATING IMMUNE INFILTRATES OF NOVEL GENETICALLY ENGINEERED MOUSE MODELS OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Carolina Salazar-Arcila
Favorite
Saleh, Mohammad

University of Miami Miller School of Medicine and Jackson Health Systems
(P 381) OLIGOMETASTATIC LEIOMYOSARCOMA: ASSOCIATION BETWEEN TREATMENT TYPE, METASTATIC PATTERN AND SURVIVAL
Mohammad Saleh
Favorite
Saleh, Ramy

MUCH
(P 153) PATTERNS, MANAGEMENT AND SURVIVAL OUTCOMES OF PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA: A NATIONWIDE ANALYSIS FROM THE CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION DATABASE
Ramy Saleh
Favorite
(P 293) CIC-REARRANGED SOFT TISSUE SARCOMAS: DOES CHEMOTHERAPY CHANGE NATURAL HISTORY AND PROGNOSIS? A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Ramy Saleh
Favorite
(P 320) WHAT IS THE ROLE OF CHEMOTHERAPY IN PATIENTS (PTS) WITH SPINDLE CELL/SCLEROSING RHABDOMYOSARCOMA (SCRMS): A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Ramy Saleh
Favorite
Salib, Alice

Children's Cancer Institute
(P 299) EXPLORING THE POTENTIAL OF PHOSPHOPROTEOMIC PROFILING FOR TARGET DISCOVERY IN HIGH-RISK OSTEOSARCOMA: A PATHWAY TO NOVEL THERAPIES?
Alice Salib
Favorite
Salvatore, Daniela

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
(P 376) IMPACT OF SITE OF ORIGIN ON THE PROGNOSIS OF PATIENTS WITH PRIMARY RESECTABLE NON-UTERINE ABDOMINAL LEIOMYOSARCOMA
Daniela Salvatore
Favorite
Salyer, Hannah

Texas Tech University Health Sciences Center
(P 292) CHARACTERIZATION OF TELOMERE MAINTENANCE MECHANISMS IN OSTEOSARCOMA PATIENT-DERIVED LABORATORY MODELS
Hannah Salyer
Favorite
Samà, Laura

IRCCS - Humanitas Research Hospital
(P 362) A NEW ROCK BAND FOR DIAPHRAGMATIC RECONSTRUCTION IN LEFT RETROPERITONEAL SARCOMA SURGERY
Laura Samà
Favorite
(P 363) A NEW SURGICAL TECHNIQUE FOR THE RECONSTRUCTION OF INGUINAL 'NEOLIGAMENT' AFTER SOFT TISSUE SARCOMA RESECTION
Laura Samà
Favorite
(P 373) EVALUATION OF HISTOLOGIC ORGAN INFILTRATION (HOI) AND VISCERAL RESECTION MARGINS (VRM) IN PRIMARY RETROPERITONEAL SARCOMAS: PROGNOSTIC IMPLICATIONS FOR LOCAL RECURRENCE
Laura Samà
Favorite
(P 388) THE ROAD TO CURATIVE SURGERY IN RETROPERITONEAL SOFT TISSUE SARCOMA: A DIFFERENT PATH IN THE ELDERLY?
Laura Samà
Favorite
(P 389) THE ROLE OF NUTRITIONAL STATUS ON POSTOPERATIVE AND ONCOLOGICAL OUTCOMES IN RETROPERITONEAL SARCOMA
Laura Samà
Favorite
Sandhu, Jagteshwar

University of Miami Miller School of Medicine
(P 369) BLAND EMBOLIZATION AS ADJUNCT TREATMENT FOR HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA
Jagteshwar Sandhu
Favorite
Sanfilippo, Roberta

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 137) TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS
Roberta Sanfilippo
Favorite
(P 160) UTERINE PECOMA: REPORT OF MOLECULAR AND CLINICAL FEATURES IN A SERIES OF PATIENTS TREATED AT A REFERRAL INSTITUTION
Roberta Sanfilippo
Favorite
(P 171) GASTROINTESTINAL STROMAL TUMOURS (GISTS) IN NEUROFIBROMATOSIS TYPE (NF1): A SINGLE-CENTER OBSERVATIONAL RETROSPECTIVE STUDY
Roberta Sanfilippo
Favorite
(P 368) AGGRESSIVE PERINEAL ANGIOMYXOMA UNDERGOING SYSTEMIC TREATMENT: AN UPDATED REPORT OF 8-YEARS' EXPERIENCE IN A REFERRAL CENTER
Roberta Sanfilippo
Favorite
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Roberta Sanfilippo
Favorite
(P 376) IMPACT OF SITE OF ORIGIN ON THE PROGNOSIS OF PATIENTS WITH PRIMARY RESECTABLE NON-UTERINE ABDOMINAL LEIOMYOSARCOMA
Roberta Sanfilippo
Favorite
(P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Roberta Sanfilippo
Favorite
(P 420) CELLULARITY DEGREES IN PRIMARY MYXOID LIPOSARCOMA: ASSOCIATION WITH TUMOR IMMUNE INFILTRATE AND PATIENT OUTCOMES
Roberta Sanfilippo
Favorite
Sangiolo, Dario

Department of Oncology, University of Turin
(P 345) TRANSCRIPTOMIC AND PHENOTYPIC CHARACTERIZATION OF AN IMMUNOCOMPETENT LEIOMYOSARCOMA MOUSE MODEL.
Dario Sangiolo
Favorite
Sankhala, Esha

University of California, Irvine
(P 140) CIRCULATING TUMOR DNA AS A TOOL OF SURVEILLANCE AND EARLY INDICATOR OF RELAPSE IN SARCOMA PATIENTS
Esha Sankhala
Favorite
Sankhala, Kamalesh

Samuel Oschin Cancer Center, Cedars Sinai Health System
(P 400) A LONG-TERM PHASE 4 STUDY TO EVALUATE THE RISK OF HEPATOTOXICITY ASSOCIATED WITH PEXIDARTINIB TREATMENT
Kamalesh Sankhala
Favorite
Santiago, Teresa

St. Jude Children's Research Hospital
(P 288) ANGIOA: A SAFETY AND TOLERABILITY STUDY OF TRIPLE ANTI-ANGIOGENIC THERAPY COMBINED WITH PD-L1 BLOCKADE IN PEDIATRIC, ADOLESCENT AND YOUNG ADULT RECURRENT/REFRACTORY SOLID TUMORS
Teresa Santiago
Favorite
Santoro, Armando

Humanitas Research Hospital
(P 124) ASSESSMENT OF THE MECHANISMS OF ACTION OF ERIBULIN IN PATIENTS WITH ADVANCED LIPOSARCOMA THROUGH THE EVALUATION OF THE RADIOLOGICAL, FUNCTIONAL AND TISSUE RESPONSE: A MONOCENTRIC PROSPECTIVE STUDY
Armando Santoro
Favorite
(P 155) PRIMARY MESENCHYMAL TUMORS OF THE HEART: A 8-YEARS, SINGLE INSTITUTION EXPERIENCE
Armando Santoro
Favorite
(P 290) ARTIFICIAL INTELLIGENCE-BASED COMPARISON OF ADULT AND ADOLESCENT AND YOUNG ADULTS (AYA) SARCOMAS: A PILOT STUDY
Armando Santoro
Favorite
Santoro, Armando

IRCCS Humanitas Research Hospital
(P 431) REAL-WORLD EXPERIENCE OF EFFICACY AND TOLERABILITY OF CONTINUOS INFUSION IFOSFAMIDE AMONG ADVANCED SOFT TISSUE AND BONE SARCOMAS PATIENTS: A SINGLE CENTRE RETROSPECTIVE COHORT.
Armando Santoro
Favorite
Santos, Miguel

Instituto Português de Oncologia de Lisboa
(P 128) DYNAMIC HETEROGENEITY AMONGST LIPOSARCOMAS
Miguel Santos
Favorite
Sapienza, Maria Rosaria

Hemolimphopathology, IEO - Istituto Europeo di Oncologia IRCCS
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Maria Rosaria Sapienza
Favorite
Sarchet, Patricia

The Ohio State University
(P 136) TARGETING MIR-138-5P TO TREAT DEDIFFERENTIATED LIPOSARCOMA
Patricia Sarchet
Favorite
Sarre Lazcano, Catherine

University of Toronto
(P 213) REGIONAL KNOWLEDGE TRANSLATION IN RETROPERITONEAL SARCOMAS: IMPACT OF AN EDUCATIONAL WEBINAR SERIES BY THE MEXICAN SARCOMA GROUP
Catherine Sarre Lazcano
Favorite
(P 376) IMPACT OF SITE OF ORIGIN ON THE PROGNOSIS OF PATIENTS WITH PRIMARY RESECTABLE NON-UTERINE ABDOMINAL LEIOMYOSARCOMA
Catherine Sarre Lazcano
Favorite
Sarre, Catherine

TARPSWG
(P 367) AGE AS A PROGNOSTIC FACTOR IN RETROPERITONEAL SARCOMA: A MULTICENTER LATIN AMERICAN STUDY
Catherine Sarre
Favorite
Sarthy, Jay

Seattle Children's Research Institute, University of Washington
(P 330) EFFICACY OF NON-CARDIOTOXIC ANTHRACYCLINES IN EWING SARCOMA
Jay Sarthy
Favorite
Sassi, Martina

Campus Bio-Medico University of Rome
(P 178) PREDICTION OF PRIMARY IMATINIB-REFRACTORY PATIENTS WITH LOCALLY ADVANCED OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) USING RADIOMICS AND ARTIFICIAL INTELLIGENCE (AI)
Martina Sassi
Favorite
Satterwhite, Audra

National Cancer Institute/National Institutes of Health
(P 163) CHARACTERIZATION OF INTRAHEPATIC RECURRENCE FOLLOWING LIVER-DIRECTED SURGERY IN PATIENTS WITH METASTATIC SDH-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST): RISE AND STABILIZATION OF THE GISTLETS
Audra Satterwhite
Favorite
Savage, Princess

Sarcoma Oncology Center
(P 251) UPDATE ON SAINT: A PHASE 2 STUDY USING TRABECTEDIN (T) IN COMBINATION WITH IPILIMUMAB (L) AND NIVOLUMAB (N) IN PREVIOUSLY TREATED SOFT TISSUE SARCOMA (NCT03138161)
Princess Savage
Favorite
Sayles, Leanne

UCSF
(P 292) CHARACTERIZATION OF TELOMERE MAINTENANCE MECHANISMS IN OSTEOSARCOMA PATIENT-DERIVED LABORATORY MODELS
Leanne Sayles
Favorite
Sbaraglia, Marta

University of Padua
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Marta Sbaraglia
Favorite
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Marta Sbaraglia
Favorite
(P 345) TRANSCRIPTOMIC AND PHENOTYPIC CHARACTERIZATION OF AN IMMUNOCOMPETENT LEIOMYOSARCOMA MOUSE MODEL.
Marta Sbaraglia
Favorite
(P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Marta Sbaraglia
Favorite
Scallo, Frankie

Yale University
(P 98) A MULTIEPITOPE MRNA VACCINE FOR KAPOSI SARCOMA: AN IMMUNOINFORMATIC APPROACH
Frankie Scallo
Favorite
Scally, Christopher

University of Texas MD Anderson Cancer Center
(P 130) HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RESECTABLE RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA (DDLPS) TREATED WITH NEOADJUVANT CHECKPOINT BLOCKADE IN A RANDOMIZED PHASE II CLINICAL TRIAL.
Christopher Scally
Favorite
Scally, Christopher

The University of Texas MD Anderson Cancer Center
(P 360) TREATMENT OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR WITH BROMODOMAIN EXTRA TERMINAL INHIBITOR (BETI) IN COMBINATION WITH RADIOTHERAPY
Christopher Scally
Favorite
Schaefer, Inga-Marie

Brigham and Women's Hospital
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Inga-Marie Schaefer
Favorite
Schaffer, Moshe

Barzilai Medical Center, Ashkelon
(P 182) A NOVEL MODEL FOR THE DIRECT REFERRAL OF ONCOLOGIC PATIENTS IN A PUBLIC HEALTH CARE SYSTEM
Moshe Schaffer
Favorite
Schalper, Kurt

Yale University School of Medicine
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Kurt Schalper
Favorite
Schelfaut, Sebastiaan

UZ Leuven
(P 291) CASE REPORT: RADICAL EN BLOC MULTI-LEVEL SPONDYLECTOMY FOR A LOCALLY RECURRENT OSTEOSARCOMA
Sebastiaan Schelfaut
Favorite
Schelling, Georg

SwissSarcomaNetwork
(P 184) A SYSTEMATIC REVIEW ABOUT CLINICAL PROGNOSTIC MODELS FOR SARCOMAS
Georg Schelling
Favorite
Scherer, Amanda

University of Iowa
(P 12) GENETIC LANDSCAPE OF MPNST DETERMINES METABOLIC STRATEGIES AND THERAPEUTIC OPPORTUNITIES FOR COPING WITH REDOX STRESS
Amanda Scherer
Favorite
Schiffman, Joshua

Peel Therapeutics; Huntsman Cancer Institute, University of Utah
(P 16) HOW TO GROW A BONE IN 60 DAYS: EXPLORING THE UNIQUE PRO-GROWTH, ANTI-CANCER ENVIRONMENT IN ELK ANTLERS
Joshua Schiffman
Favorite
Schleupner, Beatrice

Duke University School of Medicine
(P 16) HOW TO GROW A BONE IN 60 DAYS: EXPLORING THE UNIQUE PRO-GROWTH, ANTI-CANCER ENVIRONMENT IN ELK ANTLERS
Beatrice Schleupner
Favorite
Schmerling, Rafael

Latin American Cooperative Oncology Group (LACOG)
(P 192) CURRENT SCENARIO OF SARCOMA CLINICAL TRIALS IN SOUTH AMERICA: A REPORT BY THE LACOG SARCOMA GROUP
Rafael Schmerling
Favorite
(P 216) SARCOMA CARE PATHWAYS AND MULTIDISCIPLINARY TUMOR BOARDS IN LATIN AMERICA: AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Rafael Schmerling
Favorite
(P 217) SARCOMA DRUG APPROVALS IN LATIN AMERICA COMPARED TO THE FDA AND EMA: AN ANALYSIS BY THE LACOG SARCOMA GROUP
Rafael Schmerling
Favorite
(P 219) SOCIAL MEDIA USE AMONG MEDICAL PROFESSIONALS THAT TREAT PATIENTS WITH SARCOMA IN LATIN AMERICA: RESULTS OF AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Rafael Schmerling
Favorite
Schmidt, Holger

University of California Santa Cruz, Electrical and Computer Engineering, Genomics Institute
(P 147) INVESTIGATING THE POTENTIAL OF EXTRACELLULAR VESICLE BIOMARKERS IN SYNOVIAL SARCOMA DETECTION
Holger Schmidt
Favorite
Schmidt, Max

Indiana University School of Medicine
(P 384) REAL WORLD EXPERIENCE IN TREATING HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA: AN ULTRA-RARE VASCULAR TUMOR
Max Schmidt
Favorite
Schmidt, Ryan

Children's Hospital Los Angeles
(P 76) MOLECULAR AND CHROMOSOMAL MICROARRAY PROFILING OF OSTEOSARCOMA IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS: A SINGLE INSTITUTION REPORT
Ryan Schmidt
Favorite
Schoedel, Karen

University of Pittsburgh Medical Center
(P 117) THE TUMOR IMMUNE MICROENVIRONMENT OF DEDIFFERENTIATED SARCOMAS: DIGITAL SPATIAL PROFILING SHOWS IMMUNE TRANSCRIPTIONAL DIFFERENCES BETWEEN DEDIFFERENTIATED LIPOSARCOMA AND CHONDROSARCOMA
Karen Schoedel
Favorite
(P 240) INVESTIGATING MACROPHAGE POPULATION VARIABILITY IN METASTATIC SARCOMA SAMPLES
Karen Schoedel
Favorite
(P 258) COMPARING OUTCOMES FOLLOWING INTRALESIONAL VERSUS WIDE RESECTION PROCEDURES IN THE TREATMENT OF RENAL CELL CARCINOMA BONE METASTASES
Karen Schoedel
Favorite
Schöffski, Patrick

Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven
(P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE
Patrick Schöffski
Favorite
(P 331) EFFICACY OF NOVEL UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN TARGETED ANTIBODY-DRUG CONJUGATES IN PATIENT-DERIVED XENOGRAFTS OF SOFT TISSUE SARCOMA
Patrick Schöffski
Favorite
(P 334) EXPANDING THE LANDSCAPE OF PRECLINICAL MODELS OF SYNOVIAL SARCOMA: FROM 2-DIMENSIONS TO 3-DIMENSIONS TO MICE
Patrick Schöffski
Favorite
(P 340) THE DNA MINOR GROOVE BINDING AGENTS ECUBECTEDIN AND PM54 DEMONSTRATE ANTITUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT MODELS OF SOFT TISSUE SARCOMA
Patrick Schöffski
Favorite
Scholte, Claire

Leiden University Medical Center
(P 56) CHROME: PREDICTING CHONDROSARCOMA RISK OUTCOME FROM METHYLATION
Claire Scholte
Favorite
Scholten, A.N.

Netherlands Cancer Institute
(P 24) NEOADJUVANT CHEMOTHERAPY FOR RADIOTHERAPY ASSOCIATED ANGIOSARCOMA (RAAS) OF THE BREAST IMPROVES ONCOLOGICAL OUTCOMES
A.N. Scholten
Favorite
(P 349) LONG-TERM SURVIVAL OF PARTICIPANTS IN THE PASART-1 AND PASART-2 TRIALS OF NEO-ADJUVANT PAZOPANIB AND RADIOTHERAPY IN SOFT TISSUE SARCOMA
A.N. Scholten
Favorite
Schoot, Reineke

Princess Máxima Center for Pediatric Oncology
(P 287) AN INTERNATIONAL SURVEY OF PROVIDER PRACTICES REGARDING BONE MARROW SAMPLING VERSUS [18F] FDG PET/CT IN THE DIAGNOSTIC EVALUATION OF BONE MARROW METASTASIS IN PEDIATRIC RHABDOMYOSARCOMA
Reineke Schoot
Favorite
Schrage, Yvonne

Netherland Cancer Institute
(P 24) NEOADJUVANT CHEMOTHERAPY FOR RADIOTHERAPY ASSOCIATED ANGIOSARCOMA (RAAS) OF THE BREAST IMPROVES ONCOLOGICAL OUTCOMES
Yvonne Schrage
Favorite
(P 28) THE INFLUENCE OF MARGINS ON OUTCOME IN CUTANEOUS LOCATED SOFT TISSUE SARCOMAS IN THE HEAD AND NECK
Yvonne Schrage
Favorite
(P 317) SMARCB1-DEFICIENT SARCOMA OF THE GENITAL REGION/EPITHELIOID SARCOMA OF THE PROXIMAL TYPE VS EPITHELIOID SARCOMA OF THE DISTAL TYPE
Yvonne Schrage
Favorite
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Yvonne Schrage
Favorite
Schraw, Jeremy

Baylor College of Medicine
(P 315) SALVAGE THERAPY EFFICACY IS MODIFIED BY RISK GROUP AT DIAGNOSIS IN PATIENTS WITH RELAPSED RHABDOMYOSARCOMA
Jeremy Schraw
Favorite
Schremp, Emma

Vanderbilt University Medical Center
(P 199) FINANCIAL TOXICITY AMONG SARCOMA PATIENTS AND ASSOCIATED FACTORS
Emma Schremp
Favorite
(P 297) ESTABLISHING A PEDIATRIC, ADOLESCENT AND YOUNG ADULT COHORT OF SARCOMA PATIENTS TO STUDY ONCOLOGIC AND NON-ONCOLOGIC OUTCOMES
Emma Schremp
Favorite
Schreuder, Hendrik

Princess Máxima Center for pediatric oncology
(P 319) THE SURVIVAL DISPARITY BETWEEN CHILDREN AND ADOLESCENTS & YOUNG ADULTS WITH EWING SARCOMA IN THE NETHERLANDS DID NOT CHANGE SINCE THE 1990S DESPITE IMPROVED SURVIVAL: A POPULATION-BASED STUDY
Hendrik Schreuder
Favorite
Schreuder, Pim

Netherlands cancer institute
(P 28) THE INFLUENCE OF MARGINS ON OUTCOME IN CUTANEOUS LOCATED SOFT TISSUE SARCOMAS IN THE HEAD AND NECK
Pim Schreuder
Favorite
Schreuder, Willem

Antoni van Leeuwenhoek / Netherlands Cancer Institute
(P 42) RANKL-INHIBITION FOR GIANT CELL LESIONS OF THE JAW: A RETROSPECTIVE COHORT ANALYSIS
Willem Schreuder
Favorite
Schuebbe, Gesa

Department of Medicine III, LMU University Hospital, LMU Munich
(P 410) PHASE I STUDY OF THE001 (DPPG2-TSL-DOX) COMBINED WITH REGIONAL HYPERTHERMIA IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Gesa Schuebbe
Favorite
Schuetze, Scott

University of Michigan
(P 45) UTILIZATION OF MENTAL HEALTH AND SUPPORTIVE CARE RESOURCES AMONG PATIENTS WITH DESMOID TUMORS
Scott Schuetze
Favorite
(P 102) ANALYSIS OF BLOOD-BASED BIOMARKERS AS PROGNOSTIC FACTORS IN PATIENTS WITH EHE TREATED WITH TRAMETINIB IN SARC033
Scott Schuetze
Favorite
(P 202) IMPACT OF AFAMI-CEL ON THE HEALTH STATE OF PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR MYXOID/ROUND CELL LIPOSARCOMA: COHORT 1 OF SPEARHEAD-1
Scott Schuetze
Favorite
(P 308) PALLIATIVE CARE INVOLVEMENT FOR ADOLESCENTS AND YOUNG ADULTS WITH BONE AND SOFT TISSUE SARCOMAS
Scott Schuetze
Favorite
(P 423) COMPARISON OF CLINICAL COURSE AND FEATURES BETWEEN SCLEROSING EPITHELOID FIBROSARCOMA AND LOW-GRADE FIBROMYXOID SARCOMA
Scott Schuetze
Favorite
Schulpen, Maya

Princess Máxima Center for pediatric oncology
(P 319) THE SURVIVAL DISPARITY BETWEEN CHILDREN AND ADOLESCENTS & YOUNG ADULTS WITH EWING SARCOMA IN THE NETHERLANDS DID NOT CHANGE SINCE THE 1990S DESPITE IMPROVED SURVIVAL: A POPULATION-BASED STUDY
Maya Schulpen
Favorite
Schuster, Kathrin

Sarcoma Patient Advocacy Global Network (SPAGN)
(P 201) GLOBAL CROSS-SECTIONAL SURVEY ON SARCOMA DIAGNOSIS PATHWAY: A CURRENT STATE ANALYSIS
Kathrin Schuster
Favorite
Schwartz, Gary

Case Comprehensive Cancer Center
(P 413) SUSTAINED EFFICACY DURING DRUG HOLIDAY ON ATEZOLIZUMAB IN PATIENTS WITH ALVEOLAR SOFT PART SARCOMA (ASPS)
Gary Schwartz
Favorite
Schwartz, Herbert

Vanderbilt University Medical Center
(P 73) LONGER TIME INTERVAL BETWEEN NEOADJUVANT CHEMOTHERAPY AND SURGERY IS ASSOCIATED WITH DECREASED TUMOR PERCENT NECROSIS IN OSTEOSARCOMA
Herbert Schwartz
Favorite
(P 199) FINANCIAL TOXICITY AMONG SARCOMA PATIENTS AND ASSOCIATED FACTORS
Herbert Schwartz
Favorite
(P 264) INTRAOPERATIVE FROZEN BONE MARROW MARGINS: A HELP OR A HINDRANCE IN EWING SARCOMA RESECTION?
Herbert Schwartz
Favorite
(P 265) IS THERE AN IDEAL STEM TO CANAL RATIO IN LOWER EXTREMITY ONCOLOGIC ENDOPROSTHESIS RECONSTRUCTION?
Herbert Schwartz
Favorite
(P 268) LOWER TUMOR PERCENT NECROSIS IS ASSOCIATED WITH POSITIVE FINAL SURGICAL MARGINS IN OSTEOSARCOMA
Herbert Schwartz
Favorite
(P 297) ESTABLISHING A PEDIATRIC, ADOLESCENT AND YOUNG ADULT COHORT OF SARCOMA PATIENTS TO STUDY ONCOLOGIC AND NON-ONCOLOGIC OUTCOMES
Herbert Schwartz
Favorite
(P 404) ENHANCED RECOVERY AFTER SURGERY (ERAS) PROTOCOL FOR PATENTS WITH SOFT TISSUE SARCOMA OF THE EXTREMITY: A PROSPECTIVE, NON-RANDOMIZED, CONSECUTIVELY ENROLLED TRIAL
Herbert Schwartz
Favorite
Sciortino, Carolina

Fondazione IRCSS Istituto Nazionale dei Tumori
(P 171) GASTROINTESTINAL STROMAL TUMOURS (GISTS) IN NEUROFIBROMATOSIS TYPE (NF1): A SINGLE-CENTER OBSERVATIONAL RETROSPECTIVE STUDY
Carolina Sciortino
Favorite
Sciot, Raf

Department of Pathology, University Hospitals Leuven, Leuven Cancer Institute, Leuven
(P 291) CASE REPORT: RADICAL EN BLOC MULTI-LEVEL SPONDYLECTOMY FOR A LOCALLY RECURRENT OSTEOSARCOMA
Raf Sciot
Favorite
(P 334) EXPANDING THE LANDSCAPE OF PRECLINICAL MODELS OF SYNOVIAL SARCOMA: FROM 2-DIMENSIONS TO 3-DIMENSIONS TO MICE
Raf Sciot
Favorite
SCOAZEC, Jean-yves

Gustave Roussy
(P 53) CHARACTERIZING THE SPATIAL TRANSCRIPTOMIC LANDSCAPE OF OSTEOSARCOMA FROM DIAGNOSIS TO RELAPSE
Jean-yves SCOAZEC
Favorite
Scorianz, Maurizio

University Hospital Careggi, Florence, Italy
(P 274) PROXIMAL HUMERAL ENDOPROSTHETIC RECONSTRUCTION: RESULTS FROM THE MUTARS ORTHOPEDIC REGISTRY EUROPE (MORE)
Maurizio Scorianz
Favorite
Scorsetti, Marta

IRCCS, Humanitas Research Hospital
(P 155) PRIMARY MESENCHYMAL TUMORS OF THE HEART: A 8-YEARS, SINGLE INSTITUTION EXPERIENCE
Marta Scorsetti
Favorite
Scotlandi, Katia

IRCCS Istituto Orthopedico Rizzoli
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Katia Scotlandi
Favorite
Scott, Clare

Walter and Eliza Hall Institute of Medical Research
(P 325) CAN PROTEOMICS PREDICT METASTATIC RELAPSE IN LEIOMYOSARCOMA? DEVELOPMENT OF AN 8 PROTEIN SIGNATURE IN A >350 SAMPLE STUDY INCLUDING A VALIDATION COHORT
Clare Scott
Favorite
Scott, Jacob

Cleveland Clinic
(P 351) OSTEOSARCOMA STEREOTACTIC BODY RADIOTHERAPY: OUTCOMES AND PATTERN OF FAILURE
Jacob Scott
Favorite
Scott, Susan

SpringWorks Therapeutics
(P 34) DESMOID TUMOR COHORT CREATION AND CHARACTERISTICS IN THE VETERANS AFFAIRS (VA) NATIONAL DATABASE
Susan Scott
Favorite
Sebio, Ana

Hospital de la Santa Creu i Sant Pau
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Ana Sebio
Favorite
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Ana Sebio
Favorite
(P 234) IMMUNOSARC II MASTER TRIAL (PHASE II OF SUNITINIB AND NIVOLUMAB): RESULTS FROM THE CLEAR CELL SARCOMA (CCS) COHORT. A GEIS, ISG, AND UCL STUDY
Ana Sebio
Favorite
Seerat, Maaz

Midland Regional Hospital Portlaoise
(P 310) PROGNOSTICATION AND EPIDEMIOLOGY OF CLEAR CELL SARCOMA: A SEER STAT RETROSPECTIVE ANALYSIS
Maaz Seerat
Favorite
Seffar, Evan

Memorial Sloan Kettering Cancer Center
(P 129) ELUCIDATING THE EVOLUTIONARY DYNAMICS OF DDLS LIPOSARCOMA USING SINGLE-CELL SEQUENCING AND MATHEMATICAL LINEAGE TRACING
Evan Seffar
Favorite
Segers, Blair

Children's Hospital of Philadelphia
(P 318) SYNOVIAL SARCOMA REGISTRY AND BIOSPECIMEN REPOSITORY: DESCRIBING THE COHORT AND SURVIVAL OUTCOMES TO DATE
Blair Segers
Favorite
Sehouli, Jalid

Charité
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Jalid Sehouli
Favorite
Seibel, Nita Louise

Children's National Hospital
(P 50) ANALYSIS OF CLINICAL FEATURES AND OUTCOMES FOR PATIENTS WITH MULTIFOCAL OSTEOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Nita Louise Seibel
Favorite
Seidel, Kristy

Seattle Children's Research Institute
(P 226) EARLY EXPERIENCE ON ENLIGHTEN-01: A PHASE 1 STUDY OF BISPECIFIC ADAPTER MOLECULE- CONTROLLED FOLATE RECEPTOR CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY OSTEOSARCOMA
Kristy Seidel
Favorite
Selby, Luke

University of Kansas
(P 36) EARLY REAL-WORLD EXPERIENCE WITH THE USE OF NIROGACESTAT FOR THE TREATMENT OF DESMOID FIBROMATOSIS
Luke Selby
Favorite
Seligson, Nathan

University of Florida
(P 109) INTEGRATED TRANSCRIPTOMIC ANALYSIS OF CIC::DUX4 FUSION SARCOMAS REVEALS ELEVATED PROLIFERATION SIGNALING AND IMPLICATES DNA REPAIR GENE POLE
Nathan Seligson
Favorite
Sellevold, simen

Oslo University Hospital
(P 274) PROXIMAL HUMERAL ENDOPROSTHETIC RECONSTRUCTION: RESULTS FROM THE MUTARS ORTHOPEDIC REGISTRY EUROPE (MORE)
simen Sellevold
Favorite
Sems, Stephen

Mayo Clinic
(P 278) ROTATIONPLASTY AS AN EFFECTIVE LIMB SALVAGE OPTION IN THE ADULT POPULATION
Stephen Sems
Favorite
Senger, Donna

McGill University
(P 329) DEVELOPING ARMS METASTATIC MODELS TO RECAPITULATE THE TUMOR MICROENVIRONMENTS OF THE AXILLA/LYMPH NODE AND LUNGS
Donna Senger
Favorite
Senne, Lane

Inhibrx, Inc
(P 95) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN PATIENTS WITH CHONDROSARCOMA: UPDATED RESULTS FROM A PHASE 1 STUDY
Lane Senne
Favorite
Seo, Chin Jin

Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore
(P 370) DEFYING NORMS - CENTRALIZATION OF SARCOMA CARE ON AN ISLAND NATION
Chin Jin Seo
Favorite
(P 375) FROM SAPLING TO SHADE: GROWTH OF A HIGH VOLUME ASIAN TERTIARY SARCOMA SPECIALISED CENTRE
Chin Jin Seo
Favorite
Seo, Sung Wook

Samsung Medical Center
(P 127) DEDIFFERENTIATED LIPOSARCOMA OF THE EXTREMITIES: A KOREAN MULTI-CENTER STUDY OF 107 CASES
Sung Wook Seo
Favorite
Serafini, Arianna

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Arianna Serafini
Favorite
Serafini, Arianna

Fondazione IRCCS Istituto Nazionale dei Tumor
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Arianna Serafini
Favorite
serra, annalisa

BAMBINO GESU CHILDREN HOSPITAL
(P 298) EWING SARCOMA OF MAXILLOFACIAL REGION AND SKULL: A RETROSPECTIVE MONOINSTITUTIONAL PEDIATRIC SERIES
annalisa serra
Favorite
Serra, Massimo

IRCCS Istituto Ortopedico Rizzoli
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Massimo Serra
Favorite
Serrano, César

Vall d’Hebron Institute of Oncology
(P 43) SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
César Serrano
Favorite
(P 224) COMPREHENSIVE EVALUATION OF DNA DAMAGE RESPONSE PATHWAY ALTERATIONS AND ASSOCIATED IMMUNOTHERAPY-RESPONSE BIOMARKERS IN SARCOMAS
César Serrano
Favorite
(P 408) OSTEOMYC: A PHASE 2 PILOT STUDY TO EVALIATE THE SAFETY AND THE ANTITUMOR ACTIVITY OF THE MYC INHIBITOR OMO-103 ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH ADVANCED HIGH GRADE OSTEOSARCOMA
César Serrano
Favorite
Setola, Elisabetta

Istituto Europeo di Oncologia
(P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Elisabetta Setola
Favorite
Setsu, Nokitaka

Kyushu Cancer Center
(P 203) IMPACT OF COVID-19 PANDEMIC ON BONE AND SOFT TISSUE SARCOMA PATIENTS' CONSULTATION AND DIAGNOSIS
Nokitaka Setsu
Favorite
Setty, Bhuvana

Nationwide Children's Hospital
(P 309) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT SOFT TISSUE SARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Bhuvana Setty
Favorite
(P 315) SALVAGE THERAPY EFFICACY IS MODIFIED BY RISK GROUP AT DIAGNOSIS IN PATIENTS WITH RELAPSED RHABDOMYOSARCOMA
Bhuvana Setty
Favorite
Seung, Soo Jin

HOPE Research Centre
(P 135) SURVIVAL OUTCOMES AND TREATMENT PATTERNS FOR PATIENTS WITH DEDIFFERENTIATED LIPOSARCOMA: A RETROSPECTIVE COHORT STUDY IN ONTARIO, CANADA
Soo Jin Seung
Favorite
Severe, Nicolas

Pyxis Oncology
(P 339) SARCOMAS EXPRESS EXTRA DOMAIN B OF FIBRONECTIN AND PRECLINICAL PATIENT-DERIVED XENOGRAFT MODELS OF SEVERAL SARCOMA SUBTYPES ARE SENSITIVE TO THE STROMA TARGETING ANTIBODY DRUG CONJUGATE PYX-201
Nicolas Severe
Favorite
Shaberman, Amy

Boehringer Ingelheim Pharmaceuticals, Inc
(P 206) PATIENT PERSPECTIVE ON LIPOSARCOMA DIAGNOSTIC JOURNEY: INTERIM PATIENT SURVEY RESULTS
Amy Shaberman
Favorite
Shafer, Amanda

University of Michigan
(P 131) HETEROGENEITY OF THE IMMUNE MICROENVIRONMENT AND IMMUNOTHERAPY RESPONSE IN A DEDIFFERENTIATED LIPOSARCOMA MOUSE MODEL
Amanda Shafer
Favorite
(P 341) THE EFFECTS OF ULTRASOUND-GUIDED HISTOTRIPSY ON SOFT TISSUE SARCOMA
Amanda Shafer
Favorite
(P 423) COMPARISON OF CLINICAL COURSE AND FEATURES BETWEEN SCLEROSING EPITHELOID FIBROSARCOMA AND LOW-GRADE FIBROMYXOID SARCOMA
Amanda Shafer
Favorite
Shaha, Priyanshu

St. George’s Hospital, London
(P 261) EVALUATION OF CT ARTIFACTS AFTER SPINAL OLIGOMETASTATIC DISEASE RESECTION AND RECONSTRUCTION: A COMPARATIVE STUDY OF CARBON-FIBER VS. TITANIUM IMPLANTS
Priyanshu Shaha
Favorite
Shah, Rachana

Children's Hospital Los Angeles
(P 76) MOLECULAR AND CHROMOSOMAL MICROARRAY PROFILING OF OSTEOSARCOMA IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS: A SINGLE INSTITUTION REPORT
Rachana Shah
Favorite
Sha, Matthew

School of Nursing, University of British Columbia
(P 201) GLOBAL CROSS-SECTIONAL SURVEY ON SARCOMA DIAGNOSIS PATHWAY: A CURRENT STATE ANALYSIS
Matthew Sha
Favorite
Shams, Danial

Vanderbilt University Medical Center
(P 404) ENHANCED RECOVERY AFTER SURGERY (ERAS) PROTOCOL FOR PATENTS WITH SOFT TISSUE SARCOMA OF THE EXTREMITY: A PROSPECTIVE, NON-RANDOMIZED, CONSECUTIVELY ENROLLED TRIAL
Danial Shams
Favorite
Shan, Boyao

Abbisko Therapeutics Co., Ltd
(P 407) LONG-TERM EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): PHASE 1B UPDATE.
Boyao Shan
Favorite
Shapiro, David

University of Illinois Urbana-Champaign
(P 79) NOVEL THERAPEUTIC POTENTIAL THROUGH HYPERACTIVATION OF THE ANTICIPATORY UNFOLDED PROTEIN RESPONSE PATHWAY IN BONE CANCER TREATMENT
David Shapiro
Favorite
Shapiro, Geoffrey

Dana-Farber Cancer Institute, Ludwig Center at Harvard Medical School
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Geoffrey Shapiro
Favorite
(P 402) A PILOT STUDY OF BTX-A51 IN PATIENTS WITH METASTATIC AND/OR RECURRENT LIPOSARCOMAS CHARACTERIZED BY MDM2 AMPLIFICATIONS
Geoffrey Shapiro
Favorite
Shapiro, Joel

The Princess Margaret/Mount Sinai Hospital
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Joel Shapiro
Favorite
Sharib, Jeremy

University of Washington
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Jeremy Sharib
Favorite
Sharma, Ashwyn

University of California, San Diego
(P 165) COMPLETE PERITONEAL CYTOREDUCTIVE SURGERY IN HIGHLY SELECTED PATIENTS WITH AGGRESSIVE METASTATIC SDH-DEFICIENT GIST CAN PROLONG EVENT-FREE SURVIVAL
Ashwyn Sharma
Favorite
Sharma, Ayush

Sarcoma Oncology Center
(P 250) UPDATE ON GALLANT: A PHASE 2 STUDY USING METRONOMIC GEMCITABINE, DOXORUBICIN AND DOCETAXEL PLUS NIVOLUMAB IN PREVIOUSLY TREATED SARCOMA (NCT04535713)
Ayush Sharma
Favorite
Sharma, Maitreyi

Deciphera Pharmaceuticals, LLC
(P 43) SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
Maitreyi Sharma
Favorite
Sharon, Elad

Dana-Farber Cancer Institute
(P 413) SUSTAINED EFFICACY DURING DRUG HOLIDAY ON ATEZOLIZUMAB IN PATIENTS WITH ALVEOLAR SOFT PART SARCOMA (ASPS)
Elad Sharon
Favorite
Sharp, Delaney

Princess Margaret Cancer Centre
(P 321) WHOLE ABDOMINAL RADIOTHERAPY IN CHILDREN AND YOUNG ADULTS WITH SARCOMA: A CANADIAN SARCOMA AND CLINICAL COLLABORATION (CANSARCC) STUDY
Delaney Sharp
Favorite
Shaulov Kask, Angela

Fred Hutchinson Cancer Center
(P 222) ANALYSIS OF THE CITN-13 SARCOMA ARM: PEMBROLIZUMAB AND INTERFERON GAMMA FOR SYNOVIAL SARCOMA AND MYXOID/ ROUND CELL LIPOSARCOMA
Angela Shaulov Kask
Favorite
Sheel, Ankur

The Ohio State University
(P 328) DETERMINING BIOMARKERS FOR GEMCITABINE RESPONSE IN SOFT TISSUE SARCOMAS: LESSONS LEARNED FROM PANCREATIC CANCER
Ankur Sheel
Favorite
Shemla, Shanie

Memorial Sloan Kettering Cancer Center
(P 101) AN OPEN LABEL PHASE IIA STUDY EVALUATING THE PRELIMINARY EFFICACY OF INTRATUMORAL TIGILANOL TIGLATE (TT) IN ADVANCED AND/OR METASTATIC SOFT TISSUE SARCOMA (STS, NCT05755113)
Shanie Shemla
Favorite
Shen, Guoxiang George

ADC Therapeutics
(P 116) QUANTITATIVE SYSTEMS PHARMACOLOGY MODELING OF MIPASETAMAB UZOPTERINE INTEGRATES KNOWLEDGE AND DEFINES DOSING STRATEGY FOR PATIENTS WITH SARCOMA
Guoxiang George Shen
Favorite
Shen, Jiakang

Department of Orthopedic Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Bone Tumor Institution, Shanghai, China
(P 48) A SINGLE-ARM, OPEN-LABEL CLINICAL STUDY OF OVV-01 ONCOLYTIC VIRUS INJECTION AS MONOTHERAPY OR IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR ADVANCED SOLID TUMOR PATIENTS
Jiakang Shen
Favorite
Shen, Jingnan

Department of Musculoskeletal Oncology Center, The First Affiliated Hospital of Sun Yat-sen University
(P 407) LONG-TERM EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): PHASE 1B UPDATE.
Jingnan Shen
Favorite
Shen, Jing-Nan

The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
(P 132) PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND DISEASE BURDEN OF DEDIFFERENTIATED LIPOSARCOMA IN CHINA: A REAL-WORLD STUDY BASED ON NATIONAL CANCER REGISTRY
Jing-Nan Shen
Favorite
Shen, Lin

Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute
(P 180) TUMOR VASCULAR SIGN IN THE RESPONSE ASSESSMENT OF GASTROINTESTINAL STROMAL TUMOR TREATED WITH RIPRETINIB: A MULTICENTER STUDY
Lin Shen
Favorite
(P 396) LONG-TERM FOLLOW-UP EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Lin Shen
Favorite
Shepard, Dale

Cleveland Clinic
(P 403) DCC-3116 IN COMBINATION WITH RIPRETINIB FOR PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A PHASE 1/2 STUDY
Dale Shepard
Favorite
Sheppard, Brett

OHSU
(P 364) A PHASE 1B TRIAL OF PREOPERATIVE ERIBULIN AND RADIATION FOR RETROPERITONEAL LIPOSARCOMA
Brett Sheppard
Favorite
Sheppard, Heather

St. Jude Children’s Research Hospital
(P 288) ANGIOA: A SAFETY AND TOLERABILITY STUDY OF TRIPLE ANTI-ANGIOGENIC THERAPY COMBINED WITH PD-L1 BLOCKADE IN PEDIATRIC, ADOLESCENT AND YOUNG ADULT RECURRENT/REFRACTORY SOLID TUMORS
Heather Sheppard
Favorite
Sheppard, Joanna

University College London Hospital
(P 185) ADDRESSING THE GAP FOR SYMPTOM CONTROL THROUGH THE IMPLEMENTATION OF ENHANCED SUPPORTIVE CARE AT THE LONDON SARCOMA SERVICE
Joanna Sheppard
Favorite
Sherman, John

Nationwide Children's Hospital
(P 21) LSD1 INHIBITOR SP-2509 DISRUPTS IRON-SULFUR CLUSTER BIOGENESIS
John Sherman
Favorite
Sherman, Matthew

Deciphera Pharmaceuticals, LLC
(P 43) SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
Matthew Sherman
Favorite
(P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE
Matthew Sherman
Favorite
(P 403) DCC-3116 IN COMBINATION WITH RIPRETINIB FOR PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A PHASE 1/2 STUDY
Matthew Sherman
Favorite
Shi, Haosong

Abbisko Therapeutics Co., Ltd.
(P 407) LONG-TERM EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): PHASE 1B UPDATE.
Haosong Shi
Favorite
Shimada, Eijiro

Duke University
(P 15) HISTONE DEACETYLASE-3 PLAYS A ROLE IN THE METASTATIC POTENTIAL OF A SUBPOPULATION OF CELLS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Eijiro Shimada
Favorite
(P 203) IMPACT OF COVID-19 PANDEMIC ON BONE AND SOFT TISSUE SARCOMA PATIENTS' CONSULTATION AND DIAGNOSIS
Eijiro Shimada
Favorite
Shinan-Altman, Shiri

School of Social Work, Bar Ilan University, Ramat Gan Israel
(P 182) A NOVEL MODEL FOR THE DIRECT REFERRAL OF ONCOLOGIC PATIENTS IN A PUBLIC HEALTH CARE SYSTEM
Shiri Shinan-Altman
Favorite
Shinglot, Himaly

Northwestern University, Feinberg School of Medicine
(P 222) ANALYSIS OF THE CITN-13 SARCOMA ARM: PEMBROLIZUMAB AND INTERFERON GAMMA FOR SYNOVIAL SARCOMA AND MYXOID/ ROUND CELL LIPOSARCOMA
Himaly Shinglot
Favorite
(P 235) INFILTRATION OF MUCOSAL-ASSOCIATED INVARIANT T CELLS (MAITS) INTO CHONDROSARCOMA TUMORS
Himaly Shinglot
Favorite
Shinoda, Yasuo

Department of Urology, National Cancer Center Hospital, Tokyo, Japan
(P 134) REAL-WORLD CLINICAL OUTCOME OF NEOADJUVANT CHEMOTHERAPY FOR RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA
Yasuo Shinoda
Favorite
Shinohara, Eric

Vanderbilt University Medical Center
(P 199) FINANCIAL TOXICITY AMONG SARCOMA PATIENTS AND ASSOCIATED FACTORS
Eric Shinohara
Favorite
(P 297) ESTABLISHING A PEDIATRIC, ADOLESCENT AND YOUNG ADULT COHORT OF SARCOMA PATIENTS TO STUDY ONCOLOGIC AND NON-ONCOLOGIC OUTCOMES
Eric Shinohara
Favorite
Shinozaki-Ushiku, Aya

The University of Tokyo, Division of Integrative Genomics
(P 103) BRAF MUTATIONS AND CONCURRENT ALTERATIONS IN PATIENTS WITH SOFT TISSUE SARCOMA
Aya Shinozaki-Ushiku
Favorite
Shlien, Adam

The Hospital for Sick Children
(P 49) A WORKING GROUP FOR THE DEVELOPMENT OF A CLINICAL FRAMEWORK THAT STRATIFIES OSTEOSARCOMA PATIENTS USING BIOMARKERS OF CLINICAL RISK AND BIOLOGY
Adam Shlien
Favorite
(P 159) USING THE TRANSCRIPTIONAL SPECTRUM OF UTERINE SMOOTH MUSCLE TUMORS TO IDENTIFY PROGNOSTIC SIGNATURES FOR ABNORMAL LEIOMYOMAS AND SMOOTH MUSCLE TUMOURS OF UNCERTAIN MALIGNANT POTENTIAL
Adam Shlien
Favorite
(P 329) DEVELOPING ARMS METASTATIC MODELS TO RECAPITULATE THE TUMOR MICROENVIRONMENTS OF THE AXILLA/LYMPH NODE AND LUNGS
Adam Shlien
Favorite
Shoaib, Zunaira

University of Illinois Urbana-Champaign
(P 419) BONE MECHANICS INFLUENCE CANCER STEM CELL FORMATION IN OSTEOSARCOMA
Zunaira Shoaib
Favorite
Shoghi, Kooresh

Washington University in St. Louis School of Medicine
(P 145) EXPLORING L-TYPE AMINO ACID TRANSPORTER 1 (LAT1) AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)
Kooresh Shoghi
Favorite
Sholevar, Cyrus

Division of Surgical Oncology, Department of Surgery, University of California Davis
(P 230) HIGHER BODY MASS INDEX IS ASSOCIATED WITH DECREASED CIRCULATING AND INTRATUMORAL NATURAL KILLER CELLS IN SOFT TISSUE SARCOMA
Cyrus Sholevar
Favorite
Shulman, David

Dana-Farber Cancer Institute
(P 49) A WORKING GROUP FOR THE DEVELOPMENT OF A CLINICAL FRAMEWORK THAT STRATIFIES OSTEOSARCOMA PATIENTS USING BIOMARKERS OF CLINICAL RISK AND BIOLOGY
David Shulman
Favorite
Shultz, David

Princess Margaret Cancer Centre, University Health Network
(P 352) OUTCOMES OF PRIMARY INTRATHORACIC SOFT TISSUE SARCOMA
David Shultz
Favorite
(P 433) TUMOR HYPOXIA AND THE RISK OF METASTASIS IN HIGH-RISK LOCALIZED UPS/MFS
David Shultz
Favorite
Shu, Xiao-Ou

Vanderbilt University Medical Center
(P 199) FINANCIAL TOXICITY AMONG SARCOMA PATIENTS AND ASSOCIATED FACTORS
Xiao-Ou Shu
Favorite
(P 297) ESTABLISHING A PEDIATRIC, ADOLESCENT AND YOUNG ADULT COHORT OF SARCOMA PATIENTS TO STUDY ONCOLOGIC AND NON-ONCOLOGIC OUTCOMES
Xiao-Ou Shu
Favorite
Sicklick, Jason

University of California, San Diego
(P 162) ANALYSIS OF 3,144 CASE REPORTS IN THE GASTROINTESTINAL STROMAL TUMOR LITERATURE: IDENTIFICATION OF UNDERAPPRECIATED DEMOGRAPHICS, CLINICAL PRESENTATIONS, AND BIOLOGY
Jason Sicklick
Favorite
(P 165) COMPLETE PERITONEAL CYTOREDUCTIVE SURGERY IN HIGHLY SELECTED PATIENTS WITH AGGRESSIVE METASTATIC SDH-DEFICIENT GIST CAN PROLONG EVENT-FREE SURVIVAL
Jason Sicklick
Favorite
(P 167) DEFINING TEXTBOOK OUTCOMES FOR MINIMALLY INVASIVE SURGICAL RESECTION OF SMALL GASTROINTESTINAL STROMAL TUMORS (GIST) OF THE STOMACH
Jason Sicklick
Favorite
(P 175) KIT AND DOG-1 EXPRESSING GASTROINTESTINAL STROMAL TUMORS HARBORING ETV6-NTRK3 FUSIONS DO EXIST, CASE OF NEAR COMPLETE PATHOLOGIC RESPONSE FOLLOWING LAROTRECTINIB AND REVIEW OF THE LITERATURE
Jason Sicklick
Favorite
(P 246) THE GENOMIC AND IMMUNE LANDSCAPE OF LIPOSARCOMA AND ITS SUBTYPES
Jason Sicklick
Favorite
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Jason Sicklick
Favorite
Sicoli, Federico

IRCCS Humanitas Research Hospital
(P 362) A NEW ROCK BAND FOR DIAPHRAGMATIC RECONSTRUCTION IN LEFT RETROPERITONEAL SARCOMA SURGERY
Federico Sicoli
Favorite
(P 363) A NEW SURGICAL TECHNIQUE FOR THE RECONSTRUCTION OF INGUINAL 'NEOLIGAMENT' AFTER SOFT TISSUE SARCOMA RESECTION
Federico Sicoli
Favorite
(P 373) EVALUATION OF HISTOLOGIC ORGAN INFILTRATION (HOI) AND VISCERAL RESECTION MARGINS (VRM) IN PRIMARY RETROPERITONEAL SARCOMAS: PROGNOSTIC IMPLICATIONS FOR LOCAL RECURRENCE
Federico Sicoli
Favorite
(P 388) THE ROAD TO CURATIVE SURGERY IN RETROPERITONEAL SOFT TISSUE SARCOMA: A DIFFERENT PATH IN THE ELDERLY?
Federico Sicoli
Favorite
(P 389) THE ROLE OF NUTRITIONAL STATUS ON POSTOPERATIVE AND ONCOLOGICAL OUTCOMES IN RETROPERITONEAL SARCOMA
Federico Sicoli
Favorite
Sida, Deseray

University of Texas Southwestern Medical Center
(P 417) VITAS: ATEZOLIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY SOLID TUMORS: AN OPEN-LABEL, PHASE I/II, SINGLE-ARM, MULTI-CENTER TRIAL IN PROGRESS
Deseray Sida
Favorite
Siddiquee, Armaan

Memorial Sloan Kettering Cancer Center
(P 338) PRECLINICAL EFFICACY OF DAN-222, A NOVEL POLYMERIC NANOPARTICLE, IN PEDIATRIC SOLID TUMOR MODELS
Armaan Siddiquee
Favorite
Siddiqui, Maryam

Lunenfeld-Tanenbaum Research Institute
(P 329) DEVELOPING ARMS METASTATIC MODELS TO RECAPITULATE THE TUMOR MICROENVIRONMENTS OF THE AXILLA/LYMPH NODE AND LUNGS
Maryam Siddiqui
Favorite
Siegel, Geoffrey

University of Michigan Department of Orthopedic Surgery
(P 341) THE EFFECTS OF ULTRASOUND-GUIDED HISTOTRIPSY ON SOFT TISSUE SARCOMA
Geoffrey Siegel
Favorite
SIGNOLLE, Nicolas

Gustave Roussy
(P 53) CHARACTERIZING THE SPATIAL TRANSCRIPTOMIC LANDSCAPE OF OSTEOSARCOMA FROM DIAGNOSIS TO RELAPSE
Nicolas SIGNOLLE
Favorite
Silberman, Allan

Cedars-Sinai Medical Center
(P 140) CIRCULATING TUMOR DNA AS A TOOL OF SURVEILLANCE AND EARLY INDICATOR OF RELAPSE IN SARCOMA PATIENTS
Allan Silberman
Favorite
Silletta, Marianna

Fondazione Policlinico Campus Bio-Medico of Rome
(P 178) PREDICTION OF PRIMARY IMATINIB-REFRACTORY PATIENTS WITH LOCALLY ADVANCED OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) USING RADIOMICS AND ARTIFICIAL INTELLIGENCE (AI)
Marianna Silletta
Favorite
Silvia, Careri

Ospedale Pediatrico Bambino Gesù
(P 311) QUANTIFICATION OF TUMOUR-INFILTRATING IMMUNE CELLS THROUGH DECONVOLUTION OF DNA METHYLATION DATA IN EWING SARCOMAS
Careri Silvia
Favorite
Sindiri, Sivasish

Surgery Branch, NCI, NIH
(P 231) IDENTIFICATION OF NEOANTIGEN FROM PECOMA-LIKE NEOPLASM PROVIDES RATIONALE FOR TREATMENT WITH CELLULAR THERAPY
Sivasish Sindiri
Favorite
Singer, Ramsay

The Royal Marsden Hospital
(P 183) A RETROSPECTIVE STUDY OF THE EFFECTS OF PATIENT, DISEASE, AND TREATMENT FACTORS ON SURVIVAL OUTCOMES IN PATIENTS WITH SOFT TISSUE SARCOMA BRAIN METASTASES
Ramsay Singer
Favorite
Singer, Samuel

Memorial Sloan Kettering Cancer Center
(P 101) AN OPEN LABEL PHASE IIA STUDY EVALUATING THE PRELIMINARY EFFICACY OF INTRATUMORAL TIGILANOL TIGLATE (TT) IN ADVANCED AND/OR METASTATIC SOFT TISSUE SARCOMA (STS, NCT05755113)
Samuel Singer
Favorite
(P 121) ACQUIRED CYCLIN D AMPLIFICATION IS A MECHANISM FOR RESISTANCE TO CDK4/6 INHIBITORS IN DEDIFFERENTIATED LIPOSARCOMA
Samuel Singer
Favorite
(P 129) ELUCIDATING THE EVOLUTIONARY DYNAMICS OF DDLS LIPOSARCOMA USING SINGLE-CELL SEQUENCING AND MATHEMATICAL LINEAGE TRACING
Samuel Singer
Favorite
(P 229) EXPRESSION OF TRANSPOSABLE ELEMENTS AND IKZF1 PREDICTS IMMUNE INFILTRATES IN SARCOMAS AND CORRELATES WITH OUTCOMES AFTER IMMUNE CHECKPOINT INHIBITION
Samuel Singer
Favorite
(P 380) MULTIDISCIPLINARY MANAGEMENT OF INTRA-ABDOMINAL DESMOID-TYPE FIBROMATOSIS: A 30-YEARS EXPERIENCE
Samuel Singer
Favorite
Singh, Ahilya

ProCan, Children’s Medical Research Institute
(P 325) CAN PROTEOMICS PREDICT METASTATIC RELAPSE IN LEIOMYOSARCOMA? DEVELOPMENT OF AN 8 PROTEIN SIGNATURE IN A >350 SAMPLE STUDY INCLUDING A VALIDATION COHORT
Ahilya Singh
Favorite
Singh, Arun

University of California at Los Angeles
(P 400) A LONG-TERM PHASE 4 STUDY TO EVALUATE THE RISK OF HEPATOTOXICITY ASSOCIATED WITH PEXIDARTINIB TREATMENT
Arun Singh
Favorite
Singh, Reena

Vanderbilt University Medical Center
(P 73) LONGER TIME INTERVAL BETWEEN NEOADJUVANT CHEMOTHERAPY AND SURGERY IS ASSOCIATED WITH DECREASED TUMOR PERCENT NECROSIS IN OSTEOSARCOMA
Reena Singh
Favorite
(P 264) INTRAOPERATIVE FROZEN BONE MARROW MARGINS: A HELP OR A HINDRANCE IN EWING SARCOMA RESECTION?
Reena Singh
Favorite
(P 268) LOWER TUMOR PERCENT NECROSIS IS ASSOCIATED WITH POSITIVE FINAL SURGICAL MARGINS IN OSTEOSARCOMA
Reena Singh
Favorite
Singh-Varma, Anya

University of Pittsburgh School of Medicine
(P 117) THE TUMOR IMMUNE MICROENVIRONMENT OF DEDIFFERENTIATED SARCOMAS: DIGITAL SPATIAL PROFILING SHOWS IMMUNE TRANSCRIPTIONAL DIFFERENCES BETWEEN DEDIFFERENTIATED LIPOSARCOMA AND CHONDROSARCOMA
Anya Singh-Varma
Favorite
Singh, Vinit

Roswell Park Comprehensive Cancer Center
(P 35) EARLY REAL WORLD EXPERIENCE WITH NIROGACESTAT IN PATIENTS WITH DESMOID FIBROMATOSIS
Vinit Singh
Favorite
Singla, Arvind

McCaig Institute for Bone and Joint Health
(P 327) CHARACTERIZATION OF TWO NOVEL IMMUNE COMPETENT, MURINE MODELS OF SOFT TISSUE SARCOMA
Arvind Singla
Favorite
Sinnaeve, Friedl

UZ Leuven
(P 291) CASE REPORT: RADICAL EN BLOC MULTI-LEVEL SPONDYLECTOMY FOR A LOCALLY RECURRENT OSTEOSARCOMA
Friedl Sinnaeve
Favorite
(P 334) EXPANDING THE LANDSCAPE OF PRECLINICAL MODELS OF SYNOVIAL SARCOMA: FROM 2-DIMENSIONS TO 3-DIMENSIONS TO MICE
Friedl Sinnaeve
Favorite
Siontis, Brittany

Mayo Clinic
(P 120) USING AI PREDICTIONS FROM ECG TRACINGS TO PREDICT TOLERANCE TO ANTHRACYCLINE CHEMOTHERAPY IN SARCOMA
Brittany Siontis
Favorite
(P 200) FRAILTY ASSESSMENT IN OLDER PATIENTS RECEIVING SARCOMA THERAPY
Brittany Siontis
Favorite
Sirineni, Pradyoth

The Ohio State University College of Medicine
(P 244) PREDICTIVE VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO IN IMMUNOTHERAPY OUTCOMES IN ADVANCED SARCOMA
Pradyoth Sirineni
Favorite
Siriprabrydhi, Michael

Sarcoma Oncology Center
(P 250) UPDATE ON GALLANT: A PHASE 2 STUDY USING METRONOMIC GEMCITABINE, DOXORUBICIN AND DOCETAXEL PLUS NIVOLUMAB IN PREVIOUSLY TREATED SARCOMA (NCT04535713)
Michael Siriprabrydhi
Favorite
Skeie, Annette Torød

Oslo University Hospital
(P 40) PEGYLATED LIPOSOMAL DOXORUBICIN IN SYMPTOMATIC DESMOID TUMOR
Annette Torød Skeie
Favorite
skoczylas, jacek

Maria Sklodowska-Curie National Research Institute of Oncology
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
jacek skoczylas
Favorite
Skol, Andrew

Ann & Robert H Lurie Children's Hospital of Chicago
(P 04) CHROMOSOME SPECIFIC ORGANIZATIONAL CHARACTERISTICS IN RHABDOMYOSARCOMA AND NORMAL MYOGENIC CELLS
Andrew Skol
Favorite
SKubitz, Keith

University of Minnesota
(P 30) CLINICAL BENEFIT OF PEGYLATED-LIPOSOMAL DOXORUBICIN IN THE MANAGEMENT DESMOID TYPE FIBROMATOSIS: A SINGLE INSTITUTION EXPERIENCE
Keith SKubitz
Favorite
Slotkin, Emily

Memorial Sloan Kettering Cancer Center
(P 229) EXPRESSION OF TRANSPOSABLE ELEMENTS AND IKZF1 PREDICTS IMMUNE INFILTRATES IN SARCOMAS AND CORRELATES WITH OUTCOMES AFTER IMMUNE CHECKPOINT INHIBITION
Emily Slotkin
Favorite
(P 418) A SYSTEMS BIOLOGY APPROACH FOR CHARACTERIZING TUMOR HETEROGENEITY AND CELL STATE-SPECIFIC THERAPEUTIC VULNERABILITIES FROM SINGLE NUCLEUS RNA-SEQ PROFILING OF DESMOPLASTIC SMALL ROUND CELL TUMORS
Emily Slotkin
Favorite
Smith, Ed

The Christie NHS Foundation Trust
(P 60) DIAGNOSIS AND MANAGEMENT OF PAEDIATRIC EWING SARCOMA PATIENTS IN ENGLAND 2014-2017: A COMPARISON OF NATIONAL DATA WITH THE EURO-EWING 2012 CLINICAL TRIAL
Ed Smith
Favorite
Smith-Fry, Kyllie

University of Utah
(P 332) ENHANCING THERAPEUTIC EFFICACY IN SYNOVIAL SARCOMA BY TARGETING P53-MDM2 AXIS AND HDAC PATHWAYS
Kyllie Smith-Fry
Favorite
Smith-Fry, Kyllie

Department of Orthopaedics, University of Utah
(P 343) TLE1 DISRUPTION DOES NOT IMPEDE SYNOVIAL SARCOMAGENESIS
Kyllie Smith-Fry
Favorite
Smrke, Alannah

BC Canada
(P 293) CIC-REARRANGED SOFT TISSUE SARCOMAS: DOES CHEMOTHERAPY CHANGE NATURAL HISTORY AND PROGNOSIS? A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Alannah Smrke
Favorite
(P 320) WHAT IS THE ROLE OF CHEMOTHERAPY IN PATIENTS (PTS) WITH SPINDLE CELL/SCLEROSING RHABDOMYOSARCOMA (SCRMS): A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Alannah Smrke
Favorite
Smythe, Kimberly

FHCRC
(P 222) ANALYSIS OF THE CITN-13 SARCOMA ARM: PEMBROLIZUMAB AND INTERFERON GAMMA FOR SYNOVIAL SARCOMA AND MYXOID/ ROUND CELL LIPOSARCOMA
Kimberly Smythe
Favorite
Snaebjornsson, Petur

Netherlands Cancer Institute
(P 317) SMARCB1-DEFICIENT SARCOMA OF THE GENITAL REGION/EPITHELIOID SARCOMA OF THE PROXIMAL TYPE VS EPITHELIOID SARCOMA OF THE DISTAL TYPE
Petur Snaebjornsson
Favorite
Snow, Hayden

Peter MacCallum Cancer Centre
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Hayden Snow
Favorite
Snyder, Benjamin

Indiana University School of Medicine
(P 365) A SINGLE INSTITUTION COMPARISON OF OUTCOMES IN PEDIATRIC AND ADULT PATIENTS WITH GYNECOLOGIC ORIGIN RHABDOMYOSARCOMA
Benjamin Snyder
Favorite
(P 384) REAL WORLD EXPERIENCE IN TREATING HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA: AN ULTRA-RARE VASCULAR TUMOR
Benjamin Snyder
Favorite
Sobczuk, Paweł

Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
(P 46) A NEED FOR STANDARDIZATION IN TRIAL DESIGN AND DATA REPORTING IN PHASE II TRIALS IN RARE TUMORS. LESSONS LEARNED FROM PHASE II TRIALS IN BONE SARCOMAS
Paweł Sobczuk
Favorite
(P 245) PRELIMINARY RESULTS FROM A PHASE 2 EFTISARC-NEO TRIAL OF NEOADJUVANT SOUBLE LAG-3 PROTEIN EFTILAGIMOD ALPHA, PEMBROLIZUMAB, AND CONCURRENT RADIOTHERAPY IN PATIENTS WITH RESECTABLE SOFT TISSUE SARCOMA
Paweł Sobczuk
Favorite
Socci, Nicholas

Memorial Sloan Kettering Cancer Center
(P 129) ELUCIDATING THE EVOLUTIONARY DYNAMICS OF DDLS LIPOSARCOMA USING SINGLE-CELL SEQUENCING AND MATHEMATICAL LINEAGE TRACING
Nicholas Socci
Favorite
Soffientini, Cesare

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 137) TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS
Cesare Soffientini
Favorite
Soh Hann, Natalie

Singapore General Hospital
(P 370) DEFYING NORMS - CENTRALIZATION OF SARCOMA CARE ON AN ISLAND NATION
Natalie Soh Hann
Favorite
Sokol, Elizabeth

Ann & Robert H. Lurie Children's Hospital of Chicago
(P 417) VITAS: ATEZOLIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY SOLID TUMORS: AN OPEN-LABEL, PHASE I/II, SINGLE-ARM, MULTI-CENTER TRIAL IN PROGRESS
Elizabeth Sokol
Favorite
Solda, Francesca

The Royal Marsden Hospital
(P 183) A RETROSPECTIVE STUDY OF THE EFFECTS OF PATIENT, DISEASE, AND TREATMENT FACTORS ON SURVIVAL OUTCOMES IN PATIENTS WITH SOFT TISSUE SARCOMA BRAIN METASTASES
Francesca Solda
Favorite
Soliman, Steven

University of Michigan / Musculoskeletal Radiology Division
(P 341) THE EFFECTS OF ULTRASOUND-GUIDED HISTOTRIPSY ON SOFT TISSUE SARCOMA
Steven Soliman
Favorite
Solimini, Nicole

Dana-Farber Cancer Institute
(P 402) A PILOT STUDY OF BTX-A51 IN PATIENTS WITH METASTATIC AND/OR RECURRENT LIPOSARCOMAS CHARACTERIZED BY MDM2 AMPLIFICATIONS
Nicole Solimini
Favorite
Solnik, Jonathon

Mount Sinai Hospital
(P 159) USING THE TRANSCRIPTIONAL SPECTRUM OF UTERINE SMOOTH MUSCLE TUMORS TO IDENTIFY PROGNOSTIC SIGNATURES FOR ABNORMAL LEIOMYOMAS AND SMOOTH MUSCLE TUMOURS OF UNCERTAIN MALIGNANT POTENTIAL
Jonathon Solnik
Favorite
Solst, Shane

University of Iowa
(P 12) GENETIC LANDSCAPE OF MPNST DETERMINES METABOLIC STRATEGIES AND THERAPEUTIC OPPORTUNITIES FOR COPING WITH REDOX STRESS
Shane Solst
Favorite
Somaiah, Neeta

The University of Texas MD Anderson Cancer Center
(P 130) HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RESECTABLE RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA (DDLPS) TREATED WITH NEOADJUVANT CHECKPOINT BLOCKADE IN A RANDOMIZED PHASE II CLINICAL TRIAL.
Neeta Somaiah
Favorite
(P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE
Neeta Somaiah
Favorite
(P 233) IMMUNE CLASSES OF LEIOMYOSARCOMA DRIVEN BY B CELL INFILTRATE AND CTLA4 EXPRESSION
Neeta Somaiah
Favorite
Somarelli, Jason

Duke University
(P 16) HOW TO GROW A BONE IN 60 DAYS: EXPLORING THE UNIQUE PRO-GROWTH, ANTI-CANCER ENVIRONMENT IN ELK ANTLERS
Jason Somarelli
Favorite
Sommer, Josh

Chordoma Foundation
(P 02) A PRECLINICAL ASSAY PIPELINE TO IDENTIFY AND OPTIMIZE BRACHYURY-TARGETED THERAPIES IN CHORDOMA AND OTHER SOLID TUMORS
Josh Sommer
Favorite
(P 425) EXPLORING MECHANISMS OF EGFR INHIBITOR RESISTANCE IN CHORDOMA
Josh Sommer
Favorite
Song, Danjun

Department of Interventional Radiology，Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.
(P 164) CLINICAL BENEFITS OF RIPRETINIB AND CYTOREDUCTIVE SURGERY IN IMATINIB-RESISTANT ADVANCED GASTROINTESTINAL STROMAL TUMORS (GISTS): A RETROSPECTIVE DUAL-CENTER STUDY
Danjun Song
Favorite
Song, Hyojin

University of Calgary
(P 327) CHARACTERIZATION OF TWO NOVEL IMMUNE COMPETENT, MURINE MODELS OF SOFT TISSUE SARCOMA
Hyojin Song
Favorite
(P 422) COMPARISON OF ANNOTATION METHODS FOR PAN-SARCOMA SINGLE CELL DATA
Hyojin Song
Favorite
(P 424) CROSS-COHORT INTEGRATION AS A STRATEGY TO CLASSIFY IMMUNE CHECKPOINT BLOCKADE RESPONSE IN SARCOMA
Hyojin Song
Favorite
Song, Sanghoon

Lunit
(P 123) ARTIFICIAL INTELLIGENCE-POWERED MITOSIS EVALUATION TO COMPLEMENT HUMAN MITOTIC RATE INTERPRETATION IN PREDICTING PROGNOSIS IN LIPOSARCOMA
Sanghoon Song
Favorite
Song, Yunjie

Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co.
(P 83) PREDICTION OF HIGH-RISK OSTEOSARCOMA PATIENTS BASED ON MACHINE LEARNING USING TRANSCRIPTOME AND METHYLATION DATA FROM SGH-COHORT
Yunjie Song
Favorite
Song, Zheng-Qing

Zhongshan Hospital, Fudan University, Shanghai, China
(P 416) TRIPLR COMNINATION THERAPY IN THE FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA WITH HIGH TUMOR BURDEN: INTERIM ANALYSIS FROM ALTER-S007 STUDY
Zheng-Qing Song
Favorite
Soo, Khee Chee

Singapore General Hospital
(P 375) FROM SAPLING TO SHADE: GROWTH OF A HIGH VOLUME ASIAN TERTIARY SARCOMA SPECIALISED CENTRE
Khee Chee Soo
Favorite
Soragni, Alice

University of California, Los Angeles
(P 27) SUMO2 INHIBITION REVERSES ABERRANT EPIGENETIC REWIRING DRIVEN BY SYNOVIAL SARCOMA FUSION ONCOPROTEINS AND IMPAIRS SARCOMAGENESIS
Alice Soragni
Favorite
Soucek, Laura

Institució Catalana de Recerca i Estudis Avançats (ICREA), Vall d'Hebron Institute of Oncology (VHIO), Peptomyc, S.L. Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona
(P 408) OSTEOMYC: A PHASE 2 PILOT STUDY TO EVALIATE THE SAFETY AND THE ANTITUMOR ACTIVITY OF THE MYC INHIBITOR OMO-103 ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH ADVANCED HIGH GRADE OSTEOSARCOMA
Laura Soucek
Favorite
Sousa, Débora

A.C.Camargo Cancer Center
(P 300) GASTROINTESTINAL STROMAL TUMORS (GIST) IN YOUNG ADULTS (YA): A BRAZILIAN COHORT OF PATIENTS
Débora Sousa
Favorite
Soyfer, Viacheslave

Tel Aviv Medical Center, Tel Aviv, Israel
(P 350) MONITORING CHANGES IN FEMORAL BONE STRENGTH IN PATIENTS WITH METASTATIC BONE DISEASE TREATED WITH RADIATION THERAPY
Viacheslave Soyfer
Favorite
Spaanderman, Douwe

Erasmus Medical Center
(P 154) PREOPERATIVE CLASSIFICATION OF NERVE SHEATH TUMORS USING RADIOMICS-BASED MACHINE LEARNING
Douwe Spaanderman
Favorite
Spadazzi, Chiara

Istituto Romagnolo per lo studio dei Tumori "Dino Amadori" IRST IRCCS, Preclinic and Osteoncology Unit, Meldola, Italy
(P 336) IMPROVEMENT OF PHOTODYNAMIC THERAPY IN SARCOMA: IN VITRO VALIDATION ON OSTEOSARCOMA AND MYXOFIBROSARCOMA
Chiara Spadazzi
Favorite
Spalek, Mateusz

Maria Sklodowska-Curie National Research Institute of Oncology
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Mateusz Spalek
Favorite
Spentzos, Dimitris

Massachusetts General Hospital
(P 107) DOES THE USE OF ADJUVANT CHEMOTHERAPY IN LOCALIZED, RESECTABLE SOFT TISSUE SARCOMA LEAD TO BETTER SURVIVAL OUTCOMES? - A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Dimitris Spentzos
Favorite
Spierings, Diana

University Medical Centre Groningen
(P 03) CDK4 IS CO-AMPLIFIED WITH EITHER TP53 PROMOTER GENE FUSIONS OR MDM2 THROUGH DISTINCT MECHANISMS IN OSTEOSARCOMA
Diana Spierings
Favorite
Spinella, Michael

University of Illinois Urbana-Champaign
(P 79) NOVEL THERAPEUTIC POTENTIAL THROUGH HYPERACTIVATION OF THE ANTICIPATORY UNFOLDED PROTEIN RESPONSE PATHWAY IN BONE CANCER TREATMENT
Michael Spinella
Favorite
Spitz, Doug

University of Iowa
(P 12) GENETIC LANDSCAPE OF MPNST DETERMINES METABOLIC STRATEGIES AND THERAPEUTIC OPPORTUNITIES FOR COPING WITH REDOX STRESS
Doug Spitz
Favorite
Sprott, Kam

Deciphera Pharmaceuticals, LLC
(P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE
Kam Sprott
Favorite
Spunt, Sheri

ImmunoGen
(P 205) MULTI-MODAL TREATMENT IS ASSOCIATED WITH IMPROVED SURVIVAL IN AYA PATIENTS WITH METASTATIC NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA
Sheri Spunt
Favorite
(P 356) RADIATION PRACTICE PATTERNS AND OUTCOMES IN ADOLESCENT YOUNG ADULT PATIENTS WITH VISCERAL NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA
Sheri Spunt
Favorite
Spurzem, Graham

University of California, San Diego
(P 167) DEFINING TEXTBOOK OUTCOMES FOR MINIMALLY INVASIVE SURGICAL RESECTION OF SMALL GASTROINTESTINAL STROMAL TUMORS (GIST) OF THE STOMACH
Graham Spurzem
Favorite
Srikanthan, Amirrtha

The Ottawa Hospital
(P 320) WHAT IS THE ROLE OF CHEMOTHERAPY IN PATIENTS (PTS) WITH SPINDLE CELL/SCLEROSING RHABDOMYOSARCOMA (SCRMS): A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Amirrtha Srikanthan
Favorite
Srivastava, Abhilasha

Northwestern University, Feinberg School of Medicine
(P 222) ANALYSIS OF THE CITN-13 SARCOMA ARM: PEMBROLIZUMAB AND INTERFERON GAMMA FOR SYNOVIAL SARCOMA AND MYXOID/ ROUND CELL LIPOSARCOMA
Abhilasha Srivastava
Favorite
Stacchiotti, Silvia

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 37) HEALTH-RELATED QUALITY OF LIFE FROM A PHASE 4 STUDY TO EVALUATE DISCONTINUATION AND RECHALLENGE OF PEXIDARTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR PREVIOUSLY TREATED WITH PEXIDARTINIB
Silvia Stacchiotti
Favorite
(P 43) SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
Silvia Stacchiotti
Favorite
(P 44) TUMOR RESPONSE AND REGROWTH IN RELATION TO CLINICAL EVENTS AMONG PEXIDARTINIB-TREATED SUBJECTS IN THE PHASE 3 ENLIVEN TRIAL
Silvia Stacchiotti
Favorite
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Silvia Stacchiotti
Favorite
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Silvia Stacchiotti
Favorite
(P 137) TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS
Silvia Stacchiotti
Favorite
(P 234) IMMUNOSARC II MASTER TRIAL (PHASE II OF SUNITINIB AND NIVOLUMAB): RESULTS FROM THE CLEAR CELL SARCOMA (CCS) COHORT. A GEIS, ISG, AND UCL STUDY
Silvia Stacchiotti
Favorite
(P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Silvia Stacchiotti
Favorite
(P 429) PATIENTS WITH ADVANCED EPITHELIOID HEMANGIOENDOTHELIOMA TREATED WITH SIROLIMUS: OUTCOME FOLLOWING SIROLIMUS DISCONTINUATION.
Silvia Stacchiotti
Favorite
Stanhope, Stephen

Boehringer Ingelheim Pharmaceuticals Inc
(P 133) REAL-WORLD ANALYSIS OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS) IN A US COMMUNITY ONCOLOGY SETTING
Stephen Stanhope
Favorite
Stanicic, Filip

ZRx Outcomes Research Inc.
(P 55) CHONDROSARCOMA PATIENT CHARACTERISTICS AND DIAGNOSTIC AND TREATMENT PATHWAYS: GLOBAL CHONDROSARCOMA PATIENT REGISTRY
Filip Stanicic
Favorite
Stanley, Elizabeth

Boehringer Ingelheim Pharmaceuticals, Inc.
(P 133) REAL-WORLD ANALYSIS OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS) IN A US COMMUNITY ONCOLOGY SETTING
Elizabeth Stanley
Favorite
Stark, Germa'n

Biomage Ltd
(P 222) ANALYSIS OF THE CITN-13 SARCOMA ARM: PEMBROLIZUMAB AND INTERFERON GAMMA FOR SYNOVIAL SARCOMA AND MYXOID/ ROUND CELL LIPOSARCOMA
Germa'n Stark
Favorite
Starmans, Martijn

Erasmus Medical Center
(P 154) PREOPERATIVE CLASSIFICATION OF NERVE SHEATH TUMORS USING RADIOMICS-BASED MACHINE LEARNING
Martijn Starmans
Favorite
Statz-Geary, Kurt

University of Miami/ Jackson Memorial Hospital
(P 224) COMPREHENSIVE EVALUATION OF DNA DAMAGE RESPONSE PATHWAY ALTERATIONS AND ASSOCIATED IMMUNOTHERAPY-RESPONSE BIOMARKERS IN SARCOMAS
Kurt Statz-Geary
Favorite
Stebegg-Wagner, Marisa

iOmx AG
(P 337) OMX-0407 A NOVEL SPECTRUM-SELECTIVE SMALL MOLECULE KINASE INHIBITOR IS ACTIVE IN THE TREATMENT OF ANGIOSARCOMA
Marisa Stebegg-Wagner
Favorite
Steeghs, Neeltje

The Netherlands Cancer Institute
(P 24) NEOADJUVANT CHEMOTHERAPY FOR RADIOTHERAPY ASSOCIATED ANGIOSARCOMA (RAAS) OF THE BREAST IMPROVES ONCOLOGICAL OUTCOMES
Neeltje Steeghs
Favorite
(P 349) LONG-TERM SURVIVAL OF PARTICIPANTS IN THE PASART-1 AND PASART-2 TRIALS OF NEO-ADJUVANT PAZOPANIB AND RADIOTHERAPY IN SOFT TISSUE SARCOMA
Neeltje Steeghs
Favorite
Stegmaier, Kimberly

Dana Farber
(P 66) EWING TUMORS WITH STAG2 LOSS DEMOSNTRATE ALTERED INTERFERON SIGNATURES AND IMPAIRED CXCL10 EXPRESSION
Kimberly Stegmaier
Favorite
Steiner, Sabrina

Pathology and Molecular Pathology
(P 99) ACQUIRED NF2 MUTATION CONFERS RESISTANCE TO TRK INHIBITION IN AN EX VIVO LMNA::NTRK1-REARRANGED SOFT TISSUE SARCOMA CELL MODEL
Sabrina Steiner
Favorite
Stella, Valavanis

Moffitt Cancer Center
(P 309) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT SOFT TISSUE SARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Valavanis Stella
Favorite
Stencel, Sean

Northwestern University, Feinberg School of Medicine, Department of Medicine, Division of Oncology
(P 179) PRIMARY MANAGEMENT OF LOCALIZED GASTROINTESTINAL STROMAL TUMORS WITH IMATINIB MONOTHERAPY: AN ALTERNATIVE TO RESECTION FOR PATIENTS PRECLUDED FROM SURGERY
Sean Stencel
Favorite
Sternheim, Amir

National Unit of Orthopaedic Oncology, Tel Aviv Medical Center, Tel Aviv University
(P 350) MONITORING CHANGES IN FEMORAL BONE STRENGTH IN PATIENTS WITH METASTATIC BONE DISEASE TREATED WITH RADIATION THERAPY
Amir Sternheim
Favorite
Steuerwald, Nury

Levine Cancer Institute
(P 430) QUANTITATIVE EMT GENE SCORES AT DIAGNOSIS INDICATE METASTASIS RISK AND SURVIVAL IN SYNOVIAL SARCOMA
Nury Steuerwald
Favorite
Stewart, Clinton

St. Jude Children's Research Hospital
(P 288) ANGIOA: A SAFETY AND TOLERABILITY STUDY OF TRIPLE ANTI-ANGIOGENIC THERAPY COMBINED WITH PD-L1 BLOCKADE IN PEDIATRIC, ADOLESCENT AND YOUNG ADULT RECURRENT/REFRACTORY SOLID TUMORS
Clinton Stewart
Favorite
Stewart, Elizabeth

St. Jude Children's Research Hospital
(P 288) ANGIOA: A SAFETY AND TOLERABILITY STUDY OF TRIPLE ANTI-ANGIOGENIC THERAPY COMBINED WITH PD-L1 BLOCKADE IN PEDIATRIC, ADOLESCENT AND YOUNG ADULT RECURRENT/REFRACTORY SOLID TUMORS
Elizabeth Stewart
Favorite
stracuzzi, alessandra

BAMBINO GESU CHILDREN HOSPITAL
(P 298) EWING SARCOMA OF MAXILLOFACIAL REGION AND SKULL: A RETROSPECTIVE MONOINSTITUTIONAL PEDIATRIC SERIES
alessandra stracuzzi
Favorite
Strauss, Dirk

The Royal Marsden Hospital
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Dirk Strauss
Favorite
Strauss, Sandra

UCL Cancer Institute, University College London NHS Foundation Trust
(P 23) METASTATIC ALVEOLAR SOFT PART SARCOMA: PREGNANCY-RELATED WORSENING AND SPONTANEOUS EXCEPTIONAL REMISSION POSTPARTUM- A CASE REPORT.
Sandra Strauss
Favorite
Strauss, Sandra

University College, London
(P 60) DIAGNOSIS AND MANAGEMENT OF PAEDIATRIC EWING SARCOMA PATIENTS IN ENGLAND 2014-2017: A COMPARISON OF NATIONAL DATA WITH THE EURO-EWING 2012 CLINICAL TRIAL
Sandra Strauss
Favorite
Strauss, Sandra

UCL Cancer Institute, University College London NHS Foundation Trust
(P 185) ADDRESSING THE GAP FOR SYMPTOM CONTROL THROUGH THE IMPLEMENTATION OF ENHANCED SUPPORTIVE CARE AT THE LONDON SARCOMA SERVICE
Sandra Strauss
Favorite
(P 234) IMMUNOSARC II MASTER TRIAL (PHASE II OF SUNITINIB AND NIVOLUMAB): RESULTS FROM THE CLEAR CELL SARCOMA (CCS) COHORT. A GEIS, ISG, AND UCL STUDY
Sandra Strauss
Favorite
Stricker, Thomas

One Oncology
(P 427) MULTI-OMIC AND MULTI-REGION PROFILING OF DESMOID TUMORS REVEALS INTRA- AND INTER-TUMOR HETEROGENEITY
Thomas Stricker
Favorite
Stucchi, Erika

IRCCS Humanitas Research Hospital
(P 124) ASSESSMENT OF THE MECHANISMS OF ACTION OF ERIBULIN IN PATIENTS WITH ADVANCED LIPOSARCOMA THROUGH THE EVALUATION OF THE RADIOLOGICAL, FUNCTIONAL AND TISSUE RESPONSE: A MONOCENTRIC PROSPECTIVE STUDY
Erika Stucchi
Favorite
(P 290) ARTIFICIAL INTELLIGENCE-BASED COMPARISON OF ADULT AND ADOLESCENT AND YOUNG ADULTS (AYA) SARCOMAS: A PILOT STUDY
Erika Stucchi
Favorite
Studer, Gabriela

SwissSarcomaNetwork
(P 184) A SYSTEMATIC REVIEW ABOUT CLINICAL PROGNOSTIC MODELS FOR SARCOMAS
Gabriela Studer
Favorite
Studer, Gabriela

University Hospital, Luzern; Swiss Sarcoma Network
(P 204) IMPACT OF UNPéLANNED EXCISION ON THE SURVIVAL OF SARCOMA PATIENTS - A TARGET TRIAL EMULATION
Gabriela Studer
Favorite
Stutzman, Sonja

University of Texas Southwestern Medical Center
(P 417) VITAS: ATEZOLIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY SOLID TUMORS: AN OPEN-LABEL, PHASE I/II, SINGLE-ARM, MULTI-CENTER TRIAL IN PROGRESS
Sonja Stutzman
Favorite
Styring, Emelie

Skåne University Hospital
(P 03) CDK4 IS CO-AMPLIFIED WITH EITHER TP53 PROMOTER GENE FUSIONS OR MDM2 THROUGH DISTINCT MECHANISMS IN OSTEOSARCOMA
Emelie Styring
Favorite
Suarez-Navarro, Julissa

University of California Davis
(P 08) ELUCIDATING THE ROLE OF YAP IN SARCOMA DEVELOPMENT
Julissa Suarez-Navarro
Favorite
Subbiah, Vivek

MD Anderson Cancer Center
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Vivek Subbiah
Favorite
Subhawong, Ty

University of Miami
(P 358) RADIOMIC EVALUATION OF MRIS IN PATIENTS WITH SOFT TISSUE SARCOMA TREATED WITH STEREOTACTIC BOSY RADIATION THERAPY
Ty Subhawong
Favorite
Subramaniam, Aparna

The University of Texas MD Anderson Cancer Center
(P 398) PREDICTORS OF EFFICACY IN PATIENTS WITH SOFT TISSUE SARCOMAS TREATED WITH PAZOPANIB
Aparna Subramaniam
Favorite
Sukovich, Jonathan

University of Michigan
(P 341) THE EFFECTS OF ULTRASOUND-GUIDED HISTOTRIPSY ON SOFT TISSUE SARCOMA
Jonathan Sukovich
Favorite
Sullivan, Mikaela

Mayo Clinic
(P 278) ROTATIONPLASTY AS AN EFFECTIVE LIMB SALVAGE OPTION IN THE ADULT POPULATION
Mikaela Sullivan
Favorite
(P 294) COMPARING HIGH-GRADE NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA IN ADULT AND PEDIATRIC POPULATIONS
Mikaela Sullivan
Favorite
(P 307) OUTCOMES OF PEDIATRIC NON-RHABDOMYOSARCOMA SOFT-TISSUE SARCOMAS OF THE EXTREMITIES
Mikaela Sullivan
Favorite
Summers, Corrine

Seattle Children's Hospital, University of Washington
(P 226) EARLY EXPERIENCE ON ENLIGHTEN-01: A PHASE 1 STUDY OF BISPECIFIC ADAPTER MOLECULE- CONTROLLED FOLATE RECEPTOR CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY OSTEOSARCOMA
Corrine Summers
Favorite
Sundvold, Vibeke

Lytix Biopharma AS
(P 243) MYELOSUPPRESSION FOLLOWING LYMPHODEPLETING CHEMOTHERAPY AS PART OF ADOPTIVE CELL THERAPY FOR PATIENTS WITH PROGRESSIVE SOFT TISSUE SARCOMA AFTER STANDARD CHEMOTHERAPY
Vibeke Sundvold
Favorite
Sun, Lili

Vanderbilt University Medical Center
(P 199) FINANCIAL TOXICITY AMONG SARCOMA PATIENTS AND ASSOCIATED FACTORS
Lili Sun
Favorite
(P 297) ESTABLISHING A PEDIATRIC, ADOLESCENT AND YOUNG ADULT COHORT OF SARCOMA PATIENTS TO STUDY ONCOLOGIC AND NON-ONCOLOGIC OUTCOMES
Lili Sun
Favorite
sun, mengxiong

Shanghai General Hospital, School of Medicine Shanghai Jiao Tong University
(P 48) A SINGLE-ARM, OPEN-LABEL CLINICAL STUDY OF OVV-01 ONCOLYTIC VIRUS INJECTION AS MONOTHERAPY OR IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR ADVANCED SOLID TUMOR PATIENTS
mengxiong sun
Favorite
(P 90) TARGETING HIGH RISK MYC- AMPLIFIED OSTEOSARCOMA BY AURORA KINASE INHIBITOR--RESULT FROM A NGS BASED UMBRELLA TRIAL
mengxiong sun
Favorite
Sun, Wei

Department of Orthopaedics, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Bone Tumor Institution, Shanghai, China
(P 48) A SINGLE-ARM, OPEN-LABEL CLINICAL STUDY OF OVV-01 ONCOLYTIC VIRUS INJECTION AS MONOTHERAPY OR IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR ADVANCED SOLID TUMOR PATIENTS
Wei Sun
Favorite
(P 83) PREDICTION OF HIGH-RISK OSTEOSARCOMA PATIENTS BASED ON MACHINE LEARNING USING TRANSCRIPTOME AND METHYLATION DATA FROM SGH-COHORT
Wei Sun
Favorite
(P 90) TARGETING HIGH RISK MYC- AMPLIFIED OSTEOSARCOMA BY AURORA KINASE INHIBITOR--RESULT FROM A NGS BASED UMBRELLA TRIAL
Wei Sun
Favorite
sun, wenyue

nih
(P 152) NOVEL PAX3::MAML3 FUSION IDENTIFIED IN ALVEOLAR RHABDOMYOSARCOMA: USING DNA METHYLATION TO EXPANDE THE GENETIC SPECTRUM OF "FUSION POSITIVE" CASES
wenyue sun
Favorite
SUTO, HIROTAKA

Hyogo Cancer Center
(P 168) EFFICACY OF LOW-DOSE IMATINIB IN A PATIENT WITH A GIST WITH KIT EXON 11 W557_K558 DELETION
HIROTAKA SUTO
Favorite
Suzi, Birz

University of Chicago
(P 287) AN INTERNATIONAL SURVEY OF PROVIDER PRACTICES REGARDING BONE MARROW SAMPLING VERSUS [18F] FDG PET/CT IN THE DIAGNOSTIC EVALUATION OF BONE MARROW METASTASIS IN PEDIATRIC RHABDOMYOSARCOMA
Birz Suzi
Favorite
Suzuki, Rie

Osaka International Cancer Institute
(P 05) DEVELOPMENT OF SARCOMA ORGANOID MODELS WITH AIR-LIQUID INTERFACE ORGANOID CULTURES
Rie Suzuki
Favorite
(P 96) TRACP-5B AS A BIOMARKER FOR LONG-TERM DENOSUMAB TREATMENT OF UNRESECTABLE GIANT CELL TUMOR OF BONE
Rie Suzuki
Favorite
(P 272) OUTCOMES OF FOUR CASES OF TOTAL HIP ARTHROPLASTY (THA) WITH POROUS TANTALUM IMPLANT AFTER PARTIAL ACETABULAR RESECTION USING 3D PREOPERATIVE PLANNING FOR PELVIC BONE TUMORS
Rie Suzuki
Favorite
(P 283) USE OF MIXED REALITY IN PELVIC BONE TUMOR RESECTION: FIVE CASE STUDY
Rie Suzuki
Favorite
(P 387) SUCCESSFUL PAZOPANIB TREATMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA WITH COAMPLIFICATION OF PDGFRA, VEGFR2, AND KIT: A CASE REPORT
Rie Suzuki
Favorite
Svane, Inge Marie

National Center for Cancer Immune Therapy, Department of Oncology, Herlev Hospital
(P 243) MYELOSUPPRESSION FOLLOWING LYMPHODEPLETING CHEMOTHERAPY AS PART OF ADOPTIVE CELL THERAPY FOR PATIENTS WITH PROGRESSIVE SOFT TISSUE SARCOMA AFTER STANDARD CHEMOTHERAPY
Inge Marie Svane
Favorite
Sveinbjornsson, Baldur

Lytix Biopharma AS
(P 243) MYELOSUPPRESSION FOLLOWING LYMPHODEPLETING CHEMOTHERAPY AS PART OF ADOPTIVE CELL THERAPY FOR PATIENTS WITH PROGRESSIVE SOFT TISSUE SARCOMA AFTER STANDARD CHEMOTHERAPY
Baldur Sveinbjornsson
Favorite
Swallow, Carol

Princess Margaret Cancer Centre, University Health Network and Mount Sinai Hospital
(P 376) IMPACT OF SITE OF ORIGIN ON THE PROGNOSIS OF PATIENTS WITH PRIMARY RESECTABLE NON-UTERINE ABDOMINAL LEIOMYOSARCOMA
Carol Swallow
Favorite
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Carol Swallow
Favorite
Swallow, Carol

The Princess Margaret/Mount Sinai Hospital
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Carol Swallow
Favorite
Swaney, William

Expression Therapeutics
(P 106) DELTAREX-G, A TUMOR TARGETED CCNG1 INHIBITOR, DEMONSTRATES CLINICAL BENEFIT IN ADVANCED CHEMORESISTANT SARCOMA FOLLOWING FDA CBER AUTHORIZATION FOR USE AS PLATFORM THERAPY WITH FDA APPROVED DRUGS
William Swaney
Favorite
Swayambunathan, Jay

Department of Orthopaedic Surgery, Duke University
(P 148) ISOCITRATE DEHYDROGENASE MUTATIONS IN CHONDROSARCOMA: A META-ANALYSIS
Jay Swayambunathan
Favorite
Sweeney, Kyle

University of Kansas Medical Center
(P 36) EARLY REAL-WORLD EXPERIENCE WITH THE USE OF NIROGACESTAT FOR THE TREATMENT OF DESMOID FIBROMATOSIS
Kyle Sweeney
Favorite
(P 271) OUTCOMES OF DISTAL FEMORAL REPLACEMENT VS INTERNAL FIXATION FOR METASTATIC BONE DISEASE OF THE DISTAL FEMUR
Kyle Sweeney
Favorite
Sweet-Cordero, Alejandro

UCSF
(P 49) A WORKING GROUP FOR THE DEVELOPMENT OF A CLINICAL FRAMEWORK THAT STRATIFIES OSTEOSARCOMA PATIENTS USING BIOMARKERS OF CLINICAL RISK AND BIOLOGY
Alejandro Sweet-Cordero
Favorite
(P 65) EPIGENETIC HETEROGENEITY AND STATE SPECIFIC TRANSCRIPTIONAL PROGRAMS DRIVE DRUG RESPONSE IN OSTEOSARCOMA
Alejandro Sweet-Cordero
Favorite
(P 292) CHARACTERIZATION OF TELOMERE MAINTENANCE MECHANISMS IN OSTEOSARCOMA PATIENT-DERIVED LABORATORY MODELS
Alejandro Sweet-Cordero
Favorite
(P 295) DEFINING OSTEOSARCOMA HETEROGENEITY: CONSENSUS CLUSTERING REVEALS GENE EXPRESSION SUBTYPES
Alejandro Sweet-Cordero
Favorite
Swilling, Aubrey

The University of Kansas Medical Center
(P 36) EARLY REAL-WORLD EXPERIENCE WITH THE USE OF NIROGACESTAT FOR THE TREATMENT OF DESMOID FIBROMATOSIS
Aubrey Swilling
Favorite
Swinkels, Maisie

UCLH
(P 146) EXPLORING THE CLINICAL UTILITY OF WHOLE GENOME SEQUENCING FOR PAEDIATRIC, TYA AND ADULT SARCOMA PATIENTS WITHIN THE LONDON SARCOMA SERVICE: A RETROSPECTIVE COHORT ANALYSIS
Maisie Swinkels
Favorite
Switaj, Tomasz

Maria Sklodowska-Curie National Research Institute of Oncology
(P 245) PRELIMINARY RESULTS FROM A PHASE 2 EFTISARC-NEO TRIAL OF NEOADJUVANT SOUBLE LAG-3 PROTEIN EFTILAGIMOD ALPHA, PEMBROLIZUMAB, AND CONCURRENT RADIOTHERAPY IN PATIENTS WITH RESECTABLE SOFT TISSUE SARCOMA
Tomasz Switaj
Favorite
Szumera-Cieckiewicz, Anna

Maria Sklodowska-Curie National Research Institute of Oncology
(P 77) MULTI-PARAMETRICAL PROFILING OF CHONDROSARCOMA
Anna Szumera-Cieckiewicz
Favorite
(P 245) PRELIMINARY RESULTS FROM A PHASE 2 EFTISARC-NEO TRIAL OF NEOADJUVANT SOUBLE LAG-3 PROTEIN EFTILAGIMOD ALPHA, PEMBROLIZUMAB, AND CONCURRENT RADIOTHERAPY IN PATIENTS WITH RESECTABLE SOFT TISSUE SARCOMA
Anna Szumera-Cieckiewicz
Favorite
T
Taal, Walter

Erasmus Medical Center
(P 154) PREOPERATIVE CLASSIFICATION OF NERVE SHEATH TUMORS USING RADIOMICS-BASED MACHINE LEARNING
Walter Taal
Favorite
Tajima, Takashi

Kyorin University
(P 18) IMMUNOHISTOCHEMICAL ANALYSIS OF NUCLEAR β-CATENIN IN BONE AND SOFT TISSUE TUMOR MICROARRAYS
Takashi Tajima
Favorite
Takami, Haruna

Osaka University Graduate School of Medicine/Orthopaedic Surgery
(P 324) BENZIMIDAZOLE DERIVATIVES AS NOVEL THERAPEUTIC AGENTS FOR INI1-DEFICIENT EPITHELIOID SARCOMA
Haruna Takami
Favorite
(P 387) SUCCESSFUL PAZOPANIB TREATMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA WITH COAMPLIFICATION OF PDGFRA, VEGFR2, AND KIT: A CASE REPORT
Haruna Takami
Favorite
Takenaka, Satoshi

Osaka International Cancer Institute
(P 05) DEVELOPMENT OF SARCOMA ORGANOID MODELS WITH AIR-LIQUID INTERFACE ORGANOID CULTURES
Satoshi Takenaka
Favorite
(P 96) TRACP-5B AS A BIOMARKER FOR LONG-TERM DENOSUMAB TREATMENT OF UNRESECTABLE GIANT CELL TUMOR OF BONE
Satoshi Takenaka
Favorite
(P 272) OUTCOMES OF FOUR CASES OF TOTAL HIP ARTHROPLASTY (THA) WITH POROUS TANTALUM IMPLANT AFTER PARTIAL ACETABULAR RESECTION USING 3D PREOPERATIVE PLANNING FOR PELVIC BONE TUMORS
Satoshi Takenaka
Favorite
(P 283) USE OF MIXED REALITY IN PELVIC BONE TUMOR RESECTION: FIVE CASE STUDY
Satoshi Takenaka
Favorite
(P 387) SUCCESSFUL PAZOPANIB TREATMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA WITH COAMPLIFICATION OF PDGFRA, VEGFR2, AND KIT: A CASE REPORT
Satoshi Takenaka
Favorite
Talavera, Pablo

Hospital Clinico san Carlos
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Pablo Talavera
Favorite
Tamborini, Elena

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 171) GASTROINTESTINAL STROMAL TUMOURS (GISTS) IN NEUROFIBROMATOSIS TYPE (NF1): A SINGLE-CENTER OBSERVATIONAL RETROSPECTIVE STUDY
Elena Tamborini
Favorite
Tamburini, Angela

AOU Meyer IRCCS
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Angela Tamburini
Favorite
Tamiya, Hironari

Osaka International Cancer Institute
(P 05) DEVELOPMENT OF SARCOMA ORGANOID MODELS WITH AIR-LIQUID INTERFACE ORGANOID CULTURES
Hironari Tamiya
Favorite
(P 96) TRACP-5B AS A BIOMARKER FOR LONG-TERM DENOSUMAB TREATMENT OF UNRESECTABLE GIANT CELL TUMOR OF BONE
Hironari Tamiya
Favorite
(P 272) OUTCOMES OF FOUR CASES OF TOTAL HIP ARTHROPLASTY (THA) WITH POROUS TANTALUM IMPLANT AFTER PARTIAL ACETABULAR RESECTION USING 3D PREOPERATIVE PLANNING FOR PELVIC BONE TUMORS
Hironari Tamiya
Favorite
(P 283) USE OF MIXED REALITY IN PELVIC BONE TUMOR RESECTION: FIVE CASE STUDY
Hironari Tamiya
Favorite
(P 387) SUCCESSFUL PAZOPANIB TREATMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA WITH COAMPLIFICATION OF PDGFRA, VEGFR2, AND KIT: A CASE REPORT
Hironari Tamiya
Favorite
Tanaka, Sakae

The University of Tokyo Hospital
(P 103) BRAF MUTATIONS AND CONCURRENT ALTERATIONS IN PATIENTS WITH SOFT TISSUE SARCOMA
Sakae Tanaka
Favorite
Tanaka, Yasuhito

Nara Medical University
(P 313) RELATION BETWEEN NUTRITIONAL/INFLAMMATORY PARAMETERS AND PROGNOSIS IN CHILDHOOD SARCOMA PATIENTS
Yasuhito Tanaka
Favorite
Tan, Daniel

Division of Medical Oncology, National Cancer Centre Singapore and Duke-NUS Medical School
(P 396) LONG-TERM FOLLOW-UP EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Daniel Tan
Favorite
Tang, Xiaodong

Peking University People's Hospital
(P 276) RECONSTRUCTION WITH TOTAL SCAPULAR REVERSE TOTAL SHOULDER ENDOPROSTHESIS: PRELIMINARY RESULTS FROM A SINGLE INSTITUTE
Xiaodong Tang
Favorite
Tan, Minjia

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
(P 93) THE PROTEOGENOMIC SUBTYPING OF OSTEOSARCOMA
Minjia Tan
Favorite
Tannenbaum, Allen

Departments of Computer Science and Applied Mathematics and Statistics, Stony Brook University
(P 129) ELUCIDATING THE EVOLUTIONARY DYNAMICS OF DDLS LIPOSARCOMA USING SINGLE-CELL SEQUENCING AND MATHEMATICAL LINEAGE TRACING
Allen Tannenbaum
Favorite
Tan, Yurong

University of Miami
(P 58) COMBINATORY THERAPIES UTILIZING INHIBITION OF CARBONIC ANHYDRASE IX TO POTENTIATE RESPONSE IN RELAPSED/REFRACTORY OSTEOSARCOMA
Yurong Tan
Favorite
Tap, William

Department of Medicine, Memorial Sloan Kettering Cancer Center Department of Medicine, Weill Cornell Medical College
(P 37) HEALTH-RELATED QUALITY OF LIFE FROM A PHASE 4 STUDY TO EVALUATE DISCONTINUATION AND RECHALLENGE OF PEXIDARTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR PREVIOUSLY TREATED WITH PEXIDARTINIB
William Tap
Favorite
(P 43) SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
William Tap
Favorite
(P 44) TUMOR RESPONSE AND REGROWTH IN RELATION TO CLINICAL EVENTS AMONG PEXIDARTINIB-TREATED SUBJECTS IN THE PHASE 3 ENLIVEN TRIAL
William Tap
Favorite
(P 101) AN OPEN LABEL PHASE IIA STUDY EVALUATING THE PRELIMINARY EFFICACY OF INTRATUMORAL TIGILANOL TIGLATE (TT) IN ADVANCED AND/OR METASTATIC SOFT TISSUE SARCOMA (STS, NCT05755113)
William Tap
Favorite
(P 121) ACQUIRED CYCLIN D AMPLIFICATION IS A MECHANISM FOR RESISTANCE TO CDK4/6 INHIBITORS IN DEDIFFERENTIATED LIPOSARCOMA
William Tap
Favorite
(P 211) REAL-WORLD EXPERIENCE OF PATIENTS NEWLY INITIATED ON PEXIDARTINIB FOR TENOSYNOVIAL GIANT CELL TUMOR
William Tap
Favorite
(P 229) EXPRESSION OF TRANSPOSABLE ELEMENTS AND IKZF1 PREDICTS IMMUNE INFILTRATES IN SARCOMAS AND CORRELATES WITH OUTCOMES AFTER IMMUNE CHECKPOINT INHIBITION
William Tap
Favorite
(P 408) OSTEOMYC: A PHASE 2 PILOT STUDY TO EVALIATE THE SAFETY AND THE ANTITUMOR ACTIVITY OF THE MYC INHIBITOR OMO-103 ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH ADVANCED HIGH GRADE OSTEOSARCOMA
William Tap
Favorite
Tararykova, Anastasia

Federal State Budgetary Institution «N.N. Blokhin Medical Research Center of Oncology» of the Ministry of Health of the Russian Federation (N.N.Blokhin NMRCO), Moscow (Russia)
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Anastasia Tararykova
Favorite
Tarique, Usman

University of Toronto
(P 376) IMPACT OF SITE OF ORIGIN ON THE PROGNOSIS OF PATIENTS WITH PRIMARY RESECTABLE NON-UTERINE ABDOMINAL LEIOMYOSARCOMA
Usman Tarique
Favorite
Taswell, Crystal

University of Miami, Sylvester Comprehensive Cancer Center
(P 358) RADIOMIC EVALUATION OF MRIS IN PATIENTS WITH SOFT TISSUE SARCOMA TREATED WITH STEREOTACTIC BOSY RADIATION THERAPY
Crystal Taswell
Favorite
Taylor, Eric

University of Iowa
(P 12) GENETIC LANDSCAPE OF MPNST DETERMINES METABOLIC STRATEGIES AND THERAPEUTIC OPPORTUNITIES FOR COPING WITH REDOX STRESS
Eric Taylor
Favorite
Taylor, Molly

Seattle Children's Hospital, University of Washington
(P 226) EARLY EXPERIENCE ON ENLIGHTEN-01: A PHASE 1 STUDY OF BISPECIFIC ADAPTER MOLECULE- CONTROLLED FOLATE RECEPTOR CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY OSTEOSARCOMA
Molly Taylor
Favorite
Tecson, Kristen

Daiichi Sankyo, Inc.
(P 37) HEALTH-RELATED QUALITY OF LIFE FROM A PHASE 4 STUDY TO EVALUATE DISCONTINUATION AND RECHALLENGE OF PEXIDARTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR PREVIOUSLY TREATED WITH PEXIDARTINIB
Kristen Tecson
Favorite
(P 44) TUMOR RESPONSE AND REGROWTH IN RELATION TO CLINICAL EVENTS AMONG PEXIDARTINIB-TREATED SUBJECTS IN THE PHASE 3 ENLIVEN TRIAL
Kristen Tecson
Favorite
(P 211) REAL-WORLD EXPERIENCE OF PATIENTS NEWLY INITIATED ON PEXIDARTINIB FOR TENOSYNOVIAL GIANT CELL TUMOR
Kristen Tecson
Favorite
Teixeira, Maria

Hospital Israelita Albert Einstein
(P 141) COMPREHENSIVE GENOMIC PROFILING OF PATIENTS DIAGNOSED WITH SARCOMA IN BRAZIL: MOLECULAR PROFILE AND ACTIONABILITY
Maria Teixeira
Favorite
Temple, H Thomas

University of Miami
(P 253) ASSESSING THE LINK BETWEEN MYXOFIBROSARCOMA RECURRENCE AND TREATMENT ORDER: A MULTIDISCIPLINARY RETROSPECTIVE COHORT STUDY
H Thomas Temple
Favorite
(P 282) UNPLANNED RESECTION OF SOFT TISSUE SARCOMA: THE IMPACT OF RESIDUAL DISEASE IN RE-RESECTION SPECIMEN
H Thomas Temple
Favorite
(P 346) BRACHYTHERAPY FOR SOFT TISSUE SARCOMA: MAINTAINING LOCAL CONTROL WHILE MINIMIZING COMPLICATIONS
H Thomas Temple
Favorite
Teneberg, Susan

University of Gothenburg, Department of Medical Biochemistry and Cell Biology
(P 139) CHARACTERIZATION OF GLYCOSPHINGOLIPIDS IN HUMAN LEIOMYOSARCOMA
Susan Teneberg
Favorite
Teoh, Jeffrey

Umoja Biopharma
(P 226) EARLY EXPERIENCE ON ENLIGHTEN-01: A PHASE 1 STUDY OF BISPECIFIC ADAPTER MOLECULE- CONTROLLED FOLATE RECEPTOR CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY OSTEOSARCOMA
Jeffrey Teoh
Favorite
ter Horst, S.A.J.

Department of Radiology and Nuclear Medicine, Wilhelmina Children’s Hospital University Medical Centre Utrecht
(P 319) THE SURVIVAL DISPARITY BETWEEN CHILDREN AND ADOLESCENTS & YOUNG ADULTS WITH EWING SARCOMA IN THE NETHERLANDS DID NOT CHANGE SINCE THE 1990S DESPITE IMPROVED SURVIVAL: A POPULATION-BASED STUDY
S.A.J. ter Horst
Favorite
Teres, Raul

Hospital de la Santa Creu i Sant Pau
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Raul Teres
Favorite
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Raul Teres
Favorite
Teterycz, Paweł

Department of Soft Tissue, Bone/Sarcoma, and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland. Department of Computational Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
(P 77) MULTI-PARAMETRICAL PROFILING OF CHONDROSARCOMA
Paweł Teterycz
Favorite
(P 245) PRELIMINARY RESULTS FROM A PHASE 2 EFTISARC-NEO TRIAL OF NEOADJUVANT SOUBLE LAG-3 PROTEIN EFTILAGIMOD ALPHA, PEMBROLIZUMAB, AND CONCURRENT RADIOTHERAPY IN PATIENTS WITH RESECTABLE SOFT TISSUE SARCOMA
Paweł Teterycz
Favorite
Teuber, Alina

Faculty of Chemistry and Chemical Biology, TU Dortmund University, Dortmund, Germany
(P 173) IN VITRO PROFILING OF IDRX-42 AGAINST SECONDARY MUTATIONS FOUND IN TKI-RESISTANT GIST
Alina Teuber
Favorite
Thai, Zung

Edgewood Oncology
(P 402) A PILOT STUDY OF BTX-A51 IN PATIENTS WITH METASTATIC AND/OR RECURRENT LIPOSARCOMAS CHARACTERIZED BY MDM2 AMPLIFICATIONS
Zung Thai
Favorite
Theisen, Emily

Nationwide Childrens Hospital
(P 21) LSD1 INHIBITOR SP-2509 DISRUPTS IRON-SULFUR CLUSTER BIOGENESIS
Emily Theisen
Favorite
Thirumaran, Rajesh

Mercy Catholic Medical Center
(P 310) PROGNOSTICATION AND EPIDEMIOLOGY OF CLEAR CELL SARCOMA: A SEER STAT RETROSPECTIVE ANALYSIS
Rajesh Thirumaran
Favorite
Thomas, Elaine

National Cancer Institute
(P 414) TENOSYNOVIAL GIANT CELL TUMOR IN CHILDREN: INTERIM RESULTS FROM A PHASE 1 STUDY OF TURALIO®
Elaine Thomas
Favorite
Thomas, Paul

St. Jude Children's Research Hospital
(P 288) ANGIOA: A SAFETY AND TOLERABILITY STUDY OF TRIPLE ANTI-ANGIOGENIC THERAPY COMBINED WITH PD-L1 BLOCKADE IN PEDIATRIC, ADOLESCENT AND YOUNG ADULT RECURRENT/REFRACTORY SOLID TUMORS
Paul Thomas
Favorite
Thompson, Patrick

University of North Carolina at Chapel Hill
(P 309) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT SOFT TISSUE SARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Patrick Thompson
Favorite
Thomson, Chris

Veterinary Specialty Hospital
(P 115) PROSPECTIVE EVALUATION OF THORACOSCOPIC METASTASECTOMY IN DOGS: A NOVEL TRANSLATIONAL DRUG DEVELOPMENT PIPELINE TAGETING METASTATIC OSTEOSARCOMA
Chris Thomson
Favorite
Thoppey Manoharan, Varsha

University of Calgary
(P 289) APPLICATION AND ANALYSIS OF SPATIAL TRANSCRIPTOMIC PROFILING TO CLINICAL ALVEOLAR SOFT PART SARCOMA SAMPLES TO UNDERSTAND IMMUNOTHERAPY-RELEVANT VARIABLES
Varsha Thoppey Manoharan
Favorite
(P 422) COMPARISON OF ANNOTATION METHODS FOR PAN-SARCOMA SINGLE CELL DATA
Varsha Thoppey Manoharan
Favorite
Thornell, Anders

University of Gothenburg, Institute of Clinical Scinces
(P 20) LEIOMYOSARCOMA OF THE THORACIC AORTA - A RARE CASE REPORT
Anders Thornell
Favorite
(P 139) CHARACTERIZATION OF GLYCOSPHINGOLIPIDS IN HUMAN LEIOMYOSARCOMA
Anders Thornell
Favorite
(P 382) PARAGANGLIOMA AND CONGENITAL HEART DISEASE - A RARE CASE REPORT
Anders Thornell
Favorite
Thorpe, Signe

Johns Hopkins All Children's Hospital
(P 316) SECONDARY RHABDOMYOSARCOMA IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS
Signe Thorpe
Favorite
Thorpe, steven

uc denver
(P 11) GENETIC AND EPIGENETIC CHARACTERIZATION OF SARCOMA STEM CELLS ACROSS SUBTYPES IDENTIFIES EZH2 AS A THERAPEUTIC TARGET
steven Thorpe
Favorite
Thorpe, Steven

University of California, Davis/Orthopaedic Surgery
(P 230) HIGHER BODY MASS INDEX IS ASSOCIATED WITH DECREASED CIRCULATING AND INTRATUMORAL NATURAL KILLER CELLS IN SOFT TISSUE SARCOMA
Steven Thorpe
Favorite
Thorsen, Lise

Department of Oncology, Aarhus University Hospital
(P 357) RADIATION THERAPY OF EXTREMITY SOFT TISSUE SARCOMAS: A NATIONWIDE COHORT STUDY OF LATE SIDE EFFECTS - TRIAL IN PROGRESS
Lise Thorsen
Favorite
Thoulouzan, Matthieu

Centre Claudius Regaud
(P 125) CHARACTERISTICS, MANAGEMENT AND SURVIVAL OF N=7314 LIPOSARCOMAS FROM THE NATIONWIDE NETSARC REGISTRY IN FRANCE SINCE 2010
Matthieu Thoulouzan
Favorite
Thuilliez, Corentin

Institut Gustave Roussy
(P 53) CHARACTERIZING THE SPATIAL TRANSCRIPTOMIC LANDSCAPE OF OSTEOSARCOMA FROM DIAGNOSIS TO RELAPSE
Corentin Thuilliez
Favorite
TIAN, HUA

Rigel Pharmaceuticals, Inc.
(P 87) SAFETY AND EFFICACY OF OLUTASIDENIB, AN IDH1 MUTANT INHIBITOR, FOR THE TREATMENT OF RECURRENT/ RELAPSED LOCALLY ADVANCED OR METASTATIC IDH1 MUTATED CHONDROSARCOMA
HUA TIAN
Favorite
Tian, Kai

Department of Orthopaedics, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Bone Tumor Institution, Shanghai, China
(P 83) PREDICTION OF HIGH-RISK OSTEOSARCOMA PATIENTS BASED ON MACHINE LEARNING USING TRANSCRIPTOME AND METHYLATION DATA FROM SGH-COHORT
Kai Tian
Favorite
(P 90) TARGETING HIGH RISK MYC- AMPLIFIED OSTEOSARCOMA BY AURORA KINASE INHIBITOR--RESULT FROM A NGS BASED UMBRELLA TRIAL
Kai Tian
Favorite
Tian, Wen

The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital
(P 97) TRANSCRIPTOMICS REVEALS THAT OVEREXPRESSION OF LNCRNA HOTTIP REGULATES PKC PROTEIN ACTIVATION OF THE RAP1 SIGNALING PATHWAY FOR SYNOVIAL SARCOMA CELL PROGRESSION
Wen Tian
Favorite
Tiffany, Aleczandria

University of Illinois Urbana-Champaign
(P 419) BONE MECHANICS INFLUENCE CANCER STEM CELL FORMATION IN OSTEOSARCOMA
Aleczandria Tiffany
Favorite
Timmermann, Anne

Rush University Medical Center
(P 126) CHARACTERIZING THE TRANSFORMATION AND DIAGNOSIS OF ATYPICAL LIPOMATOUS TUMOR OF THE EXTREMITIES TO DEDIFFERENTIATED LIPOSARCOMA: SINGLE INSTITUTIONAL OUTCOMES
Anne Timmermann
Favorite
Tinoco, Gabriel

The Ohio State University Comprehensive Cancer Center
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Gabriel Tinoco
Favorite
(P 207) PATIENT-REPORTED GLOBAL HEALTH PREDICTS ADVERSE HEALTH OUTCOMES IN PATIENTS WITH ADVANCED SARCOMA
Gabriel Tinoco
Favorite
(P 244) PREDICTIVE VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO IN IMMUNOTHERAPY OUTCOMES IN ADVANCED SARCOMA
Gabriel Tinoco
Favorite
(P 328) DETERMINING BIOMARKERS FOR GEMCITABINE RESPONSE IN SOFT TISSUE SARCOMAS: LESSONS LEARNED FROM PANCREATIC CANCER
Gabriel Tinoco
Favorite
(P 400) A LONG-TERM PHASE 4 STUDY TO EVALUATE THE RISK OF HEPATOTOXICITY ASSOCIATED WITH PEXIDARTINIB TREATMENT
Gabriel Tinoco
Favorite
Tirotta, Fabio

Queen Elizabeth Hospital
(P 383) PRE-OPERATIVE SPLIT RENAL FUNCTION RADIONUCLIDE IMAGING IN SURGICAL PLANNING FOR MULTI-VISCERAL RESECTION OF RETROPERITONEAL SARCOMA: A RETROSPECTIVE COHORT STUDY
Fabio Tirotta
Favorite
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Fabio Tirotta
Favorite
Titerina, Elizaveta

The Ohio State University
(P 136) TARGETING MIR-138-5P TO TREAT DEDIFFERENTIATED LIPOSARCOMA
Elizaveta Titerina
Favorite
Todoroff, Karen

Ontada
(P 133) REAL-WORLD ANALYSIS OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS) IN A US COMMUNITY ONCOLOGY SETTING
Karen Todoroff
Favorite
Tokarsky, Jack

Nationwide Children's Hospital
(P 21) LSD1 INHIBITOR SP-2509 DISRUPTS IRON-SULFUR CLUSTER BIOGENESIS
Jack Tokarsky
Favorite
Toki, Shunichi

Department of Orthopedics Institute of Biomedical Sciences
(P 138) ACCURACY AND COMPLICATIONS OF CORE NEEDLE BIOPSY OF PERIPHERAL NERVE TUMORS
Shunichi Toki
Favorite
Tolcher, Anthony W.

Clinical Research, NEXT Oncology
(P 95) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN PATIENTS WITH CHONDROSARCOMA: UPDATED RESULTS FROM A PHASE 1 STUDY
Anthony W. Tolcher
Favorite
Tolomeo, Francesco

Candiolo Cancer Institute, FPO - IRCCS
(P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Francesco Tolomeo
Favorite
Tolstrup, Johan

Rigshospitalet
(P 29) ABDOMINAL LYMPHANGIOMA CAUSING EXCESSIVE GASTROINTESTINAL BLEEDING FOR MORE THAN TWO DECADES
Johan Tolstrup
Favorite
(P 385) SIMULTANEOUS OCCURRENCE OF MANTLE CELL LYMPHOMA AND LIPOSARCOMA IN THE RETROPERITONEUM
Johan Tolstrup
Favorite
Tolstrup, Johan

Surgical Dpt. Rigshospitalet. Blegdamsvej 9. 2100 Copenhagen East. Denmark
(P 386) SOLITARY FIBROUS TUMOUR: A DANISH SAMPLE FROM 2013 – 2018
Johan Tolstrup
Favorite
Tolstrup, Johan

Rigshospitalet
(P 391) VISCERAL ANGIOSARCOMA: A NATIONWIDE STUDY WITH LONG-TERM FOLLOW-UP
Johan Tolstrup
Favorite
Tong, Hanxing

Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
(P 416) TRIPLR COMNINATION THERAPY IN THE FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA WITH HIGH TUMOR BURDEN: INTERIM ANALYSIS FROM ALTER-S007 STUDY
Hanxing Tong
Favorite
Tong, Zhichao

Department of Osteopathic Oncology, Honghui Hospital, Xi'an Jiaotong University
(P 407) LONG-TERM EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): PHASE 1B UPDATE.
Zhichao Tong
Favorite
Tonini, Giuseppe

Fondazione Policlinico Universitario Campus Bio-Medico
(P 178) PREDICTION OF PRIMARY IMATINIB-REFRACTORY PATIENTS WITH LOCALLY ADVANCED OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) USING RADIOMICS AND ARTIFICIAL INTELLIGENCE (AI)
Giuseppe Tonini
Favorite
Toosi, Behzad

University of Saskatchewan
(P 01) A PILOT STUDY ON SINGLE-NUCLEUS RNA SEQUENCING IN CANINE SOFT TISSUE SARCOMAS
Behzad Toosi
Favorite
Torracca, Lucia

IRCCS Humanitas Research Hospital
(P 155) PRIMARY MESENCHYMAL TUMORS OF THE HEART: A 8-YEARS, SINGLE INSTITUTION EXPERIENCE
Lucia Torracca
Favorite
Torralbas Fitz, Sergio

University of Miami
(P 282) UNPLANNED RESECTION OF SOFT TISSUE SARCOMA: THE IMPACT OF RESIDUAL DISEASE IN RE-RESECTION SPECIMEN
Sergio Torralbas Fitz
Favorite
(P 346) BRACHYTHERAPY FOR SOFT TISSUE SARCOMA: MAINTAINING LOCAL CONTROL WHILE MINIMIZING COMPLICATIONS
Sergio Torralbas Fitz
Favorite
Torres, Keila

MD Anderson Cancer Center
(P 130) HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RESECTABLE RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA (DDLPS) TREATED WITH NEOADJUVANT CHECKPOINT BLOCKADE IN A RANDOMIZED PHASE II CLINICAL TRIAL.
Keila Torres
Favorite
(P 360) TREATMENT OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR WITH BROMODOMAIN EXTRA TERMINAL INHIBITOR (BETI) IN COMBINATION WITH RADIOTHERAPY
Keila Torres
Favorite
Toulmonde, Maud

Institut Bergonie
(P 125) CHARACTERISTICS, MANAGEMENT AND SURVIVAL OF N=7314 LIPOSARCOMAS FROM THE NATIONWIDE NETSARC REGISTRY IN FRANCE SINCE 2010
Maud Toulmonde
Favorite
(P 169) FRENCH LONG TERM REGISTRY WITH LONGITUDINAL FOLLOW UP OF PDGFRA D842V GIST PATIENTS (AVIATOR2020)
Maud Toulmonde
Favorite
Town, Ajia

OHSU Knight Cancer Institute
(P 173) IN VITRO PROFILING OF IDRX-42 AGAINST SECONDARY MUTATIONS FOUND IN TKI-RESISTANT GIST
Ajia Town
Favorite
Trabelsi, Nir

Sami Shamoon College
(P 350) MONITORING CHANGES IN FEMORAL BONE STRENGTH IN PATIENTS WITH METASTATIC BONE DISEASE TREATED WITH RADIATION THERAPY
Nir Trabelsi
Favorite
Tramm, Trine

Aarhus University Hospital
(P 228) EXPLORING THE LINK BETWEEN TUMOUR INFILTRATING IMMUNE CELLS AND PATIENT OUTCOME IN SOFT TISSUE SARCOMA: A CLOSER LOOK AT MACROPHAGES
Trine Tramm
Favorite
Trent, Jonathan

Sylvester Comprehensive Cancer Center, University of Miami Health System
(P 37) HEALTH-RELATED QUALITY OF LIFE FROM A PHASE 4 STUDY TO EVALUATE DISCONTINUATION AND RECHALLENGE OF PEXIDARTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR PREVIOUSLY TREATED WITH PEXIDARTINIB
Jonathan Trent
Favorite
(P 58) COMBINATORY THERAPIES UTILIZING INHIBITION OF CARBONIC ANHYDRASE IX TO POTENTIATE RESPONSE IN RELAPSED/REFRACTORY OSTEOSARCOMA
Jonathan Trent
Favorite
(P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE
Jonathan Trent
Favorite
(P 224) COMPREHENSIVE EVALUATION OF DNA DAMAGE RESPONSE PATHWAY ALTERATIONS AND ASSOCIATED IMMUNOTHERAPY-RESPONSE BIOMARKERS IN SARCOMAS
Jonathan Trent
Favorite
(P 246) THE GENOMIC AND IMMUNE LANDSCAPE OF LIPOSARCOMA AND ITS SUBTYPES
Jonathan Trent
Favorite
(P 253) ASSESSING THE LINK BETWEEN MYXOFIBROSARCOMA RECURRENCE AND TREATMENT ORDER: A MULTIDISCIPLINARY RETROSPECTIVE COHORT STUDY
Jonathan Trent
Favorite
(P 296) DISPARITIES IN OVERALL SURVIVAL FOR AYA PATIENTS WITH EWINGS SARCOMA: A RETROSPECTIVE COHORT STUDY AT A SINGLE SARCOMA CENTER
Jonathan Trent
Favorite
(P 314) RETROSPECTIVE EVALUATION OF DISPARITIES IN ADOLESCENT AND YOUNG ADULT (AYA) PATIENTS WITH SYNOVIAL SARCOMA: A SINGLE INSTITUTION STUDY
Jonathan Trent
Favorite
(P 369) BLAND EMBOLIZATION AS ADJUNCT TREATMENT FOR HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA
Jonathan Trent
Favorite
(P 381) OLIGOMETASTATIC LEIOMYOSARCOMA: ASSOCIATION BETWEEN TREATMENT TYPE, METASTATIC PATTERN AND SURVIVAL
Jonathan Trent
Favorite
(P 403) DCC-3116 IN COMBINATION WITH RIPRETINIB FOR PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A PHASE 1/2 STUDY
Jonathan Trent
Favorite
(P 434) UTILIZATION OF IMAGING MASS CYTOMETRY TO EVALUATE THE IMMUNE LANDSCAPE OF PEDIATRIC AND ADULT PATIENTS WITH SARCOMA TREATED WITH AN AUTOLOGOUS DENDRITIC CELL VACCINE
Jonathan Trent
Favorite
Treviño, Noe

Atlantic Health System
(P 255) CAN LARGE, LIPOMATOUS LESIONS ADJACENT TO THE SUPINATOR MUSCLE BE REMOVED WITHOUT INJURING THE POSTERIOR INTEROSSEOUS NERVE? A RETROSPECTIVE REVIEW
Noe Treviño
Favorite
(P 277) REVERSE TOTAL SHOULDER ARTHROPLASTY MAINTAINS GLOBAL FUNCTION OF THE UPPER EXTREMITY IN PATIENTS WITH ONCOLOGIC DISEASE OF THE PROXIMAL HUMERUS
Noe Treviño
Favorite
Trickett, Justin

Pyxis Oncology
(P 339) SARCOMAS EXPRESS EXTRA DOMAIN B OF FIBRONECTIN AND PRECLINICAL PATIENT-DERIVED XENOGRAFT MODELS OF SEVERAL SARCOMA SUBTYPES ARE SENSITIVE TO THE STROMA TARGETING ANTIBODY DRUG CONJUGATE PYX-201
Justin Trickett
Favorite
Trikoupis, Ioannis

First Department of orthopaedic surgery, National and Kapodistrian University of Athens, Attikon University General Hospital
(P 274) PROXIMAL HUMERAL ENDOPROSTHETIC RECONSTRUCTION: RESULTS FROM THE MUTARS ORTHOPEDIC REGISTRY EUROPE (MORE)
Ioannis Trikoupis
Favorite
Tromp, Jacqueline

Amsterdam University Medical Center
(P 42) RANKL-INHIBITION FOR GIANT CELL LESIONS OF THE JAW: A RETROSPECTIVE COHORT ANALYSIS
Jacqueline Tromp
Favorite
(P 319) THE SURVIVAL DISPARITY BETWEEN CHILDREN AND ADOLESCENTS & YOUNG ADULTS WITH EWING SARCOMA IN THE NETHERLANDS DID NOT CHANGE SINCE THE 1990S DESPITE IMPROVED SURVIVAL: A POPULATION-BASED STUDY
Jacqueline Tromp
Favorite
Trucco, Matteo

Cleveland Clinic
(P 113) METASTATIC EWING'S TRAIL TESTING SCHEDULE ENHANCEMENT TO IMPROVE OUTCOMES (METTSEO)
Matteo Trucco
Favorite
(P 152) NOVEL PAX3::MAML3 FUSION IDENTIFIED IN ALVEOLAR RHABDOMYOSARCOMA: USING DNA METHYLATION TO EXPANDE THE GENETIC SPECTRUM OF "FUSION POSITIVE" CASES
Matteo Trucco
Favorite
(P 351) OSTEOSARCOMA STEREOTACTIC BODY RADIOTHERAPY: OUTCOMES AND PATTERN OF FAILURE
Matteo Trucco
Favorite
Truong, Danh

MD Anderson Cancer Center
(P 233) IMMUNE CLASSES OF LEIOMYOSARCOMA DRIVEN BY B CELL INFILTRATE AND CTLA4 EXPRESSION
Danh Truong
Favorite
Tsang, Derek

Princess Margaret Cancer Centre
(P 321) WHOLE ABDOMINAL RADIOTHERAPY IN CHILDREN AND YOUNG ADULTS WITH SARCOMA: A CANADIAN SARCOMA AND CLINICAL COLLABORATION (CANSARCC) STUDY
Derek Tsang
Favorite
Tsoi, Kim

Division of Orthopedic Surgery, University Musculoskeletal Oncology Unit, Mount Sinai Hospital, Toronto, Ontario, Canada;; University of Toronto, Toronto, Canada
(P 71) LIMB-SALVAGE SURGERY AFTER UNPLANNED SURGERY FOR EXTREMITY BONE SARCOMAS: 30-YEAR EXPERIENCE AT A TERTIARY REFERRAL CENTER
Kim Tsoi
Favorite
(P 225) DETERMINING THE CONTRIBUTIONS OF STAT1 AND THE Y701 PHOSPHORYLATION TO THE UPS ANTI-TUMOR MICROENVIRONMENT
Kim Tsoi
Favorite
(P 238) INTRA-TUMORAL DC-LAMP EXPRESSION IS ASSOCIATED WITH PROGNOSIS IN SOFT TISSUE SARCOMA
Kim Tsoi
Favorite
(P 281) THE UTILITY OF INTRAOPERATIVE MARROW MARGIN FROZEN SECTION IN EXTREMITY BONE SARCOMA RESECTION
Kim Tsoi
Favorite
(P 326) CELL-FREE DNA AS A BIOMARKER FOR CELL DEATH AND TREATMENT RESPONSE IN ON-CHIP THREE-DIMENSIONAL SARCOMA TUMOR MODELS
Kim Tsoi
Favorite
(P 352) OUTCOMES OF PRIMARY INTRATHORACIC SOFT TISSUE SARCOMA
Kim Tsoi
Favorite
Tsuda, Yusuke

The University of Tokyo Hospital
(P 57) CLINICAL GENOMIC PROFILING OF MALIGNANT GIANT CELL TUMOR OF BONE: A RETROSPECTIVE ANALYSIS USING A REAL-WORLD DATABASE
Yusuke Tsuda
Favorite
Tsuda, Yusuke

The University of Tokyo
(P 103) BRAF MUTATIONS AND CONCURRENT ALTERATIONS IN PATIENTS WITH SOFT TISSUE SARCOMA
Yusuke Tsuda
Favorite
Tsukamoto, Shinji

Nara Medical University
(P 85) PTEROSTILBENE SENSITIZES OSTEOSARCOMA CELLS TO KILLING BY C-MYC INHIBITORS
Shinji Tsukamoto
Favorite
(P 313) RELATION BETWEEN NUTRITIONAL/INFLAMMATORY PARAMETERS AND PROGNOSIS IN CHILDHOOD SARCOMA PATIENTS
Shinji Tsukamoto
Favorite
Tu, Chongqi

Department of Orthopedics, West China Hospital, Sichuan University
(P 407) LONG-TERM EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): PHASE 1B UPDATE.
Chongqi Tu
Favorite
Tu, Darleen

Seattle Children's Research Institute
(P 330) EFFICACY OF NON-CARDIOTOXIC ANTHRACYCLINES IN EWING SARCOMA
Darleen Tu
Favorite
Tufino, Carolina

University of Pittsburgh
(P 66) EWING TUMORS WITH STAG2 LOSS DEMOSNTRATE ALTERED INTERFERON SIGNATURES AND IMPAIRED CXCL10 EXPRESSION
Carolina Tufino
Favorite
Turkmani, Amr

Rush University Medical Center
(P 270) OPIOID USE IN IMPENDING VERSUS PATHOLOGIC PROXIMAL FEMUR FRACTURES
Amr Turkmani
Favorite
Turpin, Brian

Cincinnati Children's
(P 417) VITAS: ATEZOLIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY SOLID TUMORS: AN OPEN-LABEL, PHASE I/II, SINGLE-ARM, MULTI-CENTER TRIAL IN PROGRESS
Brian Turpin
Favorite
Tu, Zhong-Qi

Department of Orthopedic Surgery and Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu, China
(P 132) PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND DISEASE BURDEN OF DEDIFFERENTIATED LIPOSARCOMA IN CHINA: A REAL-WORLD STUDY BASED ON NATIONAL CANCER REGISTRY
Zhong-Qi Tu
Favorite
Tuziak, Justyna

Department of Pathology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
(P 77) MULTI-PARAMETRICAL PROFILING OF CHONDROSARCOMA
Justyna Tuziak
Favorite
Tuzzato, Gianmarco

Orthopaedic and Traumatologic Clinic Prevalently Oncologic, IRCCS Istituto Ortopedico Rizzoli
(P 41) PEXIDARTINIB UPFRONT IN A CASE OF TENOSYNOVIAL GIANT CELL TUMOR: PROOF OF CONCEPT FOR A TREATMENT PARADIGM SHIFT
Gianmarco Tuzzato
Favorite
Tysarowski, Andrzej

Cancer Molecular and Genetic Diagnostics Laboratory, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
(P 77) MULTI-PARAMETRICAL PROFILING OF CHONDROSARCOMA
Andrzej Tysarowski
Favorite
Tzanis, Dimitrios

Institut Curie
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Dimitrios Tzanis
Favorite
U
Ulrich, Marisa

Mayo Clinic, Rochester
(P 267) LONG-TERM FUNCTIONAL OUTCOMES OF SHOULDER ARTHRODESIS FOR TUMOR RESECTION
Marisa Ulrich
Favorite
(P 294) COMPARING HIGH-GRADE NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA IN ADULT AND PEDIATRIC POPULATIONS
Marisa Ulrich
Favorite
Underdown, Mary

University of Utah
(P 94) THE ROLE OF CMYC AMPLIFICATION VERSUS CMYC PROTEIN EXPRESSION AS A PROGNOSTIC BIOMARKER IN OSTEOSARCOMA
Mary Underdown
Favorite
Unson, Gabrielle

Rush University Medical Center
(P 31) CLINICAL CHALLENGES AND EVOLVING TREATMENT STRATEGIES IN DESMOID FIBROMATOSIS: A SINGLE INSTITUTION EXPERIENCE
Gabrielle Unson
Favorite
Ur Rab, Saif

SQCCCRC
(P 68) FEASIBILITY OF FIVE-DRUG INTERVAL-COMPRESSED CHEMOTHERAPY FOR ADOLESCENTS AND YOUNG ADULTS WITH EWING SARCOMA FAMILY TUMORS IN THE REAL-WORLD SETTING IN OMAN
Saif Ur Rab
Favorite
Urakawa, Hiroshi

Nagoya university hospital
(P 280) SURGICAL OUTCOMES OF PELVIC CHONDROSARCOMA WITH A FOCUS ON WALKING ABILITY
Hiroshi Urakawa
Favorite
urbani, urbano

BAMBINO GESU CHILDREN HOSPITAL
(P 298) EWING SARCOMA OF MAXILLOFACIAL REGION AND SKULL: A RETROSPECTIVE MONOINSTITUTIONAL PEDIATRIC SERIES
urbano urbani
Favorite
Urbina, Alejandro

Hospital Clinico san Carlos
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Alejandro Urbina
Favorite
Uson Junior, Pedro

Hospital Israelita Albert Einstein
(P 141) COMPREHENSIVE GENOMIC PROFILING OF PATIENTS DIAGNOSED WITH SARCOMA IN BRAZIL: MOLECULAR PROFILE AND ACTIONABILITY
Pedro Uson Junior
Favorite
V
Valentin, Thibaud

IUCT Oncopole
(P 125) CHARACTERISTICS, MANAGEMENT AND SURVIVAL OF N=7314 LIPOSARCOMAS FROM THE NATIONWIDE NETSARC REGISTRY IN FRANCE SINCE 2010
Thibaud Valentin
Favorite
Valenzuela, Cristian

OHSU
(P 364) A PHASE 1B TRIAL OF PREOPERATIVE ERIBULIN AND RADIATION FOR RETROPERITONEAL LIPOSARCOMA
Cristian Valenzuela
Favorite
Valeri, Sergio

Università Campus Bio-Medico
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Sergio Valeri
Favorite
Vallacchi, Viviana

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 420) CELLULARITY DEGREES IN PRIMARY MYXOID LIPOSARCOMA: ASSOCIATION WITH TUMOR IMMUNE INFILTRATE AND PATIENT OUTCOMES
Viviana Vallacchi
Favorite
Vallese, Silvia

Ospedale Pediatrico Bambino Gesù
(P 311) QUANTIFICATION OF TUMOUR-INFILTRATING IMMUNE CELLS THROUGH DECONVOLUTION OF DNA METHYLATION DATA IN EWING SARCOMAS
Silvia Vallese
Favorite
Valles, Laura

Hospital Clinico san Carlos
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Laura Valles
Favorite
Valverde Morales, Claudia

Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d´Hebrón Institute of Oncology
(P 202) IMPACT OF AFAMI-CEL ON THE HEALTH STATE OF PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR MYXOID/ROUND CELL LIPOSARCOMA: COHORT 1 OF SPEARHEAD-1
Claudia Valverde Morales
Favorite
(P 234) IMMUNOSARC II MASTER TRIAL (PHASE II OF SUNITINIB AND NIVOLUMAB): RESULTS FROM THE CLEAR CELL SARCOMA (CCS) COHORT. A GEIS, ISG, AND UCL STUDY
Claudia Valverde Morales
Favorite
(P 408) OSTEOMYC: A PHASE 2 PILOT STUDY TO EVALIATE THE SAFETY AND THE ANTITUMOR ACTIVITY OF THE MYC INHIBITOR OMO-103 ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH ADVANCED HIGH GRADE OSTEOSARCOMA
Claudia Valverde Morales
Favorite
Valverdemd, Jorge

Morristown Medical Center
(P 255) CAN LARGE, LIPOMATOUS LESIONS ADJACENT TO THE SUPINATOR MUSCLE BE REMOVED WITHOUT INJURING THE POSTERIOR INTEROSSEOUS NERVE? A RETROSPECTIVE REVIEW
Jorge Valverdemd
Favorite
(P 260) EMERGING TECHNOLOGY IN ORTHOPEDIC ONCOLOGY: ROBOTIC ARM-ASSISTED TOTAL KNEE ARTHROPLASTY HAS EXCEPTIONAL FUNCTION OUTCOMES FOR PATIENTS WITH BENIGN AND MALIGNANT MUSCULOSKELETAL DISEASE
Jorge Valverdemd
Favorite
(P 266) LONG STEM CEMENTED ROBTIC ARM-ASSISTED TOTAL HIP ARTHROPLASTY: OUTCOMES IN PATIENTS WITH PRIOR ONCOLOGIC DISEASE
Jorge Valverdemd
Favorite
(P 277) REVERSE TOTAL SHOULDER ARTHROPLASTY MAINTAINS GLOBAL FUNCTION OF THE UPPER EXTREMITY IN PATIENTS WITH ONCOLOGIC DISEASE OF THE PROXIMAL HUMERUS
Jorge Valverdemd
Favorite
(P 405) LIPOSOMAL BUPIVACAINE DOESN'T REDUCE NARCOTIC USE OR PAIN SCORES COMPARED TO A MULTIDRUG COCKTAIL FOLLOWING SOFT TISSUE TUMOR REMOVAL: PRELIM RESULTS OF A PROSPECTIVE, RANDOMIZED DOUBLE-BLINDED STUDY
Jorge Valverdemd
Favorite
van Bodegom-Vos, Leti

Leiden University Medical Center
(P 194) EFFECTIVENESS OF A RISK PREDICTION TOOL (PERSARC) ON THE QUALITY OF TREATMENT DECISIONS IN SOFT-TISSUE SARCOMA PATIENTS (VALUE-PERSARC TRIAL)
Leti van Bodegom-Vos
Favorite
van Boven, Hester

Netherlands Cancer Institute/Antoni van Leeuwenhoek
(P 24) NEOADJUVANT CHEMOTHERAPY FOR RADIOTHERAPY ASSOCIATED ANGIOSARCOMA (RAAS) OF THE BREAST IMPROVES ONCOLOGICAL OUTCOMES
Hester van Boven
Favorite
(P 28) THE INFLUENCE OF MARGINS ON OUTCOME IN CUTANEOUS LOCATED SOFT TISSUE SARCOMAS IN THE HEAD AND NECK
Hester van Boven
Favorite
van de Rijin, Matt

Stanford University
(P 159) USING THE TRANSCRIPTIONAL SPECTRUM OF UTERINE SMOOTH MUSCLE TUMORS TO IDENTIFY PROGNOSTIC SIGNATURES FOR ABNORMAL LEIOMYOMAS AND SMOOTH MUSCLE TUMOURS OF UNCERTAIN MALIGNANT POTENTIAL
Matt van de Rijin
Favorite
van de Rijn, Matt

Stanford University
(P 17) IDENTIFICATION OF MARKERS PREDICTIVE OF RESPONSE TO GEMCITABINE AND DOCETAXEL IN LEIOMYOSARCOMA THROUGH MIRNA SEQUENCING
Matt van de Rijn
Favorite
(P 112) MACHINE LEARNING ANALYSIS TO DEFINE CELL LINEAGE IN LEIOMYOSARCOMA
Matt van de Rijn
Favorite
(P 176) LOSS OF PTEN EXPRESSION IN MINIGISTS AND CLINICALLY RELEVANT GISTS
Matt van de Rijn
Favorite
(P 399) SIMILARITY NETWORK FUSION IDENTIFIES DNA METHYLATION SUBTYPES OF LEIOMYOSARCOMA ASSOCIATED WITH CLINICAL OUTCOME
Matt van de Rijn
Favorite
(P 427) MULTI-OMIC AND MULTI-REGION PROFILING OF DESMOID TUMORS REVEALS INTRA- AND INTER-TUMOR HETEROGENEITY
Matt van de Rijn
Favorite
van de Sande, Michiel

Princess Maxima Center for Pediatric Oncology and LUMC Leiden
(P 43) SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
Michiel van de Sande
Favorite
(P 56) CHROME: PREDICTING CHONDROSARCOMA RISK OUTCOME FROM METHYLATION
Michiel van de Sande
Favorite
(P 194) EFFECTIVENESS OF A RISK PREDICTION TOOL (PERSARC) ON THE QUALITY OF TREATMENT DECISIONS IN SOFT-TISSUE SARCOMA PATIENTS (VALUE-PERSARC TRIAL)
Michiel van de Sande
Favorite
(P 261) EVALUATION OF CT ARTIFACTS AFTER SPINAL OLIGOMETASTATIC DISEASE RESECTION AND RECONSTRUCTION: A COMPARATIVE STUDY OF CARBON-FIBER VS. TITANIUM IMPLANTS
Michiel van de Sande
Favorite
(P 274) PROXIMAL HUMERAL ENDOPROSTHETIC RECONSTRUCTION: RESULTS FROM THE MUTARS ORTHOPEDIC REGISTRY EUROPE (MORE)
Michiel van de Sande
Favorite
(P 319) THE SURVIVAL DISPARITY BETWEEN CHILDREN AND ADOLESCENTS & YOUNG ADULTS WITH EWING SARCOMA IN THE NETHERLANDS DID NOT CHANGE SINCE THE 1990S DESPITE IMPROVED SURVIVAL: A POPULATION-BASED STUDY
Michiel van de Sande
Favorite
(P 401) A PHASE 3 MULTI-CENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO ASSESS THE EFFICACY AND SAFETY OF EMACTUZUMAB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR (TANGENT)
Michiel van de Sande
Favorite
van den Berg, Henk

Amsterdam University Medical Center
(P 42) RANKL-INHIBITION FOR GIANT CELL LESIONS OF THE JAW: A RETROSPECTIVE COHORT ANALYSIS
Henk van den Berg
Favorite
van den Bos, Hilda

University Medical Centre Groningen
(P 03) CDK4 IS CO-AMPLIFIED WITH EITHER TP53 PROMOTER GENE FUSIONS OR MDM2 THROUGH DISTINCT MECHANISMS IN OSTEOSARCOMA
Hilda van den Bos
Favorite
van den Bout, Anouk

University of California Santa Cruz, Molecular Cell and Developmental Biology, Genomics Institute
(P 147) INVESTIGATING THE POTENTIAL OF EXTRACELLULAR VESICLE BIOMARKERS IN SYNOVIAL SARCOMA DETECTION
Anouk van den Bout
Favorite
(P 156) PROFILING SYNOVIAL SARCOMA EXTRACELLULAR VESICLES FOR DIAGNOSTIC RNA BIOMARKERS
Anouk van den Bout
Favorite
Van der burg, Stijn

Netherlands Cancer Institute/ Antoni van Leeuwenhoek
(P 24) NEOADJUVANT CHEMOTHERAPY FOR RADIOTHERAPY ASSOCIATED ANGIOSARCOMA (RAAS) OF THE BREAST IMPROVES ONCOLOGICAL OUTCOMES
Stijn Van der burg
Favorite
(P 28) THE INFLUENCE OF MARGINS ON OUTCOME IN CUTANEOUS LOCATED SOFT TISSUE SARCOMAS IN THE HEAD AND NECK
Stijn Van der burg
Favorite
van der Graaf, Winette

Department of Medical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center
(P 24) NEOADJUVANT CHEMOTHERAPY FOR RADIOTHERAPY ASSOCIATED ANGIOSARCOMA (RAAS) OF THE BREAST IMPROVES ONCOLOGICAL OUTCOMES
Winette van der Graaf
Favorite
van der Graaf, Winette

The Netherlands Cancer Institute
(P 319) THE SURVIVAL DISPARITY BETWEEN CHILDREN AND ADOLESCENTS & YOUNG ADULTS WITH EWING SARCOMA IN THE NETHERLANDS DID NOT CHANGE SINCE THE 1990S DESPITE IMPROVED SURVIVAL: A POPULATION-BASED STUDY
Winette van der Graaf
Favorite
van der Heijden, Lizz

Leiden University Medical Center
(P 319) THE SURVIVAL DISPARITY BETWEEN CHILDREN AND ADOLESCENTS & YOUNG ADULTS WITH EWING SARCOMA IN THE NETHERLANDS DID NOT CHANGE SINCE THE 1990S DESPITE IMPROVED SURVIVAL: A POPULATION-BASED STUDY
Lizz van der Heijden
Favorite
van der Wal, Robert

Leiden University Medical Center
(P 274) PROXIMAL HUMERAL ENDOPROSTHETIC RECONSTRUCTION: RESULTS FROM THE MUTARS ORTHOPEDIC REGISTRY EUROPE (MORE)
Robert van der Wal
Favorite
van Houdt, Winan

Netherlands Cancer Institute
(P 24) NEOADJUVANT CHEMOTHERAPY FOR RADIOTHERAPY ASSOCIATED ANGIOSARCOMA (RAAS) OF THE BREAST IMPROVES ONCOLOGICAL OUTCOMES
Winan van Houdt
Favorite
(P 28) THE INFLUENCE OF MARGINS ON OUTCOME IN CUTANEOUS LOCATED SOFT TISSUE SARCOMAS IN THE HEAD AND NECK
Winan van Houdt
Favorite
(P 317) SMARCB1-DEFICIENT SARCOMA OF THE GENITAL REGION/EPITHELIOID SARCOMA OF THE PROXIMAL TYPE VS EPITHELIOID SARCOMA OF THE DISTAL TYPE
Winan van Houdt
Favorite
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Winan van Houdt
Favorite
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Winan van Houdt
Favorite
van IJzendoorn, David

Stanford University
(P 112) MACHINE LEARNING ANALYSIS TO DEFINE CELL LINEAGE IN LEIOMYOSARCOMA
David van IJzendoorn
Favorite
Van Meekeren, Milan

Leiden University Medical Center
(P 349) LONG-TERM SURVIVAL OF PARTICIPANTS IN THE PASART-1 AND PASART-2 TRIALS OF NEO-ADJUVANT PAZOPANIB AND RADIOTHERAPY IN SOFT TISSUE SARCOMA
Milan Van Meekeren
Favorite
van Oortmerssen, Gerard

Sarcoma Patient Advocacy Global Network e.V./Assoc.
(P 201) GLOBAL CROSS-SECTIONAL SURVEY ON SARCOMA DIAGNOSIS PATHWAY: A CURRENT STATE ANALYSIS
Gerard van Oortmerssen
Favorite
Van Putten, Sander

Adcendo ApS
(P 331) EFFICACY OF NOVEL UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN TARGETED ANTIBODY-DRUG CONJUGATES IN PATIENT-DERIVED XENOGRAFTS OF SOFT TISSUE SARCOMA
Sander Van Putten
Favorite
Van Raemdonck, Dirk

UZ Leuven
(P 334) EXPANDING THE LANDSCAPE OF PRECLINICAL MODELS OF SYNOVIAL SARCOMA: FROM 2-DIMENSIONS TO 3-DIMENSIONS TO MICE
Dirk Van Raemdonck
Favorite
van Riet, Bauke

Netherlands Cancer Institute
(P 349) LONG-TERM SURVIVAL OF PARTICIPANTS IN THE PASART-1 AND PASART-2 TRIALS OF NEO-ADJUVANT PAZOPANIB AND RADIOTHERAPY IN SOFT TISSUE SARCOMA
Bauke van Riet
Favorite
Van Tine, Brian

Washington University in St. Louis
(P 33) DESCRIPTIVE EVALUATION OF PATIENTS WITH DESMOID TUMOR AND CO-OCCURRING SOMATIC MUTATIONS OF CTNNB1 AND APC IN THE PHASE 3 DEFI TRIAL
Brian Van Tine
Favorite
(P 37) HEALTH-RELATED QUALITY OF LIFE FROM A PHASE 4 STUDY TO EVALUATE DISCONTINUATION AND RECHALLENGE OF PEXIDARTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR PREVIOUSLY TREATED WITH PEXIDARTINIB
Brian Van Tine
Favorite
(P 81) OUTCOMES DATA FOR OSTEOSARCOMA PATIENTS OVER AGE 60
Brian Van Tine
Favorite
(P 87) SAFETY AND EFFICACY OF OLUTASIDENIB, AN IDH1 MUTANT INHIBITOR, FOR THE TREATMENT OF RECURRENT/ RELAPSED LOCALLY ADVANCED OR METASTATIC IDH1 MUTATED CHONDROSARCOMA
Brian Van Tine
Favorite
(P 202) IMPACT OF AFAMI-CEL ON THE HEALTH STATE OF PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR MYXOID/ROUND CELL LIPOSARCOMA: COHORT 1 OF SPEARHEAD-1
Brian Van Tine
Favorite
(P 222) ANALYSIS OF THE CITN-13 SARCOMA ARM: PEMBROLIZUMAB AND INTERFERON GAMMA FOR SYNOVIAL SARCOMA AND MYXOID/ ROUND CELL LIPOSARCOMA
Brian Van Tine
Favorite
(P 246) THE GENOMIC AND IMMUNE LANDSCAPE OF LIPOSARCOMA AND ITS SUBTYPES
Brian Van Tine
Favorite
Van Winkle, Erin

Adaptimmune
(P 202) IMPACT OF AFAMI-CEL ON THE HEALTH STATE OF PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR MYXOID/ROUND CELL LIPOSARCOMA: COHORT 1 OF SPEARHEAD-1
Erin Van Winkle
Favorite
Vance, Dylan

University of Kansas Medical Center
(P 271) OUTCOMES OF DISTAL FEMORAL REPLACEMENT VS INTERNAL FIXATION FOR METASTATIC BONE DISEASE OF THE DISTAL FEMUR
Dylan Vance
Favorite
Vanden Bempt, Isabelle

UZ Leuven
(P 291) CASE REPORT: RADICAL EN BLOC MULTI-LEVEL SPONDYLECTOMY FOR A LOCALLY RECURRENT OSTEOSARCOMA
Isabelle Vanden Bempt
Favorite
(P 334) EXPANDING THE LANDSCAPE OF PRECLINICAL MODELS OF SYNOVIAL SARCOMA: FROM 2-DIMENSIONS TO 3-DIMENSIONS TO MICE
Isabelle Vanden Bempt
Favorite
Vanleeuw, Ulla

Laboratory of Experimental Oncology, KU Leuven, Leuven Cancer Institute
(P 331) EFFICACY OF NOVEL UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN TARGETED ANTIBODY-DRUG CONJUGATES IN PATIENT-DERIVED XENOGRAFTS OF SOFT TISSUE SARCOMA
Ulla Vanleeuw
Favorite
(P 334) EXPANDING THE LANDSCAPE OF PRECLINICAL MODELS OF SYNOVIAL SARCOMA: FROM 2-DIMENSIONS TO 3-DIMENSIONS TO MICE
Ulla Vanleeuw
Favorite
(P 340) THE DNA MINOR GROOVE BINDING AGENTS ECUBECTEDIN AND PM54 DEMONSTRATE ANTITUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT MODELS OF SOFT TISSUE SARCOMA
Ulla Vanleeuw
Favorite
Vanni, Silvia

Istituto Romagnolo per lo studio dei Tumori "Dino Amadori" IRST IRCCS, Preclinic and Osteoncology Unit, Meldola, Italy
(P 336) IMPROVEMENT OF PHOTODYNAMIC THERAPY IN SARCOMA: IN VITRO VALIDATION ON OSTEOSARCOMA AND MYXOFIBROSARCOMA
Silvia Vanni
Favorite
Varchi, Greta

Institute for the Organic Synthesis and Photoreactivity (ISOF), National Research Council (CNR)
(P 336) IMPROVEMENT OF PHOTODYNAMIC THERAPY IN SARCOMA: IN VITRO VALIDATION ON OSTEOSARCOMA AND MYXOFIBROSARCOMA
Greta Varchi
Favorite
Vaske, Olena

University of California Santa Cruz, Molecular Cell and Developmental Biology, Genomics Institute
(P 147) INVESTIGATING THE POTENTIAL OF EXTRACELLULAR VESICLE BIOMARKERS IN SYNOVIAL SARCOMA DETECTION
Olena Vaske
Favorite
(P 156) PROFILING SYNOVIAL SARCOMA EXTRACELLULAR VESICLES FOR DIAGNOSTIC RNA BIOMARKERS
Olena Vaske
Favorite
(P 295) DEFINING OSTEOSARCOMA HETEROGENEITY: CONSENSUS CLUSTERING REVEALS GENE EXPRESSION SUBTYPES
Olena Vaske
Favorite
Vasques, Hugo

Instituto Português de Oncologia de Lisboa Francisco Gentil
(P 128) DYNAMIC HETEROGENEITY AMONGST LIPOSARCOMAS
Hugo Vasques
Favorite
Vasquez, Yvonne

University of California Santa Cruz, Molecular Cell and Developmental Biology, Genomics Institute
(P 147) INVESTIGATING THE POTENTIAL OF EXTRACELLULAR VESICLE BIOMARKERS IN SYNOVIAL SARCOMA DETECTION
Yvonne Vasquez
Favorite
(P 156) PROFILING SYNOVIAL SARCOMA EXTRACELLULAR VESICLES FOR DIAGNOSTIC RNA BIOMARKERS
Yvonne Vasquez
Favorite
Vaz, Fátima

Instituto Português de Oncologia de Lisboa
(P 128) DYNAMIC HETEROGENEITY AMONGST LIPOSARCOMAS
Fátima Vaz
Favorite
Veltkamp, Sander

SynOx Therapeutics
(P 401) A PHASE 3 MULTI-CENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO ASSESS THE EFFICACY AND SAFETY OF EMACTUZUMAB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR (TANGENT)
Sander Veltkamp
Favorite
Venkataraman, Vinayak

Dana-Farber Cancer Institute / Harvard Medical School
(P 195) ENHANCING PARTICIPANT ENGAGEMENT IN A NOVEL PATIENT-PARTNERED CANCER GENOMICS RESEARCH EFFORT FOR RARE AND AGGRESSIVE SARCOMAS
Vinayak Venkataraman
Favorite
Venkat, Shree

University of Miami/Sylvester Comprehensive Cancer Center
(P 369) BLAND EMBOLIZATION AS ADJUNCT TREATMENT FOR HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA
Shree Venkat
Favorite
Vennam, Sujay

Stanford University
(P 427) MULTI-OMIC AND MULTI-REGION PROFILING OF DESMOID TUMORS REVEALS INTRA- AND INTER-TUMOR HETEROGENEITY
Sujay Vennam
Favorite
vennarini, sabina

INT MILANO
(P 298) EWING SARCOMA OF MAXILLOFACIAL REGION AND SKULL: A RETROSPECTIVE MONOINSTITUTIONAL PEDIATRIC SERIES
sabina vennarini
Favorite
Venneker, Sanne

Leiden University Medical Center
(P 56) CHROME: PREDICTING CHONDROSARCOMA RISK OUTCOME FROM METHYLATION
Sanne Venneker
Favorite
(P 114) METHYLOME PROFILING OF CARTILAGE TUMOURS: A PROMISING NEW TOOL FOR BIOPSY MATERIAL?
Sanne Venneker
Favorite
Venneman, Erik

The University of Kansas Medical Center
(P 36) EARLY REAL-WORLD EXPERIENCE WITH THE USE OF NIROGACESTAT FOR THE TREATMENT OF DESMOID FIBROMATOSIS
Erik Venneman
Favorite
Verbeeck, Kimberly

KU Leuven
(P 334) EXPANDING THE LANDSCAPE OF PRECLINICAL MODELS OF SYNOVIAL SARCOMA: FROM 2-DIMENSIONS TO 3-DIMENSIONS TO MICE
Kimberly Verbeeck
Favorite
(P 340) THE DNA MINOR GROOVE BINDING AGENTS ECUBECTEDIN AND PM54 DEMONSTRATE ANTITUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT MODELS OF SOFT TISSUE SARCOMA
Kimberly Verbeeck
Favorite
Verhey, Theodore

University of Calgary
(P 236) INTERFERON STIMULATED GENE SCORES ARE ELEVATED IN THE MYELOID COMPARTMENT OF MURINE KP UNDIFFERENTIATED PLEOMORPHIC TUMORS TREATED WITH TRANSLATIONAL STING AGONISTS
Theodore Verhey
Favorite
Verhey, Theodore

Arnie Charbonneau Cancer Institute
(P 327) CHARACTERIZATION OF TWO NOVEL IMMUNE COMPETENT, MURINE MODELS OF SOFT TISSUE SARCOMA
Theodore Verhey
Favorite
Verhey, Theodore

University of Calgary
(P 333) ESTIMATING IMMUNE INFILTRATES OF NOVEL GENETICALLY ENGINEERED MOUSE MODELS OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Theodore Verhey
Favorite
(P 424) CROSS-COHORT INTEGRATION AS A STRATEGY TO CLASSIFY IMMUNE CHECKPOINT BLOCKADE RESPONSE IN SARCOMA
Theodore Verhey
Favorite
Verhoef, Cornelis

Erasmus Medical Center
(P 154) PREOPERATIVE CLASSIFICATION OF NERVE SHEATH TUMORS USING RADIOMICS-BASED MACHINE LEARNING
Cornelis Verhoef
Favorite
Verret, Benjamin

Gustave Roussy
(P 125) CHARACTERISTICS, MANAGEMENT AND SURVIVAL OF N=7314 LIPOSARCOMAS FROM THE NATIONWIDE NETSARC REGISTRY IN FRANCE SINCE 2010
Benjamin Verret
Favorite
(P 169) FRENCH LONG TERM REGISTRY WITH LONGITUDINAL FOLLOW UP OF PDGFRA D842V GIST PATIENTS (AVIATOR2020)
Benjamin Verret
Favorite
Vetto, John

OHSU
(P 364) A PHASE 1B TRIAL OF PREOPERATIVE ERIBULIN AND RADIATION FOR RETROPERITONEAL LIPOSARCOMA
John Vetto
Favorite
Vidal Campregher, Paulo

Hospital Israelita Albert Einstein
(P 122) ACTIONABLE FUSIONS IN DEDIFFERENTIATED LIPOSARCOMA: AN ANALYSIS OF 402 CASES IN THE AACR GENIE DATABASE
Paulo Vidal Campregher
Favorite
(P 141) COMPREHENSIVE GENOMIC PROFILING OF PATIENTS DIAGNOSED WITH SARCOMA IN BRAZIL: MOLECULAR PROFILE AND ACTIONABILITY
Paulo Vidal Campregher
Favorite
Vigorito, Raffaella

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 368) AGGRESSIVE PERINEAL ANGIOMYXOMA UNDERGOING SYSTEMIC TREATMENT: AN UPDATED REPORT OF 8-YEARS' EXPERIENCE IN A REFERRAL CENTER
Raffaella Vigorito
Favorite
Vijayakumar, Gayathri

Rush University Medical Center
(P 270) OPIOID USE IN IMPENDING VERSUS PATHOLOGIC PROXIMAL FEMUR FRACTURES
Gayathri Vijayakumar
Favorite
Villano, Anthony

Fox Chase Cancer Center
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Anthony Villano
Favorite
Villar Vázquez, Ana

Hospital Clinico san Carlos
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Ana Villar Vázquez
Favorite
Villavcencio-Valencia, Sylvia V

National Cancer Institute
(P 374) FACTORS ASSOCIATED WITH RECURRENCE IN DEDIFFERENTIATED RETROPERITONEAL LIPOSARCOMA: ANALYSIS AT A REFERENCE CENTER
Sylvia V Villavcencio-Valencia
Favorite
Villette, Claire

Plant Imaging & Mass Spectrometry, PIMS- Institute of Plant Molecular Biology (IBMP), CNRS
(P 75) METABOLIC EVALUATION OF THE RELATIONSHIP BETWEEN MACROPHAGES AND OSTEOSARCOMA TUMOR CELLS
Claire Villette
Favorite
Vinader, Victoria

Bone Cancer Research Trust
(P 196) ESTABLISHING THE BONE CANCER RESEARCH TRUST'S PATIENT & PUBLIC INVOLVEMENT PANEL
Victoria Vinader
Favorite
Vincent, Tyler

Chordoma Foundation
(P 02) A PRECLINICAL ASSAY PIPELINE TO IDENTIFY AND OPTIMIZE BRACHYURY-TARGETED THERAPIES IN CHORDOMA AND OTHER SOLID TUMORS
Tyler Vincent
Favorite
Vincenzi, Bruno

Campus Bio-Medico University of Rome
(P 178) PREDICTION OF PRIMARY IMATINIB-REFRACTORY PATIENTS WITH LOCALLY ADVANCED OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) USING RADIOMICS AND ARTIFICIAL INTELLIGENCE (AI)
Bruno Vincenzi
Favorite
(P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Bruno Vincenzi
Favorite
(P 429) PATIENTS WITH ADVANCED EPITHELIOID HEMANGIOENDOTHELIOMA TREATED WITH SIROLIMUS: OUTCOME FOLLOWING SIROLIMUS DISCONTINUATION.
Bruno Vincenzi
Favorite
Vino, Connor

Alantic Health System
(P 255) CAN LARGE, LIPOMATOUS LESIONS ADJACENT TO THE SUPINATOR MUSCLE BE REMOVED WITHOUT INJURING THE POSTERIOR INTEROSSEOUS NERVE? A RETROSPECTIVE REVIEW
Connor Vino
Favorite
Visbech, Elisabeth

Aarhus University and Aarhus University Hospital
(P 228) EXPLORING THE LINK BETWEEN TUMOUR INFILTRATING IMMUNE CELLS AND PATIENT OUTCOME IN SOFT TISSUE SARCOMA: A CLOSER LOOK AT MACROPHAGES
Elisabeth Visbech
Favorite
Visgauss, Julia

Duke
(P 54) CHONDROBLASTIC OSTEOSARCOMA IS A RISK FACTOR FOR LOCAL RECURRENCE IN PATIENTS WITH SKELETAL OSTEOSARCOMA
Julia Visgauss
Favorite
(P 142) CORE NEEDLE BIOPSY OF PERIACETABULAR CHONDROSARCOMA OFTEN RESULTS IN UNDER-GRADING BUT DOES NOT CHANGE MANAGEMENT BY EXPERIENCED ORTHOPAEDIC ONCOLOGISTS.
Julia Visgauss
Favorite
(P 148) ISOCITRATE DEHYDROGENASE MUTATIONS IN CHONDROSARCOMA: A META-ANALYSIS
Julia Visgauss
Favorite
Visser, Jacob

Erasmus Medical Center
(P 154) PREOPERATIVE CLASSIFICATION OF NERVE SHEATH TUMORS USING RADIOMICS-BASED MACHINE LEARNING
Jacob Visser
Favorite
Viswanathan, Lakshmi

Deciphera Pharmaceuticals, LLC
(P 403) DCC-3116 IN COMBINATION WITH RIPRETINIB FOR PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A PHASE 1/2 STUDY
Lakshmi Viswanathan
Favorite
Vitale, Jacopo

Campus Bio-Medico University of Rome
(P 178) PREDICTION OF PRIMARY IMATINIB-REFRACTORY PATIENTS WITH LOCALLY ADVANCED OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) USING RADIOMICS AND ARTIFICIAL INTELLIGENCE (AI)
Jacopo Vitale
Favorite
Vitfell-Rasmussen, Joanna

Department of Oncology, Herlev University Hospital
(P 104) CIRQUESARC: A NATIONAL PROSPECTIVE OBSERVATIONAL STUDY OF CIRCULATING TUMOR DNA AND QUALITY OF LIFE IN PATIENTS WITH SARCOMA – PRELIMINARY RESULTS FROM THE SURGICAL COHORT
Joanna Vitfell-Rasmussen
Favorite
Viveiros, Pedro

Northwestern University
(P 179) PRIMARY MANAGEMENT OF LOCALIZED GASTROINTESTINAL STROMAL TUMORS WITH IMATINIB MONOTHERAPY: AN ALTERNATIVE TO RESECTION FOR PATIENTS PRECLUDED FROM SURGERY
Pedro Viveiros
Favorite
Viza Gomes, Paula

Department of Orthopaedic Surgery, Duke University
(P 148) ISOCITRATE DEHYDROGENASE MUTATIONS IN CHONDROSARCOMA: A META-ANALYSIS
Paula Viza Gomes
Favorite
Vlug, Lisa

METC-LDD
(P 194) EFFECTIVENESS OF A RISK PREDICTION TOOL (PERSARC) ON THE QUALITY OF TREATMENT DECISIONS IN SOFT-TISSUE SARCOMA PATIENTS (VALUE-PERSARC TRIAL)
Lisa Vlug
Favorite
Volmar, Claude-henry

University of Miami
(P 58) COMBINATORY THERAPIES UTILIZING INHIBITION OF CARBONIC ANHYDRASE IX TO POTENTIATE RESPONSE IN RELAPSED/REFRACTORY OSTEOSARCOMA
Claude-henry Volmar
Favorite
Von Harras, Joris

Leiden University Medical Center
(P 274) PROXIMAL HUMERAL ENDOPROSTHETIC RECONSTRUCTION: RESULTS FROM THE MUTARS ORTHOPEDIC REGISTRY EUROPE (MORE)
Joris Von Harras
Favorite
von Mehren, Margaret

Fox Chase Cancer Center
(P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE
Margaret von Mehren
Favorite
(P 224) COMPREHENSIVE EVALUATION OF DNA DAMAGE RESPONSE PATHWAY ALTERATIONS AND ASSOCIATED IMMUNOTHERAPY-RESPONSE BIOMARKERS IN SARCOMAS
Margaret von Mehren
Favorite
(P 246) THE GENOMIC AND IMMUNE LANDSCAPE OF LIPOSARCOMA AND ITS SUBTYPES
Margaret von Mehren
Favorite
(P 412) SARC044: A PHASE II TRIAL OF BEZUCLASTINIB IN COMBINATION WITH SUNITINIB IN PATIENTS WITH GIST WHO PROGRESSED ON SUNITINIB MONOTHERAPY
Margaret von Mehren
Favorite
Voss, Rachel

Moffitt Cancer Center
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Rachel Voss
Favorite
Vucicevic, Rajko

Rush University Medical Center
(P 271) OUTCOMES OF DISTAL FEMORAL REPLACEMENT VS INTERNAL FIXATION FOR METASTATIC BONE DISEASE OF THE DISTAL FEMUR
Rajko Vucicevic
Favorite
Vuori, Kristiina

.Cancer Molecular Therapeutics Program, National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
(P 27) SUMO2 INHIBITION REVERSES ABERRANT EPIGENETIC REWIRING DRIVEN BY SYNOVIAL SARCOMA FUSION ONCOPROTEINS AND IMPAIRS SARCOMAGENESIS
Kristiina Vuori
Favorite
W
Wągrodzki, Michał

Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
(P 77) MULTI-PARAMETRICAL PROFILING OF CHONDROSARCOMA
Michał Wągrodzki
Favorite
Waddell, Tom

University Health Network
(P 352) OUTCOMES OF PRIMARY INTRATHORACIC SOFT TISSUE SARCOMA
Tom Waddell
Favorite
Wagner, Andrew

Dana-Farber Cancer Institute
(P 37) HEALTH-RELATED QUALITY OF LIFE FROM A PHASE 4 STUDY TO EVALUATE DISCONTINUATION AND RECHALLENGE OF PEXIDARTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR PREVIOUSLY TREATED WITH PEXIDARTINIB
Andrew Wagner
Favorite
(P 43) SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
Andrew Wagner
Favorite
(P 44) TUMOR RESPONSE AND REGROWTH IN RELATION TO CLINICAL EVENTS AMONG PEXIDARTINIB-TREATED SUBJECTS IN THE PHASE 3 ENLIVEN TRIAL
Andrew Wagner
Favorite
(P 412) SARC044: A PHASE II TRIAL OF BEZUCLASTINIB IN COMBINATION WITH SUNITINIB IN PATIENTS WITH GIST WHO PROGRESSED ON SUNITINIB MONOTHERAPY
Andrew Wagner
Favorite
Wagner, Lars

Duke University
(P 309) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT SOFT TISSUE SARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Lars Wagner
Favorite
Wagner, Michael

Dana-Farber Cancer Institute
(P 202) IMPACT OF AFAMI-CEL ON THE HEALTH STATE OF PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR MYXOID/ROUND CELL LIPOSARCOMA: COHORT 1 OF SPEARHEAD-1
Michael Wagner
Favorite
(P 402) A PILOT STUDY OF BTX-A51 IN PATIENTS WITH METASTATIC AND/OR RECURRENT LIPOSARCOMAS CHARACTERIZED BY MDM2 AMPLIFICATIONS
Michael Wagner
Favorite
Wagrodzki, Michal

Maria Sklodowska-Curie National Research Institute of Oncology
(P 245) PRELIMINARY RESULTS FROM A PHASE 2 EFTISARC-NEO TRIAL OF NEOADJUVANT SOUBLE LAG-3 PROTEIN EFTILAGIMOD ALPHA, PEMBROLIZUMAB, AND CONCURRENT RADIOTHERAPY IN PATIENTS WITH RESECTABLE SOFT TISSUE SARCOMA
Michal Wagrodzki
Favorite
Wakamatsu, Toru

Osaka International Cancer Center
(P 05) DEVELOPMENT OF SARCOMA ORGANOID MODELS WITH AIR-LIQUID INTERFACE ORGANOID CULTURES
Toru Wakamatsu
Favorite
(P 96) TRACP-5B AS A BIOMARKER FOR LONG-TERM DENOSUMAB TREATMENT OF UNRESECTABLE GIANT CELL TUMOR OF BONE
Toru Wakamatsu
Favorite
(P 272) OUTCOMES OF FOUR CASES OF TOTAL HIP ARTHROPLASTY (THA) WITH POROUS TANTALUM IMPLANT AFTER PARTIAL ACETABULAR RESECTION USING 3D PREOPERATIVE PLANNING FOR PELVIC BONE TUMORS
Toru Wakamatsu
Favorite
Wakamatsu, Toru

Osaka International Cancer Institute
(P 283) USE OF MIXED REALITY IN PELVIC BONE TUMOR RESECTION: FIVE CASE STUDY
Toru Wakamatsu
Favorite
Wakamatsu, Toru

Osaka International Cancer Center
(P 387) SUCCESSFUL PAZOPANIB TREATMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA WITH COAMPLIFICATION OF PDGFRA, VEGFR2, AND KIT: A CASE REPORT
Toru Wakamatsu
Favorite
Wakeam, Elliot

Division of Thoracic Surgery, University of Toronto, Toronto General Hospital
(P 352) OUTCOMES OF PRIMARY INTRATHORACIC SOFT TISSUE SARCOMA
Elliot Wakeam
Favorite
Wakeman, Kristina

Oregon Health & Science University
(P 364) A PHASE 1B TRIAL OF PREOPERATIVE ERIBULIN AND RADIATION FOR RETROPERITONEAL LIPOSARCOMA
Kristina Wakeman
Favorite
Walker, Alexandra

Rush University Medical Center
(P 271) OUTCOMES OF DISTAL FEMORAL REPLACEMENT VS INTERNAL FIXATION FOR METASTATIC BONE DISEASE OF THE DISTAL FEMUR
Alexandra Walker
Favorite
Wallace, Asjah

Duke University
(P 15) HISTONE DEACETYLASE-3 PLAYS A ROLE IN THE METASTATIC POTENTIAL OF A SUBPOPULATION OF CELLS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Asjah Wallace
Favorite
Wallander, Karin

Karolinska Institutet
(P 26) SARCDBASE: A TOOL FOR DETECTION OF GENETIC ALTERATIONS IN SARCOMA
Karin Wallander
Favorite
Walsh, Kyle

Departments of Neurosurgery, Pediatrics, and Pathology, Duke SoM
(P 16) HOW TO GROW A BONE IN 60 DAYS: EXPLORING THE UNIQUE PRO-GROWTH, ANTI-CANCER ENVIRONMENT IN ELK ANTLERS
Kyle Walsh
Favorite
Walsh, Mark

Roswell Park Comprehensive Cancer Center
(P 35) EARLY REAL WORLD EXPERIENCE WITH NIROGACESTAT IN PATIENTS WITH DESMOID FIBROMATOSIS
Mark Walsh
Favorite
Walterhouse, David

Ann & Robert H. Lurie Children’s Hospital of Chicago
(P 315) SALVAGE THERAPY EFFICACY IS MODIFIED BY RISK GROUP AT DIAGNOSIS IN PATIENTS WITH RELAPSED RHABDOMYOSARCOMA
David Walterhouse
Favorite
Walter, Sebastian

University Hospital Cologne
(P 274) PROXIMAL HUMERAL ENDOPROSTHETIC RECONSTRUCTION: RESULTS FROM THE MUTARS ORTHOPEDIC REGISTRY EUROPE (MORE)
Sebastian Walter
Favorite
Walter, Stephanie

Seattle Children's Research Institute
(P 330) EFFICACY OF NON-CARDIOTOXIC ANTHRACYCLINES IN EWING SARCOMA
Stephanie Walter
Favorite
Wand, Ori

Pulmonology, Barzilai Medical Center, Ashkelon, Israel
(P 182) A NOVEL MODEL FOR THE DIRECT REFERRAL OF ONCOLOGIC PATIENTS IN A PUBLIC HEALTH CARE SYSTEM
Ori Wand
Favorite
Wang, Bo

Peking University International Hospital
(P 186) ANALYSIS OF FACTORS INFLUENCING POSTOPERATIVE VENOUS THROMBOEMBOLISM FORMATION IN PATIENTS WITH MASSIVE BLOOD LOSS DURING RETROPERITONEAL TUMOR RESECTION
Bo Wang
Favorite
Wang, Chao-Chi

Laboratory of Experimental Oncology, KU Leuven
(P 331) EFFICACY OF NOVEL UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN TARGETED ANTIBODY-DRUG CONJUGATES IN PATIENT-DERIVED XENOGRAFTS OF SOFT TISSUE SARCOMA
Chao-Chi Wang
Favorite
(P 334) EXPANDING THE LANDSCAPE OF PRECLINICAL MODELS OF SYNOVIAL SARCOMA: FROM 2-DIMENSIONS TO 3-DIMENSIONS TO MICE
Chao-Chi Wang
Favorite
(P 340) THE DNA MINOR GROOVE BINDING AGENTS ECUBECTEDIN AND PM54 DEMONSTRATE ANTITUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT MODELS OF SOFT TISSUE SARCOMA
Chao-Chi Wang
Favorite
Wang, Chia-Chun

National Taiwan University Cancer Center
(P 348) EVALUATING THE IMPACT OF BIOLOGICAL EFFECTIVE DOSE AND DELAYED RADIOTHERAPY ON THE SYNERGISTIC EFFICACY OF TRABECTEDIN IN METASTATIC SOFT TISSUE SARCOMA PATIENTS
Chia-Chun Wang
Favorite
Wang, Chongren

Shanghai General Hospital, School of Medicine Shanghai Jiao Tong University
(P 48) A SINGLE-ARM, OPEN-LABEL CLINICAL STUDY OF OVV-01 ONCOLYTIC VIRUS INJECTION AS MONOTHERAPY OR IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR ADVANCED SOLID TUMOR PATIENTS
Chongren Wang
Favorite
(P 90) TARGETING HIGH RISK MYC- AMPLIFIED OSTEOSARCOMA BY AURORA KINASE INHIBITOR--RESULT FROM A NGS BASED UMBRELLA TRIAL
Chongren Wang
Favorite
Wang, Gangyang

Department of Orthopaedics, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Bone Tumor Institution, Shanghai, China
(P 83) PREDICTION OF HIGH-RISK OSTEOSARCOMA PATIENTS BASED ON MACHINE LEARNING USING TRANSCRIPTOME AND METHYLATION DATA FROM SGH-COHORT
Gangyang Wang
Favorite
Wang, Guangfeng

Washington University in St. Louis School of Medicine
(P 145) EXPLORING L-TYPE AMINO ACID TRANSPORTER 1 (LAT1) AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)
Guangfeng Wang
Favorite
(P 335) FOCAL ADHESION KINASE (FAK) IS A THERPEUTIC TARGET IN CHROMOSOME 8 GAIN-ASSOCIATED MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)
Guangfeng Wang
Favorite
Wang, Hongsheng

Department of Orthopedic Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Bone Tumor Institution, Shanghai, China
(P 48) A SINGLE-ARM, OPEN-LABEL CLINICAL STUDY OF OVV-01 ONCOLYTIC VIRUS INJECTION AS MONOTHERAPY OR IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR ADVANCED SOLID TUMOR PATIENTS
Hongsheng Wang
Favorite
(P 90) TARGETING HIGH RISK MYC- AMPLIFIED OSTEOSARCOMA BY AURORA KINASE INHIBITOR--RESULT FROM A NGS BASED UMBRELLA TRIAL
Hongsheng Wang
Favorite
Wang, Jichuan

Peking University People's Hospital
(P 59) COMPREHENSIVE SINGLE CELL TRANSCRIPTOMICS ANALYSIS OF MURINE OSTEOSARCOMA UNCOVERS SKP2 FUNCTION IN METASTASIS, GENOMIC INSTABILITY AND IMMUNE ACTIVATION AND REALS ADDITIONAL TARGET PATHWAYS
Jichuan Wang
Favorite
Wang, Jiefei

University of Pittsburgh
(P 117) THE TUMOR IMMUNE MICROENVIRONMENT OF DEDIFFERENTIATED SARCOMAS: DIGITAL SPATIAL PROFILING SHOWS IMMUNE TRANSCRIPTIONAL DIFFERENCES BETWEEN DEDIFFERENTIATED LIPOSARCOMA AND CHONDROSARCOMA
Jiefei Wang
Favorite
Wang, Jiping

Brigham and Women's Hospital
(P 167) DEFINING TEXTBOOK OUTCOMES FOR MINIMALLY INVASIVE SURGICAL RESECTION OF SMALL GASTROINTESTINAL STROMAL TUMORS (GIST) OF THE STOMACH
Jiping Wang
Favorite
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Jiping Wang
Favorite
Wang, John

Northwestern University, Feinberg School of Medicine, Department of Medicine, Division of Oncology
(P 179) PRIMARY MANAGEMENT OF LOCALIZED GASTROINTESTINAL STROMAL TUMORS WITH IMATINIB MONOTHERAPY: AN ALTERNATIVE TO RESECTION FOR PATIENTS PRECLUDED FROM SURGERY
John Wang
Favorite
(P 222) ANALYSIS OF THE CITN-13 SARCOMA ARM: PEMBROLIZUMAB AND INTERFERON GAMMA FOR SYNOVIAL SARCOMA AND MYXOID/ ROUND CELL LIPOSARCOMA
John Wang
Favorite
Wang, Lucy

Vanderbilt University Medical Center
(P 199) FINANCIAL TOXICITY AMONG SARCOMA PATIENTS AND ASSOCIATED FACTORS
Lucy Wang
Favorite
(P 297) ESTABLISHING A PEDIATRIC, ADOLESCENT AND YOUNG ADULT COHORT OF SARCOMA PATIENTS TO STUDY ONCOLOGIC AND NON-ONCOLOGIC OUTCOMES
Lucy Wang
Favorite
Wang, Nuoya

Yale School of Medicine
(P 88) SPATIAL TRANSCRIPTOMICS OF EWING SARCOMA: EVOLUTION OF TUMOR MICROENVIRONMENT ASSOCIATED EXTRACELLULAR MATRIX FROM LOCALIZED TO METASTASIS-ASSOCIATED PRIMARY TUMORS
Nuoya Wang
Favorite
Wang, PengFei

Department of Gastrointestinal Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
(P 164) CLINICAL BENEFITS OF RIPRETINIB AND CYTOREDUCTIVE SURGERY IN IMATINIB-RESISTANT ADVANCED GASTROINTESTINAL STROMAL TUMORS (GISTS): A RETROSPECTIVE DUAL-CENTER STUDY
PengFei Wang
Favorite
Wang, Yufei

The Ohio State University James Comprehensive Cancer Center
(P 244) PREDICTIVE VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO IN IMMUNOTHERAPY OUTCOMES IN ADVANCED SARCOMA
Yufei Wang
Favorite
Wang, Zhi-Ming

Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
(P 416) TRIPLR COMNINATION THERAPY IN THE FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA WITH HIGH TUMOR BURDEN: INTERIM ANALYSIS FROM ALTER-S007 STUDY
Zhi-Ming Wang
Favorite
Wang, Zongyi

Department of Orthopedic Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Bone Tumor Institution, Shanghai, China
(P 48) A SINGLE-ARM, OPEN-LABEL CLINICAL STUDY OF OVV-01 ONCOLYTIC VIRUS INJECTION AS MONOTHERAPY OR IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR ADVANCED SOLID TUMOR PATIENTS
Zongyi Wang
Favorite
Wani, Khalida

The University of Texas MD Anderson Cancer Center
(P 398) PREDICTORS OF EFFICACY IN PATIENTS WITH SOFT TISSUE SARCOMAS TREATED WITH PAZOPANIB
Khalida Wani
Favorite
Wan, Xinyi

Erasmus Medical Center
(P 154) PREOPERATIVE CLASSIFICATION OF NERVE SHEATH TUMORS USING RADIOMICS-BASED MACHINE LEARNING
Xinyi Wan
Favorite
Warmke, Laura

Indiana University School of Medicine
(P 384) REAL WORLD EXPERIENCE IN TREATING HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA: AN ULTRA-RARE VASCULAR TUMOR
Laura Warmke
Favorite
Warren, Mikako

Children's Hospital Los Angeles
(P 88) SPATIAL TRANSCRIPTOMICS OF EWING SARCOMA: EVOLUTION OF TUMOR MICROENVIRONMENT ASSOCIATED EXTRACELLULAR MATRIX FROM LOCALIZED TO METASTASIS-ASSOCIATED PRIMARY TUMORS
Mikako Warren
Favorite
Warrier, Akshaya

University of Iowa
(P 12) GENETIC LANDSCAPE OF MPNST DETERMINES METABOLIC STRATEGIES AND THERAPEUTIC OPPORTUNITIES FOR COPING WITH REDOX STRESS
Akshaya Warrier
Favorite
watanabe, Makiyo

Musculoskeletal Oncology Service, Osaka International Cancer Institute
(P 387) SUCCESSFUL PAZOPANIB TREATMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA WITH COAMPLIFICATION OF PDGFRA, VEGFR2, AND KIT: A CASE REPORT
Makiyo watanabe
Favorite
Watson, Geoffrey

Department of Medical Oncology - Mount Sinai Hospital; University of Toronto
(P 293) CIC-REARRANGED SOFT TISSUE SARCOMAS: DOES CHEMOTHERAPY CHANGE NATURAL HISTORY AND PROGNOSIS? A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Geoffrey Watson
Favorite
Watson, Sarah

Curie
(P 125) CHARACTERISTICS, MANAGEMENT AND SURVIVAL OF N=7314 LIPOSARCOMAS FROM THE NATIONWIDE NETSARC REGISTRY IN FRANCE SINCE 2010
Sarah Watson
Favorite
Wattakiyanon, Nattinee

Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada
(P 352) OUTCOMES OF PRIMARY INTRATHORACIC SOFT TISSUE SARCOMA
Nattinee Wattakiyanon
Favorite
Wayne, Jeffrey

Northwestern University, Feinberg School of Medicine, Department of Surgery, Division of Surgical Oncology
(P 179) PRIMARY MANAGEMENT OF LOCALIZED GASTROINTESTINAL STROMAL TUMORS WITH IMATINIB MONOTHERAPY: AN ALTERNATIVE TO RESECTION FOR PATIENTS PRECLUDED FROM SURGERY
Jeffrey Wayne
Favorite
Weber, Lily

Dana-Farber Cancer Institute
(P 195) ENHANCING PARTICIPANT ENGAGEMENT IN A NOVEL PATIENT-PARTNERED CANCER GENOMICS RESEARCH EFFORT FOR RARE AND AGGRESSIVE SARCOMAS
Lily Weber
Favorite
Wedekind, Mary Frances

Center for Cancer Research/National Cancer Institute
(P 163) CHARACTERIZATION OF INTRAHEPATIC RECURRENCE FOLLOWING LIVER-DIRECTED SURGERY IN PATIENTS WITH METASTATIC SDH-DEFICIENT GASTROINTESTINAL STROMAL TUMOR (GIST): RISE AND STABILIZATION OF THE GISTLETS
Mary Frances Wedekind
Favorite
(P 315) SALVAGE THERAPY EFFICACY IS MODIFIED BY RISK GROUP AT DIAGNOSIS IN PATIENTS WITH RELAPSED RHABDOMYOSARCOMA
Mary Frances Wedekind
Favorite
Weerapana, Eranthie

Boston College
(P 21) LSD1 INHIBITOR SP-2509 DISRUPTS IRON-SULFUR CLUSTER BIOGENESIS
Eranthie Weerapana
Favorite
Weingertner, Noelle

University Hospital of Strasbourg
(P 89) TARGETED THERAPY OF MET, TYROSINE KINASE RECEPTOR, IN PEDIATRIC HIGH-GRADE OSTEOSARCOMAS : A NEW WAY TO TREAT PATIENTS ?
Noelle Weingertner
Favorite
(P 426) GD2 HETEROGENEIC EXPRESSION IN OSTEOSARCOMAS AND EWING SARCOMAS UNDERLYING A WORST PROGNOSIS
Noelle Weingertner
Favorite
Wei, Ran

Peking University People's Hospital
(P 276) RECONSTRUCTION WITH TOTAL SCAPULAR REVERSE TOTAL SHOULDER ENDOPROSTHESIS: PRELIMINARY RESULTS FROM A SINGLE INSTITUTE
Ran Wei
Favorite
Weisberg, Jake
(P 359) RAPIDLY PROGRESSIVE, NON-METASTATIC, CUTANEOUS ANGIOSARCOMA OF FACE AND SCALP TREATED WITH HYPOFRACTIONATED RADIATION THERAPY: A CASE SERIES
Jake Weisberg
Favorite
Weiss, Kurt

University of Pittsburgh Medical Center
(P 51) ASSESSING THE IN VIRTO EFFICACY OF DISULFIRAM AND ENZALUTAMIDE COMBINATION THERAPY IN METASTATIC OSTEOSARCOMA
Kurt Weiss
Favorite
(P 117) THE TUMOR IMMUNE MICROENVIRONMENT OF DEDIFFERENTIATED SARCOMAS: DIGITAL SPATIAL PROFILING SHOWS IMMUNE TRANSCRIPTIONAL DIFFERENCES BETWEEN DEDIFFERENTIATED LIPOSARCOMA AND CHONDROSARCOMA
Kurt Weiss
Favorite
Weiss, Kurt

UPMC Department of Orthopaedic Surgery and UPMC Hillman Cancer Center
(P 240) INVESTIGATING MACROPHAGE POPULATION VARIABILITY IN METASTATIC SARCOMA SAMPLES
Kurt Weiss
Favorite
Weiss, Kurt

University of Pittsburgh Medical Center
(P 256) CHARACTERIZING ORTHOPAEDIC ONCOLOGIC POLYTRAUMAS: A COMPARISON OF PATIENTS UNDERGOING OPERATIVE FIXATION OF MULTIPLE LESIONS WITH THOSE WITH SOLITARY LESIONS
Kurt Weiss
Favorite
(P 258) COMPARING OUTCOMES FOLLOWING INTRALESIONAL VERSUS WIDE RESECTION PROCEDURES IN THE TREATMENT OF RENAL CELL CARCINOMA BONE METASTASES
Kurt Weiss
Favorite
(P 353) PREDICTING WOUND COMPLICATIONS FOLLOWING SOFT-TISSUE SARCOMA RESECTION AMONG PATIENTS WHO RECEIVED PRE-OPERATIVE RADIATION
Kurt Weiss
Favorite
Weiss, Mia

Washington University School of Medicine
(P 81) OUTCOMES DATA FOR OSTEOSARCOMA PATIENTS OVER AGE 60
Mia Weiss
Favorite
Weistuch, Corey

Memorial Sloan Kettering Cancer Center
(P 129) ELUCIDATING THE EVOLUTIONARY DYNAMICS OF DDLS LIPOSARCOMA USING SINGLE-CELL SEQUENCING AND MATHEMATICAL LINEAGE TRACING
Corey Weistuch
Favorite
Welsh, Liam

The Royal Marsden Hospital
(P 183) A RETROSPECTIVE STUDY OF THE EFFECTS OF PATIENT, DISEASE, AND TREATMENT FACTORS ON SURVIVAL OUTCOMES IN PATIENTS WITH SOFT TISSUE SARCOMA BRAIN METASTASES
Liam Welsh
Favorite
Wendler, Jason

Seattle Children's Research Institute
(P 226) EARLY EXPERIENCE ON ENLIGHTEN-01: A PHASE 1 STUDY OF BISPECIFIC ADAPTER MOLECULE- CONTROLLED FOLATE RECEPTOR CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY OSTEOSARCOMA
Jason Wendler
Favorite
Werenski, Joseph

Massachusetts General Hospital
(P 63) DOES TUMOR NECROSIS IMPACT PROGNOSIS IN CHONDROBLASTIC AND OSTEOBLASTIC OSTEOSARCOMA? A STUDY FROM A LARGE TERTIARY CARE ACADEMIC CENTER
Joseph Werenski
Favorite
(P 284) WOUND VAC TEMPORIZATION AFTER TUMOR RESECTION OF SOFT TISSUE SARCOMAS - A COST ANALYSIS IN A PROPENSITY-SCORE MATCHED POPULATION
Joseph Werenski
Favorite
Werier, Joel

The Ottawa Hospital
(P 153) PATTERNS, MANAGEMENT AND SURVIVAL OUTCOMES OF PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA: A NATIONWIDE ANALYSIS FROM THE CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION DATABASE
Joel Werier
Favorite
wesseling, Frederik

Maastricht University Medical Center
(P 361) WOUND COMPLICATIONS AFTER SOFT TISSUE SARCOMA RESECTION: A SINGLE-CENTER RETROSPECTIVE ANALYSIS
Frederik wesseling
Favorite
Westerlind, Andreas

University of Gothenburg/Institute of Clinical Sciences
(P 20) LEIOMYOSARCOMA OF THE THORACIC AORTA - A RARE CASE REPORT
Andreas Westerlind
Favorite
Westermann, Anneke

Amsterdam University Medical Center
(P 42) RANKL-INHIBITION FOR GIANT CELL LESIONS OF THE JAW: A RETROSPECTIVE COHORT ANALYSIS
Anneke Westermann
Favorite
White, Bradley

Surgery Branch, NCI, NIH
(P 231) IDENTIFICATION OF NEOANTIGEN FROM PECOMA-LIKE NEOPLASM PROVIDES RATIONALE FOR TREATMENT WITH CELLULAR THERAPY
Bradley White
Favorite
White, Deandre

Moffitt Cancer Center
(P 237) INTRALESIONAL ADMINISTRATION OF TALIMOGENE LAHERPAREPVEC (T-VEC) INDUCES TUMOR REGRESSION IN PATIENTS WITH CUTANEOUS ANGIOSARCOMA
Deandre White
Favorite
White, Thomas

Mayo Clinic
(P 200) FRAILTY ASSESSMENT IN OLDER PATIENTS RECEIVING SARCOMA THERAPY
Thomas White
Favorite
Whittle, Sarah

Texas Children's Cancer Center, Baylor College of Medicine
(P 49) A WORKING GROUP FOR THE DEVELOPMENT OF A CLINICAL FRAMEWORK THAT STRATIFIES OSTEOSARCOMA PATIENTS USING BIOMARKERS OF CLINICAL RISK AND BIOLOGY
Sarah Whittle
Favorite
Wieder, Eric

University of Miami School of Medicine
(P 434) UTILIZATION OF IMAGING MASS CYTOMETRY TO EVALUATE THE IMMUNE LANDSCAPE OF PEDIATRIC AND ADULT PATIENTS WITH SARCOMA TREATED WITH AN AUTOLOGOUS DENDRITIC CELL VACCINE
Eric Wieder
Favorite
Wiemer, Erik

Erasmus Medical Center
(P 09) FERROPTOSIS INDUCTION: A BIOCHEMICAL VULNERABILITY OF SOFT TISSUE SARCOMAS
Erik Wiemer
Favorite
Wilkins, A. Katharina

Metrum Research Group
(P 116) QUANTITATIVE SYSTEMS PHARMACOLOGY MODELING OF MIPASETAMAB UZOPTERINE INTEGRATES KNOWLEDGE AND DEFINES DOSING STRATEGY FOR PATIENTS WITH SARCOMA
A. Katharina Wilkins
Favorite
Wilkinson, Michelle Jennifer

The Royal Marsden Hospital
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Michelle Jennifer Wilkinson
Favorite
Wilkowski, Jodi

University of Michigan
(P 131) HETEROGENEITY OF THE IMMUNE MICROENVIRONMENT AND IMMUNOTHERAPY RESPONSE IN A DEDIFFERENTIATED LIPOSARCOMA MOUSE MODEL
Jodi Wilkowski
Favorite
(P 341) THE EFFECTS OF ULTRASOUND-GUIDED HISTOTRIPSY ON SOFT TISSUE SARCOMA
Jodi Wilkowski
Favorite
Wilky, Breelyn

University of Colorado Cancer Center
(P 43) SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
Breelyn Wilky
Favorite
Wilky, Breelyn

University of Colorado School of Medicine
(P 94) THE ROLE OF CMYC AMPLIFICATION VERSUS CMYC PROTEIN EXPRESSION AS A PROGNOSTIC BIOMARKER IN OSTEOSARCOMA
Breelyn Wilky
Favorite
(P 434) UTILIZATION OF IMAGING MASS CYTOMETRY TO EVALUATE THE IMMUNE LANDSCAPE OF PEDIATRIC AND ADULT PATIENTS WITH SARCOMA TREATED WITH AN AUTOLOGOUS DENDRITIC CELL VACCINE
Breelyn Wilky
Favorite
William, Jerry

Yale University
(P 98) A MULTIEPITOPE MRNA VACCINE FOR KAPOSI SARCOMA: AN IMMUNOINFORMATIC APPROACH
Jerry William
Favorite
Williams, Ashley

Roswell Park Comprehensive Cancer Center
(P 35) EARLY REAL WORLD EXPERIENCE WITH NIROGACESTAT IN PATIENTS WITH DESMOID FIBROMATOSIS
Ashley Williams
Favorite
Williams, Caroline

University College London Hospital
(P 185) ADDRESSING THE GAP FOR SYMPTOM CONTROL THROUGH THE IMPLEMENTATION OF ENHANCED SUPPORTIVE CARE AT THE LONDON SARCOMA SERVICE
Caroline Williams
Favorite
Williams, Dennis

Adaptimmune
(P 202) IMPACT OF AFAMI-CEL ON THE HEALTH STATE OF PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR MYXOID/ROUND CELL LIPOSARCOMA: COHORT 1 OF SPEARHEAD-1
Dennis Williams
Favorite
Williams, Megan

University of Toronto
(P 159) USING THE TRANSCRIPTIONAL SPECTRUM OF UTERINE SMOOTH MUSCLE TUMORS TO IDENTIFY PROGNOSTIC SIGNATURES FOR ABNORMAL LEIOMYOMAS AND SMOOTH MUSCLE TUMOURS OF UNCERTAIN MALIGNANT POTENTIAL
Megan Williams
Favorite
Wilson-Robles, Heather

Ethos Discovery
(P 115) PROSPECTIVE EVALUATION OF THORACOSCOPIC METASTASECTOMY IN DOGS: A NOVEL TRANSLATIONAL DRUG DEVELOPMENT PIPELINE TAGETING METASTATIC OSTEOSARCOMA
Heather Wilson-Robles
Favorite
Wilson, Roger

Founder - Sarcoma UK
(P 201) GLOBAL CROSS-SECTIONAL SURVEY ON SARCOMA DIAGNOSIS PATHWAY: A CURRENT STATE ANALYSIS
Roger Wilson
Favorite
Wiltink, L.M.

Leiden University Medical Center
(P 349) LONG-TERM SURVIVAL OF PARTICIPANTS IN THE PASART-1 AND PASART-2 TRIALS OF NEO-ADJUVANT PAZOPANIB AND RADIOTHERAPY IN SOFT TISSUE SARCOMA
L.M. Wiltink
Favorite
Windsor, Rachael

UCLH
(P 146) EXPLORING THE CLINICAL UTILITY OF WHOLE GENOME SEQUENCING FOR PAEDIATRIC, TYA AND ADULT SARCOMA PATIENTS WITHIN THE LONDON SARCOMA SERVICE: A RETROSPECTIVE COHORT ANALYSIS
Rachael Windsor
Favorite
Witjes, Max

University Medical Center Groningen
(P 42) RANKL-INHIBITION FOR GIANT CELL LESIONS OF THE JAW: A RETROSPECTIVE COHORT ANALYSIS
Max Witjes
Favorite
Wittig, James

Atlantic Health System
(P 255) CAN LARGE, LIPOMATOUS LESIONS ADJACENT TO THE SUPINATOR MUSCLE BE REMOVED WITHOUT INJURING THE POSTERIOR INTEROSSEOUS NERVE? A RETROSPECTIVE REVIEW
James Wittig
Favorite
(P 260) EMERGING TECHNOLOGY IN ORTHOPEDIC ONCOLOGY: ROBOTIC ARM-ASSISTED TOTAL KNEE ARTHROPLASTY HAS EXCEPTIONAL FUNCTION OUTCOMES FOR PATIENTS WITH BENIGN AND MALIGNANT MUSCULOSKELETAL DISEASE
James Wittig
Favorite
(P 266) LONG STEM CEMENTED ROBTIC ARM-ASSISTED TOTAL HIP ARTHROPLASTY: OUTCOMES IN PATIENTS WITH PRIOR ONCOLOGIC DISEASE
James Wittig
Favorite
(P 277) REVERSE TOTAL SHOULDER ARTHROPLASTY MAINTAINS GLOBAL FUNCTION OF THE UPPER EXTREMITY IN PATIENTS WITH ONCOLOGIC DISEASE OF THE PROXIMAL HUMERUS
James Wittig
Favorite
(P 405) LIPOSOMAL BUPIVACAINE DOESN'T REDUCE NARCOTIC USE OR PAIN SCORES COMPARED TO A MULTIDRUG COCKTAIL FOLLOWING SOFT TISSUE TUMOR REMOVAL: PRELIM RESULTS OF A PROSPECTIVE, RANDOMIZED DOUBLE-BLINDED STUDY
James Wittig
Favorite
Wittmann Dayagi, Talya

The Hospital for Sick Children
(P 293) CIC-REARRANGED SOFT TISSUE SARCOMAS: DOES CHEMOTHERAPY CHANGE NATURAL HISTORY AND PROGNOSIS? A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Talya Wittmann Dayagi
Favorite
Wong, Anisia

HOPE Research Centre
(P 135) SURVIVAL OUTCOMES AND TREATMENT PATTERNS FOR PATIENTS WITH DEDIFFERENTIATED LIPOSARCOMA: A RETROSPECTIVE COHORT STUDY IN ONTARIO, CANADA
Anisia Wong
Favorite
Wong, Chao-Jen

Seattle Children's Research Institute
(P 330) EFFICACY OF NON-CARDIOTOXIC ANTHRACYCLINES IN EWING SARCOMA
Chao-Jen Wong
Favorite
Wong, Jolene

Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore
(P 370) DEFYING NORMS - CENTRALIZATION OF SARCOMA CARE ON AN ISLAND NATION
Jolene Wong
Favorite
(P 375) FROM SAPLING TO SHADE: GROWTH OF A HIGH VOLUME ASIAN TERTIARY SARCOMA SPECIALISED CENTRE
Jolene Wong
Favorite
Wong, Philip

Department of Radiation Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada; University of Toronto, Toronto, Canada
(P 326) CELL-FREE DNA AS A BIOMARKER FOR CELL DEATH AND TREATMENT RESPONSE IN ON-CHIP THREE-DIMENSIONAL SARCOMA TUMOR MODELS
Philip Wong
Favorite
Wong, Philip

Princess Margaret Cancer Centre
(P 352) OUTCOMES OF PRIMARY INTRATHORACIC SOFT TISSUE SARCOMA
Philip Wong
Favorite
Wooddell, Margaret

Daiichi Sankyo, Inc.
(P 37) HEALTH-RELATED QUALITY OF LIFE FROM A PHASE 4 STUDY TO EVALUATE DISCONTINUATION AND RECHALLENGE OF PEXIDARTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR PREVIOUSLY TREATED WITH PEXIDARTINIB
Margaret Wooddell
Favorite
(P 44) TUMOR RESPONSE AND REGROWTH IN RELATION TO CLINICAL EVENTS AMONG PEXIDARTINIB-TREATED SUBJECTS IN THE PHASE 3 ENLIVEN TRIAL
Margaret Wooddell
Favorite
(P 400) A LONG-TERM PHASE 4 STUDY TO EVALUATE THE RISK OF HEPATOTOXICITY ASSOCIATED WITH PEXIDARTINIB TREATMENT
Margaret Wooddell
Favorite
Wood, Georgina

University College London Hospital
(P 146) EXPLORING THE CLINICAL UTILITY OF WHOLE GENOME SEQUENCING FOR PAEDIATRIC, TYA AND ADULT SARCOMA PATIENTS WITHIN THE LONDON SARCOMA SERVICE: A RETROSPECTIVE COHORT ANALYSIS
Georgina Wood
Favorite
Wood, Kris

Duke University School of Medicine
(P 301) GENOME-WIDE CRISPR/CAS9 VIABILITY SCREENS UNCOVER NOVEL GENETIC DEPENDENCIES IN CIC::DUX4 SARCOMA
Kris Wood
Favorite
Woods, Lennie

Clear Cell Sarcoma Foundation
(P 189) CLEAR CELL SARCOMA - REAL WORLD DATA ANALYSIS
Lennie Woods
Favorite
Woo, Jon

Memorial Sloan Kettering Cancer Center
(P 229) EXPRESSION OF TRANSPOSABLE ELEMENTS AND IKZF1 PREDICTS IMMUNE INFILTRATES IN SARCOMAS AND CORRELATES WITH OUTCOMES AFTER IMMUNE CHECKPOINT INHIBITION
Jon Woo
Favorite
Woolsey, Lauren

Sarcoma Oncology Center
(P 251) UPDATE ON SAINT: A PHASE 2 STUDY USING TRABECTEDIN (T) IN COMBINATION WITH IPILIMUMAB (L) AND NIVOLUMAB (N) IN PREVIOUSLY TREATED SOFT TISSUE SARCOMA (NCT03138161)
Lauren Woolsey
Favorite
Woudenberg, Renst

NKI
(P 28) THE INFLUENCE OF MARGINS ON OUTCOME IN CUTANEOUS LOCATED SOFT TISSUE SARCOMAS IN THE HEAD AND NECK
Renst Woudenberg
Favorite
Wozniak, Agnieszka

KU Leuven
(P 331) EFFICACY OF NOVEL UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN TARGETED ANTIBODY-DRUG CONJUGATES IN PATIENT-DERIVED XENOGRAFTS OF SOFT TISSUE SARCOMA
Agnieszka Wozniak
Favorite
(P 334) EXPANDING THE LANDSCAPE OF PRECLINICAL MODELS OF SYNOVIAL SARCOMA: FROM 2-DIMENSIONS TO 3-DIMENSIONS TO MICE
Agnieszka Wozniak
Favorite
(P 340) THE DNA MINOR GROOVE BINDING AGENTS ECUBECTEDIN AND PM54 DEMONSTRATE ANTITUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT MODELS OF SOFT TISSUE SARCOMA
Agnieszka Wozniak
Favorite
Wrenn, Emma

Seattle Children's Research Institute
(P 330) EFFICACY OF NON-CARDIOTOXIC ANTHRACYCLINES IN EWING SARCOMA
Emma Wrenn
Favorite
Wu, Di

The First Hospital of Jilin University
(P 119) UPDATED RESULTS OF A SINGLE-ARM,MULTI-CENTER STUDY OF ANLOTINIB COMBINED WITH TORIPALIMAB IN FIRST-LINE TREATMENT OF UNRESECTABLE OR METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Di Wu
Favorite
Wunder, Jay

University of Toronto
(P 71) LIMB-SALVAGE SURGERY AFTER UNPLANNED SURGERY FOR EXTREMITY BONE SARCOMAS: 30-YEAR EXPERIENCE AT A TERTIARY REFERRAL CENTER
Jay Wunder
Favorite
(P 225) DETERMINING THE CONTRIBUTIONS OF STAT1 AND THE Y701 PHOSPHORYLATION TO THE UPS ANTI-TUMOR MICROENVIRONMENT
Jay Wunder
Favorite
(P 238) INTRA-TUMORAL DC-LAMP EXPRESSION IS ASSOCIATED WITH PROGNOSIS IN SOFT TISSUE SARCOMA
Jay Wunder
Favorite
(P 281) THE UTILITY OF INTRAOPERATIVE MARROW MARGIN FROZEN SECTION IN EXTREMITY BONE SARCOMA RESECTION
Jay Wunder
Favorite
(P 352) OUTCOMES OF PRIMARY INTRATHORACIC SOFT TISSUE SARCOMA
Jay Wunder
Favorite
Wunker, Claire

University of Toronto
(P 329) DEVELOPING ARMS METASTATIC MODELS TO RECAPITULATE THE TUMOR MICROENVIRONMENTS OF THE AXILLA/LYMPH NODE AND LUNGS
Claire Wunker
Favorite
Wu, Qing

Research Institute of the McGill University Health Center
(P 69) H3.3G34W ONCOHISTONE IN OSTEOSARCOMA
Qing Wu
Favorite
Wyns, Karo

Laboratory of Experimental Oncology, KU Leuven, Leuven Cancer Institute
(P 331) EFFICACY OF NOVEL UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN TARGETED ANTIBODY-DRUG CONJUGATES IN PATIENT-DERIVED XENOGRAFTS OF SOFT TISSUE SARCOMA
Karo Wyns
Favorite
(P 334) EXPANDING THE LANDSCAPE OF PRECLINICAL MODELS OF SYNOVIAL SARCOMA: FROM 2-DIMENSIONS TO 3-DIMENSIONS TO MICE
Karo Wyns
Favorite
(P 340) THE DNA MINOR GROOVE BINDING AGENTS ECUBECTEDIN AND PM54 DEMONSTRATE ANTITUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT MODELS OF SOFT TISSUE SARCOMA
Karo Wyns
Favorite
Wytiaz, Victoria

University of Michigan, Department of Hematology/Oncology
(P 45) UTILIZATION OF MENTAL HEALTH AND SUPPORTIVE CARE RESOURCES AMONG PATIENTS WITH DESMOID TUMORS
Victoria Wytiaz
Favorite
(P 308) PALLIATIVE CARE INVOLVEMENT FOR ADOLESCENTS AND YOUNG ADULTS WITH BONE AND SOFT TISSUE SARCOMAS
Victoria Wytiaz
Favorite
Wytiaz, Victoria

University of Michigan
(P 423) COMPARISON OF CLINICAL COURSE AND FEATURES BETWEEN SCLEROSING EPITHELOID FIBROSARCOMA AND LOW-GRADE FIBROMYXOID SARCOMA
Victoria Wytiaz
Favorite
X
Xayasak, Vanessa

Sarcoma Oncology Center
(P 241) LINNOVATE: A PHASE 1/2 STUDY OF SAFETY/EFFICACY USING LURBINECTEDIN COMBINED WITH IPILUMUMAB AND NIVOLUMAB FOR ADVANCED SOFT TISSUE SARCOMA (NCT05876715)
Vanessa Xayasak
Favorite
Xie, Sophia

Peter MacCallum Cancer Centre
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Sophia Xie
Favorite
Xie, Xianbiao

Department of Musculoskeletal Oncology Center, The First Affiliated Hospital of Sun Yat-sen University
(P 407) LONG-TERM EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): PHASE 1B UPDATE.
Xianbiao Xie
Favorite
Xiong, Angela

Boston College
(P 21) LSD1 INHIBITOR SP-2509 DISRUPTS IRON-SULFUR CLUSTER BIOGENESIS
Angela Xiong
Favorite
Xu Welliver, Meng

Mayo Clinic
(P 190) CLINICAL FEATURES ASSOCIATED WITH DIFFERENT HISTOLOGICAL SUBTYPES OF SARCOMA: A POPULATION-BASED STUDY OF 97062 CASES
Meng Xu Welliver
Favorite
(P 210) RADIATION-ASSOCIATED ANGIOSARCOMA OF THE BREAST (RAASB): A NOMOGRAM FOR PREDICTING RECURRENCE AND PROGNOSIS
Meng Xu Welliver
Favorite
Xu, Bushu

Sun Yat-sen University Cancer Center
(P 409) PHASE 2 STUDY EVALUATING SURUFATINIB IN PATIENTS WITH OSTEOSARCOMA AND SOFT TISSUE SARCOMA WHO HAVE FAILED STANDARD CHEMOTHERAPY
Bushu Xu
Favorite
Xu, Hairong

Beijing Jishuitan Hospital, Capital Medical University
(P 407) LONG-TERM EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): PHASE 1B UPDATE.
Hairong Xu
Favorite
Xu, Hai-Rong

Beijing Jishuitan Hospital, Capital Medical University, Beijing, China
(P 132) PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND DISEASE BURDEN OF DEDIFFERENTIATED LIPOSARCOMA IN CHINA: A REAL-WORLD STUDY BASED ON NATIONAL CANCER REGISTRY
Hai-Rong Xu
Favorite
Xu, Menglin

The Ohio State University Comprehensive Cancer Center
(P 207) PATIENT-REPORTED GLOBAL HEALTH PREDICTS ADVERSE HEALTH OUTCOMES IN PATIENTS WITH ADVANCED SARCOMA
Menglin Xu
Favorite
Xu, Rui-Hua

Sun Yat-sen University Cancer Center
(P 393) EFFICACY AND SAFETY OF LAROTRECTINIB AS FIRST-LINE TREATMENT IN PATIENTS WITH TRK FUSION SARCOMAS
Rui-Hua Xu
Favorite
Xu, Ruiting

University of California Santa Cruz, Electrical and Computer Engineering, Genomics Institute
(P 147) INVESTIGATING THE POTENTIAL OF EXTRACELLULAR VESICLE BIOMARKERS IN SYNOVIAL SARCOMA DETECTION
Ruiting Xu
Favorite
Xu, Zhen

University of Michigan
(P 341) THE EFFECTS OF ULTRASOUND-GUIDED HISTOTRIPSY ON SOFT TISSUE SARCOMA
Zhen Xu
Favorite
Y
yagi, toshinari

Musculoskeletal Oncology Service, Osaka International Cancer Institute
(P 387) SUCCESSFUL PAZOPANIB TREATMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA WITH COAMPLIFICATION OF PDGFRA, VEGFR2, AND KIT: A CASE REPORT
toshinari yagi
Favorite
Yamada, Tesshi

Tokyo Medical University
(P 18) IMMUNOHISTOCHEMICAL ANALYSIS OF NUCLEAR β-CATENIN IN BONE AND SOFT TISSUE TUMOR MICROARRAYS
Tesshi Yamada
Favorite
Yamagata, Yukinori

Department of Gastoric Surgery, National Cancer Center Hospital, Tokyo, Japan
(P 134) REAL-WORLD CLINICAL OUTCOME OF NEOADJUVANT CHEMOTHERAPY FOR RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA
Yukinori Yamagata
Favorite
Yang, HsihTe

Levine Cancer Institute
(P 430) QUANTITATIVE EMT GENE SCORES AT DIAGNOSIS INDICATE METASTASIS RISK AND SURVIVAL IN SYNOVIAL SARCOMA
HsihTe Yang
Favorite
Yang, Kuangying

Washington University
(P 187) BRIDGING THE GAP: UNDERSTANDING THE CURRENT TREATMENT RESPONSES TO ENHANCE THE STANDARD OF CARE AND OUTCOMES FOR MALIGNANT PERIPHERAL NERVE SHEATH TUMORS
Kuangying Yang
Favorite
Yang, Litao

Department of Gastric surgery ，Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.
(P 164) CLINICAL BENEFITS OF RIPRETINIB AND CYTOREDUCTIVE SURGERY IN IMATINIB-RESISTANT ADVANCED GASTROINTESTINAL STROMAL TUMORS (GISTS): A RETROSPECTIVE DUAL-CENTER STUDY
Litao Yang
Favorite
Yang, liuzhan

Washington University in St. Louis School of Medicine
(P 335) FOCAL ADHESION KINASE (FAK) IS A THERPEUTIC TARGET IN CHROMOSOME 8 GAIN-ASSOCIATED MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)
liuzhan Yang
Favorite
Yang, Rui

Montefiore Einstein
(P 147) INVESTIGATING THE POTENTIAL OF EXTRACELLULAR VESICLE BIOMARKERS IN SYNOVIAL SARCOMA DETECTION
Rui Yang
Favorite
(P 156) PROFILING SYNOVIAL SARCOMA EXTRACELLULAR VESICLES FOR DIAGNOSTIC RNA BIOMARKERS
Rui Yang
Favorite
Yangua Paucar, Estefania Dennisse

Facultad Psicología. Universidad Complutense de Madrid
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Estefania Dennisse Yangua Paucar
Favorite
Yao, Lan

Department of Anesthesiology, Peking University International Hospital
(P 186) ANALYSIS OF FACTORS INFLUENCING POSTOPERATIVE VENOUS THROMBOEMBOLISM FORMATION IN PATIENTS WITH MASSIVE BLOOD LOSS DURING RETROPERITONEAL TUMOR RESECTION
Lan Yao
Favorite
(P 377) INCIDENCE, RISK FACTORS, AND EFFECT ON 60-DAYS SURVIVAL OF ACUTE KIDNEY INJURY OCCURRED WITHIN 7 DAYS AFTER SURGERY IN ELDERLY PATIENTS WITH RETROPERITONEALL TUMORS: A RETROSPECTIVE COHORT STUDY
Lan Yao
Favorite
(P 379) KEY POINTS OF ANESTHESIA MANAGEMENT AND PROGNOSIS ANALYSIS OF ELDERLY PATIENTS WITH RETROPERITONEAL TUMOR
Lan Yao
Favorite
Yao, Weitao

Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital
(P 407) LONG-TERM EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): PHASE 1B UPDATE.
Weitao Yao
Favorite
Yechieli, Raphael

Sylvester Comprehensive Cancer Center
(P 358) RADIOMIC EVALUATION OF MRIS IN PATIENTS WITH SOFT TISSUE SARCOMA TREATED WITH STEREOTACTIC BOSY RADIATION THERAPY
Raphael Yechieli
Favorite
(P 381) OLIGOMETASTATIC LEIOMYOSARCOMA: ASSOCIATION BETWEEN TREATMENT TYPE, METASTATIC PATTERN AND SURVIVAL
Raphael Yechieli
Favorite
Ye, Lylee

Chris O'Brien Lifehouse
(P 325) CAN PROTEOMICS PREDICT METASTATIC RELAPSE IN LEIOMYOSARCOMA? DEVELOPMENT OF AN 8 PROTEIN SIGNATURE IN A >350 SAMPLE STUDY INCLUDING A VALIDATION COHORT
Lylee Ye
Favorite
Ye, Xin

Daiichi Sankyo, Inc.
(P 211) REAL-WORLD EXPERIENCE OF PATIENTS NEWLY INITIATED ON PEXIDARTINIB FOR TENOSYNOVIAL GIANT CELL TUMOR
Xin Ye
Favorite
Ye, Zhaoming

Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University School of Medicine
(P 407) LONG-TERM EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): PHASE 1B UPDATE.
Zhaoming Ye
Favorite
Yin, Vivien

Moffitt Cancer Center
(P 309) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT SOFT TISSUE SARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Vivien Yin
Favorite
Yokoyama, Nobuhiko

Kyushu University
(P 203) IMPACT OF COVID-19 PANDEMIC ON BONE AND SOFT TISSUE SARCOMA PATIENTS' CONSULTATION AND DIAGNOSIS
Nobuhiko Yokoyama
Favorite
Yonemori, Kan

Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
(P 134) REAL-WORLD CLINICAL OUTCOME OF NEOADJUVANT CHEMOTHERAPY FOR RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA
Kan Yonemori
Favorite
Yonemoto, Tsukasa

Chiba Cancer Center
(P 220) SPORTS ACTIVITIES IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT SURVIVORS OF MALIGNANT BONE SARCOMAS
Tsukasa Yonemoto
Favorite
(P 275) RECONSTRUCTION WITH A BURCH-SCHNEIDER CAGE AFTER BONE AND SOFT TISSUUE TUMOR SURGERY
Tsukasa Yonemoto
Favorite
Yoshida, Akihiko

Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan
(P 134) REAL-WORLD CLINICAL OUTCOME OF NEOADJUVANT CHEMOTHERAPY FOR RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA
Akihiko Yoshida
Favorite
Yoshida, Ken-ichi

Department of Diagnostic Pathology and Cytology, Osaka International Cancer Institute
(P 387) SUCCESSFUL PAZOPANIB TREATMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA WITH COAMPLIFICATION OF PDGFRA, VEGFR2, AND KIT: A CASE REPORT
Ken-ichi Yoshida
Favorite
Yoshimoto, Masato

Kyushu Rosai Hospital
(P 203) IMPACT OF COVID-19 PANDEMIC ON BONE AND SOFT TISSUE SARCOMA PATIENTS' CONSULTATION AND DIAGNOSIS
Masato Yoshimoto
Favorite
Yoshitake, Ryohei

Okayama University of Science
(P 01) A PILOT STUDY ON SINGLE-NUCLEUS RNA SEQUENCING IN CANINE SOFT TISSUE SARCOMAS
Ryohei Yoshitake
Favorite
Yosibash, Zohar

Tel Aviv University
(P 350) MONITORING CHANGES IN FEMORAL BONE STRENGTH IN PATIENTS WITH METASTATIC BONE DISEASE TREATED WITH RADIATION THERAPY
Zohar Yosibash
Favorite
You, Daoqi

Memorial Sloan Kettering Cancer Center
(P 292) CHARACTERIZATION OF TELOMERE MAINTENANCE MECHANISMS IN OSTEOSARCOMA PATIENT-DERIVED LABORATORY MODELS
Daoqi You
Favorite
(P 338) PRECLINICAL EFFICACY OF DAN-222, A NOVEL POLYMERIC NANOPARTICLE, IN PEDIATRIC SOLID TUMOR MODELS
Daoqi You
Favorite
(P 418) A SYSTEMS BIOLOGY APPROACH FOR CHARACTERIZING TUMOR HETEROGENEITY AND CELL STATE-SPECIFIC THERAPEUTIC VULNERABILITIES FROM SINGLE NUCLEUS RNA-SEQ PROFILING OF DESMOPLASTIC SMALL ROUND CELL TUMORS
Daoqi You
Favorite
Youk, Jeonghwan

Seoul National University Hospital
(P 428) OLIGOMETASTASES IN EXTREMITY SOFT TISSUE SARCOMA : SUBTYPE-SPECIFIC ANALYSES OF CHARACTERISTICS AND OUTCOMES
Jeonghwan Youk
Favorite
Youngblood, Benjamin

St. Jude Children's Research Hospital
(P 288) ANGIOA: A SAFETY AND TOLERABILITY STUDY OF TRIPLE ANTI-ANGIOGENIC THERAPY COMBINED WITH PD-L1 BLOCKADE IN PEDIATRIC, ADOLESCENT AND YOUNG ADULT RECURRENT/REFRACTORY SOLID TUMORS
Benjamin Youngblood
Favorite
You, Yang

Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
(P 416) TRIPLR COMNINATION THERAPY IN THE FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA WITH HIGH TUMOR BURDEN: INTERIM ANALYSIS FROM ALTER-S007 STUDY
Yang You
Favorite
Yuan, Ting

Department of Orthopedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital
(P 407) LONG-TERM EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): PHASE 1B UPDATE.
Ting Yuan
Favorite
Yu, Austin

Rush University Medical Center
(P 31) CLINICAL CHALLENGES AND EVOLVING TREATMENT STRATEGIES IN DESMOID FIBROMATOSIS: A SINGLE INSTITUTION EXPERIENCE
Austin Yu
Favorite
(P 80) OUTCOMES AND MANAGEMENT OF POSITIVE MARGINS IN CHONDROSARCOMA WITH SOFT TISSUE EXTENSION: A CASE SERIES AND REVIEW OF LITERATURE
Austin Yu
Favorite
(P 92) THE IMPACT OF CHONDROSARCOMA WITH POSITIVE MARGINS AND EXTRAOSSEOUS EXTENSION ON PATIENT OUTCOMES
Austin Yu
Favorite
(P 126) CHARACTERIZING THE TRANSFORMATION AND DIAGNOSIS OF ATYPICAL LIPOMATOUS TUMOR OF THE EXTREMITIES TO DEDIFFERENTIATED LIPOSARCOMA: SINGLE INSTITUTIONAL OUTCOMES
Austin Yu
Favorite
(P 270) OPIOID USE IN IMPENDING VERSUS PATHOLOGIC PROXIMAL FEMUR FRACTURES
Austin Yu
Favorite
(P 271) OUTCOMES OF DISTAL FEMORAL REPLACEMENT VS INTERNAL FIXATION FOR METASTATIC BONE DISEASE OF THE DISTAL FEMUR
Austin Yu
Favorite
Yu, Hua

Beckman Research Institute at City of Hope Cancer Center
(P 07) DIRECTLY TARGETING CIC-DUX4 FUSION AND MYC ONCOPROTEINS FOR UNDIFFERENTIATED ROUND CELL SARCOMAS
Hua Yu
Favorite
Yu, Jamie S. E.

The University of British Columbia
(P 343) TLE1 DISRUPTION DOES NOT IMPEDE SYNOVIAL SARCOMAGENESIS
Jamie S. E. Yu
Favorite
Yule, Murray

Adaptimmune
(P 202) IMPACT OF AFAMI-CEL ON THE HEALTH STATE OF PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR MYXOID/ROUND CELL LIPOSARCOMA: COHORT 1 OF SPEARHEAD-1
Murray Yule
Favorite
Yule, Steven

iOmx AG
(P 337) OMX-0407 A NOVEL SPECTRUM-SELECTIVE SMALL MOLECULE KINASE INHIBITOR IS ACTIVE IN THE TREATMENT OF ANGIOSARCOMA
Steven Yule
Favorite
Yu, Shiying

Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology
(P 409) PHASE 2 STUDY EVALUATING SURUFATINIB IN PATIENTS WITH OSTEOSARCOMA AND SOFT TISSUE SARCOMA WHO HAVE FAILED STANDARD CHEMOTHERAPY
Shiying Yu
Favorite
Yusuf, Mehran

University of Alabama
(P 246) THE GENOMIC AND IMMUNE LANDSCAPE OF LIPOSARCOMA AND ITS SUBTYPES
Mehran Yusuf
Favorite
Yu, Yiyang

Peking University People's Hospital
(P 276) RECONSTRUCTION WITH TOTAL SCAPULAR REVERSE TOTAL SHOULDER ENDOPROSTHESIS: PRELIMINARY RESULTS FROM A SINGLE INSTITUTE
Yiyang Yu
Favorite
Z
Zaborowski, Konrad

Maria Sklodowska-Curie National Research Institute of Oncology
(P 245) PRELIMINARY RESULTS FROM A PHASE 2 EFTISARC-NEO TRIAL OF NEOADJUVANT SOUBLE LAG-3 PROTEIN EFTILAGIMOD ALPHA, PEMBROLIZUMAB, AND CONCURRENT RADIOTHERAPY IN PATIENTS WITH RESECTABLE SOFT TISSUE SARCOMA
Konrad Zaborowski
Favorite
Zaffaroni, Nadia

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 137) TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS
Nadia Zaffaroni
Favorite
Zah, Vladimir

ZRx Outcomes Research Inc.
(P 55) CHONDROSARCOMA PATIENT CHARACTERISTICS AND DIAGNOSTIC AND TREATMENT PATHWAYS: GLOBAL CHONDROSARCOMA PATIENT REGISTRY
Vladimir Zah
Favorite
Zaidi, Shane

The Royal Marsden Hospital
(P 183) A RETROSPECTIVE STUDY OF THE EFFECTS OF PATIENT, DISEASE, AND TREATMENT FACTORS ON SURVIVAL OUTCOMES IN PATIENTS WITH SOFT TISSUE SARCOMA BRAIN METASTASES
Shane Zaidi
Favorite
Zając, Agnieszka

Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
(P 77) MULTI-PARAMETRICAL PROFILING OF CHONDROSARCOMA
Agnieszka Zając
Favorite
Zalcberg, John

School of Public Health, Faculty of Medicine, Monash University
(P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE
John Zalcberg
Favorite
zama, mario

BAMBINO GESU CHILDREN HOSPITAL
(P 298) EWING SARCOMA OF MAXILLOFACIAL REGION AND SKULL: A RETROSPECTIVE MONOINSTITUTIONAL PEDIATRIC SERIES
mario zama
Favorite
Zang, Jie

Peking University People's Hospital
(P 276) RECONSTRUCTION WITH TOTAL SCAPULAR REVERSE TOTAL SHOULDER ENDOPROSTHESIS: PRELIMINARY RESULTS FROM A SINGLE INSTITUTE
Jie Zang
Favorite
Zan, Pengfei

Department of Orthopedic Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Bone Tumor Institution, Shanghai, China
(P 48) A SINGLE-ARM, OPEN-LABEL CLINICAL STUDY OF OVV-01 ONCOLYTIC VIRUS INJECTION AS MONOTHERAPY OR IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR ADVANCED SOLID TUMOR PATIENTS
Pengfei Zan
Favorite
Zapardiel, Ignazio

La Par University Hospital, Madrid
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Ignazio Zapardiel
Favorite
Zapata, Maycos

LACOG
(P 217) SARCOMA DRUG APPROVALS IN LATIN AMERICA COMPARED TO THE FDA AND EMA: AN ANALYSIS BY THE LACOG SARCOMA GROUP
Maycos Zapata
Favorite
Zarifa, Abdulrazzak

Endeavor Health
(P 247) THE REAL-WORLD EFFICACY OF IMMUNE CHECKPOINT INHIBITORS WITH CONCURRENT RADIATION OR SURGERY IN MULTIMODAL TREATMENT OF SOFT TISSUE SARCOMAS: A RETROSPECTIVE STUDY
Abdulrazzak Zarifa
Favorite
Zarzour, Alex

The University of Texas MD Anderson Cancer Center
(P 233) IMMUNE CLASSES OF LEIOMYOSARCOMA DRIVEN BY B CELL INFILTRATE AND CTLA4 EXPRESSION
Alex Zarzour
Favorite
Zdzienicki, Marcin

Maria Sklodowska-Curie National Research Institute of Oncology
(P 245) PRELIMINARY RESULTS FROM A PHASE 2 EFTISARC-NEO TRIAL OF NEOADJUVANT SOUBLE LAG-3 PROTEIN EFTILAGIMOD ALPHA, PEMBROLIZUMAB, AND CONCURRENT RADIOTHERAPY IN PATIENTS WITH RESECTABLE SOFT TISSUE SARCOMA
Marcin Zdzienicki
Favorite
Zebley, Caitlin

St. Jude Children's Research Hospital
(P 288) ANGIOA: A SAFETY AND TOLERABILITY STUDY OF TRIPLE ANTI-ANGIOGENIC THERAPY COMBINED WITH PD-L1 BLOCKADE IN PEDIATRIC, ADOLESCENT AND YOUNG ADULT RECURRENT/REFRACTORY SOLID TUMORS
Caitlin Zebley
Favorite
Zeedyk, Kaitlin

Atlantic Health System
(P 260) EMERGING TECHNOLOGY IN ORTHOPEDIC ONCOLOGY: ROBOTIC ARM-ASSISTED TOTAL KNEE ARTHROPLASTY HAS EXCEPTIONAL FUNCTION OUTCOMES FOR PATIENTS WITH BENIGN AND MALIGNANT MUSCULOSKELETAL DISEASE
Kaitlin Zeedyk
Favorite
Zemp, Franz

Arnie Charbonneau Cancer Institute and McCaig Institute for Bone and Joint Health
(P 239) INVESTIGATING HOW TUMOUR ASSOCIATED MACROPHAGES INFLUENCE THE EFFICACY OF CAR T THERAPY IN A MURINE MODEL OF SOFT TISSUE SARCOMA
Franz Zemp
Favorite
(P 289) APPLICATION AND ANALYSIS OF SPATIAL TRANSCRIPTOMIC PROFILING TO CLINICAL ALVEOLAR SOFT PART SARCOMA SAMPLES TO UNDERSTAND IMMUNOTHERAPY-RELEVANT VARIABLES
Franz Zemp
Favorite
(P 327) CHARACTERIZATION OF TWO NOVEL IMMUNE COMPETENT, MURINE MODELS OF SOFT TISSUE SARCOMA
Franz Zemp
Favorite
Zenda, Sadamoto

National Cancer Center Hospital East
(P 354) PROTON BEAM THERAPY FOR PEDIATRIC AND ADOLESCENT SARCOMA FROM OVERSEAS
Sadamoto Zenda
Favorite
Zervoudakis, Guston

Moffitt Cancer Center
(P 347) CAN UPFRONT RADIOTHERAPY PRECLUDE THE NEED FOR OPERATIVE STABILIZATION IN IMPENDING EXTREMITY FRACTURES FROM LUNG CANCER METASTASES?
Guston Zervoudakis
Favorite
Zhang, Ali

Northwestern University, Feinberg School of Medicine
(P 222) ANALYSIS OF THE CITN-13 SARCOMA ARM: PEMBROLIZUMAB AND INTERFERON GAMMA FOR SYNOVIAL SARCOMA AND MYXOID/ ROUND CELL LIPOSARCOMA
Ali Zhang
Favorite
(P 235) INFILTRATION OF MUCOSAL-ASSOCIATED INVARIANT T CELLS (MAITS) INTO CHONDROSARCOMA TUMORS
Ali Zhang
Favorite
Zhang, Chen-Lu

Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
(P 416) TRIPLR COMNINATION THERAPY IN THE FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA WITH HIGH TUMOR BURDEN: INTERIM ANALYSIS FROM ALTER-S007 STUDY
Chen-Lu Zhang
Favorite
Zhang, Daiyao

Stanford University
(P 74) MATRIX DENSITY INDUCES CHEMORESISTANCE WITHIN A TISSUE-ENGINEERED MODEL OF OSTEOSARCOMA
Daiyao Zhang
Favorite
Zhang, Ellen

Stanford Health Care
(P 209) RACE AND ETHNICITY ON DIAGNOSIS, METASTASIS, AND MORTALITY OF SOFT TISSUE SARCOMAS IN RETROSPECTIVE COHORT STUDY
Ellen Zhang
Favorite
(P 214) REPRESENTATION OF CHILDREN AND OLDER ADULTS IN SARCOMA CLINICAL TRIALS SINCE THE INCLUSION ACROSS THE LIFESPAN POLICY
Ellen Zhang
Favorite
(P 215) REPRESENTATION OF RACIAL AND ETHNIC MINORITIES IN SARCOMA CLINICAL TRIALS
Ellen Zhang
Favorite
Zhang, Jianhua

The University of Texas MD Anderson Cancer Center
(P 398) PREDICTORS OF EFFICACY IN PATIENTS WITH SOFT TISSUE SARCOMAS TREATED WITH PAZOPANIB
Jianhua Zhang
Favorite
zhang, jun

Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University
(P 180) TUMOR VASCULAR SIGN IN THE RESPONSE ASSESSMENT OF GASTROINTESTINAL STROMAL TUMOR TREATED WITH RIPRETINIB: A MULTICENTER STUDY
jun zhang
Favorite
Zhang, Lihong

Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology
(P 409) PHASE 2 STUDY EVALUATING SURUFATINIB IN PATIENTS WITH OSTEOSARCOMA AND SOFT TISSUE SARCOMA WHO HAVE FAILED STANDARD CHEMOTHERAPY
Lihong Zhang
Favorite
Zhang, Lindy

Johns Hopkins School of Medicine
(P 187) BRIDGING THE GAP: UNDERSTANDING THE CURRENT TREATMENT RESPONSES TO ENHANCE THE STANDARD OF CARE AND OUTCOMES FOR MALIGNANT PERIPHERAL NERVE SHEATH TUMORS
Lindy Zhang
Favorite
Zhang, Lingxin

Mount Sinai Hospital/University of Toronto
(P 78) NOVEL EPIGENETIC MECHANISMS DRIVE AGGRESSIVE OSTEOSARCOMA PATHOGENESIS AND DRUG RESISTANCE
Lingxin Zhang
Favorite
(P 293) CIC-REARRANGED SOFT TISSUE SARCOMAS: DOES CHEMOTHERAPY CHANGE NATURAL HISTORY AND PROGNOSIS? A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Lingxin Zhang
Favorite
(P 326) CELL-FREE DNA AS A BIOMARKER FOR CELL DEATH AND TREATMENT RESPONSE IN ON-CHIP THREE-DIMENSIONAL SARCOMA TUMOR MODELS
Lingxin Zhang
Favorite
Zhang, Liuzhe

University Musculoskeletal Oncology Unit, Mount Sinai Hospital, Department of Surgery, University of Toronto, Toronto, Canada
(P 71) LIMB-SALVAGE SURGERY AFTER UNPLANNED SURGERY FOR EXTREMITY BONE SARCOMAS: 30-YEAR EXPERIENCE AT A TERTIARY REFERRAL CENTER
Liuzhe Zhang
Favorite
(P 103) BRAF MUTATIONS AND CONCURRENT ALTERATIONS IN PATIENTS WITH SOFT TISSUE SARCOMA
Liuzhe Zhang
Favorite
(P 281) THE UTILITY OF INTRAOPERATIVE MARROW MARGIN FROZEN SECTION IN EXTREMITY BONE SARCOMA RESECTION
Liuzhe Zhang
Favorite
Zhang, Peng

The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital
(P 97) TRANSCRIPTOMICS REVEALS THAT OVEREXPRESSION OF LNCRNA HOTTIP REGULATES PKC PROTEIN ACTIVATION OF THE RAP1 SIGNALING PATHWAY FOR SYNOVIAL SARCOMA CELL PROGRESSION
Peng Zhang
Favorite
Zhang, Ranxin

Montefiore Medical Center/ Albert Einstein College of Medicine
(P 59) COMPREHENSIVE SINGLE CELL TRANSCRIPTOMICS ANALYSIS OF MURINE OSTEOSARCOMA UNCOVERS SKP2 FUNCTION IN METASTASIS, GENOMIC INSTABILITY AND IMMUNE ACTIVATION AND REALS ADDITIONAL TARGET PATHWAYS
Ranxin Zhang
Favorite
(P 147) INVESTIGATING THE POTENTIAL OF EXTRACELLULAR VESICLE BIOMARKERS IN SYNOVIAL SARCOMA DETECTION
Ranxin Zhang
Favorite
(P 156) PROFILING SYNOVIAL SARCOMA EXTRACELLULAR VESICLES FOR DIAGNOSTIC RNA BIOMARKERS
Ranxin Zhang
Favorite
Zhang, Wei

Wake Forest
(P 430) QUANTITATIVE EMT GENE SCORES AT DIAGNOSIS INDICATE METASTASIS RISK AND SURVIVAL IN SYNOVIAL SARCOMA
Wei Zhang
Favorite
Zhang, xiaochun

Washington University in St. Louis School of Medicine
(P 145) EXPLORING L-TYPE AMINO ACID TRANSPORTER 1 (LAT1) AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)
xiaochun Zhang
Favorite
(P 335) FOCAL ADHESION KINASE (FAK) IS A THERPEUTIC TARGET IN CHROMOSOME 8 GAIN-ASSOCIATED MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)
xiaochun Zhang
Favorite
Zhang, Xing

Sun Yat-Sen University Cancer Center
(P 132) PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND DISEASE BURDEN OF DEDIFFERENTIATED LIPOSARCOMA IN CHINA: A REAL-WORLD STUDY BASED ON NATIONAL CANCER REGISTRY
Xing Zhang
Favorite
(P 409) PHASE 2 STUDY EVALUATING SURUFATINIB IN PATIENTS WITH OSTEOSARCOMA AND SOFT TISSUE SARCOMA WHO HAVE FAILED STANDARD CHEMOTHERAPY
Xing Zhang
Favorite
Zhang, Xinhua

Department of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University
(P 180) TUMOR VASCULAR SIGN IN THE RESPONSE ASSESSMENT OF GASTROINTESTINAL STROMAL TUMOR TREATED WITH RIPRETINIB: A MULTICENTER STUDY
Xinhua Zhang
Favorite
Zhang, yiqun

The First Hospital of Jilin University
(P 119) UPDATED RESULTS OF A SINGLE-ARM,MULTI-CENTER STUDY OF ANLOTINIB COMBINED WITH TORIPALIMAB IN FIRST-LINE TREATMENT OF UNRESECTABLE OR METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA
yiqun Zhang
Favorite
Zhang, Yong

Department of surgical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
(P 416) TRIPLR COMNINATION THERAPY IN THE FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA WITH HIGH TUMOR BURDEN: INTERIM ANALYSIS FROM ALTER-S007 STUDY
Yong Zhang
Favorite
Zhao, Lei

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
(P 93) THE PROTEOGENOMIC SUBTYPING OF OSTEOSARCOMA
Lei Zhao
Favorite
Zhao, Weisong

Department of Orthopaedics, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Bone Tumor Institution, Shanghai, China
(P 83) PREDICTION OF HIGH-RISK OSTEOSARCOMA PATIENTS BASED ON MACHINE LEARNING USING TRANSCRIPTOME AND METHYLATION DATA FROM SGH-COHORT
Weisong Zhao
Favorite
Zheng, Deyou

Albert Einstein College of Medicine
(P 59) COMPREHENSIVE SINGLE CELL TRANSCRIPTOMICS ANALYSIS OF MURINE OSTEOSARCOMA UNCOVERS SKP2 FUNCTION IN METASTASIS, GENOMIC INSTABILITY AND IMMUNE ACTIVATION AND REALS ADDITIONAL TARGET PATHWAYS
Deyou Zheng
Favorite
Zheng, Jing

The University of Texas M D Anderson Cancer Center
(P 398) PREDICTORS OF EFFICACY IN PATIENTS WITH SOFT TISSUE SARCOMAS TREATED WITH PAZOPANIB
Jing Zheng
Favorite
Zhou, Bo

Deciphera Pharmaceuticals, LLC
(P 403) DCC-3116 IN COMBINATION WITH RIPRETINIB FOR PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: A PHASE 1/2 STUDY
Bo Zhou
Favorite
Zhou, Maggie

Stanford University School of Medicine
(P 143) EARLY ASSESSMENT OF DISEASE RESPONSE TO IMMUNOTHERAPY VIA CIRCULATING TUMOR DNA IN ADVANCED SOFT TISSUE SARCOMAS
Maggie Zhou
Favorite
(P 161) UTILITY OF CTDNA MONITORING IN THE ADJUVANT AND METASTATIC SETTING IN SOFT TISSUE SARCOMA
Maggie Zhou
Favorite
Zhou, Yong

Department of Orthopedics, West China Hospital, Sichuan University
(P 407) LONG-TERM EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): PHASE 1B UPDATE.
Yong Zhou
Favorite
Zhou, Yuhong

Oncology Department Zhongshan Hospital
(P 132) PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND DISEASE BURDEN OF DEDIFFERENTIATED LIPOSARCOMA IN CHINA: A REAL-WORLD STUDY BASED ON NATIONAL CANCER REGISTRY
Yuhong Zhou
Favorite
(P 416) TRIPLR COMNINATION THERAPY IN THE FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA WITH HIGH TUMOR BURDEN: INTERIM ANALYSIS FROM ALTER-S007 STUDY
Yuhong Zhou
Favorite
Zhuang, Rong-Yuan

Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
(P 416) TRIPLR COMNINATION THERAPY IN THE FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA WITH HIGH TUMOR BURDEN: INTERIM ANALYSIS FROM ALTER-S007 STUDY
Rong-Yuan Zhuang
Favorite
Zhu, Dong-Lei

Clinical Development, Boehringer Ingelheim, Shanghai, China
(P 132) PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND DISEASE BURDEN OF DEDIFFERENTIATED LIPOSARCOMA IN CHINA: A REAL-WORLD STUDY BASED ON NATIONAL CANCER REGISTRY
Dong-Lei Zhu
Favorite
Zhu, Limin

OHSU
(P 227) EFFICACY OF IMMUNOTHERAPY IN TREATING METASTATIC MALIGNANT MYOPERICYTOMA: A CASE REPORT AND RIVEW OF LITERATURE
Limin Zhu
Favorite
(P 364) A PHASE 1B TRIAL OF PREOPERATIVE ERIBULIN AND RADIATION FOR RETROPERITONEAL LIPOSARCOMA
Limin Zhu
Favorite
Ziaee, Maryam

µFO Lab, Polytechnique Montréal, Montréal, Canada; Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), Montréal, Canada; Institut du Cancer de Montréal (ICM), Montréal, Canada
(P 326) CELL-FREE DNA AS A BIOMARKER FOR CELL DEATH AND TREATMENT RESPONSE IN ON-CHIP THREE-DIMENSIONAL SARCOMA TUMOR MODELS
Maryam Ziaee
Favorite
Ziegler, David S.

Sydney Children’s Hospital, Randwick, NSW, Australia and School of Women’s and Children’s Health, University of New South Wales Sydney
(P 393) EFFICACY AND SAFETY OF LAROTRECTINIB AS FIRST-LINE TREATMENT IN PATIENTS WITH TRK FUSION SARCOMAS
David S. Ziegler
Favorite
Zijlmans, Henry

Netherlands Cancer Institute
(P 317) SMARCB1-DEFICIENT SARCOMA OF THE GENITAL REGION/EPITHELIOID SARCOMA OF THE PROXIMAL TYPE VS EPITHELIOID SARCOMA OF THE DISTAL TYPE
Henry Zijlmans
Favorite
Zilla, Megan

University of Pittsburgh Medical Center
(P 117) THE TUMOR IMMUNE MICROENVIRONMENT OF DEDIFFERENTIATED SARCOMAS: DIGITAL SPATIAL PROFILING SHOWS IMMUNE TRANSCRIPTIONAL DIFFERENCES BETWEEN DEDIFFERENTIATED LIPOSARCOMA AND CHONDROSARCOMA
Megan Zilla
Favorite
Zoccali, Carmine

Università “La Sapienza” di Roma
(P 311) QUANTIFICATION OF TUMOUR-INFILTRATING IMMUNE CELLS THROUGH DECONVOLUTION OF DNA METHYLATION DATA IN EWING SARCOMAS
Carmine Zoccali
Favorite
Zon Filippi, Renee

Hospital Israelita Albert Einstein
(P 122) ACTIONABLE FUSIONS IN DEDIFFERENTIATED LIPOSARCOMA: AN ANALYSIS OF 402 CASES IN THE AACR GENIE DATABASE
Renee Zon Filippi
Favorite
(P 141) COMPREHENSIVE GENOMIC PROFILING OF PATIENTS DIAGNOSED WITH SARCOMA IN BRAZIL: MOLECULAR PROFILE AND ACTIONABILITY
Renee Zon Filippi
Favorite
(P 192) CURRENT SCENARIO OF SARCOMA CLINICAL TRIALS IN SOUTH AMERICA: A REPORT BY THE LACOG SARCOMA GROUP
Renee Zon Filippi
Favorite
(P 216) SARCOMA CARE PATHWAYS AND MULTIDISCIPLINARY TUMOR BOARDS IN LATIN AMERICA: AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Renee Zon Filippi
Favorite
(P 217) SARCOMA DRUG APPROVALS IN LATIN AMERICA COMPARED TO THE FDA AND EMA: AN ANALYSIS BY THE LACOG SARCOMA GROUP
Renee Zon Filippi
Favorite
(P 219) SOCIAL MEDIA USE AMONG MEDICAL PROFESSIONALS THAT TREAT PATIENTS WITH SARCOMA IN LATIN AMERICA: RESULTS OF AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Renee Zon Filippi
Favorite
(P 232) IMMUNE CHECKPOINT INHIBITORS COMBINED WITH TYROSINE KINASE INHIBITORS FOR SOFT-TISSUE SARCOMAS: A SYSTEMATIC REVIEW AND SINGLE-ARM META-ANALYSIS
Renee Zon Filippi
Favorite
(P 242) MICROSATELLITE INSTABILITY AND CLINICAL USE IN SARCOMAS: A SYSTEMATIC REVIEW
Renee Zon Filippi
Favorite
Zuckerman, Lee

Department of Orthopaedic Surgery, Keck School of Medicine of the University of Southern California
(P 197) EVALUATION OF REVIEWS OF ORTHOPAEDIC ONCOLOGISTS ON INSTITUITIONAL AND PATIENT REVIEW WEBSITES
Lee Zuckerman
Favorite
(P 259) COMPRESSION OF INTERCALARY ALLOGRAFTS WITH MAGNETIC LENGTHENING NAILS, MID-TERM RESULTS WITH A COMPARISON OF TECHNIQUES
Lee Zuckerman
Favorite
Zuco, Valentina

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 137) TARGETING PRIMARY AND SECONDARY ONCOGENIC DRIVERS IN RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMAS
Valentina Zuco
Favorite
ZUGMAN, MIGUEL

City of Hope Cancer Center
(P 141) COMPREHENSIVE GENOMIC PROFILING OF PATIENTS DIAGNOSED WITH SARCOMA IN BRAZIL: MOLECULAR PROFILE AND ACTIONABILITY
MIGUEL ZUGMAN
Favorite
Zuo, Dongqing

Department of Orthopedic Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Bone Tumor Institution, Shanghai, China
(P 48) A SINGLE-ARM, OPEN-LABEL CLINICAL STUDY OF OVV-01 ONCOLYTIC VIRUS INJECTION AS MONOTHERAPY OR IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR ADVANCED SOLID TUMOR PATIENTS
Dongqing Zuo
Favorite
(P 90) TARGETING HIGH RISK MYC- AMPLIFIED OSTEOSARCOMA BY AURORA KINASE INHIBITOR--RESULT FROM A NGS BASED UMBRELLA TRIAL
Dongqing Zuo
Favorite
Zyczynski, Laurie

University of Michigan
(P 45) UTILIZATION OF MENTAL HEALTH AND SUPPORTIVE CARE RESOURCES AMONG PATIENTS WITH DESMOID TUMORS
Laurie Zyczynski
Favorite
(P 308) PALLIATIVE CARE INVOLVEMENT FOR ADOLESCENTS AND YOUNG ADULTS WITH BONE AND SOFT TISSUE SARCOMAS
Laurie Zyczynski
Favorite
魏, 宜源

北京大学癌症医院
(P 180) TUMOR VASCULAR SIGN IN THE RESPONSE ASSESSMENT OF GASTROINTESTINAL STROMAL TUMOR TREATED WITH RIPRETINIB: A MULTICENTER STUDY
宜源魏
Favorite